1st Q
This section reports quality control (QC) statistics for the personal genotype data, as well as for the reference genotype data.
Sample QC
- The genetically determined sex is: Male
- 21 of 296,039 variants are missing, missing rate is: 0.01%
Variants count in each chromosome:
Minor allele frequency in sample based on MAF reference data:
- 292805 of 296574 variants were found in MAF reference data.
Principal Components of Sample based on PCA reference data:
Concordance check:
- In the current genotype file, 296574 of 296574 (100.00%) variants were found in previous genotype file.
- In these common variants, 185991 of 296574 (62.71%) variants were identical.
Population QC
Minor allele frequency:
Missing genotype rates:
Sex discrepancy:
Cryptic relatedness:
Hardy-Weinberg equilibrium:
Heterozygosity rate:
2nd Q
The traits listed in this section are almost definitely determined by genetics. However, the association with relevant disease outcome is certainly not definite. For example, “FTO related obesity” simply reports one widely cited FTO SNP that is associated with obesity, but obesity itself is certainly not determined by a single SNP.
Qualitative traits
| Name | Result |
|---|---|
| ABO blood type | B |
| Alcohol flush | A- |
| APOE type | ε3/ε3: the most common |
| Folic Acid metabolism | Slow |
| FTO related obesity | None allele mutated: wide type |
| HIV resistance | Susceptible |
| Lactose metabolism | Lactose tolerance |
| Muscle fiber type | Fast muscle type |
| Nicotineaddiction | Wild type |
| Altruism | More likely |
| Earwax Type | Wet |
| Perception of fish odor | Insensitive |
| Caffeine metabolism | Slow |
| Marital satisfaction | Normal |
Scientific detail:
ABO blood type
Description:
The ABO blood types were discovered by Karl Landsteiner in 1901. He received the Nobel Prize in Physiology or Medicine in 1930 for this discovery. ABO blood types are also present in other primates such as apes and Old World monkeys. The ABO blood group system is used to denote the presence of one, both, or neither of the A and B antigens on erythrocytes. In human blood transfusions it is the most important of the 38 different blood type (or group) classification systems currently recognized. A mismatch in this, or any other serotype, can cause a potentially fatal adverse reaction after a transfusion, or an unwanted immune response to an organ transplant. The associated anti-A and anti-B antibodies are usually IgM antibodies, produced in the first years of life by sensitization to environmental substances such as food, bacteria, and viruses. Usually, four tag SNPs were used for the main ABO blood group antigens (rs8176746 for B, rs687289 for O, rs507666 for A1 and rs8176704 for A2).
Result:
B
Distribution plot:
Scientific detail:
- rs41302905: C/C
- rs8176719: T/TC
- rs8176746: T/G
Reference:
- PMID: 18604267
Alcohol flush
Description:
In African and European populations, acetaldehyde is broken down quickly enough to maintain tolerably low concentrations in drinkers. In east Asian populations, there is a common loss-of-function variant of the ALDH2 gene on chromosome 12 (rs671). Even a single copy decreases acetaldehyde breakdown enough for the concentration to become uncomfortably high after drinking alcohol. This variant is an important determinant of the east Asian flushing reaction to alcohol, and of alcohol intake. Less importantly, a genetic variant of the ADH1B gene on chromosome 4 (rs1229984) that is common in east Asia increases alcohol clearance rates. Together, these two single nucleotide polymorphisms strongly affect alcohol exposure, and each has been shown to decrease substantially the incidence of alcoholism. Both variants involve a G→A mutation, with the A allele decreasing alcohol exposure. Each variant has three possible genotypes, AA, AG, and GG, so the two variants define nine possible genotypes. Alcohol intake is affected more by the decreased rate of breakdown of acetaldehyde than by the increased alcohol clearance rate. Hence, when describing these nine genotypes the rs671 genotype is given first and the rs1229984 genotype second, and alphabetic order corresponds to increasing alcohol intake: AA/AA, AA/AG, AA/GG; then AG/AA, AG/AG, AG/GG; then GG/AA, GG/AG, GG/GG. We denote this 9 genotype as A+, A, A-, B+, B, B-, C+, C, C-, respectively.
Result:
A-
Distribution plot:
Scientific detail:
- rs671: G/G
- rs1229984: C/C
Reference:
- PMID: 30955975
- PMID 6582480
APOE type
Description:
The APOE gene provides instructions for making a protein called apolipoprotein E. This protein combines with fats (lipids) in the body to form molecules called lipoproteins. Lipoproteins are responsible for packaging cholesterol and other fats and carrying them through the bloodstream. Maintaining normal levels of cholesterol is essential for the prevention of disorders that affect the heart and blood vessels (cardiovascular diseases), including heart attack and stroke.
Result:
ε3/ε3: the most common
Distribution plot:
Scientific detail:
- rs429358: T/T
- rs7412: C/C
Reference:
- PMID: 9343467
Folic Acid metabolism
Description:
The methylenetetrahydrofolate reductase gene, more commonly known as MTHFR, is the most asked-about gene by DTC customers. Some websites and products have made bold claims that common genetic variants in MTHFR can cause a wide array of health conditions, ranging from blood clots and cancer to autism and migraines. The MTHFR gene contains instructions for making an enzyme that’s important for metabolizing folate (also called folic acid or vitamin B9). MTHFR also helps our cells recycle homocysteine, a chemical in the blood, into methionine, a building block for proteins. there are two common naturally occurring variants in the MTHFR gene, called C677T (rs1801133) and A1298C. When the MTHFR gene has either of these two variants, the resulting MTHFR enzyme is slightly less active, and this can lead to decreased levels of folate and increased levels of homocysteine in the blood. Homozygous rs1801133(T;T) individuals have ~30% of the expected MTHFR enzyme activity, and rs1801133(C;T) heterozygotes have ~65% activity, compared to the most common genotype, rs1801133(C;C).
Result:
Slow
Distribution plot:
Scientific detail:
- rs1801133: G/G
- rs1801131: T/G
Reference:
- PMID: 8789576
FTO related obesity
Description:
In 2007, within a time period of three months, two studies claimed the discovery of FTO as the first GWAS-identified obesity-susceptibility gene. FTO was first discovered through a GWAS of type 2 diabetes in Europeans, comparing 1,924 cases and 2,938 controls. A cluster of single nucleotide polymorphisms (SNPs) in the first intron of the gene showed highly significant association with risk of type 2 diabetes. However, after adjusting for BMI, the association with type 2 diabetes completely abolished, suggesting that the FTO - type 2 diabetes association was mediated through FTO’s effect on BMI. Eight weeks after the first discovery, a GWAS for BMI in 4,741 Sardinians observed highly significant associations for SNPs from the same intronic cluster in FTO, which was subsequently replicated in 2,335 European and Hispanic Americans. A third study, published at around the same time as the two GWAS, identified the same FTO locus serendipitously, while testing for population stratification in their case-control obesity data. Together, these studies firmly established FTO as the first gene with common variants that affect obesity susceptibility in the general population. Although the mechanism and function of FTO is not fully understood, possible functional alterations by the gene have been reported in the HPA axis and in the reward system in the brain.
Result:
None allele mutated: wide type
Distribution plot:
Scientific detail:
- rs9939609: T/T
Reference:
- PMID: 17434869
HIV resistance
Description:
Host genetic factors are involved in resistance/susceptibility to HIV-1 infection and progression. The most relevant genetic variant of the gene encoding HIV-1 major co- receptor, CCR5 (chemokine receptor type 5). The CCR5 gene codes for a protein on the cell membrane of white blood cells, specifically T-cells, macrophages, dendritic cells, eosinophils, and microglial cells. It is a part of your immune system’s response to foreign invaders, and it is also an essential part of the way that the HIV virus is able to hijack immune cells. A mutation in CCR5, named Delta 32 (rs333), causes a change in the protein that makes it non-functional. Carrying two copies of the mutation protects most carriers from HIV. The first person in the world to be cured of HIV, the “Berlin Patient“, was Timothy Ray Brown, an American living in Berlin. While HIV positive, he contracted leukemia, and in 2007 he was given a bone marrow transplant from a donor with two copies of the CCR5 Delta32 mutation. After 3 months, he no longer had detectable HIV in his blood. The Delta32 variant is well studied on a variety of immune system topics. It is thought that the mutation first arose in Northern Europe and was preferentially passed on in Caucasian populations due to increasing resistance to smallpox.
Result:
Susceptible
Distribution plot:
Scientific detail:
- Snp (rs333) cannot be found in your genotype file!
- rs113010081: T/T
Reference:
- PMID: 31873311
- PMID: 8898752
Lactose metabolism
Description:
Lactose, a sugar in milk, is broken down by the enzyme lactase which our bodies produce in the small intestines. For some people, the production of the lactase enzyme stops when they become an adult, driven by a genetic variation near the LCT gene. This means some adults are genetically predisposed to not be able to digest larger quantities of milk. Producing lactase as an adult is the most common genotype for Caucasian populations, while in Asian populations, the majority do not produce lactase as an adult. A theory for this occurrence seems to be an adaptation by Caucasian populations in Europe who relied on dairy products as a source of protein. For people with European Caucasian ancestry, the main variant to look at is rs4988235. It is located in the MCM6 gene, which influences the LCT gene. Approximately 90% of Caucasians will have A/A or A/G and still produce lactase to break down milk as an adult. In Asian populations, less than one percent will carry the G allele. People with African ancestry may find that they carry a different variant (rs145946881) in the MCM6 gene that also causes lactase persistence as an adult.
Result:
Lactose tolerance
Distribution plot:
Scientific detail:
- rs4988235: A/G
Reference:
- PMID: 11788828
Muscle fiber type
Description:
Over the last couple of decades, research has focused on attempting to understand the genetic influence on sports performance. This has led to the identification of a number of candidate genes which may help differentiate between elite and non-elite athletes. One of the most promising genes in that regard is ACTN3, which has commonly been referred to as “a gene for speed”. Recent research has examined the influence of this gene on other performance phenotypes, including exercise adaptation, exercise recovery, and sporting injury risk. ACTN3 is a gene that encodes for alpha-actinin-3, a protein expressed only in type-II muscle fibers (North et al., 1999). A common polymorphism in this gene is R577X (rs1815739), where a C-to-T base substitution results in the transformation of an arginine base (R) to a premature stop codon (X). X allele homozygotes are deficient in the alpha-actinin-3 protein, which is associated with a lower fast-twitch fiber percentage (Vincent et al., 2007), but does not result in disease (MacArthur and North, 2004). The XX genotype frequency differs across ethnic groups, with approximately 25% of Asians, 18% of Caucasians, 11% of Ethiopians, 3% of Jamaican and US African Americans, and 1% of Kenyans and Nigerians possessing the XX genotype (Yang et al., 2007; MacArthur et al., 2008; Scott et al., 2010). ACTN3 genotype is associated with speed and power phenotypes.
Result:
Fast muscle type
Distribution plot:
Scientific detail:
- rs1815739: C/C
Reference:
- PMID: 17828264
Nicotineaddiction
Description:
Abundant data from twin and adoption studies provide evidence for the heritability of habitual cigarette smoking. Hall et al. reviewed twin and adoption data in smoking studies, including five studies of twins reared apart. Taken together, these twin studies suggest that a majority of NA risk is attributable to genetic factors. More recent twin smoking research suggests that the heritability of NA is ∼75%. In 2008, Berrettini et al. described a GWAS of ∼7000 individuals of European origin for CPD, with a P-value ∼10−5, at a CHRNA3 SNP allele. They studied a second population of equal size, for the same phenotype (CPD), reporting association to a second allele in the same haplotype, establishing the common European haplotype as conferring risk for Nicotine addition. The CHRNA5/A3/B4 is a gene cluster on chromosome 15 that encodes the α5, α3, and β4 of the nicotinic acetylcholine receptor subunits (nAChR) (Duga et al., 2001; Eng, Kozak, Beaudet, & Zoghbi, 1991). Genome-wide association studies have shown strong associations between tobacco smoking dependence and genetic variations in the CHRNA5/A3/B4 gene cluster (Saccone et al., 2007; Wen, Yang, Cui, & Li, 2016). One single nucleotide polymorphisms (SNP) that showed strong relation to tobacco smoking behavior/dependence is rs16969968 in exon 5 of CHRNA5.
Result:
Wild type
Distribution plot:
Scientific detail:
- rs429358: T/T
- rs16969968: A/G
Reference:
- https://www.nature.com/articles/nature06846
- PMID: 18519524
Altruism
Description:
William D. Hamilton postulated the existence of ‘genes underlying altruism’, under the rubric of inclusive fitness theory, a half-century ago. Humans are by nature prosocial. Nevertheless, prosocial behavior is greatly variable among individuals. By far the best-studied polymorphism within COMT is the Val158Met polymorphism (rs4680). It has long been known that there is a trimodal distribution of COMT activity in human populations (Floderus et al., 1981), which was subsequently shown to be due to the presence of this polymorphism (Lachman et al., 1996). The polymorphism is an A to G single nucleotide change that results in a valine to methionine substitution at position 158 of the MB-COMT amino acid sequence (position 108 in S-COMT Bertocci et al., 1991; Lundstrom et al., 1991). The Met158 form of COMT has a lower thermostability and therefore a lower activity at 37˚C, compared to the Val158 form (Chen et al., 2004; Lotta et al., 1995). The apparent differences in the magnitude of the Val158Met effect on activity are likely due in part to methodological factors, but could plausibly also be due to tissue-specific effects of other polymorphisms/haplotypes in COMT.
Result:
More likely
Distribution plot:
Scientific detail:
- rs4680: G/G
Reference:
- PMID: 21030481
Earwax Type
Description:
Description is unavailable.
Result:
Wet
Distribution plot:
Scientific detail:
- rs17822931: T/C
Reference:
- PMID: 16444273
Perception of fish odor
Description:
The perception of smell is enabled by olfactory receptors, which are proteins that bind odor molecules. Olfactory senses are one of the oldest and most critical senses for the organism survival that helps in identifying food, potential mating partners, as well as dangers. Due to the variation in the number of olfactory receptors in the species, different species have different olfactory abilities. These olfactory receptors (OR) are encoded by OR genes. In humans out of 855 OR genes, only ~400 were functionally coded for ORs. The genetic variation in the OR genes among individuals provides the personalized olfaction behaviour among individuals. A number of association studies for odor perception with genetic OR loci are reported. Also, a recent genome-wide association study was performed by Gisladottir et al. for odor perception on 9,122 Icelanders. They found three genetic variants i.e. p.Ser95Pro in TAAR5 gene (rs41286168), p.Lys233Asn in OR6C70 (rs60683621) and intergenic variant rs317787 associated with aversion to fish odor, increased intensity of licorice, and cinnamon odor respectively.
Result:
Insensitive
Distribution plot:
Scientific detail:
- rs41286168: A/A
Reference:
- PMID: 33035477
Caffeine metabolism
Description:
Caffeine (1,3,7-trimethylxanthine) is one of the most widely used drugs in the world and is available in many mediums for consumption. The pharmacokinetics and pharmacodynamics of caffeine have been well studied. Caffeine metabolism occurs primarily in the liver via the cytochrome P450 system (CYP1A2). The CYP1A2 proteins are encoded by the CYP1A2 gene, and CYP1A2 activity is induced when aromatic hydrocarbons bind the aryl hydrocarbon receptor. The CYP1A2 gene encodes a member of the cytochrome p450 family of proteins, which metabolize nutrients and drugs. One well known substrate of CYP1A2 is caffeine. The same amount of caffeine will therefore tend to have more stimulating effect on CYP1A2 slow metabolizers than on CYP1A2 fast metabolizers. The SNP rs762551, also known as -164A>C or -163C>A, encodes the CYP1A2*1F allele of the CYP1A2 gene. The C allele is considered the wild-type, even though it is the rarer allele in most populations. AA = CYP1A2*1F = Fast Metabolizer. CC, AC = CYP1A2*1C = Slow Metabolizer.
Result:
Slow
Distribution plot:
Scientific detail:
- rs762551: A/C
Marital satisfaction
Description:
Based on a study from Makhanova, A. at el. published in February 2021, a research team from the University of Arkansas, Florida State University, and McGill University collected data from 71 heterosexual newlywed couples (N = 142 participants) in their early 30s. Within three months of getting married, couples completed a series of baseline measures. Over the next three years, both partners completed measures of marital satisfaction every four months, along with saliva samples for DNA extraction. Those who had the rs3796863 CC genotype reported greater marital satisfaction, compared to those with the AC/AA type. In addition, those with the CC genotype also reported more trust, forgiveness, and gratitude toward their relationship partner. These associations were the same for men and women. It’s also important to realize that any genetic marker associated with a behavior — in this case marital satisfaction — isn’t causal. That is, every person with this CC genotype won’t be great at relationships. And every person without it won’t be hopeless when it comes to love. Genes aren’t destiny. But this research does show that there are genetic underpinnings to our behavior.
Result:
Normal
Distribution plot:
Scientific detail:
- rs3796863: T/T
Reference:
- PMID: 33536489
3rd Q
The risk assessment is purely based on polygenic risk score, whose association with various diseases is usually very limited. Furthermore, the information provided here should be in no way treated similarly as information from your physician. Most complex traits are determined by both genetics, lifestyle factors, and many other environmental factors.
According to SNPedia , “population statistics are a bit hard to come by, and furthermore, the more interesting ‘personal genomics’ statistic might be residual lifetime risk in light of your own genome and your current age ... but there isn't enough medical and epidemiological data to actually calculate this yet for any complex disease”. Nevertheless, we list the average lifetime risk for various traits based on SNPedia, unless otherwise specified.
Quantitative traits
| Name | Risk |
|---|---|
| Age related macular degeneration | Normal |
| Colorectal cancer | Low risk |
| Atrial fibrillation | Low risk |
| Coronary artery disease | High risk |
| Lung cancer | High risk |
| Migraine | Low risk |
| Schizophrenia | High risk |
Scientific detail:
Age related macular degeneration
Description:
Age-related macular degeneration (AMD) is an eye disease that can blur the sharp, central vision one needs for activities like reading and driving. “Age-related” means that it often happens in older people. “Macular” means it affects a part of the eye called the macula. AMD is a leading cause of vision loss for people age 50 and older. AMD doesn’t cause complete blindness, but losing one’ central vision can make it harder to see faces, drive, or do close-up work like cooking or fixing things around the house. AMD happens very slowly in some people. For some people, AMD may not experience vision loss for a long time. For other people, AMD progresses faster and can lead to central vision loss in one eye or both eyes. AMD is the very first disease that inspired genome-wide association studies (GWAS). Arguably, the best-known and most successful GWAS was on AMD, by Klein et al. in 2005, published on Science Journal.
Standardized genetic risk score:
Mean - 0.27 * SD
Distribution:
N of reference population: 2504
N below this sample: 978 (39.06%)
N above this sample: 1526 (60.94%)
Distribution plot:
Scientific detail:
- rs10033900: C/C, effect allele: C, beta: 1.15
- rs10781182: T/T, effect allele: G, beta: 1.11
- rs10922109: A/C, effect allele: C, beta: 0.38
- rs11080055: C/C, effect allele: C, beta: 0.91
- rs114092250: G/G, effect allele: G, beta: 0.7
- rs1142: C/C, effect allele: C, beta: 1.11
- Snp (rs116503776) cannot be found in your genotype file!
- rs11884770: T/T, effect allele: C, beta: 0.9
- rs12357257: G/G, effect allele: G, beta: 1.11
- rs140647181: T/T, effect allele: T, beta: 1.59
- Snp (rs142450006) cannot be found in your genotype file!
- rs1626340: G/G, effect allele: G, beta: 0.88
- rs201459901: T/T, effect allele: T, beta: 0.76
- rs2043085: T/C, effect allele: T, beta: 0.87
- rs2230199: G/G, effect allele: C, beta: 1.43
- rs2740488: A/C, effect allele: A, beta: 0.9
- rs3138141: C/C, effect allele: C, beta: 1.16
- rs3750846: T/C, effect allele: T, beta: 2.81
- rs429358: T/T, effect allele: T, beta: 0.7
- rs5754227: T/T, effect allele: T, beta: 0.77
- rs5817082: C/A/C/A, effect allele: C, beta: 0.84
- rs61941274: G/G, effect allele: G, beta: 1.51
- rs61985136: T/C, effect allele: T, beta: 0.9
- rs62247658: C/C, effect allele: T, beta: 1.14
- rs62358361: G/G, effect allele: G, beta: 1.8
- rs6565597: C/C, effect allele: C, beta: 1.13
- rs67538026: T/T, effect allele: C, beta: 0.9
- rs71507014: G/C/C/G/C/C, effect allele: GC, beta: 1.1
- rs72802342: C/C, effect allele: C, beta: 0.79
- rs7803454: C/C, effect allele: C, beta: 1.13
- Snp (rs79037040) cannot be found in your genotype file!
- rs8135665: C/C, effect allele: C, beta: 1.14
- rs943080: T/T, effect allele: T, beta: 0.88
- rs9564692: T/C, effect allele: C, beta: 0.89
Colorectal cancer
Description:
Colorectal cancer (CRC) is the third and fourth most common cancer in women and men worldwide, respectively, and the fourth most common cause of cancer death. CRC exhibits global geographic variations in its incidence with multiple factors (social, demographic, environmental, and genetic) playing different roles in its pathogenesis. Diet rich in fat and low in fiber, high levels of triglycerides, physical inactivity, diabetes, alcohol, obesity, and smoking are the identified risk factors of colorectal cancer. Hereditary factors play a definite role as well. CRC is generally sporadic but approximately 25% of the patients have a genetic predisposition. Instability in chromosomes, CpG island methylation, and microsatellite instability have been reported in key genes leading to the developing of CRC. Gene–environment interactions are also important in the pathogenesis.
Standardized genetic risk score:
Mean - 1.38 * SD
Distribution:
N of reference population: 2504
N below this sample: 208 (8.31%)
N above this sample: 2296 (91.69%)
Average lifetime risk: 4.2%
Distribution plot:
Scientific detail:
- Using "clump" and "score" function in plink to calculate PRS.
- There are 4792 variants for this trait in raw GWAS data.
- After clumping, there are 4792 valid variants for PRS.
- In this sample, there are 4791 loaded to calculate PRS.
Atrial fibrillation
Description:
Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide and may have serious cardiovascular health consequences. AF is associated with increased risk of stroke, dementia, heart failure, and death. There are several known robust, clinical risk predictors for AF, such as male sex, increasing age, and hypertension; however, during the last couple of decades, a substantive genetic component has also been established. Over the last 10 years, the discovery of novel AF-related genetic variants has accelerated, increasing our understanding of mechanisms behind AF. Current studies are focusing on mapping the polygenic structure of AF, improving risk prediction, therapeutic development, and patient-specific management. Nevertheless, it is still difficult for clinicians to interpret the role of genetics in AF prediction and management.
Standardized genetic risk score:
Mean - 1.68 * SD
Distribution:
N of reference population: 2504
N below this sample: 101 (4.03%)
N above this sample: 2403 (95.97%)
Distribution plot:
Scientific detail:
- rs11264280: C/C, effect allele: T, beta: 1.12
- rs1152591: G/G, effect allele: A, beta: 1.09
- rs11598047: A/G, effect allele: G, beta: 1.18
- rs11718898: C/C, effect allele: C, beta: 1.08
- rs12664873: T/T, effect allele: T, beta: 1.08
- rs1997572: A/A, effect allele: G, beta: 1.1
- rs2106261: C/C, effect allele: T, beta: 1.2
- rs2288327: A/G, effect allele: G, beta: 1.09
- rs2540949: A/A, effect allele: A, beta: 1.08
- rs2967791: T/C, effect allele: T, beta: 1.07
- rs337711: T/T, effect allele: T, beta: 1.07
- rs35176054: T/T, effect allele: A, beta: 1.14
- rs3771537: A/C, effect allele: A, beta: 1.09
- rs4499262: C/C, effect allele: A, beta: 1.14
- rs4946333: A/G, effect allele: G, beta: 1.08
- rs520525: A/G, effect allele: A, beta: 1.12
- rs60848348: C/C, effect allele: T, beta: 1.13
- rs6843082: A/A, effect allele: G, beta: 1.45
- rs7026071: T/C, effect allele: T, beta: 1.09
- rs72700118: C/C, effect allele: A, beta: 1.14
- rs7394190: A/A, effect allele: G, beta: 1.15
- rs74022964: C/C, effect allele: T, beta: 1.12
- rs7508: A/A, effect allele: A, beta: 1.09
- rs75190942: C/C, effect allele: A, beta: 1.17
- rs7915134: T/T, effect allele: C, beta: 1.12
- rs883079: T/C, effect allele: T, beta: 1.11
Coronary artery disease
Description:
Coronary artery disease (CAD) is a leading cause of death worldwide. The major sequelae of CAD include angina, myocardial infarction (MI), arrhythmias, heart failure, and sudden cardiac death. CAD has a complex aetiology, and various environmental factors, including cigarette smoking, sedentary lifestyle, unhealthy diet and obesity, and disease predisposition. These lifestyle-related factors can lead to type 2 diabetes, hypercholesterolaemia and arterial hypertension, which are key risk factors for CAD. In addition, the influence of heritability on CAD susceptibility has been recognized for many years and accounts for 40–50% of cases. Although the inherited CAD risk is particularly evident in large families with multiple affected members, decade ago only mutations in the LDL receptor gene were reproducibly linked to the disease. However, with the emergence of genome-wide association studies (GWAS), large number of common variants displayed strongly reproducible yet small effects and substantially broadened the spectrum of genetic factors recognized as contributing to CAD aetiology.
Standardized genetic risk score:
Mean + 1.16 * SD
Distribution:
N of reference population: 2504
N below this sample: 2188 (87.38%)
N above this sample: 316 (12.62%)
Distribution plot:
Scientific detail:
- rs10840293: A/A, effect allele: A, beta: 1.06
- rs10947789: T/T, effect allele: T, beta: 1.05
- rs10953541: C/C, effect allele: C, beta: 1.05
- rs11203042: T/C, effect allele: T, beta: 1.04
- rs11206510: T/T, effect allele: T, beta: 1.08
- rs1122608: G/G, effect allele: G, beta: 1.08
- rs11556924: T/C, effect allele: C, beta: 1.08
- rs11830157: T/T, effect allele: G, beta: 1.04
- rs12190287: C/G, effect allele: C, beta: 1.06
- rs12413409: G/G, effect allele: G, beta: 1.08
- rs12526453: C/C, effect allele: C, beta: 1.1
- rs12936587: A/G, effect allele: G, beta: 1.03
- rs12976411: A/A, effect allele: T, beta: 0.95
- rs1412444: T/C, effect allele: T, beta: 1.07
- rs1561198: T/C, effect allele: T, beta: 1.06
- rs16986953: G/G, effect allele: A, beta: 1.09
- rs17087335: T/G, effect allele: T, beta: 1.06
- rs17114036: A/A, effect allele: A, beta: 1.13
- rs17464857: T/G, effect allele: T, beta: 1.06
- rs17465637: A/A, effect allele: C, beta: 1.08
- rs17514846: A/C, effect allele: A, beta: 1.05
- rs180803: G/G, effect allele: G, beta: 1.2
- rs1878406: T/C, effect allele: T, beta: 1.06
- rs2023938: T/C, effect allele: C, beta: 1.06
- rs2047009: G/G, effect allele: G, beta: 1.06
- rs2048327: T/T, effect allele: C, beta: 1.06
- rs2075650: A/A, effect allele: G, beta: 1.07
- rs216172: C/C, effect allele: C, beta: 1.05
- rs2252641: C/C, effect allele: C, beta: 1.03
- rs2505083: T/T, effect allele: C, beta: 1.06
- rs264: G/G, effect allele: G, beta: 1.06
- rs273909: A/A, effect allele: G, beta: 1.06
- rs2895811: T/C, effect allele: C, beta: 1.04
- rs2954029: A/A, effect allele: A, beta: 1.04
- rs3184504: C/C, effect allele: T, beta: 1.07
- rs3217992: T/C, effect allele: T, beta: 1.14
- rs3798220: T/T, effect allele: C, beta: 1.42
- rs3918226: T/C, effect allele: T, beta: 1.14
- rs4252120: T/C, effect allele: T, beta: 1.03
- rs445925: G/G, effect allele: G, beta: 1.09
- rs46522: T/C, effect allele: T, beta: 1.04
- rs4773144: A/A, effect allele: G, beta: 1.05
- rs4845625: C/C, effect allele: T, beta: 1.05
- rs4977574: A/A, effect allele: G, beta: 1.21
- rs501120: T/T, effect allele: T, beta: 1.08
- rs515135: C/C, effect allele: C, beta: 1.07
- rs56062135: C/C, effect allele: C, beta: 1.07
- rs579459: T/T, effect allele: C, beta: 1.08
- rs646776: T/T, effect allele: T, beta: 1.11
- rs6544713: T/C, effect allele: T, beta: 1.05
- rs663129: G/G, effect allele: A, beta: 1.06
- rs6725887: T/T, effect allele: C, beta: 1.14
- rs7136259: C/C, effect allele: T, beta: 1.04
- rs7173743: T/C, effect allele: T, beta: 1.08
- rs7212798: C/C, effect allele: C, beta: 1.08
- rs7692387: G/G, effect allele: G, beta: 1.07
- rs8042271: G/G, effect allele: G, beta: 1.1
- rs9319428: A/G, effect allele: A, beta: 1.04
- rs9515203: T/T, effect allele: T, beta: 1.07
- rs964184: C/C, effect allele: G, beta: 1.05
- rs974819: T/T, effect allele: T, beta: 1.07
- rs9818870: C/C, effect allele: T, beta: 1.07
- rs9982601: C/C, effect allele: T, beta: 1.12
Lung cancer
Description:
Lung cancer is the leading cause of cancer-related deaths worldwide in both men and women. Although it has long been recognized that lung cancer runs strongly in families, the specific genes that are responsible for enhanced risk are just starting to be revealed. Identifying genes responsible for lung cancer before the era of GWAS has been limited. Candidate susceptibility genes coding for enzymes involved in the activation, detoxification and repair of damages caused by tobacco smoke as well as genes in inflammatory and cell-cycle pathways have been extensively studied. Many of these candidate gene studies are either preliminary or controversial. GWAS have evolved from finding lung cancer loci per se, to a more refined search strategy focused on specific subgroups of lung cancer patients. Advances in analysis strategies were also achieved moving from single marker analyses to pathway-based and variant prioritization approaches. GWAS have also been performed to find genetic loci associated with lung cancer survival, response to conventional therapies, and multiple sites of cancer. GWAS by environmental exposures and genome-wide epistasis analyses are also emerging.
Standardized genetic risk score:
Mean + 0.78 * SD
Distribution:
N of reference population: 2504
N below this sample: 1980 (79.07%)
N above this sample: 524 (20.93%)
Average lifetime risk: 6.3%
Distribution plot:
Scientific detail:
- rs1056562: T/C, effect allele: T, beta: 1.11
- rs11571833: A/A, effect allele: T, beta: 1.6
- rs11591710: A/C, effect allele: C, beta: 1.16
- Snp (rs116822326) cannot be found in your genotype file!
- rs11780471: G/G, effect allele: A, beta: 0.87
- rs13080835: T/G, effect allele: T, beta: 0.9
- rs17879961: A/A, effect allele: G, beta: 0.41
- rs41309931: G/G, effect allele: T, beta: 1.17
- rs4236709: A/A, effect allele: G, beta: 1.13
- rs55781567: G/G, effect allele: G, beta: 1.3
- rs56113850: T/C, effect allele: T, beta: 0.88
- rs66759488: A/G, effect allele: A, beta: 1.07
- rs6920364: C/C, effect allele: C, beta: 1.07
- rs71658797: T/T, effect allele: A, beta: 1.13
- rs7705526: C/C, effect allele: A, beta: 1.25
- rs77468143: T/G, effect allele: G, beta: 0.86
- rs7953330: G/G, effect allele: C, beta: 0.86
- rs885518: A/A, effect allele: G, beta: 1.17
Migraine
Description:
Migraine affects up to one-fifth of the world population. It persistently ranks among the top 10 causes of disability, and accounts for more than half of the years lived with disability from neurological causes. As such, migraine has a tremendous socioeconomic impact, not to mention lost productivity and human suffering. Despite decades of research, the complex pathophysiology of migraine is still poorly understood. Without understanding the molecular mechanisms, existing therapies are empirical, serendipitous, and of limited efficacy. It has long been recognised that migraine is a disease with a strong genetic component. Migraine runs in families, and epidemiological studies in twins and families have indicated that risk for migraine is conferred by a combination of genetic and environmental factors, both contributing equally. These studies also indicated that the genetic contribution seems stronger in migraine with aura than the more common migraine without aura subtype.
Standardized genetic risk score:
Mean - 2.28 * SD
Distribution:
N of reference population: 2504
N below this sample: 25 (1.0%)
N above this sample: 2479 (99.0%)
Distribution plot:
Scientific detail:
- rs10155855: A/A, effect allele: T, beta: 1.08
- rs10166942: C/C, effect allele: C, beta: 0.94
- rs10218452: A/A, effect allele: G, beta: 1.11
- rs1024905: G/G, effect allele: G, beta: 1.06
- rs10456100: C/C, effect allele: T, beta: 1.06
- rs10786156: G/G, effect allele: G, beta: 0.95
- rs10895275: T/T, effect allele: A, beta: 1.04
- rs11031122: T/T, effect allele: C, beta: 1.04
- Snp (rs111404218) cannot be found in your genotype file!
- rs11172113: T/C, effect allele: C, beta: 0.9
- rs11624776: A/A, effect allele: C, beta: 0.96
- rs12260159: A/A, effect allele: A, beta: 0.92
- rs1268083: T/C, effect allele: C, beta: 0.96
- rs12845494: G/G, effect allele: G, beta: 0.96
- rs13078967: A/A, effect allele: C, beta: 0.87
- rs138556413: C/C, effect allele: T, beta: 0.88
- Snp (rs140002913) cannot be found in your genotype file!
- rs144017103: C/C, effect allele: T, beta: 0.85
- rs1572668: A/G, effect allele: G, beta: 1.04
- rs17857135: T/C, effect allele: C, beta: 1.06
- rs186166891: A/A, effect allele: T, beta: 1.09
- rs1925950: A/G, effect allele: G, beta: 1.07
- rs2078371: T/T, effect allele: C, beta: 1.11
- rs2223089: G/C, effect allele: C, beta: 0.93
- rs2506142: A/G, effect allele: G, beta: 1.06
- rs28455731: G/G, effect allele: T, beta: 1.06
- rs4081947: A/A, effect allele: G, beta: 1.03
- rs4814864: G/G, effect allele: C, beta: 1.07
- rs4910165: G/G, effect allele: C, beta: 0.94
- rs561561: A/A, effect allele: T, beta: 0.94
- rs6478241: A/G, effect allele: A, beta: 1.05
- rs6693567: T/T, effect allele: C, beta: 1.05
- Snp (rs67338227) cannot be found in your genotype file!
- rs6791480: T/C, effect allele: T, beta: 1.04
- rs75213074: C/C, effect allele: T, beta: 0.89
- rs7684253: T/C, effect allele: C, beta: 0.96
- Snp (rs77505915) cannot be found in your genotype file!
- rs9349379: A/A, effect allele: G, beta: 0.93
- rs10514168: C/C, effect allele: C, beta: 1.05
- rs10752212: A/G, effect allele: G, beta: 1.03
- rs10970305: C/C, effect allele: C, beta: 1.06
- rs11129078: G/G, effect allele: G, beta: 1.06
- rs11713169: A/A, effect allele: C, beta: 1.05
- rs1195218: G/G, effect allele: G, beta: 1.1
- rs1378552: T/T, effect allele: T, beta: 1.03
- rs149951341: A/A, effect allele: C, beta: 1.05
- rs17515225: T/T, effect allele: T, beta: 1.03
- rs1782032: G/G, effect allele: G, beta: 1.03
- rs1847202: T/C, effect allele: T, beta: 1.03
- rs1858111: A/A, effect allele: G, beta: 1.04
- rs2150864: A/A, effect allele: G, beta: 1.04
- rs2153535: C/C, effect allele: G, beta: 1.05
- rs2318131: A/C, effect allele: C, beta: 1.04
- rs2360806: A/C, effect allele: C, beta: 1.05
- rs2551802: G/G, effect allele: G, beta: 1.04
- rs34311235: C/C, effect allele: T, beta: 1.03
- rs34912216: A/A, effect allele: G, beta: 1.04
- rs4076764: T/T, effect allele: T, beta: 1.03
- rs4343996: A/A, effect allele: G, beta: 1.03
- rs56051278: A/A, effect allele: G, beta: 1.07
- rs60464047: T/T, effect allele: T, beta: 1.04
- rs6069325: T/T, effect allele: T, beta: 1.07
- rs61759167: C/C, effect allele: T, beta: 1.05
- rs62018380: C/C, effect allele: C, beta: 1.05
- rs66800491: A/G, effect allele: G, beta: 1.08
- rs6833641: G/G, effect allele: G, beta: 1.05
- rs6946969: A/A, effect allele: G, beta: 1.03
- rs705145: A/C, effect allele: C, beta: 1.05
- rs7170668: C/C, effect allele: T, beta: 1.04
- rs7957589: A/A, effect allele: T, beta: 1.05
- rs9834560: A/A, effect allele: C, beta: 1.04
- rs9906289: C/C, effect allele: T, beta: 1.09
- rs997295: T/G, effect allele: T, beta: 1.03
Schizophrenia
Description:
Schizophrenia is a common and serious psychiatric illness affecting 0.5–1% of the population in early adulthood. The disease remains incurable, with the best outcome being the control of symptoms and preservation of sufficient functionality and independence. Schizophrenia is a disease with remarkable phenotypic heterogeneity. The symptoms are generally divided into three categories: positive symptoms, negative symptoms, and cognitive symptoms. Each patient can have a different mix of the three types of symptoms leading to an overall highly heterogeneous phenotype. Affective symptoms may combine with the classic symptoms of schizophrenia leading to schizoaffective disorder, which some genetic researchers categorize with schizophrenia and others with bipolar disorder (BD). It has long been recognized that schizophrenia runs in families, noted in the first detailed description of the disease by Bleuler in 1911. Formally, the heritability of the disease has been calculated at > 80%, making genetic makeup the most important factor for developing the disease.
Standardized genetic risk score:
Mean + 0.72 * SD
Distribution:
N of reference population: 2504
N below this sample: 1907 (76.16%)
N above this sample: 597 (23.84%)
Average lifetime risk: 15.2/100,000 persons
Distribution plot:
Scientific detail:
- Snp (chr1_243881945_I) cannot be found in your genotype file!
- Snp (chr1_8424984_D) cannot be found in your genotype file!
- Snp (chr10_104957618_I) cannot be found in your genotype file!
- Snp (chr11_46350213_D) cannot be found in your genotype file!
- Snp (chr18_52749216_D) cannot be found in your genotype file!
- Snp (chr2_146436222_I) cannot be found in your genotype file!
- Snp (chr2_149429178_D) cannot be found in your genotype file!
- Snp (chr2_200825237_I) cannot be found in your genotype file!
- Snp (chr22_39987017_D) cannot be found in your genotype file!
- Snp (chr3_180594593_I) cannot be found in your genotype file!
- Snp (chr5_140143664_I) cannot be found in your genotype file!
- Snp (chr6_84280274_D) cannot be found in your genotype file!
- Snp (chr7_2025096_I) cannot be found in your genotype file!
- Snp (chr7_24747494_D) cannot be found in your genotype file!
- rs10043984: C/C, effect allele: T, beta: 1.069
- rs1023500: T/C, effect allele: T, beta: 1.076
- rs10503253: A/C, effect allele: A, beta: 1.073
- rs10520163: T/T, effect allele: T, beta: 1.065
- rs10791097: T/G, effect allele: T, beta: 1.076
- rs10803138: A/G, effect allele: A, beta: 0.933
- rs10860964: T/T, effect allele: T, beta: 1.06
- rs11027857: G/G, effect allele: A, beta: 1.064
- rs1106568: A/A, effect allele: A, beta: 0.934
- rs111294930: A/A, effect allele: A, beta: 1.094
- rs11139497: T/A, effect allele: A, beta: 1.069
- rs11191419: T/T, effect allele: A, beta: 0.906
- rs11210892: G/G, effect allele: A, beta: 0.934
- Snp (rs115329265) cannot be found in your genotype file!
- rs11682175: T/T, effect allele: T, beta: 0.933
- rs11685299: C/C, effect allele: A, beta: 0.939
- rs11693094: C/C, effect allele: T, beta: 0.929
- rs117074560: C/C, effect allele: T, beta: 0.849
- rs11740474: A/A, effect allele: A, beta: 0.942
- rs12129573: C/C, effect allele: A, beta: 1.078
- rs12148337: T/T, effect allele: T, beta: 1.06
- rs12325245: A/A, effect allele: A, beta: 0.92
- rs12421382: C/C, effect allele: T, beta: 0.941
- rs12522290: C/C, effect allele: C, beta: 1.084
- rs12691307: G/G, effect allele: A, beta: 1.073
- rs12704290: G/G, effect allele: A, beta: 0.904
- rs12826178: G/G, effect allele: T, beta: 0.846
- rs12845396: A/A, effect allele: A, beta: 0.947
- rs12887734: T/G, effect allele: T, beta: 1.088
- rs12903146: G/G, effect allele: A, beta: 1.067
- rs13240464: T/T, effect allele: T, beta: 1.083
- rs1339227: C/C, effect allele: T, beta: 0.942
- rs1378559: T/T, effect allele: T, beta: 1.09
- rs140505938: C/C, effect allele: T, beta: 0.914
- rs14403: C/C, effect allele: T, beta: 0.934
- rs1498232: T/T, effect allele: T, beta: 1.069
- rs1501357: T/C, effect allele: T, beta: 0.926
- rs16867576: A/A, effect allele: A, beta: 1.101
- rs1702294: C/C, effect allele: T, beta: 0.887
- rs17194490: G/G, effect allele: T, beta: 1.101
- Snp (rs190065944) cannot be found in your genotype file!
- rs2007044: G/G, effect allele: A, beta: 0.912
- rs2053079: A/A, effect allele: A, beta: 0.931
- rs2068012: T/T, effect allele: T, beta: 0.933
- rs211829: T/C, effect allele: T, beta: 1.061
- rs215411: T/A, effect allele: A, beta: 1.064
- rs2239063: A/A, effect allele: A, beta: 1.067
- rs2332700: G/G, effect allele: C, beta: 1.073
- rs2514218: C/C, effect allele: T, beta: 0.927
- rs2535627: C/C, effect allele: T, beta: 1.071
- rs2693698: A/G, effect allele: A, beta: 0.939
- rs2851447: G/C, effect allele: C, beta: 0.915
- rs2905426: G/G, effect allele: T, beta: 0.934
- rs2909457: A/A, effect allele: A, beta: 0.944
- rs2973155: C/C, effect allele: T, beta: 0.933
- rs324017: C/C, effect allele: A, beta: 0.938
- rs35518360: A/A, effect allele: A, beta: 0.857
- rs36068923: G/G, effect allele: A, beta: 0.919
- rs3735025: T/T, effect allele: T, beta: 1.066
- rs3768644: G/G, effect allele: A, beta: 0.904
- rs3849046: T/C, effect allele: T, beta: 1.063
- rs4129585: C/C, effect allele: A, beta: 1.087
- rs4240748: C/G, effect allele: C, beta: 0.943
- rs4330281: C/C, effect allele: T, beta: 0.94
- rs4388249: C/C, effect allele: T, beta: 1.076
- rs4391122: G/G, effect allele: A, beta: 0.922
- rs4523957: G/G, effect allele: T, beta: 1.071
- rs4648845: T/C, effect allele: T, beta: 1.072
- rs4702: A/G, effect allele: A, beta: 0.922
- rs4766428: C/C, effect allele: T, beta: 1.068
- rs55661361: A/G, effect allele: A, beta: 0.926
- rs55833108: G/G, effect allele: T, beta: 1.075
- rs56205728: G/G, effect allele: A, beta: 1.074
- rs56873913: T/G, effect allele: T, beta: 1.071
- rs5937157: G/G, effect allele: T, beta: 0.938
- rs59979824: A/C, effect allele: A, beta: 0.937
- rs6002655: C/C, effect allele: T, beta: 1.066
- rs6065094: G/G, effect allele: A, beta: 0.928
- rs6434928: A/G, effect allele: A, beta: 0.929
- rs6466055: A/A, effect allele: A, beta: 1.068
- rs6670165: C/C, effect allele: T, beta: 1.075
- rs6704641: A/G, effect allele: A, beta: 1.081
- rs6704768: A/G, effect allele: A, beta: 0.93
- rs679087: C/C, effect allele: A, beta: 0.941
- rs6984242: A/A, effect allele: A, beta: 0.941
- rs715170: C/C, effect allele: T, beta: 0.935
- rs7267348: T/T, effect allele: T, beta: 0.937
- rs72934570: C/C, effect allele: T, beta: 0.873
- rs73229090: C/C, effect allele: A, beta: 0.908
- rs7405404: C/C, effect allele: T, beta: 1.077
- rs7432375: G/G, effect allele: A, beta: 0.933
- rs75059851: A/A, effect allele: A, beta: 1.091
- rs7523273: A/A, effect allele: A, beta: 1.063
- rs75575209: A/A, effect allele: A, beta: 0.902
- rs75968099: C/C, effect allele: T, beta: 1.085
- rs76869799: C/C, effect allele: C, beta: 0.846
- rs77149735: G/G, effect allele: A, beta: 1.317
- rs77502336: G/G, effect allele: C, beta: 1.066
- rs7801375: A/G, effect allele: A, beta: 0.924
- rs7819570: G/G, effect allele: T, beta: 1.079
- rs78322266: G/G, effect allele: T, beta: 1.188
- rs7893279: T/T, effect allele: T, beta: 1.125
- Snp (rs7907645) cannot be found in your genotype file!
- rs79212538: G/G, effect allele: T, beta: 1.155
- rs8042374: A/A, effect allele: A, beta: 1.093
- rs8044995: G/G, effect allele: A, beta: 1.081
- rs8082590: A/G, effect allele: A, beta: 0.939
- rs832187: T/C, effect allele: T, beta: 0.941
- rs9420: A/G, effect allele: A, beta: 1.068
- rs950169: C/C, effect allele: T, beta: 0.923
- rs9607782: T/T, effect allele: A, beta: 1.087
- rs9636107: A/A, effect allele: A, beta: 0.93
- rs9841616: T/A, effect allele: A, beta: 0.925
- rs9922678: A/G, effect allele: A, beta: 1.067
4th Q
This section uses PharmGKB and ClinVAR as an example, to illustrate how PAGEMENT could query third party genotype-based databases. Right now, only VCF file format is supported. By default, the first five INFO fields are displayed in the output table, unless specified otherwise by the user.
Clinvar
Page:
| Variant | Allele | Allele type | Genotype | Clinvar ID |
|---|---|---|---|---|
| rs10246939 | C | Drug response | TC | 2906 |
| rs1041983 | T | Drug response | TT | 375653 |
| rs1042713 | A | Drug response | AA | 225937 |
| rs16881446 | C | Risk factor | CC | 441163 |
| rs16969968 | A | Drug response | AG | 17497 |
| rs1799978 | C | Drug response | TC | 225963 |
| rs1801131 | G | Conflicting interpretations of pathogenicity | TG | 3521 |
| rs2214102 | C | Drug response | CC | 829326 |
| rs3212986 | A | Drug response | AC | 225987 |
| rs339097 | G | Drug response | AG | 225988 |
| rs405509 | G | Drug response | GG | 619951 |
| rs6025 | C | Drug response | CC | 226007 |
| rs716274 | G | Drug response | AG | 226013 |
| rs9332131 | G | Drug response | GAGA | 285601 |
| rs10066882 | A | Conflicting interpretations of pathogenicity | CC | 414373 |
| rs10509305 | C | Conflicting interpretations of pathogenicity | AA | 1720 |
| rs10509681 | C | Drug response | TT | 375654 |
| rs1051740 | C | Drug response | TT | 16604 |
| rs10979599 | T | Conflicting interpretations of pathogenicity | GG | 245634 |
| rs11078699 | T | Conflicting interpretations of pathogenicity | CC | 387361 |
| rs11104729 | C | Conflicting interpretations of pathogenicity | TT | 261849 |
| rs11466016 | A | Conflicting interpretations of pathogenicity | CC | 36516 |
| rs11541998 | T | Conflicting interpretations of pathogenicity | CC | 732303 |
| rs11549709 | A | Conflicting interpretations of pathogenicity | GG | 136294 |
| rs11568360 | A | Conflicting interpretations of pathogenicity | GG | 284547 |
| rs11569534 | T | Conflicting interpretations of pathogenicity | CC | 330292 |
| rs11569541 | G | Conflicting interpretations of pathogenicity | AA | 636934 |
| rs11570255 | A | Conflicting interpretations of pathogenicity | GG | 16646 |
| rs11571640 | C | Conflicting interpretations of pathogenicity | AA | 38258 |
| rs11575936 | T | Conflicting interpretations of pathogenicity | CC | 723758 |
| rs11807956 | A | Conflicting interpretations of pathogenicity | GG | 256741 |
| rs11840224 | A | Conflicting interpretations of pathogenicity | GG | 35723 |
| rs11893228 | T | Conflicting interpretations of pathogenicity | CC | 178627 |
| rs11971167 | A | Drug response | GG | 7164 |
| rs12161733 | A | Conflicting interpretations of pathogenicity | GG | 536220 |
| rs12324002 | G | Conflicting interpretations of pathogenicity | AA | 36133 |
| rs12562058 | A | Conflicting interpretations of pathogenicity | CC | 710715 |
| rs12713843 | T | Conflicting interpretations of pathogenicity | CC | 281142 |
| rs12720763 | A | Conflicting interpretations of pathogenicity | CC | 334059 |
| rs13098532 | G | Conflicting interpretations of pathogenicity | TT | 343746 |
| rs13171868 | C | Conflicting interpretations of pathogenicity | TT | 163597 |
| rs13306187 | T | Conflicting interpretations of pathogenicity | CC | 334146 |
| rs13306505 | T | Conflicting interpretations of pathogenicity | CC | 374957 |
| rs13306523 | T | Conflicting interpretations of pathogenicity | CC | 297984 |
| rs16024 | T | Conflicting interpretations of pathogenicity | CC | 194928 |
| rs16904791 | A | Conflicting interpretations of pathogenicity | CC | 709941 |
| rs16937932 | T | Conflicting interpretations of pathogenicity | CC | 178767 |
| rs16955859 | G | Conflicting interpretations of pathogenicity | AA | 707596 |
| rs16978578 | C | Conflicting interpretations of pathogenicity | TT | 226712 |
| rs17006082 | G | Conflicting interpretations of pathogenicity | TT | 462965 |
| rs17027133 | C | Conflicting interpretations of pathogenicity | TT | 540408 |
| rs17028450 | T | Conflicting interpretations of pathogenicity | CC | 12707 |
| rs17071686 | A | Conflicting interpretations of pathogenicity | CC | 774331 |
| rs17089782 | A | Conflicting interpretations of pathogenicity | GG | 217689 |
| rs17102066 | T | Conflicting interpretations of pathogenicity | CC | 281057 |
| rs17107315 | C | Conflicting interpretations of pathogenicity | TT | 13760 |
| rs17158558 | T | Conflicting interpretations of pathogenicity | CC | 13938 |
| rs17222674 | G | Conflicting interpretations of pathogenicity | AA | 499389 |
| rs17235409 | A | Risk factor | GG | 9233 |
| rs17354992 | T | Conflicting interpretations of pathogenicity | CC | 46987 |
| rs17500494 | G | Conflicting interpretations of pathogenicity | TT | 359958 |
| rs17514281 | G | Conflicting interpretations of pathogenicity | AA | 294581 |
| rs1762111 | G | Conflicting interpretations of pathogenicity | AA | 99311 |
| rs17860530 | A | Conflicting interpretations of pathogenicity | GG | 196346 |
| rs17878854 | A | Conflicting interpretations of pathogenicity | GG | 366730 |
| rs17879685 | T | Drug response | CC | 633846 |
| rs17879961 | G | Conflicting interpretations of pathogenicity | AA | 5591 |
| rs17883718 | A | Conflicting interpretations of pathogenicity | GG | 618661 |
| rs17885240 | T | Conflicting interpretations of pathogenicity | CC | 134361 |
| rs1799802 | T | Conflicting interpretations of pathogenicity | CC | 134148 |
| rs1800056 | C | Conflicting interpretations of pathogenicity | TT | 132736 |
| rs1800059 | C | Conflicting interpretations of pathogenicity | AA | 127399 |
| rs1800120 | T | Conflicting interpretations of pathogenicity | GG | 256253 |
| rs1800556 | T | Conflicting interpretations of pathogenicity | CC | 3830 |
| rs1800562 | A | Conflicting interpretations of pathogenicity | GG | 9 |
| rs1800629 | A | Drug response | GG | 225964 |
| rs1800888 | T | Drug response | CC | 17744 |
| rs1801133 | A | Drug response | GG | 3520 |
| rs1801278 | T | Risk factor | CC | 29761 |
| rs1801394 | G | Drug response | AA | 7029 |
| rs1801700 | A | Conflicting interpretations of pathogenicity | GG | 255981 |
| rs1805007 | T | Conflicting interpretations of pathogenicity | CC | 14312 |
| rs1805008 | T | Conflicting interpretations of pathogenicity | CC | 14310 |
| rs1805322 | T | Conflicting interpretations of pathogenicity | GG | 135946 |
| rs2070074 | G | Conflicting interpretations of pathogenicity | AA | 3613 |
| rs2219594 | A | Conflicting interpretations of pathogenicity | CC | 51695 |
| rs2227434 | T | Conflicting interpretations of pathogenicity | CC | 696149 |
| rs2228001 | T | Drug response | GG | 190215 |
| rs2228241 | A | Conflicting interpretations of pathogenicity | GG | 42334 |
| rs2229152 | T | Conflicting interpretations of pathogenicity | CC | 712435 |
| rs2229843 | T | Conflicting interpretations of pathogenicity | GG | 12690 |
| rs2230234 | T | Conflicting interpretations of pathogenicity | AA | 36014 |
| rs2230516 | T | Conflicting interpretations of pathogenicity | CC | 194960 |
| rs2232078 | T | Conflicting interpretations of pathogenicity | CC | 339211 |
| rs2233218 | A | Conflicting interpretations of pathogenicity | GG | 218640 |
| rs2233328 | G | Conflicting interpretations of pathogenicity | TT | 188374 |
| rs2235019 | A | Drug response | CC | 828595 |
| rs2235075 | G | Drug response | AA | 828561 |
| rs2271305 | C | Conflicting interpretations of pathogenicity | TT | 197782 |
| rs2272707 | A | Conflicting interpretations of pathogenicity | GG | 737320 |
| rs2275601 | C | Conflicting interpretations of pathogenicity | TT | 715943 |
| rs2276263 | A | Conflicting interpretations of pathogenicity | GG | 374733 |
| rs2276278 | T | Conflicting interpretations of pathogenicity | GG | 517205 |
| rs2287617 | T | Conflicting interpretations of pathogenicity | CC | 594929 |
| rs2288326 | T | Conflicting interpretations of pathogenicity | GG | 47548 |
| rs2295947 | A | Conflicting interpretations of pathogenicity | GG | 165063 |
| rs2296928 | G | Conflicting interpretations of pathogenicity | TT | 692098 |
| rs2303603 | A | Conflicting interpretations of pathogenicity | GG | 290657 |
| rs2303834 | G | Conflicting interpretations of pathogenicity | AA | 47086 |
| rs2307440 | A | Conflicting interpretations of pathogenicity | GG | 21313 |
| rs2491080 | A | Conflicting interpretations of pathogenicity | GG | 626489 |
| rs268 | G | Conflicting interpretations of pathogenicity | AA | 1550 |
| rs28363595 | T | Conflicting interpretations of pathogenicity | CC | 713884 |
| rs28364364 | A | Conflicting interpretations of pathogenicity | GG | 92419 |
| rs28364528 | A | Conflicting interpretations of pathogenicity | GG | 468645 |
| rs28364537 | T | Conflicting interpretations of pathogenicity | CC | 254868 |
| rs28369776 | A | Conflicting interpretations of pathogenicity | GG | 377876 |
| rs28377085 | G | Conflicting interpretations of pathogenicity | AA | 236819 |
| rs28383481 | A | Conflicting interpretations of pathogenicity | GG | 38794 |
| rs28399504 | G | Drug response | AA | 16900 |
| rs28562785 | T | Conflicting interpretations of pathogenicity | CC | 159460 |
| rs288326 | A | Risk factor | GG | 5221 |
| rs2884737 | C | Drug response | AA | 225983 |
| rs28897680 | G | Conflicting interpretations of pathogenicity | TT | 37443 |
| rs28903085 | C | Conflicting interpretations of pathogenicity | AA | 128012 |
| rs28903091 | A | Conflicting interpretations of pathogenicity | GG | 37380 |
| rs28909989 | A | Conflicting interpretations of pathogenicity | GG | 331219 |
| rs28910612 | A | Conflicting interpretations of pathogenicity | GG | 786476 |
| rs28990974 | C | Conflicting interpretations of pathogenicity | TT | 302744 |
| rs28990975 | C | Conflicting interpretations of pathogenicity | AA | 302740 |
| rs28991292 | A | Conflicting interpretations of pathogenicity | GG | 256612 |
| rs29000285 | T | Conflicting interpretations of pathogenicity | CC | 361175 |
| rs2915960 | T | Conflicting interpretations of pathogenicity | CC | 329088 |
| rs3087376 | T | Conflicting interpretations of pathogenicity | CC | 317310 |
| rs3087378 | A | Conflicting interpretations of pathogenicity | GG | 317337 |
| rs3092859 | C | Conflicting interpretations of pathogenicity | TT | 135748 |
| rs3212989 | G | Conflicting interpretations of pathogenicity | AA | 235480 |
| rs3213408 | T | Conflicting interpretations of pathogenicity | CC | 464097 |
| rs3218690 | C | Conflicting interpretations of pathogenicity | TT | 132757 |
| rs3219488 | A | Conflicting interpretations of pathogenicity | GG | 132703 |
| rs34044544 | A | Conflicting interpretations of pathogenicity | GG | 352970 |
| rs34360255 | A | Conflicting interpretations of pathogenicity | GG | 763904 |
| rs34391943 | T | Conflicting interpretations of pathogenicity | CC | 167378 |
| rs34723289 | G | Conflicting interpretations of pathogenicity | AA | 198818 |
| rs34819316 | A | Conflicting interpretations of pathogenicity | GG | 445491 |
| rs34832477 | A | Conflicting interpretations of pathogenicity | GG | 691859 |
| rs35152987 | A | Conflicting interpretations of pathogenicity | CC | 15070 |
| rs35313315 | A | Conflicting interpretations of pathogenicity | TT | 129596 |
| rs35350960 | A | Conflicting interpretations of pathogenicity | CC | 12274 |
| rs35554630 | A | Conflicting interpretations of pathogenicity | GG | 196576 |
| rs35625882 | T | Conflicting interpretations of pathogenicity | CC | 739302 |
| rs35691292 | A | Conflicting interpretations of pathogenicity | GG | 13135 |
| rs35759430 | A | Conflicting interpretations of pathogenicity | GG | 283585 |
| rs36022183 | T | Conflicting interpretations of pathogenicity | CC | 94111 |
| rs363824 | G | Conflicting interpretations of pathogenicity | TT | 42408 |
| rs3729732 | A | Conflicting interpretations of pathogenicity | GG | 631966 |
| rs3729841 | T | Conflicting interpretations of pathogenicity | CC | 43391 |
| rs3735971 | A | Conflicting interpretations of pathogenicity | GG | 363868 |
| rs3736497 | C | Conflicting interpretations of pathogenicity | AA | 437080 |
| rs3737274 | A | Conflicting interpretations of pathogenicity | GG | 299646 |
| rs3737311 | A | Conflicting interpretations of pathogenicity | GG | 285240 |
| rs3738497 | T | Conflicting interpretations of pathogenicity | GG | 468979 |
| rs3738888 | A | Conflicting interpretations of pathogenicity | GG | 136500 |
| rs3739274 | T | Conflicting interpretations of pathogenicity | CC | 361923 |
| rs3740654 | A | Conflicting interpretations of pathogenicity | GG | 514270 |
| rs3741050 | C | Conflicting interpretations of pathogenicity | GG | 769322 |
| rs3741447 | A | Conflicting interpretations of pathogenicity | GG | 434780 |
| rs3743808 | G | Conflicting interpretations of pathogenicity | AA | 632946 |
| rs3744824 | T | Conflicting interpretations of pathogenicity | CC | 159870 |
| rs3747835 | T | Conflicting interpretations of pathogenicity | CC | 100583 |
| rs3751369 | C | Conflicting interpretations of pathogenicity | TT | 311551 |
| rs3761169 | A | Conflicting interpretations of pathogenicity | GG | 288545 |
| rs3764873 | A | Conflicting interpretations of pathogenicity | CC | 310137 |
| rs3766317 | A | Conflicting interpretations of pathogenicity | GG | 21357 |
| rs3782356 | T | Conflicting interpretations of pathogenicity | CC | 134730 |
| rs3795339 | T | Conflicting interpretations of pathogenicity | CC | 129318 |
| rs3796241 | A | Conflicting interpretations of pathogenicity | TT | 730216 |
| rs3810796 | T | Conflicting interpretations of pathogenicity | CC | 378702 |
| rs3918290 | T | Drug response | CC | 432 |
| rs41428447 | A | Conflicting interpretations of pathogenicity | GG | 214786 |
| rs4148323 | A | Drug response | GG | 12280 |
| rs4148327 | C | Conflicting interpretations of pathogenicity | TT | 160241 |
| rs4148725 | T | Conflicting interpretations of pathogenicity | CC | 411121 |
| rs4149584 | T | Conflicting interpretations of pathogenicity | CC | 217017 |
| rs4150521 | A | Conflicting interpretations of pathogenicity | GG | 134120 |
| rs4151031 | A | Conflicting interpretations of pathogenicity | GG | 256188 |
| rs4253046 | G | Conflicting interpretations of pathogenicity | TT | 300083 |
| rs429358 | C | Conflicting interpretations of pathogenicity | TT | 17864 |
| rs4680 | A | Drug response | GG | 17591 |
| rs4961 | T | Drug response | GG | 18274 |
| rs4977574 | G | Risk factor | AA | 812644 |
| rs4986761 | C | Conflicting interpretations of pathogenicity | TT | 128454 |
| rs4987050 | G | Conflicting interpretations of pathogenicity | AA | 136580 |
| rs4988460 | A | Conflicting interpretations of pathogenicity | GG | 597988 |
| rs5029941 | T | Conflicting interpretations of pathogenicity | CC | 135332 |
| rs5122 | A | Conflicting interpretations of pathogenicity | GG | 2582 |
| rs5174 | T | Risk factor | CC | 6996 |
| rs5346 | A | Conflicting interpretations of pathogenicity | GG | 226623 |
| rs5350 | A | Conflicting interpretations of pathogenicity | GG | 255141 |
| rs5352 | T | Conflicting interpretations of pathogenicity | CC | 16638 |
| rs5452 | A | Conflicting interpretations of pathogenicity | GG | 329805 |
| rs5744739 | A | Conflicting interpretations of pathogenicity | GG | 240452 |
| rs5744948 | G | Conflicting interpretations of pathogenicity | TT | 240537 |
| rs5964007 | G | Conflicting interpretations of pathogenicity | AA | 287834 |
| rs5969 | G | Conflicting interpretations of pathogenicity | AA | 627369 |
| rs6035 | C | Conflicting interpretations of pathogenicity | TT | 255189 |
| rs6063 | T | Conflicting interpretations of pathogenicity | CC | 16378 |
| rs6068812 | G | Conflicting interpretations of pathogenicity | AA | 29680 |
| rs607969 | T | Conflicting interpretations of pathogenicity | CC | 41854 |
| rs6161 | T | Conflicting interpretations of pathogenicity | CC | 372354 |
| rs6170 | T | Conflicting interpretations of pathogenicity | GG | 304276 |
| rs6177 | A | Conflicting interpretations of pathogenicity | GG | 281656 |
| rs6267 | T | Drug response | GG | 17592 |
| rs6413438 | T | Drug response | CC | 39353 |
| rs6413500 | T | Conflicting interpretations of pathogenicity | CC | 626118 |
| rs6672843 | A | Conflicting interpretations of pathogenicity | GG | 260015 |
| rs6755258 | A | Conflicting interpretations of pathogenicity | GG | 528460 |
| rs7190978 | T | Conflicting interpretations of pathogenicity | GG | 320070 |
| rs7196804 | T | Conflicting interpretations of pathogenicity | CC | 201068 |
| rs7244681 | C | Conflicting interpretations of pathogenicity | GG | 196054 |
| rs7262506 | C | Conflicting interpretations of pathogenicity | AA | 338234 |
| rs730254 | T | Conflicting interpretations of pathogenicity | CC | 48422 |
| rs7334118 | C | Conflicting interpretations of pathogenicity | TT | 35724 |
| rs7412 | T | Drug response | CC | 17848 |
| rs8099917 | G | Drug response | TT | 226027 |
| rs8187798 | G | Conflicting interpretations of pathogenicity | AA | 256159 |
| rs8187808 | G | Conflicting interpretations of pathogenicity | AA | 498331 |
| rs8190976 | T | Conflicting interpretations of pathogenicity | CC | 810272 |
| rs8191498 | C | Conflicting interpretations of pathogenicity | TT | 321155 |
| rs8191996 | C | Conflicting interpretations of pathogenicity | TT | 736719 |
| rs9282564 | C | Drug response | TT | 829327 |
| rs9332604 | C | Conflicting interpretations of pathogenicity | TT | 293616 |
Page:
PharmGKB
Variants which affect phenotypes:
Page:
| Variant | Alleles | Associations | Genotype | PMID |
|---|---|---|---|---|
| rs10030044 | G | Allele G is associated with increased risk of occurence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele T. | GG | 23764426 |
| rs10248420 | G | Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A. | AG | 18215618 |
| rs1041983 | T | Allele T is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis. | TT | 18421452 |
| rs1041983 | TT | Genotype TT is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype CC. | TT | 22506592 |
| rs1041983 | T | Allele T is associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele C. | TT | 29036176 |
| rs1041983 | T | Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain or Tuberculous meningitis NOS as compared to allele C. | TT | 27488001 |
| rs1042713 | AA | Genotype AA is associated with increased risk of asthma exacerbations when exposed to salmeterol in children with Asthma as compared to genotype GG. | AA | 16772309 |
| rs1042713 | AA | Genotype AA is associated with increased risk of asthma exacerbations when exposed to salbutamol or salmeterol in children with Asthma as compared to genotype GG. | AA | 19800676 |
| rs1042713 | AA | Genotype AA is associated with increased risk of uncontrolled asthma when treated with corticosteroids in children with Asthma as compared to genotype GG. | AA | 24279851 |
| rs1042713 | AA | Genotype AA is associated with increased risk of exacerbations when treated with corticosteroids and salmeterol in children with Asthma as compared to genotype GG. | AA | 24279851 |
| rs1045644 | CG + GG | Genotypes CG + GG are associated with decreased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 30506673 |
| rs1049353 | C | Allele C is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T. | CC | 23799528 |
| rs1051740 | T | Allele T is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele C. | TT | 19952982 |
| rs10841661 | T | Allele T is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C. | TT | 19696792 |
| rs10875989 | T | Allele T is associated with increased severity of Anemia, Leukopenia, Neutropenia and Thrombocytopenia when treated with platinum in people with Lung Neoplasms as compared to allele C. | TC | 26358256 |
| rs10876844 | A | Allele A is associated with increased likelihood of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele C. | AA | 22310351 |
| rs1138272 | CT + TT | Genotypes CT + TT is associated with decreased event-free survival and overall survival when treated with cisplatin in people with Osteosarcoma as compared to genotype CC. | CC | 25592234 |
| rs1143634 | AA | Genotype AA is associated with decreased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG. | GG | 25560300 |
| rs11549467 | AG | Genotype AG is associated with decreased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotype GG. | GG | 21576632 |
| rs11549467 | AG | Genotype AG is associated with decreased progression-free survival as compared to genotype GG. | GG | 26641474 |
| rs11563250 | AG + GG | Genotypes AG + GG is associated with decreased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA. | AA | 25778466 |
| rs11587213 | AG + GG | Genotypes AG + GG are associated with increased likelihood of atopy in patients with aspirin-intolerant chronic urticaria as compared to genotype AA. | AG | 18534082 |
| rs11739136 | CT + TT | Genotypes CT + TT are associated with decreased risk of Hypertension as compared to genotype CC. | CC | 18496125 |
| rs11739136 | CT + TT | Genotypes CT + TT are associated with decreased blood pressure in men as compared to genotype CC. | CC | 18854753 |
| rs12036333 | AA + AG | Genotypes AA + AG is associated with decreased event-free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG. | GG | 28570300 |
| rs1229984 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CC | 32451486 |
| rs1229984 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CC | 15902904 |
| rs1229984 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CC | 31090166 |
| rs12721655 | AG | Genotype AG is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype AA. | AA | 20179710 |
| rs12762549 | G | Allele G is associated with increased risk of Leukopenia when treated with docetaxel. | CG | 18294295 |
| rs13181 | G | Allele G is associated with decreased event free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype TT. | TT | 19434073 |
| rs13181 | GG | Genotype GG is associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT. | TT | 22026922 |
| rs13181 | TT | Genotype TT is associated with increased risk of Neutropenia when treated with docetaxel in women with Breast Neoplasms as compared to genotypes GG + GT. | TT | 25495407 |
| rs13181 | GG + GT | Genotypes GG + GT is associated with decreased overall survival and progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT. | TT | 27636246 |
| rs13181 | GG | Genotype GG is associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT. | TT | 22026922 |
| rs1409314 | A | Allele A is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease or Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | AG | 25732572 |
| rs1611115 | T | Allele T is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele C. | CC | 25096645 |
| rs16969968 | A | Allele A is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 19706762 |
| rs16969968 | A | Allele A is associated with increased risk of Tobacco Use Disorder. | AG | 18618000 |
| rs16969968 | A | Allele A is associated with increased likelihood of Schizophrenia. | AG | 21418140 |
| rs16969968 | A | Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 20886544 |
| rs16969968 | A | Allele A is associated with increased severity of smoking when exposed to nicotine in people with smoking as compared to allele G. | AG | 21418140 |
| rs16969968 | G | Allele G is not associated with increased Tobacco Use Disorder when treated with Opium alkaloids and derivatives in people with Pain as compared to allele A. | AG | 20725741 |
| rs16969968 | A | Allele A is associated with increased severity of smoking when exposed to nicotine in people with Schizophrenia who are smokers as compared to allele G. | AG | 21418140 |
| rs16969968 | A | Allele A is associated with increased severity of Substance-Related Disorders due to Opium alkaloids and derivatives in people with Pain as compared to allele G. | AG | 20725741 |
| rs16969968 | A | Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G. | AG | 19132693 |
| rs16969968 | A | Allele A is associated with increased likelihood of Tobacco Use Disorder as compared to allele G. | AG | 27355804 |
| rs16969968 | A | Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 30453884 |
| rs16969968 | A | Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 29196725 |
| rs16969968 | G | Allele G is associated with increased likelihood of Alcoholism due to ethanol as compared to allele A. | AG | 19132693 |
| rs17024608 | A | Allele A is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G. | AA | 22267851 |
| rs17128809 | AA | Genotype AA is associated with increased risk of adverse events when treated with ritodrine as compared to genotypes AT + TT. | AA | 31324945 |
| rs17221417 | G | Allele G is associated with increased risk of Crohn Disease. | GG | 20362271 |
| rs17501011 | AA + AG | Genotypes AA + AG is associated with decreased overall survival when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotype GG. | GG | 31698983 |
| rs17501331 | AG + GG | Genotypes AG + GG are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA. | AA | 27845419 |
| rs17574269 | AG | Genotype AG is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype AA. | AA | 23478653 |
| rs17587029 | G | Allele G is associated with decreased likelihood of Amenorrhea when treated with docetaxel, FEC100, gemcitabine, trastuzumab and zoledronate in women with Breast Neoplasms as compared to allele A. | AA | 31371054 |
| rs17655652 | CC | Genotype CC is associated with decreased reduction in LDL-C when treated with pravastatin in women as compared to genotypes CT + TT. | TT | 19752398 |
| rs17661089 | AG + GG | Genotypes AG + GG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. | AA | 21636554 |
| rs1799722 | T | Allele T is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C. | TC | 10904024 |
| rs1799836 | CC | Genotype CC is associated with increased risk of Tobacco Use Disorder in women as compared to genotypes CT + TT. | CC | 28858992 |
| rs1799978 | C | Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T. | TC | 19339912 |
| rs1800629 | GG | Genotype GG is associated with increased bone marrow density in the lumbar spine when treated with atorvastatin in people with Acute coronary syndrome. | GG | 18997459 |
| rs1800629 | GG | Genotype GG is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotype AG. | GG | 22736425 |
| rs1800872 | TT | Genotype TT is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes GG + GT. | TT | 18444945 |
| rs1801123 | C | Allele C is associated with lymph node involvement when treated with in women with Breast Neoplasms as compared to allele T. | TC | 23459444 |
| rs1801131 | GG | Genotype GG is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT. | TG | 23652803 |
| rs1801131 | G | Allele G is associated with increased progression free survival in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotype TT. | TG | 15385937 |
| rs1801131 | G | Allele G is associated with increased likelihood of clinical response when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT. | TG | 20863444 |
| rs1801131 | T | Allele T is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G. | TG | 16439441 |
| rs1801131 | GG + GT | Genotypes GG + GT are associated with decreased overall survival when treated with cisplatin and pemetrexed in people with Stomach Neoplasms as compared to genotype TT. | TG | 20634689 |
| rs1801131 | G | Allele G is associated with increased likelihood of neurotoxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T. | TG | 19858780 |
| rs1801131 | TT | Genotype TT is associated with decreased Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes GG + GT. | TG | 18245544 |
| rs1801131 | GG | Genotype GG is associated with decreased risk of Myelosuppression when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT. | TG | 17323057 |
| rs1801131 | G | Allele G is associated with increased risk of side effects when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T. | TG | 16572443 |
| rs1801131 | G | Allele G is associated with increased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT. | TG | 16920564 |
| rs1801131 | GG | Genotype GG is associated with decreased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype TT. | TG | 16501586 |
| rs1801131 | GG | Genotype GG is associated with decreased risk of relapse when treated with methotrexate in people with allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia. as compared to genotype TT. | TG | 15569990 |
| rs1801131 | GG | Genotype GG is associated with decreased event-free survival and overall survival when treated with capecitabine, fluorouracil or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT. | TG | 25331073 |
| rs1801131 | G | Allele G is associated with increased likelihood of elevated transaminases when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T. | TG | 20514079 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 16870553 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with decreased survival when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG. | GG | 23488607 |
| rs1801133 | AA | Genotype AA is associated with decreased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG. | GG | 16920564 |
| rs1801133 | G | Allele G is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to allele A. | GG | 24725652 |
| rs1801133 | GG | Genotype GG is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Osteosarcoma as compared to genotypes AA + AG. | GG | 25778468 |
| rs1801133 | GG | Genotype GG is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes AA + AG. | GG | 28745575 |
| rs1801133 | AA | Genotype AA is associated with decreased overall survival when treated with azacitidine in people with Myelodysplastic Syndromes as compared to genotypes AG + GG. | GG | 29205204 |
| rs1801133 | A | Allele A is associated with decreased likelihood of event-free survival when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG. | GG | 17488658 |
| rs1801133 | GG | Genotype GG is associated with increased progression free survival when treated with antineoplastic agents in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotypes AA + AG. | GG | 15385937 |
| rs1801133 | GG | Genotype GG is associated with increased event-free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG. | GG | 21747412 |
| rs1801133 | GG | Genotype GG is associated with increased event-free survival and overall survival when treated with fluorouracil in people with Rectal Neoplasms as compared to genotype AA. | GG | 25041994 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG. | GG | 24732178 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype GG. | GG | 18299612 |
| rs1801394 | AA | Genotype AA is associated with increased red blood cell folate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AA | 20386493 |
| rs2016848 | A | Allele A is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele G. | AG | 21052031 |
| rs2066713 | A | Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G. | AG | 31595439 |
| rs2144297 | T | Allele T is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele C. | TC | 24116192 |
| rs2227956 | G | Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele A. | AA | 16538175 |
| rs2228001 | GG + GT | Genotypes GG + GT are associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT. | GG | 21047201 |
| rs2228001 | G | Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to allele T. | GG | 19434073 |
| rs2228001 | GG + GT | Genotypes GG + GT are associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT. | GG | 21047201 |
| rs2229109 | CC | Genotype CC is associated with increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes CT + TT. | CC | 18334915 |
| rs2273697 | GG | Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG. | GG | 29507678 |
| rs2274924 | C | Allele C is associated with increased risk of hypomagnesemia primary when treated with Proton pump inhibitors as compared to allele T. | TC | 27926584 |
| rs2278294 | CT + TT | Genotypes CT + TT is associated with decreased likelihood of Lymphopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype CC. | TC | 26332308 |
| rs2278294 | CT + TT | Genotypes CT + TT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with kidney transplant as compared to genotype CC. | TC | 17851563 |
| rs2278294 | T | Allele T is associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C. | TC | 20679962 |
| rs2302821 | C | Allele C is associated with increased risk of cardiovascular toxicity and symptoms when treated with celecoxib in people with Colorectal Neoplasms as compared to allele A. | CC | 23778325 |
| rs2305948 | C | Allele C is associated with increased severity of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell and Gastrointestinal Stromal Tumors as compared to allele T. | CC | 19667267 |
| rs2305948 | CC | Genotype CC is associated with increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT. | CC | 24510746 |
| rs2501873 | CC | Genotype CC is associated with decreased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT. | TC | 24193570 |
| rs2514218 | CC | Genotype CC is associated with increased severity of Psychomotor Agitation due to aripiprazole in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT. | CC | 26320194 |
| rs2562519 | T | Allele T is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele C. | TC | 21810746 |
| rs28371685 | CT | Genotype CT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CC. | CC | 15970795 |
| rs28399504 | G | Allele G is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A. | AA | 19463375 |
| rs2884737 | CC | Genotype CC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA. | AA | 18030307 |
| rs2884737 | AC + CC | Genotypes AC + CC is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype AA. | AA | 18322281 |
| rs301927 | G | Allele G is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A. | AG | 24599932 |
| rs301927 | AA | Genotype AA is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG. | AG | 26133777 |
| rs307826 | CC + CT | Genotypes CC + CT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT. | TT | 23462807 |
| rs3094188 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C. | AC | 21801394 |
| rs3094188 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele C. | AC | 21801394 |
| rs3212986 | AC | Genotype AC is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype AA. | AC | 19786980 |
| rs3212986 | AA + AC | Genotypes AA + AC are associated with increased overall survival when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C. | AC | 19362955 |
| rs3212986 | AA | Genotype AA is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AC + CC. | AC | 21902499 |
| rs3212986 | AA + AC | Genotypes AA + AC are not associated with increased risk of recurrence of disease when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype CC. | AC | 22329723 |
| rs3212986 | AA + AC | Genotypes AA + AC are not associated with increased risk of Death when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype CC. | AC | 22329723 |
| rs3212986 | A | Allele A is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C. | AC | 19620936 |
| rs3212986 | AA + AC | Genotypes AA + AC is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC. | AC | 25495407 |
| rs3212986 | AA + AC | Genotypes AA + AC are associated with increased overall survival when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype CC. | AC | 23962907 |
| rs3219484 | CT | Genotype CT is associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC. | CC | 24533712 |
| rs34399035 | T | Allele T is associated with decreased metformin uptake in HEK-293 cells and reduction in protein expression levels when exposed to metformin as compared to allele C. | CC | 21956618 |
| rs3736228 | T | Allele T is associated with decreased Bone Mineral Density as compared to allele C. | CC | 18455228 |
| rs3780126 | G | Allele G are associated with increased overall survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A. | AG | 19841321 |
| rs3780412 | C | Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia. | CC | 19884611 |
| rs3784867 | T | Allele T is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to allele C. | TC | 29999516 |
| rs3786362 | A | Allele A is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to allele G. | AA | 29955115 |
| rs3789243 | G | Allele G is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy. | AG | 19450124 |
| rs3789243 | G | Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy. | AG | 19450124 |
| rs3798220 | CT | Genotype CT is associated with decreased risk of Myocardial Infarction when treated with aspirin in women. | TT | 18775538 |
| rs3815087 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele G. | AG | 21801394 |
| rs3815087 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele G. | AG | 21801394 |
| rs4141964 | CT + TT | Genotypes CT + TT is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype CC. | TT | 25558980 |
| rs4148323 | AA | Genotype AA is associated with decreased progression-free survival when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | AA | Genotype AA is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148412 | T | Allele T is associated with increased severity of Respiratory Insufficiency when treated with morphine in children with Sleep Apnea Syndromes and tonsillectomy as compared to allele C. | TC | 26810133 |
| rs4149118 | G | Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms. | GG | 21995462 |
| rs429358 | T | Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease. | TT | 20031582 |
| rs429358 | TT | Genotype TT is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CC + CT. | TT | 21923605 |
| rs463312 | AC | Genotype AC is associated with decreased progression-free survival when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to genotype AA. | AA | 27020167 |
| rs4680 | AA | Genotype AA is associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotypes AG + GG. | GG | 27061230 |
| rs4680 | AG + GG | Genotypes AG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype AA. | GG | 24533707 |
| rs4680 | AG | Genotype AG is associated with decreased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG. | GG | 30549211 |
| rs4680 | GG | Genotype GG is associated with increased severity of withdrawal in people not taking nicotine in women Tobacco Use Disorder as compared to genotypes AA + AG. | GG | 23459442 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype GG. | GG | 18180754 |
| rs4680 | GG | Genotype GG is associated with increased reaction time when treated with tolcapone in abstinent smokers. | GG | 24095246 |
| rs4680 | GG | Genotype GG is associated with increased likelihood of relapse when treated with nicotine. | GG | 18192898 |
| rs4680 | AG | Genotype AG is associated with decreased reaction time when treated with tolcapone in abstinent smokers. | GG | 24095246 |
| rs4680 | AA + GG | Genotypes AA + GG are associated with increased likelihood of adverse events when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AG. | GG | 30549211 |
| rs4680 | AA + GG | Genotypes AA + GG are associated with increased likelihood of Sexual Dysfunctions, Psychological when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG. | GG | 30549211 |
| rs4680 | G | Allele G is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele A. | GG | 20216107 |
| rs4680 | GG | Genotype GG is associated with increased blood pressure when treated with nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. | GG | 23459442 |
| rs4680 | AA | Genotype AA is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to genotypes AG + GG. | GG | 25096645 |
| rs4693570 | C | Allele C is associated with increased risk of Myalgia unspecified when treated with hmg coa reductase inhibitors in people with Hyperlipidemias as compared to allele T. | TC | 21868014 |
| rs4790694 | A | Allele A is not associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele C. | AA | 17579607 |
| rs4790694 | A | Allele A is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele C. | AA | 17579607 |
| rs4888024 | G | Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance when treated with methotrexate as compared to allele A. | AG | 19176441 |
| rs492338 | AA | Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype GG. | AA | 24706167 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with decreased likelihood of Myocardial Infarction when treated with diuretics in people with Hypertension. | GG | 11926892 |
| rs508448 | GG | Genotype GG is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes AA + AG. | AG | 28692418 |
| rs50872 | GG | Genotype GG is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG. | GG | 27498158 |
| rs55781567 | G | Allele G is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele C. | GG | 29196725 |
| rs568408 | A | Allele A is associated with increased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele G. | AG | 21107304 |
| rs5925720 | T | Allele T is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | GG | 26378035 |
| rs598961 | AA | Genotype AA is associated with decreased time to delivery when treated with ritodrine as compared to genotypes AG + GG. | GG | 31324945 |
| rs6088638 | T | Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C. | TT | 28550509 |
| rs6090043 | C | Allele C is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele T. | TC | 20032820 |
| rs6130615 | TT | Genotype TT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT. | TT | 24193570 |
| rs652888 | G | Allele G is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele A. | AG | 27157822 |
| rs671 | GG | Genotype GG is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AA + AG. | GG | 16679777 |
| rs671 | A | Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G. | GG | 15902904 |
| rs6769511 | C | Allele C is associated with increased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to allele T. | TC | 26115082 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with decreased event-free survival when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC. | CC | 24589908 |
| rs686 | A | Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine in smokers as compared to allele G. | AA | 18092181 |
| rs6920220 | A | Allele A is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to allele G. | AG | 20921970 |
| rs6962291 | AA | Genotype AA is associated with decreased risk of intolerance when treated with aspirin in people with Asthma as compared to genotype TT. | TA | 21449675 |
| rs7131056 | CC | Genotype CC is associated with decreased likelihood of Weight gain when treated with antipsychotics as compared to genotypes AA + AC. | AC | 27217270 |
| rs716274 | AG + GG | Genotypes AG + GG are associated with increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to genotype AA. | AG | 21118971 |
| rs7242 | T | Allele T is associated with increased likelihood of Depressive Disorder, Major as compared to allele G. | TT | 18794724 |
| rs7259857 | C | Allele C is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele T. | TT | 25054431 |
| rs7305534 | CC + CT | Genotypes CC + CT is associated with increased severity of Diarrhea, Nausea and Vomiting when treated with platinum in people with Lung Neoplasms as compared to genotype TT. | CC | 26358256 |
| rs7412 | CC | Genotype CC is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CT + TT. | CC | 21923605 |
| rs762551 | AA | Genotype AA is associated with decreased risk of Iron Overload when treated with deferasirox in children with Thalassemia as compared to genotypes AC + CC. | AC | 28346059 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with increased risk of Myocardial Infarction in people with increased coffee intake. | AC | 16522833 |
| rs762551 | AA | Genotype AA is associated with decreased plasma concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C. | AC | 19636338 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to genotype AA. | AC | 17611010 |
| rs762551 | CC | Genotype CC is associated with decreased risk of Parkinson Disease when exposed to caffeine in people with coffee consumption as compared to genotype AA. | AC | 21281405 |
| rs762551 | A | Allele A is associated with increased risk of Fatigue when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C. | AC | 21121774 |
| rs762551 | C | Allele C is associated with increased likelihood of Pulmonary Disease, Chronic Obstructive as compared to allele A. | AC | 20797314 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with increased QT interval when treated with chlorpromazine in people with Schizophrenia as compared to genotype AA. | AC | 17611010 |
| rs762551 | AA | Genotype AA is associated with decreased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia as compared to genotypes AC + CC. | AC | 27681143 |
| rs778293 | C | Allele C is associated with increased likelihood of Psychotic Disorders due to methamphetamine as compared to allele T. | CC | 19482054 |
| rs7945189 | CT + TT | Genotypes CT + TT are associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype CC. | CC | 20538124 |
| rs8099917 | TT | Genotype TT is associated with increased baseline viral load in people with Hepatitis as compared to genotypes GG + GT. | TT | 21628662 |
| rs8099917 | T | Allele T is associated with increased response (SVR and RVR) in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to allele G. | TT | 23133602 |
| rs8099917 | TT | Genotype TT is associated with increased response (SVR) in HCV genotype 1 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 22438096 |
| rs8099917 | TT | Genotype TT is associated with increased response (SVR) to interferon monotherapy in HCV genotype 1 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 22438096 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28261382 |
| rs8099917 | TT | Genotype TT is associated with increased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with. | TT | 28453396 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 29104462 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with daclatasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 30431653 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 27514956 |
| rs8099917 | TT | Genotype TT is associated with increased likelihood of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes GG + GT. | TT | 21628662 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24362944 |
| rs8099917 | TT | Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 26699619 |
| rs8099917 | TT | Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 27561198 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 27027531 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with as compared to genotypes GG + GT. | TT | 25918016 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 27357737 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 27833958 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28261382 |
| rs8099917 | G | Allele G is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | TT | 28261910 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28739427 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28506030 |
| rs8099917 | TT | Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24308755 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 31803800 |
| rs8176719 | C | Allele C is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele del. | TTC | 28750087 |
| rs8176746 | T | Allele T is associated with increased ACE activity in people with Hypertension. | TG | 20066004 |
| rs879207 | AG | Genotype AG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes AA + GG. | AG | 23963862 |
| rs894160 | CT + TT | Genotypes CT + TT are associated with decreased Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC. | CC | 16732015 |
| rs9282564 | CC + CT | Genotypes CC + CT are associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotype TT. | TT | 27061230 |
| rs928655 | A | Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. | AG | 18615156 |
| rs9345389 | G | Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance. when treated with methotrexate as compared to allele A. | AG | 19176441 |
| rs951439 | CC | Genotype CC is associated with increased likelihood of positive response when treated with olanzapine and perphenazine in people with Schizophrenia as compared to genotypes CT + TT. | CC | 17588543 |
| rs9922316 | T | Allele T is associated with increased dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction when exposed to dexmedetomidine in healthy individuals as compared to allele G. | TG | 23337848 |
| rs1017860 | CC | Genotype CC is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with hemopoietic stem cell transplant as compared to genotypes CT + TT. | TC | 25425682 |
| rs1021737 | TT | Genotype TT is associated with increased risk of Hepatic Veno-Occlusive Disease when treated with busulfan and cyclophosphamide in children with hemopoietic stem cell transplant as compared to genotypes GG + GT. | GG | 27779248 |
| rs10267099 | G | Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A. | AA | 24116192 |
| rs1042713 | G | Allele G is associated with increased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia as compared to allele A. | AA | 22212732 |
| rs1042713 | GG | Genotype GG is not associated with increased risk of Hypertriglyceridemia due to atenolol or metoprolol in people with Hypertension as compared to genotypes AA + AG. | AA | 16027735 |
| rs1042713 | GG | Genotype GG is associated with increased risk of emergency department and hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AA + AG. | AA | 22543981 |
| rs10491684 | A | Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | GG | 31616045 |
| rs10509681 | C | Allele C is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele T. | TT | 23413280 |
| rs10517 | GG | Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG. | GG | 30237583 |
| rs1051740 | CC | Genotype CC is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype TT. | TT | 21057703 |
| rs1051740 | CC | Genotype CC is associated with increased likelihood of being overanticoagulated due to phenprocoumon as compared to genotypes CT + TT. | TT | 21057703 |
| rs1051740 | CT | Genotype CT is associated with increased risk of nephrotoxicity grades 1-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT. | TT | 24533712 |
| rs10792367 | G | Allele G is associated with decreased blood pressure (BP) reduction when treated with hydrochlorothiazide in people with Hypertension as compared to genotype CC. | GG | 21164499 |
| rs10846744 | GG | Genotype GG is associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG. | GG | 27561198 |
| rs10981694 | GG + GT | Genotypes GG + GT are associated with increased severity of Ototoxicity when treated with cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT. | TT | 22516052 |
| rs11212570 | AA + AG | Genotypes AA + AG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG. | GG | 30430914 |
| rs11252394 | A | Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G. | GG | 23508266 |
| rs1138272 | T | Allele T is associated with increased non-inducible thiotepa clearance and decreased tepa clearance when treated with thiotepa. | CC | 19076156 |
| rs1152003 | CC | Genotype CC is associated with increased risk of developing osteonecrosis of the jaw when treated with zoledronate in people with Multiple Myeloma as compared to genotypes CG + GG. | GC | 21517810 |
| rs11587213 | AA | Genotype AA is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes AG + GG. | AG | 18595682 |
| rs11591147 | T | Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease. | GG | 20031582 |
| rs11600347 | A | Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C. | CC | 22907731 |
| rs11710163 | AG | Genotype AG is associated with increased overall survival due to carboplatin, cisplatin, docetaxel, gemcitabine or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. | AA | 21636554 |
| rs12119882 | AG | Genotype AG is associated with increased likelihood of Hyperbilirubinemia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA. | AA | 28347776 |
| rs12210538 | G | Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A. | AA | 20179710 |
| rs1229984 | TT | Genotype TT is associated with increased Vmax of ethanol in healthy individuals as compared to genotypes CC + CT. | CC | 23240771 |
| rs12720066 | AC + CC | Genotypes AC + CC are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA. | AA | 27845419 |
| rs12720067 | T | Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C. | CC | 18215618 |
| rs13181 | GG | Genotype GG is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype TT. | TT | 15213713 |
| rs13181 | GG + GT | Genotypes GG + GT are associated with increased risk of Recurrence when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT. | TT | 18267032 |
| rs13181 | GG | Genotype GG is associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype TT. | TT | 21826087 |
| rs13181 | GT | Genotype GT is associated with increased progression-free survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + TT. | TT | 21449681 |
| rs13181 | G | Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele T. | TT | 19620936 |
| rs13181 | GG | Genotype GG is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT. | TT | 25069034 |
| rs13181 | GG + GT | Genotypes GG + GT are associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT. | TT | 30914949 |
| rs13181 | G | Allele G is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT. | TT | 20385995 |
| rs13432159 | G | Allele G is associated with increased general side-effects when treated with sertraline in people with Depressive Disorder, Major as compared to allele T. | TT | 22041458 |
| rs135543 | TT | Genotype TT is associated with increased reduction in fasting LDL-C when treated with fenofibrate as compared to genotypes CC + CT. | TC | 22547144 |
| rs1522113 | A | Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G. | GG | 23508266 |
| rs1634776 | T | Allele T is associated with increased likelihood of severe cutaneous adverse reactions when treated with allopurinol as compared to allele C. | CC | 33356553 |
| rs16969968 | A | Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder. | AG | 22648373 |
| rs16969968 | GG | Genotype GG is associated with increased functional MRI reactivity to smoking images due to nicotine in women with nicotine dependence as compared to genotypes AA + AG. | AG | 21764527 |
| rs16969968 | A | Allele A is associated with decreased variance in Tobacco Use Disorder associated with peer smoking when exposed to nicotine as compared to allele G. | AG | 20840187 |
| rs17091162 | AC + CC | Genotypes AC + CC are associated with decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype AA. | CC | 21487324 |
| rs17135437 | T | Allele T is associated with increased hearing and vision-related side-effects when treated with citalopram in people with Depressive Disorder, Major as compared to allele C. | CC | 22760553 |
| rs17655652 | CC | Genotype CC is associated with increased reduction in LDL-C when treated with pravastatin in men as compared to genotypes CT + TT. | TT | 19752398 |
| rs1799722 | CT + TT | Genotypes CT + TT are associated with increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to genotype CC. | TC | 12522467 |
| rs1799807 | C | Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T. | TT | 12724618 |
| rs1799978 | C | Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT. | TC | 16513877 |
| rs1799978 | CT | Genotype CT is associated with increased likelihood of Insulin Resistance when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotype TT. | TC | 26880915 |
| rs1800629 | AA + AG | Genotypes AA + AG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG. | GG | 18444945 |
| rs1800629 | A | Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G. | GG | 11294926 |
| rs1800629 | AA + AG | Genotypes AA + AG are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype GG. | GG | 22151084 |
| rs1800629 | AG | Genotype AG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG. | GG | 30430914 |
| rs1800629 | A | Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | GG | 31616045 |
| rs1800888 | TT | Genotype TT is not associated with increased risk of Hypertriglyceridemia due to atenolol or metoprolol in people with Hypertension as compared to genotypes CC + CT. | CC | 16027735 |
| rs1801131 | GG | Genotype GG is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GT + TT. | TG | 17488658 |
| rs1801131 | TT | Genotype TT is associated with increased response base on Disease Activity Score in 44 joints improvement at 6 months of treatment when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT. | TG | 16572443 |
| rs1801131 | TT | Genotype TT is associated with increased likelihood of red blood cell transfusions when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT. | TG | 18368069 |
| rs1801131 | GG + GT | Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT. | TG | 21343546 |
| rs1801131 | GG | Genotype GG is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotypes GT + TT. | TG | 17700593 |
| rs1801131 | TT | Genotype TT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes GG + GT. | TG | 22045187 |
| rs1801131 | GG | Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Neoplasms. | TG | 23736036 |
| rs1801131 | TT | Genotype TT is associated with increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT. | TG | 21747412 |
| rs1801131 | GG | Genotype GG is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype TT. | TG | 18580170 |
| rs1801131 | GT + TT | Genotypes GT + TT is associated with increased risk of mucositis when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | TG | 25065700 |
| rs1801131 | GG | Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotypes GT + TT. | TG | 27864592 |
| rs1801131 | GG | Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms. | TG | 20819423 |
| rs1801131 | GG | Genotype GG is associated with increased Weight gain when treated with clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotype GT. | TG | 24725652 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 18458567 |
| rs1801133 | AA | Genotype AA is associated with increased risk of gastrointestinal toxicity, Leukopenia and Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 19648163 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased risk of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | GG | 11710708 |
| rs1801133 | A | Allele A is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G. | GG | 27992285 |
| rs1801133 | AA | Genotype AA is associated with increased progression-free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 19307503 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotypes AG + GG. | GG | 12453860 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in children with Osteosarcoma as compared to genotypes AG + GG. | GG | 19159907 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of Toxic liver disease when treated with methotrexate in children with Neoplasms as compared to genotype GG. | GG | 23648444 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 25007187 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | GG | 21644011 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased Drug Toxicity when treated with methotrexate in children with as compared to genotype GG. | GG | 21644011 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased severity of Folic Acid Deficiency when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 25065700 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 25110820 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased risk of Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 25110820 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Osteosarcoma as compared to genotypes AG + GG. | GG | 28592186 |
| rs1801133 | GG | Genotype GG is associated with decreased risk of Drug Toxicity when treated with methotrexate in children with Neoplasms as compared to genotypes AA + AG. | GG | 28696419 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG. | GG | 29589488 |
| rs1801133 | A | Allele A is associated with graft vs host disease when treated with cyclosporine and methotrexate in people with recipients of HLA-identical hematopoietic stem cell transplantation. | GG | 19005482 |
| rs1801133 | A | Allele A is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics in people with Schizophrenia. | GG | 17976958 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | GG | 17488658 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | GG | 17488658 |
| rs1801133 | A | Allele A is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | GG | 20863444 |
| rs1801133 | A | Allele A is associated with increased risk of Recurrence when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. | GG | 15781665 |
| rs1801133 | AG | Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms. | GG | 20819423 |
| rs1801133 | A | Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G. | GG | 20638924 |
| rs1801133 | AA + AG | Genotypes AA + AG are not associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 18285546 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 21605004 |
| rs1801133 | GG | Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG. | GG | 19384296 |
| rs1801133 | AA | Genotype AA is associated with increased risk of toxicity when treated with methotrexate as compared to genotype GG. | GG | 22143415 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of hematological toxicity when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG. | GG | 23488607 |
| rs1801133 | A | Allele A is associated with increased risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele G. | GG | 24241962 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of Diarrhea, mucositis and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG. | GG | 29134491 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate as compared to genotype GG. | GG | 22143415 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Arthritis, Psoriatic as compared to genotypes AG + GG. | GG | 20472929 |
| rs1801133 | AA | Genotype AA is associated with increased overall survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 17512587 |
| rs1801133 | AA | Genotype AA is associated with increased risk of mucositis when treated with busulfan, cyclophosphamide and methotrexate as compared to genotype GG. | GG | 15051775 |
| rs1801133 | AA | Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | GG | 17488658 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 18458567 |
| rs1801133 | AA | Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG. | GG | 11418485 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | GG | 17512587 |
| rs1801133 | AG | Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | GG | 18381794 |
| rs1801133 | AA | Genotype AA is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype GG. | GG | 16501586 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | GG | 23095111 |
| rs1801133 | AG + GG | Genotypes AG + GG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype AA. | GG | 22926161 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG. | GG | 23314736 |
| rs1801133 | GG | Genotype GG is associated with decreased likelihood of Coronary Artery Disease and Myocardial Infarction when treated with pravastatin in people with Hypertension. | GG | 18622257 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 25303299 |
| rs1801133 | AA | Genotype AA is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype GG. | GG | 18580170 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Juvenile Rheumatoid as compared to genotype GG. | GG | 20595278 |
| rs1801394 | AG + GG | Genotypes AG + GG are associated with increased likelihood of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma. | AA | 18368069 |
| rs1801394 | GG | Genotype GG is associated with increased severity of Stomatitis when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes AA + AG. | AA | 20647221 |
| rs1801394 | AA + AG | Genotypes AA + AG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype GG. | AA | 22926161 |
| rs1801394 | G | Allele G is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A. | AA | 29589488 |
| rs1801394 | AG | Genotype AG is associated with increased speed of platelet recovery when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG. | AA | 18368069 |
| rs1804645 | CT | Genotype CT is associated with increased severity of change in Lumbar Bone Mineral Density when treated with tamoxifen as compared to genotype CC. | CC | 22174377 |
| rs1883112 | AA | Genotype AA is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | GG | 16330681 |
| rs1883112 | AA | Genotype AA is associated with increased risk of cardiotoxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG. | GG | 28485375 |
| rs1883112 | AG + GG | Genotypes AG + GG are associated with decreased risk of toxicity when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype AA. | GG | 19448608 |
| rs1978153 | C | Allele C is associated with increased severity of Respiratory Insufficiency when treated with morphine in children with Sleep Apnea Syndromes and tonsillectomy as compared to allele G. | GG | 26810133 |
| rs2070401 | GG | Genotype GG is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes AA + AG. | AG | 22341855 |
| rs2207396 | A | Allele A is associated with increased risk of Oligospermia when treated with Alkylating Agents and cisplatin in people with childhood cancer as compared to genotype GG. | GG | 21430602 |
| rs2229109 | CT | Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC. | CC | 25637052 |
| rs2229109 | CT | Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC. | CC | 29177954 |
| rs2229109 | CT | Genotype CT is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC. | CC | 27402191 |
| rs2229109 | CT + TT | Genotypes CT + TT is associated with increased risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC. | CC | 29689130 |
| rs2233406 | AG + GG | Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. | AG | 31664190 |
| rs2236418 | AG + GG | Genotypes AG + GG is associated with increased likelihood of methamphetamine dependence, Psychotic Disorders and Substance-Related Disorders when exposed to methamphetamine as compared to genotype AA. | AA | 27967329 |
| rs2241716 | TT | Genotype TT is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes CC + CT. | CC | 30430914 |
| rs2246709 | G | Allele G is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele A. | AA | 21902501 |
| rs2246709 | A | Allele A is associated with decreased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele G. | AA | 21902501 |
| rs2273697 | A | Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G. | GG | 21799461 |
| rs2273697 | A | Allele A is associated with increased risk of Bone Marrow Diseases when treated with methotrexate in children with Osteosarcoma as compared to allele G. | GG | 27566582 |
| rs2273697 | A | Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol when exposed to talinolol as compared to allele G. | GG | 18334920 |
| rs2273697 | AA + AG | Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG. | GG | 20216337 |
| rs2273697 | AA | Genotype AA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG. | GG | 18381794 |
| rs2273697 | A | Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G. | GG | 17083032 |
| rs2273697 | AG | Genotype AG is associated with increased area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG. | GG | 18946804 |
| rs2273697 | GG | Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG. | GG | 30237583 |
| rs2278294 | T | Allele T is associated with decreased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C. | TC | 20679962 |
| rs2281617 | CC | Genotype CC is associated with increased Euphoric and Energetic after amphetamine (10 mg) when exposed to amphetamine in healthy individuals as compared to genotypes CT + TT. | TC | 21029375 |
| rs2291075 | CT + TT | Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC. | TC | 26663398 |
| rs2302948 | T | Allele T is associated with decreased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C. | TC | 22584460 |
| rs2305799 | CT + TT | Genotypes CT + TT are not associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 18285546 |
| rs2305948 | TT | Genotype TT is associated with increased risk of Angina Pectoris and Myocardial Infarction when treated with clopidogrel in people with Coronary Disease as compared to genotypes CC + CT. | CC | 25738571 |
| rs2305948 | CC | Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell. | CC | 21882181 |
| rs2307441 | C | Allele C is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele T. | TT | 21038416 |
| rs2366929 | C | Allele C is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to allele T. | TT | 31792237 |
| rs2440390 | T | Allele T is associated with increased Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C. | CC | 22967772 |
| rs2476601 | AA | Genotype AA is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | GG | 20921970 |
| rs2476601 | A | Allele A is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate as compared to allele G. | GG | 30664875 |
| rs2518224 | CC | Genotype CC is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression. | AA | 17898344 |
| rs2720376 | C | Allele C is associated with increased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele T. | TT | 25829401 |
| rs2748249 | A | Allele A is associated with increased severity of Drug Toxicity when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C. | CC | 24220096 |
| rs28362731 | AG | Genotype AG is associated with increased risk of Thrombocytopenia due to cisplatin in people with Mesothelioma as compared to genotype GG. | GG | 30840592 |
| rs28399504 | G | Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A. | AA | 19106084 |
| rs28399504 | G | Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA. | AA | 19106083 |
| rs28399504 | G | Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A. | AA | 20801498 |
| rs2884737 | CC | Genotype CC is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype AA. | AA | 20354686 |
| rs2963155 | G | Allele G is associated with increased pain crisis in people with Anemia, Sickle Cell as compared to allele A. | AA | 30079801 |
| rs3087374 | A | Allele A is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele C. | CC | 21038416 |
| rs3136228 | GG | Genotype GG is associated with increased severity of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT. | TT | 22868256 |
| rs3212191 | TT | Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CC + CT. | TC | 31461081 |
| rs3212986 | CC | Genotype CC is associated with increased progression-free survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + AC. | AC | 19203783 |
| rs3212986 | AA | Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AC + CC. | AC | 29507678 |
| rs3212986 | CC | Genotype CC is associated with increased risk of mucositis when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AA + AC. | AC | 25495407 |
| rs3212986 | AC + CC | Genotypes AC + CC are associated with decreased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype AA. | AC | 30914949 |
| rs3212986 | AC | Genotype AC is associated with decreased disease-free survival and overall survival in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC. | AC | 19361884 |
| rs363341 | TT | Genotype TT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotypes CC + CT. | TC | 27272046 |
| rs3732218 | GG | Genotype GG is associated with increased glucuronidation of anastrozole in human liver microsomes as compared to genotypes AA + AG. | AG | 23371966 |
| rs3736228 | T | Allele T is associated with increased risk of osteoporotic fracture as compared to allele C. | CC | 18455228 |
| rs3736228 | T | Allele T is associated with increased risk of Osteoporosis. | CC | 18455228 |
| rs3764043 | CC | Genotype CC is associated with decreased imatinib clearance when treated with imatinib as compared to genotypes CT + TT. | CC | 21633340 |
| rs3787186 | TT | Genotype TT is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with hemopoietic stem cell transplant as compared to genotypes CC + CT. | CC | 25425682 |
| rs3856806 | TT | Genotype TT is associated with increased decline in FEV 1 after aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes CC + CT. | CC | 20224667 |
| rs3856806 | TT | Genotype TT is associated with increased risk of aspirin hypersensitivity when treated with aspirin in people with Asthma as compared to genotypes CC + CT. | CC | 20224667 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms. | CC | 17700593 |
| rs3918290 | CT | Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 30114658 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased severity of hand-foot syndrome when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24817302 |
| rs3918290 | CT | Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 26099996 |
| rs3918290 | T | Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms. | CC | 23930673 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased severity of Myelosuppression when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24817302 |
| rs3918290 | CT | Genotype CT is associated with increased Infection and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 26846104 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of mucositis when treated with fluorouracil in women with Neoplasms as compared to genotype CC. | CC | 19473056 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of Thrombocytopenia when treated with fluorouracil in women with Neoplasms as compared to genotype CC. | CC | 19473056 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 12360106 |
| rs3918290 | T | Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C. | CC | 28481884 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 20819423 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity, Leukopenia and mucositis when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 18299612 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC. | CC | 21498394 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24167597 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased severity of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24817302 |
| rs3918290 | CT + TT | Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 30723313 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC. | CC | 27454530 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype CC. | CC | 25381393 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 29134491 |
| rs3918290 | CT + TT | Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC. | CC | 26603945 |
| rs3918290 | T | Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil. | CC | 18299612 |
| rs3918290 | T | Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 23603345 |
| rs3918290 | CT + TT | Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 17121937 |
| rs3918290 | CT | Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 17064846 |
| rs4133101 | T | Allele T is associated with increased risk of gastrointestinal toxicities when treated with celecoxib in people with Colorectal Neoplasms as compared to allele C. | CC | 23778325 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased severity of Diarrhea when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG. | GG | 19299905 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased severity of Neutropenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG. | GG | 19299905 |
| rs4148323 | AG | Genotype AG is associated with increased risk of Hyperbilirubinemia when treated with indinavir in people with HIV as compared to genotype GG. | GG | 16609363 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased severity of Thrombocytopenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG. | GG | 19299905 |
| rs4148323 | AA | Genotype AA is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG. | GG | 19390945 |
| rs4148323 | AG | Genotype AG is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG. | GG | 19390945 |
| rs4148323 | AA | Genotype AA is associated with increased Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | AA | Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 18221820 |
| rs4148323 | A | Allele A is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to allele G. | GG | 28367249 |
| rs4148323 | AG | Genotype AG is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG. | GG | 26830078 |
| rs4148323 | A | Allele A is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to allele G. | GG | 28367249 |
| rs4148323 | AA + AG | Genotypes AA + AG is associated with increased risk of Neutropenia when treated with irinotecan in people with biliary tract neoplasms and Pancreatic Neoplasms as compared to genotype GG. | GG | 26229432 |
| rs4148323 | AA + AG | Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG. | GG | 28502040 |
| rs4149000 | T | Allele T is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele C. | CC | 31220337 |
| rs429358 | CC | Genotype CC is associated with increased severity of COVID-19 as compared to genotype TT. | TT | 32451547 |
| rs429358 | CC + CT | Genotypes CC + CT are associated with increased non-HDL cholesterol when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C. | TT | 15809899 |
| rs429358 | C | Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele T. | TT | 29432897 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with increased Hypertriglyceridemia in people with Coronary Disease or Hypertension as compared to genotype TT. | TT | 31559922 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with increased likelihood of Recurrence when treated with bupropion or nicotine in people with Tobacco Use Disorder as compared to genotype TT. | TT | 23247396 |
| rs429358 | C | Allele C is associated with increased risk of mortality after myocardial infarction, however this can be eliminated when treated with simvastatin as compared to allele T. | TT | 10736278 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with increased reduction in C-reactive protein (CRP) when treated with atorvastatin or pravastatin in people with Acute coronary syndrome. | TT | 19667110 |
| rs445925 | A | Allele A is associated with baseline LDL cholesterol in people with Vascular Diseases. | GG | 21977987 |
| rs4638843 | C | Allele C is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele G. | CC | 25829401 |
| rs4680 | AG + GG | Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA. | GG | 23632726 |
| rs4680 | AA + AG | Genotypes AA + AG is associated with increased diastolic blood pressure and systolic blood pressure when treated with antipsychotics in children as compared to genotype GG. | GG | 25048416 |
| rs4680 | A | Allele A is associated with increased risk of Toxic liver disease when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. | GG | 32265697 |
| rs4680 | AA | Genotype AA is associated with increased overall mean numerical rating scale (NRS) score for pain when treated with morphine as compared to genotype GG. | GG | 23210659 |
| rs4680 | G | Allele G is associated with decreased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele A. | GG | 16395295 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of relapse when treated with nicotine. | GG | 18192898 |
| rs4680 | AA | Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG. | GG | 17548664 |
| rs4680 | A | Allele A is associated with increased methylation at sites 1 and 2 in the COMT promoter when treated with antipsychotics in people with Schizophrenia as compared to allele G. | GG | 22391769 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG. | GG | 30549211 |
| rs4680 | AA | Genotype AA is associated with increased numerical rating scale (NRS) score for pain during painful procedure when treated with morphine as compared to genotype GG. | GG | 23210659 |
| rs4680 | AG + GG | Genotypes AG + GG are associated with decreased length of hospital stay in infants with Neonatal Abstinence Syndrome as compared to genotype AA. | GG | 23632726 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of extrapyramidal symptoms when treated with haloperidol in men with Schizophrenia as compared to genotypes AA + GG. | GG | 23963056 |
| rs4680 | AA | Genotype AA is associated with increased likelihood of cessation when treated with Drugs used in nicotine dependence in people with as compared to genotypes AG + GG. | GG | 26555332 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of somnolence due to fentanyl in healthy individuals as compared to genotype GG. | GG | 30281924 |
| rs4680 | AA + GG | Genotypes AA + GG is associated with decreased libido when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AG. | GG | 30549211 |
| rs4680 | AA | Genotype AA is associated with increased likelihood of Vomiting when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG. | GG | 30549211 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of Hyperalgesia due to opioids in people with Pain as compared to genotypes AA + GG. | GG | 31041874 |
| rs4790694 | C | Allele C is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele A. | AA | 17233643 |
| rs494904 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | TC | 32451486 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG. | GG | 18591455 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG. | GG | 11882573 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased ambulatory blood pressure in people with Hypertension as compared to genotype GG. | GG | 18591455 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased likelihood of Hypertension as compared to genotype GG. | GG | 9149697 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG. | GG | 21692745 |
| rs4961 | TT | Genotype TT is associated with increased hydrochlorothiazide induced calcium retention when treated with hydrochlorothiazide in men with Hypertension as compared to genotype GG. | GG | 16450155 |
| rs4961 | GT | Genotype GT is associated with increased reduction in mean arterial pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG. | GG | 9149697 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG. | GG | 10523341 |
| rs4961 | GG | Genotype GG is associated with decreased risk of Myocardial Infarction when treated with Thiazides, plain in people with Hypertension. | GG | 19145769 |
| rs5789 | C | Allele C is associated with decreased likelihood of aspirin-induced asthma when exposed to Antiinflammatory agents, non-steroids in people with Asthma as compared to allele A. | CC | 26067486 |
| rs6002674 | C | Allele C is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele T. | TC | 23508266 |
| rs6021191 | T | Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A. | AA | 25987655 |
| rs6025 | T | Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C. | CC | 28750087 |
| rs6025 | CT | Genotype CT is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 12069454 |
| rs6025 | CT + TT | Genotypes CT + TT is not associated with increased risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 15208046 |
| rs6025 | CT + TT | Genotypes CT + TT is not associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 15946211 |
| rs6025 | CT | Genotype CT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 16769590 |
| rs6071980 | C | Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T. | TT | 18615156 |
| rs6090041 | G | Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A. | AA | 20032820 |
| rs6130615 | CC | Genotype CC is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CT + TT. | TT | 31461081 |
| rs6347 | TT | Genotype TT is associated with increased risk of Death when exposed to cocaine in people with Cocaine-Related Disorders as compared to genotypes CC + CT. | TC | 23340505 |
| rs6500843 | G | Allele G is associated with increased risk of Death when treated with antineoplastic agents in women with Breast Neoplasms as compared to allele A. | AA | 25823661 |
| rs6511720 | T | Allele T is associated with baseline LDL cholesterol in people with Vascular Diseases. | GG | 21977987 |
| rs671 | AA + AG | Genotypes AA + AG are associated with increased Heroin Dependence due to heroin as compared to genotype GG. | GG | 21723677 |
| rs6714486 | A | Allele A is associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T. | TT | 16198654 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with increased overall survival when treated with cisplatin in people with Esophageal Neoplasms as compared to genotype CC. | CC | 32285752 |
| rs683369 | CC | Genotype CC is associated with decreased severity of Drug Toxicity when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 28289867 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with increased risk of conjunctival hemorrhage when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC. | CC | 28762371 |
| rs7104613 | T | Allele T is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele C. | CC | 21622719 |
| rs7170924 | GT + TT | Genotypes GT + TT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. | TG | 27498158 |
| rs7412 | T | Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C. | CC | 15809899 |
| rs7412 | T | Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease. | CC | 20031582 |
| rs7412 | CT + TT | Genotypes CT + TT is associated with increased Hyperuricemia in people with Coronary Disease or Hypertension as compared to genotype CC. | CC | 31559922 |
| rs7412 | CT + TT | Genotypes CT + TT is associated with increased percent reduction in LDL-cholesterol when treated with atorvastatin or pravastatin in people with Acute coronary syndrome as compared to genotype CC. | CC | 19667110 |
| rs7572857 | AA + AG | Genotypes AA + AG are associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype GG. | GG | 21072201 |
| rs7572857 | AA | Genotype AA is associated with increased decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes AG + GG. | GG | 21072201 |
| rs762551 | AA + AC | Genotypes AA + AC are associated with decreased on-treatment platelet reactivity when treated with clopidogrel in people with cigarette smokers as compared to genotype CC. | AC | 21148426 |
| rs762551 | AA | Genotype AA is associated with increased likelihood of insomnia due to caffeine as compared to genotypes AC + CC. | AC | 29668752 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with decreased risk of Breast Neoplasms when exposed to caffeine in people with BRCA1 mutations. | AC | 17507615 |
| rs762551 | CC | Genotype CC is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AC. | AC | 16490169 |
| rs762551 | AA | Genotype AA is associated with increased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC. | AC | 27681143 |
| rs762551 | AA | Genotype AA is associated with increased likelihood of Neural Tube Defects when exposed to caffeine in women who are pregnant as compared to genotypes AC + CC. | AC | 20641098 |
| rs762551 | CC | Genotype CC is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AC. | AC | 10889552 |
| rs7929521 | GG | Genotype GG is associated with increased IC50 of daunorubicin. | AA | 18451141 |
| rs806374 | CC | Genotype CC is associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT. | TC | 21266946 |
| rs806374 | CC | Genotype CC is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT. | TC | 21266946 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased risk of treatment failure when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 24355007 |
| rs8099917 | TT | Genotype TT is associated with decreased severity of Hepatitis C when treated with peginterferon alfa-2b and ribavirin as compared to genotypes GG + GT. | TT | 21911885 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased likelihood of retreatment failure when treated with direct acting antivirals, elbasvir / grazoprevir or ledipasvir / sofosbuvir in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 31846553 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased risk of Hypercholesterolemia when treated with asunaprevir, daclatasvir, direct acting antivirals, ledipasvir / sofosbuvir or ombitasvir / paritaprevir / ritonavir in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 31144350 |
| rs8124728 | A | Allele A is associated with decreased risk of Peripheral Nervous System Diseases due to stavudine in people with HIV Infections as compared to allele G. | AG | 30273369 |
| rs877087 | TT | Genotype TT is associated with increased risk of Heart Failure when treated with amlodipine in people with Hypertension. | CC | 22664477 |
| rs9282564 | CC + CT | Genotypes CC + CT is associated with increased risk of Respiratory Insufficiency when treated with morphine in children as compared to genotype TT. | TT | 25311385 |
| rs9394992 | CT + TT | Genotypes CT + TT are associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC. | TC | 20665488 |
| rs940052 | G | Allele G is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele A. | AG | 25054431 |
| rs951439 | TT | Genotype TT is associated with increased likelihood of response when treated with risperidone in people with Schizophrenia as compared to genotypes CC + CT. | CC | 17588543 |
| rs951439 | CT | Genotype CT is associated with increased likelihood of response when treated with olanzapine in people with Schizophrenia. | CC | 17588543 |
| rs9554320 | AA | Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC. | AA | 23421954 |
| rs9554320 | AA | Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC. | AA | 27417418 |
| rs962369 | C | Allele C is associated with increased likelihood of suicidal ideation when treated with escitalopram or nortriptyline in people with Depressive Disorder, Major as compared to allele T. | TT | 19641488 |
| rs989692 | CT + TT | Genotypes CT + TT is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to genotype CC. | TC | 23838604 |
| rs9981861 | TT | Genotype TT is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT. | TT | 21079520 |
Page:
Variants which affect drug dose, response, metabolism, etc.:
Page:
| Variant | Alleles | Associations | Genotype | PMID |
|---|---|---|---|---|
| rs1002976 | C | Allele C is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T. | TC | 29580174 |
| rs1042713 | AA | Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG. | AA | 19183167 |
| rs1042713 | AA | Genotype AA is associated with increased dose of phenylephrine in women as compared to genotype GG. | AA | 25730298 |
| rs1042713 | AA | Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG. | AA | 31090079 |
| rs10485058 | AA | Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG. | AA | 27958381 |
| rs10494227 | A | Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G. | AA | 27001119 |
| rs10514475 | A | Allele A is associated with increased response to Selective serotonin reuptake inhibitors in people with Depression as compared to allele G. | AG | 25649181 |
| rs1051740 | CC | Genotype CC is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT. | TT | 21110013 |
| rs10793902 | T | Allele T is associated with increased response to hydroxyurea in people with Anemia, Sickle Cell and beta-Thalassemia as compared to allele C. | TC | 26895070 |
| rs10954732 | GG | Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA. | GG | 31932875 |
| rs10964552 | AA + AC | Genotypes AA + AC are associated with decreased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotype CC. | CC | 27150640 |
| rs11126740 | AA | Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG. | AG | 27670765 |
| rs1126535 | T | Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C. | TT | 28639493 |
| rs11265572 | GT + TT | Genotypes GT + TT are associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype GG. | GG | 24351870 |
| rs1130864 | AG + GG | Genotypes AG + GG are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype AA. | GG | 27096233 |
| rs1143634 | A | Allele A is associated with decreased dose of morphine in women with Pain, Postoperative as compared to allele G. | GG | 27649267 |
| rs11563250 | AG + GG | Genotypes AG + GG is associated with decreased concentrations of bilirubin in people with Colorectal Neoplasms as compared to genotype AA. | AA | 25778466 |
| rs11574077 | TT | Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT. | TT | 29706892 |
| rs11702779 | AG + GG | Genotypes AG + GG are associated with increased response to methacholine chloride in children with Asthma. | GG | 21803869 |
| rs11716445 | A | Allele A is associated with decreased response to pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele G. | GG | 23166513 |
| rs11869731 | CC | Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG. | CC | 21961650 |
| rs11959113 | AA | Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG. | AA | 25615449 |
| rs12067645 | AA + AG | Genotypes AA + AG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype GG. | AA | 30088438 |
| rs12081765 | G | Allele G is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | AG | 33124499 |
| rs12505410 | G | Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T. | TG | 24123600 |
| rs12505410 | G | Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T. | TG | 24123600 |
| rs12720066 | AC + CC | Genotypes AC + CC are associated with decreased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA. | AA | 27845419 |
| rs12721655 | G | Allele G is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele A. | AA | 22354160 |
| rs1521470 | A | Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G. | GG | 29121268 |
| rs16873129 | C | Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T. | TT | 27091189 |
| rs16969968 | G | Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. | AG | 22648373 |
| rs16969968 | GG | Genotype GG is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. | AG | 23358500 |
| rs16969968 | AA + AG | Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG. | AG | 29621993 |
| rs16969968 | A | Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G. | AG | 26833182 |
| rs16969968 | AA + AG | Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG. | AG | 26142345 |
| rs16969968 | A | Allele A is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. | AG | 22648373 |
| rs16969968 | A | Allele A is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to allele G. | AG | 26010901 |
| rs17216198 | T | Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C. | CC | 30100615 |
| rs17584499 | CC | Genotype CC is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT. | CC | 23147557 |
| rs17798800 | T | Allele T is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C. | CC | 23374588 |
| rs1799722 | TT | Genotype TT is associated with decreased response to enalapril in people with Hypertension as compared to genotypes CC + CT. | TC | 22706620 |
| rs1799978 | T | Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C. | TC | 17105675 |
| rs1799978 | CC | Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype TT. | TC | 21902500 |
| rs1800562 | A | Allele A is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele G. | GG | 18025780 |
| rs1800629 | A | Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. | GG | 19365401 |
| rs1800629 | A | Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. | GG | 16909270 |
| rs1800629 | GG | Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG. | GG | 15834068 |
| rs1800629 | GG | Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. | GG | 16720636 |
| rs1800629 | G | Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis or Spondylarthropathies as compared to allele A. | GG | 26244882 |
| rs1800629 | AG + GG | Genotypes AG + GG is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotype AA. | GG | 22760475 |
| rs1800629 | GG | Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG. | GG | 18050183 |
| rs1800629 | GG | Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. | GG | 12759288 |
| rs1800629 | GG | Genotype GG is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotype AG. | GG | 17343250 |
| rs1800629 | AG + GG | Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA. | GG | 18713756 |
| rs1800629 | GG | Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. | GG | 12847678 |
| rs1800629 | GG | Genotype GG is associated with increased response to adalimumab or infliximab in people with Spondylitis, Ankylosing as compared to genotype AG. | GG | 16720636 |
| rs1800629 | GG | Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes AA + AG. | GG | 24192118 |
| rs1800888 | CT | Genotype CT is associated with decreased response to terbutaline in healthy individuals as compared to genotype CC. | CC | 11222464 |
| rs1801131 | G | Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T. | TG | 20078613 |
| rs1801131 | TT | Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT. | TG | 27676277 |
| rs1801131 | GT | Genotype GT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT. | TG | 25618758 |
| rs1801131 | GG | Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GT + TT. | TG | 27992285 |
| rs1801131 | G | Allele G is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major. | TG | 27035272 |
| rs1801133 | AG + GG | Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. | GG | 24967362 |
| rs1801133 | AA | Genotype AA is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG. | GG | 29589488 |
| rs1801133 | AA | Genotype AA is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele G. | GG | 24980946 |
| rs1801133 | AA | Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG. | GG | 27676277 |
| rs1801133 | GG | Genotype GG is associated with increased exposure to capecitabine in people with Neoplasms as compared to genotypes AA + AG. | GG | 26242222 |
| rs1801133 | AG | Genotype AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + GG. | GG | 25618758 |
| rs1801133 | AA | Genotype AA is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG. | GG | 27995989 |
| rs1801133 | AA | Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | GG | 24637499 |
| rs1801278 | CT + TT | Genotypes CT + TT is associated with decreased response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to genotype CC. | CC | 28696414 |
| rs1975974 | AG + GG | Genotypes AG + GG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype AA. | AG | 27977334 |
| rs2003569 | A | Allele A is associated with increased response to simvastatin as compared to allele G. | AA | 25493567 |
| rs204047 | GG | Genotype GG is associated with increased dose of methadone as compared to genotypes GT + TT. | GG | 31907389 |
| rs204047 | GG | Genotype GG is associated with increased concentrations of methadone as compared to genotypes GT + TT. | GG | 31907389 |
| rs2071427 | TT | Genotype TT is associated with increased response to lithium in people with Bipolar Disorder. | TT | 21781277 |
| rs2075650 | G | Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A. | AA | 27045730 |
| rs2162145 | T | Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C. | TC | 29650774 |
| rs2177370 | A | Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G. | AG | 25730470 |
| rs2273697 | A | Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G. | GG | 28624888 |
| rs2273697 | A | Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G. | GG | 28624888 |
| rs2284922 | A | Allele A is associated with increased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms. | AG | 30071039 |
| rs2291858 | G | Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A. | GG | 27001119 |
| rs2303377 | TT | Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT. | TT | 28696415 |
| rs2305948 | T | Allele T is associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele C. | CC | 25738571 |
| rs243865 | T | Allele T is associated with decreased response to ulinastatin in people with Pancreatitis as compared to allele C. | CC | 31192912 |
| rs2477134 | G | Allele G is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T. | GG | 29580174 |
| rs2514218 | CC | Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT. | CC | 26320194 |
| rs2535629 | AA | Genotype AA is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AG + GG. | AA | 27396837 |
| rs28371685 | T | Allele T is associated with decreased dose of warfarin as compared to allele C. | CC | 20072124 |
| rs28399504 | G | Allele G is associated with decreased metabolism of mephenytoin as compared to allele A. | AA | 9435198 |
| rs2860905 | A | Allele A is associated with decreased dose of warfarin as compared to allele G. | GG | 19752777 |
| rs2873804 | CC | Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT. | CC | 22947179 |
| rs2884737 | AA | Genotype AA is associated with increased dose of warfarin as compared to genotype AC. | AA | 24019055 |
| rs2884737 | C | Allele C is associated with decreased dose of warfarin as compared to allele A. | AA | 20072124 |
| rs2884737 | CC | Genotype CC is associated with decreased dose of warfarin as compared to genotype AA. | AA | 18322281 |
| rs2884737 | C | Allele C is associated with decreased dose of warfarin as compared to allele A. | AA | 16611750 |
| rs3212986 | AC + CC | Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA. | AC | 29177570 |
| rs339097 | G | Allele G is associated with increased dose of warfarin. | AG | 20200517 |
| rs339097 | G | Allele G is associated with increased dose of warfarin. | AG | 20200517 |
| rs339097 | G | Allele G is associated with increased dose of warfarin. | AG | 20200517 |
| rs3749034 | G | Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele A. | GG | 31866536 |
| rs3785143 | T | Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. | CC | 23266789 |
| rs3816877 | CC | Genotype CC is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CT. | CC | 27406852 |
| rs3918290 | CC | Genotype CC is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT. | CC | 26846104 |
| rs3918290 | CT | Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 17064846 |
| rs3918290 | CT | Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 18600527 |
| rs3918290 | CT | Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 11953843 |
| rs3918290 | CT | Genotype CT is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms as compared to genotype CC. | CC | 26792652 |
| rs3918290 | CT | Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 26216193 |
| rs3918290 | CT | Genotype CT is associated with decreased dose of capecitabine in people with Colorectal Neoplasms as compared to genotype CC. | CC | 21498394 |
| rs4086116 | T | Allele T is associated with decreased dose of acenocoumarol as compared to allele C. | CC | 19578179 |
| rs4086116 | T | Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 2.2 mg/week as compared to allele C. | CC | 21063236 |
| rs4148323 | AA | Genotype AA is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to genotype GG. | GG | 17627617 |
| rs4148323 | AA | Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | AA | Genotype AA is associated with decreased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | A | Allele A is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to allele G. | GG | 16849011 |
| rs4148386 | AA + AG | Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG. | AG | 23252947 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT. | TT | 25312789 |
| rs429358 | C | Allele C is associated with decreased dose of acenocoumarol in people with venous thromboembolism as compared to allele T. | TT | 29432897 |
| rs429358 | CT | Genotype CT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT. | TT | 25860945 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to genotype TT. | TT | 24951635 |
| rs4305746 | AA + AG | Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG. | AG | 19345712 |
| rs4364871 | CT + TT | Genotypes CT + TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype CC. | CC | 30088438 |
| rs4645962 | CT | Genotype CT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT. | TT | 26249541 |
| rs4646450 | A | Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G. | AA | 29318894 |
| rs4680 | GG | Genotype GG is associated with increased dose of opioids in women with Breast Neoplasms and Pain, Postoperative as compared to genotypes AA + AG. | GG | 27729204 |
| rs4680 | AG + GG | Genotypes AG + GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotype AA. | GG | 32459054 |
| rs4680 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. | GG | 29230023 |
| rs4680 | G | Allele G is associated with increased clearance of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. | GG | 18214865 |
| rs4680 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. | GG | 18214865 |
| rs4680 | AG + GG | Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA. | GG | 17156920 |
| rs4680 | A | Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G. | GG | 19094200 |
| rs4680 | GG | Genotype GG is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes AA + AG. | GG | 23706899 |
| rs4680 | GG | Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. | GG | 22695756 |
| rs4680 | GG | Genotype GG is associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotypes AA + AG. | GG | 28745577 |
| rs4680 | GG | Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AA + AG. | GG | 25560469 |
| rs4680 | AA | Genotype AA is associated with decreased dose of morphine in people with Pain, Postoperative as compared to genotypes AG + GG. | GG | 23686330 |
| rs4680 | AG | Genotype AG is associated with decreased dose of opioids in children as compared to genotype GG. | GG | 30704436 |
| rs4680 | GG | Genotype GG is associated with increased response to entacapone in people with Parkinson Disease as compared to genotype AA. | GG | 21280081 |
| rs4680 | AA | Genotype AA is associated with decreased dose of sufentanil in children as compared to genotypes AG + GG. | GG | 28006928 |
| rs4680 | GG | Genotype GG is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA. | GG | 25185591 |
| rs4680 | GG | Genotype GG is associated with increased response to modafinil in people with methamphetamine dependence as compared to genotypes AA + AG. | GG | 22217949 |
| rs4680 | G | Allele G is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele A. | GG | 31967515 |
| rs4910008 | CC | Genotype CC is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT. | CC | 27339827 |
| rs4986910 | G | Allele G is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele A. | AA | 12966368 |
| rs5063 | TT | Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC. | CC | 20877298 |
| rs5569 | AG + GG | Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. | AG | 15322419 |
| rs5882 | A | Allele A is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to allele G. | AG | 17931083 |
| rs5993883 | T | Allele T is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G. | GG | 26282453 |
| rs6494223 | T | Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C. | TC | 24951635 |
| rs671 | AA + AG | Genotypes AA + AG is associated with decreased response to nitroglycerin in children with Heart Defects, Congenital as compared to genotype GG. | GG | 31250045 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC. | CC | 29427770 |
| rs683369 | CC | Genotype CC is associated with increased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 24589908 |
| rs6920220 | AA | Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotypes AG + GG. | AG | 30653751 |
| rs6983267 | GG + GT | Genotypes GG + GT are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype TT. | GG | 26729200 |
| rs7412 | CC | Genotype CC is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes CT + TT. | CC | 31854268 |
| rs7412 | T | Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2. | CC | 21228733 |
| rs762551 | A | Allele A is associated with increased dose of paroxetine in people with Depressive Disorder, Major as compared to allele C. | AC | 21121774 |
| rs762551 | AC + CC | Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA. | AC | 25348619 |
| rs762551 | AA | Genotype AA is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotypes AC + CC. | AC | 25090458 |
| rs762551 | AA + AC | Genotypes AA + AC is associated with increased metabolism of caffeine as compared to genotype CC. | AC | 29282363 |
| rs762551 | CC | Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC. | AC | 30713339 |
| rs7668282 | CC + CT | Genotypes CC + CT is associated with decreased metabolism of morphine in people with Anemia, Sickle Cell as compared to genotype TT. | TT | 17724700 |
| rs7968606 | CC | Genotype CC is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CT + TT. | CC | 28332719 |
| rs800292 | GG | Genotype GG is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype AA. | AG | 22594510 |
| rs8099917 | T | Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G. | TT | 26825765 |
| rs8099917 | T | Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G. | TT | 19749757 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Hepatitis C, HIV Infections and HIV Infections as compared to genotypes GG + GT. | TT | 22328925 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or simeprevir in people with Hepatitis C as compared to genotypes GG + GT. | TT | 26264253 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21745312 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 21321200 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21254157 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21739446 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. | TT | 25278709 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. | TT | 20060832 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 25393304 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24102823 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 22301466 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 25852275 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 21346780 |
| rs8099917 | T | Allele T is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele G. | TT | 31201901 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21360545 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21112660 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21112660 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 21321200 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21246582 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21048934 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 23142377 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21466653 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 21911885 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes GG + GT. | TT | 20648473 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 20434452 |
| rs8099917 | G | Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | TT | 19749758 |
| rs8099917 | GT | Genotype GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 19749758 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 24929144 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 23281610 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 26075078 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT. | TT | 23730840 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 21384511 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 21907615 |
| rs8099917 | G | Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T. | TT | 21931540 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT. | TT | 21987611 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 26003758 |
| rs8099917 | GG | Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 19749758 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21503910 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21466653 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C. | TT | 20060832 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24768758 |
| rs9282564 | C | Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T. | TT | 17178267 |
| rs9282564 | CC + CT | Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT. | TT | 29603629 |
| rs928655 | AG + GG | Genotypes AG + GG is associated with increased response to etanercept in people with Psoriasis as compared to genotype AA. | AG | 28470127 |
| rs9332131 | del | Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA. | GAGA | 16220110 |
| rs9332131 | del | Allele del is associated with decreased dose of warfarin. | GAGA | 20072124 |
| rs933271 | CC + CT | Genotypes CC + CT are associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotype TT. | CC | 32407152 |
| rs9939609 | AA + AT | Genotypes AA + AT is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotype TT. | TT | 25367448 |
| rs10248420 | A | Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G. | AG | 22722500 |
| rs1042389 | TT | Genotype TT is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype CC. | TT | 28960269 |
| rs1042713 | AA | Genotype AA is associated with decreased response to salmeterol in children with Asthma. | AA | 23126384 |
| rs1042713 | A | Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG. | AA | 26774659 |
| rs1042713 | AA | Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG. | AA | 16322642 |
| rs1042713 | AA | Genotype AA is associated with decreased response to methacholine in people with Asthma as compared to genotype GG. | AA | 23384627 |
| rs1042713 | GG | Genotype GG is associated with increased response to propranolol in people with Liver Cirrhosis as compared to genotype AA. | AA | 26109805 |
| rs1042713 | AG + GG | Genotypes AG + GG are associated with increased response to benazepril in people with Essential hypertension as compared to genotype AA. | AA | 15554460 |
| rs10499563 | CC + CT | Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype TT. | TT | 24776844 |
| rs10509681 | C | Allele C is associated with increased metabolism of rosiglitazone in healthy individuals as compared to allele T. | TT | 17178266 |
| rs10509681 | C | Allele C is associated with increased metabolism of repaglinide in healthy individuals as compared to allele T. | TT | 14534525 |
| rs10517 | AA | Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG. | GG | 27740732 |
| rs10517 | GG | Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG. | GG | 26257249 |
| rs1051740 | CC | Genotype CC is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. | TT | 22188362 |
| rs1051740 | C | Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T. | TT | 19620853 |
| rs1051740 | CT | Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT. | TT | 22188362 |
| rs1051740 | TT | Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT. | TT | 23252947 |
| rs1051740 | CC | Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. | TT | 26555147 |
| rs1051740 | C | Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele T. | TT | 15692831 |
| rs1059513 | CC + CT | Genotypes CC + CT are associated with increased response to esomeprazole in children with eosinophilic esophagitis as compared to genotype TT. | TT | 31490856 |
| rs10841753 | CT + TT | Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | TT | 28525903 |
| rs1143634 | GG | Genotype GG is associated with decreased response to infliximab in people with Crohn Disease as compared to genotypes AA + AG. | GG | 22960943 |
| rs1143634 | A | Allele A is associated with increased dose of morphine in women with Pain, Postoperative as compared to allele G. | GG | 27649267 |
| rs11591147 | T | Allele T is associated with increased response to hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype GG. | GG | 26902539 |
| rs11702779 | AA | Genotype AA is associated with increased response to methacholine chloride in children with Asthma as compared to genotypes AG + GG. | GG | 21803869 |
| rs11960832 | TT | Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT. | TT | 23886675 |
| rs12082710 | TT | Genotype TT is associated with increased response to antidepressants in people with Depression as compared to genotypes CC + CT. | CC | 23092981 |
| rs1229984 | CT | Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes CC + TT. | CC | 31002879 |
| rs1232027 | A | Allele A is associated with increased response to methotrexate in people with Arthritis, Psoriatic as compared to allele G. | GG | 20472929 |
| rs12404655 | AG + GG | Genotypes AG + GG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype AA. | AA | 30088438 |
| rs12456693 | T | Allele T is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to allele C. | CC | 30487649 |
| rs12505410 | GG + GT | Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT. | TG | 24123600 |
| rs12505410 | GG | Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT. | TG | 29791011 |
| rs12566888 | TT | Genotype TT is associated with increased response to ticagrelor in healthy individuals as compared to genotype GT. | GG | 27937053 |
| rs1265138 | AA | Genotype AA is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG. | AG | 24024897 |
| rs1277733 | TT | Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC. | TC | 30032160 |
| rs13181 | GG | Genotype GG is associated with increased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes GT + TT. | TT | 27995989 |
| rs1412125 | CC | Genotype CC is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotypes CT + TT. | TT | 24684392 |
| rs1449683 | CC + CT | Genotypes CC + CT are associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to genotype TT. | CC | 25710119 |
| rs1611115 | CT + TT | Genotypes CT + TT are associated with increased response to levodopa in people with Cocaine-Related Disorders as compared to genotype CC. | CC | 24809448 |
| rs1611115 | CT + TT | Genotypes CT + TT is associated with increased response to naltrexone in men with Alcoholism as compared to genotype CC. | CC | 24724887 |
| rs17180299 | AG + GG | Genotypes AG + GG are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype AA. | AA | 27010727 |
| rs17268282 | T | Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G. | GG | 26927285 |
| rs1741981 | CC | Genotype CC is associated with decreased response to corticosteroids in children with Asthma as compared to genotypes CT + TT. | CC | 24307847 |
| rs1741981 | CC | Genotype CC is associated with decreased response to Corticosteroids For Systemic Use in people with Asthma as compared to genotypes CT + TT. | CC | 24307847 |
| rs17461620 | C | Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | CC | 19749758 |
| rs1799722 | CT | Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT. | TC | 29250329 |
| rs1799978 | TT | Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CT. | TC | 18855532 |
| rs1800629 | GG | Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid. | GG | 17673491 |
| rs1801131 | GT + TT | Genotypes GT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | TG | 26616421 |
| rs1801131 | GG + GT | Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT. | TG | 20385995 |
| rs1801131 | G | Allele G is associated with decreased response to benazepril in people with Hypertension. | TG | 16081343 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 21644011 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG. | GG | 23335901 |
| rs1801133 | A | Allele A is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G. | GG | 20078613 |
| rs1801133 | AA | Genotype AA is associated with increased response to benazepril in people with Hypertension as compared to genotypes AG + GG. | GG | 15226090 |
| rs1801133 | G | Allele G is associated with decreased response to benazepril in people with Hypertension. | GG | 16081343 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | GG | 25303299 |
| rs1801133 | AA | Genotype AA is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | GG | 17180579 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG. | GG | 29134491 |
| rs1801133 | A | Allele A is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major. | GG | 27035272 |
| rs1801394 | AA + AG | Genotypes AA + AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AA | 27676277 |
| rs1801394 | A | Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G. | AA | 29743634 |
| rs1801394 | AG + GG | Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA. | AA | 29589488 |
| rs1803545 | A | Allele A is associated with increased response to glibenclamide in people with as compared to allele G. | GG | 27403931 |
| rs1883112 | AA | Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG. | GG | 28485375 |
| rs191190 | CC + CT | Genotypes CC + CT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT. | CC | 27977334 |
| rs2071303 | CC + CT | Genotypes CC + CT are associated with increased response to adalimumab in people with Crohn Disease as compared to genotype TT. | TC | 27115882 |
| rs2229109 | CT | Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 25582575 |
| rs2230808 | CC | Genotype CC is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT. | TT | 20346718 |
| rs2246709 | AG + GG | Genotypes AG + GG are associated with increased response to amlodipine in people with Hypertension as compared to genotype AA. | AA | 19907160 |
| rs2273697 | AG | Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG. | GG | 28346059 |
| rs2273697 | AA + AG | Genotypes AA + AG are associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype GG. | GG | 18981587 |
| rs2273697 | AA + AG | Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG. | GG | 23252947 |
| rs2273697 | AG | Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG. | GG | 25348619 |
| rs2298805 | AA | Genotype AA is associated with increased response to desloratadine and mizolastine in people with Urticaria as compared to genotypes AG + GG. | GG | 25412950 |
| rs2303070 | T | Allele T is associated with increased response to glibenclamide in people with as compared to allele G. | GG | 27403931 |
| rs2305089 | TT | Genotype TT is associated with increased response to flunisolide in people with Asthma as compared to genotypes CC + CT. | TC | 22538805 |
| rs2305948 | CT + TT | Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC. | CC | 28488026 |
| rs2337980 | CC | Genotype CC is associated with increased response to nicotine in women as compared to genotypes CT + TT. | TC | 20231857 |
| rs2461817 | C | Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A. | AA | 23252947 |
| rs2461817 | AA | Genotype AA is associated with decreased concentrations of voriconazole as compared to genotype AC. | AA | 31932875 |
| rs2501873 | TT | Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT. | TC | 25356900 |
| rs2514218 | T | Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C. | CC | 26666695 |
| rs2532560 | G | Allele G is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele A. | AA | 27091189 |
| rs254271 | C | Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G. | GC | 29650774 |
| rs261316 | T | Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C. | TC | 29097388 |
| rs2740204 | T | Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele G. | GG | 20196918 |
| rs2776546 | A | Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C. | CC | 23753411 |
| rs28371685 | T | Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC. | CC | 16220110 |
| rs28371759 | AA | Genotype AA are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AG. | AA | 28079798 |
| rs286913 | A | Allele A is associated with increased response to ziprasidone in people with Schizophrenia as compared to allele G. | GG | 21107309 |
| rs28898617 | G | Allele G is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A. | AA | 28763744 |
| rs3025000 | CT + TT | Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC. | CC | 23149126 |
| rs3025000 | CT + TT | Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC. | CC | 23149126 |
| rs3184504 | T | Allele T is associated with increased response to candesartan in people with Hypertension as compared to allele C. | CC | 31327267 |
| rs3212986 | CC | Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC. | AC | 29662106 |
| rs3212986 | A | Allele A is not associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to allele C. | AC | 22329723 |
| rs3731722 | G | Allele G is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele A. | AA | 27798726 |
| rs3746544 | GG + GT | Genotypes GG + GT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT. | TT | 28871191 |
| rs3761555 | TT | Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT. | TT | 23394390 |
| rs3761847 | G | Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | GG | 25834819 |
| rs3768652 | AA + AC | Genotypes AA + AC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC. | CC | 30032160 |
| rs3787429 | TT | Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. | TC | 21652606 |
| rs3787430 | TT | Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. | CC | 21652606 |
| rs405509 | TT | Genotype TT is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes GG + GT. | GG | 32795354 |
| rs4148323 | AA | Genotype AA is associated with increased concentrations of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 18221820 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased exposure to letermovir as compared to genotype GG. | GG | 31022310 |
| rs4148412 | TT | Genotype TT is associated with increased concentrations of morphine-3-glucuronide in children with tonsillectomy as compared to genotypes CC + CT. | TC | 26810133 |
| rs4149118 | G | Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms. | GG | 21995462 |
| rs429358 | CC | Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Alzheimer Disease as compared to genotypes CT + TT. | TT | 28212683 |
| rs429358 | T | Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2. | TT | 21228733 |
| rs4420638 | G | Allele G is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases or Hypercholesterolemia as compared to allele A. | GG | 27648687 |
| rs445925 | A | Allele A is associated with increased response to hmg coa reductase inhibitors as compared to allele G. | GG | 25350695 |
| rs4646450 | GG | Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG. | AA | 29454235 |
| rs4680 | AA + AG | Genotypes AA + AG is associated with increased concentrations of glucose in children as compared to genotype GG. | GG | 25048416 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to opioids in children as compared to genotype GG. | GG | 30704436 |
| rs4680 | AA + AG | Genotypes AA + AG is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype GG. | GG | 23856854 |
| rs4680 | GG | Genotype GG is associated with decreased response to morphine in infants with Pain as compared to genotypes AA + AG. | GG | 27027462 |
| rs4680 | AA | Genotype AA is associated with increased response to remifentanil in infants with Pain as compared to genotypes AG + GG. | GG | 27027462 |
| rs4680 | A | Allele A is associated with increased response to morphine in people with Low Back Pain as compared to allele G. | GG | 23773341 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG. | GG | 22417933 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to morphine or remifentanil in infants with Pain as compared to genotype GG. | GG | 27027462 |
| rs4680 | GG | Genotype GG is associated with decreased response to fluvoxamine in people with Depressive Disorder, Major as compared to allele A. | GG | 20619611 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to oxycodone as compared to genotype GG. | GG | 31493434 |
| rs4680 | A | Allele A is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to allele G. | GG | 18989660 |
| rs4737771 | C | Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T. | TC | 27091189 |
| rs4795893 | AA + AG | Genotypes AA + AG is associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG. | GG | 24495780 |
| rs4795893 | G | Allele G is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele A. | GG | 26788534 |
| rs49411 | C | Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T. | TC | 27091189 |
| rs4961 | TT | Genotype TT is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG. | GG | 20877298 |
| rs4986910 | AG | Genotype AG is associated with increased response to fluvastatin as compared to genotype AA. | AA | 16103896 |
| rs5326 | CT + TT | Genotypes CT + TT are associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC. | TC | 23856854 |
| rs5569 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. | AG | 21127421 |
| rs5569 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. | AG | 29230023 |
| rs56113850 | T | Allele T is associated with decreased clearance of nicotine as compared to allele C. | TC | 26407342 |
| rs585719 | CT | Genotype CT is associated with increased response to citalopram in people with Depression as compared to genotype CC. | CC | 23158458 |
| rs5934731 | C | Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T. | TT | 21635146 |
| rs6458232 | C | Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele A. | AA | 21635146 |
| rs646776 | C | Allele C is associated with increased response to hmg coa reductase inhibitors as compared to allele T. | TT | 25350695 |
| rs671 | AA + AG | Genotypes AA + AG are associated with increased concentrations of nitroglycerin in children with Heart Defects, Congenital and Hypertension, Pulmonary as compared to genotype GG. | GG | 31250045 |
| rs671 | AG | Genotype AG is associated with increased exposure to ethanol in men as compared to genotype GG. | GG | 25365528 |
| rs671 | AG | Genotype AG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype GG. | GG | 31002879 |
| rs671 | AG | Genotype AG is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype GG. | GG | 31002879 |
| rs6806020 | C | Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | CC | 19749758 |
| rs683369 | CC | Genotype CC is associated with decreased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 24589908 |
| rs683369 | CC | Genotype CC is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 28289867 |
| rs686 | G | Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A. | AA | 21332319 |
| rs689466 | CC | Genotype CC is associated with increased response to celecoxib in healthy individuals as compared to genotypes CT + TT. | TC | 29066864 |
| rs6908425 | CT + TT | Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC. | TC | 27670765 |
| rs6961071 | GG | Genotype GG is associated with increased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG. | AA | 29502940 |
| rs7121 | CC | Genotype CC is associated with increased response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes CT + TT. | TC | 19274060 |
| rs7405404 | T | Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C. | CC | 29121268 |
| rs7412 | CT | Genotype CT is associated with increased response to atorvastatin as compared to genotype CC. | CC | 16103896 |
| rs7412 | C | Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T. | CC | 20031551 |
| rs7412 | CT + TT | Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC. | CC | 22331829 |
| rs7412 | CC | Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CT. | CC | 28079798 |
| rs7412 | CT | Genotype CT is associated with increased response to fluvastatin as compared to genotype CC. | CC | 30363031 |
| rs7412 | CT + TT | Genotypes CT + TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC. | CC | 12042669 |
| rs760370 | GG | Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG. | AA | 20812847 |
| rs760370 | A | Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G. | AA | 24361227 |
| rs760370 | AG + GG | Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA. | AA | 28992563 |
| rs7606603 | C | Allele C is associated with decreased response to atenolol in people with Hypertension as compared to allele T. | TC | 29650764 |
| rs762551 | AA | Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC. | AC | 20390257 |
| rs762551 | AA | Genotype AA is associated with increased metabolism of caffeine in people with Tobacco Use Disorder as compared to genotypes AC + CC. | AC | 17370067 |
| rs762551 | AA | Genotype AA is associated with increased clearance of carbamazepine in children with Epilepsy as compared to genotypes AC + CC. | AC | 26762380 |
| rs762551 | AA | Genotype AA is associated with increased metabolism of caffeine as compared to genotype AC. | AC | 10233211 |
| rs762551 | CC | Genotype CC is associated with increased response to nevirapine in people with HIV Infections as compared to genotypes AA + AC. | AC | 26348712 |
| rs7750468 | G | Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A. | GG | 19749758 |
| rs7772821 | GG | Genotype GG is associated with increased response to corticosteroids in people with Asthma as compared to genotypes GT + TT. | TG | 25919112 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 21503910 |
| rs8099917 | GG | Genotype GG is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes GT + TT. | TT | 26334898 |
| rs8187692 | A | Allele A is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G. | GG | 30100615 |
| rs833069 | CC + CT | Genotypes CC + CT are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype TT. | TC | 23559864 |
| rs9282564 | CT | Genotype CT is associated with increased concentrations of cyclosporine in people with heart transplantation as compared to genotype TT. | TT | 26107754 |
| rs9282564 | C | Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. | TT | 27566582 |
| rs933271 | C | Allele C is associated with decreased response to risperidone in people with Schizophrenia. | CC | 22935916 |
| rs9394992 | CT + TT | Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC. | TC | 28992563 |
| rs964184 | G | Allele G is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to allele C. | CC | 23119086 |
Page:
Variants which have in vitro functional analysis-type associations:
Page:
| Variant | Alleles | Associations | Genotype | PMID |
|---|---|---|---|---|
| rs1043657 | T | Allele T is associated with decreased enzyme activity of AKR7A2 when assayed with daunorubicin or doxorubicin as compared to allele C. | CC | 20837989 |
| rs1800629 | AG | Genotype AG is associated with decreased steady-state level of TNF when exposed to adalimumab as compared to genotype GG. | GG | 17343250 |
| rs1804645 | T | Allele T is associated with decreased activity of NCOA1 when exposed to tamoxifen. | CC | 22174377 |
| rs2229109 | T | Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C. | CC | 29443543 |
| rs304400 | AA | Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG. | AA | 28601971 |
| rs35350960 | A | Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38. | CC | 12181437 |
| rs3918290 | CT | Genotype CT is associated with decreased clearance of fluorouracil in peripheral blood mononuclear cells as compared to genotype CC. | CC | 26967565 |
| rs3918290 | CT | Genotype CT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype CC. | CC | 28295243 |
| rs3918290 | CT | Genotype CT is associated with decreased activity of DPYD as compared to genotype CC. | CC | 26804652 |
| rs3918290 | CT | Genotype CT is associated with decreased activity of DPYD as compared to genotype CC. | CC | 8698850 |
| rs4148323 | A | Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38. | GG | 12181437 |
| rs4148323 | AG | Genotype AG is associated with decreased clearance of SN-38 in human liver microsomes as compared to genotype GG. | GG | 24897286 |
| rs4148323 | AG | Genotype AG is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype GG. | GG | 24897286 |
| rs4557343 | T | Allele T is associated with increased expression of UGT2B15 in normal breast tissue. | TG | 21358749 |
| rs6962291 | AA | Genotype AA is associated with decreased steady-state level of TBX2 in plasma. | TA | 21449675 |
| rs6962291 | AA | Genotype AA is associated with decreased expression of TBXAS1 in PBMCs. | TA | 21449675 |
| rs731780 | G | Allele G is associated with increased expression of SLC29A1 as compared to allele C. | CG | 16609362 |
| rs762551 | A | Allele A is associated with increased activity of CYP1A2. | AC | 21593735 |
| rs1130169 | T | Allele T is associated with decreased expression of CD38. | TT | 20470215 |
| rs11971167 | T | Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines. | GG | 23891399 |
| rs1229984 | CT + TT | Genotypes CT + TT are associated with increased enzyme activity of ADH1B when exposed to ethanol as compared to genotype CC. | CC | 26863581 |
| rs12701634 | CC | Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT. | TT | 28601971 |
| rs17091297 | C | Allele C is associated with increased expression of ABCD1 in HapMap cells. | GG | 21383772 |
| rs1800629 | AA + AG | Genotypes AA + AG is associated with increased activity of TNF as compared to genotype GG. | GG | 18438841 |
| rs1801131 | GT | Genotype GT is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients. | TG | 15797993 |
| rs1801131 | GG + GT | Genotypes GG + GT is associated with increased sensitivity to gemcitabine as compared to genotype TT. | TG | 25560468 |
| rs1801394 | AG + GG | Genotypes AG + GG are associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients. | AA | 15797993 |
| rs1804645 | T | Allele T is associated with increased half-life of NCOA1. | CC | 22174377 |
| rs2168047 | T | Allele T is associated with increased expression of UGT2B4 in normal breast tissue. | CC | 21358749 |
| rs2515629 | G | Allele G is associated with increased expression of ABCA1 in HapMap cells. | AA | 21383772 |
| rs4773866 | T | Allele T is associated with increased expression of ABCC4 in HapMap cells. | CC | 21383772 |
| rs4898439 | A | Allele A is associated with increased expression of ABCD1 in HapMap cells. | CC | 21383772 |
| rs56113850 | CC + CT | Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT. | TC | 29232328 |
| rs6021191 | T | Allele T is associated with increased expression of NFATC2 as compared to allele A. | AA | 25987655 |
| rs6569487 | AA | Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG. | AG | 28601971 |
| rs841698 | T | Allele T is associated with increased expression of ABCD3 in HapMap cells. | CC | 21383772 |
| rs9357155 | A | Allele A is associated with increased expression of TAP2 in HapMap cells. | GG | 21383772 |
| rs9999111 | C | Allele C is associated with decreased expression of ABCG2 in human umbilical cord and T cells as compared to allele A. | AC | 28930109 |
| rs9999111 | C | Allele C is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A. | AC | 28930109 |
Page:
Third-party DB
Page:
| snp | phewas phenotype | p-value | odds-ratio | gene_name | gwas-associations |
|---|---|---|---|---|---|
| rs10033900 | Other hemoglobinopathies | 0.0106 | 0.502 | CFI | Age-related macular degeneration |
| rs10033900 | Lipoid metabolism disorder NOS | 0.0009218 | 0.7521 | CFI | Age-related macular degeneration |
| rs10033900 | Colon cancer | 0.004222 | 0.7967 | CFI | Age-related macular degeneration |
| rs10033900 | Osteoporosis | 0.006733 | 0.8851 | CFI | Age-related macular degeneration |
| rs10033900 | Epilepsy, recurrent seizures, convulsions | 3.18e-05 | 0.7614 | CFI | Age-related macular degeneration |
| rs10033900 | Colorectal cancer | 0.005395 | 0.813 | CFI | Age-related macular degeneration |
| rs10033900 | Open wounds of head; neck; and trunk | 0.01125 | 0.8775 | CFI | Age-related macular degeneration |
| rs10033900 | Poisoning by agents affecting the cardiovascular system | 0.008446 | 0.7698 | CFI | Age-related macular degeneration |
| rs10033900 | Bacterial enteritis | 0.009951 | 1.305 | CFI | Age-related macular degeneration |
| rs10033900 | Generalized convulsive epilepsy | 0.004709 | 0.6007 | CFI | Age-related macular degeneration |
| rs10033900 | Adverse effects of cardiac rhythm regulators | 0.005963 | 0.5641 | CFI | Age-related macular degeneration |
| rs10033900 | Osteoporosis, NOS or other | 0.00807 | 0.8903 | CFI | Age-related macular degeneration |
| rs10033900 | Diseases of the tongue | 0.009885 | 0.7238 | CFI | Age-related macular degeneration |
| rs10033900 | Alcohol-related disorders | 0.001194 | 0.8088 | CFI | Age-related macular degeneration |
| rs10033900 | Alcoholism | 0.001593 | 0.7903 | CFI | Age-related macular degeneration |
| rs10033900 | Epilepsy | 0.001148 | 0.6924 | CFI | Age-related macular degeneration |
| rs10033900 | Convulsions | 1.595e-05 | 0.7423 | CFI | Age-related macular degeneration |
| rs10033900 | Aseptic necrosis of bone | 0.005044 | 0.6275 | CFI | Age-related macular degeneration |
| rs10033900 | Sulfonamides | 0.0005884 | 0.7419 | CFI | Age-related macular degeneration |
| rs10033900 | Poisoning by other anti-infectives | 0.00507 | 0.8071 | CFI | Age-related macular degeneration |
| rs10033900 | Abnormal mammogram | 0.0005789 | 0.8096 | CFI | Age-related macular degeneration |
| rs10033900 | Polyneuropathy in diabetes | 0.005194 | 1.196 | CFI | Age-related macular degeneration |
| rs10045431 | Anal and rectal conditions | 0.005696 | 1.159 | IL12B | Crohn's disease |
| rs10045431 | Wheezing and painful respiration | 0.004513 | 0.8691 | IL12B | Crohn's disease |
| rs10045431 | Diseases of esophagus | 0.00257 | 0.9059 | IL12B | Crohn's disease |
| rs10045431 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.002691 | 1.284 | IL12B | Crohn's disease |
| rs10045431 | Myalgia and myositis NOS | 0.005783 | 0.8816 | IL12B | Crohn's disease |
| rs10045431 | Stomach cancer | 0.00147 | 0.4099 | IL12B | Crohn's disease |
| rs10045431 | Blister | 0.00145 | 0.3544 | IL12B | Crohn's disease |
| rs10045431 | Infertility, male | 0.008549 | 0.4266 | IL12B | Crohn's disease |
| rs10045431 | Esophagitis, GERD and related diseases | 0.00337 | 0.9061 | IL12B | Crohn's disease |
| rs10045431 | Thyroid cancer | 0.01021 | 1.476 | IL12B | Crohn's disease |
| rs10045431 | Sleep apnea | 0.008115 | 0.8862 | IL12B | Crohn's disease |
| rs10045431 | Cellulitis and abscess of leg | 0.008008 | 1.171 | IL12B | Crohn's disease |
| rs10045431 | Obstructive sleep apnea | 0.00357 | 0.8477 | IL12B | Crohn's disease |
| rs10045431 | Abnormal sputum | 0.003597 | 0.7034 | IL12B | Crohn's disease |
| rs10045431 | Other open wound of head and face | 0.009868 | 1.214 | IL12B | Crohn's disease |
| rs10045431 | Hypertrophy of female genital organs | 0.01087 | 0.5245 | IL12B | Crohn's disease |
| rs10088262 | Unspecified osteomyelitis | 0.001005 | 0.6587 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Chronic osteomyelitis | 0.008128 | 0.5743 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Arthralgia/ankylosis of temporomandibular joint | 0.007356 | 1.584 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Breast cancer | 0.0022 | 1.215 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Other open wound of head and face | 0.002539 | 0.7805 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Hematemesis | 0.007889 | 1.584 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Benign neoplasm of uterus | 0.01098 | 1.211 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Other pulmonary inflamation or edema | 0.007447 | 0.7238 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Systemic lupus erythematosus | 0.004757 | 0.5983 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Renal osteodystrophy | 0.0052 | 0.5918 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Derangement of joint, non-traumatic | 0.004486 | 0.7662 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Eustachian tube disorders | 0.002595 | 1.15 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Eustachian tube disorders | 0.009453 | 1.252 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Infections involving bone | 0.003132 | 0.7451 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Cancer of other female genital organs | 0.009138 | 1.887 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Open wounds of extremities | 0.002209 | 0.8684 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Osteomyelitis | 0.001277 | 0.6983 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Discoid lupus erythematosus | 0.001307 | 0.5744 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Open wounds of head; neck; and trunk | 0.005784 | 0.8496 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Breast cancer, including in situ | 0.001212 | 1.225 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Nonrheumatic pulmonary valve disorders | 0.005686 | 0.5424 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Breast cancer | 0.0006859 | 1.235 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Pain in limb | 0.01006 | 0.9155 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Diffuse diseases of connective tissue | 0.001544 | 0.7225 | FAM91A1 | Pancreatic cancer |
| rs10108954 | Osteoarthrosis; localized, secondary | 0.001684 | 2.997 | MFHAS1 | Prion diseases |
| rs10108954 | Type 1 diabetic ketoacidosis | 0.002179 | 2.305 | MFHAS1 | Prion diseases |
| rs10108954 | Inflammatory diseases of prostate | 0.01068 | 0.5122 | MFHAS1 | Prion diseases |
| rs10108954 | Malignant neoplasm of renal pelvis | 0.001616 | 4.243 | MFHAS1 | Prion diseases |
| rs10108954 | Endometrial hyperplasia | 0.008014 | 2.162 | MFHAS1 | Prion diseases |
| rs10108954 | Prostatitis | 0.001207 | 0.2639 | MFHAS1 | Prion diseases |
| rs10108954 | Sebaceous cyst | 0.003224 | 1.44 | MFHAS1 | Prion diseases |
| rs10108954 | Diseases of sebaceous glands | 0.00697 | 1.328 | MFHAS1 | Prion diseases |
| rs10108954 | Decubitus ulcer | 0.004701 | 1.683 | MFHAS1 | Prion diseases |
| rs1011970 | Hyperosmolality and/or hypernatremia | 0.007251 | 1.55 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Chronic lymphocytic thyroiditis | 0.005556 | 1.549 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Pain, swelling or discharge of eye | 0.009409 | 0.6391 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Cardiac arrhythmia NOS | 0.003151 | 0.8138 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Other specified cardiac dysrhythmias | 0.006973 | 0.8457 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Calculus of kidney | 0.004814 | 0.7884 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Rosacea | 0.002521 | 0.7586 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Supraventricular premature beats | 0.006424 | 0.6467 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Cardiac conduction disorders | 0.003454 | 0.8571 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Dry eyes | 0.006007 | 0.8359 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Osteoarthritis; localized | 0.001681 | 0.8344 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.005447 | 0.8674 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Atrial fibrillation | 0.008967 | 0.8564 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Epistaxis or throat hemorrhage | 0.003898 | 0.7459 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Coagulation defects | 0.002826 | 0.8636 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Abnormal electrocardiogram | 0.0108 | 0.8414 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Actinic keratosis | 0.01025 | 0.8783 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Secondary malignant neoplasm of liver | 0.01129 | 1.424 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Dyschromia and Vitiligo | 0.0003242 | 0.7015 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Other disorders of back | 0.01084 | 0.8246 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Thoracic neuritis/radiculitis | 4.595e-05 | 0.7953 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Palpitations | 0.009777 | 0.8482 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Cardiac dysrhythmias | 0.008813 | 0.9003 | CDKN2B-AS1 | Breast cancer |
| rs10166942 | Aplastic anemia | 0.01044 | 1.381 | TRPM8 | Migraine |
| rs10166942 | Hypotension NOS | 0.009278 | 0.8123 | TRPM8 | Migraine |
| rs10166942 | Chronic prostatitis | 0.009962 | 1.567 | TRPM8 | Migraine |
| rs10166942 | Disturbances of amino-acid transport | 0.002742 | 0.2784 | TRPM8 | Migraine |
| rs10166942 | Prolapse of vaginal walls | 0.006379 | 0.7865 | TRPM8 | Migraine |
| rs10166942 | Disturbances of sulphur-bearing amino-acid metabolism | 0.003296 | 0.2848 | TRPM8 | Migraine |
| rs10166942 | Myeloid leukemia | 0.006926 | 1.883 | TRPM8 | Migraine |
| rs10166942 | Redundant prepuce and phimosis/BXO | 0.006354 | 1.842 | TRPM8 | Migraine |
| rs10166942 | Ileostomy status | 0.0111 | 0.5064 | TRPM8 | Migraine |
| rs10166942 | Disorders of penis | 0.000505 | 1.572 | TRPM8 | Migraine |
| rs102275 | Abnormal heart sounds | 0.006918 | 0.848 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Other specified diseases of the salivary glands | 0.008384 | 0.5355 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Malignant neoplasm of kidney and other urinary organs | 0.008437 | 0.5593 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Lesions of stomach and duodenum | 0.008777 | 1.88 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Crohn's disease | 0.0004158 | 1.622 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Bipolar | 0.0009503 | 1.502 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Cancer of kidney and urinary organs | 0.01152 | 0.8292 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Aneurysm of artery of lower extremity | 0.00599 | 0.6 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Jaundice | 0.0003079 | 1.64 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Inflammatory disease of breast | 0.008991 | 1.527 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Vertiginous syndromes and other disorders of vestibular system | 0.0005992 | 1.125 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Inflammatory bowel disease | 0.0002721 | 1.461 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Hypocalcemia | 0.003373 | 1.474 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Ulcerative colitis | 0.01135 | 1.419 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Light-headedness and vertigo | 0.001165 | 1.123 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Disturbance of salivary secretion | 0.007191 | 0.5543 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs10237118 | Otitis externa | 0.00299 | 0.6638 | DENND2A | Optic disc parameters |
| rs10237118 | Other disorders of bladder | 0.008791 | 1.295 | DENND2A | Optic disc parameters |
| rs10237118 | Wheezing | 0.006126 | 1.576 | DENND2A | Optic disc parameters |
| rs10237118 | Alkalosis | 0.006621 | 2.286 | DENND2A | Optic disc parameters |
| rs10237118 | Injuries to the nervous system | 0.0004609 | 2.233 | DENND2A | Optic disc parameters |
| rs10237118 | Benign neoplasm of unspecified sites | 0.002912 | 2.811 | DENND2A | Optic disc parameters |
| rs10237118 | Cholangitis | 0.002965 | 2.33 | DENND2A | Optic disc parameters |
| rs10237118 | Phosphorus metabolism disorder | 0.005581 | 1.76 | DENND2A | Optic disc parameters |
| rs10237118 | Major depressive disorder | 0.001036 | 0.675 | DENND2A | Optic disc parameters |
| rs10237118 | Mechanical complication due to other implant and internal device | 0.006528 | 1.601 | DENND2A | Optic disc parameters |
| rs10237118 | Other disorders of biliary tract | 0.001525 | 2.022 | DENND2A | Optic disc parameters |
| rs10237118 | Conductive hearing loss | 0.004256 | 1.985 | DENND2A | Optic disc parameters |
| rs10237118 | Impacted cerumen | 0.005186 | 0.808 | DENND2A | Optic disc parameters |
| rs10237118 | Impetigo | 0.002147 | 2.097 | DENND2A | Optic disc parameters |
| rs1024161 | Aortic aneurysm | 0.006306 | 0.8251 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Idiopathic fibrosing alveolitis | 0.01079 | 0.5287 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Other aneurysm | 0.004168 | 0.8337 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Abdominal aortic aneurysm | 0.004001 | 0.7909 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Renal dialysis | 0.0104 | 0.7063 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Unstable angina (intermediate coronary syndrome) | 0.007574 | 0.8583 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Ischemic Heart Disease | 0.003839 | 0.9143 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Osteoarthrosis, generalized | 0.009093 | 1.207 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Atherosclerosis of the extremities | 0.006519 | 0.8731 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Hypothyroidism | 0.01144 | 1.097 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Other disorders of bone and cartilage | 0.002293 | 1.245 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Rotator cuff (capsule) sprain | 0.003137 | 1.218 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Symptomatic artificial menopause | 0.006214 | 1.501 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Thyrotoxicosis | 9.424e-05 | 1.355 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Large cell lymphoma | 0.00794 | 1.91 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Dental caries | 0.006336 | 0.8297 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Extrinsic allergic alveolitis | 0.001979 | 2.237 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Other alveolar and parietoalveolar pneumonopathy | 0.01128 | 0.6032 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Diseases of hard tissues of teeth | 0.004981 | 0.8294 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Kyphosis (acquired) | 0.01093 | 0.679 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Graves' disease | 0.002473 | 1.538 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Open wound of nose and sinus | 0.005732 | 0.4277 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Atherosclerosis | 0.00681 | 0.8881 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Coronary atherosclerosis | 0.006863 | 0.9153 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Chronic sinusitis | 0.005705 | 1.123 | CTLA4 | Alopecia areata, Graves' disease |
| rs10276619 | ASCVD | 0.002769 | 1.405 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Methicillin sensitive Staphylococcus aureus | 0.007986 | 0.7385 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Atrophy of edentulous alveolar ridge | 0.01012 | 0.6588 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Chronic osteomyelitis | 0.008347 | 0.6159 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Random mental disorder. Ignored for now | 0.002996 | 0.5998 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Strabismus (not specified as paralytic) | 0.01046 | 0.8121 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Disorders of parathyroid gland | 0.00801 | 1.281 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Type 1 diabetes | 0.006004 | 0.8437 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Diabetic retinopathy | 0.009858 | 0.8405 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Chronic sinusitis | 0.006844 | 1.122 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Allergic rhinitis | 0.001943 | 1.135 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Hematemesis | 0.004469 | 0.5776 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Peripheral retinal degenerations | 0.008706 | 1.287 | IKZF1 | Hippocampal atrophy |
| rs1033180 | Cancer of kidney and urinary organs | 0.003841 | 1.399 | IRF4 | Celiac disease |
| rs1033180 | Other hypertrophic and atrophic conditions of skin | 0.01069 | 0.8204 | IRF4 | Celiac disease |
| rs1033180 | Malignant neoplasm of kidney and other urinary organs | 0.008762 | 2.05 | IRF4 | Celiac disease |
| rs1033180 | Other abnormal blood chemistry | 0.002143 | 1.25 | IRF4 | Celiac disease |
| rs1033180 | Bladder cancer | 0.003541 | 1.519 | IRF4 | Celiac disease |
| rs1033180 | Other sprains and strains | 0.002481 | 0.4039 | IRF4 | Celiac disease |
| rs1033180 | Derangement of joint, non-traumatic | 0.01145 | 0.6317 | IRF4 | Celiac disease |
| rs1033180 | Nonrheumatic mitral valve disorders | 0.008398 | 1.258 | IRF4 | Celiac disease |
| rs1033180 | Psoriasis & related disorders | 0.008392 | 0.636 | IRF4 | Celiac disease |
| rs1033180 | Bladder cancer and neoplasms | 0.003541 | 1.503 | IRF4 | Celiac disease |
| rs1043879 | Abnormal sputum | 0.008768 | 1.328 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other specified nonpsychotic and/or transient mental disorders | 0.002277 | 1.274 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Adrenal hyperfunction | 0.01031 | 1.776 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Cystic kidney disease | 0.006752 | 0.5474 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Hallucinations | 0.007229 | 1.82 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other disorders of back | 0.003 | 1.193 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other disorders of the kidney and ureters | 0.01105 | 0.8881 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Congenital anomalies of urinary system | 0.01134 | 0.6387 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Premenstrual tension syndromes | 0.008223 | 1.882 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Diaphragmatic hernia | 0.007613 | 1.148 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other conditions of brain | 0.003519 | 1.364 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Persistent mental disorders due to other conditions | 0.00612 | 1.178 | C1orf63 | Erythrocyte sedimentation rate |
| rs10438933 | Other specified peripheral vascular diseases | 0.003469 | 2.305 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Wheezing and painful respiration | 0.00808 | 0.8375 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Balanoposthitis | 0.007836 | 1.899 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Retinal detachments and defects | 0.0005208 | 0.6616 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Contact dermatitis and other eczema due to plants [except food] | 0.005304 | 1.988 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Macular degeneration | 0.006306 | 0.8355 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Acquired deformities of finger | 0.002647 | 1.685 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Glossitis | 0.002598 | 2.327 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Hypothyroidism | 0.009487 | 1.14 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Sinoatrial node dysfunction | 0.01102 | 1.377 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10444502 | Emphysema | 0.006796 | 0.767 | KSR2 | Total Cholesterol |
| rs10444502 | Chronic cystitis | 0.008675 | 0.6346 | KSR2 | Total Cholesterol |
| rs10444502 | Male infertility and abnormal spermatozoa | 0.002069 | 1.794 | KSR2 | Total Cholesterol |
| rs10444502 | Ankylosing spondylitis | 0.00683 | 0.3096 | KSR2 | Total Cholesterol |
| rs10444502 | Hematuria | 0.009936 | 0.8957 | KSR2 | Total Cholesterol |
| rs10444502 | Infertility, male | 0.005632 | 1.909 | KSR2 | Total Cholesterol |
| rs10444502 | Abnormal heart sounds | 0.009046 | 1.167 | KSR2 | Total Cholesterol |
| rs10444502 | Secondary malignant neoplasm | 0.003785 | 1.177 | KSR2 | Total Cholesterol |
| rs10444502 | Fracture of ankle and foot | 0.002354 | 0.8446 | KSR2 | Total Cholesterol |
| rs10444502 | Open-angle glaucoma | 0.0006343 | 1.222 | KSR2 | Total Cholesterol |
| rs10444502 | Dysuria | 0.003059 | 0.8397 | KSR2 | Total Cholesterol |
| rs10444502 | Benign neoplasm of colon | 0.004908 | 0.9067 | KSR2 | Total Cholesterol |
| rs10444502 | Angina pectoris | 0.008152 | 1.133 | KSR2 | Total Cholesterol |
| rs10444502 | Abnormal findings on radiological examination intrathoracic organs | 0.00503 | 1.224 | KSR2 | Total Cholesterol |
| rs10444502 | Disease of tricuspid valve | 0.009377 | 0.7808 | KSR2 | Total Cholesterol |
| rs10444502 | Melanoma | 0.0095 | 1.263 | KSR2 | Total Cholesterol |
| rs10444502 | Prurigo | 0.002119 | 1.334 | KSR2 | Total Cholesterol |
| rs10466868 | Hemorrhage or hematoma complicating a procedure | 0.009831 | 1.324 | GPR133 | Erythropoietin |
| rs10466868 | Noninfectious disorders of lymphatic channels | 0.009535 | 0.5656 | GPR133 | Erythropoietin |
| rs10466868 | Heart transplant/surgery | 0.004582 | 1.679 | GPR133 | Erythropoietin |
| rs10466868 | Other arthropathies | 0.001589 | 1.228 | GPR133 | Erythropoietin |
| rs10466868 | Abnormal heart sounds | 0.0003431 | 1.363 | GPR133 | Erythropoietin |
| rs10466868 | Unspecified local infection of skin and subcutaneous tissue | 0.003785 | 1.439 | GPR133 | Erythropoietin |
| rs10466868 | Convulsions | 0.002768 | 1.354 | GPR133 | Erythropoietin |
| rs10466868 | Inflammatory spondylopathies | 0.008595 | 1.732 | GPR133 | Erythropoietin |
| rs10466868 | Nephritis and nephropathy in diseases classified elsewhere | 0.007359 | 1.431 | GPR133 | Erythropoietin |
| rs10466868 | Postnasal drip | 0.009435 | 2.014 | GPR133 | Erythropoietin |
| rs10466868 | Open wounds of head; neck; and trunk | 0.01022 | 1.233 | GPR133 | Erythropoietin |
| rs10466868 | Valvular heart disease/ heart chambers | 0.009581 | 1.997 | GPR133 | Erythropoietin |
| rs10466868 | Arthropathy NOS | 0.008652 | 1.284 | GPR133 | Erythropoietin |
| rs10466868 | Peripheral autonomic neuropathy | 0.007332 | 1.559 | GPR133 | Erythropoietin |
| rs10466868 | Rotator cuff (capsule) sprain | 0.003323 | 1.345 | GPR133 | Erythropoietin |
| rs10466868 | Cyst or abscess of Bartholin's gland | 0.001001 | 2.602 | GPR133 | Erythropoietin |
| rs10466868 | Posttraumatic wound infection | 0.003564 | 2.182 | GPR133 | Erythropoietin |
| rs10466868 | Epilepsy, recurrent seizures, convulsions | 0.01047 | 1.286 | GPR133 | Erythropoietin |
| rs10466868 | Venous embolism & thrombosis | 0.004849 | 0.7675 | GPR133 | Erythropoietin |
| rs10466868 | Postoperative infection | 0.00485 | 1.334 | GPR133 | Erythropoietin |
| rs10466868 | Cellulitis and abscess of trunk | 0.01147 | 1.426 | GPR133 | Erythropoietin |
| rs10466868 | Gastroparesis | 0.01054 | 1.917 | GPR133 | Erythropoietin |
| rs10466868 | Localized adiposity | 0.0007145 | 2.625 | GPR133 | Erythropoietin |
| rs10466868 | Ill-defined descriptions and complications of heart disease | 0.002304 | 1.213 | GPR133 | Erythropoietin |
| rs10486567 | Sialoadenitis | 0.006257 | 0.5845 | JAZF1 | Prostate cancer |
| rs10486567 | Nontoxic uninodular goiter | 0.005946 | 0.7695 | JAZF1 | Prostate cancer |
| rs10486567 | Pruritus and related conditions | 0.004199 | 1.237 | JAZF1 | Prostate cancer |
| rs10486567 | Respiratory failure | 0.002591 | 1.336 | JAZF1 | Prostate cancer |
| rs10486567 | Stomatitis and mucositis | 0.009818 | 0.6627 | JAZF1 | Prostate cancer |
| rs10486567 | Peritonitis and retroperitoneal infections | 0.00191 | 0.5776 | JAZF1 | Prostate cancer |
| rs10486567 | Ulcerative stomatitis & mucositis | 0.01144 | 0.4271 | JAZF1 | Prostate cancer |
| rs10486567 | Precordial pain | 0.008066 | 1.332 | JAZF1 | Prostate cancer |
| rs10486567 | Neurological disorders due to brain damage | 0.01041 | 0.8662 | JAZF1 | Prostate cancer |
| rs10486567 | Prolapse of vaginal walls | 0.009788 | 0.803 | JAZF1 | Prostate cancer |
| rs10486567 | Urethritis and urethral syndrome | 0.001967 | 1.925 | JAZF1 | Prostate cancer |
| rs10486567 | Congenital anomalies of face and neck | 0.001984 | 2.415 | JAZF1 | Prostate cancer |
| rs10486567 | Nephritis & nephropathy | 0.006057 | 0.488 | JAZF1 | Prostate cancer |
| rs10494067 | Chronic glomerulonephritis | 0.004249 | 3.096 | NTNG1 | Anorexia nervosa |
| rs10494067 | Chronic lymphocytic thyroiditis | 0.007268 | 0.2084 | NTNG1 | Anorexia nervosa |
| rs10494067 | Other abnormality of urination | 0.008646 | 0.6317 | NTNG1 | Anorexia nervosa |
| rs10494067 | Lymphadenitis | 0.006993 | 0.6613 | NTNG1 | Anorexia nervosa |
| rs10494067 | Strabismus (not specified as paralytic) | 0.006491 | 0.5681 | NTNG1 | Anorexia nervosa |
| rs10494067 | Rosacea | 0.00892 | 1.382 | NTNG1 | Anorexia nervosa |
| rs10494067 | Disorders of binocular eye movements | 0.002919 | 0.5956 | NTNG1 | Anorexia nervosa |
| rs10494067 | Secondary malignancy of lung | 0.006391 | 1.742 | NTNG1 | Anorexia nervosa |
| rs10494067 | Reflux esophagitis | 0.008196 | 1.437 | NTNG1 | Anorexia nervosa |
| rs10494067 | Gangrene | 0.001445 | 2.358 | NTNG1 | Anorexia nervosa |
| rs10500991 | Unspecified polyarthropathy or polyarthritis | 0.008388 | 1.604 | LUZP2 | Serum transferrin |
| rs10500991 | Disturbance of salivary secretion | 0.00447 | 0.304 | LUZP2 | Serum transferrin |
| rs10500991 | Nerve root lesions | 0.004786 | 1.782 | LUZP2 | Serum transferrin |
| rs10500991 | Noninflammatory female genital disorders | 0.007699 | 0.7757 | LUZP2 | Serum transferrin |
| rs10500991 | Infection of the eye | 0.0016 | 1.247 | LUZP2 | Serum transferrin |
| rs10500991 | Rheumatoid arthritis | 0.002207 | 1.329 | LUZP2 | Serum transferrin |
| rs10500991 | Prurigo | 0.00488 | 0.6671 | LUZP2 | Serum transferrin |
| rs10500991 | Conjunctivitis, infectious | 0.002231 | 1.266 | LUZP2 | Serum transferrin |
| rs10500991 | Other disorders of the nervous system | 0.0007137 | 1.852 | LUZP2 | Serum transferrin |
| rs10500991 | Sarcoidosis | 0.01151 | 0.4343 | LUZP2 | Serum transferrin |
| rs10500991 | Inflammation of eyelids | 0.003979 | 1.199 | LUZP2 | Serum transferrin |
| rs10500991 | Chronic kidney disease, Stage I or II | 0.003067 | 1.537 | LUZP2 | Serum transferrin |
| rs10500991 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.009609 | 1.244 | LUZP2 | Serum transferrin |
| rs10500991 | Prostatitis | 0.0005245 | 1.527 | LUZP2 | Serum transferrin |
| rs10500991 | Abnormal reflex | 0.00377 | 2.408 | LUZP2 | Serum transferrin |
| rs10502868 | Conjunctivitis, noninfectious | 0.00247 | 1.562 | SLC14A2 | Albumin levels |
| rs10502868 | Calculus of lower urinary tract | 0.008337 | 2.036 | SLC14A2 | Albumin levels |
| rs10502868 | Appendicitis | 0.007009 | 1.708 | SLC14A2 | Albumin levels |
| rs10502868 | Heart valve replaced | 0.00298 | 1.599 | SLC14A2 | Albumin levels |
| rs10502868 | Other local infections of skin and subcutaneous tissue | 0.005492 | 1.329 | SLC14A2 | Albumin levels |
| rs10502868 | Allergy to serum or vaccine | 0.0005339 | 2.673 | SLC14A2 | Albumin levels |
| rs10502868 | Methicillin sensitive Staphylococcus aureus | 0.005391 | 1.623 | SLC14A2 | Albumin levels |
| rs10502868 | Ill-defined descriptions and complications of heart disease | 0.003668 | 1.244 | SLC14A2 | Albumin levels |
| rs10502868 | Patellar fracture | 0.008784 | 1.718 | SLC14A2 | Albumin levels |
| rs10502868 | Circulatory disease NEC | 0.001683 | 1.368 | SLC14A2 | Albumin levels |
| rs10502868 | Antisocial/borderline personality disorder | 0.01146 | 1.977 | SLC14A2 | Albumin levels |
| rs10502868 | Allergic conjunctivitis | 0.003269 | 1.598 | SLC14A2 | Albumin levels |
| rs10502868 | Ptosis of eyelid | 0.007296 | 1.405 | SLC14A2 | Albumin levels |
| rs10502868 | Hypotony of eye | 0.005312 | 2.849 | SLC14A2 | Albumin levels |
| rs10502868 | Posterior pituitary disorders | 0.009386 | 2.103 | SLC14A2 | Albumin levels |
| rs10502868 | Localized superficial swelling, mass, or lump | 0.003148 | 1.538 | SLC14A2 | Albumin levels |
| rs10502868 | Exophthalmos | 0.003372 | 2.519 | SLC14A2 | Albumin levels |
| rs10502868 | Cyst of kidney, acquired | 0.007493 | 1.554 | SLC14A2 | Albumin levels |
| rs10502868 | Other disorders of circulatory system | 0.00116 | 1.342 | SLC14A2 | Albumin levels |
| rs10502868 | Atrial flutter | 0.0114 | 1.411 | SLC14A2 | Albumin levels |
| rs10502868 | Renal colic | 0.004687 | 2.162 | SLC14A2 | Albumin levels |
| rs10502868 | Hx of malignant neoplasm of oral cavity and pharynx | 0.0101 | 1.998 | SLC14A2 | Albumin levels |
| rs10502868 | Heart transplant/surgery | 0.002724 | 1.895 | SLC14A2 | Albumin levels |
| rs10502868 | Hyposmolality and/or hyponatremia | 0.006789 | 1.327 | SLC14A2 | Albumin levels |
| rs10502868 | Vascular disorders of penis | 0.008806 | 3.177 | SLC14A2 | Albumin levels |
| rs10502868 | Disorders of the autonomic nervous system | 0.006639 | 1.567 | SLC14A2 | Albumin levels |
| rs10502868 | Chronic obstructive asthma | 0.004141 | 1.562 | SLC14A2 | Albumin levels |
| rs10502868 | Staphylococcus infections | 0.004476 | 1.489 | SLC14A2 | Albumin levels |
| rs10502868 | Nephritis and nephropathy in diseases classified elsewhere | 0.008735 | 1.514 | SLC14A2 | Albumin levels |
| rs10502868 | Dermatophytosis | 0.01133 | 1.205 | SLC14A2 | Albumin levels |
| rs10502868 | Speech and language disorder | 0.004294 | 1.76 | SLC14A2 | Albumin levels |
| rs10502868 | Asthma | 0.0005259 | 1.313 | SLC14A2 | Albumin levels |
| rs10503019 | Chronic pharyngitis and nasopharyngitis | 0.006153 | 0.8212 | ATP8B1 | Vitiligo |
| rs10503019 | Swelling, mass, or lump in head and neck | 0.008592 | 0.7658 | ATP8B1 | Vitiligo |
| rs10503019 | Other local infections of skin and subcutaneous tissue | 0.008052 | 0.8233 | ATP8B1 | Vitiligo |
| rs10503019 | Deviated nasal septum | 0.007266 | 0.8116 | ATP8B1 | Vitiligo |
| rs10503019 | Hypoglycemia | 0.008738 | 1.505 | ATP8B1 | Vitiligo |
| rs10503019 | Unspecified local infection of skin and subcutaneous tissue | 0.008383 | 0.743 | ATP8B1 | Vitiligo |
| rs10503019 | Renal failure NOS | 0.002306 | 0.6446 | ATP8B1 | Vitiligo |
| rs10503019 | Acquired deformities of limbs | 0.006224 | 0.7687 | ATP8B1 | Vitiligo |
| rs10503019 | Nonsenile Cataract | 0.005673 | 0.6497 | ATP8B1 | Vitiligo |
| rs10503019 | Osteoporosis, NOS or other | 0.007432 | 0.8632 | ATP8B1 | Vitiligo |
| rs10503019 | Vitamin B12 deficiency anemia | 0.002648 | 1.68 | ATP8B1 | Vitiligo |
| rs10503019 | Dementia with cerebral degenerations | 0.0002449 | 0.3823 | ATP8B1 | Vitiligo |
| rs10503019 | Schizophrenia | 0.002106 | 1.845 | ATP8B1 | Vitiligo |
| rs10503019 | Other disorders of back | 0.006173 | 0.8324 | ATP8B1 | Vitiligo |
| rs10503253 | Hemiplegia | 0.00473 | 0.6502 | CSMD1 | Schizophrenia |
| rs10503253 | Genitourinary congenital anomalies | 0.00301 | 0.6032 | CSMD1 | Schizophrenia |
| rs10503253 | Unequal leg length (acquired) | 0.01042 | 0.597 | CSMD1 | Schizophrenia |
| rs10503253 | Breast disorder NOS | 0.01135 | 0.1581 | CSMD1 | Schizophrenia |
| rs10503253 | Viral Enteritis | 0.00352 | 1.594 | CSMD1 | Schizophrenia |
| rs10503253 | Disturbances of sulphur-bearing amino-acid metabolism | 0.003504 | 1.954 | CSMD1 | Schizophrenia |
| rs10503253 | Heartburn | 0.007933 | 1.421 | CSMD1 | Schizophrenia |
| rs10503253 | Disturbances of amino-acid transport | 0.005238 | 1.891 | CSMD1 | Schizophrenia |
| rs10503253 | Adverse drug events and drug allergies | 0.005236 | 0.8113 | CSMD1 | Schizophrenia |
| rs10503253 | Disorders of synovium, tendon, and bursa | 0.01148 | 0.8784 | CSMD1 | Schizophrenia |
| rs10503253 | Senile dementia | 0.003579 | 1.301 | CSMD1 | Schizophrenia |
| rs10503253 | Atherosclerosis | 0.01085 | 0.8723 | CSMD1 | Schizophrenia |
| rs10503253 | Pelvic inflammatory disease | 0.002087 | 0.1625 | CSMD1 | Schizophrenia |
| rs10503253 | Paroxysmal ventricular tachycardia | 0.001803 | 0.6746 | CSMD1 | Schizophrenia |
| rs10503253 | Adverse effects of adrenal cortical steroids | 0.006098 | 0.5108 | CSMD1 | Schizophrenia |
| rs10503253 | Macular puckering of retina | 0.0002164 | 1.376 | CSMD1 | Schizophrenia |
| rs10503253 | Chronic kidney disease, Stage I or II | 0.00922 | 0.6436 | CSMD1 | Schizophrenia |
| rs10503253 | Fracture of vertebral column without mention of spinal cord injury | 0.004569 | 1.283 | CSMD1 | Schizophrenia |
| rs10503253 | Other signs and symptoms in breast | 0.004438 | 1.442 | CSMD1 | Schizophrenia |
| rs10503253 | Mixed hyperlipidemia | 0.009826 | 0.8232 | CSMD1 | Schizophrenia |
| rs10503253 | Swelling of limb | 0.001174 | 0.7817 | CSMD1 | Schizophrenia |
| rs10508503 | Cancer of the upper aerodigestive tract | 0.01105 | 0.5096 | PTER | Obesity |
| rs10508503 | Other disorders of prostate | 0.008246 | 0.6119 | PTER | Obesity |
| rs10508503 | Other hypertensive complications | 0.005434 | 0.6308 | PTER | Obesity |
| rs10508503 | Adverse effects of antirheumatics | 0.01143 | 1.932 | PTER | Obesity |
| rs10508503 | Pseudomonal pneumonia | 0.01043 | 2.465 | PTER | Obesity |
| rs10508503 | Traumatic arthropathy | 0.001501 | 2.087 | PTER | Obesity |
| rs10508503 | Other specified peripheral vascular diseases | 0.01075 | 2.249 | PTER | Obesity |
| rs10508503 | Hidradenitis | 0.01054 | 2.439 | PTER | Obesity |
| rs10510102 | Purpura and other hemorrhagic conditions | 0.009942 | 0.8259 | ATE1 | Breast cancer |
| rs10510102 | Congenital anomalies of the eye | 0.003897 | 1.314 | ATE1 | Breast cancer |
| rs10510102 | Cyst of kidney, acquired | 0.01011 | 0.7054 | ATE1 | Breast cancer |
| rs10510102 | Psychogenic and somatoform disorders | 0.009836 | 1.321 | ATE1 | Breast cancer |
| rs10510102 | Mechanical complication due to other implant and internal device | 0.01147 | 0.667 | ATE1 | Breast cancer |
| rs10510102 | Peripheral or central vertigo | 0.00298 | 1.287 | ATE1 | Breast cancer |
| rs10510102 | Alkalosis | 0.008037 | 1.9 | ATE1 | Breast cancer |
| rs10510102 | Open wound of eye or eyelid | 0.0001119 | 2.804 | ATE1 | Breast cancer |
| rs10510102 | Infections involving bone | 0.005669 | 0.714 | ATE1 | Breast cancer |
| rs10510102 | Other disorders of the kidney and ureters | 0.00473 | 0.8573 | ATE1 | Breast cancer |
| rs10510102 | Failure to thrive | 0.01113 | 0.6268 | ATE1 | Breast cancer |
| rs10510102 | Allergic reaction to food | 0.008207 | 1.936 | ATE1 | Breast cancer |
| rs10510102 | Orchitis and epididymitis | 0.01125 | 0.6097 | ATE1 | Breast cancer |
| rs10510102 | Psychogenic disorder | 0.0002677 | 1.757 | ATE1 | Breast cancer |
| rs10510102 | Gastrointestinal malfunction arising from mental factors | 0.003113 | 2.334 | ATE1 | Breast cancer |
| rs10510102 | Empyema and pneumothorax | 0.008261 | 1.351 | ATE1 | Breast cancer |
| rs10516430 | Adverse effects of cardiac rhythm regulators | 0.01122 | 1.692 | RAP1GDS1 | Triglycerides |
| rs10516430 | Hypercoagulable state | 0.01096 | 1.478 | RAP1GDS1 | Triglycerides |
| rs10516430 | Cyst or abscess of Bartholin's gland | 0.006463 | 1.945 | RAP1GDS1 | Triglycerides |
| rs10516430 | Malignant neoplasm of ovary | 0.001978 | 1.799 | RAP1GDS1 | Triglycerides |
| rs10516430 | Bronchopneumonia and lung abscess | 0.006058 | 1.77 | RAP1GDS1 | Triglycerides |
| rs10516430 | Cancer of other female genital organs | 0.000343 | 1.663 | RAP1GDS1 | Triglycerides |
| rs10516430 | Clotting factor deficiency | 0.007321 | 2.047 | RAP1GDS1 | Triglycerides |
| rs10516430 | Diverticulosis and diverticulitis | 0.01097 | 1.112 | RAP1GDS1 | Triglycerides |
| rs10516430 | Cervical cancer | 0.0005225 | 2.185 | RAP1GDS1 | Triglycerides |
| rs10516430 | Symptoms associated with female genital organs | 0.003936 | 1.218 | RAP1GDS1 | Triglycerides |
| rs10516430 | Swelling, mass, or lump in head and neck | 0.009221 | 0.7924 | RAP1GDS1 | Triglycerides |
| rs10516430 | Poisoning by hormones and synthetic substitutes | 0.009046 | 0.6933 | RAP1GDS1 | Triglycerides |
| rs10516430 | Ovarian cancer | 0.0002133 | 1.828 | RAP1GDS1 | Triglycerides |
| rs10516430 | Corneal opacity | 0.002775 | 1.42 | RAP1GDS1 | Triglycerides |
| rs10516430 | Congenital cataract and lens anomalies | 0.01042 | 1.851 | RAP1GDS1 | Triglycerides |
| rs10518025 | Contact and allergic dermatitis of eyelid | 0.01073 | 1.851 | CENPC1 | Multiple sclerosis |
| rs10518025 | Leukoplakia of oral mucosa | 0.001894 | 2.129 | CENPC1 | Multiple sclerosis |
| rs10518025 | Other acute and subacute forms of ischemic heart disease | 0.0005549 | 2.337 | CENPC1 | Multiple sclerosis |
| rs10518025 | Fibroadenosis of breast | 0.0003446 | 3.189 | CENPC1 | Multiple sclerosis |
| rs10518025 | Alopecia Areata | 0.004589 | 2.262 | CENPC1 | Multiple sclerosis |
| rs10518025 | Sialoadenitis | 0.004464 | 1.63 | CENPC1 | Multiple sclerosis |
| rs10518025 | Primary/intrinsic cardiomyopathies | 0.01122 | 0.7852 | CENPC1 | Multiple sclerosis |
| rs10518025 | Gastrointestinal complications | 0.006792 | 1.353 | CENPC1 | Multiple sclerosis |
| rs10518025 | Aortic aneurysm | 0.002786 | 0.7389 | CENPC1 | Multiple sclerosis |
| rs10518025 | Melanoma | 0.008837 | 1.344 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cancer of other female genital organs | 0.008915 | 2.08 | CENPC1 | Multiple sclerosis |
| rs10518025 | Other aneurysm | 0.0007918 | 0.7359 | CENPC1 | Multiple sclerosis |
| rs10518025 | Fracture of unspecified bones | 0.0008159 | 0.7608 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cellulitis and abscess of trunk | 0.00151 | 1.462 | CENPC1 | Multiple sclerosis |
| rs10518025 | Dry eyes | 0.007969 | 1.192 | CENPC1 | Multiple sclerosis |
| rs10518025 | Mastodynia | 0.009463 | 1.352 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cardiomyopathy | 0.01055 | 0.7894 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cellulitis and abscess of face | 0.005262 | 1.487 | CENPC1 | Multiple sclerosis |
| rs10518025 | Abnormal kidney function | 0.007524 | 2.145 | CENPC1 | Multiple sclerosis |
| rs10518765 | Other disorders of urethra and urinary tract | 0.007939 | 1.242 | UNC13C | Alkaline phosphatase |
| rs10518765 | Urethritis and urethral syndrome | 0.008549 | 1.766 | UNC13C | Alkaline phosphatase |
| rs10518765 | Bipolar | 0.005614 | 0.6135 | UNC13C | Alkaline phosphatase |
| rs10518765 | Pain in joint | 0.00573 | 0.9034 | UNC13C | Alkaline phosphatase |
| rs10518765 | Microscopic hematuria | 0.004421 | 0.5227 | UNC13C | Alkaline phosphatase |
| rs10518765 | Benign neoplasm of brain and other parts of nervous system | 0.00673 | 1.449 | UNC13C | Alkaline phosphatase |
| rs10518765 | Cystitis and urethritis | 0.01062 | 1.227 | UNC13C | Alkaline phosphatase |
| rs10518765 | Other specified diseases of the salivary glands | 0.003621 | 0.3786 | UNC13C | Alkaline phosphatase |
| rs10518765 | Mucous polyp of cervix | 0.006876 | 0.6338 | UNC13C | Alkaline phosphatase |
| rs10518765 | Ankylosing spondylitis | 0.01036 | 2.14 | UNC13C | Alkaline phosphatase |
| rs10518765 | Pleurisy; pleural effusion | 0.01151 | 0.8544 | UNC13C | Alkaline phosphatase |
| rs10518765 | Chronic cystitis | 0.008057 | 1.553 | UNC13C | Alkaline phosphatase |
| rs10518765 | Inflammatory conditions of jaw | 0.009415 | 0.5423 | UNC13C | Alkaline phosphatase |
| rs10521222 | Disorders of esophageal motility | 0.004501 | 2.094 | SALL1 | C-reactive protein |
| rs10521222 | Osteoarthrosis; localized, primary | 0.00455 | 0.4996 | SALL1 | C-reactive protein |
| rs10521222 | Dry eyes | 0.005173 | 0.7158 | SALL1 | C-reactive protein |
| rs10521222 | Atrial fibrillation | 0.01093 | 1.299 | SALL1 | C-reactive protein |
| rs10521222 | Sepsis and SIRS | 0.01073 | 1.543 | SALL1 | C-reactive protein |
| rs10521222 | Shock | 0.006006 | 1.83 | SALL1 | C-reactive protein |
| rs10521222 | Malignant neoplasm of renal pelvis | 0.0006622 | 3.763 | SALL1 | C-reactive protein |
| rs10521222 | Other infectious diseases | 0.0005891 | 2.934 | SALL1 | C-reactive protein |
| rs1059513 | Cystic kidney disease | 0.00576 | 1.822 | STAT6 | IgE levels |
| rs1059513 | Vascular disorders of kidney/hypertrophy | 0.003478 | 2.58 | STAT6 | IgE levels |
| rs1059513 | Primary/intrinsic cardiomyopathies | 0.001185 | 1.362 | STAT6 | IgE levels |
| rs1059513 | Chronic periodontitis | 0.004382 | 1.428 | STAT6 | IgE levels |
| rs1059513 | Cholelithiasis with acute cholecystitis | 0.006356 | 1.789 | STAT6 | IgE levels |
| rs1059513 | Gingival and periodontal diseases | 0.004483 | 1.324 | STAT6 | IgE levels |
| rs1059513 | Dentofacial anomalies, including malocclusion | 0.0003886 | 2.062 | STAT6 | IgE levels |
| rs1059513 | Anomalies of tooth position/malocclusion | 0.001182 | 2.118 | STAT6 | IgE levels |
| rs1059513 | Personality disorders | 0.005954 | 1.414 | STAT6 | IgE levels |
| rs1059513 | Symptoms involving urinary system | 0.007619 | 1.394 | STAT6 | IgE levels |
| rs1059513 | Periodontitis (acute or chronic) | 0.006328 | 1.358 | STAT6 | IgE levels |
| rs1059513 | Cardiomyopathy | 0.000748 | 1.366 | STAT6 | IgE levels |
| rs1059513 | Prostatitis | 0.01112 | 1.457 | STAT6 | IgE levels |
| rs1059513 | Jaundice | 0.004649 | 1.696 | STAT6 | IgE levels |
| rs1059513 | Phosphorus metabolism disorder | 0.006973 | 1.63 | STAT6 | IgE levels |
| rs1059513 | Type 2 diabetic neuropathy | 0.00695 | 1.278 | STAT6 | IgE levels |
| rs1059513 | Type 2 diabetic peripheral circulatory disorders | 0.0003597 | 1.782 | STAT6 | IgE levels |
| rs10748128 | Dupuytren's disease | 0.0009479 | 1.481 | FRS2 | Height |
| rs10748128 | Polymyalgia Rheumatica | 0.005432 | 1.283 | FRS2 | Height |
| rs10748128 | Polycythemia vera | 0.009937 | 1.712 | FRS2 | Height |
| rs10748128 | Peritoneal or intestinal adhesions | 0.003367 | 1.673 | FRS2 | Height |
| rs10748128 | Stomach cancer | 0.004415 | 1.762 | FRS2 | Height |
| rs10748128 | Microscopic hematuria | 0.006912 | 0.628 | FRS2 | Height |
| rs10748128 | Congenital anomalies of great vessels | 0.004915 | 0.4108 | FRS2 | Height |
| rs10748128 | Hypercoagulable state | 0.009146 | 0.6399 | FRS2 | Height |
| rs10758593 | Viral hepatitis | 0.002299 | 0.7508 | GLIS3 | Type 1 diabetes |
| rs10758593 | Seborheic dermatitis | 0.006666 | 0.8433 | GLIS3 | Type 1 diabetes |
| rs10758593 | Esophageal cancer | 0.01139 | 1.702 | GLIS3 | Type 1 diabetes |
| rs10758593 | Known or suspected fetal abnormality | 0.006558 | 1.655 | GLIS3 | Type 1 diabetes |
| rs10758593 | Intracerebral hemorrhage | 0.006007 | 1.603 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cardiac shunt/ heart septal defect | 0.006668 | 1.445 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cystitis | 0.006467 | 1.219 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cardiac congenital anomalies | 0.003785 | 1.344 | GLIS3 | Type 1 diabetes |
| rs10758593 | Nodular lymphoma | 0.009398 | 1.558 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cholelithiasis with other cholecystitis | 0.009065 | 0.7796 | GLIS3 | Type 1 diabetes |
| rs10758593 | Acute, but ill-defined cerebrovascular disease | 0.004181 | 1.202 | GLIS3 | Type 1 diabetes |
| rs10758593 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.004382 | 1.333 | GLIS3 | Type 1 diabetes |
| rs10758593 | Diseases of the tongue | 0.001066 | 1.491 | GLIS3 | Type 1 diabetes |
| rs10758593 | Poisoning by primarily systemic agents | 0.005633 | 1.312 | GLIS3 | Type 1 diabetes |
| rs10758593 | Mental disorders due to brain damage | 0.008368 | 1.219 | GLIS3 | Type 1 diabetes |
| rs10758593 | Inflammatory diseases of female pelvic organs | 0.01065 | 0.8618 | GLIS3 | Type 1 diabetes |
| rs10758593 | Late effects of cerebrovascular disease | 0.0009311 | 1.217 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cystitis and urethritis | 0.00522 | 1.211 | GLIS3 | Type 1 diabetes |
| rs10776612 | Tachycardia NOS | 0.0007473 | 0.8015 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cholelithiasis and cholecystitis | 0.001854 | 0.8692 | ARHGAP22 | Conduct disorder |
| rs10776612 | Functional disorders of bladder | 0.003591 | 0.7454 | ARHGAP22 | Conduct disorder |
| rs10776612 | Acquired absence of breast | 0.003951 | 0.7382 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cholelithiasis with acute cholecystitis | 0.0009707 | 0.5675 | ARHGAP22 | Conduct disorder |
| rs10776612 | Other abnormality of urination | 0.008105 | 0.8276 | ARHGAP22 | Conduct disorder |
| rs10776612 | Chorioretinal scars | 0.006457 | 1.448 | ARHGAP22 | Conduct disorder |
| rs10776612 | Abnormal kidney function | 0.002985 | 0.4209 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cardiac conduction disorders | 0.007863 | 0.8997 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cholelithiasis | 0.00322 | 0.8678 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cardiac dysrhythmias | 0.0001013 | 0.8887 | ARHGAP22 | Conduct disorder |
| rs10776612 | Carditis | 0.0101 | 0.8172 | ARHGAP22 | Conduct disorder |
| rs10776612 | Symptoms involving urinary system | 0.005382 | 0.7878 | ARHGAP22 | Conduct disorder |
| rs10781380 | Thyrotoxicosis | 0.00617 | 1.251 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Abdominal pain | 0.01001 | 1.086 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Other sprains and strains | 0.01034 | 0.7154 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Lower gastrointestinal congenital anomalies | 0.002558 | 0.3469 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Muscular dystrophies and other myopathies | 0.008921 | 0.636 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Methicillin sensitive Staphylococcus aureus | 0.006625 | 1.356 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Subjective visual disturbances | 0.007486 | 1.219 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Altered mental status | 0.004157 | 1.311 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Acquired spondylolisthesis | 0.001991 | 1.36 | PRUNE2 | Hippocampal atrophy |
| rs10794720 | Viral warts & HPV | 0.007214 | 0.7482 | WDR37 | Serum creatinine |
| rs10794720 | Inguinal hernia | 0.01009 | 1.268 | WDR37 | Serum creatinine |
| rs10794720 | Dry eyes | 0.009581 | 0.7917 | WDR37 | Serum creatinine |
| rs10794720 | Cancer of other female genital organs | 0.003474 | 2.508 | WDR37 | Serum creatinine |
| rs10794720 | Other acquired musculoskeletal deformity | 0.008491 | 0.6352 | WDR37 | Serum creatinine |
| rs10794720 | Adverse effects of antibacterials (not penicillins) | 0.002093 | 2.321 | WDR37 | Serum creatinine |
| rs10794720 | Peripheral retinal degenerations | 0.01118 | 0.5779 | WDR37 | Serum creatinine |
| rs10794720 | Inflammatory and toxic neuropathy | 2.664e-06 | 2.066 | WDR37 | Serum creatinine |
| rs10794720 | Other cells and casts in urine | 0.005301 | 1.881 | WDR37 | Serum creatinine |
| rs10794720 | Dyschromia and Vitiligo | 0.004639 | 0.6636 | WDR37 | Serum creatinine |
| rs10794720 | Acquired spondylolisthesis | 0.00463 | 0.512 | WDR37 | Serum creatinine |
| rs10794720 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.004977 | 2.717 | WDR37 | Serum creatinine |
| rs10794720 | Obsessive-compulsive disorder | 0.006726 | 2.143 | WDR37 | Serum creatinine |
| rs10794720 | Other cardiac conduction disorders | 0.007831 | 2.129 | WDR37 | Serum creatinine |
| rs10829156 | Chronic obstructive asthma | 0.005966 | 1.339 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Chronic bronchitis | 0.005684 | 1.23 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Type 1 diabetic peripheral circulatory disorders | 0.002442 | 0.1664 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Obstructive chronic bronchitis | 0.005005 | 1.262 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Chronic airway obstruction | 0.001123 | 1.164 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Renal colic | 0.006805 | 1.722 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Type 1 diabetic neuropathy | 0.00659 | 0.5928 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Asthma with exacerbation | 0.01011 | 1.407 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Emphysema | 0.007059 | 1.31 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Impetigo | 0.00822 | 1.596 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Poisoning by hormones and synthetic substitutes | 0.01074 | 1.413 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Asthma | 0.0001056 | 1.216 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Mitral valve stenosis and/or aortic valve stenosis | 0.007361 | 0.7642 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Other rheumatic heart disease | 0.009294 | 0.2614 | ARL5B | Sudden cardiac arrest |
| rs10841496 | Acid-base balance disorder | 0.005901 | 0.7611 | PDE3A | Azoospermia |
| rs10841496 | Muscular wasting and disuse atrophy | 0.0006477 | 0.5329 | PDE3A | Azoospermia |
| rs10841496 | Acidosis | 0.002373 | 0.6988 | PDE3A | Azoospermia |
| rs10841496 | Chronic ischemic heart disease | 0.0009502 | 0.8535 | PDE3A | Azoospermia |
| rs10841496 | Leukemia | 0.001235 | 1.404 | PDE3A | Azoospermia |
| rs10841496 | Idiopathic fibrosing alveolitis | 0.01115 | 1.788 | PDE3A | Azoospermia |
| rs10841496 | Multiple myeloma | 0.0006565 | 1.792 | PDE3A | Azoospermia |
| rs10841496 | Electrolyte imbalance | 0.002106 | 0.8985 | PDE3A | Azoospermia |
| rs10841496 | Cardiac dysrhythmias | 0.006993 | 0.9221 | PDE3A | Azoospermia |
| rs10841496 | Hypopotassemia | 0.004154 | 0.8766 | PDE3A | Azoospermia |
| rs10841496 | Malaise and fatigue | 0.004231 | 0.9173 | PDE3A | Azoospermia |
| rs10841496 | Persistent mental disorders due to other conditions | 0.007418 | 0.8662 | PDE3A | Azoospermia |
| rs10841496 | Toxic multinodular goiter | 0.004438 | 1.937 | PDE3A | Azoospermia |
| rs10841496 | Type 2 diabetic retinopathy | 0.0113 | 0.8435 | PDE3A | Azoospermia |
| rs10841496 | Other specified nonpsychotic and/or transient mental disorders | 0.008026 | 0.8215 | PDE3A | Azoospermia |
| rs10841496 | Disorders of fluid, electrolyte, and acid-base balance | 0.002716 | 0.9122 | PDE3A | Azoospermia |
| rs10841496 | Superficial cellulitis and abscess | 0.004901 | 0.9077 | PDE3A | Azoospermia |
| rs10841496 | Ileostomy status | 0.005991 | 0.614 | PDE3A | Azoospermia |
| rs10841496 | Failure to thrive | 0.007734 | 0.7189 | PDE3A | Azoospermia |
| rs10841496 | Hypovolemia | 0.0006205 | 0.8636 | PDE3A | Azoospermia |
| rs10841496 | Sleep disorders | 4.312e-05 | 0.8582 | PDE3A | Azoospermia |
| rs10841496 | Insomnia | 0.002908 | 0.8468 | PDE3A | Azoospermia |
| rs10841496 | Alzheimer's disease | 0.002553 | 0.8309 | PDE3A | Azoospermia |
| rs10873876 | Gingival and periodontal diseases | 0.004087 | 1.272 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Other symptoms involving abdomen and pelvis | 0.007976 | 0.831 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Early complications of trauma or procedure | 0.01001 | 1.757 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Hepatomegaly | 0.00372 | 0.2622 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Trigeminal nerve disorders | 0.003171 | 1.602 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10882272 | Osteoporosis | 0.008036 | 1.131 | O3FAR1 | Vitamin A |
| rs10882272 | Adverse effects of antirheumatics | 0.0107 | 0.564 | O3FAR1 | Vitamin A |
| rs10882272 | Emphysema | 0.01124 | 1.25 | O3FAR1 | Vitamin A |
| rs10882272 | Disturbances of amino-acid transport | 0.009121 | 0.5285 | O3FAR1 | Vitamin A |
| rs10882272 | Respiratory failure | 0.005255 | 1.279 | O3FAR1 | Vitamin A |
| rs10882272 | Abnormal cytological, histological, immunological and DNA test findings | 0.005636 | 1.813 | O3FAR1 | Vitamin A |
| rs10882272 | Fracture of upper limb | 0.008313 | 0.8711 | O3FAR1 | Vitamin A |
| rs10882272 | Abnormal chest sounds | 0.0083 | 1.43 | O3FAR1 | Vitamin A |
| rs10882272 | Fracture of lower limb | 0.00958 | 0.8713 | O3FAR1 | Vitamin A |
| rs10882272 | Glossitis | 0.01066 | 1.875 | O3FAR1 | Vitamin A |
| rs10882272 | Back pain | 8.473e-05 | 1.127 | O3FAR1 | Vitamin A |
| rs10882272 | Aseptic necrosis of bone | 0.006732 | 1.553 | O3FAR1 | Vitamin A |
| rs10882272 | Umbilical hernia | 0.007597 | 0.7756 | O3FAR1 | Vitamin A |
| rs10882272 | Voice disturbance | 0.009404 | 1.202 | O3FAR1 | Vitamin A |
| rs10882272 | Hemorrhage NOS | 0.003378 | 1.74 | O3FAR1 | Vitamin A |
| rs10882272 | Labyrinthitis | 0.007388 | 0.7141 | O3FAR1 | Vitamin A |
| rs10882272 | Atopic or contact dermatitis | 0.004255 | 0.8988 | O3FAR1 | Vitamin A |
| rs10882272 | Diseases of the larynx and vocal cords | 0.002485 | 1.205 | O3FAR1 | Vitamin A |
| rs10898392 | Subarachnoid hemorrhage | 0.002666 | 2.124 | DLG2 | Height |
| rs10898392 | Rash and other nonspecific skin eruption | 0.00832 | 1.154 | DLG2 | Height |
| rs10898392 | Other headache syndromes | 0.002651 | 0.8973 | DLG2 | Height |
| rs10898392 | Other disorders of testis | 0.007073 | 1.378 | DLG2 | Height |
| rs10898392 | Obesity | 0.01004 | 1.088 | DLG2 | Height |
| rs10898392 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.008742 | 0.8542 | DLG2 | Height |
| rs10898392 | Abnormal glucose | 0.00319 | 1.124 | DLG2 | Height |
| rs10898392 | Benign neoplasm of unspecified sites | 0.00135 | 2.489 | DLG2 | Height |
| rs10898392 | Viral Enteritis | 0.01129 | 1.449 | DLG2 | Height |
| rs10898392 | Actinic keratosis | 0.003094 | 1.118 | DLG2 | Height |
| rs10898392 | Secondary malignant neoplasm of liver | 0.008981 | 0.7336 | DLG2 | Height |
| rs10898392 | Peyronie's disease | 0.003078 | 1.946 | DLG2 | Height |
| rs10898392 | Muscle weakness | 0.005104 | 0.7581 | DLG2 | Height |
| rs10898392 | Photodermatitis & sunburn | 0.00152 | 1.21 | DLG2 | Height |
| rs10898392 | Anal and rectal conditions | 0.007686 | 0.8751 | DLG2 | Height |
| rs10898392 | Disorders of adrenal glands | 0.006413 | 1.327 | DLG2 | Height |
| rs10898392 | Hypertensive heart and/or renal disease | 0.006159 | 1.174 | DLG2 | Height |
| rs10898392 | Chronic kidney disease, Stage I or II | 0.0001364 | 0.6268 | DLG2 | Height |
| rs10898392 | Secondary malignancy of brain/spine | 0.0009536 | 0.5368 | DLG2 | Height |
| rs10937275 | Abnormal chest sounds | 0.002318 | 1.691 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Gastrointestinal complications | 0.00291 | 0.6229 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Inflammation of the eye | 0.006456 | 0.8451 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Nodular lymphoma | 0.005593 | 1.807 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Synoviopathy | 0.005851 | 1.452 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Contact dermatitis and other eczema due to plants [except food] | 2.686e-05 | 2.684 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Photodermatitis & sunburn | 0.01087 | 1.24 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Pulmonary collapse; interstitial/compensatory emphysema | 0.001476 | 1.293 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Phobia | 0.0103 | 2.19 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Graves' disease | 0.00582 | 0.4378 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937405 | Plasma protein metabolism disorder | 0.008339 | 0.7732 | TP63 | Lung adenocarcinoma |
| rs10937405 | Hemoptysis | 0.009069 | 0.7503 | TP63 | Lung adenocarcinoma |
| rs10937405 | Antihypertensive agents causing adverse effects | 0.00977 | 1.516 | TP63 | Lung adenocarcinoma |
| rs10937405 | Impacted cerumen | 0.008749 | 1.105 | TP63 | Lung adenocarcinoma |
| rs10937405 | Lipoma | 0.008787 | 1.192 | TP63 | Lung adenocarcinoma |
| rs10937405 | Breast disorder NOS | 0.007027 | 0.405 | TP63 | Lung adenocarcinoma |
| rs10937405 | Cyst and pseudocyst of pancreas | 0.006826 | 1.597 | TP63 | Lung adenocarcinoma |
| rs10953541 | Orchitis and epididymitis | 0.001675 | 1.601 | BCAP29 | Coronary heart disease |
| rs10953541 | Chronic glomerulonephritis | 0.001597 | 2.429 | BCAP29 | Coronary heart disease |
| rs10953541 | Alcoholism | 0.0002363 | 1.345 | BCAP29 | Coronary heart disease |
| rs10953541 | Alcohol-related disorders | 0.0005849 | 1.28 | BCAP29 | Coronary heart disease |
| rs10953541 | Prostate cancer | 0.00588 | 1.218 | BCAP29 | Coronary heart disease |
| rs10953541 | Secondary malignant neoplasm of digestive systems | 0.0045 | 0.5593 | BCAP29 | Coronary heart disease |
| rs10953541 | Inflammatory diseases of prostate | 0.003663 | 1.296 | BCAP29 | Coronary heart disease |
| rs10953541 | Abdominal aortic aneurysm | 0.005118 | 1.277 | BCAP29 | Coronary heart disease |
| rs10953541 | Abnormal function study of cardiovascular system | 0.006882 | 1.198 | BCAP29 | Coronary heart disease |
| rs10953541 | Congenital cataract and lens anomalies | 0.00129 | 2.197 | BCAP29 | Coronary heart disease |
| rs10953541 | Malignant neoplasm of brain and nervous system | 0.007605 | 0.6363 | BCAP29 | Coronary heart disease |
| rs10953541 | Absent or infrequent menstruation | 0.00274 | 0.541 | BCAP29 | Coronary heart disease |
| rs10953541 | progressive myopia | 0.005386 | 1.797 | BCAP29 | Coronary heart disease |
| rs10993994 | Prostate cancer | 4.951e-05 | 1.288 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Abnormal findings on radiological breast exam | 0.009814 | 1.532 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Acquired toe deformities | 0.003009 | 1.187 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Muscular dystrophies and other myopathies | 0.001939 | 1.525 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Acute sinusitis | 0.0102 | 1.132 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Urethral stricture (not specified as infectious) | 0.003605 | 1.453 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Premature beats | 0.00495 | 0.8365 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Anomalies of pupillary function | 0.008336 | 0.4968 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Renal colic | 0.00948 | 1.609 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Symptoms involving urinary system | 0.009352 | 0.7975 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Fracture of hand or wrist | 0.0008949 | 1.214 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Hammer toe | 0.01104 | 1.184 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Other headache syndromes | 0.001523 | 1.122 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Inflammatory spondylopathies | 0.006114 | 1.503 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Rotator cuff (capsule) sprain | 0.001487 | 1.234 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs10993994 | Other disorders of bone and cartilage | 0.0005931 | 1.279 | MSMB | Prostate cancer, Prostate-specific antigen levels (men w/out prostate cancer) |
| rs11013962 | Mucous polyp of cervix | 0.001168 | 1.499 | KIAA1217 | Earlobes |
| rs11013962 | Eosinophilia | 0.009667 | 0.5558 | KIAA1217 | Earlobes |
| rs11013962 | Dermatophytosis / Dermatomycosis | 0.01013 | 1.101 | KIAA1217 | Earlobes |
| rs11013962 | Essential hypertension | 0.004281 | 1.089 | KIAA1217 | Earlobes |
| rs11013962 | Cholelithiasis and cholecystitis | 0.009395 | 0.8908 | KIAA1217 | Earlobes |
| rs11013962 | Open wound of toe(s) | 0.0112 | 0.5781 | KIAA1217 | Earlobes |
| rs11013962 | Eye infection, viral | 0.009939 | 1.367 | KIAA1217 | Earlobes |
| rs11013962 | Develomental delays and disorders | 0.006192 | 1.279 | KIAA1217 | Earlobes |
| rs11013962 | Adverse effects of cardiac rhythm regulators | 0.008606 | 0.568 | KIAA1217 | Earlobes |
| rs11013962 | Hypertension | 0.004967 | 1.087 | KIAA1217 | Earlobes |
| rs11013962 | Ankylosis of joint | 0.006849 | 1.424 | KIAA1217 | Earlobes |
| rs11013962 | Disorders of cornea | 0.01037 | 1.182 | KIAA1217 | Earlobes |
| rs11057830 | Complication of amputation stump | 0.001077 | 2.257 | SCARB1 | Vitamin E |
| rs11057830 | Chronic obstructive asthma with exacerbation | 0.004629 | 0.3291 | SCARB1 | Vitamin E |
| rs11057830 | Deficiency of humoral immunity | 0.004765 | 2.3 | SCARB1 | Vitamin E |
| rs11057830 | Cancer of larynx | 0.009032 | 0.4946 | SCARB1 | Vitamin E |
| rs11057830 | Generalized anxiety disorder | 0.008018 | 0.6683 | SCARB1 | Vitamin E |
| rs11057830 | Memory loss | 0.006162 | 0.7208 | SCARB1 | Vitamin E |
| rs11057830 | Otitis media | 0.01123 | 0.8331 | SCARB1 | Vitamin E |
| rs11057830 | Eustachian tube disorders | 0.008035 | 0.848 | SCARB1 | Vitamin E |
| rs11057830 | Prostatitis | 0.0006235 | 1.515 | SCARB1 | Vitamin E |
| rs11057830 | Diaphragmatic hernia | 0.007976 | 1.182 | SCARB1 | Vitamin E |
| rs11057830 | Hirsutism | 0.009085 | 1.774 | SCARB1 | Vitamin E |
| rs11057830 | Chronic obstructive asthma | 0.0006173 | 0.5876 | SCARB1 | Vitamin E |
| rs11057830 | Other specified gastritis | 0.00269 | 1.399 | SCARB1 | Vitamin E |
| rs11057830 | Immunity deficiency | 0.0101 | 1.756 | SCARB1 | Vitamin E |
| rs11057830 | Colostomy and enterostomy complication | 0.000644 | 2.216 | SCARB1 | Vitamin E |
| rs11062040 | Cerebral atherosclerosis | 0.008596 | 0.6207 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Nerve root lesions | 0.006443 | 1.622 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Benign neoplasm of ovary | 0.002351 | 0.6034 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Other hypertrophic and atrophic conditions of skin | 0.01143 | 1.104 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Open wound of lip and mouth | 0.006007 | 0.5588 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Exophthalmos | 0.003764 | 2.006 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Generalized hyperhidrosis | 0.002301 | 1.383 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.001918 | 0.571 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Blood vessel replaced | 0.004043 | 1.613 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Abnormal findings examination of lungs | 0.0107 | 1.157 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Obstruction of bile duct | 0.01005 | 1.559 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Other pulmonary inflamation or edema | 0.00138 | 1.385 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11064994 | Bacterial enteritis | 0.006509 | 1.56 | CCDC64 | Cognitive performance |
| rs11064994 | Benign neoplasm of lip, oral cavity, and pharynx | 0.008658 | 1.845 | CCDC64 | Cognitive performance |
| rs11064994 | Urinary obstruction | 0.01075 | 1.643 | CCDC64 | Cognitive performance |
| rs11064994 | Peritonitis and retroperitoneal infections | 0.006722 | 1.703 | CCDC64 | Cognitive performance |
| rs11064994 | Acute pancreatitis | 0.003822 | 1.533 | CCDC64 | Cognitive performance |
| rs11064994 | Hyperparathyroidism | 0.008489 | 1.509 | CCDC64 | Cognitive performance |
| rs11064994 | Clotting factor deficiency | 0.003452 | 2.821 | CCDC64 | Cognitive performance |
| rs11064994 | Idiopathic fibrosing alveolitis | 0.0001437 | 2.862 | CCDC64 | Cognitive performance |
| rs11064994 | Other specified nonpsychotic and/or transient mental disorders | 0.01011 | 1.382 | CCDC64 | Cognitive performance |
| rs11064994 | Congenital coagulation defects | 0.003936 | 2.416 | CCDC64 | Cognitive performance |
| rs11064994 | Cervical cancer and dysplasia | 0.001855 | 1.583 | CCDC64 | Cognitive performance |
| rs11064994 | Duodenitis | 0.001063 | 1.834 | CCDC64 | Cognitive performance |
| rs11064994 | Intestinal infection due to C. difficile | 0.0002771 | 1.877 | CCDC64 | Cognitive performance |
| rs11064994 | Other specified diseases of nail | 0.005006 | 0.7362 | CCDC64 | Cognitive performance |
| rs11064994 | Diseases of nail | 0.01005 | 0.764 | CCDC64 | Cognitive performance |
| rs11064994 | Fracture of tibia and fibula | 0.008033 | 0.5705 | CCDC64 | Cognitive performance |
| rs11064994 | Other alveolar and parietoalveolar pneumonopathy | 0.001539 | 2.196 | CCDC64 | Cognitive performance |
| rs11064994 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.001134 | 1.671 | CCDC64 | Cognitive performance |
| rs11082304 | Type 2 diabetic retinopathy | 0.006342 | 0.8327 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Other immunological findings | 0.005054 | 0.7486 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Varicose veins of lower extremity, symptomtic | 0.009183 | 0.8286 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Fracture of tibia and fibula | 0.009469 | 0.7918 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Other specified gastritis | 0.005138 | 0.7867 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Parkinson's disease | 0.008821 | 1.275 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Acute pharyngitis | 0.009153 | 0.8748 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Gastritis and duodenitis | 0.007031 | 0.8769 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Chronic ulcer of skin | 0.005919 | 0.8855 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Septicemia | 0.00494 | 0.8459 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Morbid obesity | 0.01064 | 0.8664 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Psychogenic and somatoform disorders | 0.005583 | 0.782 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Neutropenia | 0.008171 | 0.8154 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Chronic ulcer of unspecified site | 0.0001771 | 0.7123 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Abnormal findings examination of lungs | 0.001408 | 0.8339 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Other disorders of bone and cartilage | 0.0003868 | 0.777 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Congenital anomalies of face and neck | 0.002619 | 2.525 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Decreased white blood cell count | 0.004622 | 0.8108 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Contact dermatitis and other eczema due to plants [except food] | 0.009701 | 1.7 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Leukemia | 0.009316 | 0.7634 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Pulmonary collapse; interstitial/compensatory emphysema | 0.008523 | 0.8607 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs1109670 | Anxiety, phobic and dissociative disorders | 0.002285 | 1.136 | ASAP2 | Multiple sclerosis |
| rs1109670 | Abdominal aortic aneurysm | 0.01032 | 0.7831 | ASAP2 | Multiple sclerosis |
| rs1109670 | Other disorders of prostate | 0.001168 | 1.469 | ASAP2 | Multiple sclerosis |
| rs1109670 | Pernicious anemia | 0.00511 | 0.5993 | ASAP2 | Multiple sclerosis |
| rs1109670 | Malaise and fatigue | 0.01067 | 1.092 | ASAP2 | Multiple sclerosis |
| rs1109670 | Dermatosis NOS | 0.006984 | 1.122 | ASAP2 | Multiple sclerosis |
| rs1109670 | Ovarian cancer | 0.0103 | 1.544 | ASAP2 | Multiple sclerosis |
| rs1109670 | Known or suspected fetal abnormality | 0.00881 | 1.702 | ASAP2 | Multiple sclerosis |
| rs1109670 | progressive myopia | 0.006716 | 0.4446 | ASAP2 | Multiple sclerosis |
| rs1109670 | Calculus of kidney | 0.004261 | 1.205 | ASAP2 | Multiple sclerosis |
| rs1109670 | Neurological disorders due to brain damage | 0.004657 | 0.8574 | ASAP2 | Multiple sclerosis |
| rs1109670 | Osteopenia | 0.005382 | 1.148 | ASAP2 | Multiple sclerosis |
| rs1109670 | Fractur of unspecified part of femur | 0.004199 | 1.473 | ASAP2 | Multiple sclerosis |
| rs1109670 | Fracture of unspecified bones | 0.003234 | 1.191 | ASAP2 | Multiple sclerosis |
| rs1109670 | Cancer of other female genital organs | 0.009297 | 1.469 | ASAP2 | Multiple sclerosis |
| rs1109670 | Carbuncle and furuncle | 0.004685 | 0.5662 | ASAP2 | Multiple sclerosis |
| rs11129295 | Psoriasis vulgaris | 0.01091 | 0.7987 | EOMES | Multiple sclerosis |
| rs11129295 | Type 1 diabetes nephropathy | 0.01142 | 1.576 | EOMES | Multiple sclerosis |
| rs11129295 | Other anemias | 0.006414 | 1.089 | EOMES | Multiple sclerosis |
| rs11129295 | Type 1 diabetic retinopathy | 0.01107 | 1.385 | EOMES | Multiple sclerosis |
| rs11129295 | Umbilical hernia | 0.0002798 | 1.382 | EOMES | Multiple sclerosis |
| rs11129295 | Hepatomegaly | 0.003837 | 1.795 | EOMES | Multiple sclerosis |
| rs11129295 | Overweight | 0.01094 | 1.085 | EOMES | Multiple sclerosis |
| rs11129295 | Other acquired musculoskeletal deformity | 0.01092 | 0.8086 | EOMES | Multiple sclerosis |
| rs11129295 | Lesions of stomach and duodenum | 0.001729 | 2.172 | EOMES | Multiple sclerosis |
| rs11129295 | Sicca syndrome | 0.004759 | 0.633 | EOMES | Multiple sclerosis |
| rs11129295 | Psoriasis & related disorders | 0.01122 | 0.8135 | EOMES | Multiple sclerosis |
| rs11129295 | Intervertebral disc disorder with myelopathy | 0.009204 | 1.681 | EOMES | Multiple sclerosis |
| rs11129295 | Symptoms involving digestive system | 0.01128 | 0.8214 | EOMES | Multiple sclerosis |
| rs11129295 | Hypotension | 0.008533 | 1.131 | EOMES | Multiple sclerosis |
| rs11129295 | Gastritis and duodenitis | 0.0005445 | 1.189 | EOMES | Multiple sclerosis |
| rs11129295 | Psoriasis | 0.01123 | 0.8038 | EOMES | Multiple sclerosis |
| rs11129640 | Sleep apnea | 0.009223 | 1.132 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Chronic interstitial cystitis | 0.006236 | 2.13 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Heart valve replaced | 0.009139 | 1.311 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Nevus, non-neoplastic | 0.003347 | 1.787 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Type 2 diabetes | 0.007727 | 0.9054 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Otitis externa | 0.008499 | 1.209 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Obstructive sleep apnea | 0.006552 | 1.171 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Other aneurysm | 0.009929 | 1.199 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Iron deficiency anemia secondary to blood loss | 0.001297 | 1.451 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Pathologic fracture | 0.004201 | 1.248 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Aortic aneurysm | 0.001182 | 1.283 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Behcet's syndrome | 0.003496 | 0.5106 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Megaloblastic anemia | 0.0108 | 1.365 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Hirsutism | 0.01039 | 1.651 | ARPP21 | Entorhinal cortical thickness |
| rs11130874 | Frequency of urination and polyuria | 0.006607 | 1.16 | PTPRG | Schizophrenia |
| rs11130874 | Dysuria | 0.001214 | 1.241 | PTPRG | Schizophrenia |
| rs11130874 | Hyperosmolality and/or hypernatremia | 0.009605 | 1.513 | PTPRG | Schizophrenia |
| rs11130874 | Urethritis and urethral syndrome | 0.01145 | 1.742 | PTPRG | Schizophrenia |
| rs11130874 | Lung cancer | 0.005843 | 0.7417 | PTPRG | Schizophrenia |
| rs11130874 | Cardiac arrest & ventricular fibrillation | 0.00655 | 0.613 | PTPRG | Schizophrenia |
| rs11130874 | Adverse effects of hormones and synthetic substitutes | 0.009896 | 2.258 | PTPRG | Schizophrenia |
| rs11130874 | Hepatomegaly | 0.002619 | 1.952 | PTPRG | Schizophrenia |
| rs11130874 | Gingivitis | 7.127e-05 | 2.424 | PTPRG | Schizophrenia |
| rs11130874 | Phosphorus metabolism disorder | 0.002227 | 1.583 | PTPRG | Schizophrenia |
| rs11130874 | Abnormal loss of weight and underweight | 0.005547 | 1.341 | PTPRG | Schizophrenia |
| rs11130874 | Cancer within the respiratory system | 0.004892 | 0.7402 | PTPRG | Schizophrenia |
| rs11130874 | Sepsis | 0.01109 | 1.302 | PTPRG | Schizophrenia |
| rs11130874 | Symptoms/disorders of the urinary system | 0.005171 | 1.114 | PTPRG | Schizophrenia |
| rs11130874 | Simple goiter | 0.008311 | 0.7585 | PTPRG | Schizophrenia |
| rs11130874 | Protein-calorie malnutrition | 0.00761 | 1.201 | PTPRG | Schizophrenia |
| rs11130874 | Secondary malignant neoplasm | 0.004618 | 0.8159 | PTPRG | Schizophrenia |
| rs11130874 | Other disorders of eyelids | 0.001823 | 1.21 | PTPRG | Schizophrenia |
| rs11141915 | Genital prolapse | 0.008456 | 1.197 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Hypothyroidism | 0.004528 | 1.129 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Thyroiditis | 0.004528 | 1.429 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | severe protein-calorie malnutrition | 0.001511 | 0.4466 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Thyroid cancer | 0.003042 | 0.5153 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Prolapse of vaginal walls | 0.003654 | 1.259 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Immune disorders | 0.001694 | 1.353 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Concussion | 0.006358 | 1.553 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Disorders of esophageal motility | 0.01103 | 0.588 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Myopia | 0.007799 | 1.151 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Cervical radiculitis | 0.001393 | 1.251 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Hypertensive heart and/or renal disease | 0.00971 | 0.8281 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Urinary incontinence | 0.004403 | 1.167 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Localized adiposity | 0.009375 | 1.921 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11143230 | Other specified diseases of sebaceous glands | 0.003727 | 0.7919 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Plasma protein metabolism disorder | 0.0001924 | 1.433 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Nerve root and plexus disorders | 0.009203 | 1.302 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Pulmonary collapse; interstitial/compensatory emphysema | 0.0002604 | 1.242 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Vaginal enterocele, congenital or acquired | 0.01085 | 1.463 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Other specified osteoporosis | 0.003262 | 1.735 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Hemorrhoids | 0.009504 | 1.113 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Nontoxic multinodular goiter | 0.00384 | 1.283 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Diseases of pulp and periapical tissues | 0.01078 | 1.194 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Hypertension complicating pregnancy | 0.0009324 | 0.3098 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Oral aphthae | 0.01071 | 1.596 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Protein plasma/amino-acid transport and metabolism disorder | 0.002445 | 1.307 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Sepsis and SIRS | 0.006628 | 1.267 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Thyrotoxicosis | 0.005552 | 1.247 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Nontoxic nodular goiter | 0.005004 | 1.196 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Stomatitis and mucositis | 0.003657 | 1.422 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Prolapse of vaginal vault after hysterectomy | 0.009543 | 1.456 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11144134 | Congenital anomalies of urinary system | 0.009778 | 1.689 | TRPM6 | Magnesium levels |
| rs11144134 | Balanoposthitis | 0.009302 | 2.201 | TRPM6 | Magnesium levels |
| rs11144134 | Thrombocytopenia | 0.001797 | 0.6711 | TRPM6 | Magnesium levels |
| rs11144134 | Pain, swelling or discharge of eye | 0.003963 | 0.4465 | TRPM6 | Magnesium levels |
| rs11144134 | Purpura and other hemorrhagic conditions | 0.008421 | 0.7492 | TRPM6 | Magnesium levels |
| rs11144134 | Benign neoplasm of colon | 0.009647 | 1.16 | TRPM6 | Magnesium levels |
| rs11144134 | Hydrocele | 0.005035 | 1.962 | TRPM6 | Magnesium levels |
| rs11144134 | Vitamin deficiency | 0.001431 | 0.6821 | TRPM6 | Magnesium levels |
| rs11144134 | Viral Enteritis | 0.01099 | 0.348 | TRPM6 | Magnesium levels |
| rs11144134 | Mood disorders | 0.01082 | 0.8511 | TRPM6 | Magnesium levels |
| rs11144134 | Abnormal reflex | 0.001276 | 2.967 | TRPM6 | Magnesium levels |
| rs11144134 | Symptoms affecting skin | 0.008636 | 0.8516 | TRPM6 | Magnesium levels |
| rs11172113 | Diseases of the jaws | 0.00283 | 0.8182 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Temporomandibular joint disorder NOS | 0.0004462 | 0.5065 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Abnormal function study of cardiovascular system | 0.004637 | 0.8407 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Chronic periodontitis | 0.004828 | 0.7808 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Poisoning by agents affecting the cardiovascular system | 0.004701 | 0.7409 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | End stage renal disease | 0.00784 | 1.392 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Symptoms associated with female genital organs | 0.006851 | 0.8402 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Infection/inflammation of internal prosthetic device, implant or graft | 0.006796 | 1.274 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Mechanical complication due to other implant and internal device | 0.003944 | 1.365 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of ankle and foot | 0.01044 | 1.139 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Other abnormality of urination | 0.0005745 | 0.7778 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of upper limb | 0.002421 | 1.164 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of ribs | 0.005592 | 1.248 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Dermatomycoses | 0.002053 | 0.5168 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Acute reaction to stress | 0.001894 | 0.7646 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Early complications of trauma or procedure | 0.006659 | 1.655 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Chronic ulcer of unspecified site | 0.006673 | 0.7755 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of pelvis | 0.003732 | 1.366 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Temporomandibular joint disorders | 0.0007857 | 0.732 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Cardiac defibrillator in situ | 0.004402 | 1.449 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Acute bronchitis and bronchiolitis | 0.008704 | 0.8919 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Aplastic anemia | 0.001001 | 1.437 | LRP1 | Pulmonary function, Migraine |
| rs11203203 | Nonallopathic lesions NEC | 0.002476 | 1.147 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other disorders of back | 0.001229 | 1.199 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Chronic pharyngitis and nasopharyngitis | 0.002048 | 1.199 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Functional digestive disorders | 0.01121 | 1.137 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Intervertebral disc disorders | 3.455e-05 | 1.16 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Obsessive-compulsive disorder | 0.0104 | 1.674 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other disorders of bone and cartilage | 0.01038 | 1.205 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other disorders of pancreatic internal secretion | 0.01005 | 0.5682 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Idiopathic fibrosing alveolitis | 0.002517 | 0.4382 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Spondylosis without myelopathy | 0.01069 | 1.107 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other endocrine disorders | 0.01152 | 1.497 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other hypertensive complications | 0.0005854 | 1.342 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Disorders of coccyx | 0.004627 | 1.351 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Malunion fracture | 0.005954 | 1.434 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Tension headache | 0.007067 | 1.243 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Chronic interstitial cystitis | 0.007913 | 2.033 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Acute sinusitis | 0.006648 | 1.145 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Hyperventilation | 0.003607 | 1.76 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Chronic sinusitis | 0.007792 | 1.123 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Thoracic neuritis/radiculitis | 0.003143 | 1.131 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Back pain | 0.0001058 | 1.125 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Degeneration of intervertebral disc | 7.834e-05 | 1.182 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11204538 | Irregular menstrual bleeding | 0.009469 | 1.637 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Swelling, mass, or lump in head and neck | 0.0007572 | 0.7664 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Schizophrenia | 0.008957 | 0.6021 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Prostate cancer | 0.009377 | 0.8509 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Ulcerative stomatitis & mucositis | 0.003142 | 0.5053 | TRIM58 | Mean corpuscular volume |
| rs11206510 | Ascites (non malignant) | 0.006818 | 0.6005 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Abnormal weight gain | 0.004094 | 1.425 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Poisoning by other anti-infectives | 0.007824 | 1.285 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Respiratory failure | 0.006323 | 1.324 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Stress fracture | 0.005591 | 0.242 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Hemorrhoids | 0.01082 | 1.136 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Hemorrhage or hematoma complicating a procedure | 0.005158 | 0.7547 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Toxic multinodular goiter | 0.004587 | 1.963 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Cardiac arrest & ventricular fibrillation | 0.007312 | 1.473 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Spontaneous ecchymoses | 0.002117 | 0.3899 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Rhabdomyolysis | 0.01068 | 1.835 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Diplopia and disorders of binocular vision | 0.002681 | 0.6644 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Thyroiditis | 0.0004481 | 1.557 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11214606 | Methicillin resistant Staphylococcus aureus | 0.004804 | 2.628 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Aneurysm of iliac artery | 0.003166 | 2.497 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Complication of amputation stump | 0.00109 | 2.907 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Fracture of radius and ulna | 0.01008 | 1.385 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Other immunological findings | 0.002087 | 1.745 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Postlaminectomy syndrome | 0.0007134 | 1.997 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Type 1 diabetic neuropathy | 0.004196 | 1.95 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Peripheral autonomic neuropathy | 0.006894 | 1.797 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Congenital anomalies of great vessels | 0.004541 | 2.796 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Mycoses | 0.009217 | 1.987 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Diseases of respiratory system | 0.007101 | 0.6737 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Diseases of hair and hair follicles | 0.003381 | 0.5445 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Dysthymic disorder | 0.001419 | 0.628 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Deep vein thrombosis | 0.0066 | 1.576 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Symptoms involving respiratory system | 0.002879 | 0.5473 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Cholesteatoma | 9.689e-05 | 3.179 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Immune disorders | 0.002456 | 1.601 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Other disorders of middle ear and mastoid | 0.0005852 | 2.195 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11221332 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.0007108 | 0.6369 | ETS1 | Celiac disease |
| rs11221332 | Symptoms/disorders of the urinary system | 0.0001749 | 0.8689 | ETS1 | Celiac disease |
| rs11221332 | Gross hematuria | 0.0009977 | 0.4066 | ETS1 | Celiac disease |
| rs11221332 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.006984 | 0.7781 | ETS1 | Celiac disease |
| rs11221332 | Seborheic dermatitis | 0.003019 | 1.23 | ETS1 | Celiac disease |
| rs11221332 | Osteoarthritis; localized | 0.008838 | 0.8745 | ETS1 | Celiac disease |
| rs11221332 | Other conditions of brain, NOS | 0.002899 | 1.647 | ETS1 | Celiac disease |
| rs11221332 | Cardiac defibrillator in situ | 0.007053 | 0.614 | ETS1 | Celiac disease |
| rs11221332 | Paralytic strabismus | 0.004072 | 1.577 | ETS1 | Celiac disease |
| rs11221332 | Posterior pituitary disorders | 0.001695 | 1.891 | ETS1 | Celiac disease |
| rs11221332 | Hypertension | 0.001071 | 0.8916 | ETS1 | Celiac disease |
| rs11221332 | Abnormal findings on study of brain, nervous system | 0.008007 | 1.547 | ETS1 | Celiac disease |
| rs11221332 | Osteoarthrosis NOS | 0.005983 | 0.8992 | ETS1 | Celiac disease |
| rs11221332 | Claw toe | 0.01128 | 0.3374 | ETS1 | Celiac disease |
| rs11221332 | Osteoarthrosis | 0.005174 | 0.9046 | ETS1 | Celiac disease |
| rs11221332 | Pituitary hypofunction | 0.009257 | 1.829 | ETS1 | Celiac disease |
| rs11221332 | Aneurysm of artery of lower extremity | 0.005158 | 0.5068 | ETS1 | Celiac disease |
| rs11221332 | Superficial cellulitis and abscess | 0.003528 | 0.8851 | ETS1 | Celiac disease |
| rs11221332 | Open wounds of extremities | 0.009341 | 0.8802 | ETS1 | Celiac disease |
| rs11221332 | Hypersomnia | 0.01052 | 0.6035 | ETS1 | Celiac disease |
| rs11221332 | Essential hypertension | 0.001259 | 0.8929 | ETS1 | Celiac disease |
| rs11221332 | Cerebrovascular disease | 0.002413 | 0.8842 | ETS1 | Celiac disease |
| rs11221332 | Open wounds of head; neck; and trunk | 0.005175 | 0.8386 | ETS1 | Celiac disease |
| rs11221332 | Symptoms involving cardiovascular system | 0.006471 | 0.8339 | ETS1 | Celiac disease |
| rs11221332 | Other disorders of eye | 0.01065 | 1.13 | ETS1 | Celiac disease |
| rs11221332 | Cervical cancer and dysplasia | 0.0001415 | 0.6225 | ETS1 | Celiac disease |
| rs11221332 | Allergy to serum or vaccine | 0.01113 | 1.712 | ETS1 | Celiac disease |
| rs11221332 | Malignant neoplasm of brain and nervous system | 0.0033 | 1.51 | ETS1 | Celiac disease |
| rs11221332 | Occlusion and stenosis of precerebral arteries | 0.0009581 | 0.8275 | ETS1 | Celiac disease |
| rs11243676 | Cervical radiculitis | 0.003516 | 1.33 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Symptoms involving respiratory system | 0.002437 | 0.616 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Anomalies of jaw size/symmetry | 0.003767 | 2.73 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Carbuncle and furuncle | 0.0008375 | 2.027 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Ptosis of eyelid | 0.001758 | 1.437 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Uveitis | 0.01048 | 1.497 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Congenital musculoskeletal deformities of spine | 0.006721 | 1.672 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Insect bite | 0.001335 | 0.5571 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Develomental delays and disorders | 0.009603 | 1.456 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Other disorders of arteries and arterioles | 0.001645 | 0.5322 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Stricture of artery | 0.01004 | 0.5396 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | AV block | 0.01103 | 0.725 | NTNG2 | Systemic lupus erythematosus |
| rs11465804 | Abnormal reflex | 0.007996 | 2.868 | IL23R | Crohn's disease |
| rs11465804 | Other disorders of eye | 0.005382 | 0.7837 | IL23R | Crohn's disease |
| rs11465804 | Mechanical complication due to other implant and internal device | 0.007207 | 1.654 | IL23R | Crohn's disease |
| rs11465804 | Disorders of vitreous body | 0.009976 | 0.7832 | IL23R | Crohn's disease |
| rs11465804 | Other peripheral nerve disorders | 0.0109 | 0.8189 | IL23R | Crohn's disease |
| rs11465804 | Atrophy of edentulous alveolar ridge | 3.18e-05 | 2.638 | IL23R | Crohn's disease |
| rs11465804 | Genitourinary congenital anomalies | 0.01132 | 1.661 | IL23R | Crohn's disease |
| rs11465804 | Other diseases of the teeth and supporting structures | 2.428e-05 | 1.816 | IL23R | Crohn's disease |
| rs11465804 | Osteochondropathies | 0.004789 | 2.594 | IL23R | Crohn's disease |
| rs11465804 | Allergy to serum or vaccine | 0.0007702 | 2.801 | IL23R | Crohn's disease |
| rs11465804 | Fracture of foot | 0.007313 | 0.6203 | IL23R | Crohn's disease |
| rs11465804 | Cervical cancer | 0.004013 | 2.621 | IL23R | Crohn's disease |
| rs11465804 | Unspecified erythematous condition | 0.008822 | 0.154 | IL23R | Crohn's disease |
| rs11465804 | Osteoarthrosis; localized, primary | 0.004315 | 0.5636 | IL23R | Crohn's disease |
| rs11465804 | Hypercholesterolemia | 0.00873 | 0.7989 | IL23R | Crohn's disease |
| rs11465804 | Dental caries | 0.008656 | 1.399 | IL23R | Crohn's disease |
| rs1150754 | Adrenal hypofunction | 0.006902 | 1.752 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Rosacea | 0.0005574 | 0.712 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Disorders of lipoid metabolism | 0.01132 | 0.8933 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Keratitis, infectious | 0.001117 | 0.4812 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Peritoneal or intestinal adhesions | 0.006571 | 1.76 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Hematuria | 0.001119 | 0.8271 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Nephritis and nephropathy without mention of glomerulonephritis | 0.005348 | 1.346 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Cyst of kidney, acquired | 0.0004346 | 1.528 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetes | 0.0003616 | 1.313 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Discoid lupus erythematosus | 0.000417 | 1.762 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Seborheic dermatitis | 0.01086 | 0.7887 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Peripheral autonomic neuropathy | 0.0003163 | 1.663 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Congenital anomalies of intestine | 0.002779 | 2.513 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Inflammatory disease of cervix, vagina, and vulva | 0.009757 | 0.7933 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetic retinopathy | 8.379e-05 | 1.799 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetes nephropathy | 0.0001004 | 2.168 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Disorders of the autonomic nervous system | 0.0008045 | 1.501 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Ovarian dysfunction | 0.009312 | 0.2627 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetic peripheral circulatory disorders | 0.0001084 | 2.712 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Decreased libido | 0.0105 | 2.041 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Diabetic retinopathy | 0.008961 | 1.251 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetic neuropathy | 1.725e-08 | 2.287 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Prostatitis | 0.003974 | 0.6584 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Celiac disease | 6.711e-06 | 2.822 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Poisoning by psychotropic agents | 0.00886 | 1.878 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Other specified peripheral vascular diseases | 0.002116 | 2.366 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Abnormal mammogram | 0.006263 | 0.7838 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Adverse effects of insulins and antidiabetic agents | 0.0001532 | 2.468 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Atrophic gastritis | 0.01088 | 1.567 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Lupus erythematosus | 0.0005656 | 2.396 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Celiac or tropical sprue | 1.889e-06 | 2.92 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Immune disorders | 0.004881 | 1.352 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Stress fracture | 0.007701 | 2.004 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Pilonidal cyst | 0.007682 | 2.247 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Stricture and stenosis of esophagus | 0.007385 | 0.6873 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Nephritis and nephropathy in diseases classified elsewhere | 0.004008 | 1.401 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Urticaria | 0.005234 | 0.7053 | TNXB | Systemic lupus erythematosus |
| rs11574637 | Joint/ligament sprain | 0.008831 | 1.38 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Benign neoplasm of unspecified sites | 0.01147 | 0.162 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Subjective visual disturbances | 0.006444 | 1.265 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Anemia of chronic disease | 0.009621 | 0.7831 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Other hypertensive complications | 0.002547 | 1.366 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Bladder cancer | 0.01032 | 1.314 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Acne | 0.003341 | 0.6728 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Arterial embolism and thrombosis of lower extremity artery | 0.006578 | 1.421 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Atherosclerosis of renal artery | 0.001516 | 1.435 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Migrain with aura | 0.002359 | 1.624 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Cellulitis and abscess of foot/toes | 0.008372 | 1.336 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Bacterial infection NOS | 0.008417 | 0.8449 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | E. coli | 0.003269 | 0.6342 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Streptococcus infection | 0.01064 | 0.6653 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Disorders of parathyroid gland | 0.005538 | 1.364 | ITGAX | Systemic lupus erythematosus |
| rs11602954 | Mood disorders | 1.341e-05 | 0.8348 | BET1L | Mean platelet volume |
| rs11602954 | Anxiety disorder | 0.0002238 | 0.8272 | BET1L | Mean platelet volume |
| rs11602954 | Dysthymic disorder | 0.001063 | 0.7899 | BET1L | Mean platelet volume |
| rs11602954 | Back & neck sprains | 0.00243 | 0.8533 | BET1L | Mean platelet volume |
| rs11602954 | Macular degeneration, wet | 0.002632 | 0.6494 | BET1L | Mean platelet volume |
| rs11602954 | Chronic hepatitis | 0.01132 | 0.4259 | BET1L | Mean platelet volume |
| rs11602954 | Sicca syndrome | 0.003189 | 1.591 | BET1L | Mean platelet volume |
| rs11602954 | Colles' fracture | 0.00721 | 1.42 | BET1L | Mean platelet volume |
| rs11602954 | Personality disorders | 0.0006735 | 0.7013 | BET1L | Mean platelet volume |
| rs11602954 | Type 2 diabetic peripheral circulatory disorders | 0.01116 | 0.6674 | BET1L | Mean platelet volume |
| rs11602954 | Adjustment reaction | 0.002841 | 0.8258 | BET1L | Mean platelet volume |
| rs11602954 | Bacteremia | 0.004575 | 0.6987 | BET1L | Mean platelet volume |
| rs11602954 | Other disorders of peritoneum | 0.006069 | 1.498 | BET1L | Mean platelet volume |
| rs11602954 | Irritable Bowel Syndrome | 0.006564 | 0.8217 | BET1L | Mean platelet volume |
| rs11602954 | Non-melanoma skin cancer | 0.0108 | 0.8905 | BET1L | Mean platelet volume |
| rs11602954 | Anxiety, phobic and dissociative disorders | 2.357e-06 | 0.808 | BET1L | Mean platelet volume |
| rs11602954 | Labyrinthitis | 0.004172 | 0.638 | BET1L | Mean platelet volume |
| rs11602954 | Muscle weakness | 0.002194 | 0.6683 | BET1L | Mean platelet volume |
| rs11602954 | Depression | 3.992e-05 | 0.8402 | BET1L | Mean platelet volume |
| rs11602954 | Type 1 diabetes | 0.005352 | 0.8086 | BET1L | Mean platelet volume |
| rs11602954 | Ankylosis of joint | 0.002308 | 0.5617 | BET1L | Mean platelet volume |
| rs11602954 | Acute reaction to stress | 0.001489 | 0.7113 | BET1L | Mean platelet volume |
| rs11611208 | Chondrocalcinosis | 0.003031 | 1.814 | PDE3A | Height |
| rs11611208 | Other disorders of metabolic, endocrine, immunity disorders | 0.0102 | 2.521 | PDE3A | Height |
| rs11611208 | Pruritus and related conditions | 0.003678 | 1.448 | PDE3A | Height |
| rs11611208 | Other diseases of the teeth and supporting structures | 0.008428 | 0.5428 | PDE3A | Height |
| rs11611208 | Erectile dysfunction | 0.002083 | 1.453 | PDE3A | Height |
| rs11611208 | Crystal arthropathies | 0.002217 | 1.832 | PDE3A | Height |
| rs11611208 | Other specified disorders of liver | 0.01147 | 0.4416 | PDE3A | Height |
| rs11611208 | Hyperbilirubinemia | 0.0003887 | 2.981 | PDE3A | Height |
| rs11611647 | Vascular dementia | 0.005198 | 0.633 | CCND2 | Red blood cell count |
| rs11611647 | Appendiceal conditions | 0.005631 | 1.46 | CCND2 | Red blood cell count |
| rs11611647 | Peripheral angiopathy in diseases classified elsewhere | 0.003684 | 1.735 | CCND2 | Red blood cell count |
| rs11611647 | Respiratory insufficiency | 0.008043 | 1.328 | CCND2 | Red blood cell count |
| rs11611647 | Scoliosis | 0.001897 | 1.407 | CCND2 | Red blood cell count |
| rs11611647 | Hypertensive heart and/or renal disease | 0.005872 | 1.211 | CCND2 | Red blood cell count |
| rs11611647 | Symptoms involving head and neck | 0.001212 | 0.7596 | CCND2 | Red blood cell count |
| rs11611647 | Heart failure NOS | 0.002478 | 1.379 | CCND2 | Red blood cell count |
| rs11611647 | Hemangioma and lymphangioma, any site | 0.00937 | 1.321 | CCND2 | Red blood cell count |
| rs11611647 | Hypertensive heart disease | 0.001578 | 1.443 | CCND2 | Red blood cell count |
| rs11611647 | Disorders of the autonomic nervous system | 0.008605 | 1.346 | CCND2 | Red blood cell count |
| rs11611647 | Speech and language disorder | 0.002299 | 0.5707 | CCND2 | Red blood cell count |
| rs11611647 | Cellulitis and abscess of face | 0.005084 | 1.43 | CCND2 | Red blood cell count |
| rs11611647 | Valvular heart disease/ heart chambers | 0.006086 | 1.852 | CCND2 | Red blood cell count |
| rs11611647 | Heart failure | 0.008316 | 1.139 | CCND2 | Red blood cell count |
| rs11611647 | Idiopathic fibrosing alveolitis | 0.007807 | 0.3479 | CCND2 | Red blood cell count |
| rs11618202 | Retinal detachments and defects | 0.005345 | 0.655 | HMGB1 | Total hippocampal volume |
| rs11618202 | Behcet's syndrome | 0.003406 | 0.2211 | HMGB1 | Total hippocampal volume |
| rs11618202 | Obstructive sleep apnea | 0.002774 | 0.7365 | HMGB1 | Total hippocampal volume |
| rs11618202 | Retinal drusen | 0.001845 | 0.6177 | HMGB1 | Total hippocampal volume |
| rs11618202 | ASCVD | 0.007269 | 1.638 | HMGB1 | Total hippocampal volume |
| rs11618202 | Stomach cancer | 0.002228 | 2.266 | HMGB1 | Total hippocampal volume |
| rs11618202 | Retinal disorders | 0.005932 | 0.8205 | HMGB1 | Total hippocampal volume |
| rs11618202 | Ischemic stroke | 0.01077 | 1.329 | HMGB1 | Total hippocampal volume |
| rs11618202 | Sleep apnea | 0.009383 | 0.8135 | HMGB1 | Total hippocampal volume |
| rs11618202 | Known or suspected fetal abnormality | 0.003132 | 2.195 | HMGB1 | Total hippocampal volume |
| rs11618202 | Polyneuropathy in diabetes | 0.005772 | 0.6801 | HMGB1 | Total hippocampal volume |
| rs11618202 | Abnormal results of function study of liver | 0.008103 | 1.362 | HMGB1 | Total hippocampal volume |
| rs11618202 | Osteoporosis, NOS or other | 0.008108 | 0.8019 | HMGB1 | Total hippocampal volume |
| rs11712165 | Other disorders of peritoneum | 0.002462 | 0.6391 | ARHGAP31 | Celiac disease |
| rs11712165 | Anemia of chronic disease | 0.005743 | 0.8231 | ARHGAP31 | Celiac disease |
| rs11712165 | Fracture of lower limb | 0.0003032 | 0.828 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteopenia | 0.003682 | 0.8783 | ARHGAP31 | Celiac disease |
| rs11712165 | Pathologic fracture | 0.009386 | 0.8339 | ARHGAP31 | Celiac disease |
| rs11712165 | Peptic ulcer | 0.004238 | 0.8467 | ARHGAP31 | Celiac disease |
| rs11712165 | Other diseases of respiratory system | 0.007998 | 0.7178 | ARHGAP31 | Celiac disease |
| rs11712165 | Fracture of pelvis | 0.000101 | 0.6369 | ARHGAP31 | Celiac disease |
| rs11712165 | Peritoneal adhesions (postoperative) (postinfection) | 0.003249 | 0.5873 | ARHGAP31 | Celiac disease |
| rs11712165 | Symptoms involving female genital tract | 0.009056 | 1.348 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteoporosis, osteopenia, & pathological fractures | 0.000694 | 0.8878 | ARHGAP31 | Celiac disease |
| rs11712165 | Anemia in neoplastic disease | 0.004922 | 0.6816 | ARHGAP31 | Celiac disease |
| rs11712165 | Circumscribed scleroderma | 0.009882 | 1.375 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteoporosis, NOS or other | 0.001438 | 0.8658 | ARHGAP31 | Celiac disease |
| rs11712165 | Fracture of neck of femur | 0.000121 | 0.7587 | ARHGAP31 | Celiac disease |
| rs11712165 | Eating disorder | 0.009309 | 1.597 | ARHGAP31 | Celiac disease |
| rs11712165 | Lymphadenitis | 0.004048 | 0.8339 | ARHGAP31 | Celiac disease |
| rs11712165 | Pseudoexfoliation glaucoma | 0.009795 | 0.626 | ARHGAP31 | Celiac disease |
| rs11712165 | Hemorrhage of gastrointestinal tract | 0.006153 | 0.8472 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteoporosis | 0.004118 | 0.8754 | ARHGAP31 | Celiac disease |
| rs11712165 | Tuberculosis | 0.009822 | 0.4881 | ARHGAP31 | Celiac disease |
| rs11712165 | Congenital musculoskeletal deformities of spine | 0.01151 | 1.382 | ARHGAP31 | Celiac disease |
| rs11712165 | Other disorders of the nervous system | 0.01042 | 0.6439 | ARHGAP31 | Celiac disease |
| rs1175000 | Viral warts & HPV | 0.01008 | 0.873 | CDCA7L | Height |
| rs1175000 | Decreased white blood cell count | 0.004679 | 1.229 | CDCA7L | Height |
| rs1175000 | Neutropenia | 0.00175 | 1.269 | CDCA7L | Height |
| rs1175000 | Amblyopia | 0.008942 | 0.7499 | CDCA7L | Height |
| rs1175000 | Emphysema | 0.006171 | 0.7839 | CDCA7L | Height |
| rs1175000 | Toxic effect of venom | 0.008116 | 0.6608 | CDCA7L | Height |
| rs1175000 | Otorrhea | 0.006267 | 1.975 | CDCA7L | Height |
| rs1175000 | Abnormal pulmonary function | 0.007247 | 0.4196 | CDCA7L | Height |
| rs1175000 | Iatrogenic hypothyroidism | 0.01066 | 1.31 | CDCA7L | Height |
| rs1175000 | Morbid obesity | 0.01016 | 0.8646 | CDCA7L | Height |
| rs1175000 | Hypersomnia | 0.002763 | 0.6449 | CDCA7L | Height |
| rs1175000 | Complication of amputation stump | 0.00785 | 1.869 | CDCA7L | Height |
| rs1175000 | Reticulosarcoma | 0.003111 | 1.726 | CDCA7L | Height |
| rs1175000 | Chronic lymphocytic thyroiditis | 0.006552 | 1.435 | CDCA7L | Height |
| rs11754661 | Other specified disorders of liver | 0.009361 | 1.55 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Type 2 diabetic ketoacidosis | 0.001195 | 1.315 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other disorders of the nervous system | 0.007072 | 1.887 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Scoliosis | 0.009273 | 1.517 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other specified diseases of hair and hair follicles | 0.001336 | 1.68 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Anisometropia | 0.008866 | 1.532 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other disorders of bone and cartilage | 0.007881 | 1.386 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Infertility, female | 0.007205 | 2.508 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Postinflammatory pulmonary fibrosis | 0.003798 | 1.506 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Heart transplant/surgery | 0.01028 | 0.3705 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.006136 | 2.853 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Anorexia | 0.01136 | 0.4401 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Fracture of foot | 0.001923 | 1.442 | MTHFD1L | Alzheimer's disease |
| rs11775334 | Hypertensive heart and/or renal disease | 0.005267 | 1.185 | MSRA | Hypertension |
| rs11775334 | Chronic nonalcoholic liver disease | 0.005054 | 0.7841 | MSRA | Hypertension |
| rs11775334 | Hypertensive chronic kidney disease | 0.001433 | 1.242 | MSRA | Hypertension |
| rs11775334 | Chronic liver disease and cirrhosis | 0.00206 | 0.7761 | MSRA | Hypertension |
| rs11775334 | Type 2 diabetic nephropathy | 0.01123 | 1.203 | MSRA | Hypertension |
| rs11775334 | Pain in limb | 0.004952 | 1.096 | MSRA | Hypertension |
| rs11775334 | Extrapyramidal disease and abnormal movement disorders | 0.003167 | 1.204 | MSRA | Hypertension |
| rs11775334 | Cancer of the digestive organs and peritoneum | 0.009815 | 1.44 | MSRA | Hypertension |
| rs11775334 | Malunion fracture | 0.005261 | 1.441 | MSRA | Hypertension |
| rs11775334 | Bronchitis | 0.000511 | 0.8377 | MSRA | Hypertension |
| rs11775334 | Nephritis and nephropathy in diseases classified elsewhere | 0.01037 | 1.268 | MSRA | Hypertension |
| rs11775334 | Congenital deformities of feet | 0.006343 | 0.7382 | MSRA | Hypertension |
| rs11775334 | Hypertension | 0.002738 | 1.099 | MSRA | Hypertension |
| rs11775334 | Primary pulmonary hypertension | 0.003616 | 1.616 | MSRA | Hypertension |
| rs11775334 | Congenital anomalies of limbs | 0.005219 | 0.7622 | MSRA | Hypertension |
| rs11775334 | Other open wound of head and face | 0.001515 | 0.7852 | MSRA | Hypertension |
| rs11775334 | Anemia in chronic kidney disease | 0.008989 | 1.297 | MSRA | Hypertension |
| rs11775334 | Type 2 diabetic retinopathy | 0.008601 | 1.198 | MSRA | Hypertension |
| rs11775334 | Dyspareunia | 0.007913 | 0.5861 | MSRA | Hypertension |
| rs11775334 | Alkalosis | 0.007192 | 1.792 | MSRA | Hypertension |
| rs11775334 | Essential hypertension | 0.003089 | 1.097 | MSRA | Hypertension |
| rs11775334 | Pulmonary congestion and hypostasis | 0.001747 | 1.428 | MSRA | Hypertension |
| rs11775334 | Disorders resulting from impaired renal function | 0.006547 | 1.296 | MSRA | Hypertension |
| rs11775334 | Thoracic neuritis/radiculitis | 0.01092 | 1.112 | MSRA | Hypertension |
| rs11775334 | Anemia of chronic disease | 0.001522 | 1.245 | MSRA | Hypertension |
| rs11842874 | Hyperosmolality and/or hypernatremia | 0.006622 | 1.796 | MCF2L | Osteoarthritis |
| rs11842874 | Systolic/diastolic heart failure | 0.006287 | 1.236 | MCF2L | Osteoarthritis |
| rs11842874 | Nonallopathic lesions NEC | 0.008629 | 0.7928 | MCF2L | Osteoarthritis |
| rs11842874 | Anomalies of pupillary function | 0.006922 | 2.39 | MCF2L | Osteoarthritis |
| rs11842874 | Primary/intrinsic cardiomyopathies | 0.005869 | 1.353 | MCF2L | Osteoarthritis |
| rs11842874 | Other disorders of back | 0.009436 | 0.75 | MCF2L | Osteoarthritis |
| rs11842874 | Disturbances of sulphur-bearing amino-acid metabolism | 0.00755 | 2.281 | MCF2L | Osteoarthritis |
| rs11842874 | Cardiomyopathy | 0.002331 | 1.381 | MCF2L | Osteoarthritis |
| rs11842874 | Disturbances of amino-acid transport | 0.009627 | 2.219 | MCF2L | Osteoarthritis |
| rs11856323 | Chronic sinusitis | 0.01143 | 1.196 | CORO2B | Cognitive performance |
| rs11856323 | Suppurative and unspecified otitis media | 0.002542 | 1.324 | CORO2B | Cognitive performance |
| rs11856323 | Cholelithiasis with other cholecystitis | 0.01088 | 0.6037 | CORO2B | Cognitive performance |
| rs11856323 | Periostitis | 0.01067 | 2.144 | CORO2B | Cognitive performance |
| rs11856323 | Fever of unknown origin | 0.002796 | 1.214 | CORO2B | Cognitive performance |
| rs11856323 | Anomalies of tooth position/malocclusion | 0.006806 | 2.014 | CORO2B | Cognitive performance |
| rs11856323 | Kyphosis (acquired) | 0.001225 | 1.87 | CORO2B | Cognitive performance |
| rs11856323 | Primary open angle glaucoma | 0.004958 | 0.6422 | CORO2B | Cognitive performance |
| rs11856323 | Abnormal sputum | 0.005807 | 1.522 | CORO2B | Cognitive performance |
| rs11856323 | Eosinophilia | 0.001146 | 2.438 | CORO2B | Cognitive performance |
| rs11856323 | Peripheral angiopathy in diseases classified elsewhere | 0.006636 | 1.938 | CORO2B | Cognitive performance |
| rs11856323 | Diseases of lips | 0.000973 | 1.927 | CORO2B | Cognitive performance |
| rs11856323 | Ascites (non malignant) | 0.001599 | 1.736 | CORO2B | Cognitive performance |
| rs11856323 | Chronic pharyngitis and nasopharyngitis | 0.009534 | 1.272 | CORO2B | Cognitive performance |
| rs11880198 | Cramp of limb | 0.003678 | 1.393 | GNA15 | Heart failure |
| rs11880198 | Colles' fracture | 0.0008353 | 1.564 | GNA15 | Heart failure |
| rs11880198 | Inflammatory and toxic neuropathy | 0.002526 | 1.468 | GNA15 | Heart failure |
| rs11880198 | Breast conditions, congenital or relating to hormones | 0.009122 | 1.373 | GNA15 | Heart failure |
| rs11880198 | Corneal dystrophy | 0.0009915 | 1.444 | GNA15 | Heart failure |
| rs11880198 | Open wound of nose and sinus | 0.004353 | 2.163 | GNA15 | Heart failure |
| rs11880198 | Labyrinthitis | 0.002643 | 1.478 | GNA15 | Heart failure |
| rs11880198 | Open wound of hand except finger(s) | 0.005541 | 1.349 | GNA15 | Heart failure |
| rs11880198 | Diseases of pulp and periapical tissues | 0.003206 | 1.27 | GNA15 | Heart failure |
| rs11880198 | Frequency of urination and polyuria | 0.009332 | 1.153 | GNA15 | Heart failure |
| rs11880198 | Pityriasis | 0.001354 | 2.546 | GNA15 | Heart failure |
| rs11880198 | Fracture of radius and ulna | 0.003297 | 1.245 | GNA15 | Heart failure |
| rs11880198 | Fracture of upper limb | 0.006086 | 1.184 | GNA15 | Heart failure |
| rs11880198 | Periapical abscess | 0.00195 | 1.298 | GNA15 | Heart failure |
| rs11880198 | Dystrophy of female genital tract | 0.003401 | 2.135 | GNA15 | Heart failure |
| rs11898505 | Dysmetabolic syndrome X | 0.002398 | 1.514 | SPTBN1 | Bone mineral density |
| rs11898505 | Fracture of humerus | 0.000363 | 0.7225 | SPTBN1 | Bone mineral density |
| rs11898505 | Hemangioma and lymphangioma, any site | 0.001044 | 0.7121 | SPTBN1 | Bone mineral density |
| rs11898505 | Pelvic inflammatory disease | 0.01103 | 0.4828 | SPTBN1 | Bone mineral density |
| rs11898505 | Psoriatic arthropathy | 0.00486 | 1.864 | SPTBN1 | Bone mineral density |
| rs11898505 | Keratoderma, acquired | 0.0008561 | 1.211 | SPTBN1 | Bone mineral density |
| rs11898505 | Symptoms involving female genital tract | 0.01117 | 0.7264 | SPTBN1 | Bone mineral density |
| rs11898505 | Diseases of lips | 0.004964 | 1.504 | SPTBN1 | Bone mineral density |
| rs11898505 | Psoriasis & related disorders | 0.01091 | 1.221 | SPTBN1 | Bone mineral density |
| rs11898505 | Corneal opacity | 0.01127 | 1.333 | SPTBN1 | Bone mineral density |
| rs11898505 | Scoliosis | 0.01037 | 1.291 | SPTBN1 | Bone mineral density |
| rs11898505 | Mood disorders | 0.0007651 | 0.8872 | SPTBN1 | Bone mineral density |
| rs11898505 | Depression | 0.0008858 | 0.8861 | SPTBN1 | Bone mineral density |
| rs11957313 | Male infertility and abnormal spermatozoa | 0.006109 | 1.906 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Neurological disorders due to brain damage | 0.005224 | 1.19 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Infertility, male | 0.006035 | 2.17 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Arthropathy associated with infections | 0.006998 | 1.696 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Partial epilepsy | 0.009134 | 1.513 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Precordial pain | 0.008596 | 1.404 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Arthralgia/ankylosis of temporomandibular joint | 0.004389 | 1.775 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Type 2 diabetic nephropathy | 0.0115 | 0.7568 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Congenital anomalies of genital organs | 0.007002 | 2.138 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Diseases of pancreas | 0.004549 | 0.729 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Other diseases of the teeth and supporting structures | 0.00246 | 1.376 | KCNIP1 | Multiple sclerosis |
| rs11957313 | CNS infection and poliomyelitis | 0.00412 | 0.2986 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Swelling of limb | 0.01097 | 1.214 | KCNIP1 | Multiple sclerosis |
| rs11984075 | Benign neoplasm of other parts of digestive system | 0.002478 | 0.5318 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Impaction of intestine | 0.01041 | 2.323 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Iron metabolism disorder | 0.001663 | 2.395 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Bundle branch block | 0.002533 | 1.366 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Arthropathy NOS involving multiple sites | 0.008244 | 1.837 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Depression | 0.009294 | 1.153 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Other hypertrophic and atrophic conditions of skin | 0.007194 | 1.182 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Sensorineural hearing loss | 0.002891 | 1.191 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Parkinson's disease | 0.001387 | 0.5448 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Other disorders of metabolic, endocrine, immunity disorders | 0.002199 | 2.403 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Spondylosis with myelopathy | 0.009788 | 1.519 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Benign neoplasm of breast | 0.009804 | 1.776 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Glomerulonephritis | 0.0003997 | 2.249 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Elevated prostate specific antigen | 0.003694 | 1.329 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Major depressive disorder | 0.008689 | 1.245 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Toxic effect of venom | 0.00988 | 1.706 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Secondary malignancy of brain/spine | 0.004832 | 1.912 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Eustachian tube disorders | 0.0115 | 1.356 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Asthma with exacerbation | 0.00311 | 1.616 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Chronic prostatitis | 0.01059 | 1.756 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Pituitary hyperfunction | 0.00278 | 2.626 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11989782 | Restless legs syndrome | 0.005569 | 0.7243 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Diverticulitis | 0.004399 | 1.261 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Cholangitis | 0.005224 | 1.784 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Upper gastrointestinal congenital anomalies | 0.005521 | 1.607 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Osteoporosis | 0.008491 | 0.8698 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Amblyopia | 0.001651 | 1.444 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Acute laryngitis and tracheitis | 0.004688 | 0.5991 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Symptoms involving head and neck | 0.01122 | 0.8214 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Esophageal atresia/tracheoesophageal fistula | 0.006192 | 1.738 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Cardiac defibrillator in situ | 0.001252 | 0.5649 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Other alveolar and parietoalveolar pneumonopathy | 0.003789 | 1.727 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Atrophy of edentulous alveolar ridge | 0.006333 | 1.526 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Osteoporosis, NOS or other | 0.006812 | 0.8694 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Other signs and symptoms in breast | 0.002866 | 0.6463 | SNTB1 | Eosinophilic esophagitis |
| rs1202199 | Other cerebral degenerations | 0.008161 | 0.4392 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Facial nerve disorders | 0.002898 | 1.686 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Congenital anomalies of genital organs | 0.01111 | 2.218 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Viral hepatitis | 0.008388 | 1.434 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Hodgkin's disease | 0.007458 | 2.112 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Cancer of other lymphoid, histiocytic tissue | 0.009393 | 1.41 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Vascular disorders of penis | 0.002695 | 3.094 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs12075 | Deep vein thrombosis | 0.005533 | 1.269 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Osteoarthrosis, generalized | 0.01091 | 1.192 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Blood vessel replaced | 0.01043 | 1.509 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Chronic obstructive asthma | 0.006249 | 0.7736 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Swelling of limb | 0.006359 | 0.8541 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Acquired hemolytic anemias | 0.009433 | 0.4916 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Postmenopausal atrophic vaginitis | 0.01105 | 0.8154 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Fracture of ribs | 0.005626 | 1.243 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Fracture of humerus | 0.005997 | 1.25 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12075 | Abnormal pulmonary function | 0.001779 | 0.3299 | DARC | White blood cell count, Monocyte chemoattractant protein-1 |
| rs12141391 | Blindness and low vision | 0.00875 | 1.871 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Atrial fibrillation & flutter | 0.003216 | 1.462 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Respiratory insufficiency | 0.009869 | 0.2713 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Mechanical complication due to other implant and internal device | 0.009949 | 1.901 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Ingrowing nail | 0.007017 | 1.507 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Fracture of clavicle or scapula | 0.007142 | 2.112 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Other diseases of respiratory system | 0.001988 | 2.259 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Conjunctivitis, infectious | 0.005763 | 1.537 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Traumatic arthropathy | 0.006235 | 2.653 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Hemorrhage of rectum and anus | 0.0008837 | 1.752 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Vitamin deficiency | 0.008013 | 0.5416 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Abnormal electrocardiogram | 0.01074 | 1.469 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Other congenital anomalies of skin | 0.004142 | 2.279 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Premature beats | 0.01079 | 1.574 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Other specified diseases of sebaceous glands | 0.004092 | 1.706 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Lung involvement in conditions classified elsewhere | 0.001438 | 4.298 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Osteoarthrosis NOS | 0.01083 | 1.282 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Cystoid macular degeneration of retina | 0.003886 | 2.001 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Atrial fibrillation | 0.003756 | 1.46 | NEGR1 | Systemic lupus erythematosus |
| rs12203592 | Diseases of sebaceous glands | 0.002376 | 1.169 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Disorders of the autonomic nervous system | 0.00642 | 0.6435 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Skin cancer | 1.106e-16 | 1.457 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Carcinoma in situ of skin | 2.068e-10 | 1.874 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Non-melanoma skin cancer | 3.818e-17 | 1.495 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Neoplasm of uncertain behavior | 0.0004348 | 1.317 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Skin neoplasm of uncertain behavior | 1.029e-06 | 1.487 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Gastrointestinal complications | 0.01093 | 1.321 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other specified nonpsychotic and/or transient mental disorders | 0.00306 | 1.354 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other dermatoses | 1.825e-10 | 1.327 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Osteoporosis, osteopenia, & pathological fractures | 0.0001521 | 1.195 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other specified erythematous conditions | 0.009986 | 1.406 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other acquired musculoskeletal deformity | 0.000281 | 1.433 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Benign neoplasm of skin | 0.0002758 | 0.8237 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Chronic tonsillitis and adenoiditis | 0.003334 | 1.948 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Photodermatitis & sunburn | 6.352e-06 | 1.44 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Celiac disease | 0.008204 | 0.2596 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Congenital anomalies of intestine | 0.007945 | 2.302 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Celiac or tropical sprue | 0.005924 | 0.2458 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Voice disturbance | 0.004223 | 1.297 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Sebaceous cyst | 0.008181 | 1.18 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Mental disorders due to brain damage | 0.0007803 | 1.42 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Melanoma | 0.001373 | 1.425 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Frequency of urination and polyuria | 0.006087 | 1.176 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Seborrheic keratosis | 3.296e-05 | 1.23 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Rosacea | 0.00112 | 1.312 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Open wounds of extremities | 0.005778 | 1.167 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other disorders of intestine | 0.009831 | 1.236 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Brain cancer | 0.006601 | 0.4067 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Erythematous conditions | 0.002257 | 1.201 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other specified diseases of sebaceous glands | 0.006917 | 1.316 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Actinic keratosis | 4.141e-26 | 1.691 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Benign neoplasm of eye | 1.734e-05 | 1.544 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Inflammation of the eye | 0.004008 | 1.172 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Patellar fracture | 0.003461 | 0.5029 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Osteopenia | 6.837e-05 | 1.271 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Vitamin B-complex deficiencies | 0.004681 | 1.311 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Personal history of allergy to medicinal agents | 0.004581 | 1.392 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12210050 | Allergy/adverse effect of penicillin | 0.006033 | 1.305 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Lack of normal physiological development | 0.009643 | 1.424 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Skin cancer | 1.156e-09 | 1.315 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Rosacea | 0.002618 | 1.274 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Diseases of the larynx and vocal cords | 0.004636 | 1.243 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Chronic obstructive asthma | 0.01089 | 1.339 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Skin neoplasm of uncertain behavior | 0.0008494 | 1.322 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Open wound of nose and sinus | 0.008493 | 2.11 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Other dermatoses | 0.0003925 | 1.168 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Failure to thrive | 0.002362 | 1.554 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Melanoma | 0.00025 | 1.475 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Seborheic dermatitis | 0.003478 | 1.262 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Carcinoma in situ of skin | 3.348e-08 | 1.713 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | H. pylori | 0.00491 | 1.655 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Actinic keratosis | 1.937e-08 | 1.318 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Benign neoplasm of skin | 0.001212 | 0.8476 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Osteoporosis, osteopenia, & pathological fractures | 0.008136 | 1.129 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Hypercalcemia | 0.0007001 | 1.419 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Lipoid metabolism disorder NOS | 0.009263 | 1.349 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Other symptoms referable to back | 0.003584 | 0.6891 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Neoplasm of uncertain behavior | 0.003933 | 1.252 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Non-melanoma skin cancer | 5.952e-09 | 1.318 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Osteopenia | 0.0001865 | 1.242 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Photodermatitis & sunburn | 0.01142 | 1.218 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Voice disturbance | 0.008658 | 1.26 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Disorders of mineral metabolism | 0.004047 | 1.2 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Herpes simplex | 0.004098 | 1.41 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Viral warts & HPV | 0.0005464 | 1.264 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12212193 | Nonrheumatic pulmonary valve disorders | 0.003177 | 0.5785 | BACH2 | Multiple sclerosis |
| rs12212193 | Gouty arthropathy | 0.002098 | 1.346 | BACH2 | Multiple sclerosis |
| rs12212193 | Tuberculosis | 0.008879 | 0.5053 | BACH2 | Multiple sclerosis |
| rs12212193 | Aneurysm of artery of lower extremity | 0.007234 | 1.53 | BACH2 | Multiple sclerosis |
| rs12212193 | Other anemias | 0.005751 | 1.088 | BACH2 | Multiple sclerosis |
| rs12212193 | Cramp of limb | 0.009361 | 0.7685 | BACH2 | Multiple sclerosis |
| rs12212193 | Otorrhea | 0.009137 | 0.5016 | BACH2 | Multiple sclerosis |
| rs12212193 | Hypertrophy of female genital organs | 0.01099 | 0.5868 | BACH2 | Multiple sclerosis |
| rs12212193 | Anemia NOS | 0.002672 | 1.103 | BACH2 | Multiple sclerosis |
| rs12212193 | Complications of transplants and reattached limbs | 0.006691 | 0.614 | BACH2 | Multiple sclerosis |
| rs12212193 | Hypothyroidism | 0.002722 | 1.113 | BACH2 | Multiple sclerosis |
| rs12251307 | Anisometropia | 0.0005892 | 0.5047 | IL2RA | Type 1 diabetes |
| rs12251307 | Influenza | 0.002002 | 1.542 | IL2RA | Type 1 diabetes |
| rs12251307 | Acute laryngitis and tracheitis | 0.003309 | 1.752 | IL2RA | Type 1 diabetes |
| rs12251307 | Diverticulosis and diverticulitis | 0.003525 | 1.189 | IL2RA | Type 1 diabetes |
| rs12251307 | Peritonitis and retroperitoneal infections | 0.009657 | 1.543 | IL2RA | Type 1 diabetes |
| rs12251307 | Seborheic dermatitis | 0.006841 | 1.278 | IL2RA | Type 1 diabetes |
| rs12251307 | Atopic or contact dermatitis | 1.436e-05 | 1.265 | IL2RA | Type 1 diabetes |
| rs12251307 | Diverticulosis | 0.00821 | 1.181 | IL2RA | Type 1 diabetes |
| rs12251307 | Congenital anomalies of genital organs | 0.008604 | 2.148 | IL2RA | Type 1 diabetes |
| rs12251307 | Dyshidrosis | 0.0001473 | 2.257 | IL2RA | Type 1 diabetes |
| rs12251307 | Other disorders of soft tissues | 0.007441 | 1.572 | IL2RA | Type 1 diabetes |
| rs12279261 | Disorders of fluid, electrolyte, and acid-base balance | 0.004491 | 0.8881 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Nerve plexus lesions | 0.006389 | 1.53 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Cervical cancer and dysplasia | 0.003715 | 1.402 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Diseases of spleen | 0.001776 | 2.119 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Peritoneal or intestinal adhesions | 0.00199 | 1.841 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Cancer of oropharynx | 0.004983 | 2.205 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Abnormal cytological, histological, immunological and DNA test findings | 0.002668 | 2.029 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Benign neoplasm of unspecified sites | 0.008078 | 2.152 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Pituitary hyperfunction | 0.0006351 | 2.621 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Hypovolemia | 0.01132 | 0.861 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Stricture/obstruction of ureter | 0.002027 | 1.649 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Hydronephrosis | 0.006255 | 1.412 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Abnormal findings on study of brain, nervous system | 0.009693 | 0.5068 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Renal colic | 0.001031 | 1.958 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Benign neoplasm of colon | 0.0004711 | 1.162 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Ileostomy status | 0.009083 | 1.671 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Polyarteritis nodosa and allied conditions | 0.0029 | 1.466 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Symptoms involving respiratory system | 0.007122 | 0.7624 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Abnormal tumor markers, elevated CEA or CA 125 | 0.0006471 | 2.543 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Polycystic ovaries | 0.009025 | 2.133 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Osteoarthrosis, generalized | 0.0009477 | 0.7169 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Giant cell arteritis | 0.002178 | 1.712 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Oliguria and anuria | 0.008738 | 2.234 | NCAM1 | Entorhinal cortical thickness |
| rs12295638 | Pituitary hypofunction | 0.0106 | 2.084 | ANO3 | Extreme obesity |
| rs12295638 | Cystitis and urethritis | 0.005881 | 1.337 | ANO3 | Extreme obesity |
| rs12295638 | Atrophic gastritis | 0.008329 | 1.683 | ANO3 | Extreme obesity |
| rs12295638 | Lesions of stomach and duodenum | 0.008739 | 2.233 | ANO3 | Extreme obesity |
| rs12295638 | Schizophrenia and other psychotic disorders | 0.009516 | 1.298 | ANO3 | Extreme obesity |
| rs12295638 | Acquired deformities of ankle and foot | 0.009301 | 0.6965 | ANO3 | Extreme obesity |
| rs12295638 | E. coli | 0.0005413 | 1.653 | ANO3 | Extreme obesity |
| rs12295638 | Male genital disorders | 0.001627 | 0.5315 | ANO3 | Extreme obesity |
| rs12295638 | Acquired foot deformities | 0.004183 | 0.8129 | ANO3 | Extreme obesity |
| rs12295638 | Infections of kidney | 0.0004113 | 1.693 | ANO3 | Extreme obesity |
| rs12295638 | Cornea replaced by transplant | 0.0006231 | 2.47 | ANO3 | Extreme obesity |
| rs12295638 | Skin neoplasm of uncertain behavior | 0.004805 | 0.6878 | ANO3 | Extreme obesity |
| rs12295638 | Cystitis | 0.005688 | 1.363 | ANO3 | Extreme obesity |
| rs12413409 | Aplastic anemia | 0.003108 | 1.621 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Acute pericarditis | 0.0008842 | 2.895 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Cholelithiasis | 0.002114 | 1.266 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Hemangioma and lymphangioma, any site | 0.003919 | 1.504 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Arthropathy associated with infections | 0.0015 | 2.016 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Calculus of bile duct | 0.01014 | 1.526 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Hypotony of eye | 0.005063 | 2.643 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Blood vessel replaced | 0.01049 | 0.2711 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Other specified osteoporosis | 0.003042 | 2.101 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Nontoxic uninodular goiter | 0.009767 | 1.363 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Inflammatory spondylopathies | 0.00197 | 1.905 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Strabismus (not specified as paralytic) | 0.004401 | 0.6331 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Cholelithiasis and cholecystitis | 0.00924 | 1.209 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Fluid overload | 0.00605 | 1.449 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Hemorrhage from gastrointestinal ulcer | 0.008573 | 0.48 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Alopecia | 0.01009 | 1.484 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Cardiomyopathy | 0.0102 | 0.733 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Other abnormal blood chemistry | 0.01019 | 1.193 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Fracture of vertebral column without mention of spinal cord injury | 0.001373 | 1.443 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Aneurysm of iliac artery | 0.002835 | 2.207 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12418204 | Nephritis & nephropathy | 0.001678 | 2.413 | PDE2A | Optic disc parameters |
| rs12418204 | Osteomyelitis | 0.008532 | 1.574 | PDE2A | Optic disc parameters |
| rs12418204 | Dentofacial anomalies, including malocclusion | 0.009606 | 2.011 | PDE2A | Optic disc parameters |
| rs12418204 | Fracture of clavicle or scapula | 0.008135 | 1.774 | PDE2A | Optic disc parameters |
| rs12418204 | Lower gastrointestinal congenital anomalies | 0.009735 | 2.416 | PDE2A | Optic disc parameters |
| rs12418204 | Psychogenic and somatoform disorders | 0.008863 | 1.527 | PDE2A | Optic disc parameters |
| rs12418204 | Anomalies of tooth position/malocclusion | 0.0078 | 2.233 | PDE2A | Optic disc parameters |
| rs12418204 | Disorders resulting from impaired renal function | 0.00748 | 1.603 | PDE2A | Optic disc parameters |
| rs12418204 | Osteoarthrosis, generalized | 0.003289 | 0.59 | PDE2A | Optic disc parameters |
| rs12418204 | Thrombocytopenia | 0.006571 | 0.6556 | PDE2A | Optic disc parameters |
| rs12418204 | Chronic glomerulonephritis | 0.001699 | 3.494 | PDE2A | Optic disc parameters |
| rs12418204 | Osteoarthritis; localized | 0.01063 | 0.7795 | PDE2A | Optic disc parameters |
| rs12420464 | Other disorders of adrenal glands | 0.01095 | 1.803 | EIF3F | Depression |
| rs12420464 | Anisometropia | 0.001737 | 1.631 | EIF3F | Depression |
| rs12420464 | Eye infection, viral | 0.002174 | 1.778 | EIF3F | Depression |
| rs12420464 | Stiffness of joint | 0.007638 | 1.356 | EIF3F | Depression |
| rs12420464 | Congenital anomalies of face and neck | 0.001321 | 3.241 | EIF3F | Depression |
| rs12420464 | Diverticulosis and diverticulitis | 0.008156 | 1.204 | EIF3F | Depression |
| rs12423712 | Seborheic dermatitis | 0.01073 | 0.6978 | NCOR2 | Cognitive performance |
| rs12423712 | Trigeminal nerve disorders | 0.00138 | 1.93 | NCOR2 | Cognitive performance |
| rs12423712 | Inflammatory and toxic neuropathy | 0.005593 | 1.653 | NCOR2 | Cognitive performance |
| rs12423712 | Large cell lymphoma | 0.002815 | 2.635 | NCOR2 | Cognitive performance |
| rs12423712 | Encounter for long-term use of antiplatelets/antithrombotics | 0.008917 | 2.719 | NCOR2 | Cognitive performance |
| rs12423712 | Stiffness of joint | 0.009931 | 1.348 | NCOR2 | Cognitive performance |
| rs12423712 | Secondary malignant neoplasm of digestive systems | 0.008113 | 0.2135 | NCOR2 | Cognitive performance |
| rs12423712 | Subarachnoid hemorrhage | 0.0004281 | 2.98 | NCOR2 | Cognitive performance |
| rs12423712 | Multiple sclerosis | 0.01115 | 1.834 | NCOR2 | Cognitive performance |
| rs12423712 | Urinary obstruction | 0.00296 | 1.791 | NCOR2 | Cognitive performance |
| rs12423712 | Mitral valve stenosis and/or aortic valve stenosis | 0.003523 | 0.5954 | NCOR2 | Cognitive performance |
| rs12423712 | Partial epilepsy | 0.009608 | 1.689 | NCOR2 | Cognitive performance |
| rs12423712 | Essential hypertension | 0.006833 | 0.8573 | NCOR2 | Cognitive performance |
| rs12423712 | Open wound of hand except finger(s) | 0.01151 | 1.474 | NCOR2 | Cognitive performance |
| rs12423712 | Epilepsy | 0.003954 | 1.663 | NCOR2 | Cognitive performance |
| rs12423712 | Hallux valgus (Bunion) | 0.008342 | 1.345 | NCOR2 | Cognitive performance |
| rs12423712 | Hypertension | 0.005088 | 0.8528 | NCOR2 | Cognitive performance |
| rs12423712 | Congenital cataract and lens anomalies | 7.535e-05 | 3.263 | NCOR2 | Cognitive performance |
| rs12447690 | Calcium/phosphorus disorders | 0.002786 | 0.8092 | ZNF469 | Central corneal thickness |
| rs12447690 | Other specified osteoporosis | 0.00313 | 0.5343 | ZNF469 | Central corneal thickness |
| rs12447690 | Umbilical hernia | 0.001563 | 1.328 | ZNF469 | Central corneal thickness |
| rs12447690 | Chondrocalcinosis | 0.004989 | 0.7045 | ZNF469 | Central corneal thickness |
| rs12447690 | Crystal arthropathies | 0.005734 | 0.7118 | ZNF469 | Central corneal thickness |
| rs12447690 | Excessive or frequent menstruation | 0.01111 | 0.7709 | ZNF469 | Central corneal thickness |
| rs12447690 | Disorders of choroid | 0.001068 | 0.7124 | ZNF469 | Central corneal thickness |
| rs12447690 | Macular degeneration, wet | 0.004178 | 0.7261 | ZNF469 | Central corneal thickness |
| rs12447690 | Abnormal function study of cardiovascular system | 0.002618 | 0.8266 | ZNF469 | Central corneal thickness |
| rs12447690 | Glossitis | 0.01143 | 0.467 | ZNF469 | Central corneal thickness |
| rs12447690 | Premenstrual tension syndromes | 0.005189 | 0.528 | ZNF469 | Central corneal thickness |
| rs12447690 | Adverse effects of hormones and synthetic substitutes | 0.008422 | 0.3764 | ZNF469 | Central corneal thickness |
| rs12483205 | Retinal vascular changes and abnomalities | 0.005329 | 0.7738 | DYRK1A | HIV-1 progression |
| rs12483205 | Primary/intrinsic cardiomyopathies | 0.001924 | 0.7821 | DYRK1A | HIV-1 progression |
| rs12483205 | Celiac disease | 0.007278 | 1.798 | DYRK1A | HIV-1 progression |
| rs12483205 | Congenital musculoskeletal deformities of spine | 0.005595 | 0.6183 | DYRK1A | HIV-1 progression |
| rs12483205 | Chronic pain syndrome | 0.00714 | 0.4749 | DYRK1A | HIV-1 progression |
| rs12483205 | Lymphadenitis | 0.005321 | 1.209 | DYRK1A | HIV-1 progression |
| rs12483205 | Abnormal findings on examination of urine | 0.009419 | 0.8329 | DYRK1A | HIV-1 progression |
| rs12483205 | Psoriasis vulgaris | 0.008541 | 1.275 | DYRK1A | HIV-1 progression |
| rs12483205 | Respiratory failure; insufficiency; arrest | 0.003464 | 0.7923 | DYRK1A | HIV-1 progression |
| rs12483205 | Symptoms involving female genital tract | 0.002263 | 1.472 | DYRK1A | HIV-1 progression |
| rs12483205 | Intestinal malabsorption | 0.003505 | 1.442 | DYRK1A | HIV-1 progression |
| rs12483205 | Retinal detachments and defects | 0.007271 | 1.25 | DYRK1A | HIV-1 progression |
| rs12483205 | Cardiomyopathy | 0.00469 | 0.8058 | DYRK1A | HIV-1 progression |
| rs12483205 | Memory loss | 0.00858 | 1.254 | DYRK1A | HIV-1 progression |
| rs12483205 | Peripheral or central vertigo | 0.005088 | 1.242 | DYRK1A | HIV-1 progression |
| rs12483205 | Other nonspecific findings on examination of urine | 0.001201 | 0.767 | DYRK1A | HIV-1 progression |
| rs12483205 | Infertility, male | 0.005105 | 2.003 | DYRK1A | HIV-1 progression |
| rs12483205 | Acute cystitis | 0.008367 | 0.658 | DYRK1A | HIV-1 progression |
| rs12483205 | Viral warts & HPV | 0.00817 | 1.171 | DYRK1A | HIV-1 progression |
| rs12531488 | Glaucoma | 0.005099 | 1.132 | LOC643308 | Grey matter density |
| rs12531488 | Angina pectoris | 0.009771 | 1.138 | LOC643308 | Grey matter density |
| rs12531488 | Cancer of other male genital organs | 0.004635 | 1.801 | LOC643308 | Grey matter density |
| rs12531488 | Peripheral retinal degenerations | 0.004068 | 1.342 | LOC643308 | Grey matter density |
| rs12531488 | Somatoform disorder | 0.003426 | 1.39 | LOC643308 | Grey matter density |
| rs12531488 | Open wound of eye or eyelid | 0.00544 | 2.019 | LOC643308 | Grey matter density |
| rs12531488 | Abnormal movement | 0.007148 | 0.89 | LOC643308 | Grey matter density |
| rs12531488 | Myalgia and myositis NOS | 0.0081 | 1.124 | LOC643308 | Grey matter density |
| rs12531488 | Bundle branch block | 0.007678 | 0.8169 | LOC643308 | Grey matter density |
| rs12531488 | Left bundle branch block | 0.0002537 | 0.6706 | LOC643308 | Grey matter density |
| rs12531488 | Psychogenic and somatoform disorders | 0.005336 | 1.29 | LOC643308 | Grey matter density |
| rs12531488 | Malignant neoplasm of brain and nervous system | 0.0004201 | 0.5526 | LOC643308 | Grey matter density |
| rs12531488 | Calculus of kidney | 0.002383 | 1.209 | LOC643308 | Grey matter density |
| rs12531488 | Paroxysmal ventricular tachycardia | 0.007962 | 0.7546 | LOC643308 | Grey matter density |
| rs12559632 | Magnesium metabolism disorder | 0.003173 | 1.428 | PHEX | Fetal hemoglobin |
| rs12559632 | Cancer of kidney and renal pelvis | 0.00169 | 1.546 | PHEX | Fetal hemoglobin |
| rs12559632 | Osteoarthrosis, generalized | 0.001689 | 0.75 | PHEX | Fetal hemoglobin |
| rs12559632 | Restless legs syndrome | 0.01123 | 0.7221 | PHEX | Fetal hemoglobin |
| rs12559632 | Obesity | 0.00809 | 0.8938 | PHEX | Fetal hemoglobin |
| rs12559632 | Thyrotoxicosis | 0.0004571 | 0.7007 | PHEX | Fetal hemoglobin |
| rs12559632 | Glomerulonephritis | 0.004487 | 1.922 | PHEX | Fetal hemoglobin |
| rs12559632 | Blood in stool | 0.01042 | 0.8347 | PHEX | Fetal hemoglobin |
| rs12559632 | Swelling, mass, or lump in head and neck | 0.008488 | 1.281 | PHEX | Fetal hemoglobin |
| rs12559632 | Synoviopathy | 0.01048 | 0.7037 | PHEX | Fetal hemoglobin |
| rs12559632 | Type 2 diabetic peripheral circulatory disorders | 0.0003294 | 1.694 | PHEX | Fetal hemoglobin |
| rs12559632 | Renal cell carcinoma | 0.002876 | 1.518 | PHEX | Fetal hemoglobin |
| rs12559632 | Sleep related movement disorders | 0.005928 | 0.7368 | PHEX | Fetal hemoglobin |
| rs12559632 | Mastoiditis | 0.0019 | 2.581 | PHEX | Fetal hemoglobin |
| rs12559632 | Hemorrhoids | 0.001766 | 0.8509 | PHEX | Fetal hemoglobin |
| rs12569163 | Septicemia | 0.005178 | 1.217 | WDR64 | Radiation response |
| rs12569163 | Erectile dysfunction | 0.0003188 | 1.28 | WDR64 | Radiation response |
| rs12569163 | Muscular wasting and disuse atrophy | 0.009454 | 1.636 | WDR64 | Radiation response |
| rs12569163 | Renal colic | 0.0008711 | 1.921 | WDR64 | Radiation response |
| rs12569163 | Noninflammatory female genital disorders | 0.00537 | 0.7934 | WDR64 | Radiation response |
| rs12569163 | Spondylosis with myelopathy | 0.008678 | 1.414 | WDR64 | Radiation response |
| rs12569163 | Pallor and flushing | 0.009736 | 1.441 | WDR64 | Radiation response |
| rs12569163 | Premature beats | 0.007863 | 1.212 | WDR64 | Radiation response |
| rs12569163 | Esophageal atresia/tracheoesophageal fistula | 0.001356 | 1.929 | WDR64 | Radiation response |
| rs12569163 | Other forms of chronic heart disease | 0.006201 | 1.23 | WDR64 | Radiation response |
| rs12569163 | Throat pain | 0.0004422 | 1.924 | WDR64 | Radiation response |
| rs12569163 | Supraventricular premature beats | 0.007182 | 1.398 | WDR64 | Radiation response |
| rs12569163 | Disorders of external ear | 0.004096 | 0.4272 | WDR64 | Radiation response |
| rs12569163 | Other conditions of the mother complicating pregnancy | 0.007506 | 1.72 | WDR64 | Radiation response |
| rs12569163 | Thyrotoxicosis | 0.01005 | 1.258 | WDR64 | Radiation response |
| rs12569163 | Hematemesis | 0.005168 | 1.67 | WDR64 | Radiation response |
| rs12576239 | Poisoning by primarily systemic agents | 0.01093 | 1.384 | KCNQ1 | QT interval |
| rs12576239 | Gouty arthropathy | 0.001848 | 1.462 | KCNQ1 | QT interval |
| rs12576239 | Scar conditions and fibrosis of skin | 0.002154 | 1.47 | KCNQ1 | QT interval |
| rs12576239 | Cerebral atherosclerosis | 0.00834 | 1.802 | KCNQ1 | QT interval |
| rs12576239 | Other symptoms referable to back | 0.009245 | 0.7197 | KCNQ1 | QT interval |
| rs12576239 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.01087 | 1.395 | KCNQ1 | QT interval |
| rs12576239 | Contracture of joint | 0.008848 | 0.568 | KCNQ1 | QT interval |
| rs12576239 | Urethral hypermobility/ISD | 0.004367 | 1.808 | KCNQ1 | QT interval |
| rs12576239 | Paralysis/spasm of vocal cords or larynx | 0.0006975 | 1.968 | KCNQ1 | QT interval |
| rs12576239 | Thoracic neuritis/radiculitis | 0.006734 | 0.8519 | KCNQ1 | QT interval |
| rs12608932 | Anterior pituitary disorders | 0.0007754 | 1.873 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Malignant neoplasm of ovary | 0.002285 | 0.5005 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Stricture of artery | 0.0002466 | 1.454 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Althete's foot | 8.592e-05 | 0.689 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Abnormal loss of weight and underweight | 0.007706 | 0.768 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Tachycardia NOS | 0.007242 | 0.8311 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Vascular disorders of penis | 0.008888 | 0.3858 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Abnormal movement | 0.00479 | 0.8912 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Secondary malignant neoplasm of liver | 0.008655 | 0.7115 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Obsessive-compulsive disorder | 0.006559 | 0.5163 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Left bundle branch block | 0.009791 | 1.272 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Noninfectious disorders of lymphatic channels | 0.004538 | 0.7208 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Early or threatened labor; hemorrhage in early pregnancy | 0.003086 | 1.711 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Anisometropia | 0.0101 | 0.7567 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Other disorders of arteries and arterioles | 0.0009968 | 1.323 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Lymphadenitis | 0.007198 | 0.8388 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Nephritis and nephropathy in diseases classified elsewhere | 0.008629 | 0.768 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Seborheic dermatitis | 0.004393 | 0.8272 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Prurigo | 0.0107 | 0.7774 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Bacteremia | 0.001054 | 0.7087 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Cancer of connective tissue | 0.00217 | 0.5115 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Hemangioma and lymphangioma, any site | 0.002266 | 1.338 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Frequency of urination and polyuria | 0.003902 | 0.8745 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Cancer of larynx | 0.01023 | 1.451 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Adrenal hypofunction | 0.01116 | 1.577 | UNC13A | Amyotrophic lateral sclerosis |
| rs12643654 | Lower gastrointestinal congenital anomalies | 0.01127 | 2.082 | UNC5C | Phosphorylated tau |
| rs12643654 | Cancer within the respiratory system | 0.0006836 | 1.467 | UNC5C | Phosphorylated tau |
| rs12643654 | Allergic conjunctivitis | 0.002383 | 1.502 | UNC5C | Phosphorylated tau |
| rs12643654 | Symptoms involving respiratory system | 0.00116 | 1.397 | UNC5C | Phosphorylated tau |
| rs12643654 | Bronchitis | 0.004372 | 1.255 | UNC5C | Phosphorylated tau |
| rs12643654 | Gouty arthropathy | 0.009337 | 1.46 | UNC5C | Phosphorylated tau |
| rs12643654 | Cataract | 0.001198 | 0.8165 | UNC5C | Phosphorylated tau |
| rs12643654 | Urticaria | 0.001106 | 1.482 | UNC5C | Phosphorylated tau |
| rs12643654 | Cholelithiasis and cholecystitis | 0.003861 | 0.7928 | UNC5C | Phosphorylated tau |
| rs12643654 | Spinal stenosis of lumbar region | 0.004122 | 1.251 | UNC5C | Phosphorylated tau |
| rs12643654 | Diseases of respiratory system | 0.0002842 | 1.358 | UNC5C | Phosphorylated tau |
| rs12643654 | Spontaneous ecchymoses | 0.004136 | 1.938 | UNC5C | Phosphorylated tau |
| rs12643654 | Hemorrhage NOS | 0.002131 | 2.085 | UNC5C | Phosphorylated tau |
| rs12643654 | Disorders of esophageal motility | 0.002339 | 1.792 | UNC5C | Phosphorylated tau |
| rs12643654 | Acute upper respiratory infections | 0.005313 | 1.174 | UNC5C | Phosphorylated tau |
| rs12643654 | Salicylates causing adverse effects in therapeutic use | 0.004916 | 2.373 | UNC5C | Phosphorylated tau |
| rs12643654 | Lung cancer | 0.0006083 | 1.479 | UNC5C | Phosphorylated tau |
| rs12643654 | Acute pharyngitis | 0.006391 | 1.263 | UNC5C | Phosphorylated tau |
| rs12643654 | Cholelithiasis | 0.003701 | 0.7777 | UNC5C | Phosphorylated tau |
| rs12643654 | Nasal polyps | 0.0008247 | 1.692 | UNC5C | Phosphorylated tau |
| rs12643654 | Other specified disorders of pancreatic internal secretion | 0.01095 | 1.913 | UNC5C | Phosphorylated tau |
| rs12643654 | Noninflammatory disorders of vulva and perineum | 0.01024 | 1.71 | UNC5C | Phosphorylated tau |
| rs12644284 | Periodontitis (acute or chronic) | 0.005224 | 1.246 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Paralytic strabismus | 0.001182 | 1.636 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Cholangitis | 0.002933 | 0.4163 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Hypersomnia | 0.005662 | 0.6053 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Other disorders of the nervous system | 0.001354 | 1.653 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Gram negative septicemia | 0.004916 | 0.6468 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Myeloproliferative disease | 0.007692 | 1.367 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Sacroiliitis NEC | 0.01009 | 0.4696 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Chronic tonsillitis and adenoiditis | 0.008729 | 1.669 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Abnormality of red blood cells | 0.005331 | 1.983 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Mastodynia | 0.01014 | 1.272 | TRIM2 | Multiple sclerosis (severity) |
| rs12658202 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.01137 | 0.4677 | GRIA1 | Height |
| rs12658202 | Nonrheumatic aortic valve disorders | 0.009452 | 1.15 | GRIA1 | Height |
| rs12658202 | Gastritis and duodenitis, NOS | 0.004862 | 1.23 | GRIA1 | Height |
| rs12658202 | Other rheumatic heart disease | 0.01138 | 1.867 | GRIA1 | Height |
| rs12658202 | Reticulosarcoma | 0.003716 | 1.706 | GRIA1 | Height |
| rs12658202 | Asthma with exacerbation | 0.003962 | 0.7086 | GRIA1 | Height |
| rs12658202 | Polyp of corpus uteri | 0.004914 | 1.397 | GRIA1 | Height |
| rs12658202 | Bladder cancer and neoplasms | 0.008312 | 1.255 | GRIA1 | Height |
| rs12658202 | Deficiency of humoral immunity | 0.01019 | 2.014 | GRIA1 | Height |
| rs12658202 | Inflammatory disease of cervix, vagina, and vulva | 0.006182 | 0.8451 | GRIA1 | Height |
| rs12658202 | Heart transplant/surgery | 0.01049 | 1.405 | GRIA1 | Height |
| rs12658202 | Vaginitis and vulvovaginitis | 0.009936 | 0.8362 | GRIA1 | Height |
| rs12658202 | Hallux rigidus | 0.005851 | 0.7056 | GRIA1 | Height |
| rs12658202 | Bladder cancer | 0.004707 | 1.284 | GRIA1 | Height |
| rs12658202 | Acquired toe deformities | 0.007742 | 0.8567 | GRIA1 | Height |
| rs12658202 | Polyp of female genital organs | 0.002258 | 1.293 | GRIA1 | Height |
| rs12658202 | Mucous polyp of cervix | 0.01017 | 1.37 | GRIA1 | Height |
| rs12720356 | E. coli | 0.009151 | 1.508 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Pneumonia | 0.005838 | 1.193 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Other conditions of brain | 0.007609 | 1.514 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Ileostomy status | 0.00504 | 1.934 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Respiratory failure | 0.005926 | 1.451 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Hypovolemia | 0.006767 | 1.214 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Cancer of oropharynx | 0.004373 | 2.544 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Neck pain | 0.0007905 | 1.221 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Dyspareunia | 0.009175 | 1.911 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Respiratory failure; insufficiency; arrest | 0.0004713 | 1.419 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Localized adiposity | 0.008083 | 2.297 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Throat pain | 0.002114 | 2.096 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Disorders of fluid, electrolyte, and acid-base balance | 0.009556 | 1.147 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Atrophic gastritis | 0.004887 | 1.782 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Polyp of corpus uteri | 0.007218 | 1.622 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Hyperpotassemia | 0.00144 | 1.387 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Benign neoplasm of other endocrine glands | 0.001243 | 0.2893 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Septicemia | 0.007053 | 1.299 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Electrolyte imbalance | 0.004446 | 1.185 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Sexually transmitted infections | 0.0006784 | 2.824 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Aphakia and other disorders of lens | 0.003716 | 0.5441 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Disorders of binocular eye movements | 0.009563 | 0.7065 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12797755 | Random mental disorder. Ignored for now | 0.007969 | 1.958 | GRIK4 | Cognitive performance |
| rs12797755 | Candidiasis | 0.01028 | 1.359 | GRIK4 | Cognitive performance |
| rs12797755 | Edema | 0.01142 | 0.8177 | GRIK4 | Cognitive performance |
| rs12797755 | Peripheral enthesopathies | 0.002746 | 0.8099 | GRIK4 | Cognitive performance |
| rs12797755 | Swelling of limb | 0.0008719 | 0.625 | GRIK4 | Cognitive performance |
| rs12797755 | Vascular disorders of kidney/hypertrophy | 0.004558 | 2.817 | GRIK4 | Cognitive performance |
| rs12797755 | Sicca syndrome | 0.004244 | 1.953 | GRIK4 | Cognitive performance |
| rs12797755 | Blood vessel replaced | 0.01032 | 1.975 | GRIK4 | Cognitive performance |
| rs12807809 | Dementias | 0.007731 | 0.8271 | NRGN | Schizophrenia |
| rs12807809 | Conjunctivitis, infectious | 0.004605 | 0.8045 | NRGN | Schizophrenia |
| rs12807809 | Mechanical complication of nervous system device, implant, and graft | 0.003126 | 2.23 | NRGN | Schizophrenia |
| rs12807809 | Insomnia | 0.009989 | 1.195 | NRGN | Schizophrenia |
| rs12807809 | Alzheimer's disease | 0.00968 | 0.803 | NRGN | Schizophrenia |
| rs12807809 | Myocardial infarction | 0.002597 | 0.8318 | NRGN | Schizophrenia |
| rs12807809 | Symptoms/disorders of the urinary system | 0.0005583 | 0.8685 | NRGN | Schizophrenia |
| rs12807809 | Essential hypertension | 0.003432 | 0.8932 | NRGN | Schizophrenia |
| rs12807809 | Heart failure | 0.004431 | 0.8586 | NRGN | Schizophrenia |
| rs12807809 | Cardiac pacemaker in situ | 0.01069 | 0.7635 | NRGN | Schizophrenia |
| rs12807809 | Cardiac pacemaker/device in situ | 0.009728 | 0.7751 | NRGN | Schizophrenia |
| rs12807809 | Hypertension | 0.003648 | 0.894 | NRGN | Schizophrenia |
| rs12807809 | Ill-defined descriptions and complications of heart disease | 0.003972 | 0.8584 | NRGN | Schizophrenia |
| rs12807809 | Systolic/diastolic heart failure | 0.00251 | 0.8452 | NRGN | Schizophrenia |
| rs12807809 | Retention of urine | 0.003914 | 0.824 | NRGN | Schizophrenia |
| rs12821256 | Hyperglyceridemia | 0.007765 | 0.6942 | KITLG | Hair color |
| rs12821256 | Angina pectoris | 0.00263 | 0.8003 | KITLG | Hair color |
| rs12821256 | Benign neoplasm of eye | 0.0002035 | 1.503 | KITLG | Hair color |
| rs12821256 | Appendicitis | 0.01043 | 1.545 | KITLG | Hair color |
| rs12821256 | Dry eyes | 0.001009 | 0.7796 | KITLG | Hair color |
| rs12821256 | Acute appendicitis | 0.004273 | 1.721 | KITLG | Hair color |
| rs12821256 | Allergy to serum or vaccine | 0.01058 | 1.983 | KITLG | Hair color |
| rs12821256 | Other forms of chronic heart disease | 0.008388 | 0.7475 | KITLG | Hair color |
| rs12821256 | Disorders of lacrimal system | 0.0005731 | 0.7783 | KITLG | Hair color |
| rs12821256 | Ill-defined descriptions and complications of heart disease | 0.002331 | 0.8243 | KITLG | Hair color |
| rs12821256 | Benign neoplasm of brain and other parts of nervous system | 0.006072 | 0.4905 | KITLG | Hair color |
| rs12821256 | Epiphora | 0.009177 | 0.5731 | KITLG | Hair color |
| rs12821256 | Other congenital anomalies of skin | 0.002333 | 0.4145 | KITLG | Hair color |
| rs12821256 | Skin neoplasm of uncertain behavior | 0.01038 | 0.7401 | KITLG | Hair color |
| rs12821256 | Diseases of the salivary glands | 0.00879 | 0.6357 | KITLG | Hair color |
| rs12915189 | Fracture of ankle and foot | 0.01001 | 1.148 | CRTC3 | Cognitive performance |
| rs12915189 | Osteoporosis, osteopenia, & pathological fractures | 0.006244 | 1.105 | CRTC3 | Cognitive performance |
| rs12915189 | Nasal polyps | 0.003662 | 1.376 | CRTC3 | Cognitive performance |
| rs12915189 | Pathologic fracture | 0.007909 | 1.211 | CRTC3 | Cognitive performance |
| rs12915189 | H. pylori | 0.01084 | 1.468 | CRTC3 | Cognitive performance |
| rs12915189 | Prostate cancer | 0.007836 | 1.194 | CRTC3 | Cognitive performance |
| rs12915189 | Pervasive developmental disorders | 0.0008592 | 1.716 | CRTC3 | Cognitive performance |
| rs12915189 | Chronic obstructive asthma | 0.006426 | 1.297 | CRTC3 | Cognitive performance |
| rs12915189 | Primary pulmonary hypertension | 0.00856 | 0.5881 | CRTC3 | Cognitive performance |
| rs12915189 | Polycystic ovaries | 0.01117 | 1.925 | CRTC3 | Cognitive performance |
| rs12915189 | Osteoporosis | 0.004403 | 1.147 | CRTC3 | Cognitive performance |
| rs12915189 | Ovarian dysfunction | 0.005771 | 1.875 | CRTC3 | Cognitive performance |
| rs12915189 | Osteoporosis, NOS or other | 0.0009343 | 1.167 | CRTC3 | Cognitive performance |
| rs12915189 | Generalized anxiety disorder | 0.008791 | 1.287 | CRTC3 | Cognitive performance |
| rs12915189 | Attention deficit hyperactivity disorder | 0.0002436 | 1.978 | CRTC3 | Cognitive performance |
| rs12915189 | Herpes zoster with nervous system complications | 0.00486 | 0.5869 | CRTC3 | Cognitive performance |
| rs12989701 | Abnormal kidney function | 0.006662 | 2.192 | BIN1 | Alzheimer's disease |
| rs12989701 | Valvular heart disease/ heart chambers | 0.008573 | 1.892 | BIN1 | Alzheimer's disease |
| rs12989701 | Optic atrophy | 0.005774 | 0.4927 | BIN1 | Alzheimer's disease |
| rs12989701 | Benign neoplasm of brain and other parts of nervous system | 0.008155 | 1.497 | BIN1 | Alzheimer's disease |
| rs12989701 | Joint/ligament sprain | 0.0113 | 0.6644 | BIN1 | Alzheimer's disease |
| rs12989701 | Hypoglycemia | 0.006557 | 1.587 | BIN1 | Alzheimer's disease |
| rs12989701 | Stricture of artery | 0.003525 | 0.6255 | BIN1 | Alzheimer's disease |
| rs12989701 | Bullous dermatoses | 0.002437 | 2.109 | BIN1 | Alzheimer's disease |
| rs12989701 | Genitourinary congenital anomalies | 0.003504 | 1.529 | BIN1 | Alzheimer's disease |
| rs12989701 | Impetigo | 0.008704 | 1.667 | BIN1 | Alzheimer's disease |
| rs12989701 | Nephrotic syndrome without mention of glomerulonephritis | 0.01093 | 2.023 | BIN1 | Alzheimer's disease |
| rs12989701 | Viral Enteritis | 0.007425 | 1.618 | BIN1 | Alzheimer's disease |
| rs12989701 | Dementia with cerebral degenerations | 0.01057 | 1.648 | BIN1 | Alzheimer's disease |
| rs13088462 | Anomalies of pupillary function | 0.005295 | 2.69 | DOCK3 | Height |
| rs13088462 | Musculoskeletal symptoms referable to limbs | 0.01025 | 1.523 | DOCK3 | Height |
| rs13088462 | Intervertebral disc disorder with myelopathy | 0.008194 | 2.265 | DOCK3 | Height |
| rs13088462 | Essential hypertension | 0.0001705 | 0.7836 | DOCK3 | Height |
| rs13088462 | Chronic lymphocytic thyroiditis | 0.01146 | 0.2292 | DOCK3 | Height |
| rs13088462 | Paralytic ileus | 0.01032 | 0.4635 | DOCK3 | Height |
| rs13088462 | Other disorders of eyelids | 0.005795 | 0.7308 | DOCK3 | Height |
| rs13088462 | Mixed hyperlipidemia | 0.001487 | 0.6201 | DOCK3 | Height |
| rs13088462 | Hypertension | 0.0002191 | 0.7873 | DOCK3 | Height |
| rs13088462 | Ingrowing nail | 0.004604 | 0.6721 | DOCK3 | Height |
| rs13088462 | Disorders of lipoid metabolism | 0.009792 | 0.8293 | DOCK3 | Height |
| rs13088462 | Benign neoplasm of eye | 0.0006463 | 1.645 | DOCK3 | Height |
| rs13088462 | Dermatomycoses | 0.0001168 | 2.901 | DOCK3 | Height |
| rs13088462 | Hyperlipidemia | 0.006986 | 0.8214 | DOCK3 | Height |
| rs13088462 | Inguinal hernia | 0.002862 | 0.6642 | DOCK3 | Height |
| rs13129697 | Spontaneous ecchymoses | 0.01118 | 0.5698 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Gout | 2.414e-07 | 0.716 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Gout and other crystal arthropathies | 4.971e-06 | 0.7627 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Dupuytren's disease | 0.008395 | 0.6864 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Retinal vascular changes and abnomalities | 0.002977 | 1.265 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Other sprains and strains | 0.001239 | 0.6488 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Costochondritis | 0.001116 | 0.3328 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Corneal edema | 0.005952 | 1.672 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Muscular dystrophies and other myopathies | 0.002503 | 0.5833 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Tinnitus | 0.006338 | 1.222 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Gouty arthropathy | 0.009714 | 0.7425 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | stress incontinence, female | 0.002022 | 1.229 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Pleurisy; pleural effusion | 0.004878 | 0.8537 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs1317209 | Hemorrhage of rectum and anus | 0.001081 | 1.3 | RNF186 | Ulcerative colitis |
| rs1317209 | Other headache syndromes | 0.009919 | 1.126 | RNF186 | Ulcerative colitis |
| rs1317209 | Thoracic neuritis/radiculitis | 0.008883 | 1.144 | RNF186 | Ulcerative colitis |
| rs1317209 | Acute prostatitis | 0.0007848 | 2.022 | RNF186 | Ulcerative colitis |
| rs1317209 | Other alveolar and parietoalveolar pneumonopathy | 0.004791 | 1.786 | RNF186 | Ulcerative colitis |
| rs1317209 | Erectile dysfunction | 0.004801 | 1.231 | RNF186 | Ulcerative colitis |
| rs1317209 | Sprains and strains | 0.006542 | 1.142 | RNF186 | Ulcerative colitis |
| rs1317209 | Back pain | 0.002516 | 1.121 | RNF186 | Ulcerative colitis |
| rs1317209 | Acute, but ill-defined cerebrovascular disease | 0.009444 | 0.7939 | RNF186 | Ulcerative colitis |
| rs1317209 | Lung disease due to external agents | 0.008025 | 1.627 | RNF186 | Ulcerative colitis |
| rs1317209 | Neck pain | 0.006796 | 1.128 | RNF186 | Ulcerative colitis |
| rs1317209 | Pain in joint | 0.006763 | 1.112 | RNF186 | Ulcerative colitis |
| rs1317209 | Back & neck sprains | 0.000987 | 1.203 | RNF186 | Ulcerative colitis |
| rs1317209 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.004009 | 0.7662 | RNF186 | Ulcerative colitis |
| rs1317209 | Skin neoplasm of uncertain behavior | 0.00636 | 1.26 | RNF186 | Ulcerative colitis |
| rs1317209 | Other hemoglobinopathies | 0.003684 | 2.245 | RNF186 | Ulcerative colitis |
| rs1317209 | Benign neoplasm of thyroid glands | 0.01052 | 1.824 | RNF186 | Ulcerative colitis |
| rs1317209 | Chronic laryngitis | 0.01089 | 1.974 | RNF186 | Ulcerative colitis |
| rs13194491 | Peripheral arterial disease | 0.0008221 | 0.7416 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Iron metabolism disorder | 3.76e-16 | 7.795 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Chronic lymphoid leukemia | 0.007584 | 1.896 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Bacteremia | 0.00585 | 0.5229 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Lymphoid leukemia | 0.008482 | 1.85 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Disorders of binocular eye movements | 0.008754 | 0.6824 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Urinary incontinence | 0.007625 | 1.244 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Dystrophy of female genital tract | 0.00351 | 2.607 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Discoid lupus erythematosus | 0.01128 | 1.749 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Iron deficiency anemias NOS | 0.003885 | 0.7591 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Malignant neoplasm of kidney and other urinary organs | 0.004521 | 2.065 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Peripheral vascular disease | 0.005205 | 0.7965 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Atherosclerosis | 0.002765 | 0.7745 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.00791 | 0.7268 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Secondary malignancy of bone | 0.01065 | 1.521 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Iron deficiency anemias | 0.003409 | 0.7403 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Lupus erythematosus | 0.007535 | 2.407 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Atherosclerosis of the extremities | 0.0007135 | 0.7173 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Adrenal hypofunction | 0.008525 | 1.948 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Fractur of unspecified part of femur | 0.0107 | 1.636 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Flat foot | 0.007046 | 1.515 | HIST1H2BJ | Transferrin saturation |
| rs13194984 | Chronic lymphoid leukemia | 0.006902 | 1.728 | BTN1A1 | Transferrin saturation |
| rs13194984 | Atrial flutter | 0.005735 | 0.7108 | BTN1A1 | Transferrin saturation |
| rs13194984 | Age-related macular degeneration | 0.009419 | 0.761 | BTN1A1 | Transferrin saturation |
| rs13194984 | Other local infections of skin and subcutaneous tissue | 0.009424 | 1.241 | BTN1A1 | Transferrin saturation |
| rs13194984 | Iron metabolism disorder | 5.821e-09 | 4.109 | BTN1A1 | Transferrin saturation |
| rs13194984 | Breast conditions, congenital or relating to hormones | 0.007519 | 0.6188 | BTN1A1 | Transferrin saturation |
| rs13194984 | Hypertrophy of breast (Gynecomastia) | 0.005563 | 0.5682 | BTN1A1 | Transferrin saturation |
| rs13194984 | Poisoning by hormones and synthetic substitutes | 0.003387 | 0.5167 | BTN1A1 | Transferrin saturation |
| rs13194984 | Abnormal findings on radiological examination intrathoracic organs | 0.0106 | 0.7435 | BTN1A1 | Transferrin saturation |
| rs13194984 | Disorders of binocular eye movements | 0.003817 | 0.7254 | BTN1A1 | Transferrin saturation |
| rs13194984 | Multiple sclerosis | 0.004263 | 1.732 | BTN1A1 | Transferrin saturation |
| rs13194984 | Non-melanoma skin cancer | 0.002119 | 1.175 | BTN1A1 | Transferrin saturation |
| rs13194984 | Genu valgum or varum (acquired) | 0.007971 | 0.4974 | BTN1A1 | Transferrin saturation |
| rs13194984 | Acute pancreatitis | 0.007897 | 0.6499 | BTN1A1 | Transferrin saturation |
| rs13194984 | Carbuncle and furuncle | 0.006385 | 1.684 | BTN1A1 | Transferrin saturation |
| rs13194984 | Urinary complications | 0.01054 | 0.4915 | BTN1A1 | Transferrin saturation |
| rs13194984 | Bacteremia | 0.000246 | 0.5187 | BTN1A1 | Transferrin saturation |
| rs13194984 | Other specified cardiac dysrhythmias | 0.008608 | 0.8297 | BTN1A1 | Transferrin saturation |
| rs13194984 | Biliary cirrhosis | 0.001163 | 2.845 | BTN1A1 | Transferrin saturation |
| rs13194984 | Fracture of lower limb | 0.002446 | 1.24 | BTN1A1 | Transferrin saturation |
| rs13194984 | Diseases of the oral soft tissues | 0.008177 | 0.7838 | BTN1A1 | Transferrin saturation |
| rs13194984 | Fracture of tibia and fibula | 0.003042 | 1.421 | BTN1A1 | Transferrin saturation |
| rs13194984 | Disorders of penis | 0.0005132 | 0.5096 | BTN1A1 | Transferrin saturation |
| rs13194984 | Skin cancer | 0.004782 | 1.152 | BTN1A1 | Transferrin saturation |
| rs13230047 | Gastrointestinal malfunction arising from mental factors | 0.009419 | 3.565 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Alopecia Areata | 0.001809 | 4.089 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Pathological, developmental or recurrent dislocation | 0.0001351 | 4.398 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Noninflammatory female genital disorders | 0.007727 | 0.5083 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Otitis media | 0.003049 | 0.5953 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Suppurative and unspecified otitis media | 0.003673 | 0.5438 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Other hypertrophic and atrophic conditions of skin | 0.007423 | 0.6996 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Adjustment reaction | 0.005868 | 1.512 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13278062 | Bullous dermatoses | 0.009603 | 1.805 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Ectropion or entropion | 0.007341 | 0.7933 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Symptoms affecting skin | 0.002278 | 1.107 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Congenital anomalies of urinary system | 0.007084 | 0.6826 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Circumscribed scleroderma | 0.002845 | 0.6892 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Aneurysm of other specified artery | 0.00976 | 1.784 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Pneumonia | 0.005678 | 1.109 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Megaloblastic anemia | 0.001671 | 1.411 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Hereditary hemolytic anemias | 0.009954 | 0.6047 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Bronchiectasis | 0.006436 | 1.391 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Herpes simplex | 0.004196 | 1.318 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Other hemoglobinopathies | 0.01063 | 0.4972 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Eating disorder | 0.001766 | 1.78 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Open wounds of head; neck; and trunk | 0.002679 | 1.167 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Hyperosmolality and/or hypernatremia | 0.002188 | 0.6426 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Diaphragmatic hernia | 0.01031 | 1.127 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Kidney replaced by transpant | 0.005192 | 0.6804 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Other open wound of head and face | 0.01105 | 1.197 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Disturbance of skin sensation | 0.01067 | 1.113 | TNFRSF10A | Age-related macular degeneration |
| rs1329428 | Diabetic retinopathy | 0.002648 | 1.211 | CFH | Age-related macular degeneration |
| rs1329428 | Type 2 diabetic retinopathy | 0.004349 | 1.208 | CFH | Age-related macular degeneration |
| rs1329428 | Other specified osteoporosis | 0.007802 | 0.5904 | CFH | Age-related macular degeneration |
| rs1329428 | Left bundle branch block | 0.000674 | 1.363 | CFH | Age-related macular degeneration |
| rs1329428 | Sarcoidosis | 0.004161 | 1.634 | CFH | Age-related macular degeneration |
| rs1329428 | Bundle branch block | 0.003238 | 1.218 | CFH | Age-related macular degeneration |
| rs1329428 | Conjunctivitis, noninfectious | 0.008553 | 1.233 | CFH | Age-related macular degeneration |
| rs1329428 | Partial epilepsy | 0.005695 | 0.6872 | CFH | Age-related macular degeneration |
| rs1329428 | Type 1 diabetic neuropathy | 0.006959 | 1.423 | CFH | Age-related macular degeneration |
| rs1329428 | Encounter for long-term use of anticoagulants/antithrombotics | 0.006078 | 1.265 | CFH | Age-related macular degeneration |
| rs1329428 | Type 2 diabetic ketoacidosis | 0.005678 | 1.138 | CFH | Age-related macular degeneration |
| rs1329428 | Endometrial hyperplasia | 0.0008203 | 1.554 | CFH | Age-related macular degeneration |
| rs1329428 | Osteoarthrosis; localized, secondary | 0.0008799 | 1.724 | CFH | Age-related macular degeneration |
| rs1329428 | Osteomyelitis | 0.006309 | 1.287 | CFH | Age-related macular degeneration |
| rs1329428 | Macular degeneration, wet | 4.895e-12 | 0.4418 | CFH | Age-related macular degeneration |
| rs1329428 | Retinal drusen | 3.168e-06 | 0.6987 | CFH | Age-related macular degeneration |
| rs1329428 | Diabetes mellitus | 3.447e-06 | 1.153 | CFH | Age-related macular degeneration |
| rs1329428 | Retinal disorders | 3.004e-07 | 0.8172 | CFH | Age-related macular degeneration |
| rs1329428 | First degree AV block | 0.00933 | 1.227 | CFH | Age-related macular degeneration |
| rs1329428 | Age-related macular degeneration | 7.157e-20 | 0.514 | CFH | Age-related macular degeneration |
| rs1329428 | Type 2 diabetes | 6.374e-06 | 1.15 | CFH | Age-related macular degeneration |
| rs1329428 | Shock | 0.008697 | 1.37 | CFH | Age-related macular degeneration |
| rs1329428 | Nerve root and plexus disorders | 0.001418 | 1.372 | CFH | Age-related macular degeneration |
| rs1329428 | Encounter for long-term use of aspirin | 0.001615 | 1.349 | CFH | Age-related macular degeneration |
| rs1329428 | Macular degeneration | 7.679e-13 | 0.7212 | CFH | Age-related macular degeneration |
| rs1329428 | Type 1 diabetes | 0.0001105 | 1.258 | CFH | Age-related macular degeneration |
| rs1329428 | Macular degeneration, dry | 1.542e-09 | 0.627 | CFH | Age-related macular degeneration |
| rs1329428 | Allergic conjunctivitis | 0.01058 | 1.252 | CFH | Age-related macular degeneration |
| rs1329428 | Retinal vascular changes and abnomalities | 2.802e-05 | 0.7319 | CFH | Age-related macular degeneration |
| rs1329428 | Fracture of vertebral column without mention of spinal cord injury | 0.009076 | 0.8204 | CFH | Age-related macular degeneration |
| rs13314993 | Other symptoms involving abdomen and pelvis | 0.01012 | 0.8837 | CCR4 | Celiac disease |
| rs13314993 | Testicular dysfunction | 0.01033 | 0.7299 | CCR4 | Celiac disease |
| rs13314993 | Drug-resistant infection | 0.0005734 | 1.495 | CCR4 | Celiac disease |
| rs13314993 | Gram positive septicemia | 0.008808 | 1.571 | CCR4 | Celiac disease |
| rs13314993 | Anaphylactic shock NOS | 0.00951 | 1.456 | CCR4 | Celiac disease |
| rs13314993 | Abnormal findings on radiological examination intrathoracic organs | 0.005135 | 1.213 | CCR4 | Celiac disease |
| rs13314993 | Other cerebral degenerations | 0.006494 | 1.412 | CCR4 | Celiac disease |
| rs13314993 | Cancer of other male genital organs | 0.009176 | 0.5703 | CCR4 | Celiac disease |
| rs13314993 | Wheezing | 0.009406 | 1.306 | CCR4 | Celiac disease |
| rs13314993 | Migrain with aura | 0.008233 | 1.438 | CCR4 | Celiac disease |
| rs13314993 | Testicular hypofunction | 0.007255 | 0.7135 | CCR4 | Celiac disease |
| rs13314993 | Chronic prostatitis | 0.004999 | 1.54 | CCR4 | Celiac disease |
| rs13314993 | Ventral hernia | 0.001714 | 1.33 | CCR4 | Celiac disease |
| rs13314993 | Acute osteomyelitis | 0.002993 | 1.705 | CCR4 | Celiac disease |
| rs13333226 | Prolapse of vaginal vault after hysterectomy | 0.001911 | 0.4701 | UMOD | Hypertension |
| rs13333226 | Pyogenic arthritis | 0.008109 | 0.415 | UMOD | Hypertension |
| rs13333226 | Diseases of spleen | 0.00907 | 1.888 | UMOD | Hypertension |
| rs13333226 | Miscarriage; stillbirth | 0.01014 | 1.886 | UMOD | Hypertension |
| rs13333226 | Abnormal involuntary movements | 0.005423 | 0.7263 | UMOD | Hypertension |
| rs13333226 | Rheumatoid arthritis | 0.002612 | 1.305 | UMOD | Hypertension |
| rs13333226 | Renal failure | 0.002187 | 0.8624 | UMOD | Hypertension |
| rs13333226 | Restless legs syndrome | 0.01009 | 0.7064 | UMOD | Hypertension |
| rs13333226 | Optic atrophy | 0.01073 | 0.5888 | UMOD | Hypertension |
| rs13333226 | Testicular hypofunction | 4.459e-05 | 0.4163 | UMOD | Hypertension |
| rs13333226 | Arthropathy associated with infections | 0.004603 | 0.45 | UMOD | Hypertension |
| rs13333226 | Circumscribed scleroderma | 0.006178 | 1.472 | UMOD | Hypertension |
| rs13333226 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.004477 | 1.703 | UMOD | Hypertension |
| rs13333226 | Testicular dysfunction | 0.0001011 | 0.4539 | UMOD | Hypertension |
| rs13333226 | Noninflammatory disorders of cervix | 0.001839 | 1.894 | UMOD | Hypertension |
| rs13333226 | Noninflammatory female genital disorders | 0.006836 | 1.24 | UMOD | Hypertension |
| rs13333226 | E. coli | 0.00605 | 1.391 | UMOD | Hypertension |
| rs13333226 | Hereditary and idiopathic peripheral neuropathy | 0.006587 | 0.828 | UMOD | Hypertension |
| rs13333226 | Chronic pharyngitis and nasopharyngitis | 0.003488 | 0.8013 | UMOD | Hypertension |
| rs13333226 | Encounter for long-term use of anticoagulants/antithrombotics | 0.002008 | 0.6761 | UMOD | Hypertension |
| rs13333226 | Other abnormal glucose | 0.007161 | 1.18 | UMOD | Hypertension |
| rs13333226 | Sleep related movement disorders | 0.009949 | 0.7484 | UMOD | Hypertension |
| rs13333226 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.006818 | 1.241 | UMOD | Hypertension |
| rs13333226 | Disorders of lacrimal system | 0.006507 | 0.849 | UMOD | Hypertension |
| rs1335532 | Dysmetabolic syndrome X | 0.001176 | 1.749 | CD58 | Multiple sclerosis |
| rs1335532 | Diseases of the tongue | 0.002282 | 1.636 | CD58 | Multiple sclerosis |
| rs1335532 | Nerve root lesions | 0.002181 | 1.948 | CD58 | Multiple sclerosis |
| rs1335532 | Aphakia and other disorders of lens | 0.006154 | 1.428 | CD58 | Multiple sclerosis |
| rs1335532 | Respiratory complications | 0.01086 | 0.3422 | CD58 | Multiple sclerosis |
| rs1335532 | Retinal detachments and defects | 0.007403 | 1.31 | CD58 | Multiple sclerosis |
| rs1335532 | Astigmatism | 0.007245 | 1.205 | CD58 | Multiple sclerosis |
| rs1335532 | ASCVD | 0.009489 | 1.483 | CD58 | Multiple sclerosis |
| rs1335532 | Benign neoplasm of colon | 0.008701 | 1.134 | CD58 | Multiple sclerosis |
| rs1335532 | Hereditary and idiopathic peripheral neuropathy | 0.0006694 | 0.7494 | CD58 | Multiple sclerosis |
| rs1335532 | Multiple myeloma | 0.004289 | 0.3306 | CD58 | Multiple sclerosis |
| rs13429458 | Endocarditis | 0.0003896 | 1.649 | THADA | Polycystic ovary syndrome |
| rs13429458 | Cholecystitis without cholelithiasis | 0.01123 | 0.6304 | THADA | Polycystic ovary syndrome |
| rs13429458 | Other specified peripheral vascular diseases | 0.009024 | 2.257 | THADA | Polycystic ovary syndrome |
| rs13429458 | Adverse effects of opiates and related narcotics in therapeutic use | 0.003795 | 1.462 | THADA | Polycystic ovary syndrome |
| rs13429458 | Nonrheumatic pulmonary valve disorders | 0.006477 | 1.887 | THADA | Polycystic ovary syndrome |
| rs13429458 | Noninfectious dermatoses of eyelid | 0.01115 | 1.829 | THADA | Polycystic ovary syndrome |
| rs13429458 | Noninflammatory disorders of cervix | 0.007056 | 1.898 | THADA | Polycystic ovary syndrome |
| rs13429458 | Acute osteomyelitis | 0.006868 | 1.836 | THADA | Polycystic ovary syndrome |
| rs13429458 | Known or suspected fetal abnormality | 0.004956 | 1.996 | THADA | Polycystic ovary syndrome |
| rs13429458 | Erectile dysfunction | 0.01032 | 0.7882 | THADA | Polycystic ovary syndrome |
| rs13429458 | Salicylates causing adverse effects in therapeutic use | 0.01023 | 2.085 | THADA | Polycystic ovary syndrome |
| rs13429458 | Symptoms involving digestive system | 0.002753 | 1.373 | THADA | Polycystic ovary syndrome |
| rs13429458 | Diseases of hard tissues of teeth | 0.009311 | 0.7522 | THADA | Polycystic ovary syndrome |
| rs13429458 | Other disorders of arteries and arterioles | 0.01103 | 1.368 | THADA | Polycystic ovary syndrome |
| rs13429458 | Hallux valgus (Bunion) | 0.005543 | 1.288 | THADA | Polycystic ovary syndrome |
| rs13429458 | Atrophy of edentulous alveolar ridge | 0.001529 | 0.3162 | THADA | Polycystic ovary syndrome |
| rs13438327 | Other disorders of pancreatic internal secretion | 0.007011 | 1.999 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Acquired spondylolisthesis | 0.001253 | 1.608 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Prostate cancer | 0.001533 | 1.404 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Chronic lymphocytic thyroiditis | 0.01013 | 0.4138 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Male infertility and abnormal spermatozoa | 0.002382 | 2.266 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Cystitis and urethritis | 0.01041 | 1.344 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Abnormal weight gain | 0.009367 | 1.538 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Disturbances in tooth eruption | 0.007772 | 1.575 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Infertility, male | 4.129e-05 | 3.467 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Other specified disorders of pancreatic internal secretion | 0.005499 | 2.043 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Periostitis | 0.01122 | 2.121 | OCM2 | Sudden cardiac arrest |
| rs1354034 | Diseases of respiratory system | 0.005132 | 1.17 | ARHGEF3 | Platelet counts |
| rs1354034 | Overweight | 0.01128 | 1.084 | ARHGEF3 | Platelet counts |
| rs1354034 | Diverticulosis | 0.01033 | 1.112 | ARHGEF3 | Platelet counts |
| rs1354034 | Conjunctivitis, infectious | 0.009388 | 1.162 | ARHGEF3 | Platelet counts |
| rs1354034 | Abnormal weight gain | 0.009701 | 1.322 | ARHGEF3 | Platelet counts |
| rs1354034 | Diseases of nail | 0.0002392 | 1.207 | ARHGEF3 | Platelet counts |
| rs1354034 | Peripheral or central vertigo | 0.00686 | 1.208 | ARHGEF3 | Platelet counts |
| rs1354034 | Postoperative infection | 0.01072 | 1.194 | ARHGEF3 | Platelet counts |
| rs1354034 | Other conditions of brain, NOS | 0.009519 | 0.6368 | ARHGEF3 | Platelet counts |
| rs1354034 | Other specified diseases of nail | 0.0002147 | 1.215 | ARHGEF3 | Platelet counts |
| rs1354034 | Hereditary and idiopathic peripheral neuropathy | 0.0101 | 1.143 | ARHGEF3 | Platelet counts |
| rs1354034 | Diverticulitis | 0.01144 | 1.21 | ARHGEF3 | Platelet counts |
| rs1354034 | Dermatophytosis / Dermatomycosis | 0.0107 | 1.102 | ARHGEF3 | Platelet counts |
| rs1354034 | Diverticulosis and diverticulitis | 0.009965 | 1.107 | ARHGEF3 | Platelet counts |
| rs1354034 | Urticaria | 0.006772 | 0.7951 | ARHGEF3 | Platelet counts |
| rs1354034 | Poisoning by agents affecting the cardiovascular system | 0.004929 | 1.331 | ARHGEF3 | Platelet counts |
| rs1354034 | Symptoms involving respiratory system | 0.006747 | 1.207 | ARHGEF3 | Platelet counts |
| rs1354034 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.007869 | 1.324 | ARHGEF3 | Platelet counts |
| rs1354034 | Hyperosmolality and/or hypernatremia | 0.008259 | 1.457 | ARHGEF3 | Platelet counts |
| rs1354034 | Microscopic hematuria | 0.006184 | 0.636 | ARHGEF3 | Platelet counts |
| rs1354034 | Derangement of joint, non-traumatic | 0.009443 | 1.233 | ARHGEF3 | Platelet counts |
| rs1354034 | Anterior pituitary disorders | 0.004997 | 1.686 | ARHGEF3 | Platelet counts |
| rs1354034 | Thrombocytopenia | 0.0006659 | 1.235 | ARHGEF3 | Platelet counts |
| rs1354034 | Diffuse diseases of connective tissue | 0.004107 | 1.29 | ARHGEF3 | Platelet counts |
| rs1354034 | Purpura and other hemorrhagic conditions | 0.001391 | 1.195 | ARHGEF3 | Platelet counts |
| rs1354034 | Hydronephrosis | 0.008031 | 1.319 | ARHGEF3 | Platelet counts |
| rs1394125 | Decreased white blood cell count | 0.002489 | 1.253 | UBE2Q2 | Serum creatinine |
| rs1394125 | Chronic lymphocytic thyroiditis | 0.009949 | 1.414 | UBE2Q2 | Serum creatinine |
| rs1394125 | Thyroiditis | 0.006326 | 1.357 | UBE2Q2 | Serum creatinine |
| rs1394125 | Other specified disorders of breast | 0.007217 | 0.7904 | UBE2Q2 | Serum creatinine |
| rs1394125 | Thrombocytopenia | 0.0007112 | 1.238 | UBE2Q2 | Serum creatinine |
| rs1394125 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.00594 | 0.8247 | UBE2Q2 | Serum creatinine |
| rs1394125 | Temporomandibular joint disorders | 0.009065 | 1.269 | UBE2Q2 | Serum creatinine |
| rs1394125 | Supraventricular premature beats | 0.001738 | 1.406 | UBE2Q2 | Serum creatinine |
| rs1394125 | Spontaneous ecchymoses | 0.00405 | 1.657 | UBE2Q2 | Serum creatinine |
| rs1394125 | Abnormal coagulation profile | 0.002068 | 1.428 | UBE2Q2 | Serum creatinine |
| rs1394125 | Intestinal infection due to C. difficile | 0.005364 | 1.389 | UBE2Q2 | Serum creatinine |
| rs1394125 | Rheumatic fever / chorea | 0.009521 | 1.92 | UBE2Q2 | Serum creatinine |
| rs1394125 | Other specified gastritis | 0.007529 | 0.7783 | UBE2Q2 | Serum creatinine |
| rs1394125 | Bacterial enteritis | 0.003627 | 1.353 | UBE2Q2 | Serum creatinine |
| rs1394125 | Nonsenile Cataract | 0.003799 | 0.6921 | UBE2Q2 | Serum creatinine |
| rs1394125 | Reticulosarcoma | 0.001645 | 0.5028 | UBE2Q2 | Serum creatinine |
| rs1394125 | Purpura and other hemorrhagic conditions | 0.0001733 | 1.238 | UBE2Q2 | Serum creatinine |
| rs1394125 | Rheumatoid arthritis | 0.006366 | 0.806 | UBE2Q2 | Serum creatinine |
| rs1395479 | Noninflammatory disorders of cervix | 0.005317 | 0.4948 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Palpitations | 0.002155 | 0.8514 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Other disorders of lipoid metabolism and hyperalimentation | 0.004594 | 0.7406 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cerebral ischemia | 0.006706 | 0.8581 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.007182 | 1.59 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Transient cerebral ischemia | 0.008831 | 0.8595 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Gastritis and duodenitis, NOS | 0.009073 | 1.231 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cachexia | 0.00583 | 2.038 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Hydrocele | 0.003749 | 1.58 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cardiac dysrhythmias | 0.01112 | 0.9188 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Disorders of liver | 0.002156 | 1.137 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cellulitis and abscess of foot/toes | 0.001505 | 0.7046 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Alcoholic liver damage | 0.009846 | 1.616 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Reticulosarcoma | 0.00145 | 1.786 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Other specified disorders of liver | 0.008908 | 1.324 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cancer of connective tissue | 0.007376 | 0.5206 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Pseudoexfoliation glaucoma | 0.00993 | 1.555 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cystoid macular degeneration of retina | 0.009284 | 1.314 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1405069 | Chronic ulcer of unspecified site | 0.004507 | 1.291 | PI16 | Chemerin levels |
| rs1405069 | Poisoning by psychotropic agents | 0.003073 | 1.88 | PI16 | Chemerin levels |
| rs1405069 | Secondary malignancy of brain/spine | 0.004956 | 0.5886 | PI16 | Chemerin levels |
| rs1405069 | Emphysema | 0.007736 | 1.259 | PI16 | Chemerin levels |
| rs1405069 | Alcohol-related disorders | 0.003932 | 1.21 | PI16 | Chemerin levels |
| rs1405069 | Plasma protein metabolism disorder | 0.008044 | 1.288 | PI16 | Chemerin levels |
| rs1405069 | Cardiac arrhythmia NOS | 0.01091 | 1.14 | PI16 | Chemerin levels |
| rs1405069 | Unspecified local infection of skin and subcutaneous tissue | 0.007467 | 1.26 | PI16 | Chemerin levels |
| rs1405069 | Ileostomy status | 0.0004943 | 0.519 | PI16 | Chemerin levels |
| rs1405069 | Alcoholism | 0.004229 | 1.241 | PI16 | Chemerin levels |
| rs1405069 | Urethral stricture (not specified as infectious) | 0.003623 | 1.457 | PI16 | Chemerin levels |
| rs1405069 | Gram negative septicemia | 0.006903 | 1.398 | PI16 | Chemerin levels |
| rs1405069 | Hallucinations | 0.0007647 | 2.155 | PI16 | Chemerin levels |
| rs1412444 | Cholelithiasis | 0.009606 | 1.134 | LIPA | Coronary heart disease |
| rs1412444 | Osteopenia | 0.001949 | 0.8672 | LIPA | Coronary heart disease |
| rs1412444 | Symptomatic menopause | 0.0005515 | 0.824 | LIPA | Coronary heart disease |
| rs1412444 | Calculus of bile duct | 0.00158 | 1.418 | LIPA | Coronary heart disease |
| rs1412444 | Benign neoplasm of breast | 0.007836 | 0.6039 | LIPA | Coronary heart disease |
| rs1412444 | Polymyalgia Rheumatica | 0.00834 | 0.7764 | LIPA | Coronary heart disease |
| rs1412444 | Cholelithiasis and cholecystitis | 0.002842 | 1.146 | LIPA | Coronary heart disease |
| rs1412444 | Symptoms involving urinary system | 0.001283 | 1.31 | LIPA | Coronary heart disease |
| rs1412444 | Postmenopausal bleeding | 0.006462 | 0.8096 | LIPA | Coronary heart disease |
| rs1412444 | Menopausal & postmenopausal disorders | 0.001151 | 0.8577 | LIPA | Coronary heart disease |
| rs1412444 | Arteritis NOS | 0.0049 | 1.594 | LIPA | Coronary heart disease |
| rs1412444 | Other hypertensive complications | 0.006778 | 1.262 | LIPA | Coronary heart disease |
| rs1412444 | Althete's foot | 0.005683 | 1.264 | LIPA | Coronary heart disease |
| rs1412444 | Other pulmonary inflamation or edema | 0.004191 | 1.34 | LIPA | Coronary heart disease |
| rs1436900 | Hematuria | 0.003459 | 0.8858 | ESRRG | Optic disc parameters |
| rs1436900 | Other disorders of eyelids | 0.009143 | 0.8753 | ESRRG | Optic disc parameters |
| rs1436900 | Urinary tract infection | 0.005249 | 0.9043 | ESRRG | Optic disc parameters |
| rs1436900 | Hypothyroidism | 0.00538 | 0.9026 | ESRRG | Optic disc parameters |
| rs1436900 | Restless legs syndrome | 0.005418 | 0.759 | ESRRG | Optic disc parameters |
| rs1436900 | Other specified disorders of breast | 0.003567 | 0.7821 | ESRRG | Optic disc parameters |
| rs1436900 | Nausea and vomiting | 0.009142 | 0.9051 | ESRRG | Optic disc parameters |
| rs1436900 | Obstructive sleep apnea | 1.506e-05 | 0.795 | ESRRG | Optic disc parameters |
| rs1436900 | Torticollis | 0.009548 | 1.506 | ESRRG | Optic disc parameters |
| rs1436900 | Other disorders of the nervous system | 0.00812 | 1.514 | ESRRG | Optic disc parameters |
| rs1436900 | Dislocation | 0.01107 | 1.111 | ESRRG | Optic disc parameters |
| rs1436900 | Sleep apnea | 0.001272 | 0.8718 | ESRRG | Optic disc parameters |
| rs1436900 | Dermatophytosis of nail | 0.006828 | 0.8845 | ESRRG | Optic disc parameters |
| rs1436900 | Diseases of esophagus | 0.008165 | 0.9224 | ESRRG | Optic disc parameters |
| rs1436900 | Vertiginous syndromes and other disorders of vestibular system | 0.00645 | 0.9117 | ESRRG | Optic disc parameters |
| rs1436900 | Other diseases of lung | 0.008698 | 0.8837 | ESRRG | Optic disc parameters |
| rs1436900 | Blood in stool | 0.01101 | 0.8699 | ESRRG | Optic disc parameters |
| rs1436900 | Esophagitis, GERD and related diseases | 0.009593 | 0.9222 | ESRRG | Optic disc parameters |
| rs1436900 | Secondary thrombocytopenia | 0.008736 | 0.5947 | ESRRG | Optic disc parameters |
| rs1436900 | Cystitis and urethritis | 0.002219 | 0.8038 | ESRRG | Optic disc parameters |
| rs1436900 | Other nonmalignant breast conditions | 0.000225 | 0.8167 | ESRRG | Optic disc parameters |
| rs1436900 | Cystitis | 0.006006 | 0.8114 | ESRRG | Optic disc parameters |
| rs1436900 | Other unspecified back disorders | 0.001124 | 1.684 | ESRRG | Optic disc parameters |
| rs1436900 | Labyrinthitis | 0.008364 | 0.7303 | ESRRG | Optic disc parameters |
| rs1436900 | Macular puckering of retina | 0.00832 | 0.8186 | ESRRG | Optic disc parameters |
| rs1436900 | Postnasal drip | 0.004375 | 0.4991 | ESRRG | Optic disc parameters |
| rs1436900 | Behcet's syndrome | 0.003873 | 1.564 | ESRRG | Optic disc parameters |
| rs1436900 | Seborrheic keratosis | 0.006424 | 0.9035 | ESRRG | Optic disc parameters |
| rs1436900 | Disorders of lacrimal system | 0.008895 | 0.8854 | ESRRG | Optic disc parameters |
| rs1437898 | Cervical radiculitis | 0.0105 | 0.8532 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Bacterial enteritis | 0.01126 | 1.298 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Viral hepatitis | 0.004614 | 1.295 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Intestinal infection due to C. difficile | 0.01057 | 1.348 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Benign neoplasm of thyroid glands | 0.007397 | 1.758 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Nonspecific findings on examination of blood | 0.006672 | 0.7532 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Urethral hypermobility/ISD | 0.003614 | 1.646 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Acute appendicitis | 0.01148 | 0.6715 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Hyperplasia of prostate | 0.01042 | 0.8756 | NCKAP5 | Multiple sclerosis |
| rs1445898 | Acquired hemolytic anemias | 0.003591 | 2.072 | CAPSL | Type 1 diabetes |
| rs1445898 | Symptoms involving female genital tract | 0.01025 | 0.7395 | CAPSL | Type 1 diabetes |
| rs1445898 | Secondary malignant neoplasm of liver | 0.003107 | 0.7005 | CAPSL | Type 1 diabetes |
| rs1445898 | Pancreatic cancer | 0.001572 | 0.5888 | CAPSL | Type 1 diabetes |
| rs1445898 | Dermatomycoses | 0.005951 | 0.5759 | CAPSL | Type 1 diabetes |
| rs1445898 | Benign neoplasm of thyroid glands | 0.001694 | 1.953 | CAPSL | Type 1 diabetes |
| rs1445898 | Drug-resistant infection | 0.00862 | 1.355 | CAPSL | Type 1 diabetes |
| rs1445898 | Neuralgia, neuritis, and radiculitis NOS | 0.008948 | 1.194 | CAPSL | Type 1 diabetes |
| rs1445898 | Candidiasis | 0.01029 | 0.8495 | CAPSL | Type 1 diabetes |
| rs1445898 | Atopic or contact dermatitis | 0.006268 | 0.9063 | CAPSL | Type 1 diabetes |
| rs1445898 | Corneal edema | 0.000298 | 0.4843 | CAPSL | Type 1 diabetes |
| rs1445898 | Diplopia and disorders of binocular vision | 0.003257 | 0.7546 | CAPSL | Type 1 diabetes |
| rs1445898 | Other derangement of joint | 0.00684 | 1.28 | CAPSL | Type 1 diabetes |
| rs1457451 | Disorders of sweat glands | 0.006577 | 1.414 | LOC100131818 | Transferrin saturation |
| rs1457451 | Polycythemia vera, secondary | 0.01146 | 1.81 | LOC100131818 | Transferrin saturation |
| rs1457451 | Jaw disease NOS | 0.01003 | 1.706 | LOC100131818 | Transferrin saturation |
| rs1457451 | Degeneration of intervertebral disc | 0.006864 | 0.8281 | LOC100131818 | Transferrin saturation |
| rs1457451 | Osteoarthrosis; localized, primary | 0.008246 | 1.365 | LOC100131818 | Transferrin saturation |
| rs1457451 | Other hereditary hemolytic anemias | 0.01119 | 2.41 | LOC100131818 | Transferrin saturation |
| rs1457451 | Malignant neoplasm, other | 0.009444 | 1.344 | LOC100131818 | Transferrin saturation |
| rs1457451 | Abnormal mammogram | 0.009583 | 0.7665 | LOC100131818 | Transferrin saturation |
| rs1457451 | Intervertebral disc disorders | 0.008113 | 0.8563 | LOC100131818 | Transferrin saturation |
| rs1457451 | Methicillin sensitive Staphylococcus aureus | 0.01095 | 0.5685 | LOC100131818 | Transferrin saturation |
| rs1457451 | Glossodynia | 0.005335 | 2.217 | LOC100131818 | Transferrin saturation |
| rs1471403 | Salicylates causing adverse effects in therapeutic use | 0.01019 | 1.834 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Spontaneous ecchymoses | 0.009515 | 1.582 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Carcinoma in situ of skin | 0.00324 | 0.7673 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Pathologic fracture | 0.007176 | 0.8228 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Dysuria | 0.01014 | 1.156 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Decreased libido | 0.001962 | 2.133 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Pneumococcal pneumonia | 0.009619 | 1.785 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Sexual and gender identity disorders | 0.006037 | 1.388 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Protein plasma/amino-acid transport and metabolism disorder | 0.01025 | 1.256 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Convulsions | 0.001465 | 0.7889 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Epilepsy, recurrent seizures, convulsions | 0.004168 | 0.8173 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.01079 | 2.043 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Mycoses | 0.008796 | 1.526 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Fracture of humerus | 0.004748 | 0.7769 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Supraventricular premature beats | 0.004753 | 0.7078 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Pathologic fracture of vertebrae | 0.004155 | 0.7731 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Chronic cystitis | 0.004328 | 1.544 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1484170 | Left bundle branch block | 0.005084 | 0.697 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Exophthalmos | 0.0002211 | 2.396 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Crystal arthropathies | 0.009806 | 1.397 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Somatoform disorder | 0.008994 | 1.394 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Atrophic gastritis | 0.01088 | 1.519 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Type 1 diabetic retinopathy | 0.009381 | 0.6104 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Sebaceous cyst | 0.009964 | 0.8568 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Hepatomegaly | 0.002163 | 1.956 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Poisoning by antibiotics | 0.009996 | 1.229 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Staphylococcus infections | 0.009872 | 1.289 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Male infertility and abnormal spermatozoa | 0.008862 | 0.4296 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Bacterial infection NOS | 0.009155 | 1.16 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Nerve root and plexus disorders | 0.01038 | 0.6937 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Methicillin sensitive Staphylococcus aureus | 0.006793 | 1.398 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Allergy/adverse effect of penicillin | 0.01001 | 1.26 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Graves' disease | 0.001882 | 1.632 | NRG3 | Cardiac hypertrophy |
| rs1497546 | Mental retardation | 0.001392 | 4.117 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Fracture of hand or wrist | 0.01077 | 0.5824 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Hemorrhage or hematoma complicating a procedure | 0.008627 | 0.4451 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Open wound of ear | 0.009373 | 3.15 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Joint/ligament sprain | 0.007816 | 1.853 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Neoplasm of unspecified nature of digestive system | 0.008413 | 2.106 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Diabetes mellitus | 0.008026 | 1.262 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Osteoarthrosis | 0.00184 | 0.752 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Macular puckering of retina | 0.008954 | 0.5192 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Type 2 diabetes | 0.008102 | 1.266 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Osteoarthrosis NOS | 0.009995 | 0.777 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Cerebral atherosclerosis | 0.001679 | 3.128 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Pleurisy; pleural effusion | 0.01048 | 1.41 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1512268 | Venous embolism & thrombosis | 0.005742 | 0.859 | NKX3-1 | Prostate cancer |
| rs1512268 | Trigeminal nerve disorders | 0.004523 | 0.6702 | NKX3-1 | Prostate cancer |
| rs1512268 | Cerebrovascular disease | 0.006967 | 0.9136 | NKX3-1 | Prostate cancer |
| rs1512268 | Malaise and fatigue | 0.01012 | 0.9247 | NKX3-1 | Prostate cancer |
| rs1512268 | Nephritis and nephropathy in diseases classified elsewhere | 0.003713 | 0.7611 | NKX3-1 | Prostate cancer |
| rs1512268 | Dentofacial anomalies, including malocclusion | 0.00867 | 1.531 | NKX3-1 | Prostate cancer |
| rs1512268 | Prostate cancer | 0.00586 | 1.187 | NKX3-1 | Prostate cancer |
| rs1512268 | Altered mental status | 0.002089 | 0.7487 | NKX3-1 | Prostate cancer |
| rs1512268 | Bacterial infection NOS | 0.009511 | 0.8847 | NKX3-1 | Prostate cancer |
| rs1512268 | Arthropathy NOS | 0.01127 | 0.8543 | NKX3-1 | Prostate cancer |
| rs1512268 | Diabetes mellitus | 0.007264 | 0.9203 | NKX3-1 | Prostate cancer |
| rs1512268 | Type 1 diabetes | 0.00281 | 0.8328 | NKX3-1 | Prostate cancer |
| rs1512268 | Chronic pharyngitis and nasopharyngitis | 0.008429 | 0.8603 | NKX3-1 | Prostate cancer |
| rs1512268 | Type 1 diabetic peripheral circulatory disorders | 0.00888 | 0.4946 | NKX3-1 | Prostate cancer |
| rs1512268 | First degree AV block | 0.007499 | 0.8082 | NKX3-1 | Prostate cancer |
| rs1512268 | Type 2 diabetes | 0.006781 | 0.9187 | NKX3-1 | Prostate cancer |
| rs1512268 | Fracture of hand or wrist | 0.002299 | 0.8355 | NKX3-1 | Prostate cancer |
| rs1512268 | Reticulosarcoma | 0.005449 | 1.66 | NKX3-1 | Prostate cancer |
| rs1512268 | Rash and other nonspecific skin eruption | 0.005393 | 0.8566 | NKX3-1 | Prostate cancer |
| rs1512268 | Elevated prostate specific antigen | 0.004165 | 1.201 | NKX3-1 | Prostate cancer |
| rs1512268 | Deep vein thrombosis | 0.002907 | 0.7655 | NKX3-1 | Prostate cancer |
| rs153091 | Ischemic stroke | 0.001955 | 0.7696 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Hearing loss | 0.005308 | 1.11 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Mitral valve stenosis and/or aortic valve stenosis | 0.004792 | 0.7612 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Other cerebral degenerations | 0.00552 | 0.6129 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Somatoform disorder | 0.01109 | 1.368 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Respiratory failure | 0.002487 | 0.7054 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Thyrotoxicosis | 0.007153 | 1.266 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Pathologic fracture of vertebrae | 0.008572 | 1.285 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Occlusion of cerebral arteries | 0.003426 | 0.791 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Cyst or abscess of Bartholin's gland | 0.00702 | 0.282 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Symptoms and disorders of the joints | 0.01008 | 0.879 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Posterior pituitary disorders | 0.002212 | 0.36 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Chronic kidney disease, Stage I or II | 0.005024 | 1.449 | SHISA9 | Response to antipsychotic treatment |
| rs1532085 | Insect bite | 0.009999 | 0.8048 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Thoracic neuritis/radiculitis | 0.004718 | 0.8888 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Type 2 diabetic nephropathy | 0.004697 | 0.81 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Secondary malignant neoplasm of liver | 0.006145 | 1.371 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | stress incontinence, female | 0.00852 | 1.18 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Abnormal findings on mammogram or breast exam | 0.009362 | 1.119 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Disorders of cornea | 0.005818 | 1.198 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Abnormal mammogram | 0.003387 | 1.198 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Sebaceous cyst | 0.005842 | 0.8789 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Corneal opacity | 0.009417 | 1.34 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1534166 | Chronic pancreatitis | 0.002425 | 1.738 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Symptoms affecting skin | 0.003518 | 1.111 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | H. pylori | 0.006304 | 1.509 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Subdural hemorrhage (injury) | 0.001124 | 1.833 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Postmenopausal hormone replacement | 0.007902 | 1.307 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Type 2 diabetic ketoacidosis | 0.002141 | 1.166 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Mood disorders | 0.01099 | 0.9101 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Hypertension | 0.009169 | 1.089 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Anomalies of pupillary function | 0.009593 | 1.819 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Biliary cirrhosis | 0.00327 | 2.254 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Intracranial hemorrhage (injury) | 0.0002763 | 1.683 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Acquired hypothyroidism | 0.007575 | 1.772 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Depression | 0.005888 | 0.9008 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Carcinoma in situ of skin | 0.005286 | 1.269 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Urinary complications | 0.009784 | 1.464 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs1534166 | Elevated blood pressure reading | 0.001515 | 1.183 | SRPRB | Carbohydrate-deficient transferrin concentration |
| rs153734 | Primary angle-closure glaucoma | 0.01041 | 0.7887 | PRICKLE2 | Folate levels |
| rs153734 | Fracture of tibia and fibula | 0.01026 | 0.7332 | PRICKLE2 | Folate levels |
| rs153734 | Neck pain | 0.00276 | 1.133 | PRICKLE2 | Folate levels |
| rs153734 | Extrinsic allergic alveolitis | 0.00261 | 2.201 | PRICKLE2 | Folate levels |
| rs153734 | Sprains and strains | 0.009726 | 1.123 | PRICKLE2 | Folate levels |
| rs153734 | Strabismus (not specified as paralytic) | 0.005445 | 1.283 | PRICKLE2 | Folate levels |
| rs153734 | Disorders of liver | 0.01137 | 1.121 | PRICKLE2 | Folate levels |
| rs153734 | Chronic lymphocytic thyroiditis | 0.009076 | 1.473 | PRICKLE2 | Folate levels |
| rs153734 | Psychogenic and somatoform disorders | 0.008653 | 1.302 | PRICKLE2 | Folate levels |
| rs153734 | Abnormal loss of weight and underweight | 0.0002369 | 1.452 | PRICKLE2 | Folate levels |
| rs153734 | Althete's foot | 0.001979 | 1.344 | PRICKLE2 | Folate levels |
| rs153734 | Noninfectious disorders of lymphatic channels | 0.0099 | 0.6942 | PRICKLE2 | Folate levels |
| rs153734 | Osteomyelitis | 0.007202 | 1.323 | PRICKLE2 | Folate levels |
| rs153734 | Elevated C-reactive protein | 0.009445 | 1.923 | PRICKLE2 | Folate levels |
| rs153734 | Psychogenic disorder | 0.0007665 | 1.645 | PRICKLE2 | Folate levels |
| rs153734 | Spasm of muscle | 0.001907 | 1.294 | PRICKLE2 | Folate levels |
| rs153734 | Anemia NOS | 0.009016 | 1.107 | PRICKLE2 | Folate levels |
| rs153734 | Disease of tricuspid valve | 0.003837 | 1.324 | PRICKLE2 | Folate levels |
| rs153734 | Oliguria and anuria | 0.002159 | 2.342 | PRICKLE2 | Folate levels |
| rs153734 | Spondylosis with myelopathy | 0.006723 | 1.427 | PRICKLE2 | Folate levels |
| rs153734 | Benign neoplasm of uterus | 0.01037 | 1.234 | PRICKLE2 | Folate levels |
| rs1547374 | Joint/ligament sprain | 0.005196 | 1.334 | TFF1 | Pancreatic cancer |
| rs1547374 | Other specified diseases of hair and hair follicles | 0.008202 | 1.316 | TFF1 | Pancreatic cancer |
| rs1547374 | Abnormality of red blood cells | 0.003767 | 2.044 | TFF1 | Pancreatic cancer |
| rs1547374 | Bladder cancer and neoplasms | 0.0104 | 1.257 | TFF1 | Pancreatic cancer |
| rs1547374 | Cerebral aneurysm | 0.01006 | 0.5558 | TFF1 | Pancreatic cancer |
| rs1547374 | Blindness and low vision | 0.0004335 | 0.6719 | TFF1 | Pancreatic cancer |
| rs1547374 | Hemiplegia | 0.003927 | 0.702 | TFF1 | Pancreatic cancer |
| rs1547374 | Herpes zoster with nervous system complications | 0.009382 | 0.6168 | TFF1 | Pancreatic cancer |
| rs1547374 | Bladder cancer | 0.006842 | 1.281 | TFF1 | Pancreatic cancer |
| rs1547374 | Diverticulosis and diverticulitis | 0.004917 | 0.8909 | TFF1 | Pancreatic cancer |
| rs1547374 | Cholecystitis without cholelithiasis | 0.005527 | 0.7364 | TFF1 | Pancreatic cancer |
| rs1547374 | Nonrheumatic tricuspid valve disorders | 0.003927 | 1.489 | TFF1 | Pancreatic cancer |
| rs1547374 | Diverticulosis | 0.008272 | 0.892 | TFF1 | Pancreatic cancer |
| rs1547374 | Multiple myeloma | 0.001593 | 0.5154 | TFF1 | Pancreatic cancer |
| rs1547374 | Pulmonary collapse; interstitial/compensatory emphysema | 0.002701 | 0.8273 | TFF1 | Pancreatic cancer |
| rs1547374 | Anemia of chronic disease | 0.01141 | 0.8275 | TFF1 | Pancreatic cancer |
| rs1550976 | Duodenal ulcer | 0.007034 | 0.722 | NTM | Asperger disorder |
| rs1550976 | Osteomyelitis | 0.007643 | 1.294 | NTM | Asperger disorder |
| rs1550976 | Lack of normal physiological development | 0.003745 | 0.679 | NTM | Asperger disorder |
| rs1550976 | Raynaud's syndrome | 0.008239 | 1.316 | NTM | Asperger disorder |
| rs1550976 | Voice disturbance | 0.0003659 | 1.296 | NTM | Asperger disorder |
| rs1550976 | Cataract | 0.007398 | 1.116 | NTM | Asperger disorder |
| rs1550976 | Dry eyes | 0.01052 | 1.138 | NTM | Asperger disorder |
| rs1550976 | Nonsenile Cataract | 0.009277 | 1.394 | NTM | Asperger disorder |
| rs1550976 | Failure to thrive | 0.0005552 | 0.5974 | NTM | Asperger disorder |
| rs1550976 | Nonallopathic lesions NEC | 0.005402 | 0.8724 | NTM | Asperger disorder |
| rs1564348 | Mixed hyperlipidemia | 0.001174 | 1.289 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Duodenitis | 0.0004331 | 1.661 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Other disorders of back | 0.008498 | 0.8147 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Fracture of ribs | 0.009837 | 0.7327 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Cancer of oropharynx | 0.0004719 | 2.672 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Mammographic microcalcification | 0.01005 | 1.629 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Pulmonary embolism and infarction | 0.003026 | 1.362 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Postlaminectomy syndrome | 0.005822 | 0.5674 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Glaucoma | 0.005533 | 0.8565 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Cysts of the jaws | 0.00986 | 2.318 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Acquired spondylolisthesis | 0.005647 | 0.6537 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Diplopia and disorders of binocular vision | 0.001436 | 1.453 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Cancer of mouth | 0.005219 | 1.663 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | pulmonary heart disease | 0.0002502 | 1.292 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1566039 | Effects of radiation NOS | 0.003032 | 1.529 | PAPD7 | Sphingolipid levels |
| rs1566039 | Systemic sclerosis | 0.0005653 | 0.5268 | PAPD7 | Sphingolipid levels |
| rs1566039 | Dentofacial anomalies, including malocclusion | 0.003622 | 1.601 | PAPD7 | Sphingolipid levels |
| rs1566039 | Contact dermatitis and other eczema due to plants [except food] | 0.007869 | 1.742 | PAPD7 | Sphingolipid levels |
| rs1566039 | Polyarteritis nodosa and allied conditions | 0.0103 | 1.321 | PAPD7 | Sphingolipid levels |
| rs1566039 | Tension headache | 0.01076 | 1.225 | PAPD7 | Sphingolipid levels |
| rs1566039 | Infestation | 0.009054 | 0.5516 | PAPD7 | Sphingolipid levels |
| rs1566039 | Other sprains and strains | 0.01022 | 0.737 | PAPD7 | Sphingolipid levels |
| rs1566039 | Anomalies of tooth position/malocclusion | 0.00478 | 1.685 | PAPD7 | Sphingolipid levels |
| rs1566039 | Somatoform disorder | 0.0003603 | 1.494 | PAPD7 | Sphingolipid levels |
| rs1566039 | Psychogenic and somatoform disorders | 0.003187 | 1.306 | PAPD7 | Sphingolipid levels |
| rs1566039 | Swelling, mass, or lump in head and neck | 0.004755 | 1.251 | PAPD7 | Sphingolipid levels |
| rs1566039 | Polycythemia vera | 0.002466 | 1.897 | PAPD7 | Sphingolipid levels |
| rs1568679 | Myoneural disorders | 0.009559 | 2.212 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Congenital anomalies of lower limb, including pelvic girdle | 9.934e-05 | 2.922 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Elevated prostate specific antigen | 0.001184 | 1.438 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Diseases of nail | 0.009256 | 0.7715 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Urinary tract infection | 0.005042 | 1.192 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Cancer of bone & connective tissue | 0.01045 | 0.3723 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Cystic mastopathy | 0.006019 | 0.7497 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Blood vessel replaced | 0.01086 | 0.2722 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Cancer of the upper aerodigestive tract | 0.007692 | 0.4527 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Benign mammary dysplasias | 0.00828 | 0.7662 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Suicidal ideation or attempt | 0.005794 | 2.136 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Spasm of muscle | 0.008143 | 1.364 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Other unspecified back disorders | 0.00587 | 1.88 | MEIS2 | Response to antipsychotic treatment |
| rs1648707 | Nontoxic multinodular goiter | 0.005188 | 1.274 | ADIPOQ | Adiponectin levels |
| rs1648707 | Poisoning by psychotropic agents | 0.007502 | 0.5089 | ADIPOQ | Adiponectin levels |
| rs1648707 | Other disorders of stomach and duodenum | 0.0002897 | 0.6927 | ADIPOQ | Adiponectin levels |
| rs1648707 | Impaction of intestine | 0.006627 | 2.106 | ADIPOQ | Adiponectin levels |
| rs1648707 | Other specified intestinal malabsorption | 0.005449 | 1.664 | ADIPOQ | Adiponectin levels |
| rs1648707 | Atrophic gastritis | 0.008901 | 0.6505 | ADIPOQ | Adiponectin levels |
| rs1648707 | Hypermetropia | 0.008225 | 0.8771 | ADIPOQ | Adiponectin levels |
| rs1648707 | Nonsenile Cataract | 0.0024 | 0.674 | ADIPOQ | Adiponectin levels |
| rs1648707 | Pseudoexfoliation glaucoma | 0.001649 | 0.5407 | ADIPOQ | Adiponectin levels |
| rs1648707 | Mammographic microcalcification | 0.01073 | 1.514 | ADIPOQ | Adiponectin levels |
| rs1648707 | severe protein-calorie malnutrition | 0.001373 | 0.5404 | ADIPOQ | Adiponectin levels |
| rs1648707 | Other aneurysm | 0.009438 | 1.179 | ADIPOQ | Adiponectin levels |
| rs1668871 | Adverse effects of insulins and antidiabetic agents | 0.0001238 | 0.3452 | TMCC2 | Platelet counts |
| rs1668871 | Nontoxic uninodular goiter | 0.005446 | 1.233 | TMCC2 | Platelet counts |
| rs1668871 | Erectile dysfunction | 0.004471 | 1.182 | TMCC2 | Platelet counts |
| rs1668871 | Symptoms involving respiratory system | 0.004915 | 0.8184 | TMCC2 | Platelet counts |
| rs1668871 | Biliary cirrhosis | 0.0008583 | 2.599 | TMCC2 | Platelet counts |
| rs1668871 | Asthma with exacerbation | 0.007698 | 0.7192 | TMCC2 | Platelet counts |
| rs1668871 | Osteoarthrosis | 0.006321 | 1.087 | TMCC2 | Platelet counts |
| rs1668871 | Diseases of respiratory system | 0.004001 | 0.8484 | TMCC2 | Platelet counts |
| rs1668871 | Other benign neoplasm of connective and other soft tissue | 0.01042 | 1.439 | TMCC2 | Platelet counts |
| rs1668871 | Cirrhosis of liver without mention of alcohol | 0.001033 | 1.532 | TMCC2 | Platelet counts |
| rs1668871 | Carcinoma in situ of skin | 0.0006356 | 0.7438 | TMCC2 | Platelet counts |
| rs1668871 | Male genital disorders | 0.0004251 | 1.422 | TMCC2 | Platelet counts |
| rs1668871 | Endometriosis | 0.001163 | 1.455 | TMCC2 | Platelet counts |
| rs1668871 | Cancer within the respiratory system | 0.01146 | 0.8147 | TMCC2 | Platelet counts |
| rs1668871 | Osteoarthrosis NOS | 0.005275 | 1.096 | TMCC2 | Platelet counts |
| rs1668871 | Malignant neoplasm, other | 0.004162 | 0.7971 | TMCC2 | Platelet counts |
| rs1668871 | Neck pain | 0.004719 | 1.105 | TMCC2 | Platelet counts |
| rs1668871 | Intestinal infection due to C. difficile | 0.004348 | 1.392 | TMCC2 | Platelet counts |
| rs1668871 | Eating disorder | 0.005275 | 1.643 | TMCC2 | Platelet counts |
| rs1668871 | Cancer, suspected or other | 0.001256 | 0.8005 | TMCC2 | Platelet counts |
| rs16826658 | Nonrheumatic mitral valve disorders | 0.01109 | 0.8768 | WNT4 | Endometriosis |
| rs16826658 | Angina pectoris | 0.01151 | 0.8877 | WNT4 | Endometriosis |
| rs16826658 | Abnormal sputum | 0.005946 | 0.743 | WNT4 | Endometriosis |
| rs16826658 | Dysmenorrhea | 0.00314 | 0.6157 | WNT4 | Endometriosis |
| rs16826658 | Acquired deformities of finger | 0.006395 | 0.6703 | WNT4 | Endometriosis |
| rs16826658 | Absent or infrequent menstruation | 0.01141 | 0.6522 | WNT4 | Endometriosis |
| rs16826658 | Skin neoplasm of uncertain behavior | 0.004915 | 0.8218 | WNT4 | Endometriosis |
| rs16826658 | Fracture of tibia and fibula | 0.005195 | 1.288 | WNT4 | Endometriosis |
| rs16826658 | Secondary/extrinsic cardiomyopathies | 0.009902 | 1.723 | WNT4 | Endometriosis |
| rs16826658 | Cornea replaced by transplant | 0.008585 | 1.716 | WNT4 | Endometriosis |
| rs16826658 | Erythematous conditions | 0.007442 | 0.8864 | WNT4 | Endometriosis |
| rs16826658 | Osteoporosis | 0.007876 | 1.129 | WNT4 | Endometriosis |
| rs16826658 | Lesions of stomach and duodenum | 0.008791 | 0.4576 | WNT4 | Endometriosis |
| rs16826658 | Other open wound of head and face | 0.009457 | 1.203 | WNT4 | Endometriosis |
| rs16826658 | Eating disorder | 0.00233 | 0.537 | WNT4 | Endometriosis |
| rs16826658 | Glomerulonephritis | 0.0009122 | 1.849 | WNT4 | Endometriosis |
| rs16826658 | Derangement of joint, non-traumatic | 0.007448 | 0.8006 | WNT4 | Endometriosis |
| rs16861990 | Uterine/Uterovaginal prolapse | 0.002571 | 1.568 | NME7 | D-dimer levels |
| rs16861990 | Insect bite | 0.008303 | 1.445 | NME7 | D-dimer levels |
| rs16861990 | Alkalosis | 0.0103 | 2.227 | NME7 | D-dimer levels |
| rs16861990 | Clotting factor deficiency | 1.523e-09 | 6.02 | NME7 | D-dimer levels |
| rs16861990 | Congenital coagulation defects | 2.069e-11 | 5.429 | NME7 | D-dimer levels |
| rs16861990 | Phlebitis and thrombophlebitis | 0.002011 | 1.446 | NME7 | D-dimer levels |
| rs16861990 | Fracture of ribs | 0.005535 | 1.464 | NME7 | D-dimer levels |
| rs16861990 | Coagulation defects | 0.0005116 | 1.263 | NME7 | D-dimer levels |
| rs16861990 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.003753 | 1.227 | NME7 | D-dimer levels |
| rs16861990 | Light-headedness and vertigo | 0.00543 | 1.203 | NME7 | D-dimer levels |
| rs16861990 | Venous embolism & thrombosis | 0.001037 | 1.369 | NME7 | D-dimer levels |
| rs16861990 | Mitral valve stenosis and/or aortic valve stenosis | 0.006453 | 0.6231 | NME7 | D-dimer levels |
| rs16861990 | Phlebitis and thrombophlebitis of lower extremities | 0.005728 | 1.453 | NME7 | D-dimer levels |
| rs16861990 | Hypercoagulable state | 2e-12 | 3.709 | NME7 | D-dimer levels |
| rs16886165 | Schizophrenia and other psychotic disorders | 0.004554 | 1.262 | MAP3K1 | Breast cancer |
| rs16886165 | Open wound of foot except toe(s) alone | 0.008004 | 1.608 | MAP3K1 | Breast cancer |
| rs16886165 | Disorders of esophageal motility | 0.002152 | 1.675 | MAP3K1 | Breast cancer |
| rs16886165 | Seborrheic keratosis | 0.007964 | 1.137 | MAP3K1 | Breast cancer |
| rs16886165 | Mitral stenosis/insufficiency | 0.01106 | 0.2713 | MAP3K1 | Breast cancer |
| rs16886165 | Inflammation of eyelids | 0.001928 | 1.205 | MAP3K1 | Breast cancer |
| rs16886165 | Disorders of penis | 0.002588 | 1.488 | MAP3K1 | Breast cancer |
| rs16886165 | Other disorders of back | 0.005962 | 0.8103 | MAP3K1 | Breast cancer |
| rs16886165 | Complication of amputation stump | 0.005658 | 2.012 | MAP3K1 | Breast cancer |
| rs16886165 | Peritoneal adhesions (postoperative) (postinfection) | 0.0115 | 1.623 | MAP3K1 | Breast cancer |
| rs16886165 | Dyspepsia and disorders of function of stomach | 0.01047 | 1.199 | MAP3K1 | Breast cancer |
| rs16886165 | Inflammation of the eye | 0.01003 | 1.15 | MAP3K1 | Breast cancer |
| rs16886165 | Ankylosis of joint | 0.001917 | 1.61 | MAP3K1 | Breast cancer |
| rs16892766 | Umbilical hernia | 0.007606 | 1.471 | EIF3H | Colorectal cancer |
| rs16892766 | Acute and chronic tonsillitis | 0.01081 | 1.68 | EIF3H | Colorectal cancer |
| rs16892766 | Inflammatory spondylopathies | 0.007386 | 1.801 | EIF3H | Colorectal cancer |
| rs16892766 | Disorders of the pituitary gland and its hypothalamic control | 0.01104 | 1.554 | EIF3H | Colorectal cancer |
| rs16892766 | Chronic tonsillitis and adenoiditis | 0.007839 | 2.062 | EIF3H | Colorectal cancer |
| rs16892766 | Chronic venous hypertension | 0.005815 | 2.632 | EIF3H | Colorectal cancer |
| rs16892766 | Protein-calorie malnutrition | 0.002273 | 0.6915 | EIF3H | Colorectal cancer |
| rs16892766 | Injuries to the nervous system | 0.01148 | 1.809 | EIF3H | Colorectal cancer |
| rs16892766 | Ankylosing spondylitis | 0.009873 | 2.582 | EIF3H | Colorectal cancer |
| rs16892766 | Neuralgia, neuritis, and radiculitis NOS | 0.01023 | 1.337 | EIF3H | Colorectal cancer |
| rs16892766 | Respiratory failure; insufficiency; arrest | 0.009411 | 0.7077 | EIF3H | Colorectal cancer |
| rs16892766 | Benign neoplasm of other parts of digestive system | 0.0003235 | 1.72 | EIF3H | Colorectal cancer |
| rs16928809 | Torticollis | 0.005481 | 1.855 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Acquired deformities of finger | 0.005258 | 1.684 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Chronic nonalcoholic liver disease | 0.0002762 | 0.5311 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Neoplasm of unspecified nature of digestive system | 0.005862 | 1.635 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Costochondritis | 0.005696 | 2.143 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Seborrhea | 0.008 | 2.228 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Cervical cancer | 0.01024 | 2.109 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Chronic liver disease and cirrhosis | 0.0003976 | 0.5678 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Asthma with exacerbation | 0.004928 | 1.591 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Benign neoplasm of other parts of digestive system | 0.01029 | 0.5815 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Polyneuropathy in diabetes | 0.01101 | 0.7366 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Cerebral aneurysm | 5.207e-05 | 2.534 | SLC22A18 | Serum bilirubin levels |
| rs16944141 | Prurigo | 0.007677 | 1.521 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Unspecified monoarthritis | 0.00949 | 1.991 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Asthma | 0.0006431 | 1.309 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Chronic prostatitis | 0.005304 | 1.974 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Abnormal pulmonary function | 0.01003 | 2.756 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Emphysema | 0.011 | 1.461 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Chronic laryngitis | 0.008406 | 2.465 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Benign neoplasm of skin | 0.009097 | 0.8214 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Excessive or frequent menstruation | 0.008985 | 0.5981 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Stress fracture | 0.005813 | 2.388 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Discoid lupus erythematosus | 0.008903 | 1.807 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Dyschromia and Vitiligo | 0.009427 | 0.6686 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16991615 | Cerebral ischemia | 0.01035 | 1.274 | MCM8 | Menopause |
| rs16991615 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.005949 | 1.405 | MCM8 | Menopause |
| rs16991615 | Transient cerebral ischemia | 0.007039 | 1.295 | MCM8 | Menopause |
| rs16991615 | Exostosis of jaw | 0.00266 | 2.959 | MCM8 | Menopause |
| rs16991615 | Osteitis deformans and osteopathies associated with other disorders | 0.007037 | 2.14 | MCM8 | Menopause |
| rs16991615 | Intestinal malabsorption NOS | 0.01047 | 2.049 | MCM8 | Menopause |
| rs16991615 | Intracerebral hemorrhage | 0.004037 | 2.147 | MCM8 | Menopause |
| rs16991615 | Chronic cystitis | 0.01124 | 1.893 | MCM8 | Menopause |
| rs16991615 | Localized adiposity | 0.004673 | 2.571 | MCM8 | Menopause |
| rs16991615 | Other abnormality of urination | 0.005026 | 1.435 | MCM8 | Menopause |
| rs16991615 | Hydrocele | 0.009997 | 1.909 | MCM8 | Menopause |
| rs16991615 | Viral Enteritis | 0.001201 | 2.066 | MCM8 | Menopause |
| rs16991615 | Deficiency of humoral immunity | 0.00834 | 2.665 | MCM8 | Menopause |
| rs16991615 | Alopecia | 0.004729 | 1.632 | MCM8 | Menopause |
| rs16991615 | Venous embolism & thrombosis | 0.004174 | 0.7127 | MCM8 | Menopause |
| rs16991615 | Other disorders of testis | 0.006667 | 1.748 | MCM8 | Menopause |
| rs17066096 | Chronic liver disease and cirrhosis | 0.00422 | 1.263 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Other paralytic syndromes | 0.004714 | 1.539 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Liver abscess and sequelae of chronic liver disease | 0.008834 | 1.552 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Cirrhosis of liver without mention of alcohol | 0.006985 | 1.459 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Portal hypertension | 0.01118 | 1.675 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.002885 | 1.241 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Peripheral or central vertigo | 0.003077 | 1.257 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Retinal vascular changes and abnomalities | 0.0102 | 1.234 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Respiratory abnormalities | 6.109e-05 | 1.535 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Hemoptysis | 0.003212 | 1.406 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Hemorrhage of gastrointestinal tract | 0.01054 | 1.183 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Eye infection, viral | 0.007761 | 1.428 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Pulmonary collapse; interstitial/compensatory emphysema | 0.001325 | 1.227 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Retinal detachment with retinal defect | 0.006982 | 1.424 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Rheumatoid arthritis | 0.003025 | 1.271 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Abnormal sputum | 0.001804 | 1.409 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Other symptoms involving abdomen and pelvis | 0.005744 | 1.161 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Age-related macular degeneration | 0.006957 | 1.228 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Respiratory failure; insufficiency; arrest | 0.01013 | 1.203 | IL22RA2 | Multiple sclerosis |
| rs17111394 | Non-melanoma skin cancer | 0.009137 | 0.8799 | TSHR | Optic disc parameters |
| rs17111394 | Nonsenile Cataract | 0.008807 | 1.453 | TSHR | Optic disc parameters |
| rs17111394 | Skin cancer | 0.005905 | 0.8796 | TSHR | Optic disc parameters |
| rs17111394 | Retinoschisis and retinal cysts | 0.005901 | 2.215 | TSHR | Optic disc parameters |
| rs17111394 | Pulmonary congestion and hypostasis | 0.007712 | 0.6289 | TSHR | Optic disc parameters |
| rs17111394 | Abnormal weight gain | 0.001452 | 1.501 | TSHR | Optic disc parameters |
| rs17111394 | Other disorders of gallbladder | 0.01038 | 1.631 | TSHR | Optic disc parameters |
| rs17111394 | Delirium due to conditions classified elsewhere | 0.01117 | 0.6443 | TSHR | Optic disc parameters |
| rs17111394 | Symptoms involving digestive system | 0.01073 | 1.259 | TSHR | Optic disc parameters |
| rs17111394 | Abnormal results of function study of liver | 0.005795 | 1.273 | TSHR | Optic disc parameters |
| rs17111394 | Diseases of spleen | 0.008828 | 1.91 | TSHR | Optic disc parameters |
| rs17111394 | Bundle branch block | 0.01071 | 0.7955 | TSHR | Optic disc parameters |
| rs17277546 | Bladder cancer and neoplasms | 0.001894 | 0.3831 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Cancer of kidney and urinary organs | 0.01018 | 0.5927 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Aplastic anemia | 0.01151 | 0.3509 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Bladder cancer | 0.003702 | 0.4074 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Polymyalgia Rheumatica | 0.0008098 | 1.736 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Fracture of pelvis | 0.003816 | 1.778 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Periapical abscess | 0.01028 | 1.457 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Hemorrhage or hematoma complicating a procedure | 0.0006496 | 1.596 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Diseases of pulp and periapical tissues | 0.009044 | 1.446 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Malignant neoplasm, other | 0.003915 | 1.578 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Fibroadenosis of breast | 0.008292 | 3.207 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Malunion fracture | 0.01052 | 1.859 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Impaired fasting glucose | 0.006982 | 1.407 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Fractur of unspecified part of femur | 0.006238 | 1.878 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17291650 | Genu valgum or varum (acquired) | 0.003074 | 0.4195 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Hypovolemia | 0.007208 | 0.8155 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of lower limb | 0.003931 | 0.7741 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of upper limb | 0.0002088 | 0.718 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of foot | 0.009953 | 0.7244 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of unspecified bones | 0.005722 | 0.7717 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of hand or wrist | 0.009486 | 0.7645 | ATF1 | Sudden cardiac arrest |
| rs17291650 | progressive myopia | 0.01002 | 1.984 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Phosphorus metabolism disorder | 0.007451 | 1.642 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Ankylosis of joint | 0.0006208 | 0.2903 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Rheumatoid arthritis | 0.0081 | 0.6885 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of radius and ulna | 0.004104 | 0.7286 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Inflammatory conditions of jaw | 0.0041 | 1.893 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Acute pericarditis | 0.00657 | 2.424 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.001091 | 0.6592 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Other derangement of joint | 0.003471 | 0.5697 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of ribs | 0.008905 | 0.6779 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Colles' fracture | 0.009174 | 0.5406 | ATF1 | Sudden cardiac arrest |
| rs17415853 | Other specified disorders of pancreatic internal secretion | 0.0005846 | 3.142 | EPS8 | Serum ferritin levels |
| rs17415853 | Complications of transplants and reattached limbs | 0.003653 | 2.504 | EPS8 | Serum ferritin levels |
| rs17415853 | Osteoarthrosis; localized, secondary | 0.003099 | 2.525 | EPS8 | Serum ferritin levels |
| rs17415853 | Allergies, other | 0.00365 | 1.745 | EPS8 | Serum ferritin levels |
| rs17415853 | Symptoms involving head and neck | 0.007905 | 1.524 | EPS8 | Serum ferritin levels |
| rs17415853 | Colles' fracture | 0.006726 | 2.045 | EPS8 | Serum ferritin levels |
| rs17415853 | E. coli | 0.005473 | 1.84 | EPS8 | Serum ferritin levels |
| rs17415853 | Varicose veins | 0.007507 | 0.6538 | EPS8 | Serum ferritin levels |
| rs17415853 | Esophageal bleeding | 0.004138 | 2.717 | EPS8 | Serum ferritin levels |
| rs17415853 | Other disorders of pancreatic internal secretion | 0.0007193 | 3.081 | EPS8 | Serum ferritin levels |
| rs17415853 | Cervical cancer and dysplasia | 0.003943 | 1.818 | EPS8 | Serum ferritin levels |
| rs17415853 | Other forms of chronic heart disease | 0.00563 | 1.542 | EPS8 | Serum ferritin levels |
| rs174570 | Cyst of kidney, acquired | 0.002403 | 1.459 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Abnormal loss of weight and underweight | 0.007752 | 0.6712 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Pleurisy; pleural effusion | 0.009189 | 0.8239 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Infertility, female | 0.007218 | 0.3159 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Light-headedness and vertigo | 0.006284 | 1.145 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Other specified diseases of sebaceous glands | 0.01018 | 1.293 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Protein-calorie malnutrition | 0.005215 | 0.7774 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Genitourinary congenital anomalies | 0.0009525 | 1.612 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Vertiginous syndromes and other disorders of vestibular system | 0.006411 | 1.139 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Celiac disease | 0.006707 | 1.969 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Acute periodontitis | 0.009569 | 1.485 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Celiac or tropical sprue | 0.005255 | 1.98 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Open wound of eye or eyelid | 0.01055 | 2.107 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs17525472 | Hemoptysis | 0.008111 | 1.472 | SCG3 | Asthma |
| rs17525472 | Dental caries | 0.0009077 | 1.359 | SCG3 | Asthma |
| rs17525472 | Diseases of hard tissues of teeth | 0.0004614 | 1.369 | SCG3 | Asthma |
| rs17525472 | Allergic reaction to food | 0.009987 | 2.051 | SCG3 | Asthma |
| rs17525472 | Abnormal coagulation profile | 0.007619 | 1.493 | SCG3 | Asthma |
| rs17525472 | Intestinal malabsorption | 0.01035 | 1.496 | SCG3 | Asthma |
| rs17525472 | Abnormal results of function studies | 0.0001375 | 2.2 | SCG3 | Asthma |
| rs17525472 | Gingival and periodontal diseases | 0.007376 | 1.278 | SCG3 | Asthma |
| rs17525472 | Acute bronchospasm | 0.005176 | 2.51 | SCG3 | Asthma |
| rs17525472 | Arthropathy NOS involving multiple sites | 0.00491 | 1.841 | SCG3 | Asthma |
| rs17525472 | Circumscribed scleroderma | 0.009693 | 1.537 | SCG3 | Asthma |
| rs17525472 | Carcinoma in situ of skin | 0.009132 | 1.34 | SCG3 | Asthma |
| rs17525472 | Retinal vascular changes and abnomalities | 0.001702 | 1.381 | SCG3 | Asthma |
| rs17525472 | Chronic periodontitis | 6.318e-05 | 1.559 | SCG3 | Asthma |
| rs17525472 | Atherosclerosis of aorta | 0.008869 | 1.371 | SCG3 | Asthma |
| rs17525472 | Viral warts & HPV | 0.01009 | 1.215 | SCG3 | Asthma |
| rs17525472 | Optic atrophy | 0.004119 | 1.667 | SCG3 | Asthma |
| rs17525472 | Abnormal sputum | 0.008627 | 1.442 | SCG3 | Asthma |
| rs17525472 | Symptoms involving digestive system | 0.01126 | 1.307 | SCG3 | Asthma |
| rs17525472 | Periodontitis (acute or chronic) | 0.001854 | 1.372 | SCG3 | Asthma |
| rs17525472 | Cancer of the lower GI tract | 0.003296 | 1.551 | SCG3 | Asthma |
| rs17525472 | Type 1 diabetic ketoacidosis | 0.008222 | 0.5142 | SCG3 | Asthma |
| rs1755289 | Varicose veins | 0.009134 | 1.147 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Aseptic necrosis of bone | 7.35e-05 | 1.907 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Varicose veins of lower extremity | 0.006078 | 1.162 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Develomental delays and disorders | 0.003267 | 0.7558 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Disorders of cervical region | 0.007378 | 0.7319 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Disturbances in tooth eruption | 0.008238 | 0.7352 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Benign neoplasm of bone and articular cartilage | 0.003388 | 1.759 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Pulmonary collapse; interstitial/compensatory emphysema | 0.003926 | 1.181 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Acquired absence of breast | 0.005707 | 0.7407 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Dermatomycoses | 0.00332 | 1.737 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Lupus erythematosus | 0.003519 | 1.949 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Scoliosis | 0.00785 | 0.7605 | SH3GL2 | Multiple sclerosis |
| rs17584499 | Intracranial hemorrhage | 0.007321 | 0.6753 | PTPRD | Type 2 diabetes |
| rs17584499 | Myocardial infarction | 0.006576 | 0.8553 | PTPRD | Type 2 diabetes |
| rs17584499 | Congenital anomalies of great vessels | 0.004277 | 2.096 | PTPRD | Type 2 diabetes |
| rs17584499 | Photodermatitis & sunburn | 0.00416 | 0.8001 | PTPRD | Type 2 diabetes |
| rs17584499 | Gastrointestinal hemorrhage | 0.007917 | 1.129 | PTPRD | Type 2 diabetes |
| rs17584499 | Acute bronchospasm | 0.002386 | 2.451 | PTPRD | Type 2 diabetes |
| rs17584499 | Portal hypertension | 0.001145 | 1.983 | PTPRD | Type 2 diabetes |
| rs17584499 | Ischemic Heart Disease | 0.008935 | 0.9045 | PTPRD | Type 2 diabetes |
| rs17584499 | Pleurisy; pleural effusion | 0.001205 | 1.21 | PTPRD | Type 2 diabetes |
| rs17584499 | Urticaria | 0.007303 | 0.7524 | PTPRD | Type 2 diabetes |
| rs17584499 | Esophageal bleeding | 0.0102 | 1.732 | PTPRD | Type 2 diabetes |
| rs17584499 | Coronary atherosclerosis | 0.01042 | 0.9014 | PTPRD | Type 2 diabetes |
| rs17584499 | Microscopic hematuria | 0.002993 | 0.5037 | PTPRD | Type 2 diabetes |
| rs17584499 | Liver abscess and sequelae of chronic liver disease | 0.007552 | 1.614 | PTPRD | Type 2 diabetes |
| rs17584499 | Posttraumatic wound infection | 0.00658 | 0.3412 | PTPRD | Type 2 diabetes |
| rs17638629 | Candidiasis | 0.009611 | 0.6023 | ZNF788 | Cognitive performance |
| rs17638629 | Congenital anomalies of great vessels | 0.009083 | 2.841 | ZNF788 | Cognitive performance |
| rs17638629 | Disorders of binocular eye movements | 0.007476 | 0.5566 | ZNF788 | Cognitive performance |
| rs17638629 | Chronic ulcer of unspecified site | 0.009629 | 0.3951 | ZNF788 | Cognitive performance |
| rs17638629 | Strabismus (not specified as paralytic) | 0.009399 | 0.5036 | ZNF788 | Cognitive performance |
| rs17646946 | Parasomnia | 0.0114 | 1.651 | TCHHL1 | Hair morphology |
| rs17646946 | Bullous dermatoses | 0.001046 | 2.169 | TCHHL1 | Hair morphology |
| rs17646946 | Degeneration of intervertebral disc | 0.005125 | 0.8657 | TCHHL1 | Hair morphology |
| rs17646946 | Heart valve replaced | 0.0007095 | 1.433 | TCHHL1 | Hair morphology |
| rs17646946 | Alopecia Areata | 0.006284 | 2.065 | TCHHL1 | Hair morphology |
| rs17646946 | Cerebral atherosclerosis | 0.006886 | 0.4693 | TCHHL1 | Hair morphology |
| rs17646946 | Intracranial hemorrhage (injury) | 0.009332 | 1.505 | TCHHL1 | Hair morphology |
| rs17646946 | Spinal stenosis | 0.003173 | 0.8452 | TCHHL1 | Hair morphology |
| rs17646946 | Other dyschromia | 0.004592 | 1.311 | TCHHL1 | Hair morphology |
| rs17646946 | Megaloblastic anemia | 0.0006547 | 1.531 | TCHHL1 | Hair morphology |
| rs17646946 | Valvular heart disease/ heart chambers | 0.0005515 | 2.095 | TCHHL1 | Hair morphology |
| rs17646946 | Back pain | 0.01086 | 0.912 | TCHHL1 | Hair morphology |
| rs17646946 | Injuries to the nervous system | 0.009361 | 1.582 | TCHHL1 | Hair morphology |
| rs17646946 | Diseases of the oral soft tissues | 0.007554 | 0.8231 | TCHHL1 | Hair morphology |
| rs17646946 | Subdural hemorrhage (injury) | 0.00478 | 1.754 | TCHHL1 | Hair morphology |
| rs17646946 | Cardiac arrest | 0.001761 | 1.763 | TCHHL1 | Hair morphology |
| rs17646946 | Acid-base balance disorder | 0.009158 | 1.341 | TCHHL1 | Hair morphology |
| rs17646946 | Depression | 0.0109 | 0.8961 | TCHHL1 | Hair morphology |
| rs17646946 | Stomatitis and mucositis | 0.01119 | 0.6537 | TCHHL1 | Hair morphology |
| rs17646946 | Acidosis | 0.01071 | 1.4 | TCHHL1 | Hair morphology |
| rs17662626 | Malaise and fatigue | 0.006595 | 0.8541 | PCGEM1 | Schizophrenia |
| rs17662626 | Irregular menstrual bleeding | 0.01012 | 2.03 | PCGEM1 | Schizophrenia |
| rs17662626 | Other alveolar and parietoalveolar pneumonopathy | 0.01112 | 1.974 | PCGEM1 | Schizophrenia |
| rs17662626 | Vitamin deficiency | 0.008176 | 0.7175 | PCGEM1 | Schizophrenia |
| rs17662626 | Renal failure NOS | 0.008119 | 0.4819 | PCGEM1 | Schizophrenia |
| rs17662626 | Dermatosis NOS | 0.005948 | 0.8183 | PCGEM1 | Schizophrenia |
| rs17662626 | Idiopathic fibrosing alveolitis | 0.002455 | 2.501 | PCGEM1 | Schizophrenia |
| rs17662626 | Photodermatitis & sunburn | 0.008769 | 0.7238 | PCGEM1 | Schizophrenia |
| rs17662626 | Acute osteomyelitis | 0.01007 | 1.959 | PCGEM1 | Schizophrenia |
| rs17662626 | Sleep apnea | 0.00474 | 0.79 | PCGEM1 | Schizophrenia |
| rs17696736 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.0005808 | 1.234 | NAA25 | Type 1 diabetes |
| rs17696736 | Ventricular fibrillation & flutter | 0.001522 | 0.5496 | NAA25 | Type 1 diabetes |
| rs17696736 | Atherosclerosis of the extremities | 0.002635 | 1.159 | NAA25 | Type 1 diabetes |
| rs17696736 | Retinoschisis and retinal cysts | 0.001274 | 2.43 | NAA25 | Type 1 diabetes |
| rs17696736 | Type 2 diabetic nephropathy | 0.003832 | 0.81 | NAA25 | Type 1 diabetes |
| rs17696736 | Endometriosis | 0.005688 | 0.7172 | NAA25 | Type 1 diabetes |
| rs17696736 | Mastodynia | 0.005788 | 1.283 | NAA25 | Type 1 diabetes |
| rs17696736 | Hypothyroidism | 0.0006531 | 1.131 | NAA25 | Type 1 diabetes |
| rs17696736 | Abnormal findings on mammogram or breast exam | 0.008056 | 1.12 | NAA25 | Type 1 diabetes |
| rs17696736 | Impaired fasting glucose | 0.007954 | 0.8462 | NAA25 | Type 1 diabetes |
| rs17696736 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.0002792 | 1.335 | NAA25 | Type 1 diabetes |
| rs17696736 | Atherosclerosis | 0.006844 | 1.124 | NAA25 | Type 1 diabetes |
| rs17696736 | Abdominal aortic aneurysm | 0.006319 | 1.242 | NAA25 | Type 1 diabetes |
| rs17696736 | Aortic aneurysm | 0.005149 | 1.212 | NAA25 | Type 1 diabetes |
| rs17696736 | Peyronie's disease | 0.003004 | 1.938 | NAA25 | Type 1 diabetes |
| rs17696736 | Other aneurysm | 0.00711 | 1.182 | NAA25 | Type 1 diabetes |
| rs17696736 | Peripheral arterial disease | 0.005652 | 1.131 | NAA25 | Type 1 diabetes |
| rs17696736 | Anal and rectal polyp | 0.008345 | 0.8028 | NAA25 | Type 1 diabetes |
| rs17696736 | Insomnia | 0.006256 | 0.8562 | NAA25 | Type 1 diabetes |
| rs17760296 | Intracerebral hemorrhage | 0.01148 | 0.4663 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Keloid scar | 0.008878 | 1.709 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Hypovolemia | 0.006588 | 1.162 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Other disorders of biliary tract | 0.008536 | 1.579 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Acute pericarditis | 0.0009342 | 2.505 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Rheumatic fever / chorea | 0.0006327 | 2.41 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Chronic venous hypertension | 0.009675 | 2.02 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Chronic sinusitis | 0.002203 | 1.184 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17763373 | Other arthropathies | 0.002414 | 1.272 | CPEB4 | Prion diseases |
| rs17763373 | Contact and allergic dermatitis of eyelid | 0.005346 | 2.374 | CPEB4 | Prion diseases |
| rs17763373 | Arthropathy NOS | 0.009937 | 1.345 | CPEB4 | Prion diseases |
| rs17763373 | Secondary malignant neoplasm | 0.01128 | 1.295 | CPEB4 | Prion diseases |
| rs17763373 | Secondary malignancy of lymph nodes | 0.001742 | 1.588 | CPEB4 | Prion diseases |
| rs17763373 | Aphasia/speech disturbance | 0.007681 | 1.448 | CPEB4 | Prion diseases |
| rs17763373 | Arterial embolism and thrombosis | 0.003878 | 0.5507 | CPEB4 | Prion diseases |
| rs17763373 | Pathological, developmental or recurrent dislocation | 0.008111 | 2.494 | CPEB4 | Prion diseases |
| rs17763373 | Inflammation of the eye | 0.01099 | 0.8042 | CPEB4 | Prion diseases |
| rs17763373 | Adverse effects of antibacterials (not penicillins) | 0.003108 | 2.298 | CPEB4 | Prion diseases |
| rs17763373 | Abnormal tumor markers, elevated CEA or CA 125 | 0.006017 | 2.766 | CPEB4 | Prion diseases |
| rs17763373 | Inflammation of eyelids | 0.01001 | 0.7816 | CPEB4 | Prion diseases |
| rs17763373 | Uterine cancer | 0.0104 | 1.74 | CPEB4 | Prion diseases |
| rs17774966 | Cancer of the digestive organs and peritoneum | 0.01034 | 1.509 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Disorders of muscle, ligament, and fascia | 0.003619 | 1.217 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Rotator cuff (capsule) sprain | 0.01038 | 1.23 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Chronic ulcer of leg or foot | 0.00306 | 0.8146 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Disorders of synovium, tendon, and bursa | 0.00621 | 1.148 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Altered mental status | 0.009636 | 0.7221 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Osteoarthrosis; localized, secondary | 0.01083 | 1.627 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Symptoms and disorders of the joints | 0.003629 | 1.16 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Hypertensive chronic kidney disease | 0.004446 | 0.7808 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Fasciitis | 0.004428 | 1.218 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Ischemic Heart Disease | 0.009655 | 0.904 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Hypertensive heart and/or renal disease | 0.001057 | 0.7759 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Disorders of sacrum | 0.005215 | 1.316 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Lipoid metabolism disorder NOS | 0.00149 | 1.423 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Hypertension complicating pregnancy | 0.002259 | 2.332 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Anal and rectal polyp | 0.008625 | 0.7435 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Vitamin B-complex deficiencies | 0.002933 | 0.7318 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Urinary tract infection | 0.006185 | 0.8838 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Chronic ulcer of skin | 0.002683 | 0.8384 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Cervicitis and endocervicitis | 0.006101 | 1.704 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Cervicocranial/Cervicobrachial syndrome | 0.004695 | 1.329 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | End stage renal disease | 0.01067 | 0.6225 | TUSC1 | Entorhinal cortical thickness |
| rs17793829 | Benign neoplasm of skin | 0.0008573 | 1.155 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Retinal hemorrhage/ischemia | 0.00211 | 1.507 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Gastritis and duodenitis, NOS | 0.003456 | 1.28 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Renal dialysis | 0.009005 | 0.6214 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Gastritis and duodenitis | 9.808e-05 | 1.249 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Circulatory disease NEC | 0.002247 | 0.806 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Testicular hypofunction | 0.008506 | 1.442 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Meningitis | 0.002636 | 1.889 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Hemangioma and lymphangioma, any site | 0.0008682 | 1.417 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Other disorders of circulatory system | 0.001697 | 0.8208 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Retinal disorders | 0.003234 | 1.149 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Seborrheic keratosis | 0.0007058 | 1.158 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Immunity deficiency | 0.003741 | 0.3998 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Anomalies of jaw size/symmetry | 0.004628 | 2.161 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Other dermatoses | 0.003742 | 1.122 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Atrophic gastritis | 0.001398 | 1.636 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Other cardiac conduction disorders | 0.009307 | 1.741 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Kidney replaced by transpant | 0.005397 | 0.5784 | TTC7B | Cytomegalovirus antibody response |
| rs1800562 | Disorders of refraction and accommodation | 0.00175 | 1.259 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Torticollis | 0.0005442 | 2.321 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other congenital anomalies of skin | 0.0007272 | 2.067 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Frequency of urination and polyuria | 0.009871 | 1.25 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Skin cancer | 0.0003708 | 1.27 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other abnormality of urination | 0.0007062 | 1.527 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Diseases of sebaceous glands | 0.004228 | 1.235 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Traumatic arthropathy | 0.01109 | 2.024 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Retinoschisis and retinal cysts | 0.009263 | 2.574 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Disorders of cervical region | 6.737e-05 | 2.015 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Edema | 0.007657 | 1.211 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Iron metabolism disorder | 3.409e-25 | 12.27 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | CNS infection and poliomyelitis | 0.005992 | 2.132 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Adrenal hypofunction | 0.007443 | 2.052 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other specified diseases of sebaceous glands | 0.00453 | 1.48 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.007556 | 2.913 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Hypermetropia | 0.0005697 | 1.403 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Eosinophilia | 0.0001859 | 3.002 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Iron deficiency anemias | 0.001725 | 0.7008 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Non-melanoma skin cancer | 0.001005 | 1.262 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Polycythemia vera, secondary | 0.004248 | 2.165 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Disorders of sweat glands | 0.001038 | 1.639 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other disorders of bone and cartilage | 0.003854 | 1.456 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Iron deficiency anemias NOS | 0.001527 | 0.7151 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800775 | Esophageal atresia/tracheoesophageal fistula | 0.001229 | 1.915 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Cerebral aneurysm | 0.005014 | 0.5831 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Pervasive developmental disorders | 0.006321 | 0.6371 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Swelling of limb | 0.01038 | 1.156 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Other disorders of urethra and urinary tract | 0.01111 | 0.8361 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Other disorders of middle ear and mastoid | 0.0006579 | 1.61 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Chronic lymphocytic thyroiditis | 0.00714 | 0.6972 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Retinal disorders | 0.008095 | 1.107 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Lesions of stomach and duodenum | 0.0101 | 1.905 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Mucous polyp of cervix | 0.008911 | 0.7262 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Polyarteritis nodosa and allied conditions | 0.002284 | 1.388 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Congenital deformities of feet | 0.01104 | 0.774 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Inflammatory bowel disease | 0.007505 | 1.319 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Macular degeneration | 0.003263 | 1.139 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800961 | Prurigo | 0.002142 | 1.84 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Lyme disease | 0.004394 | 2.389 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Optic atrophy | 0.007916 | 2.115 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Spirochetal infection | 0.005994 | 2.312 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Polyp of corpus uteri | 0.003843 | 2.043 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Sinoatrial node dysfunction | 0.007842 | 0.3716 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Hypocalcemia | 0.01042 | 1.994 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Symptomatic artificial menopause | 0.007998 | 2.42 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Acid-base balance disorder | 0.004196 | 1.838 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Intracerebral hemorrhage | 0.004918 | 2.45 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Malignant neoplasm of renal pelvis | 0.002245 | 3.731 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Acidosis | 0.001798 | 2.106 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Polyp of female genital organs | 0.003143 | 1.749 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Other cerebral degenerations | 0.002351 | 2.146 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Extrinsic allergic alveolitis | 0.001435 | 3.656 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Cachexia | 0.0005511 | 4.02 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1801133 | Alzheimer's disease | 0.01097 | 1.178 | MTHFR | Homocysteine levels |
| rs1801133 | Dystrophy of female genital tract | 0.004088 | 0.3913 | MTHFR | Homocysteine levels |
| rs1801133 | Gastrointestinal hemorrhage | 0.01048 | 1.105 | MTHFR | Homocysteine levels |
| rs1801133 | Delirium dementia and amnestic disorders | 0.0008675 | 1.171 | MTHFR | Homocysteine levels |
| rs1801133 | Senile dementia | 0.004151 | 1.256 | MTHFR | Homocysteine levels |
| rs1801133 | Dementias | 0.0006514 | 1.206 | MTHFR | Homocysteine levels |
| rs1801133 | Diffuse diseases of connective tissue | 0.004595 | 1.287 | MTHFR | Homocysteine levels |
| rs1801133 | Hyperventilation | 0.01038 | 0.5446 | MTHFR | Homocysteine levels |
| rs1801133 | Insect bite | 0.00328 | 1.268 | MTHFR | Homocysteine levels |
| rs1801133 | Acute bronchitis and bronchiolitis | 0.01085 | 1.122 | MTHFR | Homocysteine levels |
| rs1801133 | Angina pectoris | 0.007287 | 1.136 | MTHFR | Homocysteine levels |
| rs1801239 | Ptosis of eyelid | 0.003772 | 0.7043 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Diseases of blood and blood-forming organs | 0.003802 | 0.6499 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Sialoadenitis | 0.0002518 | 1.962 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Sacroiliitis NEC | 0.00945 | 2.039 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Phosphorus metabolism disorder | 0.009053 | 1.609 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Acute posthemorrhagic anemia | 0.007967 | 1.266 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Mental retardation | 0.0005282 | 2.948 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Benign neoplasm of uterus | 0.005338 | 1.832 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Cardiomyopathy | 0.008455 | 0.7436 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Other disorders of eyelids | 0.005396 | 0.7886 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Diseases of the salivary glands | 0.0001792 | 1.635 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Schizoid personality disorder | 0.006412 | 1.972 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Acute bronchitis and bronchiolitis | 0.001147 | 0.7875 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Second degree AV block | 0.00783 | 0.3877 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Hallux rigidus | 0.004116 | 1.635 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1816002 | Abnormal thyroid function | 0.005029 | 0.7791 | ADAMTS14 | Weight |
| rs1816002 | Megaloblastic anemia | 0.004532 | 0.7271 | ADAMTS14 | Weight |
| rs1816002 | Cancer of the digestive organs and peritoneum | 0.0007172 | 0.6056 | ADAMTS14 | Weight |
| rs1816002 | Abdominal pain | 0.007697 | 1.08 | ADAMTS14 | Weight |
| rs1816002 | Gestational diabetes | 0.01123 | 0.4785 | ADAMTS14 | Weight |
| rs1816002 | Nervous system congenital anomalies | 0.002044 | 0.6643 | ADAMTS14 | Weight |
| rs1816002 | Chronic pain syndrome | 0.008522 | 0.6014 | ADAMTS14 | Weight |
| rs1816002 | Chronic airway obstruction | 0.008105 | 1.109 | ADAMTS14 | Weight |
| rs1816002 | Anomalies of pupillary function | 0.00569 | 1.917 | ADAMTS14 | Weight |
| rs1816002 | Neoplasm of unspecified nature of digestive system | 0.002856 | 0.6714 | ADAMTS14 | Weight |
| rs1816002 | Senile dementia | 0.003049 | 0.8046 | ADAMTS14 | Weight |
| rs1816002 | Other specified erythematous conditions | 0.005171 | 0.7558 | ADAMTS14 | Weight |
| rs1816002 | Secondary malignancy of lymph nodes | 0.008074 | 0.7962 | ADAMTS14 | Weight |
| rs1816002 | Alzheimer's disease | 0.005636 | 0.8454 | ADAMTS14 | Weight |
| rs183266 | Iron deficiency anemia secondary to blood loss | 0.008198 | 0.573 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Acute appendicitis | 0.009954 | 1.637 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Abnormal pulmonary function | 0.00769 | 2.469 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Disorders of function of stomach | 0.004817 | 1.248 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Secondary hyperparathyroidism (of renal origin) | 0.006541 | 0.5347 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Osteopenia | 0.008626 | 1.193 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Type 1 diabetes nephropathy | 0.0006462 | 2.13 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Type 1 diabetic retinopathy | 0.003159 | 1.664 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Renal osteodystrophy | 0.009292 | 0.4088 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Anemia in chronic kidney disease | 0.0004849 | 0.4857 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Hyperosmolality and/or hypernatremia | 0.009651 | 1.622 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Allergy to serum or vaccine | 0.004428 | 2.113 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Noninfectious dermatoses of eyelid | 0.007222 | 0.2056 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Disorders resulting from impaired renal function | 0.002108 | 0.5589 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Raynaud's syndrome | 0.002172 | 1.51 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Other disorders of bone and cartilage | 0.005169 | 1.332 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Gastroparesis | 8.746e-06 | 2.691 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Type 1 diabetic neuropathy | 0.00153 | 1.749 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs1837253 | Hypoventilation | 0.009498 | 0.4905 | TSLP | Asthma |
| rs1837253 | Colon cancer | 0.000848 | 1.326 | TSLP | Asthma |
| rs1837253 | Colorectal cancer | 0.0004683 | 1.32 | TSLP | Asthma |
| rs1837253 | Symptoms and disorders of the joints | 0.0005815 | 1.169 | TSLP | Asthma |
| rs1837253 | Adjustment reaction | 0.0009504 | 1.215 | TSLP | Asthma |
| rs1837253 | Symptoms affecting skin | 0.009018 | 1.102 | TSLP | Asthma |
| rs1837253 | Cancer of the lower GI tract | 0.003754 | 1.422 | TSLP | Asthma |
| rs1837253 | Hypertrophy of breast (Gynecomastia) | 0.006161 | 1.38 | TSLP | Asthma |
| rs1837253 | Stiffness of joint | 0.001602 | 1.26 | TSLP | Asthma |
| rs1837253 | Infestation | 0.00371 | 0.4538 | TSLP | Asthma |
| rs1837253 | Torsion dystonia | 0.008454 | 1.601 | TSLP | Asthma |
| rs1837253 | Rash and other nonspecific skin eruption | 0.001032 | 1.216 | TSLP | Asthma |
| rs1853665 | Peripheral autonomic neuropathy | 0.01016 | 0.614 | ULBP1 | Radiation response |
| rs1853665 | Respiratory complications | 0.007599 | 1.733 | ULBP1 | Radiation response |
| rs1853665 | Osteoarthrosis of multiple sites | 0.01105 | 0.7757 | ULBP1 | Radiation response |
| rs1853665 | Nevus, non-neoplastic | 0.001082 | 1.955 | ULBP1 | Radiation response |
| rs1853665 | Bipolar | 0.009544 | 1.452 | ULBP1 | Radiation response |
| rs1853665 | Joint effusions | 0.008421 | 1.27 | ULBP1 | Radiation response |
| rs1853665 | Anal and rectal conditions | 0.01042 | 1.177 | ULBP1 | Radiation response |
| rs1853665 | Loss of teeth or edentulism | 0.01132 | 0.6303 | ULBP1 | Radiation response |
| rs1853665 | Disorders of the autonomic nervous system | 0.001279 | 0.5977 | ULBP1 | Radiation response |
| rs1853665 | Chronic venous hypertension | 0.000428 | 2.693 | ULBP1 | Radiation response |
| rs1853665 | Primary pulmonary hypertension | 0.0006301 | 1.89 | ULBP1 | Radiation response |
| rs1853665 | Hyperlipidemia | 0.009912 | 1.119 | ULBP1 | Radiation response |
| rs1853665 | Other disorders of testis | 0.001459 | 1.595 | ULBP1 | Radiation response |
| rs1853665 | Open wound of nose and sinus | 0.0005241 | 2.551 | ULBP1 | Radiation response |
| rs1853665 | Other disorders of gallbladder | 0.006698 | 0.4274 | ULBP1 | Radiation response |
| rs1869901 | Alopecia | 0.003003 | 1.345 | PLCB2 | Schizophrenia |
| rs1869901 | Fracture of pelvis | 0.006776 | 1.332 | PLCB2 | Schizophrenia |
| rs1869901 | Chronic bronchitis | 0.006137 | 1.189 | PLCB2 | Schizophrenia |
| rs1869901 | Other disorders of peritoneum | 0.006632 | 1.438 | PLCB2 | Schizophrenia |
| rs1869901 | Myeloid leukemia | 0.002404 | 1.961 | PLCB2 | Schizophrenia |
| rs1869901 | Gingivitis | 0.007284 | 1.763 | PLCB2 | Schizophrenia |
| rs1869901 | Fracture of ribs | 0.009435 | 1.228 | PLCB2 | Schizophrenia |
| rs1869901 | Early or threatened labor; hemorrhage in early pregnancy | 0.002324 | 0.5371 | PLCB2 | Schizophrenia |
| rs1869901 | Palpitations | 0.009847 | 1.128 | PLCB2 | Schizophrenia |
| rs1869901 | Peritoneal adhesions (postoperative) (postinfection) | 0.01096 | 1.504 | PLCB2 | Schizophrenia |
| rs1869901 | Diseases of the larynx and vocal cords | 0.00784 | 1.173 | PLCB2 | Schizophrenia |
| rs1869901 | Skin neoplasm of uncertain behavior | 0.008106 | 1.194 | PLCB2 | Schizophrenia |
| rs1869901 | Multiple sclerosis | 0.006375 | 1.54 | PLCB2 | Schizophrenia |
| rs1869901 | Localized superficial swelling, mass, or lump | 0.0092 | 1.251 | PLCB2 | Schizophrenia |
| rs1869901 | Vascular disorders of penis | 0.005359 | 0.3842 | PLCB2 | Schizophrenia |
| rs1869901 | Attention deficit hyperactivity disorder | 0.00536 | 0.5606 | PLCB2 | Schizophrenia |
| rs1888414 | Bronchiectasis | 0.011 | 0.723 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Other disorders of lipoid metabolism and hyperalimentation | 0.006277 | 0.7744 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Inflammatory diseases of female pelvic organs | 0.01005 | 1.164 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Sleep apnea | 0.005856 | 1.119 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Seborheic dermatitis | 0.01144 | 1.171 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Other specified erythematous conditions | 0.002363 | 1.353 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Personality disorders | 0.006833 | 1.251 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Pyogenic arthritis | 0.0113 | 1.596 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Inflammatory disease of cervix, vagina, and vulva | 0.007843 | 1.181 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Diseases of lips | 0.006137 | 1.479 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Redundant prepuce and phimosis/BXO | 0.01003 | 1.665 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Deviated nasal septum | 0.01128 | 0.853 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Adjustment reaction | 0.002416 | 1.175 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Abnormal findings on radiological exam of musculoskeletal system | 0.007651 | 1.568 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Breast disorder NOS | 0.005141 | 2.286 | FDPSP6 | Hippocampal atrophy |
| rs1923775 | Diverticulum of esophagus, acquired | 0.0006513 | 2.28 | POLN | Alzheimer's disease |
| rs1923775 | Pilonidal cyst | 0.005943 | 2.15 | POLN | Alzheimer's disease |
| rs1923775 | Decubitus ulcer | 0.005408 | 1.247 | POLN | Alzheimer's disease |
| rs1923775 | Visual field defects | 0.01006 | 0.767 | POLN | Alzheimer's disease |
| rs1923775 | Vaginitis and vulvovaginitis | 0.002859 | 1.243 | POLN | Alzheimer's disease |
| rs1923775 | Diseases of the jaws | 0.009082 | 1.202 | POLN | Alzheimer's disease |
| rs1923775 | Colostomy and enterostomy complication | 0.004233 | 1.846 | POLN | Alzheimer's disease |
| rs1923775 | Fractur of unspecified part of femur | 0.01078 | 1.401 | POLN | Alzheimer's disease |
| rs1923775 | Benign neoplasm of uterus | 0.007586 | 1.555 | POLN | Alzheimer's disease |
| rs1926203 | Hypertensive chronic kidney disease | 0.005127 | 0.8205 | ACTA2 | Lung cancer |
| rs1926203 | Renal dialysis | 0.006395 | 0.6727 | ACTA2 | Lung cancer |
| rs1926203 | End stage renal disease | 0.01055 | 0.6963 | ACTA2 | Lung cancer |
| rs1926203 | Intracerebral hemorrhage | 0.003979 | 0.5529 | ACTA2 | Lung cancer |
| rs1926203 | Abnormal findings on radiological exam of musculoskeletal system | 7.197e-05 | 1.949 | ACTA2 | Lung cancer |
| rs1926203 | Benign neoplasm of bone and articular cartilage | 0.003572 | 0.4925 | ACTA2 | Lung cancer |
| rs1926203 | Graves' disease | 0.007328 | 0.6453 | ACTA2 | Lung cancer |
| rs1926203 | Premature beats | 0.01114 | 0.8472 | ACTA2 | Lung cancer |
| rs1927745 | Urethral stricture (not specified as infectious) | 0.009045 | 1.431 | FAM155A | Depression |
| rs1927745 | Cervical radiculitis | 0.002414 | 1.225 | FAM155A | Depression |
| rs1927745 | Plasma protein metabolism disorder | 0.00893 | 1.314 | FAM155A | Depression |
| rs1927745 | Other unspecified back disorders | 0.005392 | 1.604 | FAM155A | Depression |
| rs1927745 | Ileostomy status | 0.009931 | 1.597 | FAM155A | Depression |
| rs1927745 | Open wound of toe(s) | 0.0007496 | 2.005 | FAM155A | Depression |
| rs1927745 | Abdominal pain | 0.000678 | 1.12 | FAM155A | Depression |
| rs1927745 | Other signs and symptoms in breast | 0.004624 | 0.6553 | FAM155A | Depression |
| rs1927745 | Bronchitis | 0.007499 | 1.159 | FAM155A | Depression |
| rs1927745 | Subdural hemorrhage | 0.01059 | 0.5537 | FAM155A | Depression |
| rs1927745 | Keratoconjunctivitis sicca | 0.005866 | 1.666 | FAM155A | Depression |
| rs1980493 | Thyrotoxicosis | 0.003406 | 1.331 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Celiac disease | 3.115e-05 | 2.607 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Aneurysm of iliac artery | 0.000348 | 2.192 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Postmenopausal atrophic vaginitis | 0.001043 | 0.6866 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Celiac or tropical sprue | 9.001e-06 | 2.703 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Disorders of the pituitary gland and its hypothalamic control | 0.004338 | 1.481 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Other immunological findings | 0.001189 | 1.494 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Disorders of external ear | 0.009116 | 1.741 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Peritoneal or intestinal adhesions | 0.006031 | 1.71 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetic retinopathy | 0.01062 | 1.485 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Varicose veins of lower extremity | 0.005606 | 1.219 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetic neuropathy | 0.0005468 | 1.705 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Vaginitis and vulvovaginitis | 0.005346 | 0.7519 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Gastrointestinal complications | 0.006086 | 1.352 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Other specified peripheral vascular diseases | 0.000801 | 2.448 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Osteoarthrosis; localized, secondary | 0.00932 | 1.691 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Calculus of kidney | 0.007585 | 0.795 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Varicose veins | 0.003624 | 1.221 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Other infectious diseases | 0.01001 | 0.3384 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Polycythemia vera, secondary | 0.005948 | 1.735 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Systemic lupus erythematosus | 0.0005181 | 1.822 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Adverse effects of insulins and antidiabetic agents | 0.001068 | 2.162 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Allergic rhinitis | 0.00585 | 0.8557 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Myeloid leukemia | 0.001783 | 2.124 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Ectropion or entropion | 0.006496 | 1.353 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Urinary calculus | 0.003082 | 0.8005 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Immune disorders | 0.00156 | 1.39 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Retinoschisis and retinal cysts | 5.049e-05 | 3.006 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Lupus erythematosus | 2.914e-05 | 2.79 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Rosacea | 0.01036 | 0.7886 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Ingrowing nail | 0.002992 | 1.234 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetic ketoacidosis | 0.007371 | 1.504 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Graves' disease | 0.004545 | 1.612 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Discoid lupus erythematosus | 3.056e-05 | 1.937 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetes nephropathy | 0.0002289 | 2.088 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Varicose veins of lower extremity, symptomtic | 0.008209 | 1.28 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1983891 | Loss of teeth or edentulism | 0.008825 | 1.371 | FOXP4 | Prostate cancer |
| rs1983891 | Trigeminal nerve disorders | 0.00324 | 0.5938 | FOXP4 | Prostate cancer |
| rs1983891 | Acute pharyngitis | 0.003818 | 1.179 | FOXP4 | Prostate cancer |
| rs1983891 | Inflammation of the eye | 0.0005615 | 1.171 | FOXP4 | Prostate cancer |
| rs1983891 | Delirium dementia and amnestic disorders | 0.007541 | 1.143 | FOXP4 | Prostate cancer |
| rs1983891 | Cardiac pacemaker/device in situ | 0.002624 | 0.7874 | FOXP4 | Prostate cancer |
| rs1983891 | Incisional hernia | 0.01095 | 1.298 | FOXP4 | Prostate cancer |
| rs1983891 | Corneal edema | 0.002094 | 1.765 | FOXP4 | Prostate cancer |
| rs1983891 | Cardiac conduction disorders | 0.0008882 | 0.8627 | FOXP4 | Prostate cancer |
| rs1983891 | Conjunctivitis, noninfectious | 0.001959 | 1.322 | FOXP4 | Prostate cancer |
| rs1983891 | Abnormal electrocardiogram | 0.007577 | 0.8595 | FOXP4 | Prostate cancer |
| rs1983891 | Uveitis | 0.008003 | 1.314 | FOXP4 | Prostate cancer |
| rs1983891 | Abnormal coagulation profile | 0.00991 | 0.6982 | FOXP4 | Prostate cancer |
| rs1983891 | Paroxysmal ventricular tachycardia | 0.005446 | 0.7426 | FOXP4 | Prostate cancer |
| rs1983891 | Sexual and gender identity disorders | 0.00468 | 1.419 | FOXP4 | Prostate cancer |
| rs1983891 | Hypotony of eye | 0.002391 | 2.314 | FOXP4 | Prostate cancer |
| rs1983891 | Blood in stool | 0.007131 | 0.8473 | FOXP4 | Prostate cancer |
| rs1992950 | Other conditions of brain, NOS | 5.504e-05 | 1.906 | SATB2 | Ulcerative colitis |
| rs1992950 | Inflammatory and toxic neuropathy | 0.009094 | 0.6935 | SATB2 | Ulcerative colitis |
| rs1992950 | Chronic pharyngitis and nasopharyngitis | 0.005651 | 0.8304 | SATB2 | Ulcerative colitis |
| rs1992950 | Brain cancer | 0.002345 | 1.772 | SATB2 | Ulcerative colitis |
| rs1992950 | Acute laryngitis and tracheitis | 0.003792 | 0.5966 | SATB2 | Ulcerative colitis |
| rs1992950 | Periapical abscess | 0.007705 | 0.795 | SATB2 | Ulcerative colitis |
| rs1992950 | Neutropenia | 0.009636 | 0.7871 | SATB2 | Ulcerative colitis |
| rs1992950 | Adverse effects of hormones and synthetic substitutes | 0.00215 | 2.441 | SATB2 | Ulcerative colitis |
| rs1992950 | Acute sinusitis | 0.01077 | 0.8685 | SATB2 | Ulcerative colitis |
| rs1992950 | Diseases of pulp and periapical tissues | 0.001348 | 0.7661 | SATB2 | Ulcerative colitis |
| rs1992950 | Bipolar | 0.004069 | 1.449 | SATB2 | Ulcerative colitis |
| rs1992950 | Lack of coordination | 3.314e-05 | 1.442 | SATB2 | Ulcerative colitis |
| rs1992950 | Cancer of brain and nervous system | 0.002922 | 1.703 | SATB2 | Ulcerative colitis |
| rs1992950 | Malignant neoplasm of brain and nervous system | 0.007287 | 1.443 | SATB2 | Ulcerative colitis |
| rs2000999 | Chronic lymphocytic thyroiditis | 0.003268 | 1.552 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Abnormal thyroid function | 0.006292 | 1.331 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Abnormal sputum | 0.004466 | 1.402 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Mammographic microcalcification | 7.128e-05 | 1.982 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Blindness and low vision | 0.01067 | 0.7053 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Hemoptysis | 0.001484 | 1.482 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Bladder cancer and neoplasms | 0.008147 | 1.306 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Thyroiditis | 0.0005357 | 1.539 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Other disorders of metabolic, endocrine, immunity disorders | 0.0003333 | 2.378 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Acute upper respiratory infections | 0.005434 | 1.127 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Idiopathic fibrosing alveolitis | 0.01088 | 1.844 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Chronic hepatitis | 0.009536 | 1.798 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2002030 | Torsion dystonia | 0.005581 | 2.007 | C8orf12 | Cognitive performance |
| rs2002030 | Acquired deformities of finger | 0.01135 | 1.706 | C8orf12 | Cognitive performance |
| rs2002030 | Wheezing | 0.004743 | 1.593 | C8orf12 | Cognitive performance |
| rs2002030 | Abnormal findings examination of lungs | 0.001527 | 1.376 | C8orf12 | Cognitive performance |
| rs2002030 | Pulmonary embolism and infarction | 0.008585 | 1.432 | C8orf12 | Cognitive performance |
| rs2002030 | Acquired deformities of limbs | 0.006488 | 1.404 | C8orf12 | Cognitive performance |
| rs2002030 | Essential tremor | 0.006926 | 1.54 | C8orf12 | Cognitive performance |
| rs2002030 | Carcinoma in situ of skin | 0.002153 | 1.519 | C8orf12 | Cognitive performance |
| rs2073643 | Hyperbilirubinemia | 0.008394 | 0.5463 | SLC22A5 | Asthma |
| rs2073643 | Intracranial hemorrhage | 0.005852 | 1.333 | SLC22A5 | Asthma |
| rs2073643 | Other disorders of the kidney and ureters | 0.004578 | 1.122 | SLC22A5 | Asthma |
| rs2073643 | Dermatosis NOS | 0.01045 | 0.9081 | SLC22A5 | Asthma |
| rs2073643 | Bronchiectasis | 0.008063 | 1.378 | SLC22A5 | Asthma |
| rs2073643 | Lower gastrointestinal congenital anomalies | 0.008592 | 1.815 | SLC22A5 | Asthma |
| rs2073643 | Chronic obstructive asthma with exacerbation | 0.008655 | 0.5966 | SLC22A5 | Asthma |
| rs2073643 | Excessive or frequent menstruation | 0.0108 | 1.279 | SLC22A5 | Asthma |
| rs2073643 | Chronic venous insufficiency | 0.002492 | 0.8225 | SLC22A5 | Asthma |
| rs2073643 | Skin cancer | 0.0006228 | 0.886 | SLC22A5 | Asthma |
| rs2073643 | Viral warts & HPV | 0.007331 | 0.8666 | SLC22A5 | Asthma |
| rs2073643 | Non-melanoma skin cancer | 0.001473 | 0.8882 | SLC22A5 | Asthma |
| rs2073643 | Late effects of cerebrovascular disease | 0.001332 | 1.211 | SLC22A5 | Asthma |
| rs2073643 | Parasomnia | 0.005647 | 0.5849 | SLC22A5 | Asthma |
| rs2074404 | Testicular dysfunction | 0.00862 | 1.408 | WNT3 | Celiac disease |
| rs2074404 | Abnormal coagulation profile | 0.007325 | 1.396 | WNT3 | Celiac disease |
| rs2074404 | Anisometropia | 0.0005536 | 1.449 | WNT3 | Celiac disease |
| rs2074404 | Psychogenic disorder | 0.01106 | 1.432 | WNT3 | Celiac disease |
| rs2074404 | Psoriasis vulgaris | 0.005256 | 1.293 | WNT3 | Celiac disease |
| rs2074404 | Polycythemia vera, secondary | 0.003677 | 1.704 | WNT3 | Celiac disease |
| rs2074404 | Spontaneous ecchymoses | 0.008441 | 1.634 | WNT3 | Celiac disease |
| rs2074404 | Ulceration of intestine | 0.003826 | 1.729 | WNT3 | Celiac disease |
| rs2074404 | Infection of the eye | 0.001333 | 1.206 | WNT3 | Celiac disease |
| rs2074404 | Visual disturbances | 0.00195 | 1.152 | WNT3 | Celiac disease |
| rs2074404 | Unequal leg length (acquired) | 0.008682 | 1.488 | WNT3 | Celiac disease |
| rs2074404 | Chronic periodontitis | 0.004423 | 1.303 | WNT3 | Celiac disease |
| rs2074404 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.0003772 | 1.462 | WNT3 | Celiac disease |
| rs2074404 | Conjunctivitis, infectious | 0.007218 | 1.191 | WNT3 | Celiac disease |
| rs2075650 | Schizoid personality disorder | 0.006963 | 0.3412 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Known or suspected fetal abnormality | 0.004355 | 1.926 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Hyperlipidemia | 0.01129 | 1.124 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Age-related macular degeneration | 6.704e-05 | 0.6658 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Dry eyes | 0.0006323 | 0.7909 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Mental disorders due to brain damage | 6.257e-06 | 1.566 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Mild cognitive impairment | 0.0005436 | 2.194 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Optic atrophy | 0.0002892 | 0.3729 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Conduct disorders | 0.004435 | 1.741 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Allergic rhinitis | 0.0001426 | 0.7998 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Neurological disorders due to brain damage | 4.329e-09 | 1.452 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Memory loss | 4.677e-09 | 1.796 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Diseases of respiratory system | 6.682e-05 | 0.7078 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Dementias | 2.409e-26 | 2.114 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Sebaceous cyst | 0.006628 | 0.8351 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Retinal drusen | 0.009525 | 0.7533 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Persistent mental disorders due to other conditions | 9.183e-16 | 1.775 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Senile dementia | 1.887e-12 | 2.037 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Acute osteomyelitis | 0.004168 | 1.826 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Schizophrenia and other psychotic disorders | 4.897e-05 | 1.41 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Chronic sinusitis | 0.00057 | 0.8134 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Other peripheral nerve disorders | 0.005864 | 0.8692 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Dyspepsia and disorders of function of stomach | 0.008148 | 0.8081 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Wheezing and painful respiration | 0.00815 | 0.8433 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Type 2 diabetic ketoacidosis | 0.009998 | 0.8385 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Deviated nasal septum | 0.004151 | 0.775 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Diabetes mellitus | 0.00757 | 0.8897 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Delirium dementia and amnestic disorders | 8.027e-24 | 1.841 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Open-angle glaucoma | 0.008523 | 0.8091 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Aseptic necrosis of bone | 0.01092 | 0.4498 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Other specified nonpsychotic and/or transient mental disorders | 7.334e-06 | 1.546 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Asthma | 0.006971 | 0.8465 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Glaucoma | 0.007839 | 0.8602 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Neoplasm of unspecified nature of digestive system | 0.008922 | 1.517 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Alzheimer's disease | 5.237e-28 | 2.41 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Abnormal findings on mammogram or breast exam | 0.001891 | 0.8279 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Vascular dementia | 0.001199 | 1.682 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Symptoms involving respiratory system | 0.0008009 | 0.6943 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Diseases of sebaceous glands | 0.00117 | 0.8384 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Reticulosarcoma | 0.003455 | 1.858 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Subjective visual disturbances | 0.00365 | 0.7349 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Develomental delays and disorders | 0.001176 | 1.448 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Chronic pharyngitis and nasopharyngitis | 0.002009 | 0.7767 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Atopic or contact dermatitis | 0.00197 | 0.8538 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Macular degeneration, dry | 0.0007954 | 0.6921 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Macular degeneration, wet | 0.001038 | 0.5817 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Visual disturbances | 0.001152 | 0.8281 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Macular degeneration | 0.001732 | 0.8178 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Impaction of intestine | 0.003732 | 2.389 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Acute posthemorrhagic anemia | 0.003282 | 1.255 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Epistaxis or throat hemorrhage | 0.003292 | 0.7371 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Disorders of lacrimal system | 0.000856 | 0.8025 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Delirium due to conditions classified elsewhere | 0.003037 | 1.58 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2084385 | Voice disturbance | 0.005476 | 0.7258 | PAK2 | Total ventricular volume |
| rs2084385 | Develomental delays and disorders | 0.0001879 | 1.565 | PAK2 | Total ventricular volume |
| rs2084385 | Other arthropathies | 0.008915 | 1.17 | PAK2 | Total ventricular volume |
| rs2084385 | Osteoarthritis; localized | 0.007644 | 1.184 | PAK2 | Total ventricular volume |
| rs2084385 | Diseases of the larynx and vocal cords | 0.00439 | 0.7541 | PAK2 | Total ventricular volume |
| rs2084385 | Internal derangement of knee | 0.009501 | 1.209 | PAK2 | Total ventricular volume |
| rs2084385 | Astigmatism | 0.006872 | 0.8307 | PAK2 | Total ventricular volume |
| rs2084385 | Mental retardation | 0.007954 | 2.358 | PAK2 | Total ventricular volume |
| rs2084385 | Myoclonus | 0.001314 | 2.057 | PAK2 | Total ventricular volume |
| rs2084385 | Other cerebral degenerations | 0.003577 | 1.622 | PAK2 | Total ventricular volume |
| rs2084385 | Bullous dermatoses | 0.002165 | 2.26 | PAK2 | Total ventricular volume |
| rs2084385 | Complex regional/central pain syndrome | 0.00215 | 2.112 | PAK2 | Total ventricular volume |
| rs2114039 | Other disorders of urethra and urinary tract | 0.001323 | 1.274 | PDGFRA | Corneal curvature |
| rs2114039 | Strabismus (not specified as paralytic) | 0.001319 | 0.7387 | PDGFRA | Corneal curvature |
| rs2114039 | Inguinal hernia | 0.008781 | 1.162 | PDGFRA | Corneal curvature |
| rs2114039 | Nonspecific findings on examination of blood | 0.003351 | 1.362 | PDGFRA | Corneal curvature |
| rs2114039 | Primary angle-closure glaucoma | 0.009113 | 0.7976 | PDGFRA | Corneal curvature |
| rs2114039 | Graves' disease | 0.002158 | 0.5699 | PDGFRA | Corneal curvature |
| rs2114039 | Urethral stricture (not specified as infectious) | 0.0001167 | 1.666 | PDGFRA | Corneal curvature |
| rs2114039 | Acquired absence of breast | 0.007737 | 0.7249 | PDGFRA | Corneal curvature |
| rs2114039 | progressive myopia | 0.006057 | 0.4575 | PDGFRA | Corneal curvature |
| rs2114039 | Cardiac pacemaker/device in situ | 0.00432 | 1.239 | PDGFRA | Corneal curvature |
| rs2114039 | Sinoatrial node dysfunction | 0.002933 | 1.353 | PDGFRA | Corneal curvature |
| rs2114039 | Disorders of binocular eye movements | 0.00496 | 0.7996 | PDGFRA | Corneal curvature |
| rs2114039 | Disorders of the globe | 0.001919 | 0.5766 | PDGFRA | Corneal curvature |
| rs2114039 | Symptoms associated with female genital organs | 0.007995 | 0.8216 | PDGFRA | Corneal curvature |
| rs2114039 | Primary pulmonary hypertension | 0.004244 | 1.634 | PDGFRA | Corneal curvature |
| rs2114039 | Inflammatory spondylopathies | 0.009024 | 0.6041 | PDGFRA | Corneal curvature |
| rs2114039 | Cardiac pacemaker in situ | 0.001216 | 1.295 | PDGFRA | Corneal curvature |
| rs2121433 | Peripheral autonomic neuropathy | 0.002838 | 0.647 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Immunity deficiency | 0.001848 | 1.796 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Allergy/adverse effect of penicillin | 0.00397 | 1.265 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Spasm of muscle | 0.001082 | 0.7525 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Dermatomycoses | 0.008739 | 1.656 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Open wound of hand except finger(s) | 0.004928 | 1.31 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Abnormal results of function studies | 0.008515 | 1.601 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Fractur of unspecified part of femur | 0.00806 | 0.6612 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Poisoning by antibiotics | 0.006314 | 1.22 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Immune disorders | 0.001177 | 1.339 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Postmenopausal atrophic vaginitis | 0.004972 | 0.7743 | EPC2 | Alzheimer's disease biomarkers |
| rs2121433 | Fracture of pelvis | 0.003671 | 0.6826 | EPC2 | Alzheimer's disease biomarkers |
| rs2150702 | Astigmatism | 0.008828 | 0.8881 | MLANA | Multiple sclerosis |
| rs2150702 | Arterial embolism and thrombosis of lower extremity artery | 0.000376 | 1.483 | MLANA | Multiple sclerosis |
| rs2150702 | Behcet's syndrome | 0.001943 | 0.6094 | MLANA | Multiple sclerosis |
| rs2150702 | Heartburn | 0.006781 | 1.378 | MLANA | Multiple sclerosis |
| rs2150702 | Dystrophy of female genital tract | 0.001351 | 2.374 | MLANA | Multiple sclerosis |
| rs2150702 | Dermatomyositis and Polymyositis | 0.005867 | 0.4578 | MLANA | Multiple sclerosis |
| rs2150702 | Temporomandibular joint disorder NOS | 0.005919 | 0.6151 | MLANA | Multiple sclerosis |
| rs2150702 | Congenital anomalies of face and neck | 0.0004142 | 0.3106 | MLANA | Multiple sclerosis |
| rs2150702 | Peripheral angiopathy in diseases classified elsewhere | 0.009129 | 1.594 | MLANA | Multiple sclerosis |
| rs2150702 | Peripheral vascular disease | 0.008627 | 1.111 | MLANA | Multiple sclerosis |
| rs2150702 | Known or suspected fetal abnormality | 0.004825 | 1.693 | MLANA | Multiple sclerosis |
| rs2150702 | Apnea | 0.001235 | 2.344 | MLANA | Multiple sclerosis |
| rs2150702 | Hydrocele | 0.00538 | 0.661 | MLANA | Multiple sclerosis |
| rs2150702 | Myopia | 0.00164 | 0.8726 | MLANA | Multiple sclerosis |
| rs2150702 | Arterial embolism and thrombosis | 0.003417 | 1.259 | MLANA | Multiple sclerosis |
| rs2150702 | Iron deficiency anemia secondary to blood loss | 0.008323 | 1.319 | MLANA | Multiple sclerosis |
| rs2150702 | Allergy/adverse effect of penicillin | 0.007109 | 1.227 | MLANA | Multiple sclerosis |
| rs2166706 | Hyperglyceridemia | 1.159e-05 | 1.425 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Other abnormal glucose | 0.001566 | 1.167 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.001792 | 1.371 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Miscarriage; stillbirth | 0.01055 | 1.755 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Polycythemia vera, secondary | 0.01062 | 0.6132 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Acute pericarditis | 0.006304 | 0.4127 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Keratitis | 0.003229 | 0.7371 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Periodontitis (acute or chronic) | 0.009849 | 1.208 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Type 2 diabetes | 0.0004154 | 1.118 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Lipoid metabolism disorder NOS | 0.001912 | 1.318 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Impaired fasting glucose | 0.00684 | 1.181 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Pain, swelling or discharge of eye | 0.008723 | 0.733 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Intracranial hemorrhage (injury) | 0.005052 | 1.487 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Abnormal glucose | 0.0002139 | 1.159 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Poisoning by primarily systemic agents | 0.002661 | 1.345 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Prolapse of vaginal vault after hysterectomy | 0.00922 | 0.669 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Diabetes mellitus | 0.0002749 | 1.12 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Exostosis of jaw | 0.008836 | 0.4546 | MTNR1B | Fasting plasma glucose |
| rs2237886 | Secondary thrombocytopenia | 0.004742 | 1.896 | KCNQ1 | Height |
| rs2237886 | Alopecia | 0.005466 | 1.502 | KCNQ1 | Height |
| rs2237886 | Esophageal atresia/tracheoesophageal fistula | 0.007891 | 1.978 | KCNQ1 | Height |
| rs2237886 | Abnormal sputum | 0.003436 | 1.531 | KCNQ1 | Height |
| rs2237886 | Diseases of hair and hair follicles | 0.0004976 | 1.45 | KCNQ1 | Height |
| rs2237886 | Age-related macular degeneration | 0.002676 | 0.7032 | KCNQ1 | Height |
| rs2237886 | Symptoms involving respiratory system | 0.0009024 | 1.397 | KCNQ1 | Height |
| rs2237886 | Bladder cancer | 0.001438 | 1.486 | KCNQ1 | Height |
| rs2237886 | Obstructive chronic bronchitis | 0.003656 | 1.358 | KCNQ1 | Height |
| rs2237886 | Bladder cancer and neoplasms | 0.001346 | 1.475 | KCNQ1 | Height |
| rs2237886 | Extrinsic allergic alveolitis | 0.008297 | 2.302 | KCNQ1 | Height |
| rs2237886 | Generalized convulsive epilepsy | 0.007519 | 1.827 | KCNQ1 | Height |
| rs2237886 | Hemoptysis | 0.003046 | 1.569 | KCNQ1 | Height |
| rs2237886 | Diseases of respiratory system | 0.0006816 | 1.326 | KCNQ1 | Height |
| rs2237886 | Chronic airway obstruction | 0.002879 | 1.2 | KCNQ1 | Height |
| rs2237886 | Hammer toe | 0.003745 | 0.7071 | KCNQ1 | Height |
| rs2237886 | Liver abscess and sequelae of chronic liver disease | 0.004518 | 1.801 | KCNQ1 | Height |
| rs2237886 | Vascular dementia | 0.009268 | 1.554 | KCNQ1 | Height |
| rs2237886 | Chronic bronchitis | 0.00451 | 1.313 | KCNQ1 | Height |
| rs2237886 | Keratitis, infectious | 0.006926 | 1.588 | KCNQ1 | Height |
| rs2242073 | Iron deficiency anemias | 0.007426 | 1.189 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Iron deficiency anemias NOS | 0.001957 | 1.208 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Peritoneal or intestinal adhesions | 0.003662 | 1.817 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Osteoarthrosis of multiple sites | 0.004917 | 1.326 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Abnormal findings on mammogram or breast exam | 0.001964 | 1.194 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Chronic tonsillitis and adenoiditis | 0.006749 | 1.822 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Fuchs' dystrophy | 0.002557 | 1.653 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Enthesopathy | 0.006927 | 1.159 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Herpes zoster with nervous system complications | 0.003715 | 1.695 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Herpes zoster | 0.007777 | 1.244 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Spermatocele | 0.002362 | 2.019 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Mental retardation | 0.009809 | 2.195 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Early complications of trauma or procedure | 0.004714 | 1.815 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Generalized hyperhidrosis | 0.008897 | 0.6417 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Other diseases of respiratory system | 0.006368 | 1.481 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Unspecified polyarthropathy or polyarthritis | 0.004502 | 1.664 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Cyst of kidney, acquired | 0.009204 | 0.6811 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Lump or mass in breast | 0.00483 | 1.227 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Disorders of optic nerve and visual pathways | 0.002537 | 1.385 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Displacement of intervertebral disc | 0.005854 | 0.8072 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Symptomatic artificial menopause | 0.001159 | 1.832 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Optic atrophy | 0.004211 | 1.602 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242944 | Open-angle glaucoma | 0.01082 | 0.8623 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Functional digestive disorders | 0.009834 | 0.8768 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Irritable Bowel Syndrome | 0.01119 | 0.8592 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Bronchitis | 0.008431 | 0.876 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Hypercholesterolemia | 0.006965 | 1.118 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.002907 | 0.5362 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Hallux rigidus | 0.00554 | 1.403 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Respiratory abnormalities | 0.006412 | 0.7418 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Adverse effects of insulins and antidiabetic agents | 0.007177 | 0.5055 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Chronic interstitial cystitis | 0.00736 | 2.03 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Nevus, non-neoplastic | 0.01049 | 1.61 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Lyme disease | 0.009891 | 1.502 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Pervasive developmental disorders | 0.001199 | 1.684 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Ectropion or entropion | 0.002393 | 0.7545 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Unspecified polyarthropathy or polyarthritis | 0.002943 | 0.603 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Open wound of ear | 0.004222 | 1.998 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Malignant neoplasm of renal pelvis | 0.008219 | 2.092 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Attention deficit hyperactivity disorder | 0.0006125 | 1.892 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Eating disorder | 0.00778 | 0.5768 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Mammographic microcalcification | 0.001082 | 0.5411 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Paroxysmal supraventricular tachycardia | 0.004154 | 0.759 | PSMG1 | Ankylosing spondylitis |
| rs2252521 | Symptomatic artificial menopause | 0.01068 | 0.6472 | CPVL | Cognitive performance |
| rs2252521 | Abnormal serum enzyme levels | 0.00116 | 1.193 | CPVL | Cognitive performance |
| rs2252521 | Cancer of oropharynx | 0.003335 | 2.188 | CPVL | Cognitive performance |
| rs2252521 | Genitourinary congenital anomalies | 0.007066 | 0.6808 | CPVL | Cognitive performance |
| rs2252521 | Iron deficiency anemia secondary to blood loss | 0.001623 | 0.6633 | CPVL | Cognitive performance |
| rs2252521 | Cystic kidney disease | 0.008898 | 0.5717 | CPVL | Cognitive performance |
| rs2252521 | Cholelithiasis with other cholecystitis | 0.00499 | 0.7266 | CPVL | Cognitive performance |
| rs2252521 | Disorders of conjunctiva | 0.01027 | 0.7853 | CPVL | Cognitive performance |
| rs2274089 | Iron metabolism disorder | 7.032e-14 | 6.178 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | CNS infection and poliomyelitis | 0.01003 | 1.937 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | Disorders of cervical region | 0.006401 | 1.59 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | Nontoxic multinodular goiter | 0.009979 | 0.6245 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | Eosinophilia | 0.003617 | 2.286 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2275215 | Breast disorder NOS | 0.003549 | 2.331 | LAMA2 | Body mass index |
| rs2275215 | Vitamin B12 deficiency anemia | 0.004403 | 1.58 | LAMA2 | Body mass index |
| rs2275215 | Open wound of finger(s) | 0.0004499 | 0.787 | LAMA2 | Body mass index |
| rs2275215 | Althete's foot | 0.007771 | 0.7679 | LAMA2 | Body mass index |
| rs2275215 | Corneal dystrophy | 0.008652 | 0.7399 | LAMA2 | Body mass index |
| rs2275215 | Sepsis | 0.003364 | 1.314 | LAMA2 | Body mass index |
| rs2275215 | Arterial embolism and thrombosis | 0.008738 | 1.246 | LAMA2 | Body mass index |
| rs2275215 | Other arthropathies | 0.00233 | 1.145 | LAMA2 | Body mass index |
| rs2275215 | Sepsis and SIRS | 0.003407 | 1.302 | LAMA2 | Body mass index |
| rs2277339 | Other disorders of adrenal glands | 0.00703 | 1.75 | PRIM1 | Menopause |
| rs2277339 | Diseases of blood and blood-forming organs | 0.007013 | 1.371 | PRIM1 | Menopause |
| rs2277339 | Cataract | 0.001808 | 0.8234 | PRIM1 | Menopause |
| rs2277339 | Hypercoagulable state | 0.003759 | 1.807 | PRIM1 | Menopause |
| rs2277339 | Macular degeneration, wet | 0.005713 | 1.563 | PRIM1 | Menopause |
| rs2277339 | Cancer of the digestive organs and peritoneum | 0.006006 | 1.701 | PRIM1 | Menopause |
| rs2277339 | Aseptic necrosis of bone | 0.01083 | 1.753 | PRIM1 | Menopause |
| rs2277339 | Atherosclerosis of aorta | 0.008321 | 1.423 | PRIM1 | Menopause |
| rs2277339 | Meningitis | 0.001118 | 2.279 | PRIM1 | Menopause |
| rs2277339 | Other disorders of gallbladder | 0.002765 | 1.944 | PRIM1 | Menopause |
| rs2277339 | Bipolar | 0.01112 | 1.564 | PRIM1 | Menopause |
| rs2277339 | Other disorders of arteries and arterioles | 0.009712 | 1.396 | PRIM1 | Menopause |
| rs2277912 | Lymphadenitis | 0.0009825 | 0.7502 | FASTKD2 | Height |
| rs2277912 | Stricture and stenosis of esophagus | 0.0108 | 0.7248 | FASTKD2 | Height |
| rs2277912 | Chronic sinusitis | 0.003573 | 0.8482 | FASTKD2 | Height |
| rs2277912 | Dysphagia | 0.004986 | 0.8485 | FASTKD2 | Height |
| rs2277912 | Noninflammatory disorders of vagina | 0.002644 | 0.5897 | FASTKD2 | Height |
| rs2277912 | Other specified intestinal malabsorption | 0.007329 | 0.4059 | FASTKD2 | Height |
| rs2277912 | Otalgia | 0.01123 | 0.7311 | FASTKD2 | Height |
| rs2277912 | Infertility, male | 0.000849 | 2.382 | FASTKD2 | Height |
| rs2277912 | Dyspepsia and disorders of function of stomach | 0.003157 | 0.8008 | FASTKD2 | Height |
| rs2277912 | Magnesium metabolism disorder | 0.005736 | 0.65 | FASTKD2 | Height |
| rs2277912 | Acquired hemolytic anemias | 0.01121 | 1.986 | FASTKD2 | Height |
| rs2277912 | Disorders of function of stomach | 0.006971 | 0.8252 | FASTKD2 | Height |
| rs2277912 | Other disorders of bone and cartilage | 0.007596 | 0.7624 | FASTKD2 | Height |
| rs2277912 | Symptomatic artificial menopause | 0.001338 | 0.511 | FASTKD2 | Height |
| rs2277912 | Disorders of menstruation | 0.005396 | 0.7794 | FASTKD2 | Height |
| rs2277912 | Urticaria | 0.008754 | 0.7406 | FASTKD2 | Height |
| rs2277912 | Chronic tonsillitis and adenoiditis | 0.006544 | 0.366 | FASTKD2 | Height |
| rs2279434 | Cystitis | 0.006636 | 0.6512 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Corneal degenerations | 0.0009277 | 0.3811 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Elevated prostate specific antigen | 0.0102 | 1.335 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Myalgia and myositis NOS | 0.01058 | 0.8134 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Disorders of cornea | 0.00217 | 0.668 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Genital prolapse | 0.007577 | 1.305 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Macular degeneration | 0.01145 | 0.8082 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Retinal drusen | 0.001729 | 0.6114 | MARCH8 | Mean corpuscular hemoglobin |
| rs2281680 | Glycosuria or Acetonuria | 0.01095 | 2.128 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Chronic cystitis | 0.01103 | 0.5474 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Other specified cardiac dysrhythmias | 0.00148 | 1.201 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Meniere's disease | 0.009681 | 0.4569 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Scar conditions and fibrosis of skin | 0.005628 | 1.37 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | AV block | 0.007767 | 1.237 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Urinary obstruction | 0.01067 | 1.433 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Balanoposthitis | 0.008287 | 1.814 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Dyshidrosis | 0.008753 | 1.667 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Abnormal weight gain | 0.004106 | 1.426 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Cystoid macular degeneration of retina | 0.007542 | 0.6951 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Infertility, male | 0.006833 | 2.076 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Infestation | 0.006378 | 0.3859 | AP1G2 | Sudden cardiac arrest |
| rs2290416 | Genitourinary congenital anomalies | 0.001212 | 1.721 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Open-angle glaucoma | 0.00382 | 0.7395 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Rheumatoid arthritis | 0.004091 | 0.6414 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Cervicocranial/Cervicobrachial syndrome | 0.00767 | 0.6379 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Choroidal degenerations | 0.006413 | 0.4447 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Pneumonitis due to inhalation of food or vomitus | 0.009037 | 1.523 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Mechanical complication due to other implant and internal device | 0.004618 | 1.592 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Cystic kidney disease | 0.006852 | 1.873 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Elevated white blood cell count | 0.007422 | 1.472 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Congenital anomalies of urinary system | 0.004218 | 1.766 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Abnormal loss of weight and underweight | 0.006029 | 1.468 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Disorders of choroid | 0.001053 | 0.5142 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Glaucoma | 0.001561 | 0.7961 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Secondary thrombocytopenia | 0.0004861 | 2.283 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Pallor and flushing | 0.0008359 | 1.807 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2292354 | Other disorders of thyroid | 0.007593 | 1.329 | GIT2 | HDL Cholesterol |
| rs2292354 | Pancreatic cancer | 0.007348 | 1.544 | GIT2 | HDL Cholesterol |
| rs2292354 | Hyperglyceridemia | 0.009552 | 0.7833 | GIT2 | HDL Cholesterol |
| rs2292354 | Polyneuropathy in diabetes | 0.005348 | 0.8085 | GIT2 | HDL Cholesterol |
| rs2292354 | Chronic periodontitis | 0.004133 | 0.7484 | GIT2 | HDL Cholesterol |
| rs2292354 | Periodontitis (acute or chronic) | 0.009334 | 0.7969 | GIT2 | HDL Cholesterol |
| rs2292354 | Disorders of coccyx | 0.01082 | 0.7235 | GIT2 | HDL Cholesterol |
| rs2292354 | Random mental disorder. Ignored for now | 0.002187 | 0.5303 | GIT2 | HDL Cholesterol |
| rs2292354 | Other specified erythematous conditions | 0.0008588 | 0.6615 | GIT2 | HDL Cholesterol |
| rs2292354 | Type 2 diabetic peripheral circulatory disorders | 0.005046 | 0.6638 | GIT2 | HDL Cholesterol |
| rs2294008 | E. coli | 0.007173 | 0.7537 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Prostate cancer | 0.003843 | 1.197 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Sciatica | 0.002065 | 0.8383 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Tension headache | 0.009837 | 0.8196 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cellulitis and abscess of foot/toes | 0.007215 | 0.7793 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Chronic sinusitis | 0.005792 | 0.8901 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Esophagitis, GERD and related diseases | 0.003294 | 0.9139 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Dyspepsia and disorders of function of stomach | 0.005928 | 0.8591 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.004615 | 0.8283 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Other nonmalignant breast conditions | 0.005512 | 1.159 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Appendiceal conditions | 0.006297 | 0.7092 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Bladder cancer and neoplasms | 0.01029 | 1.248 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Acute reaction to stress | 0.01022 | 0.8039 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Reflux esophagitis | 0.009712 | 0.832 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cystitis and urethritis | 0.003581 | 0.8155 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Inflammatory disease of breast | 0.001971 | 1.65 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cancer of kidney and urinary organs | 0.009563 | 1.198 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Gastric ulcer | 0.00157 | 0.7485 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Other congenital anomalies | 0.008011 | 0.5487 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Diaphragmatic hernia | 0.006785 | 0.8806 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Diseases of esophagus | 0.007232 | 0.9229 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Peptic ulcer | 0.006217 | 0.856 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cystitis | 0.00493 | 0.8106 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Pyogenic granuloma | 0.001387 | 0.4628 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Elevated prostate specific antigen | 0.005016 | 1.196 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Generalized convulsive epilepsy | 0.007758 | 0.6129 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Age-related macular degeneration | 0.004181 | 0.8239 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Abnormal function study of cardiovascular system | 0.001431 | 0.8277 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Bladder cancer | 0.0114 | 1.252 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Other derangement of joint | 0.008387 | 0.7817 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Bacterial infection NOS | 0.0005492 | 0.8491 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Rheumatoid arthritis | 0.007598 | 0.819 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Stricture and stenosis of esophagus | 0.002246 | 0.7586 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Hyperpotassemia | 0.005981 | 0.8348 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Acute cystitis | 0.006189 | 0.7106 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Disorders of function of stomach | 0.004743 | 0.8619 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | GERD | 0.001452 | 0.9027 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Disorders of adrenal glands | 0.004286 | 0.7378 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294015 | Allergic reaction to food | 0.01121 | 1.777 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Urethral stricture (not specified as infectious) | 0.001647 | 0.6492 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Peripheral arterial disease | 0.00295 | 1.139 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Subarachnoid hemorrhage | 0.004061 | 0.4518 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Congenital anomalies of limbs | 0.009077 | 0.7854 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Hammer toe | 0.009214 | 0.8396 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Chronic ulcer of unspecified site | 0.0005603 | 1.359 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Fracture of unspecified bones | 0.009956 | 1.145 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Congenital anomalies of face and neck | 0.002287 | 0.3421 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Congenital deformities of feet | 0.008592 | 0.7572 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Pain in limb | 0.006267 | 1.089 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Acquired deformities of limbs | 0.007051 | 0.8184 | ANXA13 | Event-related brain oscillations |
| rs2304130 | Deep vein thrombosis | 0.00514 | 0.592 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Myeloproliferative disease | 0.005799 | 1.592 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Arthropathy NOS | 0.0007714 | 0.6546 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Other specified diseases of hair and hair follicles | 0.004196 | 0.5049 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Hemorrhoids | 0.008686 | 0.8274 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Renal osteodystrophy | 0.004043 | 1.83 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Nonsenile Cataract | 0.00711 | 0.5144 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Cervicitis and endocervicitis | 0.002375 | 2.057 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Colles' fracture | 0.004595 | 0.4611 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Other arthropathies | 0.006601 | 0.8108 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Joint/ligament sprain | 0.003539 | 0.5212 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Abnormal cytological, histological, immunological and DNA test findings | 0.004522 | 2.273 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2326679 | Multiple sclerosis | 0.003415 | 1.597 | LRRN4 | Menopause |
| rs2326679 | Essential tremor | 0.002402 | 1.362 | LRRN4 | Menopause |
| rs2326679 | Polyp of corpus uteri | 0.007023 | 0.6755 | LRRN4 | Menopause |
| rs2326679 | Oral aphthae | 0.002824 | 1.746 | LRRN4 | Menopause |
| rs2326679 | Symptoms of the muscles | 0.004959 | 1.278 | LRRN4 | Menopause |
| rs2326679 | Appendiceal conditions | 0.009985 | 1.391 | LRRN4 | Menopause |
| rs2326679 | Premature beats | 0.003532 | 0.815 | LRRN4 | Menopause |
| rs2326679 | Cerebrovascular disease | 0.003737 | 1.112 | LRRN4 | Menopause |
| rs2326679 | Cancer of the digestive organs and peritoneum | 0.00375 | 0.59 | LRRN4 | Menopause |
| rs2326679 | Polycythemia vera, secondary | 0.009488 | 0.5555 | LRRN4 | Menopause |
| rs233100 | Pathologic fracture of vertebrae | 0.004335 | 0.7816 | DDAH1 | Multiple sclerosis |
| rs233100 | Altered mental status | 0.0004205 | 0.7158 | DDAH1 | Multiple sclerosis |
| rs233100 | Hemoptysis | 0.01041 | 0.7477 | DDAH1 | Multiple sclerosis |
| rs233100 | Edema | 0.01143 | 0.9108 | DDAH1 | Multiple sclerosis |
| rs233100 | Protein plasma/amino-acid transport and metabolism disorder | 0.0004204 | 0.7256 | DDAH1 | Multiple sclerosis |
| rs233100 | Chronic prostatitis | 0.00702 | 1.518 | DDAH1 | Multiple sclerosis |
| rs233100 | Heart failure NOS | 0.01139 | 0.7846 | DDAH1 | Multiple sclerosis |
| rs233100 | Neck pain | 0.008958 | 0.9112 | DDAH1 | Multiple sclerosis |
| rs233100 | Hereditary and idiopathic peripheral neuropathy | 0.003504 | 0.8577 | DDAH1 | Multiple sclerosis |
| rs233100 | Hyperventilation | 0.004094 | 0.5384 | DDAH1 | Multiple sclerosis |
| rs233100 | Benign neoplasm of unspecified sites | 0.003124 | 0.3965 | DDAH1 | Multiple sclerosis |
| rs233100 | Nonrheumatic mitral valve disorders | 0.008403 | 0.8738 | DDAH1 | Multiple sclerosis |
| rs233100 | Spirochetal infection | 0.00224 | 1.61 | DDAH1 | Multiple sclerosis |
| rs233100 | Paraproteinemia | 0.004642 | 0.7063 | DDAH1 | Multiple sclerosis |
| rs233100 | Herpes simplex | 0.004034 | 0.7473 | DDAH1 | Multiple sclerosis |
| rs233100 | Premature menopause and other ovarian failure | 0.003369 | 0.4997 | DDAH1 | Multiple sclerosis |
| rs233100 | Lyme disease | 0.001427 | 1.66 | DDAH1 | Multiple sclerosis |
| rs233100 | Plasma protein metabolism disorder | 0.002685 | 0.7403 | DDAH1 | Multiple sclerosis |
| rs233100 | Bacterial pneumonia | 0.001448 | 0.732 | DDAH1 | Multiple sclerosis |
| rs233100 | Gastritis and duodenitis, NOS | 0.001879 | 0.7891 | DDAH1 | Multiple sclerosis |
| rs233100 | Adjustment reaction | 0.001888 | 0.8476 | DDAH1 | Multiple sclerosis |
| rs2395029 | Psoriasis | 4.759e-08 | 2.383 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Other specified erythematous conditions | 0.011 | 1.756 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Disorders of cervical region | 0.006257 | 1.886 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Chronic hepatitis | 0.008182 | 2.725 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Neurological disorders due to brain damage | 0.005282 | 0.6794 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Substance addiction and disorders | 0.009114 | 0.3411 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Torticollis | 0.004129 | 2.408 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Keratoconjunctivitis sicca | 0.01039 | 2.37 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Keratoconjunctivitis, noninfectious | 0.0027 | 2.295 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Psoriatic arthropathy | 0.002383 | 3.089 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Acute sinusitis | 0.005616 | 1.413 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Acute laryngitis and tracheitis | 0.005621 | 2.331 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Cystic mastopathy | 0.0106 | 1.444 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Pseudoexfoliation glaucoma | 0.01111 | 2.299 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Psoriasis & related disorders | 4.113e-07 | 2.203 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Male genital disorders | 0.004361 | 1.872 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Mitral valve stenosis and/or aortic valve stenosis | 0.006833 | 1.598 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Fracture of hand or wrist | 0.009025 | 0.6133 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Disorders of cornea | 0.006856 | 1.54 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Acute upper respiratory infections | 0.00378 | 1.307 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Retinal disorders | 0.00593 | 1.334 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Respiratory failure; insufficiency; arrest | 0.00617 | 0.5394 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Voice disturbance | 0.0007985 | 1.682 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Macular degeneration | 0.008251 | 1.373 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Psoriasis vulgaris | 1.939e-07 | 2.344 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2413583 | Eustachian tube disorders | 0.005186 | 1.171 | TAB1 | Crohn's disease |
| rs2413583 | Postlaminectomy syndrome | 0.00413 | 1.541 | TAB1 | Crohn's disease |
| rs2413583 | Complications of transplants and reattached limbs | 0.007699 | 0.4301 | TAB1 | Crohn's disease |
| rs2413583 | Jaundice | 0.00654 | 0.526 | TAB1 | Crohn's disease |
| rs2413583 | Other disorders of middle ear and mastoid | 0.007822 | 1.564 | TAB1 | Crohn's disease |
| rs2413583 | Secondary malignancy of lung | 0.01014 | 0.602 | TAB1 | Crohn's disease |
| rs2413583 | Migrain with aura | 0.001674 | 0.4557 | TAB1 | Crohn's disease |
| rs2413583 | Hyperparathyroidism | 0.007157 | 0.6619 | TAB1 | Crohn's disease |
| rs2413583 | Aplastic anemia | 0.004684 | 0.6064 | TAB1 | Crohn's disease |
| rs2413583 | Simple goiter | 0.005664 | 1.312 | TAB1 | Crohn's disease |
| rs2413583 | Mastoiditis | 0.0001248 | 2.971 | TAB1 | Crohn's disease |
| rs2413583 | Strabismus (not specified as paralytic) | 0.002845 | 1.348 | TAB1 | Crohn's disease |
| rs2413583 | Type 2 diabetic retinopathy | 0.00141 | 0.7288 | TAB1 | Crohn's disease |
| rs2413583 | Cardiac pacemaker/device in situ | 0.01127 | 0.7805 | TAB1 | Crohn's disease |
| rs2413583 | Otorrhea | 0.009171 | 2.039 | TAB1 | Crohn's disease |
| rs2413583 | Decreased white blood cell count | 0.01051 | 0.7559 | TAB1 | Crohn's disease |
| rs2413583 | Thoracic neuritis/radiculitis | 0.003137 | 1.171 | TAB1 | Crohn's disease |
| rs2413583 | Pancytopenia | 0.002965 | 0.4074 | TAB1 | Crohn's disease |
| rs2413583 | Congenital anomalies of posterior segment of eye | 0.01116 | 1.347 | TAB1 | Crohn's disease |
| rs2413583 | Salicylates causing adverse effects in therapeutic use | 0.004092 | 2.14 | TAB1 | Crohn's disease |
| rs2413583 | Type 2 diabetic peripheral circulatory disorders | 0.003264 | 0.5671 | TAB1 | Crohn's disease |
| rs2413583 | Right bundle branch block | 0.008642 | 0.7041 | TAB1 | Crohn's disease |
| rs2413583 | Congenital anomalies of urinary system | 0.003578 | 1.606 | TAB1 | Crohn's disease |
| rs2413583 | Cerebral atherosclerosis | 0.00974 | 0.4207 | TAB1 | Crohn's disease |
| rs2413583 | Diabetic retinopathy | 0.0008239 | 0.7253 | TAB1 | Crohn's disease |
| rs2413583 | Neutropenia | 0.01117 | 0.7483 | TAB1 | Crohn's disease |
| rs2413583 | Suppurative and unspecified otitis media | 0.005864 | 1.228 | TAB1 | Crohn's disease |
| rs2413583 | Dislocation | 0.00583 | 1.159 | TAB1 | Crohn's disease |
| rs2413583 | Neck pain | 0.001533 | 1.158 | TAB1 | Crohn's disease |
| rs2413583 | Other disorders of ear | 0.008575 | 1.362 | TAB1 | Crohn's disease |
| rs242557 | Pain in limb | 0.003048 | 0.9091 | MAPT | Progressive supranuclear palsy |
| rs242557 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.0105 | 1.189 | MAPT | Progressive supranuclear palsy |
| rs242557 | Shock | 0.01133 | 0.7159 | MAPT | Progressive supranuclear palsy |
| rs242557 | Intracranial hemorrhage (injury) | 0.00334 | 1.52 | MAPT | Progressive supranuclear palsy |
| rs242557 | Other disorders of soft tissues | 0.01144 | 0.7132 | MAPT | Progressive supranuclear palsy |
| rs242557 | Schizophrenia and other psychotic disorders | 0.0004327 | 1.262 | MAPT | Progressive supranuclear palsy |
| rs242557 | Other hypertrophic and atrophic conditions of skin | 0.009479 | 0.8994 | MAPT | Progressive supranuclear palsy |
| rs242557 | Subdural hemorrhage | 0.01025 | 1.544 | MAPT | Progressive supranuclear palsy |
| rs242557 | Other disorders of back | 0.003089 | 0.847 | MAPT | Progressive supranuclear palsy |
| rs242557 | Nonrheumatic mitral valve disorders | 0.003797 | 1.158 | MAPT | Progressive supranuclear palsy |
| rs242557 | Chronic venous hypertension | 0.004473 | 0.3857 | MAPT | Progressive supranuclear palsy |
| rs242557 | Alcohol-related disorders | 0.000489 | 1.258 | MAPT | Progressive supranuclear palsy |
| rs242557 | Cardiomyopathy | 0.007457 | 1.182 | MAPT | Progressive supranuclear palsy |
| rs242557 | Conduct disorders | 0.005829 | 1.566 | MAPT | Progressive supranuclear palsy |
| rs242557 | Keratitis, infectious | 0.0006616 | 0.6269 | MAPT | Progressive supranuclear palsy |
| rs242557 | Diabetic retinopathy | 0.00244 | 0.8109 | MAPT | Progressive supranuclear palsy |
| rs242557 | Diseases of hard tissues of teeth | 0.001662 | 1.23 | MAPT | Progressive supranuclear palsy |
| rs242557 | Otalgia | 0.01085 | 0.7937 | MAPT | Progressive supranuclear palsy |
| rs242557 | Adverse effects of insulins and antidiabetic agents | 0.009056 | 0.5166 | MAPT | Progressive supranuclear palsy |
| rs242557 | Subdural hemorrhage (injury) | 0.0104 | 1.614 | MAPT | Progressive supranuclear palsy |
| rs242557 | Osteoarthrosis, generalized | 0.009315 | 0.8237 | MAPT | Progressive supranuclear palsy |
| rs242557 | Chronic pain syndrome | 0.009249 | 0.5823 | MAPT | Progressive supranuclear palsy |
| rs242557 | Alcoholism | 0.002608 | 1.253 | MAPT | Progressive supranuclear palsy |
| rs242557 | Decreased libido | 0.00288 | 2.07 | MAPT | Progressive supranuclear palsy |
| rs242557 | Eustachian tube disorders | 0.01051 | 0.8022 | MAPT | Progressive supranuclear palsy |
| rs242557 | Trigeminal nerve disorders | 0.007878 | 0.6718 | MAPT | Progressive supranuclear palsy |
| rs242557 | Symptoms involving head and neck | 0.004786 | 1.203 | MAPT | Progressive supranuclear palsy |
| rs242557 | Superficial cellulitis and abscess | 0.005398 | 0.9057 | MAPT | Progressive supranuclear palsy |
| rs242557 | Mental disorders due to brain damage | 0.008543 | 1.224 | MAPT | Progressive supranuclear palsy |
| rs242557 | Dental caries | 0.001387 | 1.241 | MAPT | Progressive supranuclear palsy |
| rs242557 | Ankylosis of joint | 0.006136 | 0.6759 | MAPT | Progressive supranuclear palsy |
| rs242557 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.009142 | 0.8039 | MAPT | Progressive supranuclear palsy |
| rs243021 | Polycythemia vera, secondary | 0.005764 | 0.609 | BCL11A | Type 2 diabetes |
| rs243021 | Absent or infrequent menstruation | 0.0009403 | 1.706 | BCL11A | Type 2 diabetes |
| rs243021 | Herpes zoster | 0.006857 | 1.183 | BCL11A | Type 2 diabetes |
| rs243021 | Acute upper respiratory infections | 0.009274 | 1.094 | BCL11A | Type 2 diabetes |
| rs243021 | Gross hematuria | 0.007128 | 0.6197 | BCL11A | Type 2 diabetes |
| rs243021 | Retinal drusen | 0.002649 | 0.7946 | BCL11A | Type 2 diabetes |
| rs243021 | Abnormal glucose | 0.003096 | 1.123 | BCL11A | Type 2 diabetes |
| rs243021 | ASCVD | 0.006694 | 1.367 | BCL11A | Type 2 diabetes |
| rs243021 | Acute bronchospasm | 0.002832 | 0.3842 | BCL11A | Type 2 diabetes |
| rs243021 | Aortic aneurysm | 0.00679 | 0.8308 | BCL11A | Type 2 diabetes |
| rs243021 | Other abnormal glucose | 0.008745 | 1.136 | BCL11A | Type 2 diabetes |
| rs2430212 | Ovarian dysfunction | 0.002533 | 0.3847 | KLHL13 | Serum transferrin |
| rs2430212 | Adverse effects of hormones and synthetic substitutes | 0.008461 | 0.2542 | KLHL13 | Serum transferrin |
| rs2430212 | Eating disorder | 0.0114 | 1.636 | KLHL13 | Serum transferrin |
| rs2430212 | Polycystic ovaries | 0.003749 | 0.3475 | KLHL13 | Serum transferrin |
| rs2430212 | Plasma protein metabolism disorder | 0.001877 | 0.6613 | KLHL13 | Serum transferrin |
| rs2430212 | Vaginitis and vulvovaginitis | 0.003257 | 1.24 | KLHL13 | Serum transferrin |
| rs2430212 | Visual disturbances | 0.0008402 | 1.174 | KLHL13 | Serum transferrin |
| rs2430212 | Voice disturbance | 0.005848 | 0.7781 | KLHL13 | Serum transferrin |
| rs2430212 | Rheumatoid arthritis | 0.004712 | 0.7716 | KLHL13 | Serum transferrin |
| rs2430212 | Other alveolar and parietoalveolar pneumonopathy | 0.002492 | 0.3926 | KLHL13 | Serum transferrin |
| rs2430212 | Diseases of the larynx and vocal cords | 0.003928 | 0.7967 | KLHL13 | Serum transferrin |
| rs2430212 | Non-healing surgical wound | 0.004207 | 1.796 | KLHL13 | Serum transferrin |
| rs2430212 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.006636 | 0.802 | KLHL13 | Serum transferrin |
| rs2430212 | Ectropion or entropion | 0.004383 | 0.72 | KLHL13 | Serum transferrin |
| rs2430212 | Fracture of humerus | 0.0003679 | 0.6852 | KLHL13 | Serum transferrin |
| rs2430212 | Tachycardia NOS | 0.005244 | 0.7955 | KLHL13 | Serum transferrin |
| rs2430212 | Arthropathy associated with infections | 0.009414 | 0.528 | KLHL13 | Serum transferrin |
| rs2476601 | Retinal edema and hypertensive retinopathy | 0.01085 | 1.48 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Primary open angle glaucoma | 0.006086 | 1.415 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Jaundice | 0.00866 | 1.66 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Hypotony of eye | 0.003949 | 2.638 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Urinary calculus | 0.01121 | 0.7873 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.009674 | 1.297 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Congenital deformities of feet | 0.01006 | 1.478 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Disorders of tooth development | 0.006815 | 1.521 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Disorders of liver | 0.002959 | 1.201 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Macular degeneration, dry | 0.002992 | 1.444 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Supraventricular premature beats | 0.007937 | 1.53 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Thyrotoxicosis | 0.008105 | 1.367 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Thyroiditis | 0.0007339 | 1.703 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Neutropenia | 0.006896 | 1.368 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Polycystic ovaries | 0.0005011 | 3.149 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Pernicious anemia | 0.006919 | 1.673 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Glaucoma | 0.009954 | 1.185 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Decreased white blood cell count | 0.002305 | 1.4 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Chronic lymphocytic thyroiditis | 0.0004169 | 1.909 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Vitamin D deficiency | 0.01035 | 1.437 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Graves' disease | 0.0004271 | 1.97 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Other hypertensive complications | 0.009023 | 1.403 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Hypothyroidism | 4.02e-07 | 1.334 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Ovarian dysfunction | 0.00424 | 2.367 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Congenital anomalies of limbs | 0.005418 | 1.453 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Other disorders of gallbladder | 0.004858 | 1.873 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Malignant neoplasm of renal pelvis | 0.007431 | 2.505 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Hypocalcemia | 0.004849 | 1.674 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Open-angle glaucoma | 0.008166 | 1.269 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2484873 | Miscarriage; stillbirth | 0.00607 | 2.521 | KIAA1217 | Cognitive performance |
| rs2484873 | Perforation of tympanic membrane | 0.008245 | 1.984 | KIAA1217 | Cognitive performance |
| rs2484873 | Sexually transmitted infections | 0.01074 | 2.661 | KIAA1217 | Cognitive performance |
| rs2484873 | Cardiac defibrillator in situ | 0.005462 | 1.995 | KIAA1217 | Cognitive performance |
| rs2484873 | Hematemesis | 0.001469 | 2.375 | KIAA1217 | Cognitive performance |
| rs2484873 | Malaise and fatigue | 0.00736 | 1.202 | KIAA1217 | Cognitive performance |
| rs2484873 | Other anemias | 0.001584 | 1.24 | KIAA1217 | Cognitive performance |
| rs2484873 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.006783 | 0.6133 | KIAA1217 | Cognitive performance |
| rs2484873 | Other disorders of arteries and arterioles | 0.006808 | 1.57 | KIAA1217 | Cognitive performance |
| rs2484873 | Other forms of chronic heart disease | 0.01057 | 1.413 | KIAA1217 | Cognitive performance |
| rs2484873 | Anemia NOS | 0.0006997 | 1.281 | KIAA1217 | Cognitive performance |
| rs2484873 | Type 1 diabetic peripheral circulatory disorders | 0.003815 | 2.9 | KIAA1217 | Cognitive performance |
| rs2484873 | Other aneurysm | 0.003711 | 1.444 | KIAA1217 | Cognitive performance |
| rs2505083 | Empyema and pneumothorax | 0.01047 | 0.7787 | KIAA1462 | Coronary heart disease |
| rs2505083 | Disturbances of sulphur-bearing amino-acid metabolism | 0.005529 | 1.839 | KIAA1462 | Coronary heart disease |
| rs2505083 | Labyrinthitis | 0.008247 | 1.344 | KIAA1462 | Coronary heart disease |
| rs2505083 | Thyrotoxicosis | 0.003759 | 1.25 | KIAA1462 | Coronary heart disease |
| rs2505083 | Respiratory insufficiency | 0.01022 | 0.7811 | KIAA1462 | Coronary heart disease |
| rs2505083 | Aneurysm of artery of lower extremity | 0.002463 | 1.624 | KIAA1462 | Coronary heart disease |
| rs2505083 | Other benign neoplasm of connective and other soft tissue | 0.0008136 | 0.5993 | KIAA1462 | Coronary heart disease |
| rs2505083 | Herpes zoster with nervous system complications | 0.003633 | 1.552 | KIAA1462 | Coronary heart disease |
| rs2505083 | Disturbances of amino-acid transport | 0.00996 | 1.745 | KIAA1462 | Coronary heart disease |
| rs2505083 | Aplastic anemia | 0.0005463 | 0.6723 | KIAA1462 | Coronary heart disease |
| rs2505083 | Disorders of mineral metabolism | 0.003543 | 0.866 | KIAA1462 | Coronary heart disease |
| rs2505083 | Muscular wasting and disuse atrophy | 0.003846 | 0.5814 | KIAA1462 | Coronary heart disease |
| rs2505083 | Scoliosis | 0.006274 | 0.7632 | KIAA1462 | Coronary heart disease |
| rs2505083 | Abnormal findings examination of lungs | 0.002547 | 0.8391 | KIAA1462 | Coronary heart disease |
| rs2505083 | Allergic reaction to food | 0.0065 | 1.863 | KIAA1462 | Coronary heart disease |
| rs2515629 | Antihypertensive agents causing adverse effects | 0.00502 | 1.68 | ABCA1 | HDL Cholesterol |
| rs2515629 | Diabetic retinopathy | 0.008229 | 0.7891 | ABCA1 | HDL Cholesterol |
| rs2515629 | Obesity | 0.001578 | 0.8712 | ABCA1 | HDL Cholesterol |
| rs2515629 | Neoplasm of uncertain behavior | 0.001615 | 1.278 | ABCA1 | HDL Cholesterol |
| rs2515629 | Diabetes mellitus | 0.0006046 | 0.8698 | ABCA1 | HDL Cholesterol |
| rs2515629 | Thrombocytopenia | 0.003235 | 0.7753 | ABCA1 | HDL Cholesterol |
| rs2515629 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.001205 | 1.474 | ABCA1 | HDL Cholesterol |
| rs2515629 | Overweight | 0.004019 | 0.8881 | ABCA1 | HDL Cholesterol |
| rs2515629 | Colles' fracture | 0.001623 | 0.5582 | ABCA1 | HDL Cholesterol |
| rs2515629 | Candidiasis | 0.003405 | 0.7707 | ABCA1 | HDL Cholesterol |
| rs2515629 | Altered mental status | 0.0004352 | 0.6092 | ABCA1 | HDL Cholesterol |
| rs2515629 | Type 2 diabetic retinopathy | 0.006304 | 0.7745 | ABCA1 | HDL Cholesterol |
| rs2515629 | Arterial embolism and thrombosis | 0.002346 | 1.35 | ABCA1 | HDL Cholesterol |
| rs2515629 | Cancer, suspected or other | 0.0005484 | 1.326 | ABCA1 | HDL Cholesterol |
| rs2515629 | Malignant neoplasm, other | 0.004304 | 1.308 | ABCA1 | HDL Cholesterol |
| rs2515629 | Hemorrhage or hematoma complicating a procedure | 0.002554 | 0.7266 | ABCA1 | HDL Cholesterol |
| rs2515629 | Type 2 diabetes | 0.0007318 | 0.8702 | ABCA1 | HDL Cholesterol |
| rs2515629 | Poisoning by primarily systemic agents | 0.001097 | 1.464 | ABCA1 | HDL Cholesterol |
| rs2515629 | Secondary malignant neoplasm | 0.00133 | 1.243 | ABCA1 | HDL Cholesterol |
| rs2515629 | Glaucoma | 0.01115 | 1.139 | ABCA1 | HDL Cholesterol |
| rs2515629 | Secondary malignant neoplasm of liver | 0.004913 | 1.472 | ABCA1 | HDL Cholesterol |
| rs2515629 | Poisoning by other anti-infectives | 0.01091 | 1.277 | ABCA1 | HDL Cholesterol |
| rs2515629 | Fracture of upper limb | 0.007045 | 0.8327 | ABCA1 | HDL Cholesterol |
| rs2517388 | Diseases of respiratory system | 0.01006 | 0.8212 | ASH2L | Menopause |
| rs2517388 | Varicose veins | 0.008565 | 0.8318 | ASH2L | Menopause |
| rs2517388 | Varicose veins of lower extremity | 0.006438 | 0.8183 | ASH2L | Menopause |
| rs2517388 | Retinal detachments and defects | 0.007526 | 1.277 | ASH2L | Menopause |
| rs2517388 | Bronchopneumonia and lung abscess | 0.007704 | 0.3468 | ASH2L | Menopause |
| rs2517388 | Secondary malignant neoplasm | 0.008831 | 1.192 | ASH2L | Menopause |
| rs2523946 | Atrial fibrillation | 0.007812 | 1.124 | HCG9 | IgA nephropathy |
| rs2523946 | Obstructive sleep apnea | 0.001267 | 0.85 | HCG9 | IgA nephropathy |
| rs2523946 | Congenital anomalies of peripheral vascular system | 0.006391 | 1.801 | HCG9 | IgA nephropathy |
| rs2523946 | Prurigo | 0.005712 | 0.7724 | HCG9 | IgA nephropathy |
| rs2523946 | Arteritis NOS | 0.00168 | 1.69 | HCG9 | IgA nephropathy |
| rs2523946 | Atrial fibrillation & flutter | 0.008069 | 1.121 | HCG9 | IgA nephropathy |
| rs2523946 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.0008209 | 1.242 | HCG9 | IgA nephropathy |
| rs2523946 | Hidradenitis | 0.001209 | 0.3268 | HCG9 | IgA nephropathy |
| rs2523946 | Myalgia and myositis NOS | 0.009668 | 1.112 | HCG9 | IgA nephropathy |
| rs2523946 | Other congenital anomalies of skin | 0.009035 | 0.6982 | HCG9 | IgA nephropathy |
| rs2523946 | Viral warts & HPV | 0.002938 | 0.8531 | HCG9 | IgA nephropathy |
| rs2523946 | Blood in stool | 0.0008289 | 1.192 | HCG9 | IgA nephropathy |
| rs2523946 | Conductive hearing loss | 0.006175 | 0.64 | HCG9 | IgA nephropathy |
| rs2523946 | Herpes zoster | 0.01108 | 0.8518 | HCG9 | IgA nephropathy |
| rs2523946 | Rheumatoid arthritis | 0.000787 | 1.277 | HCG9 | IgA nephropathy |
| rs2523946 | Polyarteritis nodosa and allied conditions | 0.009866 | 1.313 | HCG9 | IgA nephropathy |
| rs2523946 | Other and unspecified disc disorder | 0.01029 | 1.441 | HCG9 | IgA nephropathy |
| rs25422 | Cervical cancer and dysplasia | 0.004379 | 1.371 | C6orf204 | Renal cell carcinoma |
| rs25422 | Lesions of stomach and duodenum | 0.004705 | 2.104 | C6orf204 | Renal cell carcinoma |
| rs25422 | Macular degeneration, dry | 0.001802 | 1.352 | C6orf204 | Renal cell carcinoma |
| rs25422 | Hypovolemia | 0.004039 | 1.168 | C6orf204 | Renal cell carcinoma |
| rs25422 | Decubitus ulcer | 0.01115 | 1.261 | C6orf204 | Renal cell carcinoma |
| rs25422 | Electrolyte imbalance | 0.005624 | 1.131 | C6orf204 | Renal cell carcinoma |
| rs25422 | Wheezing and painful respiration | 0.01086 | 0.8614 | C6orf204 | Renal cell carcinoma |
| rs25422 | Disorders of fluid, electrolyte, and acid-base balance | 0.007599 | 1.11 | C6orf204 | Renal cell carcinoma |
| rs25422 | Wheezing | 0.0007981 | 0.5954 | C6orf204 | Renal cell carcinoma |
| rs25422 | Osteoarthrosis; localized, secondary | 0.005803 | 1.68 | C6orf204 | Renal cell carcinoma |
| rs2544390 | Neoplasm of unspecified nature of digestive system | 0.003421 | 1.459 | LRP2 | Serum urate |
| rs2544390 | Essential hypertension | 0.005537 | 1.088 | LRP2 | Serum urate |
| rs2544390 | Congenital anomalies of face and neck | 0.007242 | 2.14 | LRP2 | Serum urate |
| rs2544390 | Injuries to the nervous system | 0.006041 | 0.6046 | LRP2 | Serum urate |
| rs2544390 | Stiffness of joint | 0.005614 | 0.8215 | LRP2 | Serum urate |
| rs2544390 | Hypertension | 0.003677 | 1.093 | LRP2 | Serum urate |
| rs2544390 | Other disorders of intestine | 0.01087 | 1.176 | LRP2 | Serum urate |
| rs2544390 | Tinnitus | 0.001451 | 1.242 | LRP2 | Serum urate |
| rs2544390 | Elevated blood pressure reading | 4.067e-05 | 1.228 | LRP2 | Serum urate |
| rs2544390 | Unstable angina (intermediate coronary syndrome) | 0.009963 | 1.157 | LRP2 | Serum urate |
| rs2544390 | Abnormal chest sounds | 0.008957 | 0.6805 | LRP2 | Serum urate |
| rs2544390 | Gastrointestinal complications | 0.01104 | 1.25 | LRP2 | Serum urate |
| rs255052 | Type 1 diabetic neuropathy | 0.005562 | 1.582 | DPEP2 | HDL Cholesterol |
| rs255052 | Vitamin deficiency | 0.005379 | 1.24 | DPEP2 | HDL Cholesterol |
| rs255052 | Other disorders of the nervous system | 0.01115 | 1.618 | DPEP2 | HDL Cholesterol |
| rs255052 | Balanoposthitis | 0.007714 | 0.3815 | DPEP2 | HDL Cholesterol |
| rs255052 | Osteopenia | 0.004463 | 1.184 | DPEP2 | HDL Cholesterol |
| rs255052 | Herpes zoster | 0.007952 | 1.247 | DPEP2 | HDL Cholesterol |
| rs255052 | Heart valve replaced | 0.01145 | 1.354 | DPEP2 | HDL Cholesterol |
| rs255052 | Other hypertrophic and atrophic conditions of skin | 0.007788 | 0.86 | DPEP2 | HDL Cholesterol |
| rs255052 | Fibroadenosis of breast | 0.006911 | 2.426 | DPEP2 | HDL Cholesterol |
| rs2562519 | Balanoposthitis | 0.004335 | 0.4764 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Acute tonsillitis | 0.008243 | 1.629 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Neoplasm of unspecified nature of digestive system | 0.003737 | 1.507 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Osteochondropathies | 0.009033 | 1.891 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Atrial fibrillation | 0.006422 | 0.8677 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Disorders of the pituitary gland and its hypothalamic control | 0.007886 | 1.393 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Heart failure NOS | 0.008241 | 0.7415 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Benign neoplasm of other endocrine glands | 0.004916 | 1.461 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Atrial fibrillation & flutter | 0.008552 | 0.8741 | POLR3G | Nevirapine-induced rash |
| rs2562784 | Cancer, suspected or other | 0.00294 | 1.25 | SH3GL3 | Height |
| rs2562784 | Pneumonia | 0.01131 | 1.117 | SH3GL3 | Height |
| rs2562784 | Other congenital anomalies of skin | 0.002734 | 1.54 | SH3GL3 | Height |
| rs2562784 | Fractur of unspecified part of femur | 0.001224 | 0.5628 | SH3GL3 | Height |
| rs2562784 | Cancer of connective tissue | 0.00112 | 1.864 | SH3GL3 | Height |
| rs2562784 | Cancer of bone & connective tissue | 0.01023 | 1.477 | SH3GL3 | Height |
| rs2562784 | Intestinal malabsorption NOS | 0.009014 | 1.673 | SH3GL3 | Height |
| rs2562784 | Urinary calculus | 0.01007 | 1.163 | SH3GL3 | Height |
| rs2562784 | Speech and language disorder | 0.009224 | 1.427 | SH3GL3 | Height |
| rs2562784 | Bullous dermatoses | 0.002933 | 2.014 | SH3GL3 | Height |
| rs2562784 | Disorders of cornea | 0.00687 | 1.222 | SH3GL3 | Height |
| rs2562784 | Abdominal hernia | 0.0008838 | 1.138 | SH3GL3 | Height |
| rs2562784 | Hallux valgus (Bunion) | 0.002651 | 1.24 | SH3GL3 | Height |
| rs2562784 | Other disorders of bladder | 0.007758 | 1.185 | SH3GL3 | Height |
| rs2562784 | progressive myopia | 0.01141 | 1.731 | SH3GL3 | Height |
| rs2562784 | Random mental disorder. Ignored for now | 0.002856 | 1.614 | SH3GL3 | Height |
| rs2562784 | Intestinal malabsorption | 0.002455 | 1.461 | SH3GL3 | Height |
| rs2562784 | Ventral hernia | 0.003288 | 1.349 | SH3GL3 | Height |
| rs2562784 | Other specified peripheral vascular diseases | 0.004909 | 2.054 | SH3GL3 | Height |
| rs2562784 | Hematuria | 0.0002749 | 1.183 | SH3GL3 | Height |
| rs2562784 | Sacroiliitis NEC | 0.00601 | 0.3969 | SH3GL3 | Height |
| rs2562784 | Schizophrenia | 0.007957 | 1.674 | SH3GL3 | Height |
| rs2575876 | Other peripheral nerve disorders | 0.01114 | 0.9001 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Proteinuria | 0.01122 | 1.29 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Cardiac defibrillator in situ | 0.006504 | 1.476 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Primary angle-closure glaucoma | 0.0007063 | 1.323 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Angina pectoris | 0.006518 | 0.8633 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Cellulitis and abscess of trunk | 0.002326 | 0.6901 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Adverse effects of adrenal cortical steroids | 0.005816 | 1.592 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Urethritis and urethral syndrome | 0.007397 | 0.4602 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Lupus erythematosus | 0.005514 | 1.923 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Labyrinthitis | 5.501e-05 | 0.5299 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Other infectious diseases | 0.003179 | 0.4027 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Anomalies of jaw size/symmetry | 0.009715 | 1.962 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Hypoparathyroidism | 0.007189 | 2.121 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Diverticulum of esophagus, acquired | 0.009858 | 0.396 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2597513 | Hypotension NOS | 0.001447 | 1.337 | HDAC11 | Height |
| rs2597513 | Arthralgia/ankylosis of temporomandibular joint | 0.008107 | 0.2982 | HDAC11 | Height |
| rs2597513 | Primary angle-closure glaucoma | 0.006601 | 0.7078 | HDAC11 | Height |
| rs2597513 | Known or suspected fetal abnormality | 0.006491 | 0.238 | HDAC11 | Height |
| rs2597513 | Type 2 diabetic peripheral circulatory disorders | 0.008129 | 1.535 | HDAC11 | Height |
| rs2597513 | Cancer within the respiratory system | 0.002994 | 1.4 | HDAC11 | Height |
| rs2597513 | Temporomandibular joint disorders | 0.007965 | 0.6294 | HDAC11 | Height |
| rs2597513 | Chronic ischemic heart disease | 0.002102 | 1.258 | HDAC11 | Height |
| rs2597513 | Otalgia | 0.001111 | 0.5674 | HDAC11 | Height |
| rs2597513 | Peripheral autonomic neuropathy | 0.006188 | 1.56 | HDAC11 | Height |
| rs2597513 | Claw toe | 0.0001125 | 3.057 | HDAC11 | Height |
| rs2597513 | Lung cancer | 0.002612 | 1.412 | HDAC11 | Height |
| rs2597513 | Acidosis | 0.01095 | 1.517 | HDAC11 | Height |
| rs2597513 | Acute laryngitis and tracheitis | 0.01115 | 0.4598 | HDAC11 | Height |
| rs2597513 | Hypovolemia | 0.000939 | 1.247 | HDAC11 | Height |
| rs2597513 | Urethral stricture (not specified as infectious) | 0.005133 | 1.654 | HDAC11 | Height |
| rs2597513 | Irritable Bowel Syndrome | 0.004704 | 0.7521 | HDAC11 | Height |
| rs2619566 | Erythematous conditions | 0.009337 | 0.8327 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Angina pectoris | 0.002507 | 0.8003 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Colostomy and enterostomy complication | 0.01134 | 1.946 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Hypercholesterolemia | 0.01073 | 0.852 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Chronic lymphoid leukemia | 0.002816 | 1.846 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Diffuse diseases of connective tissue | 0.008861 | 0.6679 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Leukemia | 0.005699 | 1.479 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Acquired spondylolisthesis | 0.004087 | 0.5918 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Other disorders of back | 0.006982 | 0.7849 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Fracture of unspecified bones | 0.004441 | 1.251 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Conjunctivitis, infectious | 0.004472 | 0.7662 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Seborheic dermatitis | 0.006101 | 0.752 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Lymphoid leukemia | 0.0004918 | 1.967 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Infection of the eye | 0.006559 | 0.7986 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Myeloproliferative disease | 0.007584 | 1.5 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Cancer of other female genital organs | 0.008321 | 2.137 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Heart valve disorders | 0.009972 | 0.8545 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Viral Enteritis | 0.003639 | 1.724 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Ectropion or entropion | 0.001554 | 0.6164 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Ischemic Heart Disease | 0.0004788 | 0.8457 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Coronary atherosclerosis | 0.004506 | 0.8667 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2651899 | Type 1 diabetic neuropathy | 0.005028 | 1.454 | PRDM16 | Migraine |
| rs2651899 | Pyogenic granuloma | 0.006027 | 0.5072 | PRDM16 | Migraine |
| rs2651899 | Testicular hypofunction | 0.01094 | 1.368 | PRDM16 | Migraine |
| rs2651899 | Absent or infrequent menstruation | 0.01045 | 0.6615 | PRDM16 | Migraine |
| rs2651899 | Cervical cancer and dysplasia | 0.006404 | 0.7706 | PRDM16 | Migraine |
| rs2651899 | Chronic pancreatitis | 0.003409 | 0.5572 | PRDM16 | Migraine |
| rs2651899 | Gram negative septicemia | 0.009643 | 0.7123 | PRDM16 | Migraine |
| rs2651899 | Drug-resistant infection | 0.005704 | 0.7103 | PRDM16 | Migraine |
| rs2651899 | Synoviopathy | 0.006271 | 0.7477 | PRDM16 | Migraine |
| rs2651899 | Renal colic | 0.008933 | 0.5888 | PRDM16 | Migraine |
| rs2651899 | Iatrogenic hypotension | 0.006514 | 1.585 | PRDM16 | Migraine |
| rs2651899 | Otalgia | 0.006522 | 0.7838 | PRDM16 | Migraine |
| rs2651899 | Heart transplant/surgery | 0.004742 | 0.6722 | PRDM16 | Migraine |
| rs2651899 | Prostatitis | 0.009366 | 0.7766 | PRDM16 | Migraine |
| rs2651899 | Toxic erythema | 0.006601 | 2.13 | PRDM16 | Migraine |
| rs2651899 | Methicillin sensitive Staphylococcus aureus | 0.00103 | 0.6882 | PRDM16 | Migraine |
| rs2651899 | Diverticulum of esophagus, acquired | 0.007093 | 0.4899 | PRDM16 | Migraine |
| rs2651899 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.008857 | 0.7626 | PRDM16 | Migraine |
| rs2651899 | Atrophy of edentulous alveolar ridge | 0.005239 | 0.6418 | PRDM16 | Migraine |
| rs2711721 | Congenital anomalies of urinary system | 0.006089 | 0.5918 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Cystic kidney disease | 0.002041 | 0.4619 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Alcoholic liver damage | 0.009183 | 1.645 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Macular degeneration | 0.004333 | 1.164 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Hodgkin's disease | 0.005391 | 0.3781 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spondylosis without myelopathy | 0.001622 | 1.152 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spinal stenosis | 0.0005507 | 1.195 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Degeneration of intervertebral disc | 0.005521 | 1.142 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spondylosis and allied disorders | 0.001392 | 1.149 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Urethral hypermobility/ISD | 0.001653 | 0.4203 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Abnormal function study of cardiovascular system | 0.01134 | 0.8333 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Appendicitis | 0.0004454 | 1.596 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Deviated nasal septum | 0.006185 | 1.213 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Appendiceal conditions | 0.0003871 | 1.586 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Cancer of mouth | 0.006651 | 0.5501 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Allergies, other | 0.0002106 | 1.419 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Fluid overload | 0.008901 | 0.7428 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Abnormal movement | 0.004745 | 1.137 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Microscopic hematuria | 0.003738 | 1.604 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spinal stenosis of lumbar region | 0.004846 | 1.176 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Osteoarthrosis, generalized | 0.008091 | 1.241 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2731672 | Inguinal hernia | 0.01141 | 0.8543 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Insect bite | 0.002292 | 1.306 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Uterine leiomyoma | 0.0007545 | 1.324 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Other conditions of brain | 0.0005574 | 0.6347 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Excessive or frequent menstruation | 0.005196 | 1.355 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Infertility, female | 0.001173 | 2.063 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Abnormal findings on radiological examination intrathoracic organs | 0.01047 | 0.8067 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Malignant neoplasm of brain and nervous system | 0.005273 | 0.6213 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Benign neoplasm of other parts of digestive system | 0.009053 | 0.7175 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Known or suspected fetal abnormality | 0.005593 | 1.732 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Dysmenorrhea | 0.004975 | 1.591 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Benign neoplasm of uterus | 0.0001215 | 1.353 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Keratoconjunctivitis sicca | 0.006667 | 1.653 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Gingival and periodontal diseases | 0.008028 | 0.8137 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Abnormal results of function study of liver | 0.00586 | 0.7844 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Early or threatened labor; hemorrhage in early pregnancy | 0.002205 | 1.82 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Cystic kidney disease | 0.00811 | 0.5471 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2744148 | Male genital disorders | 0.003081 | 0.6528 | SOX8 | Multiple sclerosis |
| rs2744148 | Parasomnia | 0.004719 | 1.802 | SOX8 | Multiple sclerosis |
| rs2744148 | Optic atrophy | 0.008927 | 1.536 | SOX8 | Multiple sclerosis |
| rs2744148 | Macular degeneration | 0.00505 | 0.8446 | SOX8 | Multiple sclerosis |
| rs2744148 | Personal history of allergy to medicinal agents | 0.004432 | 1.358 | SOX8 | Multiple sclerosis |
| rs2744148 | Ulcerative stomatitis & mucositis | 0.006022 | 1.932 | SOX8 | Multiple sclerosis |
| rs2744148 | Known or suspected fetal abnormality | 0.003002 | 1.898 | SOX8 | Multiple sclerosis |
| rs2744148 | Other conditions of the mother complicating pregnancy | 0.008268 | 1.758 | SOX8 | Multiple sclerosis |
| rs2744148 | Atrophy of edentulous alveolar ridge | 0.006236 | 1.604 | SOX8 | Multiple sclerosis |
| rs2744148 | Bone cancer | 0.004474 | 1.811 | SOX8 | Multiple sclerosis |
| rs2744148 | Congenital anomalies of the eye | 0.009451 | 0.7446 | SOX8 | Multiple sclerosis |
| rs2744148 | Spasm of muscle | 0.003333 | 1.303 | SOX8 | Multiple sclerosis |
| rs2744148 | Nevus, non-neoplastic | 0.005419 | 0.3769 | SOX8 | Multiple sclerosis |
| rs2744148 | Early or threatened labor; hemorrhage in early pregnancy | 0.0101 | 1.731 | SOX8 | Multiple sclerosis |
| rs2744148 | Cholangitis | 0.009404 | 0.3818 | SOX8 | Multiple sclerosis |
| rs2755237 | Other disorders of bladder | 0.002711 | 1.251 | FOXO1 | Central corneal thickness |
| rs2755237 | Alcoholism | 0.007629 | 0.7358 | FOXO1 | Central corneal thickness |
| rs2755237 | Infection/inflammation of internal prosthetic device, implant or graft | 0.000892 | 0.6069 | FOXO1 | Central corneal thickness |
| rs2755237 | Other disorders of stomach and duodenum | 0.001794 | 1.433 | FOXO1 | Central corneal thickness |
| rs2755237 | Chronic pancreatitis | 0.008008 | 1.766 | FOXO1 | Central corneal thickness |
| rs2755237 | Vitamin D deficiency | 0.005906 | 0.6618 | FOXO1 | Central corneal thickness |
| rs2755237 | Megaloblastic anemia | 0.0008538 | 0.5186 | FOXO1 | Central corneal thickness |
| rs2755237 | Neck pain | 0.00285 | 1.154 | FOXO1 | Central corneal thickness |
| rs2755237 | Degenerative disease of the spinal cord | 0.008379 | 1.563 | FOXO1 | Central corneal thickness |
| rs2755237 | Noninfectious dermatoses of eyelid | 0.005339 | 1.823 | FOXO1 | Central corneal thickness |
| rs2755237 | Early or threatened labor; hemorrhage in early pregnancy | 0.01098 | 0.4554 | FOXO1 | Central corneal thickness |
| rs2755237 | pulmonary heart disease | 0.007085 | 1.213 | FOXO1 | Central corneal thickness |
| rs2755237 | Phobia | 0.009051 | 2.165 | FOXO1 | Central corneal thickness |
| rs2755237 | Displacement of intervertebral disc | 0.00365 | 1.233 | FOXO1 | Central corneal thickness |
| rs2755237 | Magnesium metabolism disorder | 0.001465 | 0.5698 | FOXO1 | Central corneal thickness |
| rs2807278 | Other specified erythematous conditions | 0.0002548 | 0.6363 | ARG1 | Waist hip ratio |
| rs2807278 | Congenital anomalies of the eye | 0.002509 | 0.7526 | ARG1 | Waist hip ratio |
| rs2807278 | Cancer of connective tissue | 0.006076 | 0.5037 | ARG1 | Waist hip ratio |
| rs2807278 | Parkinson's disease | 0.009717 | 0.7497 | ARG1 | Waist hip ratio |
| rs2807278 | Ulceration of intestine | 0.008528 | 0.5347 | ARG1 | Waist hip ratio |
| rs2807278 | Blister | 0.006632 | 1.823 | ARG1 | Waist hip ratio |
| rs2807278 | Hematuria | 0.003174 | 0.8737 | ARG1 | Waist hip ratio |
| rs2807278 | Sleep related movement disorders | 0.01041 | 1.246 | ARG1 | Waist hip ratio |
| rs2807278 | Ulceration of the lower GI tract | 0.003828 | 0.5426 | ARG1 | Waist hip ratio |
| rs2807278 | Coagulation defects | 0.01047 | 0.901 | ARG1 | Waist hip ratio |
| rs2807278 | Chronic glomerulonephritis | 0.006783 | 2.142 | ARG1 | Waist hip ratio |
| rs2807278 | Postnasal drip | 0.005053 | 1.811 | ARG1 | Waist hip ratio |
| rs2807278 | Myeloproliferative disease | 0.009572 | 1.358 | ARG1 | Waist hip ratio |
| rs2823455 | Disorders of cervical region | 0.00714 | 0.5407 | USP25 | Panic disorder |
| rs2823455 | Acute bronchitis and bronchiolitis | 0.01126 | 0.8268 | USP25 | Panic disorder |
| rs2823455 | Acquired foot deformities | 0.0003448 | 0.7629 | USP25 | Panic disorder |
| rs2823455 | Hallux valgus (Bunion) | 0.002631 | 0.7077 | USP25 | Panic disorder |
| rs2823455 | Other disorders of bone and cartilage | 0.003203 | 0.6597 | USP25 | Panic disorder |
| rs2823455 | Macular degeneration, dry | 0.004979 | 0.6771 | USP25 | Panic disorder |
| rs2823455 | Acquired toe deformities | 0.0002232 | 0.6673 | USP25 | Panic disorder |
| rs2823455 | Sensorineural hearing loss | 0.003169 | 0.8264 | USP25 | Panic disorder |
| rs2823455 | Gouty arthropathy | 0.0108 | 1.45 | USP25 | Panic disorder |
| rs2823455 | Other disorders of tympanic membrane | 0.01123 | 1.624 | USP25 | Panic disorder |
| rs2823455 | Hammer toe | 0.002066 | 0.679 | USP25 | Panic disorder |
| rs2823455 | Atopic or contact dermatitis | 0.00577 | 0.8421 | USP25 | Panic disorder |
| rs2836878 | Sciatica | 0.007254 | 0.8415 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Lyme disease | 0.001768 | 1.653 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Hypercholesterolemia | 0.004137 | 1.134 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.006408 | 0.5278 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Bronchitis | 0.008686 | 0.8683 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Other disorders of back | 0.01032 | 0.8546 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Neoplasm of unspecified nature of digestive system | 0.00583 | 1.445 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.009798 | 0.7281 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Attention deficit hyperactivity disorder | 0.00153 | 1.816 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Respiratory abnormalities | 0.002695 | 0.6938 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Influenza | 0.01022 | 0.724 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Palpitations | 0.008184 | 0.8713 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Dysmenorrhea | 0.01139 | 0.6449 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Glaucoma | 0.005487 | 0.8834 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Mammographic microcalcification | 0.002519 | 0.524 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Spirochetal infection | 0.002991 | 1.6 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Hallux rigidus | 0.005998 | 1.412 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Adverse effects of antirheumatics | 0.002622 | 0.4487 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Disturbances in tooth eruption | 0.00752 | 0.7041 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Paroxysmal supraventricular tachycardia | 0.006037 | 0.7496 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Hemorrhage or hematoma complicating a procedure | 0.002618 | 0.7764 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Asthma with exacerbation | 0.006987 | 0.6854 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Pervasive developmental disorders | 0.01149 | 1.521 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Disorders of tooth development | 0.01131 | 0.7253 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Open-angle glaucoma | 0.005438 | 0.8395 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Other specified diseases of hair and hair follicles | 0.00764 | 0.7238 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2838815 | Abnormal mammogram | 0.002495 | 1.2 | ADARB1 | Pulmonary function |
| rs2838815 | Traumatic arthropathy | 0.005693 | 1.647 | ADARB1 | Pulmonary function |
| rs2838815 | Urinary complications | 0.007715 | 1.461 | ADARB1 | Pulmonary function |
| rs2838815 | Abnormal findings on radiological breast exam | 0.01002 | 1.539 | ADARB1 | Pulmonary function |
| rs2838815 | Contracture of joint | 0.003842 | 1.426 | ADARB1 | Pulmonary function |
| rs2838815 | Hydronephrosis | 0.005028 | 0.7412 | ADARB1 | Pulmonary function |
| rs2839619 | Visual field defects | 0.002464 | 1.304 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Calcaneal spur; Exostosis NOS | 0.01136 | 1.237 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Swelling, mass, or lump in head and neck | 0.01058 | 0.8189 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Personal history of allergy to medicinal agents | 0.002515 | 0.768 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Pallor and flushing | 0.004285 | 0.6869 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Nasal polyps | 0.007441 | 1.323 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Ulcerative colitis | 0.006172 | 1.458 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Disorders of muscle, ligament, and fascia | 0.004664 | 1.164 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Oliguria and anuria | 0.006024 | 2.178 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Fasciitis | 0.002438 | 1.182 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Disorders of function of stomach | 0.003007 | 1.167 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Hemorrhage or hematoma complicating a procedure | 0.002699 | 1.239 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Dyspepsia and disorders of function of stomach | 0.007456 | 1.157 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2853676 | Eye infection, viral | 0.008703 | 0.6729 | TERT | Glioma |
| rs2853676 | Neoplasm of unspecified nature of digestive system | 0.006993 | 0.6425 | TERT | Glioma |
| rs2853676 | Herpes zoster with nervous system complications | 0.004709 | 0.5674 | TERT | Glioma |
| rs2853676 | Balanoposthitis | 0.009542 | 1.661 | TERT | Glioma |
| rs2853676 | Cholelithiasis with acute cholecystitis | 0.003358 | 0.5366 | TERT | Glioma |
| rs2853676 | Fracture of foot | 0.008273 | 0.805 | TERT | Glioma |
| rs2853676 | Dysmetabolic syndrome X | 0.008192 | 1.451 | TERT | Glioma |
| rs2853676 | Altered mental status | 0.009799 | 0.7546 | TERT | Glioma |
| rs2853676 | Costochondritis | 0.002931 | 1.901 | TERT | Glioma |
| rs2853676 | Central/nonobstroctive sleep apnea | 0.008223 | 0.5215 | TERT | Glioma |
| rs2853676 | Paroxysmal ventricular tachycardia | 0.01115 | 0.7582 | TERT | Glioma |
| rs2853676 | Retinal drusen | 0.005417 | 1.262 | TERT | Glioma |
| rs2853676 | Other forms of chronic heart disease | 0.01123 | 0.8241 | TERT | Glioma |
| rs2853676 | Other hypertrophic and atrophic conditions of skin | 0.002504 | 0.8735 | TERT | Glioma |
| rs2853676 | Postmenopausal hormone replacement | 0.007312 | 1.323 | TERT | Glioma |
| rs2853676 | Leukoplakia of oral mucosa | 0.0001572 | 2.28 | TERT | Glioma |
| rs2853676 | Seborrheic keratosis | 1.563e-07 | 0.804 | TERT | Glioma |
| rs2853676 | Cardiac defibrillator in situ | 0.007326 | 0.6502 | TERT | Glioma |
| rs2853676 | Congenital anomalies of intestine | 0.009352 | 0.2911 | TERT | Glioma |
| rs2853676 | Other dermatoses | 0.001125 | 0.887 | TERT | Glioma |
| rs2853676 | Stricture and stenosis of esophagus | 0.005221 | 1.306 | TERT | Glioma |
| rs2857595 | Inflammatory disease of cervix, vagina, and vulva | 0.005928 | 0.8055 | NCR3 | Pulmonary function |
| rs2857595 | Disorders of the autonomic nervous system | 0.002434 | 1.406 | NCR3 | Pulmonary function |
| rs2857595 | Poisoning by antibiotics | 0.005472 | 0.7859 | NCR3 | Pulmonary function |
| rs2857595 | Hyperplasia of prostate | 0.000119 | 0.7836 | NCR3 | Pulmonary function |
| rs2857595 | Thyrotoxicosis | 0.01033 | 1.26 | NCR3 | Pulmonary function |
| rs2857595 | Other specified peripheral vascular diseases | 0.001371 | 2.28 | NCR3 | Pulmonary function |
| rs2857595 | Varicose veins | 0.0002379 | 1.261 | NCR3 | Pulmonary function |
| rs2857595 | Type 1 diabetic retinopathy | 0.0002628 | 1.671 | NCR3 | Pulmonary function |
| rs2857595 | Peripheral autonomic neuropathy | 0.000128 | 1.647 | NCR3 | Pulmonary function |
| rs2857595 | Lymphosarcoma | 0.008797 | 0.1515 | NCR3 | Pulmonary function |
| rs2857595 | Ectropion or entropion | 0.007973 | 1.324 | NCR3 | Pulmonary function |
| rs2857595 | Retinoschisis and retinal cysts | 0.005845 | 2.159 | NCR3 | Pulmonary function |
| rs2857595 | Disorders of the pituitary gland and its hypothalamic control | 0.00862 | 1.407 | NCR3 | Pulmonary function |
| rs2857595 | Other disorders of lipoid metabolism and hyperalimentation | 0.004536 | 1.344 | NCR3 | Pulmonary function |
| rs2857595 | Cardiac shunt/ heart septal defect | 0.002352 | 0.5295 | NCR3 | Pulmonary function |
| rs2857595 | Prostatitis | 0.001212 | 0.6612 | NCR3 | Pulmonary function |
| rs2857595 | Celiac or tropical sprue | 3.342e-05 | 2.451 | NCR3 | Pulmonary function |
| rs2857595 | Lipoprotein disorders | 0.00728 | 1.409 | NCR3 | Pulmonary function |
| rs2857595 | Type 1 diabetes nephropathy | 0.01011 | 1.65 | NCR3 | Pulmonary function |
| rs2857595 | Lack of coordination | 0.001541 | 1.353 | NCR3 | Pulmonary function |
| rs2857595 | Venous embolism & thrombosis | 0.007405 | 1.193 | NCR3 | Pulmonary function |
| rs2857595 | Adverse effects of insulins and antidiabetic agents | 0.003067 | 1.939 | NCR3 | Pulmonary function |
| rs2857595 | Varicose veins of lower extremity | 0.0002174 | 1.275 | NCR3 | Pulmonary function |
| rs2857595 | Bullous dermatoses | 0.002251 | 2.088 | NCR3 | Pulmonary function |
| rs2857595 | Celiac disease | 8.504e-05 | 2.385 | NCR3 | Pulmonary function |
| rs2857595 | Colon cancer | 0.004484 | 0.7333 | NCR3 | Pulmonary function |
| rs2858331 | Type 1 diabetic ketoacidosis | 0.0001121 | 0.572 | HLA-DQA2 | IgE levels |
| rs2858331 | Male genital disorders | 0.003596 | 1.34 | HLA-DQA2 | IgE levels |
| rs2858331 | Toxic erythema | 0.005248 | 0.3908 | HLA-DQA2 | IgE levels |
| rs2858331 | Breast conditions, congenital or relating to hormones | 0.006095 | 1.324 | HLA-DQA2 | IgE levels |
| rs2858331 | Open wound of finger(s) | 0.005865 | 0.8489 | HLA-DQA2 | IgE levels |
| rs2858331 | Benign neoplasm of uterus | 0.01113 | 1.199 | HLA-DQA2 | IgE levels |
| rs2858331 | Hyperpotassemia | 0.009667 | 0.8419 | HLA-DQA2 | IgE levels |
| rs2858331 | Male infertility and abnormal spermatozoa | 0.002949 | 1.8 | HLA-DQA2 | IgE levels |
| rs2858331 | Disturbances of amino-acid transport | 0.01107 | 1.709 | HLA-DQA2 | IgE levels |
| rs2858331 | Diseases of the tongue | 0.003062 | 1.441 | HLA-DQA2 | IgE levels |
| rs2858331 | Other disorders of lipoid metabolism and hyperalimentation | 0.003337 | 0.7581 | HLA-DQA2 | IgE levels |
| rs2858331 | Adverse effects of insulins and antidiabetic agents | 0.003292 | 0.48 | HLA-DQA2 | IgE levels |
| rs2858331 | Sicca syndrome | 0.005764 | 0.6451 | HLA-DQA2 | IgE levels |
| rs2858331 | Type 1 diabetes | 0.001715 | 0.8223 | HLA-DQA2 | IgE levels |
| rs2858331 | Claw toe | 0.005153 | 1.975 | HLA-DQA2 | IgE levels |
| rs2858331 | Occlusion of cerebral arteries, with cerebral infarction | 0.003528 | 0.6268 | HLA-DQA2 | IgE levels |
| rs2858331 | Type 1 diabetes nephropathy | 6.189e-05 | 0.4113 | HLA-DQA2 | IgE levels |
| rs2858331 | Chronic pancreatitis | 0.0008376 | 1.826 | HLA-DQA2 | IgE levels |
| rs2858331 | Deficiency anemias NOS | 0.004491 | 1.428 | HLA-DQA2 | IgE levels |
| rs2858331 | Ventral hernia | 0.001532 | 1.334 | HLA-DQA2 | IgE levels |
| rs2858331 | Infections involving bone | 0.007797 | 0.79 | HLA-DQA2 | IgE levels |
| rs2858331 | Acute laryngitis and tracheitis | 0.009516 | 1.44 | HLA-DQA2 | IgE levels |
| rs2858331 | Substance addiction and disorders | 0.002973 | 0.7483 | HLA-DQA2 | IgE levels |
| rs2858331 | Chronic liver disease and cirrhosis | 0.003031 | 1.249 | HLA-DQA2 | IgE levels |
| rs2858331 | Multiple sclerosis | 0.000626 | 0.5377 | HLA-DQA2 | IgE levels |
| rs2858331 | Fractur of unspecified part of femur | 0.003753 | 0.6733 | HLA-DQA2 | IgE levels |
| rs2858331 | Type 1 diabetic neuropathy | 0.001554 | 0.626 | HLA-DQA2 | IgE levels |
| rs2859631 | Hyposmolality and/or hyponatremia | 0.005685 | 1.672 | WWOX | Radiation response |
| rs2859631 | Vertiginous syndromes and other disorders of vestibular system | 0.01071 | 1.363 | WWOX | Radiation response |
| rs2859631 | Abnormal findings on radiological examination intrathoracic organs | 0.001913 | 1.985 | WWOX | Radiation response |
| rs2859631 | Hemorrhage from gastrointestinal ulcer | 0.0002506 | 3.191 | WWOX | Radiation response |
| rs2859631 | Peripheral or central vertigo | 0.0052 | 1.847 | WWOX | Radiation response |
| rs2859631 | Hydronephrosis | 0.002746 | 2.301 | WWOX | Radiation response |
| rs2859631 | Cystic mastopathy | 0.008417 | 0.5579 | WWOX | Radiation response |
| rs2859631 | Peyronie's disease | 0.00515 | 4.182 | WWOX | Radiation response |
| rs2859631 | Poisoning by psychotropic agents | 0.002337 | 3.844 | WWOX | Radiation response |
| rs2859631 | Glomerulonephritis | 0.01068 | 2.956 | WWOX | Radiation response |
| rs2859631 | Periodontitis (acute or chronic) | 0.0005143 | 2.084 | WWOX | Radiation response |
| rs2859631 | Gingival and periodontal diseases | 0.0001162 | 2.071 | WWOX | Radiation response |
| rs2859631 | Light-headedness and vertigo | 0.009642 | 1.388 | WWOX | Radiation response |
| rs2859631 | Unstable angina (intermediate coronary syndrome) | 0.006083 | 1.689 | WWOX | Radiation response |
| rs2859631 | Peptic ulcer | 0.006426 | 1.668 | WWOX | Radiation response |
| rs2859631 | Sleep apnea | 0.009329 | 1.415 | WWOX | Radiation response |
| rs2859631 | Angina pectoris | 0.0006836 | 1.732 | WWOX | Radiation response |
| rs2859631 | Viral pneumonia | 0.005238 | 4.568 | WWOX | Radiation response |
| rs2859631 | Methicillin resistant Staphylococcus aureus | 0.005388 | 3.771 | WWOX | Radiation response |
| rs2859631 | Chronic periodontitis | 3.855e-05 | 2.493 | WWOX | Radiation response |
| rs2859631 | Skin neoplasm of uncertain behavior | 0.001238 | 1.935 | WWOX | Radiation response |
| rs2859631 | Other disorders of the kidney and ureters | 0.001191 | 1.571 | WWOX | Radiation response |
| rs2859631 | Vascular dementia | 1.127e-06 | 4.531 | WWOX | Radiation response |
| rs286913 | Sleep disorders | 0.01115 | 1.225 | EHF | Response to antipsychotic treatment |
| rs286913 | Poisoning by agents primarily affecting blood constituents | 0.00668 | 2.194 | EHF | Response to antipsychotic treatment |
| rs286913 | Allergies, other | 0.009671 | 1.547 | EHF | Response to antipsychotic treatment |
| rs286913 | Type 1 diabetic peripheral circulatory disorders | 0.006266 | 2.64 | EHF | Response to antipsychotic treatment |
| rs286913 | Appendicitis | 0.005801 | 1.848 | EHF | Response to antipsychotic treatment |
| rs286913 | Althete's foot | 0.001591 | 0.4315 | EHF | Response to antipsychotic treatment |
| rs286913 | Costochondritis | 0.009114 | 2.465 | EHF | Response to antipsychotic treatment |
| rs286913 | Apnea | 0.005771 | 2.68 | EHF | Response to antipsychotic treatment |
| rs286913 | Antihypertensive agents causing adverse effects | 0.006465 | 2.117 | EHF | Response to antipsychotic treatment |
| rs286913 | Diseases of hard tissues of teeth | 0.0112 | 1.405 | EHF | Response to antipsychotic treatment |
| rs286913 | Dental caries | 0.006079 | 1.452 | EHF | Response to antipsychotic treatment |
| rs286913 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.002013 | 3.734 | EHF | Response to antipsychotic treatment |
| rs286913 | Mechanical complication due to other implant and internal device | 0.006715 | 1.701 | EHF | Response to antipsychotic treatment |
| rs286913 | Immune disorders | 0.003965 | 0.4548 | EHF | Response to antipsychotic treatment |
| rs286913 | Chronic venous hypertension | 0.009642 | 2.743 | EHF | Response to antipsychotic treatment |
| rs2870946 | Other headache syndromes | 0.01107 | 1.194 | IL26 | Ulcerative colitis |
| rs2870946 | Hyposmolality and/or hyponatremia | 0.01146 | 1.321 | IL26 | Ulcerative colitis |
| rs2870946 | Disorders of lipoid metabolism | 0.001244 | 1.239 | IL26 | Ulcerative colitis |
| rs2870946 | Psychogenic and somatoform disorders | 0.008005 | 1.508 | IL26 | Ulcerative colitis |
| rs2870946 | Anemia in neoplastic disease | 0.0006841 | 1.966 | IL26 | Ulcerative colitis |
| rs2870946 | Hyperlipidemia | 0.001985 | 1.23 | IL26 | Ulcerative colitis |
| rs2870946 | Obsessive-compulsive disorder | 8.316e-05 | 2.912 | IL26 | Ulcerative colitis |
| rs2870946 | Postmenopausal hormone replacement | 0.00375 | 1.701 | IL26 | Ulcerative colitis |
| rs2870946 | Pathologic fracture of vertebrae | 0.004558 | 1.524 | IL26 | Ulcerative colitis |
| rs2870946 | Hypercholesterolemia | 0.001848 | 1.285 | IL26 | Ulcerative colitis |
| rs2870946 | Intestinal obstruction without mention of hernia | 0.002048 | 1.433 | IL26 | Ulcerative colitis |
| rs2870946 | Nausea and vomiting | 0.0004139 | 1.284 | IL26 | Ulcerative colitis |
| rs2870946 | Osteochondropathies | 0.006603 | 2.453 | IL26 | Ulcerative colitis |
| rs2870946 | Conjunctivitis, noninfectious | 0.007277 | 0.6049 | IL26 | Ulcerative colitis |
| rs2870946 | Congenital anomalies of intestine | 0.009928 | 2.687 | IL26 | Ulcerative colitis |
| rs2870946 | Infestation | 0.009302 | 2.112 | IL26 | Ulcerative colitis |
| rs2870946 | Allergic conjunctivitis | 0.004404 | 0.5335 | IL26 | Ulcerative colitis |
| rs2870946 | Pancytopenia | 0.001637 | 2.159 | IL26 | Ulcerative colitis |
| rs2870946 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.008879 | 1.638 | IL26 | Ulcerative colitis |
| rs2870946 | Gastrointestinal malfunction arising from mental factors | 0.0001116 | 3.523 | IL26 | Ulcerative colitis |
| rs2870946 | Hypopotassemia | 0.003183 | 1.301 | IL26 | Ulcerative colitis |
| rs2870946 | Gastric ulcer | 0.008141 | 1.536 | IL26 | Ulcerative colitis |
| rs2870946 | Electrolyte imbalance | 0.0009436 | 1.256 | IL26 | Ulcerative colitis |
| rs2870946 | Psychogenic disorder | 0.001334 | 1.956 | IL26 | Ulcerative colitis |
| rs2870946 | Disorders of fluid, electrolyte, and acid-base balance | 0.001354 | 1.219 | IL26 | Ulcerative colitis |
| rs2870946 | Paralytic ileus | 0.006043 | 1.649 | IL26 | Ulcerative colitis |
| rs2870946 | Pathologic fracture | 0.01034 | 1.375 | IL26 | Ulcerative colitis |
| rs2870946 | Osteoporosis | 0.01066 | 1.25 | IL26 | Ulcerative colitis |
| rs2870946 | Anomalies of jaw size/symmetry | 0.007764 | 2.687 | IL26 | Ulcerative colitis |
| rs2870946 | Central/nonobstroctive sleep apnea | 0.002273 | 2.308 | IL26 | Ulcerative colitis |
| rs2870946 | Raynaud's syndrome | 0.000973 | 1.721 | IL26 | Ulcerative colitis |
| rs2895811 | Renal failure NOS | 0.007223 | 0.7476 | HHIPL1 | Coronary heart disease |
| rs2895811 | Pruritus and related conditions | 0.00389 | 0.8243 | HHIPL1 | Coronary heart disease |
| rs2895811 | severe protein-calorie malnutrition | 0.009246 | 0.6433 | HHIPL1 | Coronary heart disease |
| rs2895811 | ASCVD | 0.0006843 | 0.6593 | HHIPL1 | Coronary heart disease |
| rs2895811 | Femoral hernia | 0.009216 | 0.5237 | HHIPL1 | Coronary heart disease |
| rs2895811 | Testicular hypofunction | 0.003838 | 1.428 | HHIPL1 | Coronary heart disease |
| rs2895811 | Fracture of radius and ulna | 0.01056 | 1.171 | HHIPL1 | Coronary heart disease |
| rs2895811 | Protein-calorie malnutrition | 0.009594 | 0.8605 | HHIPL1 | Coronary heart disease |
| rs2895811 | Gram negative septicemia | 0.005449 | 1.413 | HHIPL1 | Coronary heart disease |
| rs2895811 | Hereditary and idiopathic peripheral neuropathy | 0.009122 | 0.8734 | HHIPL1 | Coronary heart disease |
| rs2895811 | Hypertensive heart disease | 0.004111 | 0.7337 | HHIPL1 | Coronary heart disease |
| rs2895811 | Elevated C-reactive protein | 0.003362 | 2.048 | HHIPL1 | Coronary heart disease |
| rs2895811 | Other and unspecified disc disorder | 0.003827 | 0.6462 | HHIPL1 | Coronary heart disease |
| rs2895811 | Other forms of chronic heart disease | 0.00306 | 0.8205 | HHIPL1 | Coronary heart disease |
| rs2895811 | Claw toe | 0.0008288 | 0.3742 | HHIPL1 | Coronary heart disease |
| rs2901331 | Secondary thrombocytopenia | 0.003443 | 1.683 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Disturbances of sulphur-bearing amino-acid metabolism | 0.009054 | 1.789 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Disorders of muscle, ligament, and fascia | 0.009687 | 0.8572 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Essential tremor | 0.009373 | 1.295 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Tobacco use disorder | 0.009482 | 1.104 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Gastrointestinal hemorrhage | 0.01059 | 1.106 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Congenital musculoskeletal deformities of spine | 0.011 | 0.6852 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Chronic airway obstruction | 0.01115 | 1.11 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Disturbances of amino-acid transport | 0.003828 | 1.887 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Other congenital anomalies | 0.006507 | 1.771 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Reticulosarcoma | 0.001572 | 1.775 | CNTNAP5 | Response to statin therapy |
| rs29232 | Protein plasma/amino-acid transport and metabolism disorder | 0.001316 | 1.32 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Stricture of artery | 0.001317 | 1.388 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Paraproteinemia | 0.01069 | 1.344 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Essential tremor | 0.002694 | 1.339 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Palpitations | 0.007366 | 1.134 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Plasma protein metabolism disorder | 0.001999 | 1.342 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Second degree AV block | 0.001789 | 1.621 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Other acute and subacute forms of ischemic heart disease | 0.001814 | 2.007 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Dentofacial anomalies, including malocclusion | 0.009204 | 1.506 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Other specified erythematous conditions | 0.00122 | 1.372 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Peripheral vascular disease | 0.006981 | 1.117 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Suppurative and unspecified otitis media | 0.00614 | 0.8511 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Extrapyramidal disease and abnormal movement disorders | 0.004028 | 1.194 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Circumscribed scleroderma | 0.001121 | 1.478 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Other disorders of arteries and arterioles | 0.004179 | 1.275 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Paroxysmal supraventricular tachycardia | 0.003805 | 1.293 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Peripheral arterial disease | 0.00454 | 1.135 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Sleep apnea | 0.004254 | 1.126 | GABBR1 | Nasopharyngeal carcinoma |
| rs2925979 | Graves' disease | 0.01092 | 0.6489 | CMIP | HDL Cholesterol |
| rs2925979 | Chondrocalcinosis | 0.004078 | 0.68 | CMIP | HDL Cholesterol |
| rs2925979 | Plasma protein metabolism disorder | 0.003195 | 0.7192 | CMIP | HDL Cholesterol |
| rs2925979 | Chronic renal failure | 0.005572 | 0.8807 | CMIP | HDL Cholesterol |
| rs2925979 | Umbilical hernia | 0.01132 | 0.7749 | CMIP | HDL Cholesterol |
| rs2925979 | Hypothyroidism | 0.002134 | 0.8853 | CMIP | HDL Cholesterol |
| rs2925979 | Calcium/phosphorus disorders | 0.0003548 | 0.7613 | CMIP | HDL Cholesterol |
| rs2925979 | Protein plasma/amino-acid transport and metabolism disorder | 0.003681 | 0.7471 | CMIP | HDL Cholesterol |
| rs2925979 | Other disorders of the kidney and ureters | 0.002912 | 0.8742 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders of diaphragm | 0.004337 | 0.3921 | CMIP | HDL Cholesterol |
| rs2925979 | Renal failure | 0.004296 | 0.8911 | CMIP | HDL Cholesterol |
| rs2925979 | Gout and other crystal arthropathies | 0.001456 | 0.8341 | CMIP | HDL Cholesterol |
| rs2925979 | Carbuncle and furuncle | 0.009017 | 0.6265 | CMIP | HDL Cholesterol |
| rs2925979 | Paraproteinemia | 0.002154 | 0.651 | CMIP | HDL Cholesterol |
| rs2925979 | Degenerative disease of the spinal cord | 0.008044 | 0.6453 | CMIP | HDL Cholesterol |
| rs2925979 | Hyperparathyroidism | 0.002822 | 0.7101 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders resulting from impaired renal function | 0.0107 | 0.7579 | CMIP | HDL Cholesterol |
| rs2925979 | Early complications of trauma or procedure | 0.01111 | 1.621 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders of mineral metabolism | 0.01099 | 0.8698 | CMIP | HDL Cholesterol |
| rs2925979 | Hemorrhage of rectum and anus | 0.005944 | 0.8154 | CMIP | HDL Cholesterol |
| rs2925979 | Diaphragmatic hernia | 0.009063 | 0.8732 | CMIP | HDL Cholesterol |
| rs2925979 | Gout | 0.007902 | 0.8506 | CMIP | HDL Cholesterol |
| rs2925979 | Dermatophytosis of nail | 0.009571 | 0.8816 | CMIP | HDL Cholesterol |
| rs2925979 | Other local infections of skin and subcutaneous tissue | 0.005208 | 0.8348 | CMIP | HDL Cholesterol |
| rs2925979 | Crystal arthropathies | 0.00178 | 0.6585 | CMIP | HDL Cholesterol |
| rs2925979 | Osteoporosis, osteopenia, & pathological fractures | 0.002245 | 0.8916 | CMIP | HDL Cholesterol |
| rs2925979 | Renal dialysis | 0.01009 | 0.6767 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders of parathyroid gland | 0.005097 | 0.7369 | CMIP | HDL Cholesterol |
| rs2934442 | Hydrocele | 0.01069 | 0.5876 | CGNL1 | Bipolar disorder |
| rs2934442 | Iron metabolism disorder | 0.004874 | 1.941 | CGNL1 | Bipolar disorder |
| rs2934442 | Peritoneal adhesions (postoperative) (postinfection) | 0.004632 | 1.638 | CGNL1 | Bipolar disorder |
| rs2934442 | Disorders of choroid | 0.007143 | 1.348 | CGNL1 | Bipolar disorder |
| rs2934442 | Age-related macular degeneration | 0.003196 | 1.268 | CGNL1 | Bipolar disorder |
| rs2934442 | Anisometropia | 0.00226 | 0.6615 | CGNL1 | Bipolar disorder |
| rs2934442 | Hepatic cancer, primary | 0.007318 | 2.047 | CGNL1 | Bipolar disorder |
| rs2934442 | Other disorders of peritoneum | 0.0111 | 1.458 | CGNL1 | Bipolar disorder |
| rs2934442 | Glaucoma | 0.009283 | 1.134 | CGNL1 | Bipolar disorder |
| rs2934442 | Hemorrhage NOS | 0.00168 | 0.3526 | CGNL1 | Bipolar disorder |
| rs2934442 | Macular degeneration, wet | 0.01041 | 1.373 | CGNL1 | Bipolar disorder |
| rs2934442 | Hidradenitis | 0.004548 | 2.331 | CGNL1 | Bipolar disorder |
| rs2934442 | Ovarian cyst | 0.009072 | 0.7034 | CGNL1 | Bipolar disorder |
| rs2934442 | Disorders of mineral metabolism | 0.001121 | 1.206 | CGNL1 | Bipolar disorder |
| rs2934442 | Disorders of coccyx | 0.001581 | 1.452 | CGNL1 | Bipolar disorder |
| rs2957128 | Fracture of tibia and fibula | 0.009249 | 1.262 | TNFRSF11A | Paget's disease |
| rs2957128 | Morbid obesity | 0.001417 | 1.196 | TNFRSF11A | Paget's disease |
| rs2957128 | Other conditions of the mother complicating pregnancy | 0.001154 | 1.836 | TNFRSF11A | Paget's disease |
| rs2957128 | Elevated prostate specific antigen | 0.003359 | 0.8278 | TNFRSF11A | Paget's disease |
| rs2957128 | severe protein-calorie malnutrition | 0.005022 | 1.574 | TNFRSF11A | Paget's disease |
| rs2957128 | Gestational diabetes | 0.0009648 | 2.673 | TNFRSF11A | Paget's disease |
| rs2957128 | Speech and language disorder | 0.01073 | 0.7175 | TNFRSF11A | Paget's disease |
| rs2957128 | Localized superficial swelling, mass, or lump | 0.00372 | 0.774 | TNFRSF11A | Paget's disease |
| rs2957128 | Acute renal failure | 0.006821 | 1.158 | TNFRSF11A | Paget's disease |
| rs2957128 | Carbohydrate transport and metabolism disorder | 0.007156 | 1.171 | TNFRSF11A | Paget's disease |
| rs2957128 | Chronic pain syndrome | 0.009071 | 1.619 | TNFRSF11A | Paget's disease |
| rs2957128 | Urinary complications | 0.0108 | 1.441 | TNFRSF11A | Paget's disease |
| rs2957128 | Hypercalcemia | 0.007172 | 0.7939 | TNFRSF11A | Paget's disease |
| rs2957128 | Cataract | 0.0007919 | 0.8818 | TNFRSF11A | Paget's disease |
| rs2957128 | Carbuncle and furuncle | 0.00967 | 0.6681 | TNFRSF11A | Paget's disease |
| rs296547 | Cholesteatoma | 0.003811 | 0.5049 | C1orf81 | Celiac disease |
| rs296547 | Poisoning by agents affecting the cardiovascular system | 0.00257 | 1.356 | C1orf81 | Celiac disease |
| rs296547 | Hypercalcemia | 0.002066 | 1.295 | C1orf81 | Celiac disease |
| rs296547 | Secondary malignant neoplasm of digestive systems | 0.0001622 | 1.756 | C1orf81 | Celiac disease |
| rs296547 | Bronchiectasis | 1.797e-05 | 1.671 | C1orf81 | Celiac disease |
| rs296547 | Other cerebral degenerations | 0.005455 | 0.677 | C1orf81 | Celiac disease |
| rs296547 | Muscle weakness | 0.005955 | 0.7525 | C1orf81 | Celiac disease |
| rs296547 | Symptoms involving cardiovascular system | 0.00381 | 0.8479 | C1orf81 | Celiac disease |
| rs296547 | Anaphylactic shock NOS | 0.0004205 | 1.665 | C1orf81 | Celiac disease |
| rs296547 | Stomach cancer | 0.003594 | 1.78 | C1orf81 | Celiac disease |
| rs296547 | Other upper respiratory disease | 0.006939 | 1.157 | C1orf81 | Celiac disease |
| rs296547 | Secondary malignancy of lung | 0.01021 | 1.369 | C1orf81 | Celiac disease |
| rs2979481 | Acute bronchitis and bronchiolitis | 0.002127 | 1.15 | RBPMS | Heart rate training response |
| rs2979481 | Otalgia | 0.005751 | 0.774 | RBPMS | Heart rate training response |
| rs2979481 | Other diseases of the teeth and supporting structures | 0.007702 | 1.248 | RBPMS | Heart rate training response |
| rs2979481 | Stomatitis and mucositis | 0.001684 | 1.46 | RBPMS | Heart rate training response |
| rs2979481 | Hx of malignant neoplasm of oral cavity and pharynx | 0.007572 | 1.623 | RBPMS | Heart rate training response |
| rs2979481 | Anomalies of pupillary function | 0.009711 | 1.823 | RBPMS | Heart rate training response |
| rs2979481 | Loss of teeth or edentulism | 0.002593 | 1.419 | RBPMS | Heart rate training response |
| rs2979481 | Disorders of conjunctiva | 0.002353 | 1.281 | RBPMS | Heart rate training response |
| rs2979481 | Hemorrhage NOS | 0.008302 | 0.5562 | RBPMS | Heart rate training response |
| rs2979481 | Cervical radiculitis | 0.004181 | 1.193 | RBPMS | Heart rate training response |
| rs2979481 | Diplopia and disorders of binocular vision | 0.007839 | 1.289 | RBPMS | Heart rate training response |
| rs2979481 | Cystic kidney disease | 0.008565 | 1.546 | RBPMS | Heart rate training response |
| rs2979481 | Oral aphthae | 0.002823 | 1.718 | RBPMS | Heart rate training response |
| rs2979481 | Delirium due to conditions classified elsewhere | 0.003574 | 1.414 | RBPMS | Heart rate training response |
| rs3016539 | Chronic kidney disease, Stage I or II | 0.003735 | 1.595 | PARK2 | Pancreatic cancer |
| rs3016539 | Palpitations | 0.007825 | 1.217 | PARK2 | Pancreatic cancer |
| rs3016539 | Irregular menstrual bleeding | 0.005518 | 0.252 | PARK2 | Pancreatic cancer |
| rs3016539 | Bundle branch block | 0.009845 | 1.316 | PARK2 | Pancreatic cancer |
| rs3016539 | Abnormal electrocardiogram | 0.006962 | 1.245 | PARK2 | Pancreatic cancer |
| rs3016539 | Stomach cancer | 0.004952 | 2.03 | PARK2 | Pancreatic cancer |
| rs3016539 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.006819 | 0.6143 | PARK2 | Pancreatic cancer |
| rs3016539 | Impaired fasting glucose | 0.008017 | 1.278 | PARK2 | Pancreatic cancer |
| rs3016539 | Acquired spondylolisthesis | 0.002936 | 1.501 | PARK2 | Pancreatic cancer |
| rs3016539 | Postlaminectomy syndrome | 0.002182 | 1.662 | PARK2 | Pancreatic cancer |
| rs3016539 | Alcoholism | 0.008446 | 1.34 | PARK2 | Pancreatic cancer |
| rs3016539 | Hepatic cancer, primary | 0.008311 | 2.294 | PARK2 | Pancreatic cancer |
| rs3016539 | Alcohol-related disorders | 0.007649 | 1.301 | PARK2 | Pancreatic cancer |
| rs3027409 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.002379 | 2.956 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Glaucoma | 0.001568 | 1.396 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Bursitis | 0.004379 | 1.586 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Cardiac arrest | 0.009138 | 2.524 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Dysmenorrhea | 0.0008892 | 3.031 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Irregular menstrual cycle | 0.002813 | 2.095 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Poisoning by agents primarily affecting blood constituents | 0.0105 | 2.426 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Nerve plexus lesions | 0.00898 | 1.985 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Adverse effects of antibacterials (not penicillins) | 0.0003913 | 3.468 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Eating disorder | 0.004345 | 2.576 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Cyst and pseudocyst of pancreas | 0.001672 | 2.787 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Irregular menstrual cycle/bleeding | 0.008991 | 1.542 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Abnormal findings on mammogram or breast exam | 0.002595 | 1.354 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Open-angle glaucoma | 0.001803 | 1.543 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Other acute and subacute forms of ischemic heart disease | 5.536e-05 | 4.716 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Leukoplakia of oral mucosa | 0.002722 | 3.198 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3099950 | Congenital musculoskeletal anomalies | 0.009246 | 2.329 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Polymyalgia Rheumatica | 0.004648 | 1.39 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Other infectious diseases | 0.006946 | 1.917 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Muscular wasting and disuse atrophy | 0.005731 | 0.3158 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Other congenital anomalies of skin | 0.00443 | 1.619 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Other abnormality of urination | 0.009785 | 1.28 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Acute appendicitis | 0.001742 | 1.754 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Appendicitis | 0.001633 | 1.644 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Rheumatoid arthritis | 0.001623 | 1.364 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Cancer of other male genital organs | 0.008376 | 0.1516 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Corneal edema | 0.007623 | 1.807 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Appendiceal conditions | 0.0005632 | 1.693 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Fracture of hand or wrist | 0.01014 | 1.232 | MORN2 | Amyotrophic lateral sclerosis |
| rs3129882 | Celiac disease | 0.007223 | 0.5323 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Obstructive chronic bronchitis | 0.005899 | 0.8213 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Pernicious anemia | 0.00095 | 1.583 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Diabetic retinopathy | 0.002614 | 0.8199 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Rheumatoid arthritis & related inflammatory polyarthropathies | 6.048e-07 | 0.7126 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Respiratory abnormalities | 0.007821 | 0.7578 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic retinopathy | 0.001645 | 0.6555 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Peripheral autonomic neuropathy | 0.001604 | 0.6763 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Celiac or tropical sprue | 0.00546 | 0.5271 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Rheumatoid arthritis | 2.796e-06 | 0.6987 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 2 diabetes | 0.00283 | 0.9105 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Breast conditions, congenital or relating to hormones | 0.00478 | 1.336 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Non-Hodgkins lymphoma | 0.01066 | 0.7878 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Cancer of other lymphoid, histiocytic tissue | 0.009819 | 0.79 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Diabetes mellitus | 0.00321 | 0.9128 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Disorders of the autonomic nervous system | 0.00036 | 0.6931 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic neuropathy | 2.876e-05 | 0.5453 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Secondary/extrinsic cardiomyopathies | 0.006969 | 0.5352 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetes nephropathy | 0.000184 | 0.4721 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Insulin pump user | 0.002551 | 0.774 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetes | 3.836e-06 | 0.751 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Diseases of respiratory system | 0.00146 | 0.8353 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 2 diabetic retinopathy | 0.009657 | 0.838 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Hypoglycemia | 0.0003534 | 0.5849 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Rosacea | 0.004203 | 1.198 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic peripheral circulatory disorders | 0.006086 | 0.4722 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic ketoacidosis | 1.91e-06 | 0.5052 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 2 diabetic ketoacidosis | 0.000201 | 0.8372 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Cancer of bone & connective tissue | 0.009467 | 1.434 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Hypertrophy of breast (Gynecomastia) | 0.006619 | 1.357 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Cancer of connective tissue | 0.005126 | 1.661 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Pericarditis | 0.001954 | 0.6798 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Pneumonia | 0.007601 | 0.904 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Vascular insufficiency of intestine | 0.001303 | 0.6526 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Liver replaced by transplant | 0.005138 | 0.4105 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Symptoms involving respiratory system | 0.004677 | 0.8194 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Asthma | 0.004009 | 0.883 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Paraproteinemia | 0.01147 | 0.737 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Lack of coordination | 0.002721 | 0.779 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3130573 | Uterine leiomyoma | 0.01029 | 0.8147 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Psoriasis & related disorders | 0.0002078 | 1.333 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Prostate cancer | 0.0009955 | 0.8032 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Hydronephrosis | 0.007125 | 1.327 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Acidosis | 0.007753 | 1.367 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Bullous dermatoses | 0.001419 | 2.033 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Acid-base balance disorder | 0.01034 | 1.293 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Psoriasis | 2.516e-05 | 1.41 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Renal failure NOS | 0.007062 | 1.328 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Chronic bronchitis | 0.01123 | 0.8408 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Ovarian cancer | 0.005584 | 1.554 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.001916 | 1.717 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Benign neoplasm of uterus | 0.009044 | 0.624 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Graves' disease | 0.00818 | 1.454 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Stricture/obstruction of ureter | 0.0007004 | 1.62 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Prostatitis | 0.005541 | 0.7544 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Other disorders of intestine | 0.003221 | 1.21 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Benign neoplasm of uterus | 0.009113 | 0.8215 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Memory loss | 0.00116 | 0.7598 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Inflammatory diseases of prostate | 0.007808 | 0.801 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Cancer of other female genital organs | 0.002065 | 1.529 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Acute prostatitis | 0.002817 | 0.5259 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Gastroparesis | 0.006909 | 0.5363 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Neoplasm of uncertain behavior | 0.00584 | 1.193 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Psoriasis vulgaris | 3.463e-05 | 1.414 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Sarcoidosis | 0.002197 | 1.702 | PSORS1C1 | Systemic sclerosis |
| rs3131296 | Prostatitis | 0.002896 | 0.6407 | NOTCH4 | Schizophrenia |
| rs3131296 | Diseases of sebaceous glands | 0.01049 | 0.8676 | NOTCH4 | Schizophrenia |
| rs3131296 | Varicose veins | 0.006375 | 1.219 | NOTCH4 | Schizophrenia |
| rs3131296 | Testicular hypofunction | 0.008602 | 1.511 | NOTCH4 | Schizophrenia |
| rs3131296 | Immune disorders | 0.004789 | 1.364 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetes nephropathy | 0.0001135 | 2.184 | NOTCH4 | Schizophrenia |
| rs3131296 | Testicular dysfunction | 0.004899 | 1.538 | NOTCH4 | Schizophrenia |
| rs3131296 | Rosacea | 0.0004692 | 0.6984 | NOTCH4 | Schizophrenia |
| rs3131296 | Peripheral angiopathy in diseases classified elsewhere | 0.0106 | 1.733 | NOTCH4 | Schizophrenia |
| rs3131296 | Other hereditary hemolytic anemias | 0.007103 | 2.351 | NOTCH4 | Schizophrenia |
| rs3131296 | Benign neoplasm of brain and other parts of nervous system | 0.008106 | 0.5538 | NOTCH4 | Schizophrenia |
| rs3131296 | Hyperlipidemia | 0.001415 | 0.8618 | NOTCH4 | Schizophrenia |
| rs3131296 | Hypoglycemia | 0.002659 | 1.661 | NOTCH4 | Schizophrenia |
| rs3131296 | Other specified peripheral vascular diseases | 0.001256 | 2.449 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetic neuropathy | 1.605e-05 | 1.952 | NOTCH4 | Schizophrenia |
| rs3131296 | Benign mammary dysplasias | 0.005418 | 0.8037 | NOTCH4 | Schizophrenia |
| rs3131296 | Adrenal hypofunction | 0.006614 | 1.781 | NOTCH4 | Schizophrenia |
| rs3131296 | Congenital anomalies of intestine | 0.00175 | 2.657 | NOTCH4 | Schizophrenia |
| rs3131296 | Hypercholesterolemia | 0.00214 | 0.8371 | NOTCH4 | Schizophrenia |
| rs3131296 | Posttraumatic wound infection | 0.01142 | 1.877 | NOTCH4 | Schizophrenia |
| rs3131296 | Disorders of the autonomic nervous system | 0.001969 | 1.471 | NOTCH4 | Schizophrenia |
| rs3131296 | Adverse effects of insulins and antidiabetic agents | 0.0001046 | 2.545 | NOTCH4 | Schizophrenia |
| rs3131296 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.005083 | 1.421 | NOTCH4 | Schizophrenia |
| rs3131296 | Diabetic retinopathy | 0.002288 | 1.302 | NOTCH4 | Schizophrenia |
| rs3131296 | Discoid lupus erythematosus | 0.0004842 | 1.767 | NOTCH4 | Schizophrenia |
| rs3131296 | Stricture and stenosis of esophagus | 0.006982 | 0.6791 | NOTCH4 | Schizophrenia |
| rs3131296 | Sarcoidosis | 0.005101 | 1.805 | NOTCH4 | Schizophrenia |
| rs3131296 | Vascular insufficiency of intestine | 0.004101 | 1.571 | NOTCH4 | Schizophrenia |
| rs3131296 | Systemic lupus erythematosus | 0.005399 | 1.642 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetic retinopathy | 0.0002125 | 1.764 | NOTCH4 | Schizophrenia |
| rs3131296 | Abnormal mammogram | 0.01131 | 0.7974 | NOTCH4 | Schizophrenia |
| rs3131296 | Aplastic anemia | 0.01038 | 1.437 | NOTCH4 | Schizophrenia |
| rs3131296 | Cyst of kidney, acquired | 0.001231 | 1.484 | NOTCH4 | Schizophrenia |
| rs3131296 | Multiple sclerosis | 0.01121 | 1.623 | NOTCH4 | Schizophrenia |
| rs3131296 | Celiac disease | 3.647e-07 | 3.185 | NOTCH4 | Schizophrenia |
| rs3131296 | Lupus erythematosus | 0.0005329 | 2.405 | NOTCH4 | Schizophrenia |
| rs3131296 | Bullous dermatoses | 0.001939 | 2.266 | NOTCH4 | Schizophrenia |
| rs3131296 | Peripheral autonomic neuropathy | 0.0002516 | 1.694 | NOTCH4 | Schizophrenia |
| rs3131296 | Celiac or tropical sprue | 7.517e-08 | 3.309 | NOTCH4 | Schizophrenia |
| rs3131296 | Abnormal weight gain | 0.00252 | 0.5711 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetic peripheral circulatory disorders | 0.001351 | 2.351 | NOTCH4 | Schizophrenia |
| rs3131296 | Anterior pituitary disorders | 0.006487 | 1.831 | NOTCH4 | Schizophrenia |
| rs3131296 | Cystic mastopathy | 0.004662 | 0.7932 | NOTCH4 | Schizophrenia |
| rs3131296 | Disorders of lipoid metabolism | 0.001294 | 0.8617 | NOTCH4 | Schizophrenia |
| rs3131296 | Poisoning by hormones and synthetic substitutes | 0.006505 | 1.502 | NOTCH4 | Schizophrenia |
| rs3131296 | Complication of amputation stump | 0.001337 | 2.258 | NOTCH4 | Schizophrenia |
| rs3131296 | Hematuria | 0.002582 | 0.8369 | NOTCH4 | Schizophrenia |
| rs3184504 | Other disorders of gallbladder | 0.001266 | 0.5683 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Hypertension | 0.01107 | 1.078 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Retinoschisis and retinal cysts | 0.003572 | 2.251 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Benign neoplasm of uterus | 0.001902 | 0.802 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Anal and rectal polyp | 0.01057 | 0.8123 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Endometriosis | 0.002769 | 0.7068 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Paranoid disorders | 0.01142 | 1.773 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Dentofacial anomalies, including malocclusion | 0.01059 | 0.6601 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Acute bronchospasm | 0.009458 | 0.4545 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Morbid obesity | 0.008289 | 0.862 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Osteoporosis | 0.006226 | 1.132 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis | 0.001489 | 1.145 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.001846 | 1.204 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Phlebitis and thrombophlebitis of lower extremities | 0.0111 | 1.222 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis of the extremities | 0.002085 | 1.16 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Empyema and pneumothorax | 0.009123 | 1.284 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Anomalies of tooth position/malocclusion | 0.004609 | 0.5834 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Other rheumatic heart disease | 0.005213 | 2.073 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Uterine leiomyoma | 0.006447 | 0.8148 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Arterial embolism and thrombosis | 0.00126 | 1.292 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Ischemic Heart Disease | 0.007575 | 1.084 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Abnormal findings on mammogram or breast exam | 0.007769 | 1.119 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Mastodynia | 0.00819 | 1.264 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Coronary atherosclerosis | 0.006473 | 1.091 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Myocardial infarction | 0.0004043 | 1.171 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Hypothyroidism | 7.655e-06 | 1.174 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Osteoporosis, NOS or other | 0.005418 | 1.13 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Cancer of the upper aerodigestive tract | 0.006314 | 0.7217 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.003074 | 1.264 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Peripheral vascular disease | 0.008122 | 1.113 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Essential hypertension | 0.009907 | 1.08 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Other congenital anomalies of skin | 0.006306 | 1.439 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Arterial embolism and thrombosis of lower extremity artery | 0.007384 | 1.342 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Peyronie's disease | 0.01067 | 1.784 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Aortic aneurysm | 0.008784 | 1.195 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.00686 | 1.296 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Open wound of finger(s) | 0.008962 | 0.8594 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Ventricular fibrillation & flutter | 0.01004 | 0.6286 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Peripheral arterial disease | 0.004773 | 1.132 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Abdominal aortic aneurysm | 0.01139 | 1.22 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs337847 | Hereditary and idiopathic peripheral neuropathy | 0.003629 | 1.27 | ARSB | Hippocampal atrophy |
| rs337847 | Cyst or abscess of Bartholin's gland | 0.001457 | 2.635 | ARSB | Hippocampal atrophy |
| rs337847 | Cellulitis and abscess of trunk | 0.006405 | 1.464 | ARSB | Hippocampal atrophy |
| rs337847 | Esophageal cancer | 0.01091 | 2.002 | ARSB | Hippocampal atrophy |
| rs337847 | Thyroid cancer | 0.01119 | 1.698 | ARSB | Hippocampal atrophy |
| rs337847 | Aplastic anemia | 0.007494 | 1.544 | ARSB | Hippocampal atrophy |
| rs337847 | Psychogenic disorder | 0.0009769 | 1.862 | ARSB | Hippocampal atrophy |
| rs337847 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.001299 | 2.217 | ARSB | Hippocampal atrophy |
| rs337847 | Circumscribed scleroderma | 0.006207 | 0.427 | ARSB | Hippocampal atrophy |
| rs337847 | Inguinal hernia | 0.002576 | 0.7438 | ARSB | Hippocampal atrophy |
| rs337847 | Lipoid metabolism disorder NOS | 0.005597 | 1.535 | ARSB | Hippocampal atrophy |
| rs337847 | Hyperventilation | 0.001574 | 2.195 | ARSB | Hippocampal atrophy |
| rs363512 | Pneumonitis due to inhalation of food or vomitus | 0.006951 | 1.614 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Disorders resulting from impaired renal function | 0.003628 | 1.586 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Pernicious anemia | 0.007887 | 1.765 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Fracture of humerus | 0.0021 | 1.547 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Symptoms involving urinary system | 0.002759 | 1.558 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Vascular dementia | 0.002348 | 1.824 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Empyema and pneumothorax | 0.00719 | 1.55 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Lupus erythematosus | 0.009867 | 2.334 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Spondylosis and allied disorders | 0.009657 | 0.8172 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Macular degeneration, dry | 0.007688 | 1.483 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Vitamin B12 deficiency anemia | 0.01114 | 1.838 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.008747 | 2.765 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Abnormal thyroid function | 0.008638 | 1.511 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Mental disorders due to brain damage | 0.00689 | 1.456 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Other pulmonary inflamation or edema | 0.003437 | 1.644 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Secondary hyperparathyroidism (of renal origin) | 0.005469 | 1.679 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Acute, but ill-defined cerebrovascular disease | 0.01007 | 1.344 | GRIK1 | Hyperactive-impulsive symptoms |
| rs368331 | Diaphragmatic hernia | 0.007445 | 1.263 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Upper gastrointestinal congenital anomalies | 0.00134 | 2.209 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Torsion dystonia | 0.004619 | 2.076 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Macular degeneration | 0.00646 | 1.282 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Mechanical complication of nervous system device, implant, and graft | 0.006324 | 2.599 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Esophageal atresia/tracheoesophageal fistula | 0.008269 | 2.186 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Labyrinthitis | 0.004109 | 0.3727 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Substance addiction and disorders | 0.01029 | 0.5447 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Glaucoma | 0.0003801 | 1.326 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Other conditions of the mother complicating pregnancy | 0.006307 | 2.319 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Poisoning by agents primarily affecting blood constituents | 0.007023 | 2 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Open-angle glaucoma | 0.004812 | 1.358 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Digestive congenital anomalies | 0.00299 | 1.866 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs3736228 | Stricture and stenosis of esophagus | 0.002798 | 1.417 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Fracture of humerus | 0.007888 | 1.335 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Type 2 diabetic peripheral circulatory disorders | 0.01111 | 1.453 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Carbohydrate transport and metabolism disorder | 0.001623 | 0.7427 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Benign mammary dysplasias | 0.003014 | 1.255 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Subdural hemorrhage | 0.00344 | 1.784 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Skin neoplasm of uncertain behavior | 0.00474 | 1.286 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Raynaud's syndrome | 0.01121 | 1.39 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Disaccharide malabsorption | 0.001194 | 0.7337 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Glycosuria or Acetonuria | 0.0005421 | 2.939 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Leukoplakia of oral mucosa | 0.0075 | 1.962 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Congenital cataract and lens anomalies | 0.0009981 | 2.439 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Type 1 diabetic retinopathy | 0.00704 | 1.535 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Congenital anomalies of the eye | 0.006579 | 1.329 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Cystic mastopathy | 0.002402 | 1.273 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Other conditions of brain | 0.0007325 | 1.531 | LRP5 | Bone mineral density (lumbar spine) |
| rs3743200 | Claw toe | 0.004232 | 2.072 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Persistent mental disorders due to other conditions | 0.001186 | 0.8116 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Neurological disorders due to brain damage | 0.0008965 | 0.8326 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Periodontitis (acute or chronic) | 0.009941 | 0.7945 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Intracerebral hemorrhage | 0.003571 | 0.4895 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Early complications of trauma or procedure | 0.0005802 | 0.3608 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Type 2 diabetic ketoacidosis | 0.002405 | 0.8442 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Aphasia/speech disturbance | 0.001378 | 0.7424 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Benign neoplasm of eye | 0.005564 | 1.277 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Jaw disease NOS | 0.005098 | 0.5611 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Menopausal & postmenopausal disorders | 0.0112 | 1.141 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Dentofacial anomalies, including malocclusion | 0.005454 | 0.5498 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Gingival and periodontal diseases | 0.0008792 | 0.7685 | RASGRF1 | RR interval (heart rate) |
| rs3744064 | Type 2 diabetic retinopathy | 5.223e-05 | 1.946 | SEC14L1 | Cognitive performance |
| rs3744064 | Type 2 diabetic nephropathy | 0.00562 | 1.671 | SEC14L1 | Cognitive performance |
| rs3744064 | Femoral hernia | 0.009101 | 3.061 | SEC14L1 | Cognitive performance |
| rs3744064 | Type 2 diabetic ketoacidosis | 0.0006928 | 1.541 | SEC14L1 | Cognitive performance |
| rs3744064 | Other local infections of skin and subcutaneous tissue | 0.001983 | 0.4989 | SEC14L1 | Cognitive performance |
| rs3744064 | Disorders of refraction and accommodation | 0.006386 | 0.7449 | SEC14L1 | Cognitive performance |
| rs3744064 | Type 2 diabetes | 0.002695 | 1.309 | SEC14L1 | Cognitive performance |
| rs3744064 | Diabetic retinopathy | 0.0003262 | 1.786 | SEC14L1 | Cognitive performance |
| rs3744064 | Diabetes mellitus | 0.00391 | 1.292 | SEC14L1 | Cognitive performance |
| rs3744064 | Hypermetropia | 0.001894 | 0.6367 | SEC14L1 | Cognitive performance |
| rs3744064 | Benign neoplasm of lip, oral cavity, and pharynx | 0.008214 | 2.408 | SEC14L1 | Cognitive performance |
| rs3744064 | Primary open angle glaucoma | 0.000415 | 2.017 | SEC14L1 | Cognitive performance |
| rs3744064 | Primary angle-closure glaucoma | 0.0008337 | 1.994 | SEC14L1 | Cognitive performance |
| rs3744064 | Disorders of the globe | 0.0005863 | 2.724 | SEC14L1 | Cognitive performance |
| rs3744064 | Retinal edema and hypertensive retinopathy | 2.029e-05 | 2.576 | SEC14L1 | Cognitive performance |
| rs3745516 | Sacroiliitis NEC | 0.0097 | 1.77 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Type 2 diabetic nephropathy | 0.0003054 | 1.331 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Type 1 diabetes | 0.008952 | 1.195 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Polyneuropathy in diabetes | 0.003006 | 1.242 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Derangement of joint, non-traumatic | 0.002179 | 1.319 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Deficiency of humoral immunity | 0.002976 | 2.22 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Type 2 diabetic neuropathy | 0.004478 | 1.212 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Occlusion and stenosis of precerebral arteries | 0.006509 | 1.157 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Other disorders of urethra and urinary tract | 0.007355 | 0.7877 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Nephritis and nephropathy without mention of glomerulonephritis | 0.005512 | 1.292 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Nephritis and nephropathy in diseases classified elsewhere | 0.001012 | 1.392 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Cardiac complications, not elsewhere classified | 0.0062 | 1.426 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Respiratory failure | 0.003866 | 1.321 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Antisocial/borderline personality disorder | 0.005609 | 0.488 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Open wound of lip and mouth | 0.007484 | 1.779 | SPIB | Primary biliary cirrhosis |
| rs3757840 | Delirium due to conditions classified elsewhere | 0.005482 | 1.387 | GCK | Glucose |
| rs3757840 | Alopecia Areata | 0.007736 | 0.4811 | GCK | Glucose |
| rs3757840 | Alopecia | 0.00705 | 0.759 | GCK | Glucose |
| rs3757840 | Other cells and casts in urine | 0.009316 | 1.407 | GCK | Glucose |
| rs3757840 | Ingrowing nail | 0.003697 | 0.8526 | GCK | Glucose |
| rs3757840 | Other abnormal glucose | 0.003763 | 0.8683 | GCK | Glucose |
| rs3757840 | Polymyalgia Rheumatica | 0.0009764 | 1.341 | GCK | Glucose |
| rs3757840 | Angina pectoris | 0.0008328 | 0.8577 | GCK | Glucose |
| rs3757840 | Rheumatoid arthritis | 0.0109 | 0.8283 | GCK | Glucose |
| rs3757840 | Ulcer of esophagus | 0.005914 | 0.6959 | GCK | Glucose |
| rs3757840 | Malignant neoplasm, other | 0.01046 | 1.216 | GCK | Glucose |
| rs3757840 | Anterior pituitary disorders | 0.01139 | 0.6145 | GCK | Glucose |
| rs3757840 | Morbid obesity | 0.0113 | 1.152 | GCK | Glucose |
| rs3761847 | Infections involving bone | 0.01132 | 1.24 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Congenital anomalies of great vessels | 0.006914 | 0.4729 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Malunion fracture | 0.0006047 | 0.6185 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Unspecified osteomyelitis | 0.01032 | 1.306 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Disorders of esophageal motility | 0.003891 | 0.6425 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Infestation | 0.01061 | 0.5874 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Acquired toe deformities | 0.008111 | 1.167 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Toxic effect of venom | 0.0004227 | 0.5572 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Hammer toe | 0.008102 | 1.194 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Right bundle branch block | 0.002508 | 1.321 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.01113 | 1.182 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Testicular hypofunction | 0.007693 | 1.385 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Diseases of the tongue | 0.004787 | 0.6906 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Muscular dystrophies and other myopathies | 0.003807 | 1.49 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Hallux valgus (Bunion) | 0.005208 | 1.195 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Acquired foot deformities | 0.01015 | 1.116 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Bundle branch block | 0.005257 | 1.208 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Fracture of clavicle or scapula | 0.002317 | 0.6691 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Occlusion and stenosis of precerebral arteries | 0.004511 | 1.141 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Testicular dysfunction | 0.00433 | 1.407 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Chronic ischemic heart disease | 0.006746 | 1.141 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Cerebrovascular disease | 0.005419 | 1.098 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Althete's foot | 0.009179 | 1.245 | TRAF1 | Rheumatoid arthritis |
| rs3761959 | Chronic pancreatitis | 0.01085 | 0.6098 | FCRL3 | Graves' disease |
| rs3761959 | Hypermetropia | 0.003339 | 1.149 | FCRL3 | Graves' disease |
| rs3761959 | Agorophobia, social phobia, and panic disorder | 0.001323 | 0.6751 | FCRL3 | Graves' disease |
| rs3761959 | Tension headache | 0.001752 | 0.7829 | FCRL3 | Graves' disease |
| rs3761959 | Costochondritis | 0.001246 | 0.4617 | FCRL3 | Graves' disease |
| rs3761959 | Urethral stricture (not specified as infectious) | 0.002242 | 0.6605 | FCRL3 | Graves' disease |
| rs3761959 | Disorders of coccyx | 0.008632 | 0.7569 | FCRL3 | Graves' disease |
| rs3761959 | Astigmatism | 0.005498 | 1.135 | FCRL3 | Graves' disease |
| rs3761959 | Other disorders of adrenal glands | 0.005641 | 0.6394 | FCRL3 | Graves' disease |
| rs3761959 | Otitis externa | 0.006037 | 1.191 | FCRL3 | Graves' disease |
| rs3761959 | Inflammatory spondylopathies | 0.01022 | 1.474 | FCRL3 | Graves' disease |
| rs3761959 | Hypothyroidism | 0.01017 | 1.097 | FCRL3 | Graves' disease |
| rs3761959 | Disturbance of skin sensation | 0.01093 | 0.8966 | FCRL3 | Graves' disease |
| rs3761959 | Psychogenic and somatoform disorders | 0.001332 | 0.7507 | FCRL3 | Graves' disease |
| rs3761959 | Abnormal mammogram | 0.003495 | 0.8366 | FCRL3 | Graves' disease |
| rs3764640 | Urethritis and urethral syndrome | 0.007621 | 1.76 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Patellar fracture | 0.002757 | 1.512 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Nontoxic multinodular goiter | 0.01003 | 0.7583 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Anemia NOS | 0.01106 | 0.9043 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Other open wound of head and face | 0.004161 | 1.259 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.004973 | 1.272 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Immune disorders | 0.003596 | 1.315 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Glycosuria or Acetonuria | 0.01013 | 2.099 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Plasma protein metabolism disorder | 0.009357 | 1.318 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Viral hepatitis C | 0.009671 | 1.512 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Cardiac shunt/ heart septal defect | 0.002197 | 0.5468 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Sialoadenitis | 0.003489 | 0.5475 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Fracture of lower limb | 0.005029 | 1.177 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Electrolyte imbalance | 0.007636 | 1.117 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Abnormal reflex | 0.01139 | 2.049 | STK11 | Alzheimer's disease with psychosis |
| rs3780792 | Back & neck sprains | 0.008225 | 0.8883 | VAV2 | Multiple sclerosis |
| rs3780792 | Abnormal chest sounds | 0.002103 | 0.6264 | VAV2 | Multiple sclerosis |
| rs3780792 | Ischemic stroke | 0.01135 | 1.187 | VAV2 | Multiple sclerosis |
| rs3780792 | Bacteremia | 0.008251 | 0.7594 | VAV2 | Multiple sclerosis |
| rs3780792 | Disorders resulting from impaired renal function | 0.0034 | 1.326 | VAV2 | Multiple sclerosis |
| rs3780792 | Anal and rectal polyp | 0.009709 | 1.236 | VAV2 | Multiple sclerosis |
| rs3780792 | Cramp of limb | 0.01038 | 1.291 | VAV2 | Multiple sclerosis |
| rs3780792 | Hematuria | 0.008725 | 1.115 | VAV2 | Multiple sclerosis |
| rs3780792 | Type 1 diabetic retinopathy | 0.007643 | 1.403 | VAV2 | Multiple sclerosis |
| rs3780792 | Edema | 0.005375 | 0.8987 | VAV2 | Multiple sclerosis |
| rs3780792 | Chronic pain syndrome | 0.004839 | 1.665 | VAV2 | Multiple sclerosis |
| rs3780792 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.01064 | 1.588 | VAV2 | Multiple sclerosis |
| rs3782181 | Disorders of esophageal motility | 0.002719 | 1.636 | KITLG | Testicular germ cell cancer |
| rs3782181 | Swelling of limb | 0.001073 | 1.251 | KITLG | Testicular germ cell cancer |
| rs3782181 | Choroidal degenerations | 0.008934 | 1.49 | KITLG | Testicular germ cell cancer |
| rs3782181 | Prostate cancer | 0.001264 | 0.7703 | KITLG | Testicular germ cell cancer |
| rs3782181 | Nevus, non-neoplastic | 0.01021 | 0.4652 | KITLG | Testicular germ cell cancer |
| rs3782181 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.0003047 | 1.536 | KITLG | Testicular germ cell cancer |
| rs3782181 | H. pylori | 0.008181 | 1.563 | KITLG | Testicular germ cell cancer |
| rs3782181 | Dyschromia and Vitiligo | 0.008253 | 1.235 | KITLG | Testicular germ cell cancer |
| rs3782181 | Chronic interstitial cystitis | 0.001306 | 2.421 | KITLG | Testicular germ cell cancer |
| rs3782181 | Fracture of unspecified bones | 0.007684 | 0.8302 | KITLG | Testicular germ cell cancer |
| rs3782181 | Hypersomnia | 0.003585 | 1.589 | KITLG | Testicular germ cell cancer |
| rs3782181 | Gram positive septicemia | 0.005328 | 1.701 | KITLG | Testicular germ cell cancer |
| rs3782181 | Congenital musculoskeletal deformities of spine | 0.01063 | 0.6203 | KITLG | Testicular germ cell cancer |
| rs3782181 | Paroxysmal tachycardia, unspecified | 0.006177 | 0.7869 | KITLG | Testicular germ cell cancer |
| rs3782181 | Hyperventilation | 0.006181 | 1.791 | KITLG | Testicular germ cell cancer |
| rs3782181 | Obstruction of bile duct | 0.00171 | 1.79 | KITLG | Testicular germ cell cancer |
| rs3782181 | Chronic hepatitis | 0.004934 | 1.913 | KITLG | Testicular germ cell cancer |
| rs3803662 | Breast cancer | 8.379e-05 | 1.279 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Postoperative infection | 0.004332 | 0.7927 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Disorders of esophageal motility | 0.008754 | 1.488 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Breast cancer, including in situ | 4.317e-05 | 1.294 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Skin neoplasm of uncertain behavior | 0.003886 | 0.7954 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Other benign neoplasm of connective and other soft tissue | 0.001702 | 0.5482 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Acute bronchospasm | 0.008189 | 2.131 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Breast cancer | 3.446e-05 | 1.301 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803800 | Acidosis | 0.001146 | 1.519 | TNFSF13 | IgA nephropathy |
| rs3803800 | Swelling, mass, or lump in head and neck | 0.01025 | 1.255 | TNFSF13 | IgA nephropathy |
| rs3803800 | Exophthalmos | 0.006389 | 0.3135 | TNFSF13 | IgA nephropathy |
| rs3803800 | Vitamin deficiency | 0.01078 | 1.19 | TNFSF13 | IgA nephropathy |
| rs3803800 | Pathological, developmental or recurrent dislocation | 0.009272 | 1.879 | TNFSF13 | IgA nephropathy |
| rs3803800 | Shock | 0.004542 | 1.463 | TNFSF13 | IgA nephropathy |
| rs3803800 | Hypercalcemia | 0.006009 | 0.7371 | TNFSF13 | IgA nephropathy |
| rs3803800 | Diseases of the tongue | 0.003299 | 1.496 | TNFSF13 | IgA nephropathy |
| rs3803800 | Suppurative and unspecified otitis media | 0.006158 | 0.824 | TNFSF13 | IgA nephropathy |
| rs3803800 | Eustachian tube disorders | 0.004502 | 0.8597 | TNFSF13 | IgA nephropathy |
| rs3803800 | Lymphosarcoma | 0.002169 | 2.317 | TNFSF13 | IgA nephropathy |
| rs3803800 | Sepsis and SIRS | 0.01107 | 1.28 | TNFSF13 | IgA nephropathy |
| rs3803800 | Deep vein thrombosis | 0.009877 | 1.291 | TNFSF13 | IgA nephropathy |
| rs3803800 | Depression | 0.002257 | 1.135 | TNFSF13 | IgA nephropathy |
| rs3803800 | Protein-calorie malnutrition | 0.001646 | 1.231 | TNFSF13 | IgA nephropathy |
| rs3803800 | Major depressive disorder | 0.002436 | 1.213 | TNFSF13 | IgA nephropathy |
| rs3803800 | Generalized anxiety disorder | 0.01044 | 1.316 | TNFSF13 | IgA nephropathy |
| rs3803800 | Mood disorders | 0.007724 | 1.114 | TNFSF13 | IgA nephropathy |
| rs3803800 | Acid-base balance disorder | 0.005278 | 1.364 | TNFSF13 | IgA nephropathy |
| rs3803800 | Acute laryngitis and tracheitis | 0.008767 | 0.6027 | TNFSF13 | IgA nephropathy |
| rs3803800 | Agorophobia, social phobia, and panic disorder | 0.006113 | 1.439 | TNFSF13 | IgA nephropathy |
| rs3803800 | Otitis media | 0.01091 | 0.8564 | TNFSF13 | IgA nephropathy |
| rs3806156 | Postmenopausal atrophic vaginitis | 0.005083 | 1.254 | BTNL2 | Vitiligo |
| rs3806156 | Atherosclerosis of the extremities | 0.008996 | 1.139 | BTNL2 | Vitiligo |
| rs3806156 | Discoid lupus erythematosus | 0.009324 | 0.6744 | BTNL2 | Vitiligo |
| rs3806156 | Ulceration of intestine | 0.01077 | 1.577 | BTNL2 | Vitiligo |
| rs3806156 | Lupus erythematosus | 0.001441 | 0.3884 | BTNL2 | Vitiligo |
| rs3806156 | Eosinophilia | 0.001347 | 1.98 | BTNL2 | Vitiligo |
| rs3806156 | Thyrotoxicosis | 0.008399 | 0.804 | BTNL2 | Vitiligo |
| rs3806156 | Cellulitis and abscess of leg | 0.01028 | 0.8595 | BTNL2 | Vitiligo |
| rs3806156 | Polyarteritis nodosa and allied conditions | 0.002931 | 1.377 | BTNL2 | Vitiligo |
| rs3806156 | Acquired deformities of ankle and foot | 0.006846 | 1.229 | BTNL2 | Vitiligo |
| rs3806156 | Pneumoconiosis | 0.001134 | 0.3714 | BTNL2 | Vitiligo |
| rs3806156 | Intracerebral hemorrhage | 0.007691 | 1.582 | BTNL2 | Vitiligo |
| rs3806156 | Hypoglycemia | 0.008412 | 1.439 | BTNL2 | Vitiligo |
| rs3806156 | Atrophy of edentulous alveolar ridge | 0.006682 | 1.482 | BTNL2 | Vitiligo |
| rs3806156 | Urethritis and urethral syndrome | 0.00726 | 1.721 | BTNL2 | Vitiligo |
| rs3806156 | Degenerative disease of the spinal cord | 0.00969 | 1.426 | BTNL2 | Vitiligo |
| rs3806156 | Shock | 0.004713 | 1.408 | BTNL2 | Vitiligo |
| rs3806932 | Open wound of eye or eyelid | 0.009591 | 0.4859 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other disorders of back | 0.003675 | 0.8542 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Dementias | 0.009078 | 1.144 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Skin cancer | 0.01108 | 0.9153 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Lymphoid leukemia | 0.004278 | 0.6295 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Peyronie's disease | 0.007743 | 0.5314 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Hereditary and idiopathic peripheral neuropathy | 0.006523 | 0.8701 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Chronic pharyngitis and nasopharyngitis | 0.00906 | 0.8615 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Paroxysmal ventricular tachycardia | 0.006004 | 0.776 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cancer of the lower GI tract | 0.0065 | 1.362 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other symptoms referable to back | 0.009231 | 0.804 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cancer of oropharynx | 0.007241 | 2.047 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cardiac dysrhythmias | 0.007603 | 0.9233 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Chronic lymphoid leukemia | 0.00136 | 0.5792 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Prostate cancer | 0.01118 | 0.8522 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Otosclerosis | 0.005555 | 0.661 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other diseases of respiratory system | 0.002783 | 1.42 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Disorders of sacrum | 0.00561 | 0.797 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Congenital anomalies of genital organs | 0.01147 | 0.5099 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Skin neoplasm of uncertain behavior | 0.01024 | 0.8402 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cerebral aneurysm | 0.009811 | 1.607 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Lymphadenitis | 0.007438 | 0.8493 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Posttraumatic wound infection | 0.01008 | 0.5549 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Paroxysmal tachycardia, unspecified | 0.002014 | 0.8165 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Fracture of clavicle or scapula | 0.003156 | 0.6833 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Delirium dementia and amnestic disorders | 0.0004243 | 1.17 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other disorders of ear | 0.009304 | 0.7893 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other specified cardiac dysrhythmias | 0.001494 | 0.8648 | TSLP | Eosinophilic esophagitis |
| rs3807989 | Adverse effects of opiates and related narcotics in therapeutic use | 0.007821 | 1.291 | CAV1 | PR interval |
| rs3807989 | Muscular wasting and disuse atrophy | 0.0006231 | 0.5134 | CAV1 | PR interval |
| rs3807989 | Secondary thrombocytopenia | 0.009235 | 1.581 | CAV1 | PR interval |
| rs3807989 | Abnormal chest sounds | 0.003593 | 0.6587 | CAV1 | PR interval |
| rs3807989 | Iatrogenic hypothyroidism | 0.004178 | 1.351 | CAV1 | PR interval |
| rs3807989 | Stricture/obstruction of ureter | 0.01049 | 1.433 | CAV1 | PR interval |
| rs3807989 | Nephritis and nephropathy in diseases classified elsewhere | 0.003611 | 1.302 | CAV1 | PR interval |
| rs3807989 | Glossitis | 0.009806 | 0.4822 | CAV1 | PR interval |
| rs3807989 | Phobia | 0.007839 | 2.016 | CAV1 | PR interval |
| rs3807989 | Intervertebral disc disorder with myelopathy | 0.00898 | 0.5635 | CAV1 | PR interval |
| rs3807989 | Posttraumatic stress disorder | 0.01073 | 1.509 | CAV1 | PR interval |
| rs3807989 | Other conditions of the mother complicating pregnancy | 0.002789 | 0.5683 | CAV1 | PR interval |
| rs3807989 | Nonspecific findings on examination of blood | 0.006557 | 1.305 | CAV1 | PR interval |
| rs3807989 | Other disorders of metabolic, endocrine, immunity disorders | 0.002712 | 0.436 | CAV1 | PR interval |
| rs3807989 | Hepatomegaly | 0.001555 | 1.913 | CAV1 | PR interval |
| rs3807989 | Lump or mass in breast | 0.008309 | 0.8622 | CAV1 | PR interval |
| rs3815087 | Iron deficiency anemia secondary to blood loss | 0.006844 | 1.381 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Psoriasis | 5.549e-07 | 1.571 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Malunion fracture | 0.009862 | 1.462 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Althete's foot | 0.000908 | 1.38 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Anemia of chronic disease | 0.001312 | 0.7476 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Psoriasis vulgaris | 2.448e-07 | 1.608 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Biliary cirrhosis | 0.006508 | 2.211 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Fuchs' dystrophy | 0.0102 | 1.513 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Corneal edema | 0.005093 | 1.713 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Disorders of cornea | 0.003563 | 1.249 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Esophageal cancer | 0.006612 | 1.859 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Corneal degenerations | 0.0002124 | 1.572 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Partial epilepsy | 0.01036 | 0.6239 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Psoriasis & related disorders | 1.415e-05 | 1.457 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Orchitis and epididymitis | 0.007434 | 0.6147 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Prostate cancer | 0.004508 | 0.7924 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Seborheic dermatitis | 0.0007983 | 1.277 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Depression | 0.006715 | 1.122 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Adverse effects of cardiac rhythm regulators | 0.002743 | 0.3266 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Mood disorders | 0.009784 | 1.114 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3816995 | Acquired toe deformities | 0.002212 | 0.8397 | SDK2 | Panic disorder |
| rs3816995 | Diverticulitis | 0.007515 | 1.214 | SDK2 | Panic disorder |
| rs3816995 | Respiratory insufficiency | 0.0006222 | 0.721 | SDK2 | Panic disorder |
| rs3816995 | Torticollis | 0.003718 | 1.593 | SDK2 | Panic disorder |
| rs3816995 | Perforation of tympanic membrane | 0.007536 | 0.6633 | SDK2 | Panic disorder |
| rs3816995 | Other sprains and strains | 0.002289 | 1.389 | SDK2 | Panic disorder |
| rs3816995 | Hammer toe | 0.008324 | 0.8411 | SDK2 | Panic disorder |
| rs3816995 | Anomalies of pupillary function | 0.0009165 | 0.4312 | SDK2 | Panic disorder |
| rs3816995 | Disorders of cervical region | 0.003496 | 1.372 | SDK2 | Panic disorder |
| rs3816995 | Cardiomegaly | 0.01036 | 0.8743 | SDK2 | Panic disorder |
| rs3816995 | Secondary malignant neoplasm | 0.009643 | 1.148 | SDK2 | Panic disorder |
| rs3818361 | Symptoms/disorders of the urinary system | 0.009284 | 1.106 | CR1 | Alzheimer's disease |
| rs3818361 | Palpitations | 0.005655 | 1.171 | CR1 | Alzheimer's disease |
| rs3818361 | Myopia | 0.007542 | 0.8648 | CR1 | Alzheimer's disease |
| rs3818361 | Brain cancer | 0.001152 | 1.911 | CR1 | Alzheimer's disease |
| rs3818361 | Systolic/diastolic heart failure | 0.007576 | 1.149 | CR1 | Alzheimer's disease |
| rs3818361 | Personality disorders | 0.009632 | 1.287 | CR1 | Alzheimer's disease |
| rs3818361 | Heart valve disorders | 0.0093 | 1.129 | CR1 | Alzheimer's disease |
| rs3818361 | Aortic aneurysm | 0.007273 | 1.244 | CR1 | Alzheimer's disease |
| rs3818361 | Other abnormality of urination | 0.002216 | 1.294 | CR1 | Alzheimer's disease |
| rs3818361 | Cerebral edema and compression of brain | 0.008551 | 1.91 | CR1 | Alzheimer's disease |
| rs3818361 | Reticulosarcoma | 0.006953 | 0.4385 | CR1 | Alzheimer's disease |
| rs3818361 | Congenital anomalies of peripheral vascular system | 0.002923 | 1.98 | CR1 | Alzheimer's disease |
| rs3818361 | Loose body in joint | 0.008381 | 0.1494 | CR1 | Alzheimer's disease |
| rs3818361 | Urinary obstruction | 0.002122 | 1.556 | CR1 | Alzheimer's disease |
| rs3818361 | Senile dementia | 0.008335 | 1.273 | CR1 | Alzheimer's disease |
| rs3818361 | Shock | 0.0104 | 1.426 | CR1 | Alzheimer's disease |
| rs3818361 | Posttraumatic wound infection | 0.008176 | 1.825 | CR1 | Alzheimer's disease |
| rs3818361 | Neutropenia | 0.008149 | 0.7607 | CR1 | Alzheimer's disease |
| rs3818361 | Dyschromia and Vitiligo | 0.01079 | 1.225 | CR1 | Alzheimer's disease |
| rs3818361 | Inflammatory conditions of jaw | 0.007862 | 1.625 | CR1 | Alzheimer's disease |
| rs3818361 | Decreased white blood cell count | 0.002488 | 0.7384 | CR1 | Alzheimer's disease |
| rs3818361 | Diseases of pancreas | 0.002091 | 1.294 | CR1 | Alzheimer's disease |
| rs3818361 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.007775 | 0.3485 | CR1 | Alzheimer's disease |
| rs3818361 | Other aneurysm | 0.002818 | 1.246 | CR1 | Alzheimer's disease |
| rs385893 | Genu valgum or varum (acquired) | 0.007622 | 0.7002 | AK3 | Platelet counts |
| rs385893 | Symptoms of the muscles | 0.001289 | 0.7649 | AK3 | Platelet counts |
| rs385893 | Herpes zoster with nervous system complications | 0.009865 | 0.6659 | AK3 | Platelet counts |
| rs385893 | Other disorders of metabolic, endocrine, immunity disorders | 0.009217 | 1.892 | AK3 | Platelet counts |
| rs385893 | Chronic ulcer of unspecified site | 0.00156 | 1.33 | AK3 | Platelet counts |
| rs385893 | Unspecified polyarthropathy or polyarthritis | 0.003784 | 0.643 | AK3 | Platelet counts |
| rs385893 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.005694 | 0.4159 | AK3 | Platelet counts |
| rs385893 | Astigmatism | 0.009969 | 1.123 | AK3 | Platelet counts |
| rs385893 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.008267 | 1.305 | AK3 | Platelet counts |
| rs385893 | Myopia | 0.004188 | 1.131 | AK3 | Platelet counts |
| rs385893 | Hypermetropia | 0.007591 | 1.133 | AK3 | Platelet counts |
| rs385893 | Cervical cancer and dysplasia | 0.005091 | 1.299 | AK3 | Platelet counts |
| rs385893 | Cyst or abscess of Bartholin's gland | 0.009205 | 1.966 | AK3 | Platelet counts |
| rs385893 | Miscarriage; stillbirth | 0.006612 | 1.851 | AK3 | Platelet counts |
| rs385893 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.002512 | 0.5722 | AK3 | Platelet counts |
| rs385893 | Hirsutism | 0.007201 | 1.664 | AK3 | Platelet counts |
| rs3885683 | Dysmenorrhea | 0.005266 | 1.755 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Acute pancreatitis | 0.004662 | 1.413 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Microscopic hematuria | 0.0008606 | 1.846 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Paroxysmal ventricular tachycardia | 0.007333 | 1.391 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Chronic pancreatitis | 0.008298 | 1.813 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Other disorders of thyroid | 0.007556 | 0.6174 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Multiple myeloma | 0.008602 | 1.713 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Cardiac defibrillator in situ | 0.01032 | 1.558 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Vascular disorders of penis | 0.001506 | 2.79 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Atrial fibrillation & flutter | 0.0102 | 1.178 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Diseases of pancreas | 0.005878 | 1.307 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Hemorrhage NOS | 0.005955 | 1.871 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Personal history of allergy to medicinal agents | 0.006094 | 0.6684 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Paroxysmal tachycardia, unspecified | 0.01149 | 1.26 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Fracture of radius and ulna | 0.004002 | 1.277 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Carbuncle and furuncle | 0.004173 | 1.696 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Dental caries | 0.01001 | 1.268 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3923809 | Mood disorders | 0.005768 | 0.9041 | BTBD9 | Restless legs syndrome |
| rs3923809 | Idiopathic fibrosing alveolitis | 0.003053 | 1.916 | BTBD9 | Restless legs syndrome |
| rs3923809 | Other disorders of biliary tract | 0.001921 | 0.5641 | BTBD9 | Restless legs syndrome |
| rs3923809 | Other diseases of the teeth and supporting structures | 0.005914 | 0.7774 | BTBD9 | Restless legs syndrome |
| rs3923809 | Extrapyramidal disease and abnormal movement disorders | 0.001653 | 0.806 | BTBD9 | Restless legs syndrome |
| rs3923809 | Adverse drug events and drug allergies | 0.004887 | 0.8368 | BTBD9 | Restless legs syndrome |
| rs3923809 | Chronic pancreatitis | 0.004237 | 0.515 | BTBD9 | Restless legs syndrome |
| rs3923809 | Acute bronchospasm | 0.006919 | 2.156 | BTBD9 | Restless legs syndrome |
| rs3923809 | Incisional hernia | 0.005495 | 1.314 | BTBD9 | Restless legs syndrome |
| rs3923809 | Iron deficiency anemias NOS | 0.01012 | 0.8805 | BTBD9 | Restless legs syndrome |
| rs3923809 | Malignant neoplasm of ovary | 0.002316 | 1.77 | BTBD9 | Restless legs syndrome |
| rs3923809 | Traumatic arthropathy | 0.003637 | 1.693 | BTBD9 | Restless legs syndrome |
| rs3923809 | Depression | 0.006716 | 0.9039 | BTBD9 | Restless legs syndrome |
| rs3923809 | Other alveolar and parietoalveolar pneumonopathy | 9.832e-05 | 2.022 | BTBD9 | Restless legs syndrome |
| rs3923809 | Nonrheumatic aortic valve disorders | 0.003677 | 1.179 | BTBD9 | Restless legs syndrome |
| rs398652 | Second degree AV block | 0.007397 | 1.682 | PELI2 | Telomere length |
| rs398652 | Varicose veins | 0.0001513 | 1.304 | PELI2 | Telomere length |
| rs398652 | Varicose veins of lower extremity | 0.001043 | 1.272 | PELI2 | Telomere length |
| rs398652 | Hallux valgus (Bunion) | 0.008305 | 1.248 | PELI2 | Telomere length |
| rs398652 | Neoplasm of unspecified nature of digestive system | 0.01009 | 1.52 | PELI2 | Telomere length |
| rs398652 | Disorders of the autonomic nervous system | 0.009562 | 1.389 | PELI2 | Telomere length |
| rs398652 | Osteoarthrosis; localized, primary | 0.001516 | 1.384 | PELI2 | Telomere length |
| rs398652 | Anomalies of jaw size/symmetry | 0.007244 | 2.185 | PELI2 | Telomere length |
| rs398652 | Osteoarthritis; localized | 0.007789 | 1.17 | PELI2 | Telomere length |
| rs398652 | Subjective visual disturbances | 0.001818 | 1.334 | PELI2 | Telomere length |
| rs398652 | Postnasal drip | 0.009507 | 1.893 | PELI2 | Telomere length |
| rs398652 | Congenital anomalies of great vessels | 0.008167 | 2.104 | PELI2 | Telomere length |
| rs398652 | Osteoarthrosis NOS | 0.01092 | 1.124 | PELI2 | Telomere length |
| rs4086116 | Other specified disorders of pancreatic internal secretion | 0.002662 | 0.3318 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Open wound of lip and mouth | 0.007902 | 1.805 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Acute reaction to stress | 0.0001331 | 1.45 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Congenital deformities of feet | 0.01033 | 1.357 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Nervous system congenital anomalies | 0.007939 | 1.475 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Sprains and strains | 0.007189 | 1.135 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Shock | 0.009594 | 1.429 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Corneal degenerations | 0.005327 | 0.6504 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Hypotension NOS | 0.006367 | 1.224 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Infection/inflammation of internal prosthetic device, implant or graft | 0.002968 | 1.36 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Elevated prostate specific antigen | 0.01086 | 0.8102 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Atrial flutter | 0.00986 | 1.262 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Leukoplakia of oral mucosa | 0.00545 | 1.899 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Anal and rectal conditions | 0.004318 | 1.188 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Calcaneal spur; Exostosis NOS | 0.006637 | 1.317 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Functional disorders of bladder | 0.008576 | 1.346 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Other disorders of pancreatic internal secretion | 0.002217 | 0.3254 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Barrett's esophagus | 0.002944 | 1.488 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Spontaneous ecchymoses | 0.0009734 | 1.892 | CYP2C9 | Warfarin maintenance dose |
| rs4132509 | Other arthropathies | 0.006479 | 0.862 | AKT3 | RR interval (heart rate) |
| rs4132509 | Impetigo | 0.002789 | 1.714 | AKT3 | RR interval (heart rate) |
| rs4132509 | Benign neoplasm of eye | 0.007167 | 1.294 | AKT3 | RR interval (heart rate) |
| rs4132509 | Hemiplegia | 0.0073 | 0.6584 | AKT3 | RR interval (heart rate) |
| rs4132509 | Inflammatory spondylopathies | 0.007822 | 0.5224 | AKT3 | RR interval (heart rate) |
| rs4132509 | Osteoarthrosis | 0.007005 | 0.9004 | AKT3 | RR interval (heart rate) |
| rs4132509 | Fracture of humerus | 0.006998 | 0.7322 | AKT3 | RR interval (heart rate) |
| rs4132509 | Bursitis | 0.01019 | 0.802 | AKT3 | RR interval (heart rate) |
| rs4132509 | Sacroiliitis NEC | 0.00832 | 0.3522 | AKT3 | RR interval (heart rate) |
| rs4132509 | Joint/ligament sprain | 0.008064 | 0.6881 | AKT3 | RR interval (heart rate) |
| rs4132509 | Viral Enteritis | 0.001015 | 1.702 | AKT3 | RR interval (heart rate) |
| rs4132509 | Osteoarthrosis NOS | 0.002842 | 0.8824 | AKT3 | RR interval (heart rate) |
| rs4141463 | Anomalies of tooth position/malocclusion | 0.003148 | 1.732 | MACROD2 | Autism |
| rs4141463 | Mastoiditis | 0.001649 | 2.349 | MACROD2 | Autism |
| rs4141463 | Streptococcus infection | 0.00533 | 0.7323 | MACROD2 | Autism |
| rs4141463 | Other specified disorders of liver | 0.009817 | 0.7605 | MACROD2 | Autism |
| rs4141463 | Acquired deformities of limbs | 0.003372 | 0.8027 | MACROD2 | Autism |
| rs4141463 | Sulfonamides | 0.001797 | 0.7559 | MACROD2 | Autism |
| rs4141463 | Muscular wasting and disuse atrophy | 0.006082 | 0.5955 | MACROD2 | Autism |
| rs4141463 | Muscle weakness | 0.007046 | 0.7642 | MACROD2 | Autism |
| rs4141463 | Gout | 0.007836 | 0.8636 | MACROD2 | Autism |
| rs4141463 | Pulmonary embolism and infarction | 0.007813 | 0.8006 | MACROD2 | Autism |
| rs4141463 | Chronic sinusitis | 0.009532 | 0.8955 | MACROD2 | Autism |
| rs4141463 | Poisoning by other anti-infectives | 0.005433 | 0.8031 | MACROD2 | Autism |
| rs4141463 | Myasthenia gravis | 0.00527 | 0.4382 | MACROD2 | Autism |
| rs4141463 | Disorders of the autonomic nervous system | 0.004452 | 1.321 | MACROD2 | Autism |
| rs4141463 | Thyroiditis | 0.0104 | 0.7432 | MACROD2 | Autism |
| rs4141463 | Atherosclerosis of the extremities | 0.008411 | 1.138 | MACROD2 | Autism |
| rs4148441 | Diseases of nail | 0.001539 | 0.7383 | ABCC4 | Platelet counts |
| rs4148441 | Nonspecific findings on examination of blood | 5.24e-05 | 0.3614 | ABCC4 | Platelet counts |
| rs4148441 | Phlebitis and thrombophlebitis | 0.009332 | 0.7187 | ABCC4 | Platelet counts |
| rs4148441 | Ingrowing nail | 0.005147 | 0.7474 | ABCC4 | Platelet counts |
| rs4148441 | Other congenital anomalies | 0.007841 | 2.099 | ABCC4 | Platelet counts |
| rs4148441 | Polyp of corpus uteri | 0.006863 | 1.608 | ABCC4 | Platelet counts |
| rs4148441 | Primary angle-closure glaucoma | 0.01033 | 1.374 | ABCC4 | Platelet counts |
| rs4148441 | Anal and rectal polyp | 0.003254 | 1.457 | ABCC4 | Platelet counts |
| rs4148441 | Other specified diseases of nail | 0.001319 | 0.7283 | ABCC4 | Platelet counts |
| rs4148441 | Osteoarthrosis NOS | 0.0108 | 0.8662 | ABCC4 | Platelet counts |
| rs4148441 | Acute sinusitis | 0.006261 | 0.7828 | ABCC4 | Platelet counts |
| rs4148441 | Phlebitis and thrombophlebitis of lower extremities | 0.008666 | 0.6818 | ABCC4 | Platelet counts |
| rs4148441 | Chronic ulcer of skin | 0.008226 | 0.804 | ABCC4 | Platelet counts |
| rs4148441 | Bone cancer | 0.003345 | 2.09 | ABCC4 | Platelet counts |
| rs4148441 | Synoviopathy | 0.01144 | 1.511 | ABCC4 | Platelet counts |
| rs4148441 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.00112 | 2.864 | ABCC4 | Platelet counts |
| rs4149268 | Congenital anomalies of urinary system | 0.003134 | 1.505 | ABCA1 | HDL Cholesterol |
| rs4149268 | Cardiac defibrillator in situ | 0.005247 | 1.454 | ABCA1 | HDL Cholesterol |
| rs4149268 | Cancer of other female genital organs | 0.001357 | 0.6036 | ABCA1 | HDL Cholesterol |
| rs4149268 | Chondrocalcinosis | 0.005723 | 1.369 | ABCA1 | HDL Cholesterol |
| rs4149268 | Other disorders of eyelids | 0.0111 | 0.8787 | ABCA1 | HDL Cholesterol |
| rs4149268 | Dysmenorrhea | 0.00596 | 0.6453 | ABCA1 | HDL Cholesterol |
| rs4149268 | Sensorineural hearing loss | 0.002958 | 0.8916 | ABCA1 | HDL Cholesterol |
| rs4149268 | Myeloid leukemia | 0.006614 | 1.816 | ABCA1 | HDL Cholesterol |
| rs4149268 | Diverticulum of esophagus, acquired | 0.003017 | 0.4276 | ABCA1 | HDL Cholesterol |
| rs4149268 | Ovarian cancer | 0.004677 | 0.5964 | ABCA1 | HDL Cholesterol |
| rs4149268 | Late effects of cerebrovascular disease | 0.002325 | 0.8271 | ABCA1 | HDL Cholesterol |
| rs4149268 | Symptoms associated with female genital organs | 0.004418 | 0.8242 | ABCA1 | HDL Cholesterol |
| rs4149268 | Constipation | 0.00143 | 1.167 | ABCA1 | HDL Cholesterol |
| rs4149268 | Light-headedness and vertigo | 0.003644 | 0.901 | ABCA1 | HDL Cholesterol |
| rs4149268 | Delirium dementia and amnestic disorders | 0.00773 | 1.13 | ABCA1 | HDL Cholesterol |
| rs4149268 | Keloid scar | 0.0007647 | 1.866 | ABCA1 | HDL Cholesterol |
| rs4149268 | Malignant neoplasm of ovary | 0.00919 | 0.5716 | ABCA1 | HDL Cholesterol |
| rs4149268 | Crystal arthropathies | 0.006279 | 1.36 | ABCA1 | HDL Cholesterol |
| rs4149268 | Benign neoplasm of bone and articular cartilage | 0.001179 | 0.4683 | ABCA1 | HDL Cholesterol |
| rs4149268 | Vertiginous syndromes and other disorders of vestibular system | 0.003112 | 0.9036 | ABCA1 | HDL Cholesterol |
| rs4149268 | Labyrinthitis | 0.0001292 | 0.6121 | ABCA1 | HDL Cholesterol |
| rs4149268 | Ovarian cyst | 0.004149 | 0.7426 | ABCA1 | HDL Cholesterol |
| rs4149268 | Acquired hypothyroidism | 0.001073 | 0.4262 | ABCA1 | HDL Cholesterol |
| rs4149268 | Facial nerve disorders | 0.004807 | 1.412 | ABCA1 | HDL Cholesterol |
| rs4233356 | Pneumococcal pneumonia | 0.005761 | 1.842 | DUSP23 | Interstitial lung disease |
| rs4233356 | Sicca syndrome | 0.0001718 | 1.739 | DUSP23 | Interstitial lung disease |
| rs4233356 | Postmenopausal bleeding | 0.006331 | 1.234 | DUSP23 | Interstitial lung disease |
| rs4233356 | Lymphosarcoma | 0.002898 | 2.215 | DUSP23 | Interstitial lung disease |
| rs4233356 | Menopausal & postmenopausal disorders | 0.005933 | 1.138 | DUSP23 | Interstitial lung disease |
| rs4233356 | Urethral stricture (not specified as infectious) | 0.004709 | 1.449 | DUSP23 | Interstitial lung disease |
| rs4233356 | Keratoconjunctivitis sicca | 0.002035 | 0.5218 | DUSP23 | Interstitial lung disease |
| rs4233356 | Benign neoplasm of other parts of digestive system | 0.002006 | 0.707 | DUSP23 | Interstitial lung disease |
| rs4233356 | Keratoconjunctivitis, noninfectious | 0.008908 | 0.662 | DUSP23 | Interstitial lung disease |
| rs4233356 | Internal derangement of knee | 0.009669 | 0.8714 | DUSP23 | Interstitial lung disease |
| rs4238010 | Alcohol-related disorders | 0.008517 | 1.265 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Pituitary hypofunction | 0.00251 | 2.175 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Benign neoplasm of respiratory and intrathoracic organs | 0.004237 | 1.998 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Dermatophytosis of the body | 0.005924 | 1.483 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Chronic hepatitis | 0.01041 | 1.9 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Bladder neck obstruction | 0.001209 | 1.451 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | stress incontinence, female | 0.001716 | 1.309 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Premature beats | 0.008158 | 1.258 | CCND2 | Major depressive disorder (recurrent) |
| rs4295627 | Aphasia/speech disturbance | 0.01028 | 1.271 | CCDC26 | Glioma |
| rs4295627 | Nephritis & nephropathy | 0.0007761 | 1.904 | CCDC26 | Glioma |
| rs4295627 | Cardiac arrest & ventricular fibrillation | 0.01093 | 0.6101 | CCDC26 | Glioma |
| rs4295627 | Diseases of the tongue | 0.001773 | 1.56 | CCDC26 | Glioma |
| rs4295627 | Urinary calculus | 0.002658 | 1.211 | CCDC26 | Glioma |
| rs4295627 | Dysphagia | 0.009846 | 1.151 | CCDC26 | Glioma |
| rs4295627 | Speech and language disorder | 0.004791 | 1.512 | CCDC26 | Glioma |
| rs4295627 | Bacterial enteritis | 0.01019 | 1.368 | CCDC26 | Glioma |
| rs4295627 | Benign neoplasm of colon | 0.007497 | 1.117 | CCDC26 | Glioma |
| rs4295627 | Seborrhea | 0.008535 | 1.96 | CCDC26 | Glioma |
| rs4295627 | Fluid overload | 0.006308 | 1.335 | CCDC26 | Glioma |
| rs4295627 | Diseases of hair and hair follicles | 0.001939 | 1.312 | CCDC26 | Glioma |
| rs4295627 | Noninfectious gastroenteritis | 0.005909 | 1.206 | CCDC26 | Glioma |
| rs4295627 | Intracerebral hemorrhage | 0.006102 | 1.698 | CCDC26 | Glioma |
| rs4295627 | Neurological disorders due to brain damage | 0.01065 | 1.162 | CCDC26 | Glioma |
| rs4295627 | Calculus of kidney | 0.006116 | 1.219 | CCDC26 | Glioma |
| rs4295627 | Acute sinusitis | 0.00667 | 1.183 | CCDC26 | Glioma |
| rs4295627 | Paroxysmal tachycardia, unspecified | 0.007101 | 0.7831 | CCDC26 | Glioma |
| rs4295627 | Type 1 diabetic peripheral circulatory disorders | 0.00878 | 1.991 | CCDC26 | Glioma |
| rs4295627 | Spondylosis with myelopathy | 0.008389 | 0.6187 | CCDC26 | Glioma |
| rs4299376 | pulmonary heart disease | 0.004486 | 0.8438 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Contracture of joint | 0.002715 | 1.452 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cholelithiasis with other cholecystitis | 0.0004307 | 0.6828 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Secondary malignant neoplasm | 0.001148 | 0.8233 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Pulmonary embolism and infarction | 0.002084 | 0.7515 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Mammographic microcalcification | 0.00697 | 0.5875 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Malunion fracture | 0.0006441 | 1.563 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Constipation | 0.006202 | 0.8683 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cellulitis and abscess of hand/fingers | 0.005287 | 0.8232 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Hyperlipidemia | 0.009822 | 1.094 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Meniere's disease | 0.004909 | 1.663 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Open wounds of extremities | 0.005969 | 1.126 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Calculus of bile duct | 0.005144 | 0.7002 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cholelithiasis and cholecystitis | 6.913e-05 | 0.8227 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cholelithiasis | 0.0002329 | 0.8246 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Fracture of hand or wrist | 0.005193 | 1.187 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Lung cancer | 0.004026 | 0.7738 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Disorders of lipoid metabolism | 0.008687 | 1.095 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Balanoposthitis | 0.00594 | 1.693 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cancer within the respiratory system | 0.005354 | 0.7835 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Phobia | 0.001748 | 0.2786 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4410871 | Other disorders of bone and cartilage | 0.005267 | 1.237 | PVT1 | Multiple sclerosis |
| rs4410871 | Viral warts & HPV | 0.00901 | 0.8553 | PVT1 | Multiple sclerosis |
| rs4410871 | Allergic conjunctivitis | 0.007134 | 1.291 | PVT1 | Multiple sclerosis |
| rs4410871 | Congenital deformities of feet | 0.000637 | 0.653 | PVT1 | Multiple sclerosis |
| rs4410871 | Rheumatoid arthritis | 0.005831 | 0.7894 | PVT1 | Multiple sclerosis |
| rs4410871 | Arthropathy NOS involving multiple sites | 0.007147 | 0.5522 | PVT1 | Multiple sclerosis |
| rs4410871 | Primary/intrinsic cardiomyopathies | 0.007767 | 1.2 | PVT1 | Multiple sclerosis |
| rs4410871 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.0005546 | 0.7669 | PVT1 | Multiple sclerosis |
| rs4410871 | Fuchs' dystrophy | 0.004518 | 1.521 | PVT1 | Multiple sclerosis |
| rs4410871 | Congenital anomalies of limbs | 0.001694 | 0.7155 | PVT1 | Multiple sclerosis |
| rs4410871 | Ascites (non malignant) | 0.003835 | 1.441 | PVT1 | Multiple sclerosis |
| rs4410871 | Corneal dystrophy | 0.006763 | 1.317 | PVT1 | Multiple sclerosis |
| rs4410871 | Other specified diseases of sebaceous glands | 0.01055 | 0.802 | PVT1 | Multiple sclerosis |
| rs4410871 | Hypotony of eye | 0.006896 | 0.2811 | PVT1 | Multiple sclerosis |
| rs4410871 | Cardiomyopathy | 0.004642 | 1.207 | PVT1 | Multiple sclerosis |
| rs4430796 | Other acquired musculoskeletal deformity | 0.004052 | 0.7947 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Drug-resistant infection | 0.01125 | 0.7358 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Pain, swelling or discharge of eye | 0.0009046 | 0.6748 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Lipoid metabolism disorder NOS | 0.007868 | 0.7879 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Back & neck sprains | 0.002733 | 0.8789 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Bladder neck obstruction | 0.004413 | 0.7792 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Diplopia and disorders of binocular vision | 0.003212 | 1.322 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Prostate cancer | 0.001525 | 0.8192 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Other immunological findings | 0.002555 | 0.729 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Periostitis | 0.001938 | 2.003 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Internal derangement of knee | 0.01133 | 0.8784 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Other disorders of peritoneum | 0.00683 | 0.6866 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Myocardial infarction | 0.008184 | 1.127 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Immune disorders | 0.0003148 | 0.733 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Nerve root and plexus disorders | 0.01004 | 1.297 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Carbuncle and furuncle | 0.01113 | 0.6771 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Symptoms involving head and neck | 0.01008 | 0.8452 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Congenital musculoskeletal deformities of spine | 0.003467 | 0.6793 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs443198 | Hemorrhage of gastrointestinal tract | 0.01076 | 1.163 | NOTCH4 | Systemic sclerosis |
| rs443198 | Lymphadenitis | 0.009123 | 1.173 | NOTCH4 | Systemic sclerosis |
| rs443198 | Abdominal hernia | 0.002258 | 1.11 | NOTCH4 | Systemic sclerosis |
| rs443198 | Keratitis | 0.001102 | 0.7097 | NOTCH4 | Systemic sclerosis |
| rs443198 | Abnormality of red blood cells | 0.01148 | 0.4664 | NOTCH4 | Systemic sclerosis |
| rs443198 | Atherosclerosis of the extremities | 0.01143 | 1.134 | NOTCH4 | Systemic sclerosis |
| rs443198 | Chronic prostatitis | 0.00682 | 0.6266 | NOTCH4 | Systemic sclerosis |
| rs443198 | Prostatitis | 0.001497 | 0.7271 | NOTCH4 | Systemic sclerosis |
| rs443198 | Celiac or tropical sprue | 1.197e-05 | 2.566 | NOTCH4 | Systemic sclerosis |
| rs443198 | Abnormal tumor markers, elevated CEA or CA 125 | 0.0007364 | 2.424 | NOTCH4 | Systemic sclerosis |
| rs443198 | Dental caries | 0.01106 | 1.185 | NOTCH4 | Systemic sclerosis |
| rs443198 | Other benign neoplasm of connective and other soft tissue | 0.005554 | 1.49 | NOTCH4 | Systemic sclerosis |
| rs443198 | Aneurysm of iliac artery | 0.00402 | 1.777 | NOTCH4 | Systemic sclerosis |
| rs443198 | Cervicocranial/Cervicobrachial syndrome | 0.005079 | 0.7776 | NOTCH4 | Systemic sclerosis |
| rs443198 | Stress fracture | 0.004655 | 1.909 | NOTCH4 | Systemic sclerosis |
| rs443198 | Celiac disease | 3.545e-05 | 2.478 | NOTCH4 | Systemic sclerosis |
| rs443198 | Macular degeneration, dry | 0.0004992 | 1.312 | NOTCH4 | Systemic sclerosis |
| rs443198 | Stiffness of joint | 0.004576 | 1.212 | NOTCH4 | Systemic sclerosis |
| rs443198 | Mitral valve stenosis and/or aortic valve stenosis | 0.0007132 | 1.295 | NOTCH4 | Systemic sclerosis |
| rs443198 | Liver replaced by transplant | 0.002693 | 2.247 | NOTCH4 | Systemic sclerosis |
| rs443198 | Inflammatory diseases of prostate | 0.002448 | 0.7807 | NOTCH4 | Systemic sclerosis |
| rs443198 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.006928 | 1.181 | NOTCH4 | Systemic sclerosis |
| rs443198 | Acute tonsillitis | 0.008783 | 0.6178 | NOTCH4 | Systemic sclerosis |
| rs443198 | Stomatitis and mucositis | 0.01003 | 0.7149 | NOTCH4 | Systemic sclerosis |
| rs443198 | Infertility, female | 0.01049 | 0.5679 | NOTCH4 | Systemic sclerosis |
| rs443198 | Aneurysm of artery of lower extremity | 0.001994 | 1.639 | NOTCH4 | Systemic sclerosis |
| rs443198 | Cellulitis and abscess of face | 0.003281 | 0.6932 | NOTCH4 | Systemic sclerosis |
| rs4444235 | Other conditions of brain | 0.0009686 | 1.396 | BMP4 | Colorectal cancer |
| rs4444235 | Other disorders of prostate | 0.004617 | 0.7471 | BMP4 | Colorectal cancer |
| rs4444235 | Nerve root lesions | 0.005469 | 0.6018 | BMP4 | Colorectal cancer |
| rs4444235 | Ulceration of the lower GI tract | 0.004628 | 1.57 | BMP4 | Colorectal cancer |
| rs4444235 | Superficial cellulitis and abscess | 0.001866 | 1.114 | BMP4 | Colorectal cancer |
| rs4444235 | Keratitis, infectious | 0.00267 | 1.449 | BMP4 | Colorectal cancer |
| rs4444235 | Viral Enteritis | 0.0043 | 0.6516 | BMP4 | Colorectal cancer |
| rs4444235 | Convulsions | 0.01116 | 1.189 | BMP4 | Colorectal cancer |
| rs4444235 | Cerebral edema and compression of brain | 0.00734 | 1.882 | BMP4 | Colorectal cancer |
| rs4444235 | Ileostomy status | 0.005513 | 1.623 | BMP4 | Colorectal cancer |
| rs4444235 | Fracture of pelvis | 0.01068 | 1.316 | BMP4 | Colorectal cancer |
| rs4444235 | Acute reaction to stress | 0.003858 | 0.7808 | BMP4 | Colorectal cancer |
| rs4444235 | Temporomandibular joint disorder NOS | 0.0008509 | 0.538 | BMP4 | Colorectal cancer |
| rs4444235 | Anal and rectal conditions | 0.0005056 | 1.187 | BMP4 | Colorectal cancer |
| rs4444235 | Epilepsy, recurrent seizures, convulsions | 0.007482 | 1.189 | BMP4 | Colorectal cancer |
| rs445 | Keratoderma, acquired | 0.002489 | 0.7419 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Secondary hyperparathyroidism (of renal origin) | 0.006204 | 1.57 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Photodermatitis & sunburn | 0.005656 | 0.7454 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Cerebrovascular disease | 0.006187 | 1.157 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Arthropathy associated with infections | 0.008869 | 1.757 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Acne | 0.001394 | 1.526 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Polymyalgia Rheumatica | 0.008885 | 0.6415 | CDK6 | White blood cell count, Neutrophil count |
| rs4516970 | Congenital cataract and lens anomalies | 0.001265 | 3.989 | WTAP | Serum ferritin |
| rs4516970 | Precordial pain | 0.001992 | 2.148 | WTAP | Serum ferritin |
| rs4516970 | Angina pectoris | 0.01047 | 1.438 | WTAP | Serum ferritin |
| rs4516970 | Ischemic Heart Disease | 0.007942 | 1.291 | WTAP | Serum ferritin |
| rs4516970 | Other acute and subacute forms of ischemic heart disease | 0.0009088 | 4.244 | WTAP | Serum ferritin |
| rs4516970 | Mastodynia | 0.008235 | 1.921 | WTAP | Serum ferritin |
| rs4516970 | Myocardial infarction | 0.003639 | 1.478 | WTAP | Serum ferritin |
| rs4516970 | Light-headedness and vertigo | 0.002115 | 1.388 | WTAP | Serum ferritin |
| rs4516970 | Disorders of cervical region | 0.001669 | 2.25 | WTAP | Serum ferritin |
| rs4516970 | Occlusion of cerebral arteries | 0.00968 | 1.558 | WTAP | Serum ferritin |
| rs4516970 | Spinal stenosis | 0.003469 | 1.456 | WTAP | Serum ferritin |
| rs4516970 | Sexual and gender identity disorders | 0.005419 | 2.213 | WTAP | Serum ferritin |
| rs4516970 | Chronic ischemic heart disease | 0.0001755 | 1.68 | WTAP | Serum ferritin |
| rs4516970 | Aneurysm of iliac artery | 0.009261 | 3.346 | WTAP | Serum ferritin |
| rs4516970 | Hypocalcemia | 0.003359 | 2.324 | WTAP | Serum ferritin |
| rs4516970 | Spinal stenosis of lumbar region | 0.001692 | 1.553 | WTAP | Serum ferritin |
| rs4516970 | Sarcoidosis | 0.002498 | 2.816 | WTAP | Serum ferritin |
| rs4516970 | Coronary atherosclerosis | 0.01031 | 1.297 | WTAP | Serum ferritin |
| rs4516970 | Other disorders of gallbladder | 0.002492 | 2.862 | WTAP | Serum ferritin |
| rs4516970 | Disorders of liver | 0.007416 | 1.353 | WTAP | Serum ferritin |
| rs4516970 | Dentofacial anomalies, including malocclusion | 0.006756 | 2.62 | WTAP | Serum ferritin |
| rs4516970 | Postmenopausal hormone replacement | 0.00153 | 2.406 | WTAP | Serum ferritin |
| rs4516970 | Degeneration of intervertebral disc | 0.01036 | 1.372 | WTAP | Serum ferritin |
| rs4516970 | Muscular wasting and disuse atrophy | 0.001319 | 2.859 | WTAP | Serum ferritin |
| rs4516970 | Congenital anomalies of peripheral vascular system | 0.001627 | 3.377 | WTAP | Serum ferritin |
| rs4528684 | Primary pulmonary hypertension | 0.007917 | 0.2596 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Chronic renal failure | 0.007049 | 0.8182 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Curvature of spine | 0.005877 | 0.6418 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Other hypertensive complications | 0.006924 | 0.6281 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Uterine/Uterovaginal prolapse | 0.001519 | 1.54 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Phlebitis and thrombophlebitis | 0.007079 | 0.7126 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Dementia with cerebral degenerations | 0.008054 | 1.811 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Cyst or abscess of Bartholin's gland | 0.002311 | 2.52 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Noninflammatory disorders of vulva and perineum | 0.00715 | 1.754 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Acute periodontitis | 0.01109 | 0.516 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Attention deficit hyperactivity disorder | 0.002645 | 2.108 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Type 2 diabetic peripheral circulatory disorders | 0.008459 | 0.4941 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Pervasive developmental disorders | 0.0005345 | 2.095 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Coagulation defects | 0.007026 | 0.8437 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Hypertrophy of female genital organs | 0.001268 | 2.22 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Poisoning by antibiotics | 0.01142 | 0.7258 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Infection/inflammation of internal prosthetic device, implant or graft | 0.006211 | 0.5943 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.0007754 | 0.7993 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Allergy/adverse effect of penicillin | 0.01089 | 0.688 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Excessive or frequent menstruation | 0.006501 | 1.525 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Peptic ulcer | 0.003065 | 0.7312 | LPHN1 | Mortality among heart failure patients |
| rs4537545 | Keloid scar | 0.00797 | 0.5823 | IL6R | C-reactive protein |
| rs4537545 | Iron deficiency anemia secondary to blood loss | 0.003672 | 1.35 | IL6R | C-reactive protein |
| rs4537545 | Cerebral edema and compression of brain | 0.003606 | 1.943 | IL6R | C-reactive protein |
| rs4537545 | Other specified intestinal malabsorption | 0.005915 | 1.709 | IL6R | C-reactive protein |
| rs4537545 | Constipation | 0.001219 | 1.166 | IL6R | C-reactive protein |
| rs4537545 | Morbid obesity | 0.004567 | 1.173 | IL6R | C-reactive protein |
| rs4537545 | Dementia with cerebral degenerations | 0.005672 | 1.552 | IL6R | C-reactive protein |
| rs4537545 | Psychogenic and somatoform disorders | 0.007786 | 1.258 | IL6R | C-reactive protein |
| rs4537545 | Malignant neoplasm of renal pelvis | 0.005581 | 0.391 | IL6R | C-reactive protein |
| rs4537545 | Cancer of larynx | 0.004356 | 1.496 | IL6R | C-reactive protein |
| rs4537545 | Disease of capillaries | 0.007804 | 0.7349 | IL6R | C-reactive protein |
| rs4537545 | Cancer of the upper aerodigestive tract | 0.007393 | 1.366 | IL6R | C-reactive protein |
| rs4537545 | Vitamin B12 deficiency anemia | 0.001118 | 1.662 | IL6R | C-reactive protein |
| rs4537545 | Somatoform disorder | 0.00312 | 1.378 | IL6R | C-reactive protein |
| rs4537545 | Renal cell carcinoma | 0.01129 | 0.7484 | IL6R | C-reactive protein |
| rs4537545 | Arthropathy NOS | 0.004482 | 1.189 | IL6R | C-reactive protein |
| rs4537545 | Polycythemia vera, secondary | 0.001701 | 1.72 | IL6R | C-reactive protein |
| rs4537545 | Diseases of the tongue | 0.005594 | 1.406 | IL6R | C-reactive protein |
| rs4537545 | Dystrophy of female genital tract | 0.003714 | 2.073 | IL6R | C-reactive protein |
| rs4537545 | Bipolar | 0.01095 | 1.363 | IL6R | C-reactive protein |
| rs4537545 | Bladder cancer | 0.003144 | 1.297 | IL6R | C-reactive protein |
| rs454305 | Deep vein thrombosis | 0.008907 | 1.267 | TGFA | Neutrophil count |
| rs454305 | Disorders of other cranial nerves | 0.008775 | 0.7697 | TGFA | Neutrophil count |
| rs454305 | Occlusion of cerebral arteries, with cerebral infarction | 0.01011 | 1.477 | TGFA | Neutrophil count |
| rs454305 | Valvular heart disease/ heart chambers | 0.009776 | 0.5184 | TGFA | Neutrophil count |
| rs454305 | Other biliary tract disease | 0.007369 | 1.269 | TGFA | Neutrophil count |
| rs454305 | Postmenopausal bleeding | 0.003858 | 1.251 | TGFA | Neutrophil count |
| rs454305 | Other disorders of gallbladder | 0.005606 | 1.606 | TGFA | Neutrophil count |
| rs454305 | Hypertensive heart disease | 0.005534 | 1.344 | TGFA | Neutrophil count |
| rs454305 | Premature menopause and other ovarian failure | 0.00469 | 1.929 | TGFA | Neutrophil count |
| rs454305 | Stomach cancer | 0.0003054 | 2.052 | TGFA | Neutrophil count |
| rs454305 | Epistaxis or throat hemorrhage | 0.005983 | 0.8089 | TGFA | Neutrophil count |
| rs454305 | Sicca syndrome | 0.003847 | 1.526 | TGFA | Neutrophil count |
| rs454305 | Trigeminal nerve disorders | 0.003451 | 0.6281 | TGFA | Neutrophil count |
| rs454305 | Hyperosmolality and/or hypernatremia | 0.001888 | 1.552 | TGFA | Neutrophil count |
| rs454305 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.01089 | 1.33 | TGFA | Neutrophil count |
| rs454305 | Intestinal infection due to C. difficile | 0.009541 | 1.364 | TGFA | Neutrophil count |
| rs454305 | Peritoneal or intestinal adhesions | 0.001483 | 1.734 | TGFA | Neutrophil count |
| rs454305 | Corneal degenerations | 0.006039 | 1.366 | TGFA | Neutrophil count |
| rs454305 | Nerve plexus lesions | 0.008167 | 1.424 | TGFA | Neutrophil count |
| rs454305 | Vascular insufficiency of intestine | 0.007803 | 1.41 | TGFA | Neutrophil count |
| rs454305 | Subarachnoid hemorrhage (injury) | 0.005634 | 2.133 | TGFA | Neutrophil count |
| rs454305 | Functional disorders of bladder | 0.001488 | 1.373 | TGFA | Neutrophil count |
| rs4649203 | Congenital musculoskeletal deformities of spine | 0.009175 | 1.424 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Renal colic | 0.004719 | 0.4834 | IL28RA | Psoriasis vulgaris |
| rs4649203 | stress incontinence, female | 0.002176 | 1.23 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Cardiomegaly | 0.009264 | 1.162 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Syncope and collapse | 0.004206 | 1.139 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Lupus erythematosus | 0.01054 | 0.4327 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Cyst and pseudocyst of pancreas | 0.007696 | 1.617 | IL28RA | Psoriasis vulgaris |
| rs4650608 | Posttraumatic stress disorder | 0.00633 | 0.5924 | PTGFR | Bipolar disorder |
| rs4650608 | Polyneuropathy in diabetes | 0.0009243 | 0.7915 | PTGFR | Bipolar disorder |
| rs4650608 | Failure to thrive | 0.009219 | 0.6958 | PTGFR | Bipolar disorder |
| rs4650608 | Hematemesis | 0.002197 | 0.5246 | PTGFR | Bipolar disorder |
| rs4650608 | Other abnormal glucose | 0.005284 | 0.8634 | PTGFR | Bipolar disorder |
| rs4650608 | Other specified disorders of breast | 0.0004519 | 1.341 | PTGFR | Bipolar disorder |
| rs4650608 | Dysthymic disorder | 0.005749 | 0.84 | PTGFR | Bipolar disorder |
| rs4650608 | Other disorders of bone and cartilage | 0.001266 | 0.7751 | PTGFR | Bipolar disorder |
| rs4650608 | Acidosis | 0.00184 | 0.6584 | PTGFR | Bipolar disorder |
| rs4650608 | Corneal dystrophy | 0.008343 | 1.306 | PTGFR | Bipolar disorder |
| rs4650608 | Labyrinthitis | 0.0002808 | 1.517 | PTGFR | Bipolar disorder |
| rs4650608 | Symptoms involving cardiovascular system | 0.006541 | 1.167 | PTGFR | Bipolar disorder |
| rs4650608 | Type 2 diabetes | 0.007024 | 0.9145 | PTGFR | Bipolar disorder |
| rs4650608 | Type 2 diabetic neuropathy | 0.0111 | 0.8497 | PTGFR | Bipolar disorder |
| rs4650608 | Keratoderma, acquired | 0.005149 | 0.8443 | PTGFR | Bipolar disorder |
| rs4650608 | Acid-base balance disorder | 0.009097 | 0.7502 | PTGFR | Bipolar disorder |
| rs4650608 | Diabetes mellitus | 0.01046 | 0.9196 | PTGFR | Bipolar disorder |
| rs4650608 | Gastroparesis | 0.00357 | 0.4927 | PTGFR | Bipolar disorder |
| rs4650608 | Genu valgum or varum (acquired) | 0.00286 | 1.484 | PTGFR | Bipolar disorder |
| rs4650608 | Lack of normal physiological development | 0.01129 | 0.7225 | PTGFR | Bipolar disorder |
| rs4650608 | Althete's foot | 0.00278 | 0.7566 | PTGFR | Bipolar disorder |
| rs4650608 | Bladder neck obstruction | 0.001552 | 1.325 | PTGFR | Bipolar disorder |
| rs4656461 | Intestinal obstruction without mention of hernia | 0.007237 | 0.7531 | TMCO1 | Glaucoma |
| rs4656461 | Appendicitis | 0.005743 | 1.574 | TMCO1 | Glaucoma |
| rs4656461 | Ventral hernia | 0.005013 | 0.6312 | TMCO1 | Glaucoma |
| rs4656461 | Benign neoplasm of unspecified sites | 0.004004 | 2.433 | TMCO1 | Glaucoma |
| rs4656461 | Back pain | 0.007638 | 0.8873 | TMCO1 | Glaucoma |
| rs4656461 | Eating disorder | 0.009317 | 1.811 | TMCO1 | Glaucoma |
| rs4656461 | Cancer of larynx | 0.01065 | 1.604 | TMCO1 | Glaucoma |
| rs4656461 | Other hypertrophic and atrophic conditions of skin | 0.00611 | 0.8444 | TMCO1 | Glaucoma |
| rs4656461 | Allergic conjunctivitis | 0.001744 | 1.478 | TMCO1 | Glaucoma |
| rs4656461 | Ankylosis of joint | 0.004355 | 0.4632 | TMCO1 | Glaucoma |
| rs4656461 | Breast disorder NOS | 0.003761 | 2.651 | TMCO1 | Glaucoma |
| rs4656461 | Noninflammatory disorders of vagina | 0.00707 | 1.487 | TMCO1 | Glaucoma |
| rs4656461 | Heartburn | 0.009822 | 1.502 | TMCO1 | Glaucoma |
| rs4656461 | Conjunctivitis, noninfectious | 0.003271 | 1.402 | TMCO1 | Glaucoma |
| rs4656461 | Acute pancreatitis | 0.009797 | 1.382 | TMCO1 | Glaucoma |
| rs4656461 | Dermatophytosis of the body | 0.009616 | 0.5792 | TMCO1 | Glaucoma |
| rs4656461 | Heart valve disorders | 0.009751 | 0.8569 | TMCO1 | Glaucoma |
| rs4656461 | Paralytic ileus | 0.008707 | 0.6087 | TMCO1 | Glaucoma |
| rs4657178 | Non-Hodgkins lymphoma | 0.0003084 | 0.6562 | NOS1AP | QT interval |
| rs4657178 | Malignant neoplasm of ovary | 0.003137 | 0.4375 | NOS1AP | QT interval |
| rs4657178 | Degeneration of intervertebral disc | 0.007678 | 1.132 | NOS1AP | QT interval |
| rs4657178 | Hallucinations | 0.001428 | 2.08 | NOS1AP | QT interval |
| rs4657178 | Disaccharide malabsorption | 0.01005 | 1.187 | NOS1AP | QT interval |
| rs4657178 | Cancer of other lymphoid, histiocytic tissue | 0.0009112 | 0.6885 | NOS1AP | QT interval |
| rs4657178 | Symptoms involving urinary system | 0.008506 | 1.271 | NOS1AP | QT interval |
| rs4657178 | Ovarian cancer | 0.008385 | 0.5585 | NOS1AP | QT interval |
| rs4657178 | Hypertensive heart disease | 0.0007945 | 1.473 | NOS1AP | QT interval |
| rs4657178 | Elevated prostate specific antigen | 0.005001 | 1.226 | NOS1AP | QT interval |
| rs4657178 | Spondylosis with myelopathy | 0.003484 | 1.445 | NOS1AP | QT interval |
| rs4657178 | Hallux rigidus | 0.00885 | 1.417 | NOS1AP | QT interval |
| rs4657178 | Disorders of choroid | 0.009449 | 0.7361 | NOS1AP | QT interval |
| rs4657178 | Lymphosarcoma | 0.002982 | 0.2131 | NOS1AP | QT interval |
| rs4657178 | Septicemia | 0.004198 | 0.8128 | NOS1AP | QT interval |
| rs4657178 | Adverse effects of hormones and synthetic substitutes | 0.008993 | 0.255 | NOS1AP | QT interval |
| rs4676406 | Labyrinthitis | 0.003291 | 1.402 | GPR35 | Ulcerative colitis |
| rs4676406 | Aneurysm of other specified artery | 0.005288 | 1.892 | GPR35 | Ulcerative colitis |
| rs4676406 | Pruritus and related conditions | 0.009164 | 1.186 | GPR35 | Ulcerative colitis |
| rs4676406 | Chronic prostatitis | 0.002429 | 1.611 | GPR35 | Ulcerative colitis |
| rs4676406 | Unspecified monoarthritis | 0.007319 | 1.626 | GPR35 | Ulcerative colitis |
| rs4676406 | Open wound of foot except toe(s) alone | 0.003012 | 0.63 | GPR35 | Ulcerative colitis |
| rs4676406 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.002677 | 0.7998 | GPR35 | Ulcerative colitis |
| rs4676406 | Nonrheumatic tricuspid valve disorders | 0.007452 | 1.441 | GPR35 | Ulcerative colitis |
| rs4676406 | Late effects of cerebrovascular disease | 0.009645 | 1.166 | GPR35 | Ulcerative colitis |
| rs4676406 | Right bundle branch block | 0.007062 | 1.281 | GPR35 | Ulcerative colitis |
| rs4676406 | Pneumonitis due to inhalation of food or vomitus | 0.0002181 | 0.6727 | GPR35 | Ulcerative colitis |
| rs4676406 | Anomalies of tooth position/malocclusion | 0.005245 | 1.672 | GPR35 | Ulcerative colitis |
| rs4676406 | Lump or mass in breast | 0.005704 | 0.8614 | GPR35 | Ulcerative colitis |
| rs4701252 | Nontoxic multinodular goiter | 0.007647 | 0.7216 | CDH12 | Waist circumference |
| rs4701252 | Other immunological findings | 0.008614 | 1.383 | CDH12 | Waist circumference |
| rs4701252 | Fracture of radius and ulna | 0.003816 | 1.248 | CDH12 | Waist circumference |
| rs4701252 | Type 2 diabetic neuropathy | 0.006198 | 0.7977 | CDH12 | Waist circumference |
| rs4701252 | Other aneurysm | 0.002689 | 0.7781 | CDH12 | Waist circumference |
| rs4701252 | Behcet's syndrome | 0.006824 | 1.67 | CDH12 | Waist circumference |
| rs4701252 | Abdominal aortic aneurysm | 0.005425 | 0.7383 | CDH12 | Waist circumference |
| rs4701252 | Agorophobia, social phobia, and panic disorder | 0.006155 | 0.6079 | CDH12 | Waist circumference |
| rs4701252 | Chronic obstructive asthma with exacerbation | 0.005296 | 1.798 | CDH12 | Waist circumference |
| rs4701252 | Osteoporosis, osteopenia, & pathological fractures | 0.006279 | 1.129 | CDH12 | Waist circumference |
| rs4701252 | Nephritis & nephropathy | 0.007313 | 0.429 | CDH12 | Waist circumference |
| rs4701252 | Diseases of lips | 0.008027 | 1.561 | CDH12 | Waist circumference |
| rs4701252 | Aortic aneurysm | 0.003249 | 0.7597 | CDH12 | Waist circumference |
| rs4701252 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.008267 | 0.4335 | CDH12 | Waist circumference |
| rs4704970 | Valvular heart disease/ heart chambers | 0.01103 | 1.764 | SGCD | Multiple sclerosis |
| rs4704970 | Essential tremor | 0.00653 | 0.6864 | SGCD | Multiple sclerosis |
| rs4704970 | Arthropathy NOS involving multiple sites | 0.008042 | 1.651 | SGCD | Multiple sclerosis |
| rs4704970 | Personal history of allergy to medicinal agents | 0.005505 | 1.322 | SGCD | Multiple sclerosis |
| rs4704970 | Heart valve replaced | 0.006915 | 1.34 | SGCD | Multiple sclerosis |
| rs4704970 | Open-angle glaucoma | 0.01046 | 0.8332 | SGCD | Multiple sclerosis |
| rs4704970 | Other acute and subacute forms of ischemic heart disease | 0.01044 | 1.838 | SGCD | Multiple sclerosis |
| rs4704970 | Unspecified local infection of skin and subcutaneous tissue | 0.001281 | 1.373 | SGCD | Multiple sclerosis |
| rs4704970 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.00792 | 1.231 | SGCD | Multiple sclerosis |
| rs4713693 | Late effects of cerebrovascular disease | 0.006263 | 1.173 | HLA-E | Graves' disease |
| rs4713693 | Urethral stricture (not specified as infectious) | 0.01039 | 0.7076 | HLA-E | Graves' disease |
| rs4713693 | Heart transplant/surgery | 0.002646 | 1.487 | HLA-E | Graves' disease |
| rs4713693 | Viral Enteritis | 0.009568 | 0.6808 | HLA-E | Graves' disease |
| rs4713693 | Other hypertrophic and atrophic conditions of skin | 0.0008197 | 1.138 | HLA-E | Graves' disease |
| rs4713693 | Cystitis and urethritis | 0.00907 | 0.8351 | HLA-E | Graves' disease |
| rs4713693 | Osteochondropathies | 0.007917 | 0.5109 | HLA-E | Graves' disease |
| rs4713693 | Psoriasis & related disorders | 0.00986 | 0.8192 | HLA-E | Graves' disease |
| rs4713693 | Vascular insufficiency of intestine | 0.007236 | 0.7073 | HLA-E | Graves' disease |
| rs4713693 | Gastrointestinal complications | 0.01059 | 1.246 | HLA-E | Graves' disease |
| rs4713693 | Plasma protein metabolism disorder | 0.01056 | 1.271 | HLA-E | Graves' disease |
| rs4713693 | Genital prolapse | 0.009546 | 1.157 | HLA-E | Graves' disease |
| rs4713693 | Secondary malignancy of lymph nodes | 0.006291 | 0.7917 | HLA-E | Graves' disease |
| rs4732812 | Generalized anxiety disorder | 0.003146 | 1.34 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Develomental delays and disorders | 0.004398 | 1.311 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Late effects of cerebrovascular disease | 0.001831 | 1.218 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Senile dementia | 0.007047 | 1.247 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Speech and language disorder | 0.004268 | 1.451 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Occlusion of cerebral arteries | 0.0005604 | 1.261 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Dysphagia | 0.002476 | 1.152 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Other disorders of middle ear and mastoid | 0.0007011 | 1.62 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Mastoiditis | 1.927e-06 | 3.685 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Acute, but ill-defined cerebrovascular disease | 0.009917 | 1.196 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hematuria | 0.01103 | 1.118 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Arthropathy NOS | 0.007834 | 1.189 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Aphasia/speech disturbance | 0.009055 | 1.235 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Gingival and periodontal diseases | 0.001838 | 1.241 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Abnormal findings on radiological breast exam | 0.002358 | 1.664 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Lipoid metabolism disorder NOS | 0.0006649 | 0.705 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Symptoms involving urinary system | 0.0005292 | 1.359 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Nonspecific findings on examination of blood | 0.01078 | 1.304 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Polyp of female genital organs | 0.005818 | 1.282 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hemiplegia | 0.002727 | 1.392 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Acute periodontitis | 0.00155 | 1.469 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Ischemic stroke | 0.0008945 | 1.264 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Influenza | 0.008465 | 1.353 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Peripheral enthesopathies | 0.004598 | 1.109 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Allergic conjunctivitis | 0.00392 | 0.7441 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hallucinations | 0.01147 | 1.778 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Periodontitis (acute or chronic) | 0.00261 | 1.265 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Intracranial hemorrhage (injury) | 0.001721 | 1.584 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Keratitis, infectious | 0.009175 | 0.6832 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Disorders of parathyroid gland | 0.002589 | 1.346 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Exophthalmos | 0.000282 | 2.286 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hyperparathyroidism | 0.008556 | 1.31 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Mucous polyp of cervix | 0.003077 | 1.46 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Blood vessel replaced | 0.008289 | 0.5796 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Chronic periodontitis | 0.006648 | 1.272 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4764043 | Gastrointestinal complications | 0.005568 | 1.487 | GRIN2B | Aging |
| rs4764043 | Pallor and flushing | 0.01088 | 1.65 | GRIN2B | Aging |
| rs4764043 | Abnormal glucose | 0.003081 | 0.7935 | GRIN2B | Aging |
| rs4764043 | Schizophrenia and other psychotic disorders | 0.001403 | 0.6285 | GRIN2B | Aging |
| rs4764043 | Congenital musculoskeletal anomalies | 0.006508 | 2.691 | GRIN2B | Aging |
| rs4764043 | Jaw disease NOS | 0.007498 | 1.826 | GRIN2B | Aging |
| rs4764043 | Type 2 diabetes | 0.005528 | 0.8427 | GRIN2B | Aging |
| rs4764043 | Wheezing and painful respiration | 0.001061 | 0.7423 | GRIN2B | Aging |
| rs4764043 | Diabetes mellitus | 0.01105 | 0.8572 | GRIN2B | Aging |
| rs4764043 | Retinal detachment with retinal defect | 0.001617 | 1.849 | GRIN2B | Aging |
| rs4789939 | Adverse effects of opiates and related narcotics in therapeutic use | 0.0003853 | 1.531 | TIMP2 | Dupuytren's disease |
| rs4789939 | Anemia of chronic disease | 0.0002829 | 1.356 | TIMP2 | Dupuytren's disease |
| rs4789939 | Decreased libido | 0.001089 | 2.448 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic nonalcoholic liver disease | 0.0008139 | 1.388 | TIMP2 | Dupuytren's disease |
| rs4789939 | Hyposmolality and/or hyponatremia | 0.001882 | 1.257 | TIMP2 | Dupuytren's disease |
| rs4789939 | Spinal stenosis of lumbar region | 0.005828 | 1.194 | TIMP2 | Dupuytren's disease |
| rs4789939 | Complications of gastrostomy, colostomy and enterostomy | 0.0006032 | 2.408 | TIMP2 | Dupuytren's disease |
| rs4789939 | Anemia in chronic kidney disease | 0.002773 | 1.426 | TIMP2 | Dupuytren's disease |
| rs4789939 | Type 2 diabetic retinopathy | 0.004156 | 1.275 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic ulcer of skin | 0.002307 | 1.189 | TIMP2 | Dupuytren's disease |
| rs4789939 | Open wound of eye or eyelid | 0.003158 | 2.317 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic ulcer of leg or foot | 0.01103 | 1.183 | TIMP2 | Dupuytren's disease |
| rs4789939 | Malaise and fatigue | 0.008185 | 0.8977 | TIMP2 | Dupuytren's disease |
| rs4789939 | Other cerebral degenerations | 0.008044 | 0.5744 | TIMP2 | Dupuytren's disease |
| rs4789939 | Carbuncle and furuncle | 0.01047 | 1.571 | TIMP2 | Dupuytren's disease |
| rs4789939 | Systolic/diastolic heart failure | 0.003679 | 1.174 | TIMP2 | Dupuytren's disease |
| rs4789939 | Other nonspecific findings on examination of urine | 0.01067 | 1.245 | TIMP2 | Dupuytren's disease |
| rs4789939 | Neoplasm of uncertain behavior | 0.0009312 | 0.7384 | TIMP2 | Dupuytren's disease |
| rs4789939 | Abnormal heart sounds | 0.0009693 | 1.272 | TIMP2 | Dupuytren's disease |
| rs4789939 | Heart failure | 0.003185 | 1.17 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic liver disease and cirrhosis | 0.0002251 | 1.406 | TIMP2 | Dupuytren's disease |
| rs4789939 | Acquired spondylolisthesis | 0.003753 | 1.414 | TIMP2 | Dupuytren's disease |
| rs4789939 | Abnormal findings examination of lungs | 0.003263 | 1.244 | TIMP2 | Dupuytren's disease |
| rs4789939 | Mastodynia | 0.008119 | 0.7089 | TIMP2 | Dupuytren's disease |
| rs4789939 | Abnormal kidney function | 0.008781 | 2.075 | TIMP2 | Dupuytren's disease |
| rs4789939 | Other acquired musculoskeletal deformity | 0.0006204 | 1.397 | TIMP2 | Dupuytren's disease |
| rs4789939 | Spinal stenosis | 0.008535 | 1.166 | TIMP2 | Dupuytren's disease |
| rs4795067 | Eye infection, viral | 0.006636 | 1.402 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Dermatomycoses | 0.004875 | 0.5318 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Other hemoglobinopathies | 0.005945 | 0.4104 | NOS2 | Psoriasis vulgaris |
| rs4795067 | First degree AV block | 0.006896 | 1.245 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Central/nonobstroctive sleep apnea | 0.007201 | 0.5617 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Benign neoplasm of respiratory and intrathoracic organs | 5.476e-05 | 0.3127 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Peritoneal or intestinal adhesions | 0.0076 | 0.5913 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Gingival and periodontal diseases | 0.00166 | 1.231 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Calculus of bile duct | 0.00732 | 0.7225 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Ulcerative stomatitis & mucositis | 0.007092 | 1.776 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Other disorders of soft tissues | 0.01115 | 1.362 | NOS2 | Psoriasis vulgaris |
| rs4815868 | Postmenopausal atrophic vaginitis | 0.009616 | 1.297 | C20orf196 | Cognitive performance |
| rs4815868 | Malignant neoplasm of renal pelvis | 6.331e-05 | 3.148 | C20orf196 | Cognitive performance |
| rs4815868 | Nerve root lesions | 0.008099 | 1.718 | C20orf196 | Cognitive performance |
| rs4815868 | Torsion dystonia | 0.0114 | 1.641 | C20orf196 | Cognitive performance |
| rs4815868 | Paroxysmal tachycardia, unspecified | 0.004369 | 0.7691 | C20orf196 | Cognitive performance |
| rs4815868 | Facial nerve disorders | 0.01142 | 1.457 | C20orf196 | Cognitive performance |
| rs4815868 | Tinnitus | 0.01145 | 1.242 | C20orf196 | Cognitive performance |
| rs4815868 | Dyspareunia | 0.008375 | 1.683 | C20orf196 | Cognitive performance |
| rs4815868 | Cancer of kidney and renal pelvis | 0.008592 | 1.41 | C20orf196 | Cognitive performance |
| rs4815868 | Disorders of coccyx | 0.008167 | 0.6618 | C20orf196 | Cognitive performance |
| rs4815868 | Perforation of tympanic membrane | 0.004137 | 1.643 | C20orf196 | Cognitive performance |
| rs4815868 | Pruritus and related conditions | 0.01012 | 0.7869 | C20orf196 | Cognitive performance |
| rs4815868 | Plasma protein metabolism disorder | 0.005614 | 1.376 | C20orf196 | Cognitive performance |
| rs4815868 | Paraproteinemia | 0.005719 | 1.465 | C20orf196 | Cognitive performance |
| rs4815868 | Cardiac arrhythmia NOS | 0.006197 | 0.829 | C20orf196 | Cognitive performance |
| rs4820268 | Polycystic ovaries | 0.003577 | 0.4373 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Other anemias | 0.007442 | 1.084 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Anemia NOS | 0.003312 | 1.1 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Iron deficiency anemias | 0.0006038 | 1.178 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Iron deficiency anemias NOS | 0.0006182 | 1.167 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.002273 | 1.781 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Other intestinal obstruction | 0.007002 | 1.243 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Nontoxic uninodular goiter | 0.009928 | 0.8227 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Functional digestive disorders | 0.002635 | 1.157 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Noninfectious gastroenteritis | 0.0001486 | 1.223 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Ovarian dysfunction | 0.001634 | 0.462 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.003314 | 1.371 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Scar conditions and fibrosis of skin | 0.006442 | 1.294 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Deficiency anemias NOS | 0.002055 | 1.474 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Keratoconjunctivitis sicca | 0.005631 | 0.6077 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4820268 | Superficial cellulitis and abscess | 0.01058 | 1.091 | TMPRSS6 | Serum iron concentration, Iron levels, Mean corpuscular volume, Mean corpuscular hemoglobin concentration, Mean corpuscular hemoglobin, Serum iron levels |
| rs4838605 | Pallor and flushing | 0.005063 | 0.6741 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Mastoiditis | 0.006568 | 0.4009 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Thrombocytopenia | 0.007818 | 1.18 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Osteoporosis, osteopenia, & pathological fractures | 0.007129 | 1.099 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Senile dementia | 0.00665 | 1.226 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Sacroiliitis NEC | 0.006789 | 0.5079 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Gout | 0.00672 | 0.8564 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Other biliary tract disease | 0.01012 | 1.249 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Ovarian dysfunction | 0.007584 | 0.4981 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Benign neoplasm of colon | 0.005343 | 0.9101 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Polycystic ovaries | 0.008473 | 0.451 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Gout and other crystal arthropathies | 0.006556 | 0.8653 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Insulin pump user | 0.008954 | 0.7939 | ARHGAP22 | Diabetic retinopathy |
| rs4902642 | Sinoatrial node dysfunction | 0.004996 | 0.7595 | ZFP36L1 | Crohn's disease |
| rs4902642 | Other specified diseases of hair and hair follicles | 0.00139 | 1.384 | ZFP36L1 | Crohn's disease |
| rs4902642 | Meningitis | 0.0001116 | 2.225 | ZFP36L1 | Crohn's disease |
| rs4902642 | Psychogenic and somatoform disorders | 0.009567 | 0.7937 | ZFP36L1 | Crohn's disease |
| rs4902642 | Heart failure NOS | 0.005187 | 0.7652 | ZFP36L1 | Crohn's disease |
| rs4902642 | Multiple sclerosis | 0.01085 | 0.6545 | ZFP36L1 | Crohn's disease |
| rs4902642 | Other immunological findings | 0.007842 | 1.313 | ZFP36L1 | Crohn's disease |
| rs4902642 | Cellulitis and abscess of arm | 0.0009029 | 0.7561 | ZFP36L1 | Crohn's disease |
| rs4902642 | Ptosis of eyelid | 0.009669 | 0.8379 | ZFP36L1 | Crohn's disease |
| rs4902642 | Circumscribed scleroderma | 0.007965 | 0.714 | ZFP36L1 | Crohn's disease |
| rs4902642 | Intestinal malabsorption | 0.004517 | 0.7118 | ZFP36L1 | Crohn's disease |
| rs4902642 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.004131 | 0.7331 | ZFP36L1 | Crohn's disease |
| rs4902642 | Cancer of the lower GI tract | 0.009481 | 1.344 | ZFP36L1 | Crohn's disease |
| rs4902642 | Other congenital anomalies of skin | 0.0008059 | 1.556 | ZFP36L1 | Crohn's disease |
| rs4902642 | Cardiac pacemaker in situ | 0.009572 | 0.8232 | ZFP36L1 | Crohn's disease |
| rs4902642 | Congenital deformities of feet | 0.001674 | 1.376 | ZFP36L1 | Crohn's disease |
| rs4902642 | Congenital anomalies of limbs | 0.003665 | 1.296 | ZFP36L1 | Crohn's disease |
| rs4902642 | Immune disorders | 0.006565 | 1.257 | ZFP36L1 | Crohn's disease |
| rs4917014 | Fever of unknown origin | 0.01127 | 0.8974 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Stomach cancer | 0.0112 | 0.5354 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Breast disorder NOS | 0.0006827 | 0.1924 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Ischemic Heart Disease | 0.001521 | 0.902 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Pulmonary congestion and hypostasis | 0.007123 | 0.7047 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Chronic ischemic heart disease | 0.006277 | 0.8674 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Symptoms/disorders of the urinary system | 0.004528 | 0.9106 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Cornea replaced by transplant | 0.007342 | 0.5047 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Hallux rigidus | 0.00888 | 1.387 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Encounter for long-term use of antiplatelets/antithrombotics | 0.001147 | 0.2666 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Coronary atherosclerosis | 0.00211 | 0.8999 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Premenstrual tension syndromes | 0.005987 | 0.5187 | IKZF1 | Systemic lupus erythematosus |
| rs4935969 | Vascular complications of surgery and medical procedures | 0.002377 | 1.639 | KIRREL3 | Hair color |
| rs4935969 | Varicose veins of lower extremity, symptomtic | 0.006422 | 1.219 | KIRREL3 | Hair color |
| rs4935969 | Congenital anomalies of peripheral vascular system | 0.0103 | 1.731 | KIRREL3 | Hair color |
| rs4935969 | Cholecystitis without cholelithiasis | 0.01079 | 0.7703 | KIRREL3 | Hair color |
| rs4935969 | Type 2 diabetic ketoacidosis | 0.004126 | 1.146 | KIRREL3 | Hair color |
| rs4935969 | Acquired deformities of limbs | 0.009249 | 1.21 | KIRREL3 | Hair color |
| rs4935969 | Hypermetropia | 0.0089 | 0.8828 | KIRREL3 | Hair color |
| rs4935969 | Nonrheumatic aortic valve disorders | 0.007598 | 1.155 | KIRREL3 | Hair color |
| rs4935969 | Cancer of the upper aerodigestive tract | 0.001215 | 1.461 | KIRREL3 | Hair color |
| rs4935969 | Allergic rhinitis | 0.005195 | 1.121 | KIRREL3 | Hair color |
| rs4935969 | Cancer of oropharynx | 0.001918 | 2.257 | KIRREL3 | Hair color |
| rs4935969 | Duodenal ulcer | 0.01009 | 1.302 | KIRREL3 | Hair color |
| rs4935969 | Drug-resistant infection | 0.008583 | 1.358 | KIRREL3 | Hair color |
| rs4935969 | Neutropenia | 0.007999 | 1.226 | KIRREL3 | Hair color |
| rs4935969 | Abnormal reflex | 0.01151 | 2.018 | KIRREL3 | Hair color |
| rs4935969 | Retinal detachments and defects | 0.01113 | 0.8244 | KIRREL3 | Hair color |
| rs4935969 | Unequal leg length (acquired) | 0.001946 | 1.539 | KIRREL3 | Hair color |
| rs4935969 | Protein plasma/amino-acid transport and metabolism disorder | 0.008878 | 1.253 | KIRREL3 | Hair color |
| rs4935969 | Other and unspecified disc disorder | 0.001023 | 1.596 | KIRREL3 | Hair color |
| rs4935969 | Insulin pump user | 0.009209 | 1.241 | KIRREL3 | Hair color |
| rs4935969 | Anomalies of pupillary function | 0.004024 | 0.4532 | KIRREL3 | Hair color |
| rs4935969 | Nontoxic nodular goiter | 0.001721 | 0.8175 | KIRREL3 | Hair color |
| rs4935969 | Arteritis NOS | 0.00559 | 1.58 | KIRREL3 | Hair color |
| rs4935969 | Chronic sinusitis | 0.007823 | 1.119 | KIRREL3 | Hair color |
| rs494620 | Dermatomyositis and Polymyositis | 0.005836 | 0.4196 | SLC44A4 | Menopause |
| rs494620 | Second degree AV block | 0.008453 | 1.487 | SLC44A4 | Menopause |
| rs494620 | Bacteremia | 0.0004042 | 1.392 | SLC44A4 | Menopause |
| rs494620 | Pulmonary collapse; interstitial/compensatory emphysema | 0.001802 | 1.195 | SLC44A4 | Menopause |
| rs494620 | Fracture of hand or wrist | 0.0006194 | 1.219 | SLC44A4 | Menopause |
| rs494620 | Colon cancer | 0.007274 | 1.235 | SLC44A4 | Menopause |
| rs494620 | Esophageal cancer | 0.001345 | 1.95 | SLC44A4 | Menopause |
| rs494620 | Adverse effects of adrenal cortical steroids | 0.006425 | 1.553 | SLC44A4 | Menopause |
| rs494620 | Joint effusions | 0.003457 | 1.235 | SLC44A4 | Menopause |
| rs494620 | Lymphosarcoma | 0.01047 | 1.985 | SLC44A4 | Menopause |
| rs494620 | Personal history of allergy to medicinal agents | 0.001868 | 1.31 | SLC44A4 | Menopause |
| rs494620 | Seborheic dermatitis | 0.01055 | 1.171 | SLC44A4 | Menopause |
| rs494620 | Corneal degenerations | 0.002898 | 1.387 | SLC44A4 | Menopause |
| rs494620 | Stomach cancer | 0.0003761 | 2.05 | SLC44A4 | Menopause |
| rs494620 | Disorders of lipoid metabolism | 0.005162 | 1.096 | SLC44A4 | Menopause |
| rs494620 | Rheumatoid arthritis | 0.002713 | 1.247 | SLC44A4 | Menopause |
| rs494620 | Osteoarthrosis | 0.006941 | 1.085 | SLC44A4 | Menopause |
| rs494620 | Benign neoplasm of colon | 0.002033 | 1.106 | SLC44A4 | Menopause |
| rs494620 | Septicemia | 0.001539 | 1.208 | SLC44A4 | Menopause |
| rs494620 | Other specified peripheral vascular diseases | 0.006979 | 0.4551 | SLC44A4 | Menopause |
| rs494620 | Hyperlipidemia | 0.01045 | 1.088 | SLC44A4 | Menopause |
| rs4952590 | Osteoarthrosis NOS | 0.003867 | 0.8712 | PKDCC | Atopy |
| rs4952590 | Other disorders of testis | 0.003672 | 1.596 | PKDCC | Atopy |
| rs4952590 | Polycythemia vera | 0.0009457 | 2.227 | PKDCC | Atopy |
| rs4952590 | Chronic obstructive asthma with exacerbation | 0.004406 | 1.874 | PKDCC | Atopy |
| rs4952590 | Pleurisy; pleural effusion | 0.008875 | 1.201 | PKDCC | Atopy |
| rs4952590 | Peripheral enthesopathies | 0.01023 | 0.8831 | PKDCC | Atopy |
| rs4952590 | Lung disease due to external agents | 0.01132 | 1.692 | PKDCC | Atopy |
| rs4952590 | Temporomandibular joint disorder NOS | 0.008709 | 0.3594 | PKDCC | Atopy |
| rs4952590 | Disorders of vitreous body | 0.01137 | 0.8471 | PKDCC | Atopy |
| rs4952590 | Iron deficiency anemias | 0.01097 | 1.193 | PKDCC | Atopy |
| rs4952590 | Hydrocele | 0.0002061 | 2.028 | PKDCC | Atopy |
| rs4952590 | Myeloproliferative disease | 0.0007342 | 1.615 | PKDCC | Atopy |
| rs4952590 | Pseudomonal pneumonia | 0.009014 | 2.333 | PKDCC | Atopy |
| rs4952590 | Pneumoconiosis | 0.007481 | 2.159 | PKDCC | Atopy |
| rs4952590 | Corneal degenerations | 0.01041 | 1.457 | PKDCC | Atopy |
| rs4952590 | Pruritus and related conditions | 0.009335 | 0.7564 | PKDCC | Atopy |
| rs4952590 | Otitis externa | 0.005445 | 0.7526 | PKDCC | Atopy |
| rs495366 | Herpes zoster with nervous system complications | 0.007687 | 0.5819 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Disorders of adrenal glands | 0.01034 | 1.329 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Throat pain | 0.003768 | 1.701 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Chronic pain syndrome | 0.004445 | 1.715 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Spondylosis and allied disorders | 0.008982 | 0.8936 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Disorders of other cranial nerves | 0.009795 | 0.7541 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Nerve plexus lesions | 0.009235 | 0.6427 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.005518 | 1.34 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Benign neoplasm of ovary | 0.004355 | 1.61 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Respiratory complications | 0.0007254 | 1.866 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Voice disturbance | 0.005912 | 1.231 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Cholecystitis without cholelithiasis | 0.007751 | 1.32 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Other disorders of gallbladder | 0.006796 | 1.61 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Eye infection, viral | 0.0008221 | 1.544 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Corneal edema | 0.004206 | 0.4937 | MMP3 | Matrix metalloproteinase-1 levels |
| rs4959235 | Intervertebral disc disorder with myelopathy | 0.004078 | 2.306 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Noninfectious disorders of lymphatic channels | 0.01084 | 1.557 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Sensorineural hearing loss | 0.007918 | 1.213 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Bronchitis | 0.002463 | 1.324 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Influenza | 0.001782 | 1.725 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Pernicious anemia | 0.003072 | 1.872 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Osteochondropathies | 0.005101 | 2.448 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.006428 | 1.613 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Asthma | 0.004822 | 1.26 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Conjunctivitis, noninfectious | 0.001777 | 1.536 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4964469 | Paranoid disorders | 0.006146 | 1.802 | LOC100287944 | Parkinson's disease |
| rs4964469 | Noninflammatory disorders of vagina | 0.005035 | 0.72 | LOC100287944 | Parkinson's disease |
| rs4964469 | Gouty arthropathy | 0.004227 | 1.321 | LOC100287944 | Parkinson's disease |
| rs4964469 | Aneurysm of artery of lower extremity | 0.002403 | 1.619 | LOC100287944 | Parkinson's disease |
| rs4964469 | Acute posthemorrhagic anemia | 0.001227 | 1.207 | LOC100287944 | Parkinson's disease |
| rs4964469 | Seborrhea | 0.00669 | 0.4695 | LOC100287944 | Parkinson's disease |
| rs4964469 | Noninflammatory female genital disorders | 0.003741 | 0.8237 | LOC100287944 | Parkinson's disease |
| rs4964469 | Cervicocranial/Cervicobrachial syndrome | 0.001704 | 0.7576 | LOC100287944 | Parkinson's disease |
| rs4964469 | Pneumonia | 0.01017 | 0.9061 | LOC100287944 | Parkinson's disease |
| rs4964469 | Posttraumatic wound infection | 0.002149 | 1.927 | LOC100287944 | Parkinson's disease |
| rs4964469 | Other specified diseases of the salivary glands | 0.005088 | 0.5304 | LOC100287944 | Parkinson's disease |
| rs4964469 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.01066 | 0.7451 | LOC100287944 | Parkinson's disease |
| rs4964469 | Hypercholesterolemia | 0.008947 | 1.111 | LOC100287944 | Parkinson's disease |
| rs4964469 | Otorrhea | 0.004143 | 0.4293 | LOC100287944 | Parkinson's disease |
| rs4977574 | Other forms of chronic heart disease | 0.001179 | 1.236 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cystitis and urethritis | 0.009029 | 1.197 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Chronic ischemic heart disease | 7.667e-06 | 1.239 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ulcerative colitis | 0.008605 | 0.6942 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | stress incontinence, female | 0.007042 | 0.8469 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Acute, but ill-defined cerebrovascular disease | 0.007128 | 1.19 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Neurological disorders due to brain damage | 0.005108 | 1.138 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ventricular fibrillation & flutter | 0.007578 | 1.612 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Abnormal electrocardiogram | 0.004546 | 1.154 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ill-defined descriptions and complications of heart disease | 0.001024 | 1.137 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac complications, not elsewhere classified | 0.002296 | 1.433 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Hypotension | 0.001051 | 1.162 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Symptoms involving digestive system | 0.00818 | 0.8235 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac conduction disorders | 0.002514 | 1.126 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Acne | 0.003665 | 0.764 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 2 diabetic neuropathy | 0.003474 | 1.191 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Renal failure NOS | 0.005621 | 1.336 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Unstable angina (intermediate coronary syndrome) | 2.164e-09 | 1.396 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Costochondritis | 0.002352 | 0.4994 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac pacemaker/device in situ | 0.007091 | 1.204 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Angina pectoris | 4.924e-05 | 1.203 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ischemic Heart Disease | 6.335e-10 | 1.207 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cystitis | 0.008031 | 1.214 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Aortic aneurysm | 0.008855 | 1.197 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Other aneurysm | 0.003168 | 1.201 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cerebrovascular disease | 0.00161 | 1.111 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Primary thrombocytopenia | 0.009887 | 0.6255 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Mild cognitive impairment | 0.01135 | 1.613 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Disorders of penis | 0.007013 | 0.7483 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 2 diabetic peripheral circulatory disorders | 0.004353 | 1.408 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Other infectious diseases | 0.005661 | 1.773 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Nephritis; nephrosis; renal sclerosis | 0.002849 | 1.249 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 2 diabetic nephropathy | 0.0003253 | 1.296 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Pseudomonal pneumonia | 0.009758 | 0.4471 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Hypotension NOS | 0.002286 | 1.207 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Atrial flutter | 0.01122 | 1.209 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 1 diabetic ketoacidosis | 0.005221 | 1.435 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Abdominal aortic aneurysm | 0.001384 | 1.289 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Symptoms involving cardiovascular system | 0.006124 | 1.158 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Polyneuropathy in diabetes | 0.0002201 | 1.273 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Occlusion and stenosis of precerebral arteries | 5.597e-05 | 1.205 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Central/nonobstroctive sleep apnea | 0.005889 | 1.681 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Myocardial infarction | 4.003e-08 | 1.28 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Paraproteinemia | 0.007277 | 0.7271 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac arrest & ventricular fibrillation | 0.005456 | 1.421 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.003054 | 1.196 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Coronary atherosclerosis | 1.002e-12 | 1.258 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac dysrhythmias | 0.004224 | 1.09 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Hemorrhoids | 0.0005759 | 0.8736 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4979906 | Prostate cancer | 0.01065 | 1.214 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Neck pain | 0.005454 | 1.128 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Optic neuritis/neuropathy | 0.005318 | 1.426 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Retinal disorders | 0.009923 | 1.134 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Osteoporosis, osteopenia, & pathological fractures | 0.004714 | 1.129 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Osteopenia | 0.001966 | 1.182 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Viral hepatitis C | 0.01005 | 1.542 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Arthropathy NOS involving multiple sites | 0.000336 | 1.942 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Pain in limb | 0.01123 | 1.104 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Respiratory failure; insufficiency; arrest | 0.002749 | 1.255 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Respiratory failure | 0.0005051 | 1.414 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Hemorrhage NOS | 0.008112 | 1.73 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Otosclerosis | 0.0009807 | 0.4521 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Respiratory insufficiency | 0.001798 | 1.405 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Heartburn | 0.01148 | 1.421 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Coronary atherosclerosis | 0.008337 | 1.112 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Anemia in neoplastic disease | 0.01141 | 0.6212 | KCNMA1 | Mortality among heart failure patients |
| rs4986172 | Vascular dementia | 0.005272 | 0.6933 | ACBD4 | Height |
| rs4986172 | Gout and other crystal arthropathies | 0.0004108 | 1.2 | ACBD4 | Height |
| rs4986172 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.00543 | 1.831 | ACBD4 | Height |
| rs4986172 | Mitral stenosis/insufficiency | 0.009819 | 0.4939 | ACBD4 | Height |
| rs4986172 | Aneurysm of artery of lower extremity | 0.006454 | 1.554 | ACBD4 | Height |
| rs4986172 | Lichen | 0.005842 | 0.6161 | ACBD4 | Height |
| rs4986172 | Elevated blood pressure reading | 0.009968 | 1.141 | ACBD4 | Height |
| rs4986172 | Essential tremor | 0.009729 | 0.7598 | ACBD4 | Height |
| rs4986172 | Alzheimer's disease | 0.004731 | 0.8319 | ACBD4 | Height |
| rs4986172 | Gout | 0.0002388 | 1.225 | ACBD4 | Height |
| rs4986172 | Hyperventilation | 0.001595 | 0.4617 | ACBD4 | Height |
| rs4986172 | Joint effusions | 0.006893 | 1.224 | ACBD4 | Height |
| rs4986172 | Abnormal results of function study of liver | 0.006834 | 1.219 | ACBD4 | Height |
| rs4986172 | Optic neuritis/neuropathy | 0.005076 | 1.362 | ACBD4 | Height |
| rs4986172 | Substance addiction and disorders | 0.007527 | 1.285 | ACBD4 | Height |
| rs4986172 | Random mental disorder. Ignored for now | 0.009228 | 1.498 | ACBD4 | Height |
| rs4986172 | Unequal leg length (acquired) | 0.0108 | 1.434 | ACBD4 | Height |
| rs4986172 | Cystic mastopathy | 0.007459 | 0.8523 | ACBD4 | Height |
| rs4986172 | Ankylosis of joint | 0.01072 | 1.402 | ACBD4 | Height |
| rs4986172 | Respiratory abnormalities | 0.005016 | 0.7305 | ACBD4 | Height |
| rs4986172 | Gastritis and duodenitis | 0.006877 | 1.146 | ACBD4 | Height |
| rs4986172 | Dementias | 0.002335 | 0.8445 | ACBD4 | Height |
| rs499697 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.00119 | 0.6756 | LCE3E | Hair morphology |
| rs499697 | Known or suspected fetal abnormality | 0.005684 | 0.5193 | LCE3E | Hair morphology |
| rs499697 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.01126 | 0.8036 | LCE3E | Hair morphology |
| rs499697 | Herpes zoster | 0.007064 | 0.8217 | LCE3E | Hair morphology |
| rs499697 | Symptoms and disorders of the joints | 0.0002037 | 0.8404 | LCE3E | Hair morphology |
| rs499697 | Decreased libido | 0.009028 | 0.3864 | LCE3E | Hair morphology |
| rs499697 | Acquired spondylolisthesis | 0.003311 | 1.351 | LCE3E | Hair morphology |
| rs499697 | H. pylori | 0.0003308 | 1.743 | LCE3E | Hair morphology |
| rs499697 | Fracture of foot | 0.00295 | 0.787 | LCE3E | Hair morphology |
| rs499697 | Stiffness of joint | 0.00508 | 0.8043 | LCE3E | Hair morphology |
| rs499697 | Temporomandibular joint disorder NOS | 0.005193 | 0.53 | LCE3E | Hair morphology |
| rs499697 | Cervical cancer and dysplasia | 0.006046 | 0.74 | LCE3E | Hair morphology |
| rs499697 | Amblyopia | 0.002468 | 0.6665 | LCE3E | Hair morphology |
| rs499697 | Paralysis/spasm of vocal cords or larynx | 0.003228 | 1.655 | LCE3E | Hair morphology |
| rs5015480 | Disorders of parathyroid gland | 0.001433 | 0.7308 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetic ketoacidosis | 0.0005544 | 0.8476 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetic retinopathy | 0.0002704 | 0.7756 | HHEX | Type 2 diabetes |
| rs5015480 | Diabetic retinopathy | 0.001266 | 0.8063 | HHEX | Type 2 diabetes |
| rs5015480 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.001289 | 0.7078 | HHEX | Type 2 diabetes |
| rs5015480 | Diseases of nail | 0.008335 | 0.8725 | HHEX | Type 2 diabetes |
| rs5015480 | Type 1 diabetic retinopathy | 0.004661 | 0.682 | HHEX | Type 2 diabetes |
| rs5015480 | Other specified diseases of nail | 0.003006 | 0.8539 | HHEX | Type 2 diabetes |
| rs5015480 | Hyperlipidemia | 0.006061 | 0.9138 | HHEX | Type 2 diabetes |
| rs5015480 | Glomerulonephritis | 0.007899 | 1.624 | HHEX | Type 2 diabetes |
| rs5015480 | Peripheral enthesopathies | 0.007593 | 0.9153 | HHEX | Type 2 diabetes |
| rs5015480 | Back pain | 0.004757 | 1.087 | HHEX | Type 2 diabetes |
| rs5015480 | Diabetes mellitus | 0.0006201 | 0.8993 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetes | 0.0004393 | 0.8955 | HHEX | Type 2 diabetes |
| rs5015480 | Postlaminectomy syndrome | 0.009516 | 1.373 | HHEX | Type 2 diabetes |
| rs5015480 | Hyperparathyroidism | 0.001488 | 0.7217 | HHEX | Type 2 diabetes |
| rs5015480 | Poisoning by primarily systemic agents | 0.003448 | 0.7383 | HHEX | Type 2 diabetes |
| rs5015480 | Enthesopathy | 0.005141 | 0.8917 | HHEX | Type 2 diabetes |
| rs5015480 | Chronic glomerulonephritis | 0.00962 | 2.073 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetic neuropathy | 0.001707 | 0.826 | HHEX | Type 2 diabetes |
| rs5015480 | Renal failure | 0.004645 | 0.9009 | HHEX | Type 2 diabetes |
| rs5015480 | Lipoid metabolism disorder NOS | 3.396e-05 | 0.6934 | HHEX | Type 2 diabetes |
| rs5015480 | Type 1 diabetes | 0.0006206 | 0.8098 | HHEX | Type 2 diabetes |
| rs5015480 | Superficial cellulitis and abscess | 0.008787 | 0.9126 | HHEX | Type 2 diabetes |
| rs5015480 | Hypercholesterolemia | 0.004465 | 0.8917 | HHEX | Type 2 diabetes |
| rs5015480 | Disorders of lipoid metabolism | 0.004905 | 0.9124 | HHEX | Type 2 diabetes |
| rs5015480 | Intervertebral disc disorders | 0.005254 | 1.103 | HHEX | Type 2 diabetes |
| rs5015480 | Epiphora | 0.01118 | 1.347 | HHEX | Type 2 diabetes |
| rs5031002 | Acute pancreatitis | 0.0003742 | 2.291 | AR | LDL Cholesterol |
| rs5031002 | Pneumonitis due to inhalation of food or vomitus | 0.004286 | 2.221 | AR | LDL Cholesterol |
| rs5031002 | Other acute and subacute forms of ischemic heart disease | 0.009918 | 3.49 | AR | LDL Cholesterol |
| rs5031002 | Cornea replaced by transplant | 0.008677 | 3.24 | AR | LDL Cholesterol |
| rs5031002 | Altered mental status | 0.009851 | 1.959 | AR | LDL Cholesterol |
| rs5031002 | Abnormal findings on study of brain, nervous system | 0.007808 | 2.568 | AR | LDL Cholesterol |
| rs5031002 | Fluid overload | 0.001472 | 2.15 | AR | LDL Cholesterol |
| rs531676 | Elevated sedimentation rate | 0.01035 | 0.7359 | CRTAC1 | Type 2 diabetes |
| rs531676 | Endometriosis | 0.00896 | 1.357 | CRTAC1 | Type 2 diabetes |
| rs531676 | Anxiety disorder | 0.001401 | 1.141 | CRTAC1 | Type 2 diabetes |
| rs531676 | Intestinal infection | 0.007695 | 1.21 | CRTAC1 | Type 2 diabetes |
| rs531676 | Derangement of joint, non-traumatic | 0.008039 | 1.233 | CRTAC1 | Type 2 diabetes |
| rs531676 | Acidosis | 0.004528 | 1.39 | CRTAC1 | Type 2 diabetes |
| rs531676 | Anxiety, phobic and dissociative disorders | 0.009169 | 1.099 | CRTAC1 | Type 2 diabetes |
| rs531676 | Jaundice | 0.006278 | 0.6803 | CRTAC1 | Type 2 diabetes |
| rs531676 | Schizophrenia | 0.002497 | 1.753 | CRTAC1 | Type 2 diabetes |
| rs531676 | Abnormal coagulation profile | 0.009595 | 1.341 | CRTAC1 | Type 2 diabetes |
| rs531676 | Anticoagulants causing adverse effects | 0.006844 | 1.639 | CRTAC1 | Type 2 diabetes |
| rs544368 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.0003512 | 1.606 | SIAE | Bipolar disorder |
| rs544368 | Joint/ligament sprain | 0.005827 | 0.6124 | SIAE | Bipolar disorder |
| rs544368 | Pneumoconiosis | 0.01087 | 2.07 | SIAE | Bipolar disorder |
| rs544368 | Electrolyte imbalance | 0.001381 | 1.178 | SIAE | Bipolar disorder |
| rs544368 | Colles' fracture | 0.005223 | 1.542 | SIAE | Bipolar disorder |
| rs544368 | Phosphorus metabolism disorder | 0.006481 | 1.588 | SIAE | Bipolar disorder |
| rs544368 | Deficiency of humoral immunity | 0.008419 | 2.266 | SIAE | Bipolar disorder |
| rs544368 | Wheezing | 0.00411 | 1.474 | SIAE | Bipolar disorder |
| rs544368 | Open wounds of extremities | 0.009457 | 1.167 | SIAE | Bipolar disorder |
| rs544368 | Hyperparathyroidism | 0.004762 | 0.6063 | SIAE | Bipolar disorder |
| rs544368 | Hemiplegia | 0.01085 | 1.432 | SIAE | Bipolar disorder |
| rs544368 | Iron deficiency anemias NOS | 0.008096 | 1.188 | SIAE | Bipolar disorder |
| rs544368 | Open wound of eye or eyelid | 0.00809 | 2.245 | SIAE | Bipolar disorder |
| rs544368 | Retinal drusen | 0.008775 | 1.337 | SIAE | Bipolar disorder |
| rs544368 | Atherosclerosis of the extremities | 0.009983 | 1.204 | SIAE | Bipolar disorder |
| rs544368 | Mechanical complication due to other implant and internal device | 0.004424 | 1.492 | SIAE | Bipolar disorder |
| rs544368 | Urinary incontinence | 0.01128 | 1.185 | SIAE | Bipolar disorder |
| rs544368 | E. coli | 3.436e-05 | 1.72 | SIAE | Bipolar disorder |
| rs544368 | Other disorders of ear | 0.008991 | 1.384 | SIAE | Bipolar disorder |
| rs544368 | Peritonitis and retroperitoneal infections | 0.0005454 | 1.737 | SIAE | Bipolar disorder |
| rs544368 | AV block | 0.01148 | 1.268 | SIAE | Bipolar disorder |
| rs544368 | Bacterial infection NOS | 2.454e-05 | 1.316 | SIAE | Bipolar disorder |
| rs544368 | Cellulitis and abscess of arm | 0.001151 | 1.425 | SIAE | Bipolar disorder |
| rs544368 | Eosinophilia | 0.001134 | 2.248 | SIAE | Bipolar disorder |
| rs544368 | Other infectious diseases | 0.008885 | 1.886 | SIAE | Bipolar disorder |
| rs544368 | Urinary tract infection | 0.00115 | 1.182 | SIAE | Bipolar disorder |
| rs544368 | Bacteremia | 0.0005032 | 1.54 | SIAE | Bipolar disorder |
| rs544368 | Acute renal failure | 0.00915 | 1.221 | SIAE | Bipolar disorder |
| rs544368 | Fracture of radius and ulna | 0.005029 | 1.275 | SIAE | Bipolar disorder |
| rs544368 | Lung disease due to external agents | 0.0005663 | 1.97 | SIAE | Bipolar disorder |
| rs544368 | Protein-calorie malnutrition | 0.0004058 | 1.319 | SIAE | Bipolar disorder |
| rs544368 | Nervous system congenital anomalies | 0.007459 | 1.556 | SIAE | Bipolar disorder |
| rs544368 | Tachycardia NOS | 0.003218 | 1.302 | SIAE | Bipolar disorder |
| rs544368 | Generalized anxiety disorder | 0.002687 | 1.458 | SIAE | Bipolar disorder |
| rs544368 | Cellulitis and abscess of foot/toes | 0.008818 | 1.383 | SIAE | Bipolar disorder |
| rs544368 | Late effects of cerebrovascular disease | 0.005114 | 1.263 | SIAE | Bipolar disorder |
| rs544368 | Symptoms/disorders of the urinary system | 2.405e-05 | 1.212 | SIAE | Bipolar disorder |
| rs544368 | Hepatic cancer | 0.00757 | 1.888 | SIAE | Bipolar disorder |
| rs5498 | Disorders of menstruation | 0.0009807 | 0.7988 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Irregular menstrual cycle/bleeding | 0.002706 | 0.8056 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Irregular menstrual cycle | 0.002041 | 0.6936 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Congenital anomalies of posterior segment of eye | 0.007021 | 1.291 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Hemorrhage NOS | 0.004723 | 0.5631 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Hematemesis | 0.008849 | 1.574 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Phobia | 0.001303 | 2.447 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Complication of amputation stump | 0.003917 | 1.953 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Unspecified polyarthropathy or polyarthritis | 0.00207 | 1.595 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Calculus of lower urinary tract | 0.01141 | 0.611 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Adverse effects of antirheumatics | 0.01104 | 1.657 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Otosclerosis | 0.008949 | 0.6693 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Seborheic dermatitis | 0.01065 | 1.174 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Prostate cancer | 0.00928 | 0.848 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Blood vessel replaced | 0.008787 | 1.532 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Cardiac complications, not elsewhere classified | 0.00915 | 0.7259 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs603424 | Thyroid cancer | 0.01007 | 1.539 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Hallux valgus (Bunion) | 0.006218 | 0.7933 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Hammer toe | 0.0008791 | 0.7355 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Hyperlipidemia | 0.0008354 | 1.151 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Corns and callosities | 0.00413 | 0.8109 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Miscarriage; stillbirth | 0.01025 | 1.838 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Torticollis | 0.001939 | 0.426 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Chronic liver disease and cirrhosis | 0.003667 | 1.296 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Acquired toe deformities | 0.0002295 | 0.7456 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Cardiac complications, not elsewhere classified | 0.001893 | 1.526 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Respiratory failure | 0.002894 | 1.36 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Secondary thrombocytopenia | 0.004699 | 1.748 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Dermatomycoses | 0.01013 | 1.713 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Disorders of lipoid metabolism | 0.000928 | 1.149 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Complications of transplants and reattached limbs | 0.004043 | 1.722 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Chronic nonalcoholic liver disease | 0.004944 | 1.303 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs6051520 | Atherosclerosis | 0.0003399 | 1.197 | TRIB3 | Cognitive performance |
| rs6051520 | Aortic aneurysm | 0.002314 | 1.273 | TRIB3 | Cognitive performance |
| rs6051520 | Femoral hernia | 0.0002623 | 2.335 | TRIB3 | Cognitive performance |
| rs6051520 | Decreased libido | 0.002934 | 2.16 | TRIB3 | Cognitive performance |
| rs6051520 | Nevus, non-neoplastic | 0.004198 | 1.774 | TRIB3 | Cognitive performance |
| rs6051520 | Disorders of the autonomic nervous system | 0.01047 | 1.322 | TRIB3 | Cognitive performance |
| rs6051520 | Ventral hernia | 0.004763 | 1.333 | TRIB3 | Cognitive performance |
| rs6051520 | Peripheral arterial disease | 0.00153 | 1.177 | TRIB3 | Cognitive performance |
| rs6051520 | Periostitis | 0.001055 | 2.078 | TRIB3 | Cognitive performance |
| rs6051520 | Immunity deficiency | 0.004156 | 1.737 | TRIB3 | Cognitive performance |
| rs6051520 | Disease of capillaries | 0.0002595 | 1.557 | TRIB3 | Cognitive performance |
| rs6051520 | Infections involving bone | 0.008096 | 1.285 | TRIB3 | Cognitive performance |
| rs6051520 | Pityriasis | 0.008907 | 2.116 | TRIB3 | Cognitive performance |
| rs6051520 | Sarcoidosis | 0.007391 | 1.634 | TRIB3 | Cognitive performance |
| rs6051520 | Aneurysm of artery of lower extremity | 0.01065 | 1.587 | TRIB3 | Cognitive performance |
| rs6051520 | Noninflammatory disorders of cervix | 0.0008545 | 1.925 | TRIB3 | Cognitive performance |
| rs6051520 | Peripheral vascular disease | 0.001818 | 1.159 | TRIB3 | Cognitive performance |
| rs6051520 | Bone cancer | 0.01132 | 0.4945 | TRIB3 | Cognitive performance |
| rs6051520 | Primary/intrinsic cardiomyopathies | 0.008734 | 1.206 | TRIB3 | Cognitive performance |
| rs6051520 | Other aneurysm | 0.0005021 | 1.283 | TRIB3 | Cognitive performance |
| rs6051520 | Disease of tricuspid valve | 0.008716 | 1.29 | TRIB3 | Cognitive performance |
| rs6051520 | Abdominal aortic aneurysm | 0.003192 | 1.306 | TRIB3 | Cognitive performance |
| rs6051520 | Atherosclerosis of the extremities | 0.0007311 | 1.213 | TRIB3 | Cognitive performance |
| rs6051520 | Arterial embolism and thrombosis | 0.006997 | 1.282 | TRIB3 | Cognitive performance |
| rs6051520 | Other specified disorders of plasma protein metabolism | 0.008994 | 0.2578 | TRIB3 | Cognitive performance |
| rs6051520 | Congenital cataract and lens anomalies | 0.00215 | 2.165 | TRIB3 | Cognitive performance |
| rs6051520 | Esophageal cancer | 0.003608 | 0.3606 | TRIB3 | Cognitive performance |
| rs6051520 | Internal derangement of knee | 0.008034 | 1.166 | TRIB3 | Cognitive performance |
| rs6080550 | Atopic or contact dermatitis | 0.005153 | 0.8569 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Angina pectoris | 0.003596 | 0.8091 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Musculoskeletal symptoms referable to limbs | 0.007831 | 0.675 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Other specified cardiac dysrhythmias | 4.763e-05 | 0.7437 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Cardiac arrhythmia NOS | 0.003137 | 0.7895 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Large cell lymphoma | 0.00744 | 2.15 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Postmenopausal atrophic vaginitis | 0.00802 | 0.7201 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atherosclerosis of renal artery | 0.007804 | 0.6526 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | AV block | 0.01111 | 0.7724 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Cardiac conduction disorders | 0.0005179 | 0.8098 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Alzheimer's disease | 0.005111 | 1.282 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atrial flutter | 0.0009198 | 0.6584 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Alcoholism | 0.003962 | 0.6864 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Other disorders of eyelids | 0.009772 | 0.8177 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atrial fibrillation | 0.00804 | 0.8344 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Unstable angina (intermediate coronary syndrome) | 0.001429 | 0.7471 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atrial fibrillation & flutter | 0.00771 | 0.8359 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Alcohol-related disorders | 0.008517 | 0.7466 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Exostosis of jaw | 0.0008252 | 2.652 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Abnormal electrocardiogram | 0.000137 | 0.7393 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Cardiac dysrhythmias | 0.0009902 | 0.8591 | LOC100289473 | Non-obstructive azoospermia |
| rs6092477 | Functional disorders of bladder | 0.002757 | 0.7165 | RBM38 | Mean corpuscular volume |
| rs6092477 | Other disorders of bladder | 0.0007349 | 0.8113 | RBM38 | Mean corpuscular volume |
| rs6092477 | Parkinson's disease | 0.01079 | 0.7675 | RBM38 | Mean corpuscular volume |
| rs6092477 | Perforation of tympanic membrane | 0.00902 | 1.487 | RBM38 | Mean corpuscular volume |
| rs6092477 | Swelling, mass, or lump in head and neck | 0.007214 | 0.7943 | RBM38 | Mean corpuscular volume |
| rs6092477 | Alcohol-related disorders | 0.01132 | 1.189 | RBM38 | Mean corpuscular volume |
| rs6092477 | Dermatophytosis of the body | 0.00104 | 0.6535 | RBM38 | Mean corpuscular volume |
| rs6092477 | Corneal degenerations | 0.01096 | 1.334 | RBM38 | Mean corpuscular volume |
| rs6092477 | Insect bite | 0.007856 | 0.7906 | RBM38 | Mean corpuscular volume |
| rs6092477 | Other disorders of tympanic membrane | 0.003906 | 1.48 | RBM38 | Mean corpuscular volume |
| rs6092477 | Nevus, non-neoplastic | 0.009491 | 1.617 | RBM38 | Mean corpuscular volume |
| rs6118083 | Wheezing and painful respiration | 0.002883 | 0.8425 | PLCB1 | Cognitive performance |
| rs6118083 | Other rheumatic heart disease | 0.004107 | 0.1272 | PLCB1 | Cognitive performance |
| rs6118083 | Other headache syndromes | 0.004988 | 1.133 | PLCB1 | Cognitive performance |
| rs6118083 | Disorders of function of stomach | 0.000401 | 1.247 | PLCB1 | Cognitive performance |
| rs6118083 | Mitral stenosis/insufficiency | 0.005241 | 0.2757 | PLCB1 | Cognitive performance |
| rs6118083 | Dislocation | 0.004121 | 1.154 | PLCB1 | Cognitive performance |
| rs6118083 | Other immunological findings | 0.009674 | 1.361 | PLCB1 | Cognitive performance |
| rs6118083 | Testicular hypofunction | 0.009762 | 1.441 | PLCB1 | Cognitive performance |
| rs6118083 | Other unspecified back disorders | 0.01011 | 1.59 | PLCB1 | Cognitive performance |
| rs6118083 | Dyspepsia and disorders of function of stomach | 0.000959 | 1.241 | PLCB1 | Cognitive performance |
| rs6118083 | Gastroparesis | 0.009523 | 1.746 | PLCB1 | Cognitive performance |
| rs6118083 | Pneumoconiosis | 0.00407 | 2.037 | PLCB1 | Cognitive performance |
| rs6118083 | Eustachian tube disorders | 0.0009961 | 1.363 | PLCB1 | Cognitive performance |
| rs6118083 | Symptomatic artificial menopause | 0.00405 | 0.548 | PLCB1 | Cognitive performance |
| rs6118083 | Noninfectious disorders of lymphatic channels | 0.002318 | 0.6305 | PLCB1 | Cognitive performance |
| rs6118083 | Memory loss | 0.002279 | 1.319 | PLCB1 | Cognitive performance |
| rs6118083 | Disorders of synovium, tendon, and bursa | 0.009084 | 1.138 | PLCB1 | Cognitive performance |
| rs6118083 | Mechanical complication due to other implant and internal device | 0.00206 | 0.6088 | PLCB1 | Cognitive performance |
| rs613872 | Appendiceal conditions | 0.0002756 | 1.664 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Enthesopathy | 0.008243 | 0.8643 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Sialoadenitis | 0.008187 | 1.552 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Cornea replaced by transplant | 0.005965 | 1.927 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Conjunctivitis, infectious | 0.00411 | 0.7999 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Umbilical hernia | 0.005277 | 0.694 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Appendicitis | 0.0005255 | 1.647 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Poisoning by antibiotics | 0.009504 | 0.786 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Corneal dystrophy | 3.156e-05 | 1.63 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Cervical radiculitis | 0.006032 | 0.7927 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Subarachnoid hemorrhage | 0.003304 | 2.131 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Fuchs' dystrophy | 2.891e-09 | 2.609 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Type 2 diabetic retinopathy | 0.007472 | 0.7743 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Acute appendicitis | 6.013e-06 | 2.045 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Nephritis and nephropathy in diseases classified elsewhere | 0.008845 | 0.6993 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Corneal edema | 0.00704 | 1.75 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Decreased libido | 0.005864 | 2.149 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Hemorrhage NOS | 0.006209 | 1.8 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Open wound of toe(s) | 0.003413 | 1.933 | TCF4 | Fuchs's corneal dystrophy |
| rs619865 | Cancer of other female genital organs | 0.009289 | 2.15 | EIF6 | Freckling |
| rs619865 | First degree AV block | 0.006132 | 0.6619 | EIF6 | Freckling |
| rs619865 | Pancreatic cancer | 0.002638 | 1.84 | EIF6 | Freckling |
| rs619865 | Skin cancer | 5.812e-05 | 1.251 | EIF6 | Freckling |
| rs619865 | Non-melanoma skin cancer | 0.0001073 | 1.254 | EIF6 | Freckling |
| rs619865 | Angina pectoris | 0.006075 | 0.8008 | EIF6 | Freckling |
| rs619865 | Other dermatoses | 0.007435 | 1.155 | EIF6 | Freckling |
| rs619865 | Prostatitis | 0.004198 | 1.511 | EIF6 | Freckling |
| rs619865 | Other endocrine disorders | 0.003666 | 1.845 | EIF6 | Freckling |
| rs619865 | Osteoarthrosis; localized, secondary | 0.01082 | 1.866 | EIF6 | Freckling |
| rs619865 | Iron metabolism disorder | 0.002726 | 2.393 | EIF6 | Freckling |
| rs619865 | Disorders of lipoid metabolism | 0.009332 | 0.8705 | EIF6 | Freckling |
| rs619865 | Hyperlipidemia | 0.007508 | 0.8661 | EIF6 | Freckling |
| rs619865 | Elevated sedimentation rate | 0.00989 | 1.557 | EIF6 | Freckling |
| rs619865 | Actinic keratosis | 0.000184 | 1.252 | EIF6 | Freckling |
| rs619865 | Phlebitis and thrombophlebitis | 0.006349 | 0.7099 | EIF6 | Freckling |
| rs619865 | Hypercholesterolemia | 0.00325 | 0.8203 | EIF6 | Freckling |
| rs6437740 | Dermatophytosis / Dermatomycosis | 0.006349 | 0.8868 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Schizophrenia | 0.007871 | 0.4825 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Diseases of nail | 0.007003 | 0.8504 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Other nonspecific findings on examination of urine | 0.006351 | 0.8034 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Dermatophytosis of nail | 0.004883 | 0.8637 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Dermatophytosis | 0.00534 | 0.882 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Adverse effects of adrenal cortical steroids | 0.007243 | 1.555 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Neuralgia, neuritis, and radiculitis NOS | 0.002196 | 0.7685 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Fracture of unspecified bones | 0.01032 | 0.8489 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Fracture of clavicle or scapula | 0.001502 | 0.5831 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Other specified diseases of nail | 0.004193 | 0.8374 | BBX | Smoking behavior (cigarettes per day) |
| rs6457617 | Elevated prostate specific antigen | 0.007034 | 1.185 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Lupus erythematosus | 0.01132 | 0.5451 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Keratoderma, acquired | 0.01083 | 1.154 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hearing loss | 0.0004866 | 1.115 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Diseases of the larynx and vocal cords | 0.01132 | 1.164 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Celiac disease | 0.004203 | 0.5232 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Polymyalgia Rheumatica | 0.0001792 | 1.394 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Male genital disorders | 0.002398 | 1.351 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Conjunctivitis, infectious | 0.01014 | 1.157 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Discoid lupus erythematosus | 0.00178 | 0.6468 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Non-melanoma skin cancer | 0.003482 | 1.114 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Acute sinusitis | 0.005204 | 1.143 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Celiac or tropical sprue | 0.001385 | 0.4885 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hypothyroidism | 0.007327 | 1.1 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Systemic lupus erythematosus | 0.007172 | 0.6707 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Acute upper respiratory infections | 0.003449 | 1.106 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Infertility, female | 0.003302 | 1.926 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Toxic multinodular goiter | 0.008756 | 1.813 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Abnormal electrocardiogram | 0.01027 | 1.137 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Congenital anomalies of great vessels | 0.008309 | 0.5043 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Varicose veins | 0.01127 | 0.8779 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Rheumatoid arthritis | 4.538e-05 | 1.354 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hematuria | 0.00217 | 1.131 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Photodermatitis & sunburn | 0.006967 | 1.172 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Sensorineural hearing loss | 0.008088 | 1.103 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Skin cancer | 0.00741 | 1.098 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Type 1 diabetes | 0.001502 | 1.209 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Adverse effects of insulins and antidiabetic agents | 0.0008516 | 0.4637 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hyperglyceridemia | 0.00644 | 1.243 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Multiple sclerosis | 0.000949 | 0.5818 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hyperplasia of prostate | 0.007619 | 1.143 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Psoriasis & related disorders | 0.01093 | 1.214 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Rheumatoid arthritis & related inflammatory polyarthropathies | 5.685e-05 | 1.304 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs646776 | Mixed hyperlipidemia | 0.001525 | 0.7957 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Renal failure | 0.005301 | 0.8829 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Disorders of lipoid metabolism | 1.189e-08 | 0.8008 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Chronic renal failure | 0.00481 | 0.867 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Osteoarthrosis, generalized | 0.01058 | 1.236 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hypertensive chronic kidney disease | 0.008289 | 0.8062 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Calcium/phosphorus disorders | 0.009375 | 1.218 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.008534 | 0.8234 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Atherosclerosis | 0.002304 | 0.8527 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hyperlipidemia | 1.743e-08 | 0.8015 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Early or threatened labor; hemorrhage in early pregnancy | 0.002246 | 1.878 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | ASCVD | 0.007436 | 0.6651 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Acute reaction to stress | 0.009428 | 1.283 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Scar conditions and fibrosis of skin | 0.01068 | 0.7252 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Unstable angina (intermediate coronary syndrome) | 0.009855 | 0.8371 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hypocalcemia | 0.003179 | 1.531 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hypercholesterolemia | 1.043e-07 | 0.7725 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs6499188 | Bladder cancer | 0.01021 | 0.754 | ZFP90 | Ulcerative colitis |
| rs6499188 | Irregular menstrual cycle/bleeding | 0.002074 | 1.28 | ZFP90 | Ulcerative colitis |
| rs6499188 | Benign neoplasm of uterus | 0.01076 | 1.225 | ZFP90 | Ulcerative colitis |
| rs6499188 | Bladder cancer and neoplasms | 0.009095 | 0.7572 | ZFP90 | Ulcerative colitis |
| rs6499188 | Acid-base balance disorder | 0.005501 | 0.7072 | ZFP90 | Ulcerative colitis |
| rs6499188 | Attention deficit hyperactivity disorder | 0.004043 | 1.743 | ZFP90 | Ulcerative colitis |
| rs6499188 | Secondary malignant neoplasm | 0.009313 | 1.171 | ZFP90 | Ulcerative colitis |
| rs6499188 | Myocardial infarction | 0.002462 | 0.851 | ZFP90 | Ulcerative colitis |
| rs6499188 | Subarachnoid hemorrhage | 0.008122 | 1.899 | ZFP90 | Ulcerative colitis |
| rs6499188 | Strabismus (not specified as paralytic) | 0.01063 | 1.25 | ZFP90 | Ulcerative colitis |
| rs6499188 | Other paralytic syndromes | 0.003721 | 0.5599 | ZFP90 | Ulcerative colitis |
| rs6499188 | Disorders of menstruation | 0.00216 | 1.262 | ZFP90 | Ulcerative colitis |
| rs6499188 | Behcet's syndrome | 0.001708 | 0.5233 | ZFP90 | Ulcerative colitis |
| rs6499188 | Melanoma | 0.0003239 | 1.41 | ZFP90 | Ulcerative colitis |
| rs6499188 | Unstable angina (intermediate coronary syndrome) | 0.002252 | 0.8164 | ZFP90 | Ulcerative colitis |
| rs6499188 | Malignant neoplasm of kidney and other urinary organs | 0.0001476 | 2.069 | ZFP90 | Ulcerative colitis |
| rs6499188 | Other nonspecific findings on examination of urine | 0.001977 | 0.7775 | ZFP90 | Ulcerative colitis |
| rs6499188 | Polycystic ovaries | 0.00294 | 2.188 | ZFP90 | Ulcerative colitis |
| rs6499188 | Pulmonary congestion and hypostasis | 0.01002 | 0.6911 | ZFP90 | Ulcerative colitis |
| rs6499188 | Personal history of allergy to medicinal agents | 0.00855 | 1.284 | ZFP90 | Ulcerative colitis |
| rs6499188 | Abnormal findings on examination of urine | 0.001066 | 0.7945 | ZFP90 | Ulcerative colitis |
| rs6499188 | Uterine leiomyoma | 0.003104 | 1.281 | ZFP90 | Ulcerative colitis |
| rs6499640 | Aneurysm of iliac artery | 0.009358 | 0.573 | FTO | Body mass index, Weight |
| rs6499640 | Abdominal aortic aneurysm | 0.004234 | 0.7921 | FTO | Body mass index, Weight |
| rs6499640 | Althete's foot | 0.009963 | 1.245 | FTO | Body mass index, Weight |
| rs6499640 | Non-Hodgkins lymphoma | 0.009113 | 0.7785 | FTO | Body mass index, Weight |
| rs6499640 | Gingivitis | 0.001483 | 0.4508 | FTO | Body mass index, Weight |
| rs6499640 | End stage renal disease | 0.004562 | 0.6818 | FTO | Body mass index, Weight |
| rs6499640 | Frequency of urination and polyuria | 0.004099 | 0.8773 | FTO | Body mass index, Weight |
| rs6499640 | Adverse effects of insulins and antidiabetic agents | 0.008263 | 0.5224 | FTO | Body mass index, Weight |
| rs6499640 | Shock | 0.0005104 | 0.6315 | FTO | Body mass index, Weight |
| rs6499640 | Cancer of other lymphoid, histiocytic tissue | 0.004358 | 0.7647 | FTO | Body mass index, Weight |
| rs651164 | Symptoms associated with female genital organs | 0.004743 | 1.208 | SLC22A1 | Prostate cancer |
| rs651164 | Oral aphthae | 0.01047 | 1.596 | SLC22A1 | Prostate cancer |
| rs651164 | Type 2 diabetic nephropathy | 0.0005723 | 0.7586 | SLC22A1 | Prostate cancer |
| rs651164 | Vascular insufficiency of intestine | 0.01032 | 0.687 | SLC22A1 | Prostate cancer |
| rs651164 | Open wound of lip and mouth | 0.0008366 | 1.938 | SLC22A1 | Prostate cancer |
| rs651164 | Keloid scar | 0.000513 | 1.883 | SLC22A1 | Prostate cancer |
| rs651164 | Periostitis | 0.006529 | 1.796 | SLC22A1 | Prostate cancer |
| rs651164 | Type 2 diabetic peripheral circulatory disorders | 0.0001671 | 0.5877 | SLC22A1 | Prostate cancer |
| rs651164 | Acquired foot deformities | 0.008229 | 1.124 | SLC22A1 | Prostate cancer |
| rs651164 | Aneurysm of other specified artery | 0.002104 | 1.969 | SLC22A1 | Prostate cancer |
| rs651164 | Mixed hyperlipidemia | 0.009225 | 0.8457 | SLC22A1 | Prostate cancer |
| rs651164 | Other hereditary hemolytic anemias | 0.008584 | 0.3434 | SLC22A1 | Prostate cancer |
| rs651164 | Pain, swelling or discharge of eye | 0.00418 | 1.387 | SLC22A1 | Prostate cancer |
| rs651164 | Osteoporosis, osteopenia, & pathological fractures | 0.007793 | 0.9072 | SLC22A1 | Prostate cancer |
| rs651164 | Peripheral angiopathy in diseases classified elsewhere | 0.004579 | 0.5337 | SLC22A1 | Prostate cancer |
| rs651164 | Trigeminal nerve disorders | 0.0007351 | 1.589 | SLC22A1 | Prostate cancer |
| rs651164 | Essential tremor | 0.008177 | 0.7467 | SLC22A1 | Prostate cancer |
| rs6511720 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.004911 | 0.6592 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Reflux esophagitis | 0.01018 | 1.31 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Hyperlipidemia | 6.739e-06 | 0.7948 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Hypercholesterolemia | 2.492e-06 | 0.7387 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Temporomandibular joint disorders | 0.002623 | 0.59 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Disorders of lipoid metabolism | 4.148e-06 | 0.7919 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Poisoning by antibiotics | 0.002142 | 1.368 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Diverticulitis | 0.004986 | 1.37 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Other arthropathies | 0.004869 | 1.193 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Diseases of the jaws | 0.006082 | 0.7238 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Allergy/adverse effect of penicillin | 0.003232 | 1.4 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Allergy to serum or vaccine | 0.0002801 | 2.505 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Diseases of white blood cells | 0.01138 | 1.263 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Mixed hyperlipidemia | 0.00471 | 0.7639 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Corneal edema | 0.008885 | 0.2643 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Pain in limb | 0.001092 | 1.174 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Other peripheral nerve disorders | 0.00484 | 1.17 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Congenital musculoskeletal anomalies | 0.0002646 | 3.172 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Cardiac arrhythmia NOS | 0.007568 | 1.237 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Abnormal results of function studies | 0.01072 | 1.814 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Retinal edema and hypertensive retinopathy | 0.004468 | 1.495 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs652889 | Atrial fibrillation & flutter | 0.007333 | 1.136 | PTPRG | QT interval |
| rs652889 | Other specified cardiac dysrhythmias | 0.003315 | 1.156 | PTPRG | QT interval |
| rs652889 | Cholecystitis without cholelithiasis | 0.002191 | 1.356 | PTPRG | QT interval |
| rs652889 | Hemorrhage or hematoma complicating a procedure | 0.003932 | 1.241 | PTPRG | QT interval |
| rs652889 | Other disorders of metabolism | 0.0004326 | 0.4359 | PTPRG | QT interval |
| rs652889 | Palpitations | 0.01052 | 1.136 | PTPRG | QT interval |
| rs652889 | Cerebral edema and compression of brain | 0.001437 | 2.054 | PTPRG | QT interval |
| rs652889 | Atrial fibrillation | 0.003374 | 1.152 | PTPRG | QT interval |
| rs652889 | Disorders of optic nerve and visual pathways | 0.009887 | 0.7785 | PTPRG | QT interval |
| rs652889 | Arthropathy associated with neurological disorders | 0.005681 | 1.865 | PTPRG | QT interval |
| rs652889 | Allergies, other | 0.009609 | 0.7825 | PTPRG | QT interval |
| rs652889 | Cellulitis and abscess of arm | 0.0009428 | 0.7298 | PTPRG | QT interval |
| rs652889 | Hyperventilation | 0.009978 | 1.656 | PTPRG | QT interval |
| rs652889 | Optic neuritis/neuropathy | 0.009147 | 0.7196 | PTPRG | QT interval |
| rs652889 | Symptoms involving cardiovascular system | 0.007493 | 1.166 | PTPRG | QT interval |
| rs652889 | Pyogenic granuloma | 0.009351 | 0.4662 | PTPRG | QT interval |
| rs652889 | Dyshidrosis | 0.005466 | 0.533 | PTPRG | QT interval |
| rs652889 | Cardiac dysrhythmias | 0.00764 | 1.091 | PTPRG | QT interval |
| rs653178 | Other rheumatic heart disease | 0.005799 | 2.053 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Coronary atherosclerosis | 0.006311 | 1.091 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.001173 | 1.214 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis | 0.001768 | 1.142 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Arterial embolism and thrombosis | 0.003545 | 1.261 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Abnormal findings on mammogram or breast exam | 0.006219 | 1.123 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Open wound of finger(s) | 0.008721 | 0.8589 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Peyronie's disease | 0.01148 | 1.772 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Osteoporosis | 0.007409 | 1.129 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Ischemic Heart Disease | 0.008778 | 1.082 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Morbid obesity | 0.01029 | 0.8655 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Retinoschisis and retinal cysts | 0.004073 | 2.223 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Anomalies of tooth position/malocclusion | 0.00667 | 0.5976 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Benign neoplasm of uterus | 0.001757 | 0.8004 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Uterine leiomyoma | 0.006187 | 0.8137 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of the extremities | 0.002111 | 1.16 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Myocardial infarction | 0.0004842 | 1.169 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Hypothyroidism | 4.031e-06 | 1.18 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Endometriosis | 0.003504 | 0.7128 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of renal artery | 0.009476 | 1.275 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Peripheral vascular disease | 0.01039 | 1.109 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Other congenital anomalies of skin | 0.004834 | 1.457 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Peripheral arterial disease | 0.006118 | 1.128 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Cancer of the upper aerodigestive tract | 0.005419 | 0.7174 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Aortic aneurysm | 0.01004 | 1.191 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.01043 | 1.279 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Hypertension | 0.007377 | 1.083 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Disease of tricuspid valve | 0.008312 | 1.247 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Other disorders of gallbladder | 0.001089 | 0.5639 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Mastodynia | 0.01011 | 1.256 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Essential hypertension | 0.006539 | 1.084 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Ventricular fibrillation & flutter | 0.008967 | 0.6252 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Acute bronchospasm | 0.008823 | 0.4516 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Osteoporosis, NOS or other | 0.005962 | 1.129 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.006289 | 1.241 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs6544713 | Balanoposthitis | 0.009255 | 1.644 | ABCG8 | LDL Cholesterol |
| rs6544713 | Disorders of lipoid metabolism | 0.0068 | 1.098 | ABCG8 | LDL Cholesterol |
| rs6544713 | Contracture of joint | 0.001021 | 1.503 | ABCG8 | LDL Cholesterol |
| rs6544713 | Phobia | 0.004104 | 0.3306 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cholelithiasis and cholecystitis | 8.515e-05 | 0.8245 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cellulitis and abscess of hand/fingers | 0.005621 | 0.824 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cholelithiasis with other cholecystitis | 0.000489 | 0.6853 | ABCG8 | LDL Cholesterol |
| rs6544713 | Constipation | 0.006136 | 0.8679 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cholelithiasis | 0.00023 | 0.8242 | ABCG8 | LDL Cholesterol |
| rs6544713 | Meniere's disease | 0.008345 | 1.614 | ABCG8 | LDL Cholesterol |
| rs6544713 | Lung cancer | 0.00462 | 0.7766 | ABCG8 | LDL Cholesterol |
| rs6544713 | Calculus of bile duct | 0.007952 | 0.7138 | ABCG8 | LDL Cholesterol |
| rs6544713 | pulmonary heart disease | 0.009898 | 0.8573 | ABCG8 | LDL Cholesterol |
| rs6544713 | Malunion fracture | 0.0003264 | 1.601 | ABCG8 | LDL Cholesterol |
| rs6544713 | Pulmonary embolism and infarction | 0.001559 | 0.7445 | ABCG8 | LDL Cholesterol |
| rs6544713 | Fracture of hand or wrist | 0.004027 | 1.193 | ABCG8 | LDL Cholesterol |
| rs6544713 | Secondary malignant neoplasm | 0.000967 | 0.8205 | ABCG8 | LDL Cholesterol |
| rs6544713 | Hyperlipidemia | 0.008437 | 1.096 | ABCG8 | LDL Cholesterol |
| rs6544713 | Diseases of the oral soft tissues | 0.009239 | 0.8498 | ABCG8 | LDL Cholesterol |
| rs6544713 | Mammographic microcalcification | 0.004132 | 0.5645 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cancer within the respiratory system | 0.006127 | 0.7864 | ABCG8 | LDL Cholesterol |
| rs6554809 | Diabetes mellitus | 0.008727 | 0.8957 | DNAH5 | IgE grass sensitization |
| rs6554809 | Gross hematuria | 0.01083 | 1.66 | DNAH5 | IgE grass sensitization |
| rs6554809 | Myeloid leukemia | 0.005969 | 1.973 | DNAH5 | IgE grass sensitization |
| rs6554809 | Type 2 diabetes | 0.007661 | 0.8927 | DNAH5 | IgE grass sensitization |
| rs6554809 | Disorders of vitreous body | 0.005403 | 1.179 | DNAH5 | IgE grass sensitization |
| rs6554809 | Other specified intestinal malabsorption | 0.004232 | 1.883 | DNAH5 | IgE grass sensitization |
| rs6554809 | Paralytic strabismus | 0.00326 | 1.674 | DNAH5 | IgE grass sensitization |
| rs6554809 | Asthma | 0.004919 | 1.169 | DNAH5 | IgE grass sensitization |
| rs6554809 | Acute posthemorrhagic anemia | 0.008646 | 0.7993 | DNAH5 | IgE grass sensitization |
| rs6554809 | Other disorders of eye | 0.01017 | 1.151 | DNAH5 | IgE grass sensitization |
| rs6554809 | Joint/ligament sprain | 0.008877 | 1.397 | DNAH5 | IgE grass sensitization |
| rs6554809 | Type 2 diabetic ketoacidosis | 0.004451 | 0.8266 | DNAH5 | IgE grass sensitization |
| rs6554809 | Pityriasis | 0.01043 | 2.218 | DNAH5 | IgE grass sensitization |
| rs6554809 | Hyperpotassemia | 0.01083 | 0.7875 | DNAH5 | IgE grass sensitization |
| rs6563943 | Macular degeneration, dry | 0.004267 | 0.7992 | CDH13 | Height |
| rs6563943 | Atrophic gastritis | 0.006521 | 0.6493 | CDH13 | Height |
| rs6563943 | Systemic sclerosis | 0.01035 | 0.643 | CDH13 | Height |
| rs6563943 | Secondary malignancy of lymph nodes | 0.005906 | 0.7797 | CDH13 | Height |
| rs6563943 | Retinal drusen | 0.004668 | 0.8002 | CDH13 | Height |
| rs6563943 | Other disorders of back | 0.007407 | 0.8597 | CDH13 | Height |
| rs6563943 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.008892 | 0.8336 | CDH13 | Height |
| rs6563943 | Lower gastrointestinal congenital anomalies | 0.003741 | 0.4478 | CDH13 | Height |
| rs6563943 | Anal and rectal polyp | 0.008132 | 1.24 | CDH13 | Height |
| rs6563943 | Other hemoglobinopathies | 0.008114 | 1.93 | CDH13 | Height |
| rs6563943 | Abnormal findings on radiological exam of musculoskeletal system | 0.003352 | 1.635 | CDH13 | Height |
| rs6563943 | Other specified gastritis | 0.007105 | 0.7793 | CDH13 | Height |
| rs6563943 | Viral pneumonia | 0.001407 | 2.329 | CDH13 | Height |
| rs6563943 | Other arthropathies | 0.002388 | 0.8786 | CDH13 | Height |
| rs6563943 | Muscle/tendon sprain | 0.005316 | 1.92 | CDH13 | Height |
| rs6563943 | Other disorders of biliary tract | 0.002577 | 0.5965 | CDH13 | Height |
| rs6563943 | Arthropathy NOS | 0.004595 | 0.8331 | CDH13 | Height |
| rs6563943 | Macular degeneration, wet | 0.01066 | 0.7537 | CDH13 | Height |
| rs6564851 | Retinal detachments and defects | 0.01009 | 1.209 | BCMO1 | Beta-carotene |
| rs6564851 | Chronic glomerulonephritis | 0.002148 | 0.38 | BCMO1 | Beta-carotene |
| rs6564851 | Primary pulmonary hypertension | 0.003216 | 0.6034 | BCMO1 | Beta-carotene |
| rs6564851 | Anemia NOS | 0.009826 | 1.088 | BCMO1 | Beta-carotene |
| rs6564851 | Cerebral edema and compression of brain | 0.005651 | 0.5119 | BCMO1 | Beta-carotene |
| rs6564851 | Hypertrophy of breast (Gynecomastia) | 0.0109 | 0.7523 | BCMO1 | Beta-carotene |
| rs6564851 | Scar conditions and fibrosis of skin | 0.01128 | 0.782 | BCMO1 | Beta-carotene |
| rs6564851 | Alcohol-related disorders | 0.007935 | 1.186 | BCMO1 | Beta-carotene |
| rs6564851 | Peripheral autonomic neuropathy | 0.009576 | 1.36 | BCMO1 | Beta-carotene |
| rs6564851 | Bronchopneumonia and lung abscess | 0.003982 | 0.542 | BCMO1 | Beta-carotene |
| rs6564851 | Other local infections of skin and subcutaneous tissue | 0.008236 | 0.8592 | BCMO1 | Beta-carotene |
| rs6564851 | Thyroiditis | 0.005146 | 0.7347 | BCMO1 | Beta-carotene |
| rs6564851 | Angina pectoris | 0.002601 | 1.144 | BCMO1 | Beta-carotene |
| rs6564851 | Pyogenic granuloma | 0.006405 | 0.537 | BCMO1 | Beta-carotene |
| rs6585827 | Essential tremor | 0.001274 | 1.367 | PLEKHA1 | Height |
| rs6585827 | Hypercholesterolemia | 0.003578 | 1.121 | PLEKHA1 | Height |
| rs6585827 | Benign neoplasm of other endocrine glands | 0.003487 | 1.441 | PLEKHA1 | Height |
| rs6585827 | Macular degeneration | 0.008794 | 1.121 | PLEKHA1 | Height |
| rs6585827 | Cataract | 0.003069 | 1.116 | PLEKHA1 | Height |
| rs6585827 | Type 1 diabetic ketoacidosis | 0.006401 | 0.7041 | PLEKHA1 | Height |
| rs6585827 | Rheumatoid arthritis & related inflammatory polyarthropathies | 2.102e-05 | 1.317 | PLEKHA1 | Height |
| rs6585827 | Rheumatoid arthritis | 2.319e-05 | 1.362 | PLEKHA1 | Height |
| rs6585827 | Blood vessel replaced | 0.006269 | 0.6306 | PLEKHA1 | Height |
| rs6585827 | Symptoms involving respiratory system | 0.003524 | 1.218 | PLEKHA1 | Height |
| rs6585827 | Congenital anomalies of lower limb, including pelvic girdle | 0.01006 | 0.5674 | PLEKHA1 | Height |
| rs6585827 | Arterial embolism and thrombosis | 0.001841 | 0.7798 | PLEKHA1 | Height |
| rs6585827 | Corneal dystrophy | 0.0005382 | 1.385 | PLEKHA1 | Height |
| rs6585827 | Paraproteinemia | 0.005943 | 1.374 | PLEKHA1 | Height |
| rs6585827 | Extrapyramidal disease and abnormal movement disorders | 0.006973 | 1.178 | PLEKHA1 | Height |
| rs6585827 | Asthma | 0.009977 | 1.115 | PLEKHA1 | Height |
| rs6585827 | Contracture of joint | 0.004106 | 0.7017 | PLEKHA1 | Height |
| rs6585827 | Acne | 0.003513 | 1.304 | PLEKHA1 | Height |
| rs6585827 | Blister | 0.005723 | 0.5357 | PLEKHA1 | Height |
| rs6585827 | Macular degeneration, wet | 4.062e-06 | 1.621 | PLEKHA1 | Height |
| rs6585827 | Mastodynia | 0.007775 | 1.262 | PLEKHA1 | Height |
| rs6585827 | Genu valgum or varum (acquired) | 0.006065 | 0.7003 | PLEKHA1 | Height |
| rs6585827 | Age-related macular degeneration | 5.279e-05 | 1.302 | PLEKHA1 | Height |
| rs6585827 | Aphakia and other disorders of lens | 0.007296 | 1.283 | PLEKHA1 | Height |
| rs6585827 | Arterial embolism and thrombosis of lower extremity artery | 0.01062 | 0.7535 | PLEKHA1 | Height |
| rs6585827 | Other specified osteoporosis | 0.005426 | 1.66 | PLEKHA1 | Height |
| rs6586282 | Mitral stenosis/insufficiency | 0.001313 | 2.171 | CBS | Homocysteine levels |
| rs6586282 | Thyrotoxicosis | 0.01079 | 1.275 | CBS | Homocysteine levels |
| rs6586282 | Benign neoplasm of eye | 0.006038 | 1.307 | CBS | Homocysteine levels |
| rs6586282 | Dyspareunia | 0.00353 | 0.3897 | CBS | Homocysteine levels |
| rs6586282 | Visual disturbances | 2.3e-06 | 0.7697 | CBS | Homocysteine levels |
| rs6586282 | Disturbances in tooth eruption | 0.01001 | 0.6688 | CBS | Homocysteine levels |
| rs6586282 | Suppurative and unspecified otitis media | 0.01135 | 1.197 | CBS | Homocysteine levels |
| rs6586282 | Aseptic necrosis of bone | 0.008398 | 1.625 | CBS | Homocysteine levels |
| rs6586282 | Keratitis | 0.005564 | 0.6693 | CBS | Homocysteine levels |
| rs6586282 | Lichen | 0.009038 | 1.601 | CBS | Homocysteine levels |
| rs6586282 | Optic neuritis/neuropathy | 0.0009179 | 0.5844 | CBS | Homocysteine levels |
| rs6586282 | Diseases of hard tissues of teeth | 0.007596 | 0.788 | CBS | Homocysteine levels |
| rs6586282 | Chronic rheumatic disease of the heart valves | 0.009085 | 1.194 | CBS | Homocysteine levels |
| rs6586282 | Pyogenic arthritis | 0.0009896 | 1.959 | CBS | Homocysteine levels |
| rs6586282 | Subjective visual disturbances | 0.006147 | 0.764 | CBS | Homocysteine levels |
| rs6586282 | Prolapse of vaginal vault after hysterectomy | 0.0003611 | 1.772 | CBS | Homocysteine levels |
| rs6586282 | Disorders of optic nerve and visual pathways | 0.002614 | 0.6948 | CBS | Homocysteine levels |
| rs6586282 | Prurigo | 0.0068 | 1.355 | CBS | Homocysteine levels |
| rs6586282 | Noninflammatory disorders of vagina | 0.007844 | 0.6375 | CBS | Homocysteine levels |
| rs6586282 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.007723 | 0.4586 | CBS | Homocysteine levels |
| rs6586282 | Disease of tricuspid valve | 0.01096 | 1.303 | CBS | Homocysteine levels |
| rs6586282 | Lung involvement in conditions classified elsewhere | 0.009123 | 2.094 | CBS | Homocysteine levels |
| rs660895 | Intracerebral hemorrhage | 0.007255 | 1.663 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Disorders of refraction and accommodation | 0.004377 | 1.136 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Chronic bronchitis | 0.001559 | 1.27 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Unspecified polyarthropathy or polyarthritis | 0.006699 | 1.578 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Other specified osteoporosis | 0.003603 | 1.775 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Other diseases of lung | 0.005994 | 1.162 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Type 1 diabetic ketoacidosis | 3.648e-09 | 2.217 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Other headache syndromes | 0.006336 | 1.127 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Obstructive chronic bronchitis | 0.005075 | 1.265 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Type 2 diabetes | 0.0006831 | 1.138 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Abnormal findings examination of lungs | 0.01091 | 1.194 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Hearing loss | 0.003982 | 1.118 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Voice disturbance | 0.003952 | 1.271 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Pseudomonal pneumonia | 0.003345 | 2.393 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Miscarriage; stillbirth | 0.008095 | 1.864 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Atopic or contact dermatitis | 0.00366 | 1.137 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Sepsis | 0.006638 | 1.32 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Varicose veins | 0.007921 | 0.8373 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Glaucoma | 0.003159 | 1.159 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Viral pneumonia | 0.0002655 | 2.728 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Anorexia | 0.004712 | 1.437 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Bronchiectasis | 0.002064 | 1.518 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Acquired deformities of ankle and foot | 0.004676 | 1.287 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Diabetes mellitus | 0.0006937 | 1.136 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Gastroparesis | 0.00193 | 1.911 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Conjunctivitis, infectious | 0.0008296 | 1.259 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Personal history of allergy to medicinal agents | 0.007833 | 1.31 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Arteritis NOS | 0.002978 | 1.715 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Nasal polyps | 0.0009302 | 1.498 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Eustachian tube disorders | 0.006702 | 0.7379 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Astigmatism | 0.004691 | 1.179 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Benign neoplasm of ovary | 0.009989 | 0.5241 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Diseases of the larynx and vocal cords | 0.004086 | 1.231 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Polyarteritis nodosa and allied conditions | 3.138e-05 | 1.639 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Pneumonia | 0.000586 | 1.172 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Infection of the eye | 0.001789 | 1.215 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Toxic effect of venom | 0.005457 | 0.5076 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Shock | 0.0009537 | 1.554 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Osteoarthrosis | 0.002339 | 1.12 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Polyneuropathy in diabetes | 0.0006278 | 1.296 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Giant cell arteritis | 6.323e-05 | 1.938 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Visual field defects | 0.0008717 | 1.403 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Adverse effects of antirheumatics | 0.005946 | 1.784 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Type 1 diabetic neuropathy | 2.578e-06 | 1.942 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Diseases of white blood cells | 0.001953 | 1.255 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Sepsis and SIRS | 0.005311 | 1.316 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Insomnia | 0.004326 | 1.208 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Disorders of fluid, electrolyte, and acid-base balance | 0.009419 | 1.104 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Varicose veins of lower extremity | 0.006941 | 0.8282 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Rheumatoid arthritis | 6.658e-08 | 1.561 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Ulceration of intestine | 0.003497 | 1.784 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Rheumatoid arthritis & related inflammatory polyarthropathies | 4.672e-08 | 1.501 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Type 1 diabetes | 7.123e-08 | 1.444 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Adverse effects of cardiac rhythm regulators | 0.002911 | 1.951 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Abnormal electrocardiogram | 0.002376 | 1.206 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Inflammation of the eye | 0.003554 | 1.158 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Type 1 diabetes nephropathy | 1.683e-05 | 2.228 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs660895 | Congenital anomalies of posterior segment of eye | 0.006511 | 1.349 | HLA-DRB1 | IgA nephropathy, Rheumatoid arthritis (anti-CCP+) |
| rs6610953 | Other specified diseases of the salivary glands | 0.01011 | 1.925 | FUNDC1 | Personality dimensions |
| rs6610953 | Carcinoma in situ of skin | 6.656e-05 | 1.568 | FUNDC1 | Personality dimensions |
| rs6610953 | Phosphorus metabolism disorder | 0.007641 | 1.633 | FUNDC1 | Personality dimensions |
| rs6610953 | Fracture of vertebral column without mention of spinal cord injury | 0.007304 | 1.316 | FUNDC1 | Personality dimensions |
| rs6610953 | Cancer of other female genital organs | 0.003678 | 2.13 | FUNDC1 | Personality dimensions |
| rs6610953 | Otosclerosis | 0.00247 | 1.784 | FUNDC1 | Personality dimensions |
| rs6610953 | Pneumonitis due to inhalation of food or vomitus | 0.005377 | 1.504 | FUNDC1 | Personality dimensions |
| rs6610953 | Menopausal & postmenopausal disorders | 0.009685 | 1.167 | FUNDC1 | Personality dimensions |
| rs6610953 | Disorders of mineral metabolism | 0.002257 | 1.238 | FUNDC1 | Personality dimensions |
| rs6610953 | Other specified osteoporosis | 0.009632 | 1.802 | FUNDC1 | Personality dimensions |
| rs6610953 | Intestinal obstruction without mention of hernia | 0.007758 | 1.283 | FUNDC1 | Personality dimensions |
| rs6610953 | Inflammatory conditions of jaw | 0.01124 | 1.736 | FUNDC1 | Personality dimensions |
| rs6610953 | Cramp of limb | 0.003626 | 1.467 | FUNDC1 | Personality dimensions |
| rs6610953 | Pseudomonal pneumonia | 7.751e-05 | 4.133 | FUNDC1 | Personality dimensions |
| rs6610953 | Endometriosis | 0.005403 | 1.497 | FUNDC1 | Personality dimensions |
| rs6610953 | Calcium/phosphorus disorders | 0.001798 | 1.341 | FUNDC1 | Personality dimensions |
| rs6610953 | Nausea and vomiting | 0.007462 | 1.154 | FUNDC1 | Personality dimensions |
| rs6611365 | Otorrhea | 0.002066 | 2.381 | ZNF157 | Optic disc parameters |
| rs6611365 | Stricture of artery | 0.01119 | 0.6749 | ZNF157 | Optic disc parameters |
| rs6611365 | Open wound of lip and mouth | 0.00651 | 0.2818 | ZNF157 | Optic disc parameters |
| rs6611365 | Peritoneal adhesions (postoperative) (postinfection) | 0.006202 | 0.4576 | ZNF157 | Optic disc parameters |
| rs6611365 | Seborrhea | 0.005513 | 2.098 | ZNF157 | Optic disc parameters |
| rs6611365 | Dysmenorrhea | 0.009179 | 0.5865 | ZNF157 | Optic disc parameters |
| rs6611365 | Benign neoplasm of colon | 0.008087 | 0.8846 | ZNF157 | Optic disc parameters |
| rs6611365 | Respiratory failure | 0.004656 | 0.6734 | ZNF157 | Optic disc parameters |
| rs6611365 | Uterine/Uterovaginal prolapse | 0.007443 | 0.7221 | ZNF157 | Optic disc parameters |
| rs6611365 | Unstable angina (intermediate coronary syndrome) | 0.001808 | 1.272 | ZNF157 | Optic disc parameters |
| rs6708166 | Other disorders of lipoid metabolism and hyperalimentation | 0.0104 | 0.7817 | LBH | Factor VIII activity |
| rs6708166 | Cerebrovascular disease | 0.002173 | 0.8985 | LBH | Factor VIII activity |
| rs6708166 | Intestinal obstruction without mention of hernia | 0.009572 | 0.839 | LBH | Factor VIII activity |
| rs6708166 | Personality disorders | 0.003971 | 0.7754 | LBH | Factor VIII activity |
| rs6708166 | Renal failure | 0.008308 | 0.904 | LBH | Factor VIII activity |
| rs6708166 | Nevus, non-neoplastic | 0.0008948 | 0.4784 | LBH | Factor VIII activity |
| rs6708166 | Acquired deformities of finger | 0.008652 | 1.431 | LBH | Factor VIII activity |
| rs6708166 | Infestation | 0.00989 | 0.5629 | LBH | Factor VIII activity |
| rs6708166 | Other hypertrophic and atrophic conditions of skin | 4.908e-06 | 0.8282 | LBH | Factor VIII activity |
| rs6708166 | Corns and callosities | 0.01116 | 0.867 | LBH | Factor VIII activity |
| rs6708166 | Encounter for long-term use of antiplatelets/antithrombotics | 0.01036 | 0.4374 | LBH | Factor VIII activity |
| rs6708166 | Keratoderma, acquired | 1.104e-05 | 0.7688 | LBH | Factor VIII activity |
| rs6708166 | Disease of capillaries | 0.001506 | 0.6798 | LBH | Factor VIII activity |
| rs6708166 | Atherosclerosis of renal artery | 0.00199 | 0.7307 | LBH | Factor VIII activity |
| rs6708166 | Other disorders of thyroid | 0.006762 | 0.7434 | LBH | Factor VIII activity |
| rs6708166 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.01054 | 0.8509 | LBH | Factor VIII activity |
| rs6708166 | Cervicocranial/Cervicobrachial syndrome | 0.007824 | 0.7893 | LBH | Factor VIII activity |
| rs6708166 | Viral pneumonia | 0.008753 | 2.018 | LBH | Factor VIII activity |
| rs6708166 | Suicidal ideation or attempt | 0.01035 | 1.667 | LBH | Factor VIII activity |
| rs6711606 | Disorders of synovium, tendon, and bursa | 0.003573 | 1.155 | RNF149 | Pancreatic cancer |
| rs6711606 | Osteoarthrosis, generalized | 0.0105 | 0.7857 | RNF149 | Pancreatic cancer |
| rs6711606 | Gram positive septicemia | 0.001032 | 1.848 | RNF149 | Pancreatic cancer |
| rs6711606 | Glomerulonephritis | 0.006733 | 0.4368 | RNF149 | Pancreatic cancer |
| rs6711606 | Abnormal results of function studies | 0.006981 | 1.685 | RNF149 | Pancreatic cancer |
| rs6711606 | Paroxysmal supraventricular tachycardia | 0.006986 | 0.7192 | RNF149 | Pancreatic cancer |
| rs6711606 | Deviated nasal septum | 0.008871 | 0.8093 | RNF149 | Pancreatic cancer |
| rs6711606 | Infection of the eye | 0.004009 | 1.198 | RNF149 | Pancreatic cancer |
| rs6711606 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.000921 | 2.659 | RNF149 | Pancreatic cancer |
| rs6725887 | Osteitis deformans and osteopathies associated with other disorders | 0.002839 | 1.995 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Psoriasis | 0.005051 | 1.358 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Aortic aneurysm | 0.005209 | 0.7347 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Fracture of neck of femur | 0.006685 | 1.308 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Occlusion of cerebral arteries | 0.007269 | 1.267 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Benign neoplasm of bone and articular cartilage | 0.005938 | 1.91 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Alopecia | 0.006896 | 1.436 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Neutropenia | 0.01035 | 1.307 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Inflammatory diseases of prostate | 0.003634 | 0.7036 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Psoriasis vulgaris | 0.005267 | 1.366 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Ischemic stroke | 0.009485 | 1.27 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Unspecified erythematous condition | 0.0103 | 1.59 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Benign neoplasm of colon | 0.004503 | 0.8698 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Fracture of lower limb | 0.006995 | 1.217 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Disease of tricuspid valve | 0.002742 | 1.398 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Bacterial enteritis | 0.0007579 | 1.562 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Other aneurysm | 0.008377 | 0.7719 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Heart transplant/surgery | 0.005508 | 1.594 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Upper gastrointestinal congenital anomalies | 0.009801 | 0.4107 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Gastritis and duodenitis, NOS | 0.007505 | 0.7211 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Benign neoplasm of ovary | 0.005873 | 1.743 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.001883 | 1.89 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Paget's disease of bone | 0.0109 | 2.316 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6782029 | Insulin pump user | 0.006776 | 1.283 | VGLL4 | Anorexia nervosa |
| rs6782029 | Disorders of cervical region | 0.007096 | 0.6843 | VGLL4 | Anorexia nervosa |
| rs6782029 | Lymphadenitis | 0.009643 | 0.8248 | VGLL4 | Anorexia nervosa |
| rs6782029 | Staphylococcus infections | 0.0002317 | 0.6666 | VGLL4 | Anorexia nervosa |
| rs6782029 | Bacterial infection NOS | 0.001123 | 0.8293 | VGLL4 | Anorexia nervosa |
| rs6782029 | Disease of tricuspid valve | 0.001908 | 0.7099 | VGLL4 | Anorexia nervosa |
| rs6782029 | Schizoid personality disorder | 0.01046 | 0.4966 | VGLL4 | Anorexia nervosa |
| rs6782029 | Drug-resistant infection | 0.004362 | 0.6385 | VGLL4 | Anorexia nervosa |
| rs6782029 | Posttraumatic stress disorder | 0.003641 | 1.649 | VGLL4 | Anorexia nervosa |
| rs6782029 | Alopecia Areata | 0.0002844 | 2.571 | VGLL4 | Anorexia nervosa |
| rs6782029 | Leukoplakia of oral mucosa | 0.009419 | 1.802 | VGLL4 | Anorexia nervosa |
| rs6782029 | Myasthenia gravis | 0.006039 | 2.059 | VGLL4 | Anorexia nervosa |
| rs6782029 | Methicillin sensitive Staphylococcus aureus | 0.009489 | 0.6959 | VGLL4 | Anorexia nervosa |
| rs6782029 | Chronic liver disease and cirrhosis | 0.008633 | 0.7791 | VGLL4 | Anorexia nervosa |
| rs6791644 | Congenital anomalies of peripheral vascular system | 0.007399 | 2.069 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Patellar fracture | 0.003294 | 1.649 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Cardiac pacemaker in situ | 0.003615 | 1.381 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Cirrhosis of liver without mention of alcohol | 0.005864 | 1.621 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Infestation | 0.003859 | 2.005 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Cardiac arrest & ventricular fibrillation | 0.0002338 | 1.861 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Congenital anomalies of posterior segment of eye | 0.004698 | 0.608 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Plasma protein metabolism disorder | 0.007443 | 1.434 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Biliary cirrhosis | 0.0004131 | 3.116 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | AV block | 0.0002882 | 1.421 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | First degree AV block | 0.0002606 | 1.536 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Retinal detachments and defects | 0.01004 | 1.321 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Congenital anomalies of the eye | 0.0002848 | 0.5793 | FHIT | Attention deficit hyperactivity disorder |
| rs6807064 | Renal colic | 0.008716 | 0.5255 | ATP2B2 | Phenylalanine |
| rs6807064 | Herpes zoster | 0.006912 | 1.199 | ATP2B2 | Phenylalanine |
| rs6807064 | Type 2 diabetic peripheral circulatory disorders | 0.01104 | 1.362 | ATP2B2 | Phenylalanine |
| rs6807064 | Breast disorder NOS | 0.004864 | 2.232 | ATP2B2 | Phenylalanine |
| rs6807064 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.008969 | 0.8025 | ATP2B2 | Phenylalanine |
| rs6807064 | Plasma protein metabolism disorder | 0.01126 | 1.29 | ATP2B2 | Phenylalanine |
| rs6807064 | Posttraumatic stress disorder | 0.006929 | 0.5738 | ATP2B2 | Phenylalanine |
| rs6807064 | Other conditions of the mother complicating pregnancy | 0.00175 | 0.5011 | ATP2B2 | Phenylalanine |
| rs6807064 | Periapical abscess | 0.002929 | 1.253 | ATP2B2 | Phenylalanine |
| rs6807064 | Diseases of pulp and periapical tissues | 0.001094 | 1.267 | ATP2B2 | Phenylalanine |
| rs6807064 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.0004113 | 1.804 | ATP2B2 | Phenylalanine |
| rs6807064 | Nephritis & nephropathy | 0.002468 | 1.717 | ATP2B2 | Phenylalanine |
| rs6807064 | Chronic obstructive asthma with exacerbation | 0.0003286 | 1.962 | ATP2B2 | Phenylalanine |
| rs6845865 | Cervical cancer | 0.01006 | 1.942 | ARHGAP10 | QT interval |
| rs6845865 | Disorders of tooth development | 0.008774 | 0.6481 | ARHGAP10 | QT interval |
| rs6845865 | Spirochetal infection | 0.00496 | 1.664 | ARHGAP10 | QT interval |
| rs6845865 | Lyme disease | 0.002316 | 1.744 | ARHGAP10 | QT interval |
| rs6845865 | Torticollis | 0.009877 | 1.616 | ARHGAP10 | QT interval |
| rs6845865 | Polycythemia vera, secondary | 0.009307 | 0.4399 | ARHGAP10 | QT interval |
| rs6845865 | Nonrheumatic mitral valve disorders | 0.01095 | 1.181 | ARHGAP10 | QT interval |
| rs6845865 | Renal colic | 0.0005439 | 2.035 | ARHGAP10 | QT interval |
| rs6845865 | Hematuria | 0.000717 | 0.8283 | ARHGAP10 | QT interval |
| rs6869388 | Superficial cellulitis and abscess | 0.007667 | 1.121 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hyperosmolality and/or hypernatremia | 0.003955 | 1.578 | C5orf36 | Gallbladder cancer |
| rs6869388 | Sensorineural hearing loss | 0.003263 | 1.145 | C5orf36 | Gallbladder cancer |
| rs6869388 | Disorders of uterus, NEC | 0.003707 | 1.956 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hearing loss | 0.001356 | 1.133 | C5orf36 | Gallbladder cancer |
| rs6869388 | Melanoma | 0.004799 | 0.7033 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hemorrhage from gastrointestinal ulcer | 0.009558 | 1.453 | C5orf36 | Gallbladder cancer |
| rs6869388 | Other acquired musculoskeletal deformity | 0.003407 | 0.7259 | C5orf36 | Gallbladder cancer |
| rs6869388 | Torticollis | 0.006263 | 1.605 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hypertrophy of female genital organs | 0.008697 | 1.757 | C5orf36 | Gallbladder cancer |
| rs690037 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.008108 | 0.8106 | RFTN1 | Optic disc parameters |
| rs690037 | Mitral valve stenosis and/or aortic valve stenosis | 0.0006365 | 0.7739 | RFTN1 | Optic disc parameters |
| rs690037 | Iatrogenic hypotension | 0.006609 | 0.6256 | RFTN1 | Optic disc parameters |
| rs690037 | Other diseases of respiratory system | 0.01097 | 1.351 | RFTN1 | Optic disc parameters |
| rs690037 | Intestinal infection due to C. difficile | 0.0002108 | 0.6378 | RFTN1 | Optic disc parameters |
| rs690037 | Bacterial enteritis | 3.684e-06 | 0.608 | RFTN1 | Optic disc parameters |
| rs690037 | Gout and other crystal arthropathies | 0.009479 | 1.139 | RFTN1 | Optic disc parameters |
| rs690037 | Spondylosis with myelopathy | 0.004582 | 1.395 | RFTN1 | Optic disc parameters |
| rs690037 | Abnormal findings on radiological examination intrathoracic organs | 0.008987 | 0.8319 | RFTN1 | Optic disc parameters |
| rs690037 | Hydrocele | 0.005189 | 1.489 | RFTN1 | Optic disc parameters |
| rs690037 | Gout | 0.0107 | 1.148 | RFTN1 | Optic disc parameters |
| rs690037 | Retinal edema and hypertensive retinopathy | 0.005349 | 1.329 | RFTN1 | Optic disc parameters |
| rs690037 | Psoriasis & related disorders | 0.004388 | 1.244 | RFTN1 | Optic disc parameters |
| rs690037 | Anal and rectal polyp | 0.001078 | 0.765 | RFTN1 | Optic disc parameters |
| rs690037 | Cardiac arrhythmia NOS | 0.002986 | 0.8568 | RFTN1 | Optic disc parameters |
| rs690037 | Psoriasis | 0.005672 | 1.251 | RFTN1 | Optic disc parameters |
| rs690037 | Intestinal infection | 0.0001501 | 0.7572 | RFTN1 | Optic disc parameters |
| rs690705 | Open wound of eye or eyelid | 0.008435 | 1.939 | RFC3 | Alzheimer's disease |
| rs690705 | Other disorders of back | 0.002632 | 1.187 | RFC3 | Alzheimer's disease |
| rs690705 | Traumatic arthropathy | 0.01014 | 1.593 | RFC3 | Alzheimer's disease |
| rs690705 | Other and unspecified disc disorder | 0.008303 | 1.475 | RFC3 | Alzheimer's disease |
| rs690705 | Benign neoplasm of colon | 0.009745 | 0.9133 | RFC3 | Alzheimer's disease |
| rs690705 | Known or suspected fetal abnormality | 2.278e-05 | 2.196 | RFC3 | Alzheimer's disease |
| rs690705 | Acute, but ill-defined cerebrovascular disease | 0.00678 | 1.202 | RFC3 | Alzheimer's disease |
| rs690705 | Disorders of sacrum | 0.0003334 | 1.359 | RFC3 | Alzheimer's disease |
| rs690705 | Dislocation | 0.00163 | 1.145 | RFC3 | Alzheimer's disease |
| rs690705 | Hearing loss | 0.008768 | 1.092 | RFC3 | Alzheimer's disease |
| rs690705 | Loose body in joint | 0.003983 | 2.175 | RFC3 | Alzheimer's disease |
| rs6908425 | Urinary obstruction | 0.007454 | 0.6385 | CDKAL1 | Crohn's disease |
| rs6908425 | Adverse drug events and drug allergies | 0.008995 | 0.8279 | CDKAL1 | Crohn's disease |
| rs6908425 | End stage renal disease | 0.003697 | 1.493 | CDKAL1 | Crohn's disease |
| rs6908425 | Premenstrual tension syndromes | 0.00885 | 1.954 | CDKAL1 | Crohn's disease |
| rs6908425 | Poisoning by other anti-infectives | 0.009496 | 0.7762 | CDKAL1 | Crohn's disease |
| rs6908425 | Non-healing surgical wound | 0.0007508 | 1.859 | CDKAL1 | Crohn's disease |
| rs6908425 | Esophageal cancer | 0.004829 | 1.86 | CDKAL1 | Crohn's disease |
| rs6908425 | Epiphora | 0.003607 | 0.6216 | CDKAL1 | Crohn's disease |
| rs6908425 | Stomach cancer | 0.002757 | 1.877 | CDKAL1 | Crohn's disease |
| rs6908425 | Cyst or abscess of Bartholin's gland | 0.00155 | 2.208 | CDKAL1 | Crohn's disease |
| rs6908425 | Endometrial hyperplasia | 0.008928 | 1.464 | CDKAL1 | Crohn's disease |
| rs6908425 | Emphysema | 0.009057 | 0.7379 | CDKAL1 | Crohn's disease |
| rs6908425 | Fibroadenosis of breast | 0.002258 | 2.417 | CDKAL1 | Crohn's disease |
| rs6908425 | Other rheumatic heart disease | 0.002538 | 2.139 | CDKAL1 | Crohn's disease |
| rs6919346 | Peripheral autonomic neuropathy | 0.006665 | 1.463 | LPA | Lipoprotein(a) levels |
| rs6919346 | Flat foot | 0.0007706 | 1.425 | LPA | Lipoprotein(a) levels |
| rs6919346 | Acquired deformities of ankle and foot | 0.0001084 | 1.413 | LPA | Lipoprotein(a) levels |
| rs6919346 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.01076 | 1.13 | LPA | Lipoprotein(a) levels |
| rs6919346 | Gastrointestinal complications | 0.003519 | 1.357 | LPA | Lipoprotein(a) levels |
| rs6919346 | Contact dermatitis and other eczema due to plants [except food] | 0.00605 | 1.851 | LPA | Lipoprotein(a) levels |
| rs6919346 | Intestinal malabsorption | 0.00845 | 1.443 | LPA | Lipoprotein(a) levels |
| rs6919346 | Corns and callosities | 0.008421 | 1.194 | LPA | Lipoprotein(a) levels |
| rs6919346 | Spontaneous ecchymoses | 0.002224 | 1.813 | LPA | Lipoprotein(a) levels |
| rs6919346 | Chronic ulcer of leg or foot | 0.007269 | 1.19 | LPA | Lipoprotein(a) levels |
| rs6919346 | Subdural hemorrhage | 0.008117 | 0.4606 | LPA | Lipoprotein(a) levels |
| rs6919346 | Chronic ulcer of skin | 0.007671 | 1.161 | LPA | Lipoprotein(a) levels |
| rs6919346 | Vascular insufficiency of intestine | 0.002504 | 1.544 | LPA | Lipoprotein(a) levels |
| rs6919346 | Hepatomegaly | 0.007022 | 1.836 | LPA | Lipoprotein(a) levels |
| rs6922632 | Diseases of hard tissues of teeth | 0.001332 | 0.7285 | NRSN1 | Cognitive performance |
| rs6922632 | Osteoporosis, NOS or other | 0.001139 | 0.8142 | NRSN1 | Cognitive performance |
| rs6922632 | Conduct disorders | 0.003594 | 1.759 | NRSN1 | Cognitive performance |
| rs6922632 | Spondylosis and allied disorders | 0.007504 | 0.8668 | NRSN1 | Cognitive performance |
| rs6922632 | Altered mental status | 0.003542 | 0.6506 | NRSN1 | Cognitive performance |
| rs6922632 | Dental caries | 0.00184 | 0.7295 | NRSN1 | Cognitive performance |
| rs6922632 | Spondylosis without myelopathy | 0.003872 | 0.8526 | NRSN1 | Cognitive performance |
| rs6922632 | First degree AV block | 0.006473 | 1.335 | NRSN1 | Cognitive performance |
| rs6922632 | Open wound of toe(s) | 0.00645 | 1.902 | NRSN1 | Cognitive performance |
| rs6922632 | Infection of the eye | 0.01036 | 0.8292 | NRSN1 | Cognitive performance |
| rs6922632 | Cystic mastopathy | 0.007001 | 0.8039 | NRSN1 | Cognitive performance |
| rs6922632 | Gout and other crystal arthropathies | 0.000308 | 0.7566 | NRSN1 | Cognitive performance |
| rs6922632 | Mechanical complication due to other implant and internal device | 0.008857 | 0.6215 | NRSN1 | Cognitive performance |
| rs6922632 | Osteoporosis | 0.002683 | 0.8237 | NRSN1 | Cognitive performance |
| rs6922632 | Pulmonary collapse; interstitial/compensatory emphysema | 0.007102 | 0.794 | NRSN1 | Cognitive performance |
| rs6922632 | Herpes simplex | 0.007937 | 0.6594 | NRSN1 | Cognitive performance |
| rs6922632 | Gout | 0.0006442 | 0.7526 | NRSN1 | Cognitive performance |
| rs6922632 | Displacement of intervertebral disc | 0.01069 | 0.8155 | NRSN1 | Cognitive performance |
| rs6922632 | Periapical abscess | 0.01007 | 0.7631 | NRSN1 | Cognitive performance |
| rs6922632 | Edema | 0.009248 | 0.8735 | NRSN1 | Cognitive performance |
| rs6922632 | Intracerebral hemorrhage | 0.003696 | 1.806 | NRSN1 | Cognitive performance |
| rs6922632 | Lump or mass in breast | 0.009252 | 0.8159 | NRSN1 | Cognitive performance |
| rs6922632 | Other sprains and strains | 0.003145 | 0.5848 | NRSN1 | Cognitive performance |
| rs6922632 | Osteoporosis, osteopenia, & pathological fractures | 0.00929 | 0.8817 | NRSN1 | Cognitive performance |
| rs6922632 | Atopic or contact dermatitis | 0.009471 | 0.8767 | NRSN1 | Cognitive performance |
| rs6922632 | Benign mammary dysplasias | 0.01022 | 0.8186 | NRSN1 | Cognitive performance |
| rs6922632 | Contact dermatitis and other eczema due to plants [except food] | 0.003044 | 0.2194 | NRSN1 | Cognitive performance |
| rs693 | Sensorineural hearing loss | 0.003553 | 0.898 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hyperlipidemia | 8.821e-08 | 0.841 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Renal dialysis | 0.003152 | 0.6845 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Disorders of lipoid metabolism | 1.813e-07 | 0.8457 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Fluid overload | 0.007591 | 0.7907 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Conjunctivitis, noninfectious | 0.01097 | 1.226 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hypertensive chronic kidney disease | 0.002937 | 0.8236 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Disturbances of sensation of smell and taste | 0.001655 | 0.5721 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hearing loss | 0.002005 | 0.9086 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Lymphosarcoma | 0.005401 | 2.203 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Insect bite | 0.008525 | 0.8119 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hypercholesterolemia | 7.419e-10 | 0.7838 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Celiac disease | 0.001706 | 0.4966 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Adverse effects of opiates and related narcotics in therapeutic use | 0.002014 | 1.339 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Ileostomy status | 0.007113 | 1.611 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Cardiac pacemaker/device in situ | 0.007731 | 0.833 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hypertensive heart and/or renal disease | 0.0002992 | 0.81 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Celiac or tropical sprue | 0.002167 | 0.5135 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Cardiac arrest | 0.008338 | 0.6358 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Subdural hemorrhage (injury) | 0.003603 | 0.5719 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Localized superficial swelling, mass, or lump | 0.009725 | 0.8004 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Paralytic strabismus | 0.01076 | 1.461 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Tachycardia NOS | 0.009035 | 0.8471 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Peripheral retinal degenerations | 0.01073 | 0.7856 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Mixed hyperlipidemia | 1.348e-05 | 0.7735 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs6959888 | Chronic pancreatitis | 0.008748 | 0.2644 | ZNF804B | Anorexia nervosa |
| rs6959888 | Excessive or frequent menstruation | 0.0003751 | 0.5408 | ZNF804B | Anorexia nervosa |
| rs6959888 | Dysmenorrhea | 0.005335 | 0.4547 | ZNF804B | Anorexia nervosa |
| rs6959888 | Other diseases of lung | 0.004992 | 1.208 | ZNF804B | Anorexia nervosa |
| rs6959888 | Disorders of menstruation | 0.01091 | 0.7625 | ZNF804B | Anorexia nervosa |
| rs6959888 | Painful respiration | 0.008669 | 1.227 | ZNF804B | Anorexia nervosa |
| rs6959888 | Alzheimer's disease | 0.006078 | 1.281 | ZNF804B | Anorexia nervosa |
| rs6959888 | Disorders of fluid, electrolyte, and acid-base balance | 0.002733 | 1.15 | ZNF804B | Anorexia nervosa |
| rs6959888 | Abnormal findings examination of lungs | 0.006636 | 1.253 | ZNF804B | Anorexia nervosa |
| rs6959888 | Infections of kidney | 0.01094 | 1.451 | ZNF804B | Anorexia nervosa |
| rs6959888 | Hypovolemia | 0.00223 | 1.215 | ZNF804B | Anorexia nervosa |
| rs697739 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.004561 | 0.8133 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Rheumatoid arthritis | 0.00021 | 0.7321 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Viral Enteritis | 0.0003801 | 1.672 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Secondary thrombocytopenia | 0.009126 | 1.594 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Disorders of optic nerve and visual pathways | 0.008513 | 0.7799 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Hyperglyceridemia | 0.002717 | 0.7672 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Substance addiction and disorders | 0.00327 | 1.32 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Optic neuritis/neuropathy | 0.003933 | 0.7009 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Chronic glomerulonephritis | 0.0002253 | 2.817 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Abnormal kidney function | 0.002836 | 2.1 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Scoliosis | 0.01066 | 0.7552 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Peripheral vascular disease | 0.00497 | 0.8834 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Glomerulonephritis | 0.0009807 | 1.837 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Absent or infrequent menstruation | 0.008554 | 1.508 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Spondylosis with myelopathy | 0.009076 | 1.37 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Urethral stricture (not specified as infectious) | 0.009476 | 0.6756 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Type 2 diabetic peripheral circulatory disorders | 0.006348 | 0.6879 | ATXN1 | Amyotrophic lateral sclerosis |
| rs7023329 | Other disorders of biliary tract | 0.009518 | 1.484 | MTAP | Melanoma |
| rs7023329 | Other upper respiratory disease | 0.005173 | 0.8636 | MTAP | Melanoma |
| rs7023329 | Myocardial infarction | 0.009395 | 1.124 | MTAP | Melanoma |
| rs7023329 | Varicose veins | 0.0002104 | 0.8249 | MTAP | Melanoma |
| rs7023329 | progressive myopia | 0.004399 | 1.811 | MTAP | Melanoma |
| rs7023329 | Varicose veins of lower extremity, symptomtic | 7.985e-05 | 0.7493 | MTAP | Melanoma |
| rs7023329 | Aneurysm of artery of lower extremity | 0.008596 | 0.647 | MTAP | Melanoma |
| rs7023329 | Ischemic Heart Disease | 0.004051 | 1.091 | MTAP | Melanoma |
| rs7023329 | Mucous polyp of cervix | 0.005542 | 0.7137 | MTAP | Melanoma |
| rs7023329 | Memory loss | 0.001782 | 0.7846 | MTAP | Melanoma |
| rs7023329 | Chronic pharyngitis and nasopharyngitis | 0.006394 | 0.8573 | MTAP | Melanoma |
| rs7023329 | Varicose veins of lower extremity | 0.0001925 | 0.8172 | MTAP | Melanoma |
| rs7023329 | Abnormal coagulation profile | 0.002002 | 1.421 | MTAP | Melanoma |
| rs7023329 | Other cells and casts in urine | 0.004948 | 0.6871 | MTAP | Melanoma |
| rs7023329 | Diseases of pulp and periapical tissues | 0.008577 | 0.8375 | MTAP | Melanoma |
| rs7023329 | Complication of internal orthopedic device | 0.001876 | 1.262 | MTAP | Melanoma |
| rs7023329 | Cardiomyopathy | 0.0111 | 1.169 | MTAP | Melanoma |
| rs7023329 | Major depressive disorder | 0.007168 | 0.8645 | MTAP | Melanoma |
| rs7023329 | Gastrointestinal malfunction arising from mental factors | 0.006385 | 2.097 | MTAP | Melanoma |
| rs7023329 | Coronary atherosclerosis | 0.006459 | 1.091 | MTAP | Melanoma |
| rs7023329 | Primary/intrinsic cardiomyopathies | 0.0112 | 1.174 | MTAP | Melanoma |
| rs7025486 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.004632 | 1.272 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Acute pancreatitis | 0.005876 | 0.7333 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Facial nerve disorders | 0.00588 | 1.433 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Arterial embolism and thrombosis of lower extremity artery | 0.009655 | 1.358 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Persistent mental disorders due to other conditions | 0.01048 | 0.8537 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Dermatophytosis of the body | 0.003203 | 1.412 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Peritonitis and retroperitoneal infections | 0.008623 | 0.6554 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Sprains and strains | 0.0008684 | 1.151 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Other alveolar and parietoalveolar pneumonopathy | 0.003259 | 1.722 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Abnormal chest sounds | 0.004568 | 1.505 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Cystoid macular degeneration of retina | 0.0009133 | 1.42 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Diseases of pulp and periapical tissues | 0.006532 | 1.227 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Other pulmonary inflamation or edema | 0.005744 | 0.709 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Diverticulitis | 0.008381 | 0.7957 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Hyperbilirubinemia | 0.007118 | 0.4339 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Arterial embolism and thrombosis | 0.008812 | 1.253 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Nonrheumatic tricuspid valve disorders | 0.006976 | 1.476 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Senile dementia | 0.003066 | 0.7719 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Fracture of clavicle or scapula | 0.001956 | 1.499 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Abnormal thyroid function | 0.008552 | 0.7561 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Disorders of other cranial nerves | 0.002475 | 1.333 | DAB2IP | Abdominal aortic aneurysm |
| rs7072268 | Nontoxic nodular goiter | 0.003962 | 1.193 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Myocardial infarction | 0.001723 | 0.8693 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Celiac or tropical sprue | 0.01027 | 1.725 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Colostomy and enterostomy complication | 0.003659 | 1.914 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Anemia NOS | 0.0005756 | 1.119 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Other anemias | 0.001687 | 1.1 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Abnormal findings on radiological exam of musculoskeletal system | 0.0001351 | 1.967 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Hypercalcemia | 0.01017 | 1.242 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Insulin pump user | 0.001396 | 0.7677 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Redundant prepuce and phimosis/BXO | 0.009051 | 0.6048 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Aphakia and other disorders of lens | 0.008044 | 1.28 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Cancer of oropharynx | 0.004298 | 2.213 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Diplopia and disorders of binocular vision | 0.007189 | 0.7772 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Acid-base balance disorder | 0.008898 | 1.294 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Celiac disease | 0.009152 | 1.762 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Diseases of hair and hair follicles | 0.01064 | 0.8311 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Keratoderma, acquired | 0.0003726 | 0.8195 | HK1 | Glycated hemoglobin levels |
| rs7085433 | Disorders of sweat glands | 0.006524 | 1.397 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Disorders of parathyroid gland | 0.007389 | 0.6194 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Enthesopathy | 0.002847 | 1.205 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Other sprains and strains | 0.001629 | 1.58 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Intervertebral disc disorders | 0.005139 | 1.163 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Disorders of synovium, tendon, and bursa | 0.009295 | 1.174 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Degeneration of intervertebral disc | 0.001094 | 1.226 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Open wound of ear | 0.01065 | 2.161 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Synoviopathy | 0.00704 | 1.506 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Aortic aneurysm | 0.005939 | 1.317 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Anemia in chronic kidney disease | 0.002404 | 0.5606 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Contact dermatitis and other eczema due to plants [except food] | 0.0009842 | 2.327 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Sepsis and SIRS | 0.0001054 | 1.563 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Sepsis | 0.000126 | 1.578 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Dermatomyositis and Polymyositis | 0.007962 | 2.298 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Nontoxic uninodular goiter | 0.00666 | 0.6894 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Muscle weakness | 0.007398 | 0.6097 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Fracture of clavicle or scapula | 0.01031 | 0.5148 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Generalized hyperhidrosis | 0.002175 | 1.565 | TIMM23 | Mean corpuscular hemoglobin |
| rs712039 | Retinal vascular changes and abnomalities | 0.006757 | 1.246 | DUSP14 | Tuberculosis |
| rs712039 | Personal history of allergy to medicinal agents | 0.001746 | 0.7181 | DUSP14 | Tuberculosis |
| rs712039 | Abnormal thyroid function | 0.002771 | 0.7235 | DUSP14 | Tuberculosis |
| rs712039 | Arthropathy NOS | 0.01058 | 0.8303 | DUSP14 | Tuberculosis |
| rs712039 | Subarachnoid hemorrhage | 0.008777 | 1.884 | DUSP14 | Tuberculosis |
| rs712039 | Other specified nonpsychotic and/or transient mental disorders | 0.00159 | 0.7556 | DUSP14 | Tuberculosis |
| rs712039 | Cervical cancer | 0.001839 | 0.3104 | DUSP14 | Tuberculosis |
| rs712039 | Mental disorders due to brain damage | 0.001045 | 0.7422 | DUSP14 | Tuberculosis |
| rs712039 | Partial epilepsy | 0.001758 | 1.516 | DUSP14 | Tuberculosis |
| rs712039 | Nontoxic uninodular goiter | 0.003079 | 0.7613 | DUSP14 | Tuberculosis |
| rs712039 | Vascular insufficiency of intestine | 0.01051 | 1.402 | DUSP14 | Tuberculosis |
| rs712039 | Poisoning by primarily systemic agents | 0.008595 | 0.7261 | DUSP14 | Tuberculosis |
| rs712039 | Abnormal findings on mammogram or breast exam | 0.01036 | 1.13 | DUSP14 | Tuberculosis |
| rs712039 | Age-related macular degeneration | 0.001228 | 1.276 | DUSP14 | Tuberculosis |
| rs712039 | Ptosis of eyelid | 0.01064 | 1.214 | DUSP14 | Tuberculosis |
| rs7122539 | Viral hepatitis | 0.003117 | 0.7429 | PC | HIV-1 susceptibility |
| rs7122539 | Postinflammatory pulmonary fibrosis | 0.008165 | 1.26 | PC | HIV-1 susceptibility |
| rs7122539 | Asthma | 0.00808 | 0.887 | PC | HIV-1 susceptibility |
| rs7122539 | Dermatomycoses | 0.0002423 | 1.995 | PC | HIV-1 susceptibility |
| rs7122539 | Temporomandibular joint disorders | 0.003182 | 0.751 | PC | HIV-1 susceptibility |
| rs7122539 | Gram negative septicemia | 0.003974 | 1.43 | PC | HIV-1 susceptibility |
| rs7122539 | Urinary tract infection | 0.006543 | 0.905 | PC | HIV-1 susceptibility |
| rs7122539 | Chronic venous hypertension | 0.008603 | 0.4214 | PC | HIV-1 susceptibility |
| rs7122539 | Cervicocranial/Cervicobrachial syndrome | 0.004656 | 0.7772 | PC | HIV-1 susceptibility |
| rs7122539 | Other congenital anomalies | 0.0005578 | 0.3765 | PC | HIV-1 susceptibility |
| rs7122539 | Septicemia | 0.0009978 | 1.223 | PC | HIV-1 susceptibility |
| rs7122539 | Fracture of foot | 0.009669 | 1.198 | PC | HIV-1 susceptibility |
| rs7122539 | Noninflammatory disorders of cervix | 0.005464 | 0.5325 | PC | HIV-1 susceptibility |
| rs7136572 | Obsessive-compulsive disorder | 0.009435 | 3.628 | USP44 | Response to antidepressant treatment |
| rs7136572 | Myopia | 0.005327 | 0.5772 | USP44 | Response to antidepressant treatment |
| rs7136572 | Hammer toe | 0.002891 | 2.026 | USP44 | Response to antidepressant treatment |
| rs7136572 | Ulcerative stomatitis & mucositis | 0.01111 | 3.758 | USP44 | Response to antidepressant treatment |
| rs7136572 | Parkinson's disease | 0.003507 | 2.416 | USP44 | Response to antidepressant treatment |
| rs7136572 | Epilepsy, recurrent seizures, convulsions | 0.004803 | 1.87 | USP44 | Response to antidepressant treatment |
| rs7136572 | Symptoms involving cardiovascular system | 0.002799 | 0.3494 | USP44 | Response to antidepressant treatment |
| rs7136572 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.00916 | 3.966 | USP44 | Response to antidepressant treatment |
| rs7136572 | Prolapse of vaginal walls | 0.005276 | 1.922 | USP44 | Response to antidepressant treatment |
| rs7136572 | Disorders of refraction and accommodation | 0.007626 | 0.664 | USP44 | Response to antidepressant treatment |
| rs7136572 | Ileostomy status | 0.004687 | 3.345 | USP44 | Response to antidepressant treatment |
| rs7136572 | Extrapyramidal disease and abnormal movement disorders | 0.008763 | 1.786 | USP44 | Response to antidepressant treatment |
| rs7136572 | Pneumonitis due to inhalation of food or vomitus | 0.00758 | 2.271 | USP44 | Response to antidepressant treatment |
| rs7136572 | Pseudomonal pneumonia | 0.004807 | 5.7 | USP44 | Response to antidepressant treatment |
| rs7136572 | Genital prolapse | 0.01096 | 1.701 | USP44 | Response to antidepressant treatment |
| rs7136572 | Functional digestive disorders | 0.004377 | 0.4877 | USP44 | Response to antidepressant treatment |
| rs7137869 | Primary pulmonary hypertension | 0.01019 | 1.588 | CCDC60 | Aging |
| rs7137869 | Malignant neoplasm, other | 0.009379 | 0.7728 | CCDC60 | Aging |
| rs7137869 | Torsion dystonia | 0.003976 | 1.685 | CCDC60 | Aging |
| rs7137869 | Pneumoconiosis | 0.009809 | 1.897 | CCDC60 | Aging |
| rs7137869 | Iatrogenic hypothyroidism | 0.006721 | 0.6741 | CCDC60 | Aging |
| rs7137869 | Temporomandibular joint disorder NOS | 0.007456 | 1.644 | CCDC60 | Aging |
| rs7137869 | Malignant neoplasm of brain and nervous system | 0.01139 | 0.6338 | CCDC60 | Aging |
| rs7137869 | Cardiac congenital anomalies | 0.01117 | 1.343 | CCDC60 | Aging |
| rs7137869 | Acute pharyngitis | 0.001764 | 0.8204 | CCDC60 | Aging |
| rs7137869 | Other forms of chronic heart disease | 0.00527 | 1.233 | CCDC60 | Aging |
| rs7137869 | Diseases of the salivary glands | 0.009389 | 1.316 | CCDC60 | Aging |
| rs7137869 | Angina pectoris | 0.007999 | 1.154 | CCDC60 | Aging |
| rs7137869 | Rash and other nonspecific skin eruption | 0.0112 | 0.8408 | CCDC60 | Aging |
| rs7137869 | Cancer, suspected or other | 0.008334 | 0.7978 | CCDC60 | Aging |
| rs7137869 | Sialoadenitis | 0.005172 | 1.535 | CCDC60 | Aging |
| rs7140150 | Intracranial hemorrhage | 0.00946 | 0.7552 | FRMD6 | Brain structure |
| rs7140150 | Open wound of hand except finger(s) | 0.009842 | 1.263 | FRMD6 | Brain structure |
| rs7140150 | Varicose veins of lower extremity, symptomtic | 0.007007 | 0.8187 | FRMD6 | Brain structure |
| rs7140150 | Other cerebral degenerations | 0.0001451 | 1.624 | FRMD6 | Brain structure |
| rs7140150 | Diseases of blood and blood-forming organs | 0.006334 | 0.8047 | FRMD6 | Brain structure |
| rs7140150 | Viral warts & HPV | 0.007134 | 1.153 | FRMD6 | Brain structure |
| rs7140150 | Secondary malignancy of brain/spine | 0.006181 | 1.622 | FRMD6 | Brain structure |
| rs7140150 | Inflammatory and toxic neuropathy | 0.0006224 | 1.459 | FRMD6 | Brain structure |
| rs7140150 | Pathologic fracture | 0.004328 | 1.214 | FRMD6 | Brain structure |
| rs7140150 | Otalgia | 0.008158 | 1.254 | FRMD6 | Brain structure |
| rs7140150 | Nerve plexus lesions | 0.000335 | 1.601 | FRMD6 | Brain structure |
| rs7140150 | Nerve root and plexus disorders | 0.001564 | 1.372 | FRMD6 | Brain structure |
| rs7140150 | Calcaneal spur; Exostosis NOS | 0.006952 | 1.26 | FRMD6 | Brain structure |
| rs7157785 | Skin neoplasm of uncertain behavior | 0.003959 | 0.7495 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.006085 | 1.726 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Patellar fracture | 0.01113 | 1.472 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Other disorders of tympanic membrane | 0.009589 | 0.5679 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Plasma protein metabolism disorder | 0.001988 | 1.426 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Disorders of choroid | 0.009867 | 0.691 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Reticulosarcoma | 0.007445 | 0.3958 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Bacterial enteritis | 0.001704 | 1.47 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Disorders of penis | 0.008499 | 1.429 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Other endocrine disorders | 0.008817 | 0.4795 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Uterine cancer | 0.003365 | 0.535 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Peripheral enthesopathies | 0.0006612 | 0.8604 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Peyronie's disease | 0.000789 | 2.312 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Cancer of oropharynx | 0.002424 | 2.345 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Conductive hearing loss | 0.001994 | 0.4079 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Multiple sclerosis | 0.005785 | 1.642 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7158173 | Intestinal infection due to C. difficile | 0.004395 | 0.7091 | MAX | Waist circumference |
| rs7158173 | Immune disorders | 0.008818 | 0.8003 | MAX | Waist circumference |
| rs7158173 | Bacterial enteritis | 0.001506 | 0.7146 | MAX | Waist circumference |
| rs7158173 | Other disorders of tympanic membrane | 0.004345 | 1.467 | MAX | Waist circumference |
| rs7158173 | Cancer of bone & connective tissue | 0.008412 | 0.6839 | MAX | Waist circumference |
| rs7158173 | Cancer of other female genital organs | 0.003419 | 0.6544 | MAX | Waist circumference |
| rs7158173 | Perforation of tympanic membrane | 0.007696 | 1.495 | MAX | Waist circumference |
| rs7158173 | Malignant neoplasm of ovary | 0.006413 | 0.581 | MAX | Waist circumference |
| rs7158173 | Stricture/obstruction of ureter | 0.005319 | 0.6643 | MAX | Waist circumference |
| rs7158173 | Anorexia | 0.009069 | 1.336 | MAX | Waist circumference |
| rs7158173 | Intestinal malabsorption | 0.0109 | 1.343 | MAX | Waist circumference |
| rs7158173 | Benign neoplasm of brain and other parts of nervous system | 0.005737 | 0.7028 | MAX | Waist circumference |
| rs7158173 | Infertility, male | 0.003538 | 0.47 | MAX | Waist circumference |
| rs7158173 | Ovarian cancer | 0.002878 | 0.6032 | MAX | Waist circumference |
| rs7158173 | Cancer of kidney and urinary organs | 0.01001 | 0.8356 | MAX | Waist circumference |
| rs7191888 | Abnormal glucose | 0.009917 | 0.8715 | C16orf47 | Multiple sclerosis |
| rs7191888 | Other abnormal glucose | 0.01138 | 0.8443 | C16orf47 | Multiple sclerosis |
| rs7191888 | Other paralytic syndromes | 0.002338 | 1.653 | C16orf47 | Multiple sclerosis |
| rs7191888 | Acute pharyngitis | 0.001218 | 0.7993 | C16orf47 | Multiple sclerosis |
| rs7191888 | Nonrheumatic aortic valve disorders | 0.007189 | 0.8172 | C16orf47 | Multiple sclerosis |
| rs7191888 | Acute sinusitis | 0.001828 | 0.8164 | C16orf47 | Multiple sclerosis |
| rs7191888 | Sialoadenitis | 0.009832 | 1.532 | C16orf47 | Multiple sclerosis |
| rs7191888 | Varicose veins of lower extremity | 0.006725 | 0.8177 | C16orf47 | Multiple sclerosis |
| rs7191888 | Anal and rectal polyp | 0.008768 | 0.7413 | C16orf47 | Multiple sclerosis |
| rs7191888 | Stricture and stenosis of esophagus | 0.00411 | 1.358 | C16orf47 | Multiple sclerosis |
| rs7219585 | Malignant neoplasm, other | 0.0113 | 1.304 | DNAI2 | Cognitive performance |
| rs7219585 | Other disorders of urethra and urinary tract | 0.01081 | 0.7452 | DNAI2 | Cognitive performance |
| rs7219585 | Myasthenia gravis | 0.009834 | 2.152 | DNAI2 | Cognitive performance |
| rs7219585 | Inguinal hernia | 0.002301 | 0.7813 | DNAI2 | Cognitive performance |
| rs7219585 | Nasal polyps | 0.006501 | 1.468 | DNAI2 | Cognitive performance |
| rs7219585 | Complication of internal orthopedic device | 0.002923 | 0.6861 | DNAI2 | Cognitive performance |
| rs7219585 | Premature menopause and other ovarian failure | 0.003117 | 2.126 | DNAI2 | Cognitive performance |
| rs7219585 | Primary angle-closure glaucoma | 0.004873 | 1.343 | DNAI2 | Cognitive performance |
| rs7219585 | Subarachnoid hemorrhage | 0.00179 | 2.299 | DNAI2 | Cognitive performance |
| rs7219585 | Adverse drug events and drug allergies | 0.01076 | 1.227 | DNAI2 | Cognitive performance |
| rs7219585 | Synoviopathy | 0.001766 | 1.539 | DNAI2 | Cognitive performance |
| rs7219585 | Cancer, suspected or other | 0.01045 | 1.266 | DNAI2 | Cognitive performance |
| rs7219585 | Retinal edema and hypertensive retinopathy | 0.004978 | 1.456 | DNAI2 | Cognitive performance |
| rs7219585 | Ingrowing nail | 0.006062 | 0.791 | DNAI2 | Cognitive performance |
| rs7219585 | AV block | 0.003654 | 0.7529 | DNAI2 | Cognitive performance |
| rs7219585 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.002824 | 1.864 | DNAI2 | Cognitive performance |
| rs7219585 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.001342 | 1.918 | DNAI2 | Cognitive performance |
| rs7219585 | Secondary malignancy of bone | 1.358e-05 | 1.771 | DNAI2 | Cognitive performance |
| rs7253363 | Congenital anomalies of peripheral vascular system | 0.007428 | 2.511 | ACP5 | Multiple sclerosis |
| rs7253363 | Acute laryngitis and tracheitis | 0.005152 | 2.069 | ACP5 | Multiple sclerosis |
| rs7253363 | Periapical abscess | 0.00739 | 0.569 | ACP5 | Multiple sclerosis |
| rs7253363 | Cholesteatoma | 0.01132 | 2.333 | ACP5 | Multiple sclerosis |
| rs7253363 | Paralysis/spasm of vocal cords or larynx | 0.008036 | 2.19 | ACP5 | Multiple sclerosis |
| rs7253363 | Primary pulmonary hypertension | 0.004404 | 2.32 | ACP5 | Multiple sclerosis |
| rs7253363 | Anisometropia | 0.004249 | 1.74 | ACP5 | Multiple sclerosis |
| rs7253363 | Scleritis and episcleritis | 0.003662 | 2.297 | ACP5 | Multiple sclerosis |
| rs7253363 | Cramp of limb | 0.01007 | 1.635 | ACP5 | Multiple sclerosis |
| rs7253363 | Otosclerosis | 0.007092 | 2.015 | ACP5 | Multiple sclerosis |
| rs7253363 | Sacroiliitis NEC | 0.01052 | 2.365 | ACP5 | Multiple sclerosis |
| rs7315438 | Oliguria and anuria | 0.005206 | 2.187 | MED13L | Colorectal cancer |
| rs7315438 | Other endocrine disorders | 0.002704 | 0.5961 | MED13L | Colorectal cancer |
| rs7315438 | Nerve plexus lesions | 0.006296 | 0.6877 | MED13L | Colorectal cancer |
| rs7315438 | Cholangitis | 0.008164 | 0.5623 | MED13L | Colorectal cancer |
| rs7315438 | Hyperplasia of prostate | 0.007772 | 0.8742 | MED13L | Colorectal cancer |
| rs7315438 | Melanoma | 0.0008162 | 0.7349 | MED13L | Colorectal cancer |
| rs7315438 | Neoplasm of uncertain behavior | 0.001861 | 0.8191 | MED13L | Colorectal cancer |
| rs7315438 | Keratitis, infectious | 0.003243 | 0.6835 | MED13L | Colorectal cancer |
| rs7315438 | Hypoparathyroidism | 0.007758 | 0.4285 | MED13L | Colorectal cancer |
| rs7315438 | Disorders resulting from impaired renal function | 0.0043 | 1.308 | MED13L | Colorectal cancer |
| rs735172 | Hepatomegaly | 0.002796 | 0.4305 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Urethral stricture (not specified as infectious) | 0.008148 | 1.418 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Conduct disorders | 0.01116 | 0.6042 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Other disorders of urethra and urinary tract | 0.003487 | 1.239 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Adjustment reaction | 0.002155 | 1.183 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Other specified disorders of pancreatic internal secretion | 0.01003 | 0.5358 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Allergies, other | 0.002665 | 0.7512 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Diseases of pulp and periapical tissues | 0.01083 | 0.8262 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Periostitis | 0.00649 | 0.4711 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Esophageal atresia/tracheoesophageal fistula | 0.01112 | 1.646 | EVC | Prostate cancer (gene x gene interaction) |
| rs735854 | Neurological disorders due to brain damage | 0.005371 | 0.8744 | MYH9 | Optic disc parameters |
| rs735854 | Osteoarthrosis of multiple sites | 0.0005331 | 0.7695 | MYH9 | Optic disc parameters |
| rs735854 | Varicose veins of lower extremity, symptomtic | 0.006461 | 0.8138 | MYH9 | Optic disc parameters |
| rs735854 | Disorders of cervical region | 0.007757 | 0.7307 | MYH9 | Optic disc parameters |
| rs735854 | Varicose veins | 0.0002051 | 0.8175 | MYH9 | Optic disc parameters |
| rs735854 | Ulceration of the lower GI tract | 0.00121 | 0.549 | MYH9 | Optic disc parameters |
| rs735854 | Hypermetropia | 0.007212 | 0.8769 | MYH9 | Optic disc parameters |
| rs735854 | Other disorders of tympanic membrane | 0.002239 | 1.509 | MYH9 | Optic disc parameters |
| rs735854 | Benign neoplasm of respiratory and intrathoracic organs | 0.005253 | 1.756 | MYH9 | Optic disc parameters |
| rs735854 | Dental caries | 0.001403 | 1.241 | MYH9 | Optic disc parameters |
| rs735854 | Diseases of pulp and periapical tissues | 0.002639 | 1.231 | MYH9 | Optic disc parameters |
| rs735854 | Chronic venous insufficiency | 0.006316 | 0.8371 | MYH9 | Optic disc parameters |
| rs735854 | Back & neck sprains | 0.002061 | 0.8719 | MYH9 | Optic disc parameters |
| rs735854 | Joint/ligament sprain | 0.00473 | 0.7406 | MYH9 | Optic disc parameters |
| rs735854 | Acquired deformities of ankle and foot | 0.00783 | 0.8074 | MYH9 | Optic disc parameters |
| rs735854 | Enthesopathy | 0.008865 | 0.8961 | MYH9 | Optic disc parameters |
| rs735854 | Varicose veins of lower extremity | 0.0001414 | 0.8063 | MYH9 | Optic disc parameters |
| rs735854 | Sprains and strains | 0.007508 | 0.9008 | MYH9 | Optic disc parameters |
| rs735854 | Diseases of hard tissues of teeth | 0.0004071 | 1.262 | MYH9 | Optic disc parameters |
| rs735854 | Open wound of lip and mouth | 0.005092 | 0.5128 | MYH9 | Optic disc parameters |
| rs735854 | Angiodysplasia of intestine | 0.0003386 | 0.2548 | MYH9 | Optic disc parameters |
| rs735854 | Internal derangement of knee | 0.008326 | 0.8692 | MYH9 | Optic disc parameters |
| rs735854 | Chronic obstructive asthma | 0.009424 | 1.273 | MYH9 | Optic disc parameters |
| rs735854 | Fractur of unspecified part of femur | 0.001499 | 0.6385 | MYH9 | Optic disc parameters |
| rs735854 | Symptoms involving female genital tract | 0.00945 | 0.723 | MYH9 | Optic disc parameters |
| rs735854 | Torticollis | 0.001916 | 0.5685 | MYH9 | Optic disc parameters |
| rs735854 | Hemorrhoids | 0.000725 | 0.8705 | MYH9 | Optic disc parameters |
| rs735854 | Aphasia/speech disturbance | 0.01072 | 0.8155 | MYH9 | Optic disc parameters |
| rs735854 | Acute posthemorrhagic anemia | 0.003807 | 0.8368 | MYH9 | Optic disc parameters |
| rs735854 | Ulceration of intestine | 0.003331 | 0.5434 | MYH9 | Optic disc parameters |
| rs735854 | Nonspecific findings on examination of blood | 5.266e-05 | 1.492 | MYH9 | Optic disc parameters |
| rs744373 | Joint/ligament sprain | 0.006058 | 0.7184 | BIN1 | Alzheimer's disease |
| rs744373 | Adrenal hypofunction | 0.005266 | 1.666 | BIN1 | Alzheimer's disease |
| rs744373 | Vaginitis and vulvovaginitis | 0.01085 | 1.207 | BIN1 | Alzheimer's disease |
| rs744373 | Alopecia Areata | 0.00386 | 2.119 | BIN1 | Alzheimer's disease |
| rs744373 | Postmenopausal hormone replacement | 0.001673 | 1.374 | BIN1 | Alzheimer's disease |
| rs744373 | Anal and rectal conditions | 0.001273 | 1.188 | BIN1 | Alzheimer's disease |
| rs744373 | Diseases of hair and hair follicles | 0.005523 | 1.241 | BIN1 | Alzheimer's disease |
| rs744373 | Menopausal & postmenopausal disorders | 0.0105 | 1.134 | BIN1 | Alzheimer's disease |
| rs744373 | Other specified diseases of hair and hair follicles | 0.008096 | 1.328 | BIN1 | Alzheimer's disease |
| rs744373 | Cancer of other male genital organs | 0.009824 | 1.727 | BIN1 | Alzheimer's disease |
| rs749005 | Chronic prostatitis | 0.01023 | 1.642 | F13A1 | Entorhinal cortical volume |
| rs749005 | Seborrheic keratosis | 0.003106 | 1.16 | F13A1 | Entorhinal cortical volume |
| rs749005 | Nervous system congenital anomalies | 0.004634 | 1.57 | F13A1 | Entorhinal cortical volume |
| rs749005 | Altered mental status | 0.005241 | 1.393 | F13A1 | Entorhinal cortical volume |
| rs749005 | Discoid lupus erythematosus | 0.006768 | 0.511 | F13A1 | Entorhinal cortical volume |
| rs749005 | Systemic lupus erythematosus | 0.007102 | 0.4823 | F13A1 | Entorhinal cortical volume |
| rs749005 | Ulceration of the lower GI tract | 0.002165 | 1.808 | F13A1 | Entorhinal cortical volume |
| rs749005 | Phosphorus metabolism disorder | 0.01014 | 0.5385 | F13A1 | Entorhinal cortical volume |
| rs749005 | Retinal detachments and defects | 0.01072 | 1.288 | F13A1 | Entorhinal cortical volume |
| rs749005 | Other specified diseases of nail | 0.01025 | 1.201 | F13A1 | Entorhinal cortical volume |
| rs749005 | Chronic bronchitis | 0.01067 | 1.246 | F13A1 | Entorhinal cortical volume |
| rs7495052 | Hypercalcemia | 0.003021 | 0.7723 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Periapical abscess | 0.001731 | 1.254 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Nonrheumatic aortic valve disorders | 0.003724 | 0.8508 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Renal colic | 0.01119 | 1.602 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Lymphadenitis | 0.007762 | 1.175 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Disorders of mineral metabolism | 0.0007307 | 0.8439 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Secondary malignancy of lymph nodes | 0.005897 | 1.261 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Diseases of pulp and periapical tissues | 0.004955 | 1.215 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Anisometropia | 0.002017 | 0.7284 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Open wound of foot except toe(s) alone | 0.005804 | 1.509 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Fracture of upper limb | 0.01065 | 0.8788 | SLCO3A1 | Inattentive symptoms |
| rs7498403 | Gout and other crystal arthropathies | 0.01093 | 1.261 | MAF | Height |
| rs7498403 | Arthropathy associated with other disorders classified elsewhere | 0.005053 | 2.265 | MAF | Height |
| rs7498403 | Irritable Bowel Syndrome | 0.009155 | 1.321 | MAF | Height |
| rs7498403 | Personality disorders | 0.008863 | 1.498 | MAF | Height |
| rs7498403 | Develomental delays and disorders | 0.00266 | 1.559 | MAF | Height |
| rs7498403 | Osteoarthrosis of multiple sites | 0.003129 | 1.505 | MAF | Height |
| rs7498403 | Cholelithiasis | 0.008811 | 1.254 | MAF | Height |
| rs7498403 | Cardiac congenital anomalies | 0.001342 | 1.684 | MAF | Height |
| rs7498403 | Cardiac shunt/ heart septal defect | 4.076e-05 | 2.235 | MAF | Height |
| rs7498403 | Deviated nasal septum | 0.009722 | 1.348 | MAF | Height |
| rs7498403 | Arthropathy associated with neurological disorders | 0.001419 | 2.66 | MAF | Height |
| rs7498403 | Other upper respiratory disease | 0.0105 | 1.292 | MAF | Height |
| rs7498403 | Other specified diseases of hair and hair follicles | 0.01006 | 1.545 | MAF | Height |
| rs7498403 | Cardiac and circulatory congenital anomalies | 0.006922 | 1.507 | MAF | Height |
| rs7498403 | Osteoarthrosis | 0.008539 | 1.166 | MAF | Height |
| rs750338 | Valvular heart disease/ heart chambers | 0.0007409 | 2.057 | PKNOX2 | Alcoholism |
| rs750338 | Renal colic | 0.004574 | 0.4325 | PKNOX2 | Alcoholism |
| rs750338 | Hypertension complicating pregnancy | 0.005583 | 0.2664 | PKNOX2 | Alcoholism |
| rs750338 | Abnormal cytological, histological, immunological and DNA test findings | 0.004171 | 0.3444 | PKNOX2 | Alcoholism |
| rs750338 | Chronic airway obstruction | 0.004749 | 1.139 | PKNOX2 | Alcoholism |
| rs750338 | Disaccharide malabsorption | 0.001519 | 0.7881 | PKNOX2 | Alcoholism |
| rs750338 | Urticaria | 0.005699 | 0.7516 | PKNOX2 | Alcoholism |
| rs750338 | Carbohydrate transport and metabolism disorder | 0.002026 | 0.7951 | PKNOX2 | Alcoholism |
| rs750338 | Pain in joint | 0.008451 | 1.102 | PKNOX2 | Alcoholism |
| rs750338 | Asthma | 0.009295 | 1.14 | PKNOX2 | Alcoholism |
| rs7517337 | severe protein-calorie malnutrition | 0.004892 | 1.559 | KCNT2 | Total ventricular volume |
| rs7517337 | Adrenal hyperfunction | 0.003166 | 0.4751 | KCNT2 | Total ventricular volume |
| rs7517337 | Electrolyte imbalance | 0.008596 | 1.096 | KCNT2 | Total ventricular volume |
| rs7517337 | Hypopotassemia | 0.006026 | 1.135 | KCNT2 | Total ventricular volume |
| rs7517337 | Meniere's disease | 0.009761 | 1.573 | KCNT2 | Total ventricular volume |
| rs7517337 | Functional disorders of bladder | 0.007933 | 1.291 | KCNT2 | Total ventricular volume |
| rs7517337 | Other specified disorders of pancreatic internal secretion | 0.01009 | 1.64 | KCNT2 | Total ventricular volume |
| rs7517337 | Pathologic fracture | 0.002097 | 1.232 | KCNT2 | Total ventricular volume |
| rs7517337 | Otalgia | 0.009118 | 1.253 | KCNT2 | Total ventricular volume |
| rs7517337 | Back pain | 0.0005839 | 1.106 | KCNT2 | Total ventricular volume |
| rs7517337 | Lymphosarcoma | 0.002892 | 0.3811 | KCNT2 | Total ventricular volume |
| rs7517337 | Pulmonary embolism and infarction | 0.001641 | 1.294 | KCNT2 | Total ventricular volume |
| rs7517337 | Pathologic fracture of vertebrae | 0.000301 | 1.35 | KCNT2 | Total ventricular volume |
| rs7517337 | Osteoporosis, osteopenia, & pathological fractures | 0.006422 | 1.098 | KCNT2 | Total ventricular volume |
| rs7517337 | Prurigo | 0.009059 | 0.7814 | KCNT2 | Total ventricular volume |
| rs7517337 | Atrophic gastritis | 0.001166 | 1.591 | KCNT2 | Total ventricular volume |
| rs755383 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.001287 | 1.237 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Neuralgia, neuritis, and radiculitis NOS | 0.003883 | 1.222 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Dental caries | 0.01021 | 1.189 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Calculus of ureter | 0.0005033 | 1.319 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Otorrhea | 0.00918 | 1.897 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Complications of gastrostomy, colostomy and enterostomy | 0.000743 | 2.312 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Premature beats | 0.006522 | 0.8385 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Jaundice | 0.003429 | 0.64 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Ankylosing spondylitis | 0.004686 | 2.255 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Urinary calculus | 0.007675 | 1.149 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Ileostomy status | 0.00648 | 1.603 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Multiple sclerosis | 0.002988 | 1.595 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Chronic ulcer of unspecified site | 0.006274 | 1.279 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Injuries to the nervous system | 0.01111 | 1.509 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Patellar fracture | 0.007506 | 1.408 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs7561317 | Nodular lymphoma | 0.008278 | 1.675 | TMEM18 | Body mass index, Weight |
| rs7561317 | Inflammatory disease of cervix, vagina, and vulva | 0.004938 | 0.7875 | TMEM18 | Body mass index, Weight |
| rs7561317 | Parasomnia | 0.009435 | 1.702 | TMEM18 | Body mass index, Weight |
| rs7561317 | Hypopotassemia | 0.01114 | 0.8512 | TMEM18 | Body mass index, Weight |
| rs7561317 | Abnormal findings on radiological exam of musculoskeletal system | 0.002766 | 1.767 | TMEM18 | Body mass index, Weight |
| rs7561317 | Unequal leg length (acquired) | 0.002799 | 0.4911 | TMEM18 | Body mass index, Weight |
| rs7561317 | Other headache syndromes | 0.008041 | 0.8798 | TMEM18 | Body mass index, Weight |
| rs7561317 | Migraine | 0.00129 | 0.7742 | TMEM18 | Body mass index, Weight |
| rs7561317 | Shock | 0.000504 | 0.4814 | TMEM18 | Body mass index, Weight |
| rs7561317 | Subarachnoid hemorrhage | 0.007032 | 2.006 | TMEM18 | Body mass index, Weight |
| rs7561317 | Phosphorus metabolism disorder | 0.006869 | 0.5516 | TMEM18 | Body mass index, Weight |
| rs7561317 | Torsion dystonia | 0.008104 | 1.671 | TMEM18 | Body mass index, Weight |
| rs7577851 | Barrett's esophagus | 0.005988 | 1.491 | AAK1 | Parkinson's disease |
| rs7577851 | Peripheral autonomic neuropathy | 0.008858 | 0.6162 | AAK1 | Parkinson's disease |
| rs7577851 | Ulcer of esophagus | 0.005831 | 1.557 | AAK1 | Parkinson's disease |
| rs7577851 | Unequal leg length (acquired) | 0.0003571 | 0.4047 | AAK1 | Parkinson's disease |
| rs7577851 | Diseases of pulp and periapical tissues | 0.001267 | 0.7296 | AAK1 | Parkinson's disease |
| rs7577851 | Other disorders of soft tissues | 0.007535 | 0.6138 | AAK1 | Parkinson's disease |
| rs7577851 | Disorders of cornea | 0.009326 | 0.7907 | AAK1 | Parkinson's disease |
| rs7577851 | Psychogenic and somatoform disorders | 0.009514 | 0.7213 | AAK1 | Parkinson's disease |
| rs7577851 | Edema | 0.004849 | 0.8688 | AAK1 | Parkinson's disease |
| rs7577851 | Fuchs' dystrophy | 0.004583 | 0.5194 | AAK1 | Parkinson's disease |
| rs7577851 | Anemia in neoplastic disease | 0.00386 | 1.548 | AAK1 | Parkinson's disease |
| rs7577851 | Decreased white blood cell count | 0.001454 | 1.336 | AAK1 | Parkinson's disease |
| rs7577851 | Rash and other nonspecific skin eruption | 0.0046 | 0.8025 | AAK1 | Parkinson's disease |
| rs7577851 | Spinal stenosis | 0.007004 | 0.845 | AAK1 | Parkinson's disease |
| rs7577851 | Crystal arthropathies | 0.01151 | 0.6515 | AAK1 | Parkinson's disease |
| rs7577851 | Anal and rectal conditions | 0.007581 | 0.8298 | AAK1 | Parkinson's disease |
| rs7577851 | Spinal stenosis of lumbar region | 0.01112 | 0.8387 | AAK1 | Parkinson's disease |
| rs7577851 | Lymphosarcoma | 0.01098 | 2.103 | AAK1 | Parkinson's disease |
| rs7577851 | Other disorders of tympanic membrane | 0.004161 | 0.5324 | AAK1 | Parkinson's disease |
| rs7577851 | Other specified diseases of sebaceous glands | 0.008672 | 0.759 | AAK1 | Parkinson's disease |
| rs7577851 | Photodermatitis & sunburn | 0.005111 | 0.793 | AAK1 | Parkinson's disease |
| rs7577851 | Periapical abscess | 0.002733 | 0.7373 | AAK1 | Parkinson's disease |
| rs7577851 | Other disorders of back | 0.005979 | 0.8125 | AAK1 | Parkinson's disease |
| rs7577851 | Osteoporosis, NOS or other | 0.01069 | 1.159 | AAK1 | Parkinson's disease |
| rs7577851 | Anemia of chronic disease | 0.003529 | 1.282 | AAK1 | Parkinson's disease |
| rs7577851 | Neutropenia | 0.000975 | 1.364 | AAK1 | Parkinson's disease |
| rs7577851 | Esophageal cancer | 0.008206 | 1.881 | AAK1 | Parkinson's disease |
| rs7577851 | Acquired deformities of limbs | 0.003243 | 0.7287 | AAK1 | Parkinson's disease |
| rs7577851 | Enthesopathy | 0.01067 | 0.8699 | AAK1 | Parkinson's disease |
| rs7577851 | Trigeminal nerve disorders | 0.003157 | 1.608 | AAK1 | Parkinson's disease |
| rs7577925 | Iatrogenic hypotension | 0.001102 | 1.736 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Skin neoplasm of uncertain behavior | 0.009174 | 0.8277 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Migraine | 0.005978 | 1.171 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Irritable Bowel Syndrome | 0.007627 | 0.8481 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Symptoms involving digestive system | 0.005758 | 0.8065 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Benign neoplasm of other parts of digestive system | 0.0092 | 1.307 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Cornea replaced by transplant | 0.009918 | 0.5286 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Renal colic | 0.009983 | 1.613 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Other diseases of the teeth and supporting structures | 0.008448 | 1.245 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Inflammatory diseases of female pelvic organs | 0.01086 | 0.8566 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Optic neuritis/neuropathy | 0.008319 | 0.7344 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Bronchitis | 0.004276 | 1.152 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Osteoarthrosis; localized, primary | 0.00613 | 0.7977 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Inflammatory disease of cervix, vagina, and vulva | 0.007149 | 0.8405 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | CNS infection and poliomyelitis | 0.0006833 | 1.877 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Polyneuropathy in diabetes | 0.009368 | 1.188 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Pseudoexfoliation glaucoma | 0.004451 | 1.597 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Symptoms involving female genital tract | 0.001642 | 0.6661 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Noninflammatory female genital disorders | 0.002052 | 0.8088 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs758642 | AV block | 0.008983 | 1.188 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Abnormal findings on mammogram or breast exam | 0.002926 | 1.138 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Varicose veins of lower extremity | 0.002561 | 1.183 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Lump or mass in breast | 0.0002123 | 1.226 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Varicose veins | 0.002669 | 1.175 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Cystic mastopathy | 0.0001188 | 1.249 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Overweight | 0.006875 | 1.09 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Mastodynia | 0.002618 | 1.306 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Spondylolisthesis, congenital | 0.002937 | 1.604 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Miscarriage; stillbirth | 0.008393 | 0.4948 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Congenital cataract and lens anomalies | 0.001731 | 2.114 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Transient cerebral ischemia | 0.005703 | 0.8632 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Disorders of mineral metabolism | 0.01106 | 1.135 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Retinal hemorrhage/ischemia | 0.01044 | 0.7173 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Benign mammary dysplasias | 0.0003286 | 1.221 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Tuberculosis | 0.003695 | 1.99 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Phobia | 3.858e-05 | 3.046 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Cerebral ischemia | 0.001859 | 0.8502 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Congenital musculoskeletal deformities of spine | 0.0002498 | 1.591 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs7610017 | Atrial fibrillation | 0.008097 | 1.273 | TP63 | Grey matter density |
| rs7610017 | Sprains and strains | 0.005347 | 1.249 | TP63 | Grey matter density |
| rs7610017 | Keratitis | 0.006071 | 1.6 | TP63 | Grey matter density |
| rs7610017 | Coagulation defects | 0.0106 | 1.205 | TP63 | Grey matter density |
| rs7610017 | Jaundice | 0.001104 | 2.042 | TP63 | Grey matter density |
| rs7610017 | Symptoms involving digestive system | 0.01061 | 1.418 | TP63 | Grey matter density |
| rs7610017 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.01145 | 1.211 | TP63 | Grey matter density |
| rs7610017 | Bacterial infection NOS | 0.00623 | 1.286 | TP63 | Grey matter density |
| rs7610017 | Other disorders of back | 0.008277 | 1.318 | TP63 | Grey matter density |
| rs7610017 | Muscular wasting and disuse atrophy | 0.008699 | 2.062 | TP63 | Grey matter density |
| rs7610017 | Mechanical complication of nervous system device, implant, and graft | 0.008756 | 2.712 | TP63 | Grey matter density |
| rs7610017 | Mixed hyperlipidemia | 0.006565 | 0.6606 | TP63 | Grey matter density |
| rs7610017 | Other immunological findings | 0.006986 | 1.59 | TP63 | Grey matter density |
| rs7610017 | Urethral stricture (not specified as infectious) | 0.003085 | 1.903 | TP63 | Grey matter density |
| rs7610017 | Congenital anomalies of genital organs | 0.006463 | 2.632 | TP63 | Grey matter density |
| rs7610017 | Spinal stenosis | 0.008547 | 1.267 | TP63 | Grey matter density |
| rs7610017 | Rotator cuff (capsule) sprain | 0.003704 | 1.465 | TP63 | Grey matter density |
| rs7610017 | Other specified cardiac dysrhythmias | 0.008755 | 1.28 | TP63 | Grey matter density |
| rs7610017 | Back & neck sprains | 0.003963 | 1.298 | TP63 | Grey matter density |
| rs7672826 | Abdominal aortic aneurysm | 0.004699 | 0.783 | MGC45800 | Multiple sclerosis |
| rs7672826 | Aortic aneurysm | 0.001124 | 0.7839 | MGC45800 | Multiple sclerosis |
| rs7672826 | Peripheral or central vertigo | 0.003823 | 1.232 | MGC45800 | Multiple sclerosis |
| rs7672826 | Epilepsy, recurrent seizures, convulsions | 0.002547 | 0.8057 | MGC45800 | Multiple sclerosis |
| rs7672826 | Dyspepsia and disorders of function of stomach | 0.01057 | 0.858 | MGC45800 | Multiple sclerosis |
| rs7672826 | Disorders of esophageal motility | 0.0001406 | 1.729 | MGC45800 | Multiple sclerosis |
| rs7672826 | Hyperbilirubinemia | 0.0002242 | 2.214 | MGC45800 | Multiple sclerosis |
| rs7672826 | Convulsions | 0.006902 | 0.8166 | MGC45800 | Multiple sclerosis |
| rs7672826 | Other aneurysm | 0.003489 | 0.8224 | MGC45800 | Multiple sclerosis |
| rs7672826 | Disorders of function of stomach | 0.009641 | 0.8627 | MGC45800 | Multiple sclerosis |
| rs7672826 | Conductive hearing loss | 0.003862 | 1.574 | MGC45800 | Multiple sclerosis |
| rs7672826 | Other disorders of urethra and urinary tract | 0.00191 | 1.254 | MGC45800 | Multiple sclerosis |
| rs7672826 | Inflammation of the eye | 0.003741 | 1.133 | MGC45800 | Multiple sclerosis |
| rs7672826 | Inflammation of eyelids | 0.002823 | 1.155 | MGC45800 | Multiple sclerosis |
| rs7672826 | Secondary/extrinsic cardiomyopathies | 0.003044 | 1.865 | MGC45800 | Multiple sclerosis |
| rs7672826 | Noninfectious disorders of lymphatic channels | 0.008838 | 1.32 | MGC45800 | Multiple sclerosis |
| rs7672826 | Thyroiditis | 0.008853 | 1.344 | MGC45800 | Multiple sclerosis |
| rs7672826 | Nonallopathic lesions NEC | 0.009174 | 1.129 | MGC45800 | Multiple sclerosis |
| rs7672826 | Symptoms of the muscles | 0.003706 | 1.279 | MGC45800 | Multiple sclerosis |
| rs7672826 | Calculus of lower urinary tract | 0.009856 | 0.5715 | MGC45800 | Multiple sclerosis |
| rs7715811 | Postmenopausal hormone replacement | 0.001842 | 0.7252 | DNAH5 | Ankle brachial index |
| rs7715811 | Toxic effect of venom | 0.003698 | 0.5636 | DNAH5 | Ankle brachial index |
| rs7715811 | Simple goiter | 0.003957 | 0.7724 | DNAH5 | Ankle brachial index |
| rs7715811 | Mucous polyp of cervix | 0.001594 | 0.6201 | DNAH5 | Ankle brachial index |
| rs7715811 | Excessive or frequent menstruation | 0.003672 | 0.7259 | DNAH5 | Ankle brachial index |
| rs7715811 | Acute bronchospasm | 0.009412 | 2.033 | DNAH5 | Ankle brachial index |
| rs7715811 | Benign mammary dysplasias | 0.002355 | 0.8312 | DNAH5 | Ankle brachial index |
| rs7715811 | Rash and other nonspecific skin eruption | 0.006372 | 0.8427 | DNAH5 | Ankle brachial index |
| rs7715811 | Cystic mastopathy | 0.002138 | 0.8233 | DNAH5 | Ankle brachial index |
| rs7715811 | Infertility, male | 0.004781 | 1.988 | DNAH5 | Ankle brachial index |
| rs7715811 | Other specified disorders of breast | 0.005153 | 0.7718 | DNAH5 | Ankle brachial index |
| rs7715811 | Asthma | 0.007527 | 0.8784 | DNAH5 | Ankle brachial index |
| rs7715811 | Multiple sclerosis | 0.01033 | 1.511 | DNAH5 | Ankle brachial index |
| rs7715811 | Pathologic fracture | 0.006414 | 0.8061 | DNAH5 | Ankle brachial index |
| rs7715811 | Hypothyroidism | 0.003935 | 0.8897 | DNAH5 | Ankle brachial index |
| rs7715811 | Vitamin D deficiency | 0.0105 | 0.7499 | DNAH5 | Ankle brachial index |
| rs7742369 | Hemorrhage NOS | 0.001434 | 1.961 | HMGA1 | Height |
| rs7742369 | Duodenal ulcer | 0.008938 | 0.6642 | HMGA1 | Height |
| rs7742369 | Benign neoplasm of respiratory and intrathoracic organs | 0.002978 | 1.927 | HMGA1 | Height |
| rs7742369 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.007016 | 1.764 | HMGA1 | Height |
| rs7742369 | Neuralgia, neuritis, and radiculitis NOS | 0.003498 | 0.751 | HMGA1 | Height |
| rs7742369 | Hypertrophy of female genital organs | 0.002587 | 1.943 | HMGA1 | Height |
| rs7742369 | Other disorders of circulatory system | 0.003564 | 1.199 | HMGA1 | Height |
| rs7742369 | Orchitis and epididymitis | 0.005723 | 1.552 | HMGA1 | Height |
| rs7742369 | Disorders of uterus, NEC | 0.008388 | 1.877 | HMGA1 | Height |
| rs7742369 | Ptosis of eyelid | 0.01082 | 1.246 | HMGA1 | Height |
| rs7742369 | Torsion dystonia | 0.01026 | 1.649 | HMGA1 | Height |
| rs7742369 | Nontoxic multinodular goiter | 0.002203 | 0.6836 | HMGA1 | Height |
| rs7742369 | Circulatory disease NEC | 0.004115 | 1.219 | HMGA1 | Height |
| rs7742369 | Acute, but ill-defined cerebrovascular disease | 0.001626 | 1.289 | HMGA1 | Height |
| rs7742369 | Disorders of esophageal motility | 0.0005785 | 1.747 | HMGA1 | Height |
| rs7774434 | Chronic sinusitis | 0.008639 | 1.12 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Labyrinthitis | 0.01114 | 1.34 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Bullous dermatoses | 0.003318 | 0.4509 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Other local infections of skin and subcutaneous tissue | 0.006121 | 0.8483 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Other disorders of adrenal glands | 0.009332 | 0.6447 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Type 1 diabetic neuropathy | 0.01003 | 1.411 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Vitamin B-complex deficiencies | 0.003554 | 0.7919 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Retinal hemorrhage/ischemia | 0.002346 | 1.448 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Diplopia and disorders of binocular vision | 0.01028 | 1.274 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Lupus erythematosus | 0.003281 | 0.4469 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Rheumatic fever / chorea | 0.009812 | 0.4599 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Rheumatoid arthritis | 0.001984 | 1.256 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Eosinophilia | 0.0006764 | 2.074 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Other specified erythematous conditions | 0.00652 | 0.7513 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Insomnia | 0.008948 | 1.159 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.004704 | 1.204 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Multiple sclerosis | 0.004638 | 0.6061 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Gastroparesis | 0.001771 | 1.828 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Allergic rhinitis | 0.009658 | 1.112 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Discoid lupus erythematosus | 0.004498 | 0.6579 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7789197 | Diseases of hard tissues of teeth | 0.004686 | 1.256 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Gastritis and duodenitis | 0.005061 | 1.19 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Throat pain | 0.009417 | 1.687 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Noninflammatory disorders of vagina | 0.01057 | 0.6503 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Other disorders of middle ear and mastoid | 0.008451 | 1.528 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Diseases of the jaws | 0.01015 | 1.232 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Periostitis | 0.005115 | 1.916 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Diaphragmatic hernia | 0.002318 | 1.192 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Otalgia | 3.507e-05 | 1.521 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Acute bronchospasm | 0.001731 | 2.526 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Primary angle-closure glaucoma | 0.007229 | 0.7606 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Other signs and symptoms in breast | 0.01033 | 0.6399 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Other specified cardiac dysrhythmias | 0.008679 | 1.165 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Cardiac defibrillator in situ | 0.001109 | 1.605 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Epilepsy | 0.01139 | 1.401 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | First degree AV block | 0.003654 | 1.322 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Epilepsy, recurrent seizures, convulsions | 0.00136 | 1.288 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Convulsions | 0.001052 | 1.311 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.01071 | 1.86 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Dental caries | 0.0009868 | 1.31 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Adverse effects of insulins and antidiabetic agents | 0.009215 | 1.859 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7792939 | Acute cystitis | 0.003734 | 0.5444 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Cystitis | 0.0005567 | 0.6637 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Fibroadenosis of breast | 0.01135 | 2.232 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Cachexia | 0.002491 | 2.385 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Dysuria | 0.007735 | 0.8008 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Chronic ulcer of skin | 0.008632 | 0.8354 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Decubitus ulcer | 0.01076 | 0.7313 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Chronic cystitis | 0.008979 | 0.4809 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Hemiplegia | 0.008644 | 0.6148 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Stress fracture | 0.01057 | 1.99 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Mental retardation | 0.007869 | 2.286 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Cystitis and urethritis | 0.004533 | 0.7354 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7804356 | Hallux valgus (Bunion) | 0.005117 | 1.226 | SKAP2 | Type 1 diabetes |
| rs7804356 | Adverse drug events and drug allergies | 0.001563 | 1.232 | SKAP2 | Type 1 diabetes |
| rs7804356 | Noninfectious dermatoses of eyelid | 0.005505 | 1.77 | SKAP2 | Type 1 diabetes |
| rs7804356 | Renal osteodystrophy | 0.008136 | 1.53 | SKAP2 | Type 1 diabetes |
| rs7804356 | Aplastic anemia | 0.006076 | 0.6691 | SKAP2 | Type 1 diabetes |
| rs7804356 | Joint/ligament sprain | 0.006483 | 0.7011 | SKAP2 | Type 1 diabetes |
| rs7804356 | Abnormal loss of weight and underweight | 0.01015 | 1.296 | SKAP2 | Type 1 diabetes |
| rs7865146 | Dermatosis NOS | 0.003974 | 0.8942 | ENG | Diastolic blood pressure |
| rs7865146 | Open-angle glaucoma | 0.003521 | 0.8438 | ENG | Diastolic blood pressure |
| rs7865146 | Occlusion and stenosis of precerebral arteries | 0.01136 | 0.8841 | ENG | Diastolic blood pressure |
| rs7865146 | Congenital anomalies of peripheral vascular system | 0.008943 | 0.5208 | ENG | Diastolic blood pressure |
| rs7865146 | Impetigo | 0.006819 | 0.6179 | ENG | Diastolic blood pressure |
| rs7865146 | Other disorders of gallbladder | 0.006972 | 1.576 | ENG | Diastolic blood pressure |
| rs7865146 | Congenital cataract and lens anomalies | 0.008297 | 0.4675 | ENG | Diastolic blood pressure |
| rs7865146 | Rhabdomyolysis | 0.009632 | 1.776 | ENG | Diastolic blood pressure |
| rs7865146 | Cardiac shunt/ heart septal defect | 0.002571 | 0.6372 | ENG | Diastolic blood pressure |
| rs7865146 | Cardiac and circulatory congenital anomalies | 0.004 | 0.7534 | ENG | Diastolic blood pressure |
| rs7865146 | Abnormal pulmonary function | 0.007717 | 2.159 | ENG | Diastolic blood pressure |
| rs7865146 | Secondary malignancy of lymph nodes | 0.01018 | 1.243 | ENG | Diastolic blood pressure |
| rs7865146 | Retinal vascular changes and abnomalities | 0.0001875 | 0.7475 | ENG | Diastolic blood pressure |
| rs7865146 | Unspecified monoarthritis | 0.007151 | 1.629 | ENG | Diastolic blood pressure |
| rs7866070 | Myeloproliferative disease | 0.001948 | 1.415 | PRRX2 | Astigmatism |
| rs7866070 | Fasciitis | 0.008844 | 1.163 | PRRX2 | Astigmatism |
| rs7866070 | Disorders of synovium, tendon, and bursa | 0.01004 | 1.113 | PRRX2 | Astigmatism |
| rs7866070 | Migraine | 0.01018 | 0.8565 | PRRX2 | Astigmatism |
| rs7866070 | Ulcer of esophagus | 0.0008379 | 1.539 | PRRX2 | Astigmatism |
| rs7866070 | Peptic ulcer | 0.0006551 | 1.215 | PRRX2 | Astigmatism |
| rs7866070 | Pulmonary embolism and infarction | 0.006773 | 1.251 | PRRX2 | Astigmatism |
| rs7866070 | Abdominal hernia | 0.009863 | 1.094 | PRRX2 | Astigmatism |
| rs7866070 | Gastric ulcer | 6.299e-05 | 1.435 | PRRX2 | Astigmatism |
| rs7866070 | Scoliosis | 0.007445 | 1.304 | PRRX2 | Astigmatism |
| rs7866070 | Barrett's esophagus | 0.009742 | 1.358 | PRRX2 | Astigmatism |
| rs7866070 | Curvature of spine | 0.009293 | 1.236 | PRRX2 | Astigmatism |
| rs7866070 | Viral hepatitis C | 0.001414 | 0.5753 | PRRX2 | Astigmatism |
| rs7866070 | Pseudoexfoliation glaucoma | 0.002382 | 0.5526 | PRRX2 | Astigmatism |
| rs7866070 | Sciatica | 0.003328 | 1.186 | PRRX2 | Astigmatism |
| rs7866070 | Viral hepatitis | 0.001998 | 0.7322 | PRRX2 | Astigmatism |
| rs7866070 | Crohn's disease | 0.009215 | 1.429 | PRRX2 | Astigmatism |
| rs786870 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.008386 | 1.212 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Hereditary and idiopathic peripheral neuropathy | 0.01114 | 1.155 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Disturbance of skin sensation | 0.008544 | 1.133 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Paranoid disorders | 0.001664 | 1.973 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Iron metabolism disorder | 0.006679 | 1.871 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Muscular dystrophies and other myopathies | 0.0113 | 1.448 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Upper gastrointestinal congenital anomalies | 0.001941 | 1.687 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Failure to thrive | 0.003099 | 1.468 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Other open wound of head and face | 0.002107 | 0.769 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Disorders of adrenal glands | 0.004416 | 1.369 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Vitamin B12 deficiency anemia | 0.005286 | 1.581 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Chronic kidney disease, Stage I or II | 0.003108 | 0.6338 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Orchitis and epididymitis | 0.001429 | 0.5714 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs7871764 | Vitamin D deficiency | 0.006313 | 1.308 | DCAF12 | Height |
| rs7871764 | Adverse effects of insulins and antidiabetic agents | 0.005575 | 1.818 | DCAF12 | Height |
| rs7871764 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.007289 | 1.114 | DCAF12 | Height |
| rs7871764 | Retinal disorders | 0.008983 | 1.116 | DCAF12 | Height |
| rs7871764 | Age-related macular degeneration | 0.001637 | 1.258 | DCAF12 | Height |
| rs7871764 | Precordial pain | 0.01128 | 0.7464 | DCAF12 | Height |
| rs7871764 | Barrett's esophagus | 0.008599 | 1.375 | DCAF12 | Height |
| rs7871764 | Infections involving bone | 0.007358 | 0.7704 | DCAF12 | Height |
| rs7871764 | Dermatophytosis of the body | 0.006701 | 0.696 | DCAF12 | Height |
| rs7871764 | Urticaria | 0.007511 | 0.7842 | DCAF12 | Height |
| rs7871764 | Vascular dementia | 0.003768 | 1.436 | DCAF12 | Height |
| rs7871764 | Polycystic ovaries | 0.007358 | 0.3874 | DCAF12 | Height |
| rs7871764 | Extrinsic allergic alveolitis | 0.000184 | 2.576 | DCAF12 | Height |
| rs7873102 | Symptoms involving nervous and musculoskeletal systems | 0.007016 | 0.7883 | SHB | Brain structure |
| rs7873102 | Gram negative septicemia | 0.004812 | 1.411 | SHB | Brain structure |
| rs7873102 | Other sprains and strains | 0.005416 | 1.348 | SHB | Brain structure |
| rs7873102 | Cysts of the jaws | 0.001742 | 2.492 | SHB | Brain structure |
| rs7873102 | Fasciitis | 0.01039 | 1.15 | SHB | Brain structure |
| rs7873102 | Male infertility and abnormal spermatozoa | 0.01104 | 1.618 | SHB | Brain structure |
| rs7873102 | Viral Enteritis | 0.006066 | 1.482 | SHB | Brain structure |
| rs7873102 | Acute laryngitis and tracheitis | 0.001482 | 1.562 | SHB | Brain structure |
| rs7873102 | Fracture of unspecified bones | 0.006533 | 1.156 | SHB | Brain structure |
| rs7873102 | Chronic kidney disease, Stage I or II | 0.003529 | 1.407 | SHB | Brain structure |
| rs7873102 | Diaphragmatic hernia | 0.003623 | 1.147 | SHB | Brain structure |
| rs7873102 | Optic atrophy | 0.002445 | 0.6378 | SHB | Brain structure |
| rs789560 | Type 2 diabetic peripheral circulatory disorders | 0.009042 | 1.503 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Contracture of joint | 0.00112 | 1.664 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Disorders of penis | 0.008682 | 1.474 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Emphysema | 0.002829 | 1.426 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Develomental delays and disorders | 0.009156 | 1.375 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | severe protein-calorie malnutrition | 0.004332 | 1.783 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Hypercoagulable state | 0.01145 | 1.629 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Uterine leiomyoma | 0.005285 | 1.341 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs7916697 | Cellulitis and abscess of trunk | 0.006713 | 0.7204 | ATOH7 | Optic disc parameters |
| rs7916697 | Bronchiectasis | 0.006573 | 1.414 | ATOH7 | Optic disc parameters |
| rs7916697 | Melanoma | 0.006393 | 1.299 | ATOH7 | Optic disc parameters |
| rs7916697 | Abnormal reflex | 0.007259 | 2.153 | ATOH7 | Optic disc parameters |
| rs7916697 | Inflammatory conditions of jaw | 0.003484 | 1.621 | ATOH7 | Optic disc parameters |
| rs7916697 | Esophageal atresia/tracheoesophageal fistula | 0.00407 | 0.4373 | ATOH7 | Optic disc parameters |
| rs7916697 | Inflammatory bowel disease | 0.008765 | 1.338 | ATOH7 | Optic disc parameters |
| rs7916697 | Toxic erythema | 0.003095 | 2.219 | ATOH7 | Optic disc parameters |
| rs7916697 | Other rheumatic heart disease | 0.002711 | 2.084 | ATOH7 | Optic disc parameters |
| rs7916697 | Crohn's disease | 0.0006647 | 1.626 | ATOH7 | Optic disc parameters |
| rs7916697 | Photodermatitis & sunburn | 0.009268 | 0.832 | ATOH7 | Optic disc parameters |
| rs7916697 | Nevus, non-neoplastic | 0.0005633 | 0.3604 | ATOH7 | Optic disc parameters |
| rs7916697 | Heartburn | 0.005917 | 1.413 | ATOH7 | Optic disc parameters |
| rs7922491 | Disorders of coccyx | 0.005041 | 1.572 | PRKG1 | Asthma |
| rs7922491 | Deficiency of humoral immunity | 0.01023 | 2.343 | PRKG1 | Asthma |
| rs7922491 | Lung cancer | 0.0001059 | 1.537 | PRKG1 | Asthma |
| rs7922491 | Chronic pain syndrome | 0.001564 | 2.108 | PRKG1 | Asthma |
| rs7922491 | Spondylosis and allied disorders | 0.009143 | 1.171 | PRKG1 | Asthma |
| rs7922491 | Intestinal malabsorption NOS | 0.005418 | 2.023 | PRKG1 | Asthma |
| rs7922491 | Viral hepatitis | 0.003704 | 1.467 | PRKG1 | Asthma |
| rs7922491 | Osteoarthrosis of multiple sites | 0.003509 | 1.412 | PRKG1 | Asthma |
| rs7922491 | Hypotension | 0.003752 | 1.231 | PRKG1 | Asthma |
| rs7922491 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.01144 | 1.51 | PRKG1 | Asthma |
| rs7922491 | Herpes zoster with nervous system complications | 0.003419 | 1.863 | PRKG1 | Asthma |
| rs7922491 | Cancer within the respiratory system | 5.545e-05 | 1.551 | PRKG1 | Asthma |
| rs7922491 | Fracture of unspecified bones | 0.00441 | 1.261 | PRKG1 | Asthma |
| rs7922491 | Spinal stenosis of lumbar region | 0.007157 | 1.236 | PRKG1 | Asthma |
| rs7922491 | Diseases of respiratory system | 0.001035 | 1.317 | PRKG1 | Asthma |
| rs7922491 | Other hereditary hemolytic anemias | 0.009381 | 2.437 | PRKG1 | Asthma |
| rs7922491 | Fuchs' dystrophy | 0.009471 | 1.697 | PRKG1 | Asthma |
| rs7922491 | Poisoning by other anti-infectives | 0.0005344 | 1.514 | PRKG1 | Asthma |
| rs7922491 | Purpura and other hemorrhagic conditions | 0.01102 | 0.7752 | PRKG1 | Asthma |
| rs7922491 | Lump or mass in breast | 0.008548 | 0.7804 | PRKG1 | Asthma |
| rs7922491 | Hypotension NOS | 0.005857 | 1.297 | PRKG1 | Asthma |
| rs7922491 | Erythematous conditions | 0.01055 | 0.8211 | PRKG1 | Asthma |
| rs7922491 | Sulfonamides | 0.001313 | 1.533 | PRKG1 | Asthma |
| rs7922491 | Concussion | 0.00973 | 1.688 | PRKG1 | Asthma |
| rs7922491 | Abnormal findings on radiological examination intrathoracic organs | 0.01099 | 1.327 | PRKG1 | Asthma |
| rs7922491 | Syncope and collapse | 0.004902 | 1.2 | PRKG1 | Asthma |
| rs7937 | Deficiency of humoral immunity | 0.006781 | 2.099 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Lack of normal physiological development | 0.008723 | 1.343 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Diffuse diseases of connective tissue | 0.009626 | 1.254 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Seborrhea | 0.0114 | 0.523 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Malaise and fatigue | 0.0114 | 1.08 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Osteopenia | 0.006506 | 1.127 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Viral infection | 0.0003421 | 1.236 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Asthma | 0.003651 | 1.133 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Cramp of limb | 9.811e-05 | 1.47 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Cachexia | 0.003834 | 2.122 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7961894 | Type 1 diabetes | 0.005331 | 1.282 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Other diseases of the teeth and supporting structures | 0.003651 | 1.412 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Adjustment reaction | 0.004856 | 1.255 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Aplastic anemia | 1.931e-05 | 1.85 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Generalized anxiety disorder | 0.008896 | 1.431 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Cellulitis and abscess of foot/toes | 0.005073 | 1.447 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Pseudomonal pneumonia | 0.007612 | 2.524 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Vitamin B-complex deficiencies | 0.008673 | 1.336 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Posttraumatic stress disorder | 0.008248 | 1.796 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Mental retardation | 0.0007206 | 2.968 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Multiple myeloma | 0.004376 | 1.845 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Pancytopenia | 0.000773 | 1.996 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Peripheral autonomic neuropathy | 0.007981 | 1.543 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Enthesopathy | 0.01142 | 1.177 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Colon cancer | 0.006707 | 0.6718 | WDR66 | Platelet counts, Mean platelet volume |
| rs8016947 | Known or suspected fetal abnormality | 0.001156 | 0.5205 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Mycoses | 0.005324 | 1.562 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Cervical cancer | 0.00687 | 0.5087 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Abnormal results of function study of liver | 0.004749 | 1.223 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Crohn's disease | 0.006783 | 1.448 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Diaphragmatic hernia | 0.00883 | 0.8836 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Other unspecified back disorders | 0.007313 | 0.6356 | NFKBIA | Psoriasis vulgaris |
| rs8017161 | Cervical cancer and dysplasia | 0.002563 | 0.7427 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.003599 | 0.7325 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Disorders of parathyroid gland | 0.005431 | 1.299 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Subarachnoid hemorrhage (injury) | 0.009961 | 0.4293 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Barrett's esophagus | 0.003283 | 1.411 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Inguinal hernia | 0.006343 | 1.158 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Encounter for long-term use of anticoagulants/antithrombotics | 0.000219 | 0.7041 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Herpes zoster with nervous system complications | 0.004487 | 0.616 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Testicular dysfunction | 0.01016 | 0.7172 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Nodular lymphoma | 0.00493 | 0.5816 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Hyperparathyroidism | 0.005555 | 1.313 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Other disorders of metabolism | 0.01046 | 0.6144 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Nephritis and nephropathy without mention of glomerulonephritis | 0.007486 | 1.249 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Encounter for long-term use of aspirin | 8.282e-05 | 0.6558 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Bladder neck obstruction | 0.00856 | 0.7891 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Melanoma | 0.01146 | 0.7908 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Jaw disease NOS | 0.0009016 | 1.655 | TNFAIP2 | Primary biliary cirrhosis |
| rs8023445 | Secondary malignant neoplasm | 0.007275 | 0.7819 | SHC4 | Major depressive disorder |
| rs8023445 | Hepatomegaly | 0.001031 | 2.268 | SHC4 | Major depressive disorder |
| rs8023445 | Dermatosis NOS | 0.0108 | 0.8591 | SHC4 | Major depressive disorder |
| rs8023445 | Fracture of vertebral column without mention of spinal cord injury | 0.002773 | 1.359 | SHC4 | Major depressive disorder |
| rs8023445 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.001822 | 2.757 | SHC4 | Major depressive disorder |
| rs8023445 | Thrombocytopenia | 0.0037 | 1.296 | SHC4 | Major depressive disorder |
| rs8023445 | Purpura and other hemorrhagic conditions | 0.003701 | 1.265 | SHC4 | Major depressive disorder |
| rs8023445 | Fracture of foot | 0.00847 | 1.291 | SHC4 | Major depressive disorder |
| rs8038465 | Femoral hernia | 0.003641 | 0.4587 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Spondylosis and allied disorders | 0.0004319 | 0.8742 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Balanoposthitis | 0.00666 | 1.665 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Ulcerative colitis | 0.006626 | 0.6704 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Ulceration of the lower GI tract | 0.00881 | 0.6347 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Cancer of oropharynx | 0.01105 | 1.953 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Congenital anomalies of peripheral vascular system | 0.01097 | 0.5377 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Pneumonia | 0.0009646 | 1.132 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Cardiomegaly | 0.001205 | 1.187 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Iatrogenic hypothyroidism | 0.002497 | 0.7122 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | E. coli | 0.004082 | 0.7319 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Spondylosis without myelopathy | 0.0003026 | 0.8675 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Inflammatory bowel disease | 0.01013 | 0.7564 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Other hypertensive complications | 0.004052 | 1.272 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Graves' disease | 0.003289 | 0.6352 | CD276 | Gamma-glutamyl transferase |
| rs8041675 | Congenital anomalies of limbs | 2.989e-06 | 1.517 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Congenital deformities of feet | 2.935e-05 | 1.528 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Malignant neoplasm of kidney and other urinary organs | 0.006375 | 1.678 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Impaired fasting glucose | 0.003994 | 1.192 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Abnormal glucose | 0.005691 | 1.115 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Congenital anomalies of lower limb, including pelvic girdle | 0.008863 | 1.771 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Chronic tonsillitis and adenoiditis | 0.01059 | 0.595 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Blindness and low vision | 0.01104 | 1.282 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Disorders of uterus, NEC | 0.01065 | 1.771 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Malunion fracture | 0.005724 | 1.436 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8042374 | Chronic nonalcoholic liver disease | 0.005345 | 1.28 | CHRNA3 | Lung cancer |
| rs8042374 | Cancer of other male genital organs | 0.009007 | 1.747 | CHRNA3 | Lung cancer |
| rs8042374 | Peripheral vascular disease | 0.006403 | 0.8754 | CHRNA3 | Lung cancer |
| rs8042374 | Peripheral arterial disease | 0.002107 | 0.8493 | CHRNA3 | Lung cancer |
| rs8042374 | Hyperparathyroidism | 0.002401 | 0.6736 | CHRNA3 | Lung cancer |
| rs8042374 | Pneumonia | 0.005332 | 0.8828 | CHRNA3 | Lung cancer |
| rs8042374 | Gout and other crystal arthropathies | 0.0006565 | 1.218 | CHRNA3 | Lung cancer |
| rs8042374 | Gout | 0.0006843 | 1.234 | CHRNA3 | Lung cancer |
| rs8042374 | Disorders of parathyroid gland | 0.001375 | 0.6701 | CHRNA3 | Lung cancer |
| rs8042374 | Cirrhosis of liver without mention of alcohol | 0.004586 | 1.495 | CHRNA3 | Lung cancer |
| rs8042374 | Type 2 diabetic ketoacidosis | 0.001265 | 1.191 | CHRNA3 | Lung cancer |
| rs8042374 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.006277 | 0.8203 | CHRNA3 | Lung cancer |
| rs8042374 | Gouty arthropathy | 0.004039 | 1.364 | CHRNA3 | Lung cancer |
| rs8042374 | Atherosclerosis of the extremities | 0.006508 | 0.8529 | CHRNA3 | Lung cancer |
| rs8047014 | Mitral stenosis/insufficiency | 0.003459 | 0.4652 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Periapical abscess | 0.01087 | 0.8281 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Other disorders of soft tissues | 0.006995 | 0.7057 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Cancer of kidney and urinary organs | 0.008696 | 1.201 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Morbid obesity | 0.0002051 | 0.8054 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Hemorrhage from gastrointestinal ulcer | 0.004385 | 0.6876 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Abnormal findings on examination of urine | 0.01103 | 0.8579 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Renal cell carcinoma | 0.001152 | 1.431 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Other biliary tract disease | 0.001084 | 1.324 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Cancer of kidney and renal pelvis | 0.001569 | 1.415 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Urticaria | 0.003144 | 0.7813 | HAS3 | Attention deficit hyperactivity disorder |
| rs8062326 | Ulcerative stomatitis & mucositis | 3.24e-05 | 3.893 | SYT17 | Alcoholism |
| rs8062326 | Fracture of vertebral column without mention of spinal cord injury | 0.008876 | 1.559 | SYT17 | Alcoholism |
| rs8062326 | Glossitis | 0.006284 | 3.016 | SYT17 | Alcoholism |
| rs8062326 | Noninflammatory female genital disorders | 0.01076 | 1.475 | SYT17 | Alcoholism |
| rs8062326 | Sprains and strains | 0.01011 | 1.294 | SYT17 | Alcoholism |
| rs8062326 | Otorrhea | 0.008101 | 2.889 | SYT17 | Alcoholism |
| rs8062326 | Intestinal malabsorption | 0.001559 | 2.069 | SYT17 | Alcoholism |
| rs8062326 | Peripheral or central vertigo | 0.003693 | 0.4785 | SYT17 | Alcoholism |
| rs8062326 | Rotator cuff (capsule) sprain | 2.519e-05 | 1.893 | SYT17 | Alcoholism |
| rs8062326 | Fracture of ribs | 0.001817 | 1.728 | SYT17 | Alcoholism |
| rs8062326 | Hypoglycemia | 0.006774 | 2.087 | SYT17 | Alcoholism |
| rs8074980 | Attention deficit hyperactivity disorder | 0.01052 | 1.72 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Aphakia and other disorders of lens | 0.007361 | 1.368 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Peripheral enthesopathies | 0.00909 | 1.119 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Calcaneal spur; Exostosis NOS | 0.007386 | 1.336 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Hyperbilirubinemia | 0.001524 | 2.09 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Disease of tricuspid valve | 0.01074 | 0.7362 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Secondary malignancy of lymph nodes | 0.004986 | 0.7004 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Secondary malignancy of bone | 0.003127 | 0.6106 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.005495 | 1.787 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Respiratory insufficiency | 0.007309 | 0.6819 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Prostatitis | 0.002198 | 0.6615 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Syncope and collapse | 0.007013 | 0.8587 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Prostate cancer | 0.006267 | 0.7919 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Unspecified erythematous condition | 0.01058 | 0.5495 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Ventral hernia | 0.0005311 | 1.462 | CUEDC1 | Multiple sclerosis |
| rs8079702 | Nerve plexus lesions | 0.006641 | 0.6895 | KCNJ2 | Primary tooth development |
| rs8079702 | Fracture of radius and ulna | 0.005455 | 0.8419 | KCNJ2 | Primary tooth development |
| rs8079702 | Disorders of liver | 0.008869 | 0.9042 | KCNJ2 | Primary tooth development |
| rs8079702 | Loss of teeth or edentulism | 0.003607 | 0.709 | KCNJ2 | Primary tooth development |
| rs8079702 | Benign neoplasm of eye | 0.009254 | 1.227 | KCNJ2 | Primary tooth development |
| rs8079702 | Fuchs' dystrophy | 0.002408 | 0.6304 | KCNJ2 | Primary tooth development |
| rs8079702 | Other cerebral degenerations | 0.01147 | 1.373 | KCNJ2 | Primary tooth development |
| rs8079702 | Fracture of upper limb | 0.00798 | 0.8763 | KCNJ2 | Primary tooth development |
| rs8079702 | Open wound of nose and sinus | 0.01044 | 0.4775 | KCNJ2 | Primary tooth development |
| rs8079702 | Chronic hepatitis | 0.01059 | 1.711 | KCNJ2 | Primary tooth development |
| rs8079702 | Other diseases of the teeth and supporting structures | 0.002638 | 0.7792 | KCNJ2 | Primary tooth development |
| rs8079702 | Other disorders of intestine | 0.003696 | 0.8299 | KCNJ2 | Primary tooth development |
| rs8079702 | Open wounds of head; neck; and trunk | 0.006505 | 0.8679 | KCNJ2 | Primary tooth development |
| rs8079702 | Intestinal obstruction without mention of hernia | 0.005702 | 0.8353 | KCNJ2 | Primary tooth development |
| rs8083432 | Dupuytren's disease | 0.002948 | 1.497 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Orchitis and epididymitis | 0.002036 | 1.619 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Otitis externa | 0.008155 | 1.22 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Phobia | 0.003063 | 2.312 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Psoriasis | 0.008774 | 1.279 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Eustachian tube disorders | 0.001273 | 1.182 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Occlusion of cerebral arteries, with cerebral infarction | 0.009329 | 0.5668 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Skin neoplasm of uncertain behavior | 0.006763 | 1.242 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Glossodynia | 0.01081 | 0.3625 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Paralytic strabismus | 0.0008719 | 1.722 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Empyema and pneumothorax | 0.00689 | 0.7014 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Epilepsy, recurrent seizures, convulsions | 0.00142 | 1.269 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Peyronie's disease | 0.005804 | 1.965 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Bladder neck obstruction | 0.009768 | 1.308 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Photodermatitis & sunburn | 0.0001962 | 1.303 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Intestinal infection | 0.01052 | 0.7827 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Cervicitis and endocervicitis | 0.000601 | 1.883 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Partial epilepsy | 0.009754 | 1.446 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Convulsions | 0.002245 | 1.27 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8099917 | Arthropathy NOS | 0.005483 | 1.228 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Chronic renal failure | 0.0009885 | 1.182 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Stomatitis and mucositis | 0.01129 | 1.415 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Edema | 0.0104 | 1.122 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Umbilical hernia | 0.009425 | 1.309 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Corneal edema | 0.009356 | 1.662 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Complications of transplants and reattached limbs | 0.003757 | 1.731 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Anal and rectal polyp | 0.008502 | 0.7466 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Anemia of chronic disease | 0.003413 | 1.267 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Complication of internal orthopedic device | 0.00766 | 1.268 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Dysmetabolic syndrome X | 0.002055 | 1.594 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Other paralytic syndromes | 0.005266 | 1.571 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Disorders of fluid, electrolyte, and acid-base balance | 0.004118 | 1.117 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Renal failure | 0.001055 | 1.159 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Adverse effects of hormones and synthetic substitutes | 0.009668 | 2.173 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Conduct disorders | 0.008778 | 0.5003 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8101881 | Retinal vascular changes and abnomalities | 0.00152 | 0.7833 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Anomalies of tooth position/malocclusion | 0.00739 | 1.644 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Malignant neoplasm of renal pelvis | 0.009278 | 0.4093 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Insect bite | 0.000445 | 1.331 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Cholelithiasis with other cholecystitis | 0.007278 | 1.29 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Brain cancer | 0.008901 | 0.584 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Cyst or abscess of Bartholin's gland | 0.0104 | 1.898 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Inflammatory spondylopathies | 0.01105 | 0.6552 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Conduct disorders | 0.007135 | 0.6099 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Electrolyte imbalance | 0.00552 | 0.9039 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Bipolar | 0.00446 | 1.421 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Dupuytren's disease | 0.001329 | 1.464 | SLC7A9 | Lysine/valine ratio |
| rs8109578 | Other benign neoplasm of connective and other soft tissue | 0.0001431 | 1.954 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Other disorders of the nervous system | 0.005515 | 1.754 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cerebrovascular disease | 0.004418 | 0.8566 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cervical cancer and dysplasia | 0.004683 | 0.6094 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Amblyopia | 0.007176 | 0.5472 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Speech and language disorder | 0.007171 | 1.57 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Rosacea | 0.005972 | 0.733 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Thyroiditis | 0.005941 | 0.5298 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cancer of connective tissue | 0.01075 | 1.804 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Magnesium metabolism disorder | 0.01009 | 1.434 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Duodenitis | 0.01015 | 1.513 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cerebral ischemia | 0.009414 | 0.8067 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Femoral hernia | 0.009689 | 2.023 | ANGPTL6 | Thyroid stimulating hormone |
| rs8111589 | Esophageal atresia/tracheoesophageal fistula | 0.004863 | 0.5535 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Inguinal hernia | 0.001249 | 0.8418 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Shock | 0.008638 | 0.7191 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Speech and language disorder | 0.002479 | 1.462 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Abdominal pain | 0.0006638 | 0.9056 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Elevated white blood cell count | 0.00712 | 0.7707 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Develomental delays and disorders | 0.002022 | 1.319 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Rheumatic fever / chorea | 0.007455 | 0.472 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Diseases of white blood cells | 0.008026 | 0.8454 | OPA3 | Depression and alcohol dependence |
| rs8139900 | Enthesopathy | 0.01117 | 1.107 | MYO18B | Uric acid levels |
| rs8139900 | Hypotension | 0.003874 | 1.141 | MYO18B | Uric acid levels |
| rs8139900 | Secondary malignancy of lung | 0.006402 | 0.7136 | MYO18B | Uric acid levels |
| rs8139900 | Secondary malignant neoplasm of liver | 0.003873 | 0.7116 | MYO18B | Uric acid levels |
| rs8139900 | Dysmenorrhea | 0.006894 | 1.486 | MYO18B | Uric acid levels |
| rs8139900 | Iatrogenic hypotension | 0.01051 | 1.542 | MYO18B | Uric acid levels |
| rs8139900 | Open wound of hand except finger(s) | 0.006235 | 1.28 | MYO18B | Uric acid levels |
| rs8139900 | Aseptic necrosis of bone | 0.001681 | 1.676 | MYO18B | Uric acid levels |
| rs8139900 | Abnormal weight gain | 0.007782 | 1.326 | MYO18B | Uric acid levels |
| rs8139900 | Benign neoplasm of other endocrine glands | 0.009365 | 1.384 | MYO18B | Uric acid levels |
| rs8139900 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.01111 | 1.184 | MYO18B | Uric acid levels |
| rs8139900 | Infection/inflammation of internal prosthetic device, implant or graft | 0.008736 | 1.264 | MYO18B | Uric acid levels |
| rs8139900 | Polymyalgia Rheumatica | 0.007164 | 1.267 | MYO18B | Uric acid levels |
| rs8139900 | Methicillin resistant Staphylococcus aureus | 0.01037 | 1.813 | MYO18B | Uric acid levels |
| rs8139900 | Disorders of synovium, tendon, and bursa | 0.002268 | 1.13 | MYO18B | Uric acid levels |
| rs8139900 | Methicillin sensitive Staphylococcus aureus | 0.001335 | 1.414 | MYO18B | Uric acid levels |
| rs8139900 | Hypotension NOS | 0.004951 | 1.187 | MYO18B | Uric acid levels |
| rs8139900 | Abnormal serum enzyme levels | 0.004583 | 1.153 | MYO18B | Uric acid levels |
| rs8139900 | Macular degeneration, dry | 0.009469 | 1.216 | MYO18B | Uric acid levels |
| rs8139900 | Acute reaction to stress | 0.00577 | 1.257 | MYO18B | Uric acid levels |
| rs8139900 | Urethritis and urethral syndrome | 0.005228 | 0.5493 | MYO18B | Uric acid levels |
| rs8139900 | Staphylococcus infections | 0.003419 | 1.278 | MYO18B | Uric acid levels |
| rs8139900 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.007869 | 2.103 | MYO18B | Uric acid levels |
| rs8139900 | Neoplasm of unspecified nature of digestive system | 0.002173 | 1.49 | MYO18B | Uric acid levels |
| rs8176746 | Osteitis deformans and osteopathies associated with other disorders | 0.007349 | 2.019 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Breast cancer, including in situ | 0.004371 | 0.701 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Thyroiditis | 0.003117 | 1.624 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Chronic lymphocytic thyroiditis | 0.01075 | 1.652 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Occlusion of cerebral arteries, with cerebral infarction | 0.0006516 | 2.003 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Other conditions of the mother complicating pregnancy | 0.006168 | 2.187 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Depression | 0.01073 | 1.172 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Unspecified monoarthritis | 0.005301 | 1.985 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Breast cancer | 0.004212 | 0.7017 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Other disorders of thyroid | 0.008681 | 1.511 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Osteoarthrosis NOS | 0.004135 | 1.182 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Arthropathy associated with neurological disorders | 0.00383 | 2.389 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Vascular dementia | 0.008358 | 1.668 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Pseudomonal pneumonia | 0.007634 | 2.673 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Diseases of pancreas | 0.007903 | 1.361 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Paget's disease of bone | 0.01011 | 2.532 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Chronic ulcer of leg or foot | 0.003392 | 1.29 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Breast cancer | 0.004004 | 0.6957 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Back & neck sprains | 0.004221 | 1.247 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Peripheral retinal degenerations | 0.002144 | 1.568 | ABO | Mean corpuscular hemoglobin |
| rs8192917 | Nerve root and plexus disorders | 0.005887 | 0.7002 | GZMB | Vitiligo |
| rs8192917 | Calcium/phosphorus disorders | 0.005639 | 1.228 | GZMB | Vitiligo |
| rs8192917 | Primary thrombocytopenia | 0.005753 | 1.669 | GZMB | Vitiligo |
| rs8192917 | Abnormal pulmonary function | 0.01057 | 2.094 | GZMB | Vitiligo |
| rs8192917 | Internal derangement of knee | 0.01102 | 0.8561 | GZMB | Vitiligo |
| rs8192917 | Fracture of pelvis | 0.007454 | 1.364 | GZMB | Vitiligo |
| rs8192917 | Abnormal thyroid function | 0.002874 | 1.329 | GZMB | Vitiligo |
| rs8192917 | Respiratory abnormalities | 0.008919 | 1.335 | GZMB | Vitiligo |
| rs837763 | Age-related macular degeneration | 0.009504 | 1.189 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Abnormal involuntary movements | 0.0005172 | 1.325 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Astigmatism | 0.005956 | 1.136 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Cervicocranial/Cervicobrachial syndrome | 0.006653 | 1.258 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Corneal edema | 0.004171 | 1.668 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Chronic venous insufficiency | 0.0007046 | 1.243 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Congenital anomalies of face and neck | 0.001168 | 2.6 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Aneurysm of iliac artery | 0.007729 | 0.567 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Rosacea | 0.007777 | 1.184 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Lack of coordination | 0.003131 | 1.271 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Altered mental status | 0.00934 | 1.265 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Disorders of refraction and accommodation | 0.005912 | 1.105 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Amblyopia | 0.005978 | 1.351 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Kidney replaced by transpant | 0.0008554 | 0.6218 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Adrenal hypofunction | 0.01059 | 1.583 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Pleurisy; pleural effusion | 0.005902 | 1.146 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Varicose veins | 0.003839 | 1.163 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Lymphoid leukemia | 0.003934 | 1.569 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Other symptoms referable to back | 0.01035 | 1.235 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Varicose veins of lower extremity | 0.007978 | 1.155 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Cystoid macular degeneration of retina | 0.007426 | 1.302 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Disorders of external ear | 0.005102 | 1.68 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Atrophy of edentulous alveolar ridge | 0.003544 | 0.6293 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Rash and other nonspecific skin eruption | 0.0008157 | 1.202 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Other hypertrophic and atrophic conditions of skin | 0.009695 | 1.108 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Corneal dystrophy | 0.001966 | 1.35 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Fuchs' dystrophy | 0.0005885 | 1.646 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Benign neoplasm of brain and other parts of nervous system | 0.01048 | 1.372 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Appendicitis | 0.009384 | 1.386 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Chronic lymphoid leukemia | 0.01112 | 1.507 | CDT1 | Mean corpuscular hemoglobin |
| rs855913 | Antihypertensive agents causing adverse effects | 0.002576 | 2.157 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Scar conditions and fibrosis of skin | 0.0106 | 1.538 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.0002453 | 0.5384 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Iatrogenic hypotension | 0.0001761 | 2.402 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Effects of radiation NOS | 0.0001063 | 2.255 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Coronary atherosclerosis | 0.005937 | 0.835 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Diabetic retinopathy | 0.002894 | 1.405 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Nephritis; nephrosis; renal sclerosis | 0.002413 | 1.469 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Cancer of other male genital organs | 0.004958 | 2.321 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Blindness and low vision | 0.000534 | 1.764 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Other disorders of biliary tract | 0.002992 | 1.975 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Hypoglycemia | 0.005995 | 1.837 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Degenerative disease of the spinal cord | 0.007604 | 1.797 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Fracture of ribs | 0.009997 | 1.439 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Fracture of clavicle or scapula | 0.004786 | 1.774 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Type 2 diabetic retinopathy | 0.01054 | 1.363 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Endocarditis | 0.007004 | 0.4193 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Neoplasm of uncertain behavior | 0.002273 | 1.415 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Type 1 diabetes nephropathy | 0.003758 | 2.152 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Ischemic Heart Disease | 0.007726 | 0.8484 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Toxic erythema | 0.007626 | 2.695 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Nonallopathic lesions NEC | 0.009729 | 0.7834 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Acute laryngitis and tracheitis | 0.001971 | 2.035 | ZNF746 | Amyotrophic lateral sclerosis |
| rs873917 | Inflammatory bowel disease | 0.01022 | 0.7386 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Abnormal findings on radiological breast exam | 0.008752 | 1.544 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Congenital anomalies of lower limb, including pelvic girdle | 0.001386 | 0.3816 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Degeneration of intervertebral disc | 0.003123 | 0.8764 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Other disorders of pancreatic internal secretion | 0.008263 | 0.5309 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Ulcerative colitis | 0.003605 | 0.6216 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Vascular insufficiency of intestine | 0.006932 | 0.6721 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Intervertebral disc disorders | 0.003039 | 0.8937 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Nontoxic multinodular goiter | 0.003519 | 0.7582 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Spinal stenosis | 0.01069 | 0.8829 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Acute sinusitis | 0.01013 | 0.8737 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Other specified disorders of pancreatic internal secretion | 0.01114 | 0.5434 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Posterior pituitary disorders | 0.001094 | 1.902 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Other disorders of intestine | 0.002789 | 0.8083 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Benign neoplasm of uterus | 0.006191 | 1.228 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Spinal stenosis of lumbar region | 0.003559 | 0.8533 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Gastrointestinal complications | 0.006622 | 0.7621 | NT5C1A | Amyotrophic lateral sclerosis |
| rs908821 | Gangrene | 0.0101 | 0.5647 | SLC25A36 | Multiple sclerosis |
| rs908821 | Nerve root and plexus disorders | 0.008554 | 1.316 | SLC25A36 | Multiple sclerosis |
| rs908821 | Chronic obstructive asthma | 0.003352 | 0.7284 | SLC25A36 | Multiple sclerosis |
| rs908821 | Parasomnia | 0.009035 | 1.615 | SLC25A36 | Multiple sclerosis |
| rs908821 | Other specified nonpsychotic and/or transient mental disorders | 0.01132 | 0.8099 | SLC25A36 | Multiple sclerosis |
| rs908821 | Nerve plexus lesions | 0.00826 | 1.431 | SLC25A36 | Multiple sclerosis |
| rs908821 | Toxic erythema | 0.009303 | 2.017 | SLC25A36 | Multiple sclerosis |
| rs908821 | Primary/intrinsic cardiomyopathies | 0.008194 | 1.193 | SLC25A36 | Multiple sclerosis |
| rs908821 | Cancer of the lower GI tract | 0.00694 | 1.382 | SLC25A36 | Multiple sclerosis |
| rs908821 | End stage renal disease | 0.008574 | 1.403 | SLC25A36 | Multiple sclerosis |
| rs908821 | Other disorders of lipoid metabolism and hyperalimentation | 0.009796 | 1.275 | SLC25A36 | Multiple sclerosis |
| rs908821 | Calculus of lower urinary tract | 0.01063 | 1.602 | SLC25A36 | Multiple sclerosis |
| rs909116 | Nonspecific findings on examination of blood | 0.000329 | 0.6976 | TNNT3 | Breast cancer |
| rs909116 | Other diseases of the teeth and supporting structures | 0.008643 | 1.235 | TNNT3 | Breast cancer |
| rs909116 | Stomatitis and mucositis | 0.01063 | 0.7343 | TNNT3 | Breast cancer |
| rs909116 | Cellulitis and abscess of trunk | 0.007627 | 1.288 | TNNT3 | Breast cancer |
| rs909116 | Open wound of nose and sinus | 0.009958 | 1.975 | TNNT3 | Breast cancer |
| rs909116 | Cerebrovascular disease | 0.0007719 | 1.119 | TNNT3 | Breast cancer |
| rs909116 | Occlusion and stenosis of precerebral arteries | 0.002158 | 1.153 | TNNT3 | Breast cancer |
| rs909116 | Myeloid leukemia | 0.01032 | 0.5499 | TNNT3 | Breast cancer |
| rs909116 | Chronic rheumatic disease of the heart valves | 0.007467 | 1.155 | TNNT3 | Breast cancer |
| rs909116 | Mitral valve stenosis and/or aortic valve stenosis | 0.000823 | 1.285 | TNNT3 | Breast cancer |
| rs9282641 | Systolic/diastolic heart failure | 0.008943 | 1.203 | CD86 | Multiple sclerosis |
| rs9282641 | Emphysema | 0.002392 | 1.5 | CD86 | Multiple sclerosis |
| rs9282641 | Ill-defined descriptions and complications of heart disease | 0.008607 | 1.191 | CD86 | Multiple sclerosis |
| rs9282641 | Heart transplant/surgery | 0.007215 | 1.709 | CD86 | Multiple sclerosis |
| rs9282641 | Mitral valve stenosis and/or aortic valve stenosis | 0.0007489 | 1.484 | CD86 | Multiple sclerosis |
| rs9282641 | Polyp of female genital organs | 0.006649 | 1.413 | CD86 | Multiple sclerosis |
| rs9282641 | Asthma | 0.0003411 | 1.281 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic ischemic heart disease | 0.0101 | 1.23 | CD86 | Multiple sclerosis |
| rs9282641 | Spontaneous ecchymoses | 0.0001681 | 2.39 | CD86 | Multiple sclerosis |
| rs9282641 | Malignant neoplasm of renal pelvis | 0.007151 | 2.675 | CD86 | Multiple sclerosis |
| rs9282641 | Heart failure | 0.008766 | 1.197 | CD86 | Multiple sclerosis |
| rs9282641 | Abnormal function study of cardiovascular system | 0.003273 | 1.33 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic obstructive asthma | 0.009075 | 1.448 | CD86 | Multiple sclerosis |
| rs9282641 | Symptoms involving urinary system | 0.01019 | 1.403 | CD86 | Multiple sclerosis |
| rs9282641 | Subarachnoid hemorrhage (injury) | 0.0103 | 2.413 | CD86 | Multiple sclerosis |
| rs9282641 | Primary/intrinsic cardiomyopathies | 0.005555 | 1.323 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic airway obstruction | 0.003855 | 1.207 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic lymphocytic thyroiditis | 0.004363 | 1.698 | CD86 | Multiple sclerosis |
| rs9282641 | Cardiomegaly | 0.003614 | 1.282 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic rheumatic disease of the heart valves | 0.01094 | 1.255 | CD86 | Multiple sclerosis |
| rs9282641 | Benign neoplasm of thyroid glands | 0.007837 | 2.088 | CD86 | Multiple sclerosis |
| rs9282641 | Thyroiditis | 0.0003746 | 1.73 | CD86 | Multiple sclerosis |
| rs9282641 | Nonspecific findings on examination of blood | 0.0001777 | 1.718 | CD86 | Multiple sclerosis |
| rs9303401 | Acne | 0.00994 | 1.283 | PPM1E | Cognitive performance |
| rs9303401 | Lung involvement in conditions classified elsewhere | 0.003761 | 0.2873 | PPM1E | Cognitive performance |
| rs9303401 | E. coli | 0.009904 | 0.7285 | PPM1E | Cognitive performance |
| rs9303401 | Acquired spondylolisthesis | 0.004138 | 1.34 | PPM1E | Cognitive performance |
| rs9303401 | Peripheral arterial disease | 0.01112 | 1.129 | PPM1E | Cognitive performance |
| rs9303401 | Symptoms involving female genital tract | 0.01047 | 1.362 | PPM1E | Cognitive performance |
| rs9303401 | Memory loss | 0.0008662 | 0.7331 | PPM1E | Cognitive performance |
| rs9303401 | Persistent mental disorders due to other conditions | 0.002694 | 0.8308 | PPM1E | Cognitive performance |
| rs9303401 | Eustachian tube disorders | 0.006542 | 1.135 | PPM1E | Cognitive performance |
| rs9303401 | Retinal hemorrhage/ischemia | 0.006506 | 1.429 | PPM1E | Cognitive performance |
| rs9303401 | Alzheimer's disease | 0.003617 | 0.8141 | PPM1E | Cognitive performance |
| rs9303401 | Bone cancer | 0.002619 | 0.4536 | PPM1E | Cognitive performance |
| rs9303401 | Cellulitis and abscess of hand/fingers | 0.01005 | 1.19 | PPM1E | Cognitive performance |
| rs9303401 | Cancer of bone & connective tissue | 0.007752 | 0.6258 | PPM1E | Cognitive performance |
| rs932316 | Polymyalgia Rheumatica | 0.009534 | 0.7237 | SCGN | Transferrin saturation |
| rs932316 | Cholelithiasis with other cholecystitis | 0.00765 | 0.6963 | SCGN | Transferrin saturation |
| rs932316 | Other symptoms involving abdomen and pelvis | 0.008722 | 0.8435 | SCGN | Transferrin saturation |
| rs932316 | Hypertension | 0.003626 | 1.118 | SCGN | Transferrin saturation |
| rs932316 | Essential hypertension | 0.00341 | 1.119 | SCGN | Transferrin saturation |
| rs932316 | Iron deficiency anemias NOS | 0.006995 | 0.8487 | SCGN | Transferrin saturation |
| rs932316 | Disorders of esophageal motility | 0.003963 | 0.5068 | SCGN | Transferrin saturation |
| rs932316 | Iron metabolism disorder | 4.153e-07 | 3.215 | SCGN | Transferrin saturation |
| rs933688 | Nonrheumatic aortic valve disorders | 0.007597 | 0.816 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Symptoms involving digestive system | 0.005309 | 0.7498 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Allergic rhinitis | 0.003492 | 1.168 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Labyrinthitis | 0.003588 | 1.499 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Other disorders of bladder | 0.01023 | 0.8147 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Diseases of respiratory system | 0.002113 | 1.24 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Other upper respiratory disease | 0.007798 | 1.205 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Obstructive sleep apnea | 0.01 | 1.182 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Temporomandibular joint disorder NOS | 0.00126 | 1.875 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Sarcoidosis | 0.01068 | 1.684 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Primary open angle glaucoma | 0.008009 | 0.7357 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Precordial pain | 0.003677 | 1.422 | LOC133789 | Smoking behavior (ever vs. never) |
| rs9349379 | Myocardial infarction | 0.0001591 | 1.188 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Benign neoplasm of uterus | 0.0008352 | 1.713 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Loss of teeth or edentulism | 0.007059 | 1.356 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Anorexia | 0.003189 | 1.396 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Coronary atherosclerosis | 0.001074 | 1.112 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Unstable angina (intermediate coronary syndrome) | 0.0004332 | 1.217 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Uterine/Uterovaginal prolapse | 0.01138 | 0.7862 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Major depressive disorder | 0.01014 | 1.15 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Other forms of chronic heart disease | 0.003718 | 1.211 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Chronic ischemic heart disease | 0.002944 | 1.156 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Ischemic Heart Disease | 0.005244 | 1.09 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Epiphora | 0.002547 | 1.432 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Pancreatic cancer | 0.002941 | 0.6058 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Chronic pain syndrome | 0.002228 | 1.749 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Hyposmolality and/or hyponatremia | 0.006475 | 1.172 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Subjective visual disturbances | 0.008313 | 1.202 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9357155 | Type 1 diabetes nephropathy | 0.004187 | 1.896 | PSMB8 | IgA nephropathy |
| rs9357155 | Vitamin D deficiency | 0.0005629 | 0.5239 | PSMB8 | IgA nephropathy |
| rs9357155 | Upper gastrointestinal congenital anomalies | 0.005564 | 1.784 | PSMB8 | IgA nephropathy |
| rs9357155 | Keratitis | 0.009441 | 1.415 | PSMB8 | IgA nephropathy |
| rs9357155 | Pervasive developmental disorders | 0.001998 | 1.841 | PSMB8 | IgA nephropathy |
| rs9357155 | Open-angle glaucoma | 0.001424 | 1.306 | PSMB8 | IgA nephropathy |
| rs9357155 | Hypertrophy of female genital organs | 0.0007655 | 2.17 | PSMB8 | IgA nephropathy |
| rs9357155 | Attention deficit hyperactivity disorder | 0.003151 | 1.94 | PSMB8 | IgA nephropathy |
| rs9357155 | Heartburn | 0.007602 | 1.524 | PSMB8 | IgA nephropathy |
| rs9357155 | Psoriasis | 0.002555 | 1.404 | PSMB8 | IgA nephropathy |
| rs9357155 | Psoriasis & related disorders | 0.003427 | 1.369 | PSMB8 | IgA nephropathy |
| rs9357155 | Other disorders of soft tissues | 0.0001737 | 1.832 | PSMB8 | IgA nephropathy |
| rs9357155 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.002676 | 1.318 | PSMB8 | IgA nephropathy |
| rs9357155 | Other nonspecific findings on examination of urine | 0.009866 | 1.277 | PSMB8 | IgA nephropathy |
| rs9357155 | Arteritis NOS | 0.005744 | 1.791 | PSMB8 | IgA nephropathy |
| rs9357155 | Osteomyelitis | 0.008361 | 1.399 | PSMB8 | IgA nephropathy |
| rs9357155 | Psoriasis vulgaris | 0.004851 | 1.386 | PSMB8 | IgA nephropathy |
| rs9357155 | Glaucoma | 0.004042 | 1.194 | PSMB8 | IgA nephropathy |
| rs9357155 | Unspecified osteomyelitis | 0.01093 | 1.431 | PSMB8 | IgA nephropathy |
| rs9357155 | Symptoms involving cardiovascular system | 0.008615 | 1.232 | PSMB8 | IgA nephropathy |
| rs9357155 | Abnormal findings on examination of urine | 0.003069 | 1.28 | PSMB8 | IgA nephropathy |
| rs9357155 | Type 1 diabetic neuropathy | 0.003863 | 1.652 | PSMB8 | IgA nephropathy |
| rs9357155 | Digestive congenital anomalies | 0.01115 | 1.561 | PSMB8 | IgA nephropathy |
| rs9357155 | Exophthalmos | 0.01036 | 1.998 | PSMB8 | IgA nephropathy |
| rs9357155 | Type 1 diabetic retinopathy | 0.006056 | 1.592 | PSMB8 | IgA nephropathy |
| rs9357155 | Rheumatoid arthritis | 0.001631 | 1.378 | PSMB8 | IgA nephropathy |
| rs9357155 | Other intestinal obstruction | 0.009584 | 1.341 | PSMB8 | IgA nephropathy |
| rs9357155 | Infection/inflammation of internal prosthetic device, implant or graft | 0.001271 | 1.472 | PSMB8 | IgA nephropathy |
| rs9364554 | Benign neoplasm of skin | 0.00356 | 1.121 | SLC22A3 | Prostate cancer |
| rs9364554 | Chronic interstitial cystitis | 0.009076 | 0.3502 | SLC22A3 | Prostate cancer |
| rs9364554 | Other disorders of soft tissues | 0.001985 | 0.6229 | SLC22A3 | Prostate cancer |
| rs9364554 | Elevated C-reactive protein | 0.009194 | 1.874 | SLC22A3 | Prostate cancer |
| rs9364554 | Known or suspected fetal abnormality | 0.009218 | 1.655 | SLC22A3 | Prostate cancer |
| rs9364554 | Elevated sedimentation rate | 0.008987 | 1.39 | SLC22A3 | Prostate cancer |
| rs9364554 | Fracture of radius and ulna | 0.009064 | 1.187 | SLC22A3 | Prostate cancer |
| rs9364554 | Hidradenitis | 0.006637 | 2.166 | SLC22A3 | Prostate cancer |
| rs9364554 | Peptic ulcer | 0.005855 | 1.181 | SLC22A3 | Prostate cancer |
| rs9364554 | Diseases of nail | 0.009216 | 1.153 | SLC22A3 | Prostate cancer |
| rs9364554 | Hodgkin's disease | 0.004836 | 0.4396 | SLC22A3 | Prostate cancer |
| rs9364554 | Pain in joint | 0.007147 | 1.094 | SLC22A3 | Prostate cancer |
| rs9364554 | Cramp of limb | 0.001612 | 1.386 | SLC22A3 | Prostate cancer |
| rs9364554 | Diseases of esophagus | 0.01013 | 1.087 | SLC22A3 | Prostate cancer |
| rs9364554 | Glycosuria or Acetonuria | 0.002483 | 2.365 | SLC22A3 | Prostate cancer |
| rs9364554 | Esophagitis, GERD and related diseases | 0.00441 | 1.099 | SLC22A3 | Prostate cancer |
| rs9364554 | Essential tremor | 0.008232 | 1.314 | SLC22A3 | Prostate cancer |
| rs9364554 | Primary thrombocytopenia | 0.005014 | 1.659 | SLC22A3 | Prostate cancer |
| rs9364554 | Precordial pain | 0.007971 | 1.321 | SLC22A3 | Prostate cancer |
| rs9364554 | GERD | 0.00353 | 1.107 | SLC22A3 | Prostate cancer |
| rs9364554 | Hyperglyceridemia | 0.0005931 | 1.345 | SLC22A3 | Prostate cancer |
| rs9364554 | Ill-defined descriptions and complications of heart disease | 0.01054 | 1.115 | SLC22A3 | Prostate cancer |
| rs9364554 | Deviated nasal septum | 0.0062 | 1.203 | SLC22A3 | Prostate cancer |
| rs9364554 | Symptoms involving cardiovascular system | 0.001361 | 1.203 | SLC22A3 | Prostate cancer |
| rs9364554 | Cellulitis and abscess of hand/fingers | 0.00182 | 1.234 | SLC22A3 | Prostate cancer |
| rs9364554 | Stiffness of joint | 0.003443 | 1.234 | SLC22A3 | Prostate cancer |
| rs9364554 | Eustachian tube disorders | 0.006457 | 1.264 | SLC22A3 | Prostate cancer |
| rs9368699 | Psoriasis & related disorders | 2.557e-06 | 2.068 | C6orf48 | HIV-1 progression |
| rs9368699 | Acute laryngitis and tracheitis | 0.004556 | 2.29 | C6orf48 | HIV-1 progression |
| rs9368699 | Stricture/obstruction of ureter | 0.009058 | 2.043 | C6orf48 | HIV-1 progression |
| rs9368699 | Cancer of bone & connective tissue | 0.004033 | 2.138 | C6orf48 | HIV-1 progression |
| rs9368699 | Unspecified local infection of skin and subcutaneous tissue | 0.003022 | 0.3636 | C6orf48 | HIV-1 progression |
| rs9368699 | Respiratory failure; insufficiency; arrest | 0.007797 | 0.5703 | C6orf48 | HIV-1 progression |
| rs9368699 | Neurological disorders due to brain damage | 0.007064 | 0.7019 | C6orf48 | HIV-1 progression |
| rs9368699 | Corneal dystrophy | 0.00215 | 1.899 | C6orf48 | HIV-1 progression |
| rs9368699 | Acute upper respiratory infections | 0.001362 | 1.335 | C6orf48 | HIV-1 progression |
| rs9368699 | Fracture of hand or wrist | 0.003596 | 0.5864 | C6orf48 | HIV-1 progression |
| rs9368699 | Rosacea | 0.004853 | 1.507 | C6orf48 | HIV-1 progression |
| rs9368699 | Voice disturbance | 0.0009477 | 1.641 | C6orf48 | HIV-1 progression |
| rs9368699 | Respiratory failure | 0.008348 | 0.4093 | C6orf48 | HIV-1 progression |
| rs9368699 | Vascular disorders of penis | 0.004812 | 4.083 | C6orf48 | HIV-1 progression |
| rs9368699 | Pseudoexfoliation glaucoma | 0.004069 | 2.545 | C6orf48 | HIV-1 progression |
| rs9368699 | Persistent mental disorders due to other conditions | 0.009801 | 0.6707 | C6orf48 | HIV-1 progression |
| rs9368699 | Male genital disorders | 0.00116 | 2.009 | C6orf48 | HIV-1 progression |
| rs9368699 | Abnormal findings on radiological breast exam | 0.009758 | 2.219 | C6orf48 | HIV-1 progression |
| rs9368699 | Genital prolapse | 0.003337 | 0.5943 | C6orf48 | HIV-1 progression |
| rs9368699 | Psoriasis vulgaris | 6.542e-06 | 2.101 | C6orf48 | HIV-1 progression |
| rs9368699 | Psoriasis | 2.059e-06 | 2.137 | C6orf48 | HIV-1 progression |
| rs9395066 | Osteoporosis, NOS or other | 0.007445 | 0.8861 | SUPT3H | Height |
| rs9395066 | Osteoporosis | 0.01048 | 0.8882 | SUPT3H | Height |
| rs9395066 | Adjustment reaction | 0.003738 | 0.8554 | SUPT3H | Height |
| rs9395066 | Curvature of spine | 0.004969 | 0.7949 | SUPT3H | Height |
| rs9395066 | pulmonary heart disease | 0.002002 | 0.8411 | SUPT3H | Height |
| rs9395066 | Salicylates causing adverse effects in therapeutic use | 0.006797 | 0.4913 | SUPT3H | Height |
| rs9395066 | Lesions of stomach and duodenum | 0.004621 | 2.028 | SUPT3H | Height |
| rs9395066 | Periodontitis (acute or chronic) | 0.01065 | 0.8243 | SUPT3H | Height |
| rs9395066 | Cholecystitis without cholelithiasis | 0.001916 | 0.7275 | SUPT3H | Height |
| rs9395066 | Umbilical hernia | 0.002939 | 0.7597 | SUPT3H | Height |
| rs9395066 | Bacterial pneumonia | 0.004863 | 0.7565 | SUPT3H | Height |
| rs9395066 | Restless legs syndrome | 0.01114 | 1.267 | SUPT3H | Height |
| rs9395066 | Epistaxis or throat hemorrhage | 0.005302 | 0.8168 | SUPT3H | Height |
| rs9395066 | Hidradenitis | 0.002288 | 0.3255 | SUPT3H | Height |
| rs939876 | Eating disorder | 0.0005518 | 2.075 | TBC1D30 | Cognitive performance |
| rs939876 | Posttraumatic wound infection | 0.004766 | 2.017 | TBC1D30 | Cognitive performance |
| rs939876 | Bacterial enteritis | 0.009178 | 1.412 | TBC1D30 | Cognitive performance |
| rs939876 | Ulceration of the lower GI tract | 0.008716 | 1.664 | TBC1D30 | Cognitive performance |
| rs939876 | Benign neoplasm of other endocrine glands | 0.002774 | 1.586 | TBC1D30 | Cognitive performance |
| rs939876 | Atherosclerosis | 0.008159 | 0.8494 | TBC1D30 | Cognitive performance |
| rs939876 | Diseases of hair and hair follicles | 0.002062 | 1.349 | TBC1D30 | Cognitive performance |
| rs939876 | Generalized anxiety disorder | 0.01106 | 1.375 | TBC1D30 | Cognitive performance |
| rs939876 | Cholesteatoma | 0.005156 | 1.924 | TBC1D30 | Cognitive performance |
| rs939876 | Essential tremor | 0.009115 | 1.392 | TBC1D30 | Cognitive performance |
| rs939876 | Dermatophytosis of nail | 0.008038 | 1.179 | TBC1D30 | Cognitive performance |
| rs939876 | Somatoform disorder | 0.003594 | 1.521 | TBC1D30 | Cognitive performance |
| rs939876 | Disturbance of skin sensation | 0.00146 | 1.205 | TBC1D30 | Cognitive performance |
| rs939876 | Other disorders of middle ear and mastoid | 0.009452 | 1.561 | TBC1D30 | Cognitive performance |
| rs939876 | Seborheic dermatitis | 0.001365 | 1.306 | TBC1D30 | Cognitive performance |
| rs939876 | Type 1 diabetic neuropathy | 0.0008093 | 1.711 | TBC1D30 | Cognitive performance |
| rs939876 | Diseases of sebaceous glands | 0.006087 | 1.154 | TBC1D30 | Cognitive performance |
| rs939876 | Postmenopausal atrophic vaginitis | 0.005947 | 1.343 | TBC1D30 | Cognitive performance |
| rs939876 | Symptoms affecting skin | 0.001914 | 1.156 | TBC1D30 | Cognitive performance |
| rs939876 | Mastoiditis | 0.00329 | 2.375 | TBC1D30 | Cognitive performance |
| rs939876 | Conductive hearing loss | 7.585e-06 | 2.218 | TBC1D30 | Cognitive performance |
| rs939876 | Urinary incontinence | 0.009711 | 1.179 | TBC1D30 | Cognitive performance |
| rs939876 | Other disorders of tympanic membrane | 0.01026 | 1.538 | TBC1D30 | Cognitive performance |
| rs939876 | Mucous polyp of cervix | 0.005294 | 0.5512 | TBC1D30 | Cognitive performance |
| rs939876 | Intestinal infection due to C. difficile | 0.00952 | 1.47 | TBC1D30 | Cognitive performance |
| rs939876 | Hirsutism | 0.005437 | 1.853 | TBC1D30 | Cognitive performance |
| rs939876 | Transient cerebral ischemia | 0.009339 | 0.8197 | TBC1D30 | Cognitive performance |
| rs939876 | Dysthymic disorder | 0.0001123 | 1.363 | TBC1D30 | Cognitive performance |
| rs939876 | Neoplasm of uncertain behavior | 0.006076 | 1.259 | TBC1D30 | Cognitive performance |
| rs939876 | Myoclonus | 0.0004994 | 2.111 | TBC1D30 | Cognitive performance |
| rs939876 | Vitamin B12 deficiency anemia | 0.006116 | 1.705 | TBC1D30 | Cognitive performance |
| rs944260 | Pneumoconiosis | 0.008473 | 1.855 | CDH4 | Sudden cardiac arrest |
| rs944260 | Abnormal pulmonary function | 0.009351 | 2.108 | CDH4 | Sudden cardiac arrest |
| rs944260 | Fibroadenosis of breast | 0.001684 | 2.461 | CDH4 | Sudden cardiac arrest |
| rs944260 | Mastoiditis | 0.006769 | 2.037 | CDH4 | Sudden cardiac arrest |
| rs944260 | Photodermatitis & sunburn | 0.006035 | 0.83 | CDH4 | Sudden cardiac arrest |
| rs944260 | Ankylosis of joint | 0.00983 | 0.663 | CDH4 | Sudden cardiac arrest |
| rs944260 | Mixed hyperlipidemia | 0.007162 | 0.8359 | CDH4 | Sudden cardiac arrest |
| rs944260 | Type 1 diabetes nephropathy | 0.007188 | 0.5285 | CDH4 | Sudden cardiac arrest |
| rs944797 | Other forms of chronic heart disease | 0.005053 | 0.8328 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ischemic stroke | 0.01038 | 0.8435 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Plasma protein metabolism disorder | 0.01143 | 1.275 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Acute, but ill-defined cerebrovascular disease | 0.0008165 | 0.8056 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Myocardial infarction | 1.104e-07 | 0.7874 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cystitis and urethritis | 0.004266 | 0.8214 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Angina pectoris | 8.807e-05 | 0.8367 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Gastrointestinal hemorrhage | 0.005379 | 1.109 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Occlusion of cerebral arteries | 0.005181 | 0.8377 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cerebrovascular disease | 0.0007004 | 0.8931 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 1 diabetic ketoacidosis | 0.003658 | 0.683 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac conduction disorders | 0.003856 | 0.8925 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac complications, not elsewhere classified | 0.0004845 | 0.6579 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Unstable angina (intermediate coronary syndrome) | 1.993e-08 | 0.7309 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Chronic airway obstruction | 0.002331 | 1.126 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Hemorrhoids | 0.002319 | 1.126 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ill-defined descriptions and complications of heart disease | 0.0002053 | 0.8646 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Coronary atherosclerosis | 7.283e-11 | 0.8108 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ulcerative colitis | 0.005244 | 1.472 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Hypotension NOS | 0.002939 | 0.8327 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 2 diabetic neuropathy | 0.008593 | 0.8544 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac dysrhythmias | 0.003098 | 0.9149 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Symptoms involving cardiovascular system | 0.002829 | 0.8519 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cystitis | 0.004433 | 0.8119 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Symptoms involving digestive system | 0.003148 | 1.241 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ischemic Heart Disease | 9.421e-09 | 0.8398 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cerebral ischemia | 0.01109 | 0.8818 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Renal failure NOS | 0.009525 | 0.7612 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Primary thrombocytopenia | 0.009705 | 1.591 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Acne | 0.006766 | 1.285 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Abnormal electrocardiogram | 0.005819 | 0.87 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 1 diabetic neuropathy | 0.00811 | 0.6965 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Aphasia/speech disturbance | 0.006266 | 0.8147 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Polyneuropathy in diabetes | 0.0002279 | 0.7855 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac arrest & ventricular fibrillation | 0.009289 | 0.7185 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Mild cognitive impairment | 0.00487 | 0.5834 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Nephritis and nephropathy without mention of glomerulonephritis | 0.005272 | 0.7919 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Nephritis; nephrosis; renal sclerosis | 0.0005887 | 0.7729 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 2 diabetic peripheral circulatory disorders | 0.003058 | 0.6994 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Other infectious diseases | 0.002082 | 0.5213 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Hypotension | 0.002058 | 0.8683 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Chronic ischemic heart disease | 4.12e-05 | 0.8212 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Late effects of cerebrovascular disease | 0.007493 | 0.8538 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 2 diabetic nephropathy | 0.0001187 | 0.7566 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Neurological disorders due to brain damage | 0.001325 | 0.8623 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Costochondritis | 0.001146 | 2.087 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Peptic ulcer | 0.004881 | 0.8544 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Occlusion and stenosis of precerebral arteries | 0.0003023 | 0.846 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Paraproteinemia | 0.003308 | 1.412 | CDKN2B-AS1 | Coronary heart disease |
| rs9468925 | Age-related macular degeneration | 0.00777 | 0.8345 | HLA-B | Vitiligo |
| rs9468925 | Iron deficiency anemias NOS | 0.009583 | 1.127 | HLA-B | Vitiligo |
| rs9468925 | Renal cell carcinoma | 0.005451 | 0.72 | HLA-B | Vitiligo |
| rs9468925 | Aseptic necrosis of bone | 0.01026 | 1.507 | HLA-B | Vitiligo |
| rs9468925 | Subjective visual disturbances | 0.001037 | 0.7865 | HLA-B | Vitiligo |
| rs9468925 | Diseases of lips | 0.006627 | 0.6533 | HLA-B | Vitiligo |
| rs9468925 | Cancer of kidney and renal pelvis | 0.004806 | 0.7178 | HLA-B | Vitiligo |
| rs9468925 | Renal osteodystrophy | 0.006465 | 1.497 | HLA-B | Vitiligo |
| rs9468925 | Systemic lupus erythematosus | 0.01033 | 0.6649 | HLA-B | Vitiligo |
| rs9468925 | Other disorders of eye | 0.009658 | 1.111 | HLA-B | Vitiligo |
| rs9468925 | Blood in stool | 0.01055 | 1.145 | HLA-B | Vitiligo |
| rs9468925 | Discoid lupus erythematosus | 0.003996 | 0.6503 | HLA-B | Vitiligo |
| rs947583 | Visual disturbances | 0.002944 | 0.8743 | PDE7B | Phosphorus levels |
| rs947583 | Anisometropia | 0.0003883 | 0.6502 | PDE7B | Phosphorus levels |
| rs947583 | Other specified peripheral vascular diseases | 0.001167 | 2.269 | PDE7B | Phosphorus levels |
| rs947583 | Chronic rheumatic disease of the heart valves | 0.01124 | 1.159 | PDE7B | Phosphorus levels |
| rs947583 | Ulceration of the lower GI tract | 0.005889 | 0.5674 | PDE7B | Phosphorus levels |
| rs947583 | Esophagitis, GERD and related diseases | 0.00291 | 1.105 | PDE7B | Phosphorus levels |
| rs947583 | Bladder cancer | 0.002721 | 1.318 | PDE7B | Phosphorus levels |
| rs947583 | Diseases of esophagus | 0.00124 | 1.111 | PDE7B | Phosphorus levels |
| rs947583 | Chronic venous hypertension | 0.006176 | 0.3313 | PDE7B | Phosphorus levels |
| rs947583 | GERD | 0.009895 | 1.095 | PDE7B | Phosphorus levels |
| rs947583 | Arteritis NOS | 0.007094 | 0.5574 | PDE7B | Phosphorus levels |
| rs947583 | Bladder cancer and neoplasms | 0.0037 | 1.298 | PDE7B | Phosphorus levels |
| rs947583 | Fracture of ribs | 0.0009633 | 1.316 | PDE7B | Phosphorus levels |
| rs947583 | Osteoarthrosis; localized, primary | 0.007168 | 1.253 | PDE7B | Phosphorus levels |
| rs9491140 | Obsessive-compulsive disorder | 0.005044 | 1.753 | NKAIN2 | Personality dimensions |
| rs9491140 | Type 2 diabetic neuropathy | 0.006082 | 1.186 | NKAIN2 | Personality dimensions |
| rs9491140 | Benign neoplasm of skin | 0.01058 | 0.9046 | NKAIN2 | Personality dimensions |
| rs9491140 | Type 2 diabetic peripheral circulatory disorders | 0.001714 | 1.455 | NKAIN2 | Personality dimensions |
| rs9491140 | Renal dialysis | 0.005356 | 1.436 | NKAIN2 | Personality dimensions |
| rs9491140 | Streptococcus infection | 0.006095 | 1.35 | NKAIN2 | Personality dimensions |
| rs9502893 | Bacterial pneumonia | 0.008056 | 1.282 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Hammer toe | 0.006724 | 1.194 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Obstructive chronic bronchitis | 0.0009366 | 1.261 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Dermatophytosis | 0.007056 | 1.108 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Dermatophytosis of nail | 0.0008395 | 1.158 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Anomalies of tooth position/malocclusion | 0.01136 | 0.6113 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Obesity | 0.008457 | 0.9174 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Develomental delays and disorders | 1.145e-05 | 1.478 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Other disorders of eye | 0.004188 | 0.8905 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Dermatophytosis / Dermatomycosis | 0.003365 | 1.115 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Speech and language disorder | 0.001569 | 1.48 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Impacted cerumen | 0.01115 | 1.101 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Other sprains and strains | 0.00454 | 1.356 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Other diseases of lung | 0.003931 | 1.138 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Abnormal findings examination of lungs | 0.005787 | 1.168 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Infestation | 0.01102 | 0.5949 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Acquired foot deformities | 0.009115 | 1.115 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Chronic obstructive asthma | 0.01034 | 1.264 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Acquired toe deformities | 0.0005214 | 1.219 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Decubitus ulcer | 0.001281 | 1.271 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Chronic bronchitis | 0.001236 | 1.225 | FOXQ1 | Pancreatic cancer |
| rs951005 | Benign neoplasm of thyroid glands | 0.007549 | 1.882 | CCL21 | Rheumatoid arthritis |
| rs951005 | Hypotension NOS | 0.007771 | 1.232 | CCL21 | Rheumatoid arthritis |
| rs951005 | Posttraumatic stress disorder | 0.008745 | 1.668 | CCL21 | Rheumatoid arthritis |
| rs951005 | Claw toe | 0.00889 | 2.082 | CCL21 | Rheumatoid arthritis |
| rs951005 | Personality disorders | 4.643e-05 | 1.545 | CCL21 | Rheumatoid arthritis |
| rs951005 | Aneurysm of artery of lower extremity | 0.002625 | 0.4121 | CCL21 | Rheumatoid arthritis |
| rs951005 | Adverse effects of antibacterials (not penicillins) | 0.01023 | 1.846 | CCL21 | Rheumatoid arthritis |
| rs951005 | Generalized anxiety disorder | 0.004385 | 1.403 | CCL21 | Rheumatoid arthritis |
| rs951005 | Arthropathy associated with neurological disorders | 0.01087 | 1.906 | CCL21 | Rheumatoid arthritis |
| rs951005 | Secondary hyperparathyroidism (of renal origin) | 0.003214 | 1.499 | CCL21 | Rheumatoid arthritis |
| rs951005 | Disorders of cervical region | 0.007033 | 0.6273 | CCL21 | Rheumatoid arthritis |
| rs951005 | Alopecia Areata | 0.003647 | 2.299 | CCL21 | Rheumatoid arthritis |
| rs951005 | Tachycardia NOS | 0.007707 | 1.246 | CCL21 | Rheumatoid arthritis |
| rs951005 | Functional disorders of bladder | 0.004349 | 1.407 | CCL21 | Rheumatoid arthritis |
| rs951005 | Spirochetal infection | 0.01035 | 0.4949 | CCL21 | Rheumatoid arthritis |
| rs951005 | Schizoid personality disorder | 0.01099 | 1.821 | CCL21 | Rheumatoid arthritis |
| rs951005 | Disorders of optic nerve and visual pathways | 0.003709 | 1.372 | CCL21 | Rheumatoid arthritis |
| rs951005 | Ulcerative stomatitis & mucositis | 0.001342 | 2.149 | CCL21 | Rheumatoid arthritis |
| rs951005 | Optic neuritis/neuropathy | 0.0001081 | 1.686 | CCL21 | Rheumatoid arthritis |
| rs951005 | Aphakia and other disorders of lens | 0.005457 | 1.415 | CCL21 | Rheumatoid arthritis |
| rs951005 | Stomach cancer | 0.008044 | 0.3273 | CCL21 | Rheumatoid arthritis |
| rs9574199 | Cervical radiculitis | 0.01134 | 0.8424 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Type 2 diabetes | 0.008505 | 1.092 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Nervous system congenital anomalies | 0.001716 | 0.6091 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Diabetes mellitus | 0.009917 | 1.089 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Open wound of lip and mouth | 0.005726 | 0.4826 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Infections of kidney | 0.006079 | 0.7131 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Obsessive-compulsive disorder | 0.005036 | 0.4827 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Bursitis | 0.007936 | 0.8231 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Methicillin resistant Staphylococcus aureus | 0.008145 | 1.822 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Scleritis and episcleritis | 0.003754 | 1.657 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Muscle/tendon sprain | 0.007927 | 0.4278 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Pruritus and related conditions | 0.003827 | 1.225 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Spasm of muscle | 0.01076 | 0.8085 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Fibroadenosis of breast | 0.0039 | 2.24 | POU4F1-AS1 | Total ventricular volume |
| rs958798 | Disease of tricuspid valve | 0.008942 | 0.7457 | KCNC4 | Self-rated health |
| rs958798 | Cardiomyopathy | 0.0009369 | 0.7607 | KCNC4 | Self-rated health |
| rs958798 | Alopecia | 0.009928 | 1.349 | KCNC4 | Self-rated health |
| rs958798 | Benign neoplasm of other endocrine glands | 0.007587 | 1.456 | KCNC4 | Self-rated health |
| rs958798 | Symptoms/disorders of the urinary system | 0.006502 | 0.9001 | KCNC4 | Self-rated health |
| rs958798 | Primary/intrinsic cardiomyopathies | 0.001671 | 0.7658 | KCNC4 | Self-rated health |
| rs958798 | Abnormal sputum | 0.01056 | 1.348 | KCNC4 | Self-rated health |
| rs958798 | Cardiac dysrhythmias | 0.006003 | 0.903 | KCNC4 | Self-rated health |
| rs958798 | Generalized anxiety disorder | 0.003206 | 0.6828 | KCNC4 | Self-rated health |
| rs958798 | Polycythemia vera | 0.0106 | 1.787 | KCNC4 | Self-rated health |
| rs958798 | Pituitary hyperfunction | 0.0108 | 2.054 | KCNC4 | Self-rated health |
| rs958798 | Depression | 0.01058 | 0.8952 | KCNC4 | Self-rated health |
| rs958798 | Malunion fracture | 0.007753 | 1.479 | KCNC4 | Self-rated health |
| rs958798 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.003541 | 2.342 | KCNC4 | Self-rated health |
| rs958798 | Schizophrenia and other psychotic disorders | 0.004845 | 0.7885 | KCNC4 | Self-rated health |
| rs958798 | Other derangement of joint | 0.005018 | 1.349 | KCNC4 | Self-rated health |
| rs958798 | Arthralgia/ankylosis of temporomandibular joint | 0.004701 | 1.673 | KCNC4 | Self-rated health |
| rs9594293 | Elevated blood pressure reading | 0.003163 | 0.8259 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Toxic multinodular goiter | 0.004646 | 2.013 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Vascular disorders of penis | 0.001227 | 2.687 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Other disorders of middle ear and mastoid | 0.008278 | 0.5621 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Joint effusions | 0.00574 | 1.279 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Open wound of nose and sinus | 0.0004583 | 2.589 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Chronic venous hypertension | 0.01099 | 0.218 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Hypertensive heart disease | 0.009369 | 0.6897 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Mood disorders | 0.001527 | 1.147 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Other specified erythematous conditions | 0.003482 | 0.6513 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Anxiety, phobic and dissociative disorders | 0.007583 | 1.135 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Postnasal drip | 0.007781 | 1.848 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Skin neoplasm of uncertain behavior | 0.0006867 | 1.327 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Benign neoplasm of uterus | 0.007219 | 1.27 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Dysthymic disorder | 0.0001775 | 1.322 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Other hypertensive complications | 0.003616 | 0.7135 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Dysuria | 0.005208 | 1.213 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Suicidal ideation or attempt | 0.00111 | 2.064 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Uterine leiomyoma | 0.008637 | 1.28 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Depression | 0.00351 | 1.139 | FREM2 | Cytomegalovirus antibody response |
| rs960089 | Nasal polyps | 0.005 | 0.518 | TOX | Cognitive performance |
| rs960089 | Benign neoplasm of uterus | 0.003155 | 0.6452 | TOX | Cognitive performance |
| rs960089 | Morbid obesity | 0.009077 | 0.747 | TOX | Cognitive performance |
| rs960089 | Skin cancer | 0.002405 | 0.8175 | TOX | Cognitive performance |
| rs960089 | Other upper respiratory disease | 0.01046 | 0.7761 | TOX | Cognitive performance |
| rs960089 | Non-melanoma skin cancer | 0.001392 | 0.7985 | TOX | Cognitive performance |
| rs960089 | Stiffness of joint | 0.009096 | 0.6949 | TOX | Cognitive performance |
| rs960089 | Other anemias | 0.007661 | 0.8602 | TOX | Cognitive performance |
| rs960089 | Gastrointestinal hemorrhage | 0.00653 | 0.8249 | TOX | Cognitive performance |
| rs960089 | Chronic sinusitis | 0.002363 | 0.7883 | TOX | Cognitive performance |
| rs960089 | Peripheral arterial disease | 0.008268 | 0.8016 | TOX | Cognitive performance |
| rs960089 | Concussion | 0.009524 | 1.735 | TOX | Cognitive performance |
| rs960089 | Infections involving bone | 0.00869 | 0.608 | TOX | Cognitive performance |
| rs960089 | Vaginal enterocele, congenital or acquired | 0.004256 | 1.818 | TOX | Cognitive performance |
| rs960089 | Renal failure | 0.007427 | 0.8318 | TOX | Cognitive performance |
| rs960089 | Epistaxis or throat hemorrhage | 0.01096 | 0.7037 | TOX | Cognitive performance |
| rs960089 | Biliary cirrhosis | 0.007576 | 2.607 | TOX | Cognitive performance |
| rs964184 | Anxiety disorder | 0.001142 | 1.219 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Hyperglyceridemia | 5.782e-13 | 2.216 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Decreased libido | 0.008158 | 2.148 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Delirium due to conditions classified elsewhere | 0.006134 | 1.516 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Hyperlipidemia | 2.532e-05 | 1.226 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Retinal detachment with retinal defect | 0.006147 | 1.594 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Abnormal findings on radiological exam of musculoskeletal system | 0.000233 | 2.085 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Disorders of lipoid metabolism | 1.1e-05 | 1.235 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Sexual and gender identity disorders | 0.004895 | 1.546 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Inflammatory disease of cervix, vagina, and vulva | 0.007259 | 1.266 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Obsessive-compulsive disorder | 0.008965 | 1.895 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Anxiety, phobic and dissociative disorders | 0.005319 | 1.162 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Sensorineural hearing loss | 0.006686 | 1.159 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Mixed hyperlipidemia | 0.001367 | 1.307 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Inflammatory diseases of female pelvic organs | 0.002264 | 1.288 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Dysmetabolic syndrome X | 0.001717 | 1.707 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Vaginitis and vulvovaginitis | 0.009078 | 1.293 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Peyronie's disease | 0.001247 | 2.328 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Urinary complications | 0.008332 | 0.4647 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Lipoprotein disorders | 0.01115 | 0.6116 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Chronic ischemic heart disease | 0.01069 | 1.197 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Hypercholesterolemia | 7.818e-05 | 1.26 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Coronary atherosclerosis | 0.009791 | 1.13 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Phlebitis and thrombophlebitis of lower extremities | 0.003755 | 0.6851 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Anomalies of pupillary function | 0.005881 | 2.15 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Cataract | 0.003336 | 1.178 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Lipoid metabolism disorder NOS | 0.004591 | 1.461 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Other disorders of urethra and urinary tract | 0.004713 | 0.714 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Tinnitus | 0.008866 | 1.283 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs9642880 | Light-headedness and vertigo | 0.007893 | 0.9127 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Unspecified local infection of skin and subcutaneous tissue | 0.003616 | 1.283 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Other specified diseases of the salivary glands | 0.005462 | 1.731 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Abnormal glucose | 0.00345 | 1.121 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Hepatic cancer | 0.003936 | 1.752 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Vertiginous syndromes and other disorders of vestibular system | 0.009537 | 0.9181 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Cancer of kidney and urinary organs | 0.009604 | 1.195 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Other local infections of skin and subcutaneous tissue | 0.00261 | 1.19 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Cancer of larynx | 0.008057 | 1.462 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Other abnormal glucose | 0.007558 | 1.138 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Epiphora | 0.001829 | 0.6914 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Bladder cancer | 0.0006372 | 1.352 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Secondary malignant neoplasm | 0.009711 | 1.148 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Bladder cancer and neoplasms | 0.000877 | 1.33 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Cancer of the upper aerodigestive tract | 0.001751 | 1.445 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9649213 | Cirrhosis of liver without mention of alcohol | 0.002555 | 0.6309 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Anemia of chronic disease | 0.006879 | 0.822 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Contracture of joint | 0.002287 | 1.458 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other disorders of stomach and duodenum | 0.007897 | 0.7709 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other congenital anomalies of skin | 0.002313 | 1.498 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other specified diseases of hair and hair follicles | 0.004488 | 1.336 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Benign neoplasm of other endocrine glands | 0.009097 | 1.385 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Hemorrhage of rectum and anus | 0.001636 | 1.232 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Chronic kidney disease, Stage I or II | 0.00824 | 1.367 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Muscular dystrophies and other myopathies | 0.0003015 | 1.637 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other specified diseases of sebaceous glands | 0.0001847 | 1.325 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Femoral hernia | 0.0108 | 0.4932 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Lack of normal physiological development | 0.005193 | 0.7001 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Diseases of hair and hair follicles | 0.009026 | 1.214 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Anemia in chronic kidney disease | 0.006146 | 0.748 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Dysphagia | 0.002843 | 0.8723 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs975334 | Chronic pain syndrome | 0.008342 | 0.5793 | CNTN4 | Gallbladder cancer |
| rs975334 | Diseases of pancreas | 0.001581 | 1.254 | CNTN4 | Gallbladder cancer |
| rs975334 | Other unspecified back disorders | 0.007312 | 1.532 | CNTN4 | Gallbladder cancer |
| rs975334 | Disorders of synovium, tendon, and bursa | 0.007178 | 0.8945 | CNTN4 | Gallbladder cancer |
| rs975334 | Sicca syndrome | 0.0007751 | 1.615 | CNTN4 | Gallbladder cancer |
| rs975334 | Other disorders of gallbladder | 0.007064 | 1.577 | CNTN4 | Gallbladder cancer |
| rs975334 | Nervous system congenital anomalies | 0.002423 | 0.6486 | CNTN4 | Gallbladder cancer |
| rs975334 | Pulmonary collapse; interstitial/compensatory emphysema | 0.007857 | 1.166 | CNTN4 | Gallbladder cancer |
| rs9846480 | Other dyschromia | 0.003078 | 0.7691 | TXNDC6 | Whole-brain volume |
| rs9846480 | Prostatitis | 0.001339 | 0.725 | TXNDC6 | Whole-brain volume |
| rs9846480 | Other specified gastritis | 0.005786 | 0.7746 | TXNDC6 | Whole-brain volume |
| rs9846480 | Irregular menstrual bleeding | 0.00731 | 1.646 | TXNDC6 | Whole-brain volume |
| rs9846480 | Benign neoplasm of uterus | 0.002995 | 0.802 | TXNDC6 | Whole-brain volume |
| rs9846480 | Cyst or abscess of Bartholin's gland | 0.008183 | 0.4557 | TXNDC6 | Whole-brain volume |
| rs9846480 | Other specified disorders of liver | 0.006255 | 0.7408 | TXNDC6 | Whole-brain volume |
| rs9846480 | Seborrheic keratosis | 0.007961 | 0.9051 | TXNDC6 | Whole-brain volume |
| rs9846480 | Symptoms involving respiratory system | 0.00822 | 0.8265 | TXNDC6 | Whole-brain volume |
| rs9846480 | Dyschromia and Vitiligo | 0.01052 | 0.8365 | TXNDC6 | Whole-brain volume |
| rs9846480 | Displacement of intervertebral disc | 0.003395 | 1.176 | TXNDC6 | Whole-brain volume |
| rs9846480 | Uterine leiomyoma | 0.003682 | 0.7958 | TXNDC6 | Whole-brain volume |
| rs9846480 | Chronic prostatitis | 0.00204 | 0.5871 | TXNDC6 | Whole-brain volume |
| rs991316 | Wheezing | 0.01094 | 1.296 | ADH7 | Hypertension |
| rs991316 | Thyrotoxicosis | 0.008031 | 1.229 | ADH7 | Hypertension |
| rs991316 | Keratoderma, acquired | 0.004791 | 1.168 | ADH7 | Hypertension |
| rs991316 | Abnormal findings on radiological examination intrathoracic organs | 0.001369 | 1.248 | ADH7 | Hypertension |
| rs991316 | Impacted cerumen | 0.00947 | 0.9059 | ADH7 | Hypertension |
| rs991316 | Acute pharyngitis | 0.009584 | 0.8748 | ADH7 | Hypertension |
| rs991316 | Graves' disease | 0.002899 | 1.535 | ADH7 | Hypertension |
| rs991316 | Type 2 diabetes | 0.004895 | 0.9162 | ADH7 | Hypertension |
| rs991316 | Postmenopausal atrophic vaginitis | 0.001013 | 0.7674 | ADH7 | Hypertension |
| rs991316 | Diabetes mellitus | 0.009202 | 0.9232 | ADH7 | Hypertension |
| rs991316 | Cancer of other lymphoid, histiocytic tissue | 0.01039 | 1.254 | ADH7 | Hypertension |
| rs991316 | Non-Hodgkins lymphoma | 0.006921 | 1.276 | ADH7 | Hypertension |
| rs9923451 | Hypertrophy of breast (Gynecomastia) | 0.006785 | 2.779 | WWOX | Hip circumference |
| rs9923451 | Benign neoplasm of unspecified sites | 0.01056 | 4.682 | WWOX | Hip circumference |
| rs9923451 | Vitamin D deficiency | 0.0007964 | 2.708 | WWOX | Hip circumference |
| rs9923451 | Arterial embolism and thrombosis of lower extremity artery | 0.001245 | 3.321 | WWOX | Hip circumference |
| rs9923451 | Bacterial pneumonia | 0.001324 | 2.75 | WWOX | Hip circumference |
| rs9923451 | Appendiceal conditions | 0.01114 | 2.683 | WWOX | Hip circumference |
| rs9923451 | Hyperglyceridemia | 0.002533 | 2.963 | WWOX | Hip circumference |
| rs9923451 | Injuries to the nervous system | 0.01042 | 3.254 | WWOX | Hip circumference |
| rs9923451 | Calculus of bile duct | 0.008648 | 2.609 | WWOX | Hip circumference |
| rs9923451 | Infestation | 0.005359 | 4.234 | WWOX | Hip circumference |
| rs9923451 | Seborrheic keratosis | 0.009148 | 1.556 | WWOX | Hip circumference |
| rs9923451 | Vitamin deficiency | 0.003332 | 1.925 | WWOX | Hip circumference |
| rs9929218 | Disorders of menstruation | 0.000429 | 1.288 | CDH1 | Colorectal cancer |
| rs9929218 | Irregular menstrual cycle/bleeding | 0.000203 | 1.325 | CDH1 | Colorectal cancer |
| rs9929218 | Inflammatory spondylopathies | 0.0109 | 0.6286 | CDH1 | Colorectal cancer |
| rs9929218 | Electrolyte imbalance | 0.008484 | 0.9036 | CDH1 | Colorectal cancer |
| rs9929218 | Schizoid personality disorder | 0.003593 | 1.804 | CDH1 | Colorectal cancer |
| rs9929218 | Strabismus (not specified as paralytic) | 0.005674 | 1.258 | CDH1 | Colorectal cancer |
| rs9929218 | Cardiomegaly | 0.01089 | 0.8626 | CDH1 | Colorectal cancer |
| rs9929218 | Psychogenic and somatoform disorders | 0.01003 | 1.271 | CDH1 | Colorectal cancer |
| rs9929218 | Attention deficit hyperactivity disorder | 0.005562 | 1.685 | CDH1 | Colorectal cancer |
| rs9929218 | Constipation | 0.009887 | 0.8748 | CDH1 | Colorectal cancer |
| rs9929218 | Diseases of respiratory system | 0.009269 | 1.166 | CDH1 | Colorectal cancer |
| rs9929218 | Other paralytic syndromes | 0.001882 | 0.5645 | CDH1 | Colorectal cancer |
| rs9929218 | Sacroiliitis NEC | 0.01022 | 0.5012 | CDH1 | Colorectal cancer |
| rs9929218 | Bladder cancer and neoplasms | 0.00874 | 0.7712 | CDH1 | Colorectal cancer |
| rs9943849 | Open wound of toe(s) | 0.008855 | 0.4558 | CPM | Major depressive disorder |
| rs9943849 | Disorders of fluid, electrolyte, and acid-base balance | 0.007793 | 0.9092 | CPM | Major depressive disorder |
| rs9943849 | Abnormal findings on study of brain, nervous system | 0.005302 | 0.559 | CPM | Major depressive disorder |
| rs9943849 | Left bundle branch block | 0.008414 | 0.7431 | CPM | Major depressive disorder |
| rs9943849 | Cornea replaced by transplant | 0.000492 | 2.123 | CPM | Major depressive disorder |
| rs9943849 | Hypopotassemia | 0.005709 | 0.8595 | CPM | Major depressive disorder |
| rs9943849 | Secondary malignancy of bone | 0.002671 | 0.6628 | CPM | Major depressive disorder |
| rs9943849 | Congenital anomalies of great vessels | 0.003067 | 2.06 | CPM | Major depressive disorder |
| rs9943849 | Edema | 0.008792 | 0.8952 | CPM | Major depressive disorder |
| rs9989419 | Infection/inflammation of internal prosthetic device, implant or graft | 0.005616 | 1.28 | CETP | HDL Cholesterol |
| rs9989419 | Psychogenic and somatoform disorders | 0.004174 | 1.284 | CETP | HDL Cholesterol |
| rs9989419 | Major depressive disorder | 0.00304 | 1.175 | CETP | HDL Cholesterol |
| rs9989419 | Lesions of stomach and duodenum | 0.00477 | 0.4442 | CETP | HDL Cholesterol |
| rs9989419 | Posttraumatic stress disorder | 0.002503 | 1.625 | CETP | HDL Cholesterol |
| rs9989419 | Staphylococcus infections | 0.003464 | 1.276 | CETP | HDL Cholesterol |
| rs9989419 | Astigmatism | 0.01137 | 0.8907 | CETP | HDL Cholesterol |
| rs9989419 | Antisocial/borderline personality disorder | 0.002832 | 1.708 | CETP | HDL Cholesterol |
| rs9989419 | Cardiac congenital anomalies | 0.00687 | 1.319 | CETP | HDL Cholesterol |
| rs9989419 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.008311 | 1.299 | CETP | HDL Cholesterol |
| rs9989419 | Disorders of esophageal motility | 0.001424 | 0.607 | CETP | HDL Cholesterol |
| rs9989419 | Somatoform disorder | 0.002438 | 1.39 | CETP | HDL Cholesterol |
| rs9989419 | Anxiety, phobic and dissociative disorders | 0.005667 | 1.108 | CETP | HDL Cholesterol |
| rs9989419 | Methicillin sensitive Staphylococcus aureus | 0.006514 | 1.337 | CETP | HDL Cholesterol |
| rs999943 | Benign neoplasm of other endocrine glands | 0.007089 | 1.416 | ITPR3 | Extreme obesity |
| rs999943 | Hyperpotassemia | 0.00385 | 0.8098 | ITPR3 | Extreme obesity |
| rs999943 | Iatrogenic hypotension | 0.003041 | 0.5256 | ITPR3 | Extreme obesity |
| rs999943 | Heart transplant/surgery | 0.001423 | 0.5902 | ITPR3 | Extreme obesity |
| rs999943 | Other disorders of peritoneum | 0.009955 | 0.6563 | ITPR3 | Extreme obesity |
| rs999943 | Polycystic ovaries | 0.006605 | 0.3667 | ITPR3 | Extreme obesity |
| rs999943 | Type 2 diabetic nephropathy | 0.01128 | 0.8135 | ITPR3 | Extreme obesity |
| rs999943 | Abdominal pain | 0.007678 | 1.088 | ITPR3 | Extreme obesity |
| rs999943 | Electrolyte imbalance | 0.005746 | 0.8984 | ITPR3 | Extreme obesity |
| rs999943 | Arthropathy NOS involving multiple sites | 0.009153 | 1.579 | ITPR3 | Extreme obesity |
| rs999943 | Non-healing surgical wound | 0.002519 | 0.4993 | ITPR3 | Extreme obesity |
| rs999943 | Somatoform disorder | 0.008947 | 1.342 | ITPR3 | Extreme obesity |
| rs999943 | Bladder cancer and neoplasms | 0.003274 | 1.301 | ITPR3 | Extreme obesity |
| rs999943 | Hydronephrosis | 0.007266 | 1.336 | ITPR3 | Extreme obesity |
| rs999943 | Cystitis and urethritis | 0.008749 | 1.216 | ITPR3 | Extreme obesity |
| rs999943 | Salicylates causing adverse effects in therapeutic use | 0.006516 | 1.894 | ITPR3 | Extreme obesity |
| rs999943 | Bladder cancer | 0.002103 | 1.326 | ITPR3 | Extreme obesity |
| rs999943 | Other acquired musculoskeletal deformity | 0.006801 | 0.783 | ITPR3 | Extreme obesity |
| rs999943 | Postoperative infection | 0.0007167 | 0.7637 | ITPR3 | Extreme obesity |
| rs999943 | Nephritis and nephropathy in diseases classified elsewhere | 0.006239 | 0.7469 | ITPR3 | Extreme obesity |
| rs999943 | Nephritis; nephrosis; renal sclerosis | 0.003786 | 0.7808 | ITPR3 | Extreme obesity |
Page:
5th Q
QR Code
This section allows users to specify a relatively concise list of SNPs freely and to generate a QR code. This feature is expected to facilitate genetic data transmission and encryption, while increasing the possibility to maintain individual privacy.
Doctor QR code:
User QR code:
Decrypted user genotype:
rs7514102: GG, rs2274064: CC, rs2297950: TC, rs3811445: GG, rs935172: TC, rs6756597: CC, rs7793096: AA, rs10246939: TC, rs2294008: CC, rs1539172: GG, rs1043836: TT, rs10901333: AG, rs3136618: TC, rs2185724: CC, rs4680: GG
Running Log
Input file:
./personal_genome/sample.vcf.gz
Database directory:
- ./algorithm_database/Qualitative\Qualitative_traits
- ./algorithm_database/Quantitative\Quantitative_traits
Reference population data:
- ['D:\\software_win\\PAGEANT_Win\\population_genome\\G1K.vcf.gz']
Log:
2021-08-04 18:48:52,569 - INFO: Logging start.
2021-08-04 18:48:52,571 - INFO: Recode and sex impute start
2021-08-04 18:48:57,924 - INFO: Recode and sex impute used time: 5.35s
2021-08-04 18:48:57,924 - INFO: Progress of the analysis: 5.0%
2021-08-04 18:48:58,477 - INFO: Sample QC start
2021-08-04 18:49:21,162 - INFO: Sample QC used time: 22.69s
2021-08-04 18:49:21,163 - INFO: Progress of the analysis: 14.0%
2021-08-04 18:49:21,163 - INFO: Reference data QC start
2021-08-04 18:49:30,831 - INFO: Reference data QC used time: 9.67s
2021-08-04 18:49:30,832 - INFO: Progress of the analysis: 23.0%
2021-08-04 18:49:30,832 - INFO: Initial reference data start
2021-08-04 18:49:30,833 - INFO: Get reference result data start
2021-08-04 18:49:31,080 - INFO: Get reference result data used time: 0.25s
2021-08-04 18:49:31,080 - INFO: Initial reference data used time: 0.25s
2021-08-04 18:49:31,080 - INFO: Progress of the analysis: 38.0%
2021-08-04 18:49:31,088 - WARNING: Code(R0008) has no corresponding algorithm!
2021-08-04 18:49:31,088 - INFO: Load sample vcf start
2021-08-04 18:49:31,329 - INFO: Load sample vcf used time: 0.24s
2021-08-04 18:49:31,329 - INFO: Progress of the analysis: 48.0%
2021-08-04 18:49:31,330 - INFO: Load indicator data start
2021-08-04 18:49:31,383 - WARNING: Snp (rs333) cannot be found in your genotype file!
2021-08-04 18:49:31,383 - WARNING: Snp (rs333) cannot be found in your genotype file!
2021-08-04 18:49:31,433 - WARNING: Snp (rs116503776) cannot be found in your genotype file!
2021-08-04 18:49:31,433 - WARNING: Snp (rs142450006) cannot be found in your genotype file!
2021-08-04 18:49:31,434 - WARNING: Snp (rs79037040) cannot be found in your genotype file!
2021-08-04 18:49:31,649 - WARNING: There are duplicate snps (rs11264280) when calculate the quantitative trait!
2021-08-04 18:49:31,651 - WARNING: There are duplicate snps (rs6843082) when calculate the quantitative trait!
2021-08-04 18:49:31,668 - WARNING: Snp (rs116822326) cannot be found in your genotype file!
2021-08-04 18:49:31,676 - WARNING: Snp (rs111404218) cannot be found in your genotype file!
2021-08-04 18:49:31,677 - WARNING: Snp (rs140002913) cannot be found in your genotype file!
2021-08-04 18:49:31,678 - WARNING: Snp (rs67338227) cannot be found in your genotype file!
2021-08-04 18:49:31,679 - WARNING: Snp (rs77505915) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr1_243881945_I) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr1_8424984_D) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr10_104957618_I) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr11_46350213_D) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr18_52749216_D) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr2_146436222_I) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr2_149429178_D) cannot be found in your genotype file!
2021-08-04 18:49:31,689 - WARNING: Snp (chr2_200825237_I) cannot be found in your genotype file!
2021-08-04 18:49:31,690 - WARNING: Snp (chr22_39987017_D) cannot be found in your genotype file!
2021-08-04 18:49:31,690 - WARNING: Snp (chr3_180594593_I) cannot be found in your genotype file!
2021-08-04 18:49:31,690 - WARNING: Snp (chr5_140143664_I) cannot be found in your genotype file!
2021-08-04 18:49:31,690 - WARNING: Snp (chr6_84280274_D) cannot be found in your genotype file!
2021-08-04 18:49:31,690 - WARNING: Snp (chr7_2025096_I) cannot be found in your genotype file!
2021-08-04 18:49:31,690 - WARNING: Snp (chr7_24747494_D) cannot be found in your genotype file!
2021-08-04 18:49:31,691 - WARNING: Snp (rs115329265) cannot be found in your genotype file!
2021-08-04 18:49:31,693 - WARNING: Snp (rs190065944) cannot be found in your genotype file!
2021-08-04 18:49:31,699 - WARNING: Snp (rs7907645) cannot be found in your genotype file!
2021-08-04 18:49:31,704 - INFO: Load indicator data used time: 0.38s
2021-08-04 18:49:31,706 - INFO: Progress of the analysis: 58.0%
2021-08-04 18:49:31,706 - INFO: Add population distribution start
2021-08-04 18:49:41,543 - INFO: Add population distribution used time: 9.84s
2021-08-04 18:49:41,544 - INFO: Progress of the analysis: 62.5%
2021-08-04 18:49:41,544 - INFO: Query database start
2021-08-04 18:49:49,464 - INFO: Progress of the analysis: 71.5%
2021-08-04 18:49:49,472 - INFO: Progress of the analysis: 80.5%
2021-08-04 18:49:49,983 - INFO: Query database used time: 8.44s
2021-08-04 18:49:49,984 - INFO: Produce QR code start
2021-08-04 18:49:50,353 - INFO: Produce QR code used time: 0.37s
2021-08-04 18:49:50,354 - INFO: Progress of the analysis: 85.0%
2021-08-04 18:49:50,354 - INFO: Export report result start
2021-08-04 18:49:50,459 - INFO: Export report result used time: 0.11s
2021-08-04 18:49:50,459 - INFO: Progress of the analysis: 95.0%
2021-08-04 18:49:50,459 - INFO: Analysis runs successfully!